PMID,OWN,STAT,DCOM,LR,IS,VI,IP,DP,TI,PG,FAU,AU,LA,PT,TT,PL,TA,JT,JID,RN,SB,MH,OID,OTO,OT,EDAT,MHDA,CRDT,PHST,PST,SO,AID,PMC,AB,AD,DEP,GR,RF,CIN,CON,CI,EIN,CN,SI,CRI
14955063,NLM,MEDLINE,20040215,20181201,0016-6464 (Print) 0016-6464 (Linking),30,7,1952 Apr 3,[A question of systemic disease].,145-50,"['VAN HEES, C A']",['VAN HEES CA'],['und'],['Journal Article'],Welke systeemziekte?,Netherlands,Geneeskd Gids,Geneeskundige gids,0225640,"['Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', 'Humans', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5222:41521:398'],['NLM'],['*RETICULOENDOTHELIOSIS'],1952/04/03 00:00,1952/04/03 00:01,['1952/04/03 00:00'],"['1952/04/03 00:00 [pubmed]', '1952/04/03 00:01 [medline]', '1952/04/03 00:00 [entrez]']",ppublish,Geneeskd Gids. 1952 Apr 3;30(7):145-50.,,,,,,,,,,,,,,
14955046,NLM,MEDLINE,20040215,20181201,,5,2,1952,[Green pigment of the chloroma].,300-2,"['DE CARVALHO, S']",['DE CARVALHO S'],['und'],['Journal Article'],Sobre o pigmento verde do cloroma.,Portugal,Gaz Med Port,Gazeta medica portuguesa,17040250R,['0 (Biological Products)'],OM,"['*Biological Products', '*Leukemia', '*Sarcoma, Myeloid']",['CLML: 5222:41504:253'],['NLM'],['*LEUKOSARCOMA'],1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Gaz Med Port. 1952;5(2):300-2.,,,,,,,,,,,,,,
14954900,NLM,MEDLINE,20040215,20181201,0014-5491 (Print) 0014-5491 (Linking),31,6,1952 Jun,Oral manifestations of the blood diseases.,309-15,"['BLUEFARB, S M', 'RODIN, H H']","['BLUEFARB SM', 'RODIN HH']",['eng'],['Journal Article'],,United States,Eye Ear Nose Throat Mon,"Eye, ear, nose & throat monthly",0370714,,OM,"['*Anemia', '*Hematologic Diseases', 'Humans', '*Leukemia', '*Mouth Diseases']",['CLML: 5222:41358:25:64:252:288'],['NLM'],"['*ANEMIA/manifestations', '*BLOOD/diseases', '*LEUKEMIA/manifestations', '*MOUTH/diseases']",1952/06/01 00:00,1952/06/01 00:01,['1952/06/01 00:00'],"['1952/06/01 00:00 [pubmed]', '1952/06/01 00:01 [medline]', '1952/06/01 00:00 [entrez]']",ppublish,Eye Ear Nose Throat Mon. 1952 Jun;31(6):309-15.,,,,,,,,,,,,,,
14954791,NLM,MEDLINE,20040215,20181201,0012-0790 (Print) 0012-0790 (Linking),2,6,1952 Jun,[Alveolar hemorrhage as first symptom of a case of acute myeloid leukemia].,158-9,"['DETTKE, H']",['DETTKE H'],['und'],['Journal Article'],Alveolarblutung als erstes Symptom eines Falls von akuter myeloischer Leukamie.,Germany,Dtsch Stomatol,Deutsche Stomatologie,0421425,,OM,"['*Hemorrhage', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Myeloid, Acute', '*Tooth Extraction']",['CLML: 5222:41249:252:452'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/manifestations', '*TEETH EXTRACTION']",1952/06/01 00:00,1952/06/01 00:01,['1952/06/01 00:00'],"['1952/06/01 00:00 [pubmed]', '1952/06/01 00:01 [medline]', '1952/06/01 00:00 [entrez]']",ppublish,Dtsch Stomatol. 1952 Jun;2(6):158-9.,,,,,,,,,,,,,,
14953950,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),7,9,1952 Sep,A case of erythremic myelosis (Di Guglielmo's anemia).,927-33,"['MACKENZIE, I', 'STEPHENSON, A G']","['MACKENZIE I', 'STEPHENSON AG']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,,OM,"['*Anemia', 'Humans', '*Leukemia, Erythroblastic, Acute', '*Polycythemia Vera']",['CLML: 5222:40408:364'],['NLM'],['*POLYCYTHEMIA VERA'],1952/09/01 00:00,1952/09/01 00:01,['1952/09/01 00:00'],"['1952/09/01 00:00 [pubmed]', '1952/09/01 00:01 [medline]', '1952/09/01 00:00 [entrez]']",ppublish,Blood. 1952 Sep;7(9):927-33.,['S0006-4971(20)68205-2 [pii]'],,,,,,,,,,,,,
14953850,NLM,MEDLINE,20040215,20181201,0365-0723 (Print) 0365-0723 (Linking),42,5-6,1952 May-Jun,[Exchange resins; its use in congestive heart insufficiency].,209-12,"['AGUIAR, J A']",['AGUIAR JA'],['und'],['Journal Article'],Resinas de troca: seu emprego na insuficiencia cardiaca congestiva.,Brazil,Arq Bras Med,Arquivos brasileiros de medicina,15310420R,"['0 (Resins, Plant)', '0 (Resins, Synthetic)']",OM,"['*Fever', 'Heart Failure/*therapy', '*Leukemia', 'Leukemia, Lymphoid/*therapy', '*Resins, Plant', '*Resins, Synthetic']",['CLML: 5222:40308:114:172:252:396'],['NLM'],"['*CONGESTIVE HEART FAILURE/therapy', '*FEVER', '*LEUKEMIA, LYMPHATIC/therapy', '*RESINS']",1952/05/01 00:00,1952/05/01 00:01,['1952/05/01 00:00'],"['1952/05/01 00:00 [pubmed]', '1952/05/01 00:01 [medline]', '1952/05/01 00:00 [entrez]']",ppublish,Arq Bras Med. 1952 May-Jun;42(5-6):209-12.,,,,,,,,,,,,,,
14953761,NLM,MEDLINE,20040215,20181201,0004-0312 (Print) 0004-0312 (Linking),93,2,1952 Feb,[So-called mediastinal leukosarcomatosis].,161-80,"['PINO SACCA, F', 'VANDELLI, B']","['PINO SACCA F', 'VANDELLI B']",['und'],['Journal Article'],Sulla cosidetta leucosarcomatosi del mediastino.,Italy,Arch Sci Med (Torino),Archivio per le scienze mediche,0372451,,OM,"['*Leukemia', '*Mediastinal Neoplasms', '*Mediastinum']",['CLML: 5222:40208:253:274'],['NLM'],"['*LEUKOSARCOMA', '*MEDIASTINUM/neoplasms']",1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,Arch Sci Med (Torino). 1952 Feb;93(2):161-80.,,,,,,,,,,,,,,
14953589,NLM,MEDLINE,20040215,20181201,0003-9691 (Print) 0003-9691 (Linking),13,4,1952,[Myeloid leukemia in a workman exposed to vapors of pitch].,388-9,"['CROIZAT, P', 'ROCHE, L', 'BIANCO, E']","['CROIZAT P', 'ROCHE L', 'BIANCO E']",['und'],['Journal Article'],Leucemie myeloide chez un ouvrier expose aux vapeurs de brai.,France,Arch Mal Prof,Archives des maladies professionnelles de medecine du travail et de securite sociale,2985157R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Occupational Diseases']",['CLML: 5222:40036:252:317'],['NLM'],"['*LEUKEMIA, MYELOCYTIC', '*OCCUPATIONAL DISEASES']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Arch Mal Prof. 1952;13(4):388-9.,,,,,,,,,,,,,,
14953291,NLM,MEDLINE,20040215,20200304,0003-9012 (Print) 0003-9012 (Linking),4,5,1952,[Experimental dates in favor of viral etiology of human leukemia].,621-48,"['MAGRASSI, F']",['MAGRASSI F'],['und'],['Journal Article'],Dati sperimentali in favore dell'eziologia virale della malattia leucemica umana.,Austria,Arch Gesamte Virusforsch,Archiv fur die gesamte Virusforschung,7506868,,OM,"['Humans', 'Leukemia/*etiology']",['CLML: 5222:39738:252'],['NLM'],['*LEUKEMIA/etiology and pathogenesis'],1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Arch Gesamte Virusforsch. 1952;4(5):621-48.,,,,,,,,,,,,,,
14953257,NLM,MEDLINE,20040215,20181201,,214,5,1952,[Problems of leucocyte metabolism. III. Effects of nitrogen mustard and nitrogen mustard in combination with urethan on the metabolism of cells of myeloid leukemia].,534-9,"['KEIBL, E', 'SPITZY, K H', 'STORCH, L']","['KEIBL E', 'SPITZY KH', 'STORCH L']",['und'],['Journal Article'],Zum Problem des Leukocytenstoffwechsels. III. Einfluss von N-Lost und N-Lost + Urethan auf den Stoffwechsel myeloisch-leukamischer Zellen.,Germany,Naunyn Schmiedebergs Arch Exp Pathol Pharmakol,Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie,0054224,"['0 (Nitrogen Mustard Compounds)', '3IN71E75Z5 (Urethane)', '50D9XSG0VR (Mechlorethamine)']",OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukocytes', '*Mechlorethamine', 'Nitrogen Mustard Compounds/*pharmacology', 'Urethane/*pharmacology']",['CLML: 5222:39704:252:313:482'],['NLM'],"['*LEUKEMIA, MONOCYTIC', '*NITROGEN MUSTARDS/effects', '*URETHANE/effects']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1952;214(5):534-9.,,,,,,,,,,,,,,
14952246,NLM,MEDLINE,20040215,20181201,0365-3285 (Print) 0365-3285 (Linking),7,4,1952 Apr,[Relation of infection to acute leukemia; case of hemocytoblastic leukemia with initial lymphatic course appearing in an infectious and suppurative condition].,88-92,"['COTRUFO, P', 'LUCREZI, G']","['COTRUFO P', 'LUCREZI G']",['und'],['Journal Article'],"Rapporti tra sepsi e leucemie acute; su un caso di leucemia acuta emocitoblastica con iniziale evoluzione linfatica, impiantatasi su stato setticopiemico.",Italy,Acta Med Ital Mal Infett Parassit,Acta medica Italica di malattie infettive e parassitarie,14540070R,,OM,"['*Acute Disease', '*Communicable Diseases', 'Humans', '*Leukemia', '*Suppuration']",['CLML: 5222:38689:251'],['NLM'],['*LEUKEMIA'],1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Acta Med Ital Mal Infett Parassit. 1952 Apr;7(4):88-92.,,,,,,,,,,,,,,
14952241,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),7,4,1952 Apr,[The problem of eosinophile leukemia; pathogenesis of leucoses].,230-56,"['DITTRICH, H']",['DITTRICH H'],['und'],['Journal Article'],Zur Frage der eosinophilen Leukamie; (Zugleich ein Beitrag zur Pathogenese der Leukosen).,Switzerland,Acta Haematol,Acta haematologica,0141053,,OM,"['Humans', '*Hypereosinophilic Syndrome', '*Leukemia']",['CLML: 5222:38684:251'],['NLM'],['*LEUKEMIA'],1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Acta Haematol. 1952 Apr;7(4):230-56. doi: 10.1159/000204057.,['10.1159/000204057 [doi]'],,,,,,,,,,,,,
14952237,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),7,4,1952 Apr,"Present status of ACTH, cortisone, and the antimetabolites in the treatment of leukemia and related diseases.",193-205,"['BURCHENAL, J H']",['BURCHENAL JH'],['eng'],['Journal Article'],,Switzerland,Acta Haematol,Acta haematologica,0141053,"['0 (Antimetabolites)', '0 (Folic Acid Antagonists)', '9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['Adrenocorticotropic Hormone/*therapeutic use', '*Antimetabolites', 'Cortisone/*therapeutic use', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5222:38680:8:120:177:252'],['NLM'],"['*ACTH/therapeutic use', '*CORTISONE/therapeutic use', '*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Acta Haematol. 1952 Apr;7(4):193-205. doi: 10.1159/000204053.,['10.1159/000204053 [doi]'],,,,,,,,,,,,,
14952100,NLM,MEDLINE,20040215,20190917,0096-6339 (Print) 0096-6339 (Linking),48,3,1952 Sep,Coexistence of intraocular melanoma and lymphatic leukemia.,349-51,"['NADBATH, R P', 'BULLWINKEL, H G']","['NADBATH RP', 'BULLWINKEL HG']",['eng'],['Journal Article'],,United States,AMA Arch Ophthalmol,A.M.A. archives of ophthalmology,7706524,['Uveal melanoma'],OM,"['*Choroid', '*Choroid Neoplasms', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Melanoma', '*Uveal Neoplasms']",['CLML: 5222:38543:106:252:277'],['NLM'],"['*CHOROID/neoplasms', '*LEUKEMIA, LYMPHATIC', '*MELANOMA']",1952/09/01 00:00,1952/09/01 00:01,['1952/09/01 00:00'],"['1952/09/01 00:00 [pubmed]', '1952/09/01 00:01 [medline]', '1952/09/01 00:00 [entrez]']",ppublish,AMA Arch Ophthalmol. 1952 Sep;48(3):349-51. doi: 10.1001/archopht.1952.00920010357013.,['10.1001/archopht.1952.00920010357013 [doi]'],,,,,,,,,,,,,
14951809,NLM,MEDLINE,20040215,20181201,0044-4030 (Print) 0044-4030 (Linking),88,7,1952 Feb,[Gastrointestinal pathology in lymphatic leukemia].,259-62,"['NAGEL, W']",['NAGEL W'],['und'],['Journal Article'],Beitrag zur Frage der Magen-Darmveranderungen bei der lymphatischen Liukamie.,Germany,Zentralbl Allg Pathol,Zentralblatt fur allgemeine Pathologie u. pathologische Anatomie,9105593,,OM,"['Gastrointestinal Tract/*pathology', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5222:38215:184:252'],['NLM'],"['*GASTROINTESTINAL SYSTEM/pathology', '*LEUKEMIA, LYMPHATIC/manifestations']",1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,Zentralbl Allg Pathol. 1952 Feb;88(7):259-62.,,,,,,,,,,,,,,
14951799,NLM,MEDLINE,20040215,20181201,0044-4030 (Print) 0044-4030 (Linking),88,5-6,1952 Jan,[Hemorrhages into the spleen tissue in myelocytic leukemia].,200-3,"['FRITZSCH, W']",['FRITZSCH W'],['und'],['Journal Article'],Blutungen im Milzgewebe bei Myelose.,Germany,Zentralbl Allg Pathol,Zentralblatt fur allgemeine Pathologie u. pathologische Anatomie,9105593,,OM,"['*Disease', '*Hemorrhage', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Spleen', '*Splenic Diseases']",['CLML: 5222:38205:252:429'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/manifestations', '*SPLEEN/diseases']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Zentralbl Allg Pathol. 1952 Jan;88(5-6):200-3.,,,,,,,,,,,,,,
14951155,NLM,MEDLINE,20040215,20181201,0043-5325 (Print) 0043-5325 (Linking),64,17,1952 Apr,[Aminopterin therapy of acute leukemias].,309-11,"['KOLBL, H', 'ROSENKRANZ, A']","['KOLBL H', 'ROSENKRANZ A']",['und'],['Journal Article'],Ein Beitrag zur Aminopterintherapie akuter Leukamien.,Austria,Wien Klin Wochenschr,Wiener klinische Wochenschrift,21620870R,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Acute Disease', '*Aminopterin', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5222:37557:177:252'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Wien Klin Wochenschr. 1952 Apr;64(17):309-11.,,,,,,,,,,,,,,
14950373,NLM,MEDLINE,20040215,20181201,0256-9574 (Print),26,15,1952 Apr 12,Leukaemic tonsils.,316-7,"['DICK, A M']",['DICK AM'],['eng'],['Journal Article'],,South Africa,S Afr Med J,South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,0404520,,OM,"['Humans', '*Leukemia', 'Leukemia, Lymphoid/*diagnosis', 'Palatine Tonsil/*pathology']",['CLML: 5222:36737:252:463'],['NLM'],"['*LEUKEMIA, LYMPHATIC/diagnosis', '*TONSILS/pathology']",1952/04/12 00:00,1952/04/12 00:01,['1952/04/12 00:00'],"['1952/04/12 00:00 [pubmed]', '1952/04/12 00:01 [medline]', '1952/04/12 00:00 [entrez]']",ppublish,S Afr Med J. 1952 Apr 12;26(15):316-7.,,,,,,,,,,,,,,
14950203,NLM,MEDLINE,20040215,20190619,0036-8075 (Print) 0036-8075 (Linking),116,3005,1952 Aug 1,The metabolism of betaine and sodium formate by leukemic mice.,121-2,"['DINNING, J S', 'SEAGER, L D', 'PAYNE, L D', 'TOTTER, J R']","['DINNING JS', 'SEAGER LD', 'PAYNE LD', 'TOTTER JR']",['eng'],['Journal Article'],,United States,Science,"Science (New York, N.Y.)",0404511,"['0 (Formates)', '0YIW783RG1 (formic acid)', '3SCV180C9W (Betaine)', 'N91BDP6H0X (Choline)']",OM,"['Animals', '*Betaine', '*Biochemical Phenomena', 'Choline/analogs & derivatives', 'Formates/*metabolism', '*Leukemia', '*Leukemia, Experimental', 'Mice']",['CLML: 5222:36567:104:178:252'],['NLM'],"['*CHOLINE/derivatives', '*FORMATES/metabolism', '*LEUKEMIA/experimental']",1952/08/01 00:00,1952/08/01 00:01,['1952/08/01 00:00'],"['1952/08/01 00:00 [pubmed]', '1952/08/01 00:01 [medline]', '1952/08/01 00:00 [entrez]']",ppublish,Science. 1952 Aug 1;116(3005):121-2. doi: 10.1126/science.116.3005.121.,['10.1126/science.116.3005.121 [doi]'],,,,,,,,,,,,,
14950071,NLM,MEDLINE,20040215,20181201,,25,2,1952,"[Reticulosis, reticuloendotheliosis, and reticulosarcoma].",64-5,,,['und'],['Journal Article'],"RETICOLOSI, reticoloendoteliosi e reticolosarcomi.",Spain,Sangue,Il Sangue,20540400R,"['Reticuloendotheliosis, X-linked']",OM,"['Animals', '*Disease', '*Genetic Diseases, X-Linked', 'Humans', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Lymphoma, Large B-Cell, Diffuse', '*Lymphoma, Non-Hodgkin', '*Mononuclear Phagocyte System', '*Neoplasms', '*Sarcoma', '*Severe Combined Immunodeficiency']",['CLML: 5222:36435:398:411'],['NLM'],"['*RETICULOENDOTHELIAL SYSTEM/diseases', '*RETICULOENDOTHELIOSIS', '*SARCOMA, RETICULUM CELL']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Sangue. 1952;25(2):64-5.,,,,,,,,,,,,,,
14949941,NLM,MEDLINE,20040215,20181201,0035-5259 (Print) 0035-5259 (Linking),66,22,1952 May 31,[ACTH and eosinophil leukemia].,600-4,"['MORELLI, A', 'MAUREA, C']","['MORELLI A', 'MAUREA C']",['und'],['Journal Article'],ACTH e leucemia eosinofila.,Italy,Riforma Med,La Riforma medica,0404345,['9002-60-2 (Adrenocorticotropic Hormone)'],OM,"['Adrenocorticotropic Hormone/*therapeutic use', '*Eosinophils', '*Hypereosinophilic Syndrome', '*Leukemia', 'Leukemia, Myeloid/*therapy']",['CLML: 5222:36305:8:252'],['NLM'],"['*ACTH/therapeutic use', '*LEUKEMIA, MYELOCYTIC/therapy']",1952/05/31 00:00,1952/05/31 00:01,['1952/05/31 00:00'],"['1952/05/31 00:00 [pubmed]', '1952/05/31 00:01 [medline]', '1952/05/31 00:00 [entrez]']",ppublish,Riforma Med. 1952 May 31;66(22):600-4.,,,,,,,,,,,,,,
14949145,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),8,9,1952 May 15,[Case of leukemia with initial aplastic phase and with remission].,264-72,"['SILVESTRONI, E']",['SILVESTRONI E'],['und'],['Journal Article'],Su di un caso di leucemia con fase iniziale aplastica e con remissione.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5222:35483:252'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1952/05/15 00:00,1952/05/15 00:01,['1952/05/15 00:00'],"['1952/05/15 00:00 [pubmed]', '1952/05/15 00:01 [medline]', '1952/05/15 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1952 May 15;8(9):264-72.,,,,,,,,,,,,,,
14949143,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),8,9,1952 May 15,[Research on blood cytochemistry; polysaccharide reaction in cytodiagnosis of acute leukosis].,257-60,"['STORTI, E', 'PERUGINI, S']","['STORTI E', 'PERUGINI S']",['und'],['Journal Article'],Ricerche di citochimica ematologica; le reazioni dei polisaccaridi applicate alla diagnostica citologica delle leucosi acute.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,['0 (Polysaccharides)'],OM,"['*Cytodiagnosis', '*Histocytochemistry', 'Humans', 'Leukemia/*diagnosis', '*Polysaccharides', '*Research']",['CLML: 5222:35481:251'],['NLM'],['*LEUKEMIA/diagnosis'],1952/05/15 00:00,1952/05/15 00:01,['1952/05/15 00:00'],"['1952/05/15 00:00 [pubmed]', '1952/05/15 00:01 [medline]', '1952/05/15 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1952 May 15;8(9):257-60.,,,,,,,,,,,,,,
14949139,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),8,8,1952 Apr 30,[Association of diabetes mellitus and leukemia; clinical aspects and review of the literature].,229-32,"['IANNACCONE, A', 'NICOLETTI, M']","['IANNACCONE A', 'NICOLETTI M']",['und'],['Journal Article'],Associazione di diabete mellito e leucemia; contributo clinico e rassegna della letteratura.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,,OM,"['*Diabetes Mellitus', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5222:35477:134:252'],['NLM'],"['*DIABETES MELLITUS', '*LEUKEMIA, MYELOCYTIC']",1952/04/30 00:00,1952/04/30 00:01,['1952/04/30 00:00'],"['1952/04/30 00:00 [pubmed]', '1952/04/30 00:01 [medline]', '1952/04/30 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1952 Apr 30;8(8):229-32.,,,,,,,,,,,,,,
14949094,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),80,3,1952 Jul,Comparative effectiveness of five newly synthesized arsenical compounds in treatment of leukemia in mice.,489-92,"['ENGLE, R L Jr', 'REZNIKOFF, P', 'LOTT, W A', 'YALE, H L']","['ENGLE RL Jr', 'REZNIKOFF P', 'LOTT WA', 'YALE HL']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,['0 (Arsenicals)'],OM,"['Animals', 'Arsenicals/*pharmacology', '*Leukemia', '*Leukemia, Experimental', 'Mice']",['CLML: 5222:35432:40:252'],['NLM'],"['*ARSENICALS/effects', '*LEUKEMIA/experimental']",1952/07/01 00:00,1952/07/01 00:01,['1952/07/01 00:00'],"['1952/07/01 00:00 [pubmed]', '1952/07/01 00:01 [medline]', '1952/07/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1952 Jul;80(3):489-92. doi: 10.3181/00379727-80-19666.,['10.3181/00379727-80-19666 [doi]'],,,,,,,,,,,,,
14948325,NLM,MEDLINE,20040215,20181201,0031-3939 (Print) 0031-3939 (Linking),27,7,1952 Jul,[Unusual form of chloroma of the bone marrow in a 12-year-old girl].,845-7,"['MIKULOWSKI, W']",['MIKULOWSKI W'],['und'],['Journal Article'],Rzadka postac zieleniaka szpikowego u dziewczynki 12-letniej.,Poland,Pediatr Pol,Pediatria polska,2985039R,,OM,"['*Bone Marrow', '*Bone Marrow Neoplasms', 'Female', 'Humans', '*Leukemia', '*Sarcoma, Myeloid']",['CLML: 5222:34663:72:253'],['NLM'],"['*BONE MARROW/neoplasms', '*LEUKOSARCOMA']",1952/07/01 00:00,1952/07/01 00:01,['1952/07/01 00:00'],"['1952/07/01 00:00 [pubmed]', '1952/07/01 00:01 [medline]', '1952/07/01 00:00 [entrez]']",ppublish,Pediatr Pol. 1952 Jul;27(7):845-7.,,,,,,,,,,,,,,
14948285,NLM,MEDLINE,20040215,20181201,0031-3939 (Print) 0031-3939 (Linking),27,1,1952 Jan,"[A case of leukemia in a child treated with aminopterin, and a case of leukemic reaction in the course of infection].",78-81,"['GERWELOWA, H', 'SZCZEPSKI, O']","['GERWELOWA H', 'SZCZEPSKI O']",['und'],['Journal Article'],Przypadek bialaczki u dziecka leczony aminopteryna oraz przypadek odczynu blalaczkowego w przebiegu zaka1zenia.,Poland,Pediatr Pol,Pediatria polska,2985039R,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Aminopterin', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5222:34623:177:252'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Pediatr Pol. 1952 Jan;27(1):78-81.,,,,,,,,,,,,,,
14948274,NLM,MEDLINE,20040215,20181201,0031-3890 (Print) 0031-3890 (Linking),60,3-4,1952 Mar-Apr,[Position of Jaksch-Hayem-Luzet anemia in the field of blood diseases in children].,216-21,"['CROCCO, G']",['CROCCO G'],['und'],['Journal Article'],La posizione attuale del' l'anemia di Jaksch-Hayem-Luzet nel campo delle emopatie infantili.,Italy,Pediatria (Napoli),La Pediatria,0401207,,OM,"['*Anemia', '*Hematologic Diseases', '*Leukemia']",['CLML: 5222:34612:375'],['NLM'],['*PSEUDOLEUKEMIA INFANTUM'],1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Pediatria (Napoli). 1952 Mar-Apr;60(3-4):216-21.,,,,,,,,,,,,,,
14948107,NLM,MEDLINE,20040215,20181201,0029-1420 (Print) 0029-1420 (Linking),47,30,1952 Jul 25,"[Polycythemia vera, radioactive phosphorus, acute leukemia].",1037-8,"['BJERKELUND, C J']",['BJERKELUND CJ'],['und'],['Journal Article'],"Polycythaemia vera radioaktivt fosfor, leucaemia acuta.",Sweden,Nord Med,Nordisk medicin,0401001,"['0 (Phosphorus Radioisotopes)', '0 (Phosphorus, Dietary)', '27YLU75U4W (Phosphorus)']",OM,"['*Leukemia', 'Leukemia, Myeloid/*etiology', '*Phosphorus', 'Phosphorus Radioisotopes/*toxicity', '*Phosphorus, Dietary', 'Polycythemia Vera/*therapy', '*Radioactivity']",['CLML: 5222:34445:252:350:364'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/etiology and pathogenesis', '*PHOSPHORUS, RADIOACTIVE/toxicity', '*POLYCYTHEMIA VERA/therapy']",1952/07/25 00:00,1952/07/25 00:01,['1952/07/25 00:00'],"['1952/07/25 00:00 [pubmed]', '1952/07/25 00:01 [medline]', '1952/07/25 00:00 [entrez]']",ppublish,Nord Med. 1952 Jul 25;47(30):1037-8.,,,,,,,,,,,,,,
14947071,NLM,MEDLINE,20040215,20181201,,7,15-16,1952 Aug 1,[Present state of leukemia].,372-5,"['UHER, V']",['UHER V'],['und'],['Journal Article'],Dne6sni stav otazky leukemii.,Czech Republic,Lek List,Lekarske listy,18310680R,,OM,['Leukemia/*therapy'],['CLML: 5222:33409:252'],['NLM'],['*LEUKEMIA/therapy'],1952/08/01 00:00,1952/08/01 00:01,['1952/08/01 00:00'],"['1952/08/01 00:00 [pubmed]', '1952/08/01 00:01 [medline]', '1952/08/01 00:00 [entrez]']",ppublish,Lek List. 1952 Aug 1;7(15-16):372-5.,,,,,,,,,,,,,,
14946150,NLM,MEDLINE,20040215,20181201,0302-7430 (Print) 0302-7430 (Linking),34,4,1951,[Triethylene melamine in combination with radiotherapy].,489-93,"['SARASIN, R', 'DUBOIS-FERRIERE, H']","['SARASIN R', 'DUBOIS-FERRIERE H']",['und'],['Journal Article'],Possibilites de traitements associes au triethylene-melamine et de la radiotherapie.,Belgium,J Belge Radiol,Journal belge de radiologie,0420407,['F7IY6HZG9D (Triethylenemelamine)'],OM,"['Leukemia/*therapy', '*Radiotherapy', 'Triethylenemelamine/*therapeutic use']",['CLML: 5222:32487:252:391:467'],['NLM'],"['*LEUKEMIA/therapy', '*RADIOTHERAPY', '*TRIETHYLENE MELAMINE/therapeutic use']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,J Belge Radiol. 1951;34(4):489-93.,,,,,,,,,,,,,,
14945727,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),36,4,1952,[ACTH and cortisone therapy of acute and chronic leukemia].,387-97,"['SALARIS, C', 'TANSINI, G']","['SALARIS C', 'TANSINI G']",['und'],['Journal Article'],Contributo alla conoscenza della terapia con ACTH e cortisone nelle leucemie acute e croniche.,Italy,Haematologica,Haematologica,0417435,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['Adrenocorticotropic Hormone/*therapeutic use', '*Chronic Disease', 'Cortisone/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5222:32064:8:120:252'],['NLM'],"['*ACTH/therapeutic use', '*CORTISONE/therapeutic use', '*LEUKEMIA/therapy']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Haematologica. 1952;36(4):387-97.,,,,,,,,,,,,,,
14945032,NLM,MEDLINE,20040215,20181201,0008-4409 (Print) 0008-4409 (Linking),66,6,1952 Jun,The effect of plasma infusions in acute leukaemia in children.,576-8,"['DARTE, J M M', 'SNELLING, C E', 'DONOHUE, W L']","['DARTE JM', 'SNELLING CE', 'DONOHUE WL']",['eng'],['Journal Article'],,Canada,Can Med Assoc J,Canadian Medical Association journal,0414110,,OM,"['*Acute Disease', 'Child', 'Humans', 'Leukemia/*therapy', '*Plasma']",['CLML: 5222:31368:252'],['NLM'],['*LEUKEMIA/therapy'],1952/06/01 00:00,1952/06/01 00:01,['1952/06/01 00:00'],"['1952/06/01 00:00 [pubmed]', '1952/06/01 00:01 [medline]', '1952/06/01 00:00 [entrez]']",ppublish,Can Med Assoc J. 1952 Jun;66(6):576-8.,,PMC1822518,,,,,,,,,,,,
14945004,NLM,MEDLINE,20040215,20181201,0366-1334 (Print) 0366-1334 (Linking),68,9-10,1952,[Acute cryptoleukemia of prolonged evolution associated with a primary tuberculous infection].,379-81,"['DUROUX, A', 'JARNIOU, P', 'DUCHENE']","['DUROUX A', 'JARNIOU P', 'DUCHENE']",['und'],['Journal Article'],"Crypto-leucose aigue d'evolution prolongee, associee a une primo-infection tuberculeuse.",France,Bull Mem Soc Med Hop Paris,Bulletins et memoires de la Societe medicale des hopitaux de Paris,7503472,,OM,"['*Biological Evolution', 'Humans', '*Leukemia', '*Tuberculosis', '*Tuberculosis, Pulmonary']",['CLML: 5222:31340:251:474'],['NLM'],"['*LEUKEMIA', '*TUBERCULOSIS, PULMONARY']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Bull Mem Soc Med Hop Paris. 1952;68(9-10):379-81.,,,,,,,,,,,,,,
14945003,NLM,MEDLINE,20040215,20181201,0366-1334 (Print) 0366-1334 (Linking),68,9-10,1952,[Neoplastic leukosis simulating an abscess of the breast].,376-9,"['GELIN, G']",['GELIN G'],['und'],['Journal Article'],Leucose tumorale simulant un abces du sein.,France,Bull Mem Soc Med Hop Paris,Bulletins et memoires de la Societe medicale des hopitaux de Paris,7503472,,OM,"['*Abscess', '*Breast', '*Breast Neoplasms', 'Humans', '*Leukemia']",['CLML: 5222:31339:78:251'],['NLM'],"['*BREAST/neoplasms', '*LEUKEMIA']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Bull Mem Soc Med Hop Paris. 1952;68(9-10):376-9.,,,,,,,,,,,,,,
14944458,NLM,MEDLINE,20040215,20181201,0004-0568 (Print) 0004-0568 (Linking),15,1,1952,[Morphological and experimental investigations on the etiology and pathogenesis of chronic human myeloid and lymphatic leukemia. I. Experimental myeloid and lymphatic leukemia in the guinea pig by transmission with human material].,75-90,"['MAS Y MAGRO, F']",['MAS Y MAGRO F'],['und'],['Journal Article'],Investigaciones morfologicas y experimentales sobre la etiologaa y la patogenia de la leucemia cronica humana (mieloide y linfatica). I. Leucemia (mieloide y linfatica) experimental del cobaya por transmision con material humano.,Spain,Arch Med Exp,Archivos de medicina experimental; trabajos del Instituto Nacional de Ciencias Medicas,15230250R,,OM,"['Animals', 'Guinea Pigs', 'Humans', '*Leukemia', '*Leukemia, Experimental', '*Leukemia, Lymphoid', '*Leukemia, Myeloid']",['CLML: 5222:30794:252'],['NLM'],"['*LEUKEMIA, LYMPHATIC/experimental', '*LEUKEMIA, MYELOCYTIC/experimental']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Arch Med Exp. 1952;15(1):75-90.,,,,,,,,,,,,,,
14944457,NLM,MEDLINE,20040215,20181201,0004-0568 (Print) 0004-0568 (Linking),15,1,1952,[Morphological and experimental investigations on the etiology and pathogenesis of acute lymphatic leukemia. II. Leukocyte alterations of the blood and the cytological aspect of the lymphoid follicles].,69-74,"['MAS Y MAGRO, F']",['MAS Y MAGRO F'],['und'],['Journal Article'],Investigaciones morfologicas y experimentales sobre la etiologaa y la patogenia de la leucemia linfatica aguda. II. Alteraciones leucocitarias de la sangre y aspecto citologico de los folaculos linfoides.,Spain,Arch Med Exp,Archivos de medicina experimental; trabajos del Instituto Nacional de Ciencias Medicas,15230250R,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Leukocytes', '*Lymphatic Vessels']",['CLML: 5222:30793:252'],['NLM'],"['*LEUKEMIA, LYMPHATIC/experimental']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Arch Med Exp. 1952;15(1):69-74.,,,,,,,,,,,,,,
14944455,NLM,MEDLINE,20040215,20181201,0004-0568 (Print) 0004-0568 (Linking),15,1,1952,[Morphological and experimental investigations on the etiology and pathogenesis of acute lymphatic leukemia. I. Experiments in transmission].,55-9,"['MAS Y MAGRO, F']",['MAS Y MAGRO F'],['und'],['Journal Article'],Investigaciones morfologicas y experimentales sobre la etiologia y la patogenia de la leucemia linfatica aguda. I. Experimentos de transmision.,Spain,Arch Med Exp,Archivos de medicina experimental; trabajos del Instituto Nacional de Ciencias Medicas,15230250R,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5222:30791:252'],['NLM'],"['*LEUKEMIA, LYMPHATIC/experimental']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Arch Med Exp. 1952;15(1):55-9.,,,,,,,,,,,,,,
14944453,NLM,MEDLINE,20040215,20181201,0004-0568 (Print) 0004-0568 (Linking),15,1,1952,"[Leukemias, basal metabolism and thiouracil].",21-4,"['VALDES RUIZ, M', 'JUANES GONZALEZ, A']","['VALDES RUIZ M', 'JUANES GONZALEZ A']",['und'],['Journal Article'],"Leucemias, metabolismo basal y tiouracilo.",Spain,Arch Med Exp,Archivos de medicina experimental; trabajos del Instituto Nacional de Ciencias Medicas,15230250R,['59X161SCYL (Thiouracil)'],OM,"['*Basal Metabolism', 'Leukemia/*therapy', 'Thiouracil/*therapeutic use']",['CLML: 5222:30789:252:457'],['NLM'],"['*LEUKEMIA/therapy', '*THIOURACIL/therapeutic use']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Arch Med Exp. 1952;15(1):21-4.,,,,,,,,,,,,,,
14944370,NLM,MEDLINE,20040215,20181201,0004-0231 (Print) 0004-0231 (Linking),25,1-2,1952,[Funicular myelosis due to folic acid in Mus musculus albinus; preliminary note].,23-8,"['SPAMPINATO, V']",['SPAMPINATO V'],['und'],['Journal Article'],Mielosi funicolare da acido folico nel Mus musculus albinus; nota preventiva.,Italy,Arch Ital Anat Istol Patol,Archivio italiano di anatomia e istologia patologica,0372443,['935E97BOY8 (Folic Acid)'],OM,"['Folic Acid/*pharmacology', 'Humans', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Myelitis']",['CLML: 5222:30706:176:293'],['NLM'],"['*FOLIC ACID/effects', '*MYELITIS, FUNICULAR']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Arch Ital Anat Istol Patol. 1952;25(1-2):23-8.,,,,,,,,,,,,,,
14944331,NLM,MEDLINE,20040215,20181201,0003-9691 (Print) 0003-9691 (Linking),13,3,1952,[Discovery of a case of myeloid leukemia in industrial medical examination of apprentices].,282-3,"['MULLER, F']",['MULLER F'],['und'],['Journal Article'],Depistage d'une leucemie myeloide en visite d'embauche.,France,Arch Mal Prof,Archives des maladies professionnelles de medecine du travail et de securite sociale,2985157R,,OM,"['Humans', '*Industry', '*Leukemia', 'Leukemia, Myeloid/*diagnosis', '*Occupational Diseases', '*Occupations']",['CLML: 5222:30667:224:252'],['NLM'],"['*INDUSTRY AND OCCUPATIONS', '*LEUKEMIA, MYELOCYTIC/diagnosis']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Arch Mal Prof. 1952;13(3):282-3.,,,,,,,,,,,,,,
14944124,NLM,MEDLINE,20040215,20190619,0003-4819 (Print) 0003-4819 (Linking),37,2,1952 Aug,The present status of therapy in acute leukemia.,400-3,"['SACKS, M S']",['SACKS MS'],['eng'],['Journal Article'],,United States,Ann Intern Med,Annals of internal medicine,0372351,,OM,"['*Acute Disease', 'Humans', 'Leukemia/*therapy']",['CLML: 5222:30460:252'],['NLM'],['*LEUKEMIA/therapy'],1952/08/01 00:00,1952/08/01 00:01,['1952/08/01 00:00'],"['1952/08/01 00:00 [pubmed]', '1952/08/01 00:01 [medline]', '1952/08/01 00:00 [entrez]']",ppublish,Ann Intern Med. 1952 Aug;37(2):400-3. doi: 10.7326/0003-4819-37-2-400.,['10.7326/0003-4819-37-2-400 [doi]'],,,,,,,,,,,,,
14943718,NLM,MEDLINE,20040215,20190717,0002-9629 (Print) 0002-9629 (Linking),224,2,1952 Aug,Leukemia and other malignancies in physicians.,154-9,"['PELLER, S', 'PICK, P']","['PELLER S', 'PICK P']",['eng'],['Journal Article'],,United States,Am J Med Sci,The American journal of the medical sciences,0370506,,OM,"['Humans', 'Leukemia/*epidemiology/*statistics & numerical data', '*Neoplasms', '*Physicians']",['CLML: 5222:30053:252'],['NLM'],['*LEUKEMIA/epidemiology and statistics'],1952/08/01 00:00,1952/08/01 00:01,['1952/08/01 00:00'],"['1952/08/01 00:00 [pubmed]', '1952/08/01 00:01 [medline]', '1952/08/01 00:00 [entrez]']",ppublish,Am J Med Sci. 1952 Aug;224(2):154-9. doi: 10.1097/00000441-195208000-00005.,['10.1097/00000441-195208000-00005 [doi]'],,,,,,,,,,,,,
14943710,NLM,MEDLINE,20040215,20200824,0002-9297 (Print) 0002-9297 (Linking),4,2,1952 Jun,Familial leukemia; a report of three cases of leukemia and one leukemoid reaction in one family.,90-3,"['WARD, J E', 'GALINSKY, I', 'NEWTON, B L']","['WARD JE', 'GALINSKY I', 'NEWTON BL']",['eng'],['Journal Article'],,United States,Am J Hum Genet,American journal of human genetics,0370475,,OM,"['*Heredity', 'Humans', 'Leukemia/*genetics', '*Leukemoid Reaction']",['CLML: 5222:30045:252'],['NLM'],['*LEUKEMIA/heredity'],1952/06/01 00:00,1952/06/01 00:01,['1952/06/01 00:00'],"['1952/06/01 00:00 [pubmed]', '1952/06/01 00:01 [medline]', '1952/06/01 00:00 [entrez]']",ppublish,Am J Hum Genet. 1952 Jun;4(2):90-3.,,PMC1716435,,,,,,,,,,,,
14943538,NLM,MEDLINE,20040215,20181201,0365-5504 (Print) 0365-5504 (Linking),5,2,1952 Mar-Apr,[Therapeutic value of certain anticellular substances in erythroblastic blood diseases].,214-22,"['ROMEO, G']",['ROMEO G'],['und'],['Journal Article'],Sul valore terapeutico di alcune sostanze ad azione anticellulare nelle emopatie a tipo eritroblastico.,Italy,Acta Paediatr Lat,Acta paediatrica Latina,0370360,"['0 (Folic Acid Antagonists)', '0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Anemia', 'Folic Acid Antagonists/*therapeutic use', '*Hematologic Diseases', 'Humans', 'Leukemia/*therapy', '*Mechlorethamine', 'Nitrogen Mustard Compounds/*therapeutic use', 'beta-Thalassemia/*therapy']",['CLML: 5222:29873:25:177:252:313'],['NLM'],"['*ANEMIA, ERYTHROBLASTIC/therapy', '*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy', '*NITROGEN MUSTARDS/therapeutic use']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Acta Paediatr Lat. 1952 Mar-Apr;5(2):214-22.,,,,,,,,,,,,,,
14943277,NLM,MEDLINE,20040215,20181201,0096-5979 (Print) 0096-5979 (Linking),66,2,1952 Aug,Letterer-Siwe disease.,291-2,"['BREMERS, H H', 'GEORGE, C', 'SUNIT, C', 'MERCER, R D']","['BREMERS HH', 'GEORGE C', 'SUNIT C', 'MERCER RD']",['eng'],['Journal Article'],,United States,AMA Arch Derm Syphilol,A.M.A. archives of dermatology and syphilology,14470040R,"['Familial Letterer-Siwe disease', 'Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', '*Histiocytosis, Langerhans-Cell', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5222:29612:398'],['NLM'],['*RETICULOENDOTHELIOSIS'],1952/08/01 00:00,1952/08/01 00:01,['1952/08/01 00:00'],"['1952/08/01 00:00 [pubmed]', '1952/08/01 00:01 [medline]', '1952/08/01 00:00 [entrez]']",ppublish,AMA Arch Derm Syphilol. 1952 Aug;66(2):291-2.,,,,,,,,,,,,,,
14942522,NLM,MEDLINE,20040215,20181201,,27,94,1951 Dec 22,[On leukosarcomatosis].,3803-6,"['OLMER, J', 'MONGIN, M', 'RABINOVITZ']","['OLMER J', 'MONGIN M', 'RABINOVITZ']",['und'],['Journal Article'],Remarques sur la leucosarcomatose.,France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,,OM,['*Leukemia'],['CLML: 5222:28798:253'],['NLM'],['*LEUKOSARCOMA'],1951/12/22 00:00,1951/12/22 00:01,['1951/12/22 00:00'],"['1951/12/22 00:00 [pubmed]', '1951/12/22 00:01 [medline]', '1951/12/22 00:00 [entrez]']",ppublish,Sem Hop. 1951 Dec 22;27(94):3803-6.,,,,,,,,,,,,,,
14942521,NLM,MEDLINE,20040215,20181201,,27,94,1951 Dec 22,[On the association of leukosis and polycythemia].,3798-3802,"['OLMER, J', 'MONGES, A', 'BOYER, J']","['OLMER J', 'MONGES A', 'BOYER J']",['und'],['Journal Article'],De l'association leucose-polyglobulie.,France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,,OM,"['Humans', '*Leukemia', '*Polycythemia', '*Polycythemia Vera']",['CLML: 5222:28797:251:363'],['NLM'],"['*LEUKEMIA', '*POLYCYTHEMIA VERA']",1951/12/22 00:00,1951/12/22 00:01,['1951/12/22 00:00'],"['1951/12/22 00:00 [pubmed]', '1951/12/22 00:01 [medline]', '1951/12/22 00:00 [entrez]']",ppublish,Sem Hop. 1951 Dec 22;27(94):3798-3802.,,,,,,,,,,,,,,
14942520,NLM,MEDLINE,20040215,20181201,,27,94,1951 Dec 22,"[Retinal manifestations in acute leukoses; clinical, ophthalmologic and anatomical study].",3783-98,"['OLMER, J', 'POURSINES, Y', 'FARNARIER, G']","['OLMER J', 'POURSINES Y', 'FARNARIER G']",['und'],['Journal Article'],"Les manifestations retiniennes des leucoses aigues; etude clinique, ophtalmologique et anatomique.",France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,,OM,"['*Eye', 'Humans', '*Leukemia', '*Ophthalmology', '*Retina']",['CLML: 5222:28796:167:252'],['NLM'],"['*EYE', '*LEUKEMIA/manifestations']",1951/12/22 00:00,1951/12/22 00:01,['1951/12/22 00:00'],"['1951/12/22 00:00 [pubmed]', '1951/12/22 00:01 [medline]', '1951/12/22 00:00 [entrez]']",ppublish,Sem Hop. 1951 Dec 22;27(94):3783-98.,,,,,,,,,,,,,,
14942519,NLM,MEDLINE,20040215,20181201,,27,94,1951 Dec 22,[Attempt at an interpretation of acute leukoses].,3771-82,"['OLMER, J', 'GASCARD, E']","['OLMER J', 'GASCARD E']",['und'],['Journal Article'],Essai d'interpretation des leucoses aigues.,France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,,OM,"['*General Adaptation Syndrome', '*Leukemia']",['CLML: 5222:28795:185:251'],['NLM'],"['*GENERAL ADAPTATION SYNDROME', '*LEUKEMIA']",1951/12/22 00:00,1951/12/22 00:01,['1951/12/22 00:00'],"['1951/12/22 00:00 [pubmed]', '1951/12/22 00:01 [medline]', '1951/12/22 00:00 [entrez]']",ppublish,Sem Hop. 1951 Dec 22;27(94):3771-82.,,,,,,,,,,,,,,
14942475,NLM,MEDLINE,20040215,20181201,,28,14,1952 Feb 22,[Effect of ACTH and cortisone treatment of panmyelophthisis and aleukemic myeloid leukemia].,561-3,"['DE LANDSHEERE, B C', 'BEKAERT, J L', 'LEUSEN, I']","['DE LANDSHEERE BC', 'BEKAERT JL', 'LEUSEN I']",['und'],['Journal Article'],Effets du traitement a l'A.C.T.H. et a la cortisone dans un cas de panmyelophtisie et dans un cas de leucemie myeloide aleucemique.,France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['Adrenocorticotropic Hormone/*therapeutic use', '*Bone Marrow', '*Bone Marrow Diseases', 'Cortisone/*therapeutic use', '*Hematologic Diseases', 'Leukemia/*therapy', '*Leukemia, Myeloid']",['CLML: 5222:28750:8:72:120:252'],['NLM'],"['*ACTH/therapeutic use', '*BONE MARROW/diseases', '*CORTISONE/therapeutic use', '*LEUKEMIA, ALEUKEMIC/therapy']",1952/02/22 00:00,1952/02/22 00:01,['1952/02/22 00:00'],"['1952/02/22 00:00 [pubmed]', '1952/02/22 00:01 [medline]', '1952/02/22 00:00 [entrez]']",ppublish,Sem Hop. 1952 Feb 22;28(14):561-3.,,,,,,,,,,,,,,
14941627,NLM,MEDLINE,20040215,20181201,0031-3890 (Print) 0031-3890 (Linking),60,1-2,1952 Jan-Feb,[Fibrinolysis in children].,27-43,"['GRASSO, E']",['GRASSO E'],['und'],['Journal Article'],Studio sulla fibrinolisi ematica dell'infanzia.,Italy,Pediatria (Napoli),La Pediatria,0401207,['EC 3.4.21.7 (Fibrinolysin)'],OM,"['Bronchopneumonia/*blood', '*Fibrinolysin', '*Fibrinolysis', 'Leukemia/*blood']",['CLML: 5222:27775:81:173:251'],['NLM'],"['*BRONCHOPNEUMONIA/blood in', '*FIBRINOLYSIN', '*LEUKEMIA/blood in']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Pediatria (Napoli). 1952 Jan-Feb;60(1-2):27-43.,,,,,,,,,,,,,,
14940890,NLM,MEDLINE,20040215,20181201,0026-4946 (Print) 0026-4946 (Linking),3,14,1951 Dec 15,[Case of chloroleukemia].,751-2,"['NORDIO, S']",['NORDIO S'],['und'],['Journal Article'],Su di un caso di cloroleucemia.,Italy,Minerva Pediatr,Minerva pediatrica,0400740,,OM,['*Leukemia'],['CLML: 5222:27038:253'],['NLM'],['*LEUKOSARCOMA'],1951/12/15 00:00,1951/12/15 00:01,['1951/12/15 00:00'],"['1951/12/15 00:00 [pubmed]', '1951/12/15 00:01 [medline]', '1951/12/15 00:00 [entrez]']",ppublish,Minerva Pediatr. 1951 Dec 15;3(14):751-2.,,,,,,,,,,,,,,
14940889,NLM,MEDLINE,20040215,20181201,0026-4946 (Print) 0026-4946 (Linking),3,14,1951 Dec 15,[Acute lymphatic leukemia with predominantly thymic localization with invasive characteristics].,750-1,"['CAFFARENA, G']",['CAFFARENA G'],['und'],['Journal Article'],Leucemia linfatica acuta con prevalente localizzazione timica a tendenza invasiva.,Italy,Minerva Pediatr,Minerva pediatrica,0400740,,OM,"['*Acute Disease', 'Humans', '*Leukemia', 'Leukemia, Lymphoid/*pathology']",['CLML: 5222:27037:252'],['NLM'],"['*LEUKEMIA, LYMPHATIC/pathology']",1951/12/15 00:00,1951/12/15 00:01,['1951/12/15 00:00'],"['1951/12/15 00:00 [pubmed]', '1951/12/15 00:01 [medline]', '1951/12/15 00:00 [entrez]']",ppublish,Minerva Pediatr. 1951 Dec 15;3(14):750-1.,,,,,,,,,,,,,,
14940858,NLM,MEDLINE,20040215,20181201,0026-4946 (Print) 0026-4946 (Linking),3,13,1952 Dec 1,[Histochemical research on the cells of acute infantile leukemia].,671-5,"['NEGRI, M', 'PECCHIAI, L']","['NEGRI M', 'PECCHIAI L']",['und'],['Journal Article'],Ricerche istochimiche sulle cellule delle leucemia acuta dell'infanzia.,Italy,Minerva Pediatr,Minerva pediatrica,0400740,,OM,"['*Acute Disease', 'Humans', 'Leukemia/*pathology']",['CLML: 5222:27006:252'],['NLM'],['*LEUKEMIA/pathology'],1952/12/01 00:00,1952/12/01 00:01,['1952/12/01 00:00'],"['1952/12/01 00:00 [pubmed]', '1952/12/01 00:01 [medline]', '1952/12/01 00:00 [entrez]']",ppublish,Minerva Pediatr. 1952 Dec 1;3(13):671-5.,,,,,,,,,,,,,,
14939865,NLM,MEDLINE,20040215,20190612,0140-6736 (Print) 0140-6736 (Linking),2,6726,1952 Jul 26,Alkylamines in the treatment of leukaemia.,161-6,"['GARDIKAS, C', 'WILKINSON, J F']","['GARDIKAS C', 'WILKINSON JF']",['eng'],['Journal Article'],,England,Lancet,"Lancet (London, England)",2985213R,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['Leukemia/*therapy', '*Mechlorethamine', 'Nitrogen Mustard Compounds/*therapeutic use']",['CLML: 5222:26013:252:313'],['NLM'],"['*LEUKEMIA/therapy', '*NITROGEN MUSTARDS/therapeutic use']",1952/07/26 00:00,1952/07/26 00:01,['1952/07/26 00:00'],"['1952/07/26 00:00 [pubmed]', '1952/07/26 00:01 [medline]', '1952/07/26 00:00 [entrez]']",ppublish,Lancet. 1952 Jul 26;2(6726):161-6. doi: 10.1016/s0140-6736(52)91694-2.,"['S0140-6736(52)91694-2 [pii]', '10.1016/s0140-6736(52)91694-2 [doi]']",,,,,,,,,,,,,
14939118,NLM,MEDLINE,20040215,20190630,0022-3476 (Print) 0022-3476 (Linking),41,1,1952 Jul,The treatment of acute leukemia in children.,40-6,"['LEIKIN, S', 'RICE, E C', 'BELL, D F Jr', 'WATERS, R J']","['LEIKIN S', 'RICE EC', 'BELL DF Jr', 'WATERS RJ']",['eng'],['Journal Article'],,United States,J Pediatr,The Journal of pediatrics,0375410,,OM,"['*Acute Disease', 'Child', 'Humans', 'Infant', '*Leukemia']",['CLML: 5222:25266:252'],['NLM'],['*LEUKEMIA/in infant and child'],1952/07/01 00:00,1952/07/01 00:01,['1952/07/01 00:00'],"['1952/07/01 00:00 [pubmed]', '1952/07/01 00:01 [medline]', '1952/07/01 00:00 [entrez]']",ppublish,J Pediatr. 1952 Jul;41(1):40-6. doi: 10.1016/s0022-3476(52)80026-5.,"['S0022-3476(52)80026-5 [pii]', '10.1016/s0022-3476(52)80026-5 [doi]']",,,,,,,,,,,,,
14938996,NLM,MEDLINE,20040215,20181201,0099-9695 (Print) 0099-9695 (Linking),19,1,1952 May-Jun,The relationship of xanthoma juvenile to systemic reticuloendotheliosis.,243-8,"['FREUD, P']",['FREUD P'],['eng'],['Journal Article'],,United States,J Mt Sinai Hosp N Y,"Journal of the Mount Sinai Hospital, New York",0242260,"['Reticuloendotheliosis, X-linked']",OM,"['Child', '*Genetic Diseases, X-Linked', 'Humans', 'Infant', '*Leukemia, Hairy Cell', '*Lipidoses', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency', '*Xanthomatosis']",['CLML: 5222:25144:255:398'],['NLM'],"['*LIPOIDOSIS/in infant and child', '*RETICULOENDOTHELIOSIS']",1952/05/01 00:00,1952/05/01 00:01,['1952/05/01 00:00'],"['1952/05/01 00:00 [pubmed]', '1952/05/01 00:01 [medline]', '1952/05/01 00:00 [entrez]']",ppublish,J Mt Sinai Hosp N Y. 1952 May-Jun;19(1):243-8.,,,,,,,,,,,,,,
14937908,NLM,MEDLINE,20040215,20181201,,4-5,,1951,[Treatment of leukemia with urethane and nitrogen mustards].,9-38,"['CHILOV, K', 'IVANOV, S']","['CHILOV K', 'IVANOV S']",['und'],['Journal Article'],Lechenie na levkemiite s urethan i nitrogen mustard.,Bulgaria,Izv Meditsinskite Inst Bulg Akad Naukite Sofia Otd Biol Meditsinski Nauki,Izvestiia na meditsinskite instituti. [Bulletin des instituts de medecine]. Bulgarska akademiia na naukite. Otdelenie za biologicheski i meditsinski nauki,15751080R,"['0 (Nitrogen Mustard Compounds)', '3IN71E75Z5 (Urethane)', '50D9XSG0VR (Mechlorethamine)']",OM,"['Humans', '*Leukemia', 'Leukemia, Myeloid/*therapy', '*Mechlorethamine', 'Nitrogen Mustard Compounds/*therapeutic use', 'Urethane/*therapeutic use']",['CLML: 5222:24048:252:313:482'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/therapy', '*NITROGEN MUSTARDS/therapeutic use', '*URETHANE/therapeutic use']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Izv Meditsinskite Inst Bulg Akad Naukite Sofia Otd Biol Meditsinski Nauki. 1951;4-5:9-38.,,,,,,,,,,,,,,
14935811,NLM,MEDLINE,20040215,20181201,0366-1334 (Print) 0366-1334 (Linking),68,1-2,1952 Jan 11-18,[A case of reticulosarcomatosis giving the clinical appearance of chloroma].,99-103,"['PICARD, R', 'HOREAU, J', 'KERNEIS, J P', 'CORNIERE, J', 'GUINOT, U']","['PICARD R', 'HOREAU J', 'KERNEIS JP', 'CORNIERE J', 'GUINOT U']",['und'],['Journal Article'],Un cas de reticulosarcomatose evoquant cliniquement le chlorome.,France,Bull Mem Soc Med Hop Paris,Bulletins et memoires de la Societe medicale des hopitaux de Paris,7503472,,OM,"['*Connective Tissue Cells', 'Humans', 'Lymphoma, Large B-Cell, Diffuse/*pathology', 'Lymphoma, Non-Hodgkin/*pathology', '*Neoplasms', '*Sarcoma', '*Sarcoma, Myeloid']",['CLML: 5222:21949:411'],['NLM'],"['*SARCOMA, RETICULUM CELL/pathology']",1952/01/11 00:00,1952/01/11 00:01,['1952/01/11 00:00'],"['1952/01/11 00:00 [pubmed]', '1952/01/11 00:01 [medline]', '1952/01/11 00:00 [entrez]']",ppublish,Bull Mem Soc Med Hop Paris. 1952 Jan 11-18;68(1-2):99-103.,,,,,,,,,,,,,,
14934903,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),27,12,1951 Dec,[Results of various experiments to modify the seasonal variations in the provocability of disease induced in the guinea pig by inoculation of leukemic matter].,1644-5,"['NEGRONI, G', 'TOLU, A']","['NEGRONI G', 'TOLU A']",['und'],['Journal Article'],Risultati ottenuti nei vari tentativi di modificare la variazioni stagionali nella provocabilita della malattia indotta nella cavia con l'inoculazione di materiali leucemici.,Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,,OM,"['Animals', 'Guinea Pigs', '*Leukemia, Experimental', '*Seasons', '*Vaccination']",['CLML: 5222:21041:252'],['NLM'],['*LEUKEMIA/experimental'],1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1951 Dec;27(12):1644-5.,,,,,,,,,,,,,,
14934901,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),27,12,1951 Dec,"[Use of the interference phenomenon for the demonstration of a viral entity in matter derived from leukemia, malignant lymphogranuloma and systemic lymphogranuloma].",1639-41,"['GIORDANO, G']",['GIORDANO G'],['und'],['Journal Article'],"Utilizzazione del fenomeno di interferenza per la rivelazione di entita virali in materiali derivati da leucemie da linfogranuloma maligno, da linfogranuloma sistemico.",Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,,OM,"['*Hodgkin Disease', '*Leukemia']",['CLML: 5222:21039:211:251'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1951 Dec;27(12):1639-41.,,,,,,,,,,,,,,
14934839,NLM,MEDLINE,20040215,20181201,0021-2547 (Print) 0021-2547 (Linking),31,1-2,1952 Jan-Feb,[The presence of a viral factor in leucosis in the dog].,7-22,"['VENDRAMINI, R', 'BRUNI, A', 'MAJORI, L']","['VENDRAMINI R', 'BRUNI A', 'MAJORI L']",['und'],['Journal Article'],Sulla presenza di un fattore virale nella leucosi del cane.,Italy,Boll Ist Sieroter Milan,Bollettino dell'Istituto sieroterapico milanese,17720040R,,OM,"['Animals', 'Dogs', '*Leukemia, Experimental']",['CLML: 5222:20977:252'],['NLM'],['*LEUKEMIA/experimental'],1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Boll Ist Sieroter Milan. 1952 Jan-Feb;31(1-2):7-22.,,,,,,,,,,,,,,
14934773,NLM,MEDLINE,20040215,20181201,0539-6115 (Print) 0539-6115 (Linking),9,1,1952 Feb,[Folic acid antagonists and acute leukemias in children].,19-28,"['SOTO, R']",['SOTO R'],['und'],['Journal Article'],Antifolicos y leucemias agudas infantiles.,Mexico,Bol Med Hosp Infant Mex,Boletin medico del Hospital Infantil de Mexico,0414106,['0 (Folic Acid Antagonists)'],OM,"['*Acute Disease', 'Folic Acid Antagonists/*therapeutic use', 'Hodgkin Disease/*therapy', 'Leukemia/*therapy']",['CLML: 5222:20911:177:211:252'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', ""*HODGKIN'S DISEASE/therapy"", '*LEUKEMIA/therapy']",1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,Bol Med Hosp Infant Mex. 1952 Feb;9(1):19-28.,,,,,,,,,,,,,,
14934762,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),7,8,1952 Aug,"Erythremic myelosis (Dl Guglielmo's disease); critical review with report of four cases, and comments on erythroleukemia.",765-93,"['SCHWARTZ, S O', 'CRITCHLOW, J']","['SCHWARTZ SO', 'CRITCHLOW J']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,,OM,"['Humans', '*Leukemia, Erythroblastic, Acute', '*Polycythemia Vera']",['CLML: 5222:20900:364'],['NLM'],['*POLYCYTHEMIA VERA'],1952/08/01 00:00,1952/08/01 00:01,['1952/08/01 00:00'],"['1952/08/01 00:00 [pubmed]', '1952/08/01 00:01 [medline]', '1952/08/01 00:00 [entrez]']",ppublish,Blood. 1952 Aug;7(8):765-93.,['S0006-4971(20)67995-2 [pii]'],,,,,,,,,,,,,
14934758,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),7,7,1952 Jul,The clinical use of triethylene melamine.,729-42,"['KRAVITZ, S C', 'DIAMOND, H D', 'CRAVER, L F']","['KRAVITZ SC', 'DIAMOND HD', 'CRAVER LF']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,['F7IY6HZG9D (Triethylenemelamine)'],OM,"['Hodgkin Disease/*therapy', '*Leukemia', 'Leukemia, Lymphoid/*therapy', 'Leukemia, Myeloid/*therapy', '*Lymphatic Vessels', 'Triethylenemelamine/*therapeutic use']",['CLML: 5222:20896:212:252:467'],['NLM'],"[""*HODGKIN'S DISEASE/therapy"", '*LEUKEMIA, LYMPHATIC/therapy', '*LEUKEMIA, MYELOCYTIC/therapy', '*TRIETHYLENE MELAMINE/therapeutic use']",1952/07/01 00:00,1952/07/01 00:01,['1952/07/01 00:00'],"['1952/07/01 00:00 [pubmed]', '1952/07/01 00:01 [medline]', '1952/07/01 00:00 [entrez]']",ppublish,Blood. 1952 Jul;7(7):729-42.,['S0006-4971(20)68013-2 [pii]'],,,,,,,,,,,,,
14934128,NLM,MEDLINE,20040215,20181201,,213,5,1951,"[Influence of x-rays, urethane & colchicine on the metabolism of cells of myeloid leukemia].",365-72,"['KEIBL, E', 'SPITZY, K H']","['KEIBL E', 'SPITZY KH']",['und'],['Journal Article'],"Zum Problem des Leukozytenstoffwechsels. II. Einfluss von Rontgenstrahlen, Urethan und Colchizin auf den Stoffwechsel myeloisch-leukamischer Zellen.",Germany,Naunyn Schmiedebergs Arch Exp Pathol Pharmakol,Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie,0054224,"['0 (Antineoplastic Agents)', '3IN71E75Z5 (Urethane)', 'SML2Y3J35T (Colchicine)']",OM,"['*Antineoplastic Agents', 'Colchicine/analogs & derivatives', '*Diploidy', '*Leukemia', '*Leukemia, Myeloid', 'Urethane/*pharmacology', 'X-Rays']",['CLML: 5222:20266:110:252:482'],['NLM'],"['*COLCHICINE/derivatives', '*LEUKEMIA, MYELOCYTIC', '*URETHANE/effects']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1951;213(5):365-72.,,,,,,,,,,,,,,
14933327,NLM,MEDLINE,20040215,20190513,0002-9173 (Print) 0002-9173 (Linking),22,6,1952 Jun,Unusual histiocytic reaction to lymph nodes in Letterer-Siwe disease.,520-34,"['McLETCHIE, N G B']",['McLETCHIE NG'],['eng'],['Journal Article'],,England,Am J Clin Pathol,American journal of clinical pathology,0370470,"['Familial Letterer-Siwe disease', 'Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', '*Histiocytosis, Langerhans-Cell', 'Humans', '*Leukemia, Hairy Cell', 'Lymph Nodes/*pathology', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5222:19456:267:398'],['NLM'],"['*LYMPH NODES/pathology', '*RETICULOENDOTHELIOSIS']",1952/06/01 00:00,1952/06/01 00:01,['1952/06/01 00:00'],"['1952/06/01 00:00 [pubmed]', '1952/06/01 00:01 [medline]', '1952/06/01 00:00 [entrez]']",ppublish,Am J Clin Pathol. 1952 Jun;22(6):520-34. doi: 10.1093/ajcp/22.6.520.,['10.1093/ajcp/22.6.520 [doi]'],,,,,,,,,,,,,
14933197,NLM,MEDLINE,20040215,20190917,0001-6926 (Print) 0001-6926 (Linking),37,3-4,1952 Mar-Apr,The topographical distribution of leukemia and Hodgkin's disease in Denmark 1942-46.,223-30,"['CLEMMESEN, J', 'BUSK, T', 'NIELSEN, A']","['CLEMMESEN J', 'BUSK T', 'NIELSEN A']",['eng'],['Journal Article'],,Sweden,Acta radiol,Acta radiologica,0000221,,OM,"['*Biometry', 'Denmark', 'Hodgkin Disease/*epidemiology/*statistics & numerical data', 'Humans', 'Leukemia/*epidemiology/*statistics & numerical data']",['CLML: 5222:19326:211:252'],['NLM'],"[""*HODGKIN'S DISEASE/epidemiology and statistics"", '*LEUKEMIA/epidemiology and statistics']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Acta radiol. 1952 Mar-Apr;37(3-4):223-30. doi: 10.3109/00016925209139872.,['10.3109/00016925209139872 [doi]'],,,,,,,,,,,,,
14933193,NLM,MEDLINE,20040215,20190917,0001-6926 (Print) 0001-6926 (Linking),37,3-4,1952 Mar-Apr,Leukemic myelomatosis (plasma cell leukemia); a review with report of four cases.,196-207,"['BICHEL, J', 'EFFERSOE, P', 'GORMSEN, H', 'HARBOE, N']","['BICHEL J', 'EFFERSOE P', 'GORMSEN H', 'HARBOE N']",['eng'],['Journal Article'],,Sweden,Acta radiol,Acta radiologica,0000221,,OM,"['Humans', '*Leukemia, Plasma Cell', 'Multiple Myeloma/*pathology', '*Plasma Cells']",['CLML: 5222:19322:294'],['NLM'],"['*MYELOMA, PLASMA CELL/pathology']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Acta radiol. 1952 Mar-Apr;37(3-4):196-207. doi: 10.3109/00016925209139868.,['10.3109/00016925209139868 [doi]'],,,,,,,,,,,,,
14932763,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),7,5,1952 May,Leukemia in old age.,289-94,"['ROSENOW, G']",['ROSENOW G'],['eng'],['Journal Article'],,Switzerland,Acta Haematol,Acta haematologica,0141053,,OM,"['Aged', '*Disease', 'Humans', '*Leukemia']",['CLML: 5222:18892:14:251'],['NLM'],"['*AGED/diseases', '*LEUKEMIA/in aged']",1952/05/01 00:00,1952/05/01 00:01,['1952/05/01 00:00'],"['1952/05/01 00:00 [pubmed]', '1952/05/01 00:01 [medline]', '1952/05/01 00:00 [entrez]']",ppublish,Acta Haematol. 1952 May;7(5):289-94. doi: 10.1159/000204062.,['10.1159/000204062 [doi]'],,,,,,,,,,,,,
14932759,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),7,2,1952 Feb,The biological action and clinical application of folic acid antagonists; review.,117-27,"['DRESNER, E', 'WHITE, J C']","['DRESNER E', 'WHITE JC']",['eng'],['Journal Article'],,Switzerland,Acta Haematol,Acta haematologica,0141053,['0 (Folic Acid Antagonists)'],OM,"['Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5222:18888:177:252'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,Acta Haematol. 1952 Feb;7(2):117-27. doi: 10.1159/000204044.,['10.1159/000204044 [doi]'],,,,,,,,,,,,,
14932539,NLM,MEDLINE,20040215,20190917,0888-2479 (Print) 0888-2479 (Linking),90,1,1952 Jul,Familial chronic lymphatic leukemia.,87-9,"['REILLY, E B', 'RAPAPORT, S I', 'KARR, N W', 'MILLS, H', 'CARPENTER, G E']","['REILLY EB', 'RAPAPORT SI', 'KARR NW', 'MILLS H', 'CARPENTER GE']",['eng'],['Journal Article'],,United States,AMA Arch Intern Med,A.M.A. archives of internal medicine,14470100R,,OM,"['*Heredity', 'Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', 'Leukemia, Lymphoid/*genetics', '*Lymphatic Vessels']",['CLML: 5222:18668:252'],['NLM'],"['*LEUKEMIA, LYMPHATIC/heredity']",1952/07/01 00:00,1952/07/01 00:01,['1952/07/01 00:00'],"['1952/07/01 00:00 [pubmed]', '1952/07/01 00:01 [medline]', '1952/07/01 00:00 [entrez]']",ppublish,AMA Arch Intern Med. 1952 Jul;90(1):87-9. doi: 10.1001/archinte.1952.00240070093009.,['10.1001/archinte.1952.00240070093009 [doi]'],,,,,,,,,,,,,
14932441,NLM,MEDLINE,20040215,20181201,0044-4588 (Print) 0044-4588 (Linking),52,3,1952 Mar,[Evaluation of vascular tonus in electroshock therapy].,27-9,"['CHEKIN, V IA']",['CHEKIN VI'],['und'],['Journal Article'],K otsenke sostoianiia sosudistogo tonusa pri elektroshokovoi terapii.,Russia (Federation),Zh Nevropatol Psikhiatr Im S S Korsakova,"Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)",8710066,,OM,"['*Blood Vessels', '*Convulsive Therapy', '*Electroconvulsive Therapy', '*Leukemia', 'Leukemia, Lymphoid/*metabolism', '*Lymphatic Vessels']",['CLML: 5222:18507:70:252:418'],['NLM'],"['*BLOOD VESSELS', '*LEUKEMIA, LYMPHATIC/metabolism in', '*SHOCK THERAPY']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Zh Nevropatol Psikhiatr Im S S Korsakova. 1952 Mar;52(3):27-9.,,,,,,,,,,,,,,
14932155,NLM,MEDLINE,20040215,20181201,0044-2917 (Print) 0044-2917 (Linking),70,2,1951,[Generalized tuberculosis in childhood with hepatolienal syndrome and myeloid reaction].,148-62,"['HAASE, K E']",['HAASE KE'],['und'],['Journal Article'],Generalisierte Tuberkulose im Kindesalter mit hepato-lienalem Syndrom and myeloischer Reaktion.,Germany,Z Kinderheilkd,Zeitschrift fur Kinderheilkunde,7604363,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Splenomegaly', '*Tuberculosis', '*Tuberculosis, Miliary']",['CLML: 5222:18214:252:430:468'],['NLM'],"['*LEUKEMIA, MYELOCYTIC', '*SELENOMEGALY', '*TUBERCULOSIS']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Z Kinderheilkd. 1951;70(2):148-62.,,,,,,,,,,,,,,
14932036,NLM,MEDLINE,20040215,20181201,0044-2542 (Print) 0044-2542 (Linking),7,2,1952 Jan 15,"[Stilbestrol, aminopterin and aureomycin therapy of leukoses in children].",81-9,"['WEICKER, H', 'SCHREIER, K']","['WEICKER H', 'SCHREIER K']",['und'],['Journal Article'],"Die Leukosen des Kindes unter Stilboestrol, Aminopterin und Aureomycin.",Germany,Z Gesamte Inn Med,Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,21730470R,"['0 (Folic Acid Antagonists)', '731DCA35BT (Diethylstilbestrol)', 'JYB41CTM2Q (Aminopterin)', 'WCK1KIQ23Q (Chlortetracycline)']",OM,"['*Aminopterin', 'Child', 'Chlortetracycline/*therapeutic use', '*Diethylstilbestrol', 'Folic Acid Antagonists/*therapeutic use', 'Humans', 'Infant', '*Leukemia']",['CLML: 5222:18095:48:177:252'],['NLM'],"['*AUREOMYCIN/therapeutic use', '*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/in infant and child']",1952/01/15 00:00,1952/01/15 00:01,['1952/01/15 00:00'],"['1952/01/15 00:00 [pubmed]', '1952/01/15 00:01 [medline]', '1952/01/15 00:00 [entrez]']",ppublish,Z Gesamte Inn Med. 1952 Jan 15;7(2):81-9.,,,,,,,,,,,,,,
14931887,NLM,MEDLINE,20040215,20181201,0042-8450 (Print) 0042-8450 (Linking),9,1-2,1952 Jan-Feb,[Leukemia and hypophysis].,32-7,"['BRANKOVAN, K']",['BRANKOVAN K'],['srp'],['Journal Article'],Leukoze i hipofiza.,Serbia,Vojnosanit Pregl,Vojnosanitetski pregled,21530700R,,OM,"['Humans', 'Leukemia/*pathology', 'Pituitary Gland/*pathology']",['CLML: 5222:17946:252:354'],['NLM'],"['*LEUKEMIA/pathology', '*PITUITARY GLAND/pathology']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Vojnosanit Pregl. 1952 Jan-Feb;9(1-2):32-7.,,,,,,,,,,,,,,
14931538,NLM,MEDLINE,20040215,20181201,,7,4,1952 Apr,Reticulum cell tumour leukaemia; treatment with cortisone.,166-8,"['BRANCH, A', 'MACLELLAN, N', 'GREEN, L']","['BRANCH A', 'MACLELLAN N', 'GREEN L']",['eng'],['Journal Article'],,Canada,Treat Serv Bull,Treatment services bulletin. Canada. Department of Veterans' Affairs,16020690R,['V27W9254FZ (Cortisone)'],OM,"['*Cortisone', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels', '*Neoplasms']",['CLML: 5222:17596:252'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Treat Serv Bull. 1952 Apr;7(4):166-8.,,,,,,,,,,,,,,
14931034,NLM,MEDLINE,20040215,20190702,0038-4348 (Print) 0038-4348 (Linking),45,6,1951 Jun,Pernicious anemia complicated by acute granulocytic leukemia; a case report.,559-61,"['TALLEY, R W', 'DOHERTY, J E', 'SHUKERS, C F']","['TALLEY RW', 'DOHERTY JE', 'SHUKERS CF']",['eng'],['Journal Article'],,United States,South Med J,Southern medical journal,0404522,,OM,"['*Anemia', 'Anemia, Pernicious/*complications', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Myeloid, Acute']",['CLML: 5222:17092:27:252'],['NLM'],"['*ANEMIA, PERNICIOUS/complications', '*LEUKEMIA, MYELOCYTIC']",1951/06/01 00:00,1951/06/01 00:01,['1951/06/01 00:00'],"['1951/06/01 00:00 [pubmed]', '1951/06/01 00:01 [medline]', '1951/06/01 00:00 [entrez]']",ppublish,South Med J. 1951 Jun;45(6):559-61. doi: 10.1097/00007611-195206000-00018.,['10.1097/00007611-195206000-00018 [doi]'],,,,,,,,,,,,,
14930938,NLM,MEDLINE,20040215,20181201,0370-9590 (Print) 0370-9590 (Linking),27,78,1951 Dec 26,[A case of chronic lymphoid leukosis; transformation into acute leukosis with osteoarticular manifestations].,1093-6,"['LAURENT, F']",['LAURENT F'],['und'],['Journal Article'],Sur un cas de leucose lymphoidique chronique; transformation en leucose aigue avec apparition de manifestations osteo-articulaires.,Argentina,Sem Med,La Semana medica,0404403,,OM,"['Animals', '*Avian Leukosis', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5222:16996:252'],['NLM'],"['*LEUKEMIA, LYMPHATIC/manifestations']",1951/12/26 00:00,1951/12/26 00:01,['1951/12/26 00:00'],"['1951/12/26 00:00 [pubmed]', '1951/12/26 00:01 [medline]', '1951/12/26 00:00 [entrez]']",ppublish,Sem Med. 1951 Dec 26;27(78):1093-6.,,,,,,,,,,,,,,
14930894,NLM,MEDLINE,20040215,20181201,,28,8,1952 Jan 30,"[Hemolytic jaundice in malignant diseases (leukemias, malignant granulomatoses, cancer)].",290-308,"['PARAF, A', 'DAUSSET, J']","['PARAF A', 'DAUSSET J']",['und'],['Journal Article'],"Les icteres hemolytiques au cours des affections malignes (leucemies, granulomatose maligne, cancers).",France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,,OM,"['*Anemia', '*Anemia, Hemolytic', 'Humans', '*Jaundice', '*Leukemia', 'Neoplasms/*complications']",['CLML: 5222:16952:25:299'],['NLM'],"['*ANEMIA, HEMOLYTIC', '*NEOPLASMS/complications']",1952/01/30 00:00,1952/01/30 00:01,['1952/01/30 00:00'],"['1952/01/30 00:00 [pubmed]', '1952/01/30 00:01 [medline]', '1952/01/30 00:00 [entrez]']",ppublish,Sem Hop. 1952 Jan 30;28(8):290-308.,,,,,,,,,,,,,,
14930118,NLM,MEDLINE,20040215,20181201,0033-2240 (Print) 0033-2240 (Linking),8,1,1952,[Pathogenesis of leukemia in the light of the Krakow authors and own observations].,12-7,"['KIRCHMAYER, S', 'BROMOWICZOWA, K']","['KIRCHMAYER S', 'BROMOWICZOWA K']",['und'],['Journal Article'],Zagadnienie patogenezy bialaczek w oswietleniu badan autorow krakowskich i wlasnych obserwacji.,Poland,Przegl Lek,Przeglad lekarski,19840720R,,OM,"['Humans', 'Leukemia/*etiology']",['CLML: 5222:16111:252'],['NLM'],['*LEUKEMIA/etiology and pathogenesis'],1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Przegl Lek. 1952;8(1):12-7.,,,,,,,,,,,,,,
14930027,NLM,MEDLINE,20040215,20181201,0091-746X (Print) 0091-746X (Linking),19,5,1952 May 15,Recent experimental studies and current concepts on the etiology and nature of leukemia.,95-104,"['FURTH, J']",['FURTH J'],['eng'],['Journal Article'],,United States,Proc Inst Med Chic,The Proceedings of the Institute of Medicine of Chicago,7505869,,OM,"['Animals', '*Leukemia', '*Leukemia, Experimental']",['CLML: 5222:16020:252'],['NLM'],['*LEUKEMIA/experimental'],1952/05/15 00:00,1952/05/15 00:01,['1952/05/15 00:00'],"['1952/05/15 00:00 [pubmed]', '1952/05/15 00:01 [medline]', '1952/05/15 00:00 [entrez]']",ppublish,Proc Inst Med Chic. 1952 May 15;19(5):95-104.,,,,,,,,,,,,,,
14929505,NLM,MEDLINE,20040215,20181201,,29,,1951,"[Atypical leukemias, reticuloendotheliosis and neoplasms of the reticuloendothelial system; limits and relations].",1-137,"['MICHELAZZI, A M']",['MICHELAZZI AM'],['und'],['Journal Article'],Leucemie atipiche; reticoloendoteliosi neoplasie del s.r.e; limiti e rapporti.,Italy,Omnia Med,Omnia medica,0212412,"['Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', '*Leukemia', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Mononuclear Phagocyte System', '*Neoplasms', '*Severe Combined Immunodeficiency']",['CLML: 5222:15498:251:398'],['NLM'],"['*LEUKEMIA', '*RETICULOENDOTHELIAL SYSTEM/neoplasms', '*RETICULOENDOTHELIOSIS']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Omnia Med. 1951;29:1-137.,,,,,,,,,,,,,,
14929275,NLM,MEDLINE,20040215,20181201,0028-1956 (Print) 0028-1956 (Linking),37,4,1952 Apr,Leukemia cases at the University of Nebraska hospital.,95-9,"['RUBNITZ, A S']",['RUBNITZ AS'],['eng'],['Journal Article'],,United States,Nebr State Med J,The Nebraska state medical journal,0326157,,OM,"['*Biometry', '*Hospitals', 'Humans', 'Leukemia/*epidemiology/*statistics & numerical data']",['CLML: 5222:15268:252'],['NLM'],['*LEUKEMIA/epidemiology and statistics'],1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Nebr State Med J. 1952 Apr;37(4):95-9.,,,,,,,,,,,,,,
14929259,NLM,MEDLINE,20040215,20190618,0028-0836 (Print) 0028-0836 (Linking),169,4302,1952 Apr 12,Origin of the resistance of leukaemic cells to folic acid antagonists.,628-9,"['LAW, L W']",['LAW LW'],['eng'],['Journal Article'],,England,Nature,Nature,0410462,['0 (Folic Acid Antagonists)'],OM,"['Animals', '*Biochemical Phenomena', '*Folic Acid Antagonists', '*Leukemia, Experimental']",['CLML: 5222:15252:176:252'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA/experimental']",1952/04/12 00:00,1952/04/12 00:01,['1952/04/12 00:00'],"['1952/04/12 00:00 [pubmed]', '1952/04/12 00:01 [medline]', '1952/04/12 00:00 [entrez]']",ppublish,Nature. 1952 Apr 12;169(4302):628-9. doi: 10.1038/169628a0.,['10.1038/169628a0 [doi]'],,,,,,,,,,,,,
14928995,NLM,MEDLINE,20040215,20181201,,32,646,1952 Feb 25,"[Leukemia, control of blood cancer].",Suppl 25-7,,,['und'],['Journal Article'],"LA leucemia, cancer de la sangre esta siendo combatida.",Mexico,Rev Asoc Medica Mex,Revista. Asociacion Medica Mexicana,0002552,,OM,"['*Hematologic Neoplasms', 'Humans', 'Leukemia/*therapy']",['CLML: 5222:14983:252'],['NLM'],['*LEUKEMIA/therapy'],1952/02/25 00:00,1952/02/25 00:01,['1952/02/25 00:00'],"['1952/02/25 00:00 [pubmed]', '1952/02/25 00:01 [medline]', '1952/02/25 00:00 [entrez]']",ppublish,Rev Asoc Medica Mex. 1952 Feb 25;32(646):Suppl 25-7.,,,,,,,,,,,,,,
14928453,NLM,MEDLINE,20040215,20181201,0023-2149 (Print) 0023-2149 (Linking),30,4,1952 Apr,[Erythroleukemia (erythroleukomyelosis)].,86,"['CHEKULAEV, G N']",['CHEKULAEV GN'],['und'],['Journal Article'],Ob eritroleikemii (eritroleikomieloze).,Russia (Federation),Klin Med (Mosk),Klinicheskaia meditsina,2985204R,,OM,"['Aged', 'Humans', '*Leukemia, Erythroblastic, Acute', '*Polycythemia']",['CLML: 5222:14441:363'],['NLM'],['*POLYCYTHEMIA'],1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Klin Med (Mosk). 1952 Apr;30(4):86.,,,,,,,,,,,,,,
14928452,NLM,MEDLINE,20040215,20181201,0023-2149 (Print) 0023-2149 (Linking),30,4,1952 Apr,[Association of leukemias and malignant neoplasms].,85,"['CHEKULAEV, G N']",['CHEKULAEV GN'],['und'],['Journal Article'],K voprosu o sochetanni leikemii i zlokachestvennykh novoobrazovanii.,Russia (Federation),Klin Med (Mosk),Klinicheskaia meditsina,2985204R,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lung Neoplasms', '*Neoplasms']",['CLML: 5222:14440:252:264'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*LUNGS/neoplasms']",1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Klin Med (Mosk). 1952 Apr;30(4):85.,,,,,,,,,,,,,,
14928451,NLM,MEDLINE,20040215,20181201,0023-2149 (Print) 0023-2149 (Linking),30,4,1952 Apr,[Case of acute hemocytoblastoma].,85,"['DASHTAIANTS, G A', 'DAGAEV, A L']","['DASHTAIANTS GA', 'DAGAEV AL']",['und'],['Journal Article'],Ob odnom sluchae ostroi gemotsitoblastomy.,Russia (Federation),Klin Med (Mosk),Klinicheskaia meditsina,2985204R,,OM,['*Leukemia'],['CLML: 5222:14439:253'],['NLM'],['*LEUKOSARCOMA'],1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Klin Med (Mosk). 1952 Apr;30(4):85.,,,,,,,,,,,,,,
14928058,NLM,MEDLINE,20040215,20181201,0027-8874 (Print) 0027-8874 (Linking),12,5,1952 Apr,The flexed-tail-anemia gene (f) and induced leukemia in mice.,1119-26,"['LAW, L W']",['LAW LW'],['eng'],['Journal Article'],,United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,,OM,"['*Anemia', 'Animals', '*Leukemia', '*Leukemia, Experimental', 'Mice']",['CLML: 5222:14046:252'],['NLM'],['*LEUKEMIA/experimental'],1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,J Natl Cancer Inst. 1952 Apr;12(5):1119-26.,,,,,,,,,,,,,,
14927931,NLM,MEDLINE,20040215,20181201,0096-557X (Print) 0096-557X (Linking),17,4,1952 Apr,Acute myelogenous leukemia simulating acute appendicitis.,445-8,"['CHAREST, L R', 'HOLT, C L']","['CHAREST LR', 'HOLT CL']",['eng'],['Journal Article'],,United States,J Int Coll Surg,The Journal of the International College of Surgeons,7507208,,OM,"['*Acute Disease', '*Appendicitis', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Myeloid, Acute']",['CLML: 5222:13919:252'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/manifestations']",1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,J Int Coll Surg. 1952 Apr;17(4):445-8.,,,,,,,,,,,,,,
14927167,NLM,MEDLINE,20040215,20181201,0018-5469 (Print) 0018-5469 (Linking),41,1,1952 Jan,[Chronic myeloid leukemia. II. Clinical therapeutic study in the light of modern knowledge].,53-78,"['FONSECA, A DE S', 'DA COSTA, P D', 'DE CASTRO, A']","['FONSECA Ade S', 'DA COSTA PD', 'DE CASTRO A']",['und'],['Journal Article'],Leucemia mieloide cronica. II. Estudo clinico terapeutico a luz das modernas aquisicoes.,Brazil,Hospital (Rio J),"Hospital (Rio de Janeiro, Brazil)",9427238,,OM,"['Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'Leukemia, Myeloid/*diagnosis', '*Light']",['CLML: 5222:13155:252'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/diagnosis']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Hospital (Rio J). 1952 Jan;41(1):53-78.,,,,,,,,,,,,,,
14926098,NLM,MEDLINE,20040215,20181201,,13,3-4,1951 Jul 21-28,[Comparative statistical evaluation of malignant tumor and leukemia mortality].,74-83,"['DE RITIS, F', 'ZACCO, M']","['DE RITIS F', 'ZACCO M']",['und'],['Journal Article'],Valutazione statistica comparativa della mortalita per tumori mallgni e leucemie.,Italy,Clin Nuova Rass Prog Med Int,Clinica nuova; rassegna del progresso medico internazionale,16230300R,,OM,"['*Biometry', 'Leukemia/*epidemiology/*statistics & numerical data', 'Neoplasms/*epidemiology/*statistics & numerical data']",['CLML: 5222:12086:252:300'],['NLM'],"['*LEUKEMIA/epidemiology and statistics', '*NEOPLASMS/epidemiology and statistics']",1951/07/21 00:00,1951/07/21 00:01,['1951/07/21 00:00'],"['1951/07/21 00:00 [pubmed]', '1951/07/21 00:01 [medline]', '1951/07/21 00:00 [entrez]']",ppublish,Clin Nuova Rass Prog Med Int. 1951 Jul 21-28;13(3-4):74-83.,,,,,,,,,,,,,,
14926005,NLM,MEDLINE,20040215,20191007,1002-0187 (Print) 1002-0187 (Linking),69,7-8,1951 Jul-Aug,Chloroma; report of a case.,320-33,"['MA, A C', 'DENG, Y L', 'LIU, S']","['MA AC', 'DENG YL', 'LIU S']",['eng'],['Journal Article'],,China,Chin Med J,"Chinese medical journal (Peking, China : 1932)",0005256,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Sarcoma, Myeloid']",['CLML: 5222:11993:252:253'],['NLM'],"['*LEUKEMIA, MYELOCYTIC', '*LEUKOSARCOMA']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Chin Med J. 1951 Jul-Aug;69(7-8):320-33.,,,,,,,,,,,,,,
14925948,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),12,5,1952 May,An ultracentrifugal analysis of the macromolecular particles of normal and leukemic mouse spleen.,373-8,"['PETERMANN, M L', 'HAMILTON, M G']","['PETERMANN ML', 'HAMILTON MG']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,['0 (Nucleoproteins)'],OM,"['Animals', 'Leukemia/*pathology', 'Mice', '*Nucleoproteins', 'Spleen/*metabolism']",['CLML: 5222:11936:252:315:429'],['NLM'],"['*LEUKEMIA/pathology', '*NUCLEOPROTEINS', '*SPLEEN/metabolism']",1952/05/01 00:00,1952/05/01 00:01,['1952/05/01 00:00'],"['1952/05/01 00:00 [pubmed]', '1952/05/01 00:01 [medline]', '1952/05/01 00:00 [entrez]']",ppublish,Cancer Res. 1952 May;12(5):373-8.,,,,,,,,,,,,,,
14925947,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),12,5,1952 May,The failure of C14-formate to affect the course of mouse leukemia.,371-2,"['SKIPPER, H E', 'BELL, M', 'CHAPMAN, J B']","['SKIPPER HE', 'BELL M', 'CHAPMAN JB']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,"['0 (Carbon Radioisotopes)', '0 (Formates)', '0YIW783RG1 (formic acid)', '7440-44-0 (Carbon)']",OM,"['Animals', '*Carbon', 'Carbon Radioisotopes/*pharmacology', '*Formates', '*Leukemia', '*Leukemia, Experimental']",['CLML: 5222:11935:86:252'],['NLM'],"['*CARBON, RADIOACTIVE/effects', '*LEUKEMIA/experimental']",1952/05/01 00:00,1952/05/01 00:01,['1952/05/01 00:00'],"['1952/05/01 00:00 [pubmed]', '1952/05/01 00:01 [medline]', '1952/05/01 00:00 [entrez]']",ppublish,Cancer Res. 1952 May;12(5):371-2.,,,,,,,,,,,,,,
14925941,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),12,5,1952 May,"An inhibitor of desoxyribonuclease in human white blood and bone marrow cells, and its relationship to cellular maturity.",346-9,"['HENSTELL, H H', 'FREEDMAN, R I', 'GINSBURG, B']","['HENSTELL HH', 'FREEDMAN RI', 'GINSBURG B']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,"['63231-63-0 (RNA)', '9007-49-2 (DNA)', 'EC 3.1.- (Deoxyribonucleases)']",OM,"['Aged', '*Bone Marrow', '*Bone Marrow Cells', '*DNA', '*Deoxyribonucleases', 'Humans', 'Leukemia/*pathology', '*Leukocytes', '*RNA']",['CLML: 5222:11929:72:252:253:314'],['NLM'],"['*BONE MARROW/in aged', '*LEUKEMIA/pathology', '*LEUKOCYTES', '*NUCLEASES']",1952/05/01 00:00,1952/05/01 00:01,['1952/05/01 00:00'],"['1952/05/01 00:00 [pubmed]', '1952/05/01 00:01 [medline]', '1952/05/01 00:00 [entrez]']",ppublish,Cancer Res. 1952 May;12(5):346-9.,,,,,,,,,,,,,,
14925934,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),5,3,1952 May,Delayed effects of inoculation of Ak-leukemic cells in mice of the C3H line; a working hypothesis on the etiology of mouse leukemia.,620-4,"['GROSS, L']",['GROSS L'],['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,,OM,"['Animals', '*Leukemia', '*Leukemia, Experimental', 'Mice', 'Mice, Inbred C3H', '*Vaccination']",['CLML: 5222:11922:252'],['NLM'],['*LEUKEMIA/experimental'],1952/05/01 00:00,1952/05/01 00:01,['1952/05/01 00:00'],"['1952/05/01 00:00 [pubmed]', '1952/05/01 00:01 [medline]', '1952/05/01 00:00 [entrez]']",ppublish,Cancer. 1952 May;5(3):620-4. doi: 10.1002/1097-0142(195205)5:3<620::aid-cncr2820050326>3.0.co;2-3.,['10.1002/1097-0142(195205)5:3<620::aid-cncr2820050326>3.0.co;2-3 [doi]'],,,,,,,,,,,,,
14925920,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),5,3,1952 May,A case of acute plasma-cell leukemia supporting the concept of unity of plasmacellular neoplasia.,514-20,"['NEWMAN, W', 'DIEFENBACH, W C L', 'QUINN, M', 'MEYER, L M']","['NEWMAN W', 'DIEFENBACH WC', 'QUINN M', 'MEYER LM']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Plasma Cell', '*Monocytes']",['CLML: 5222:11908:252'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1952/05/01 00:00,1952/05/01 00:01,['1952/05/01 00:00'],"['1952/05/01 00:00 [pubmed]', '1952/05/01 00:01 [medline]', '1952/05/01 00:00 [entrez]']",ppublish,Cancer. 1952 May;5(3):514-20. doi: 10.1002/1097-0142(195205)5:3<514::aid-cncr2820050311>3.0.co;2-b.,['10.1002/1097-0142(195205)5:3<514::aid-cncr2820050311>3.0.co;2-b [doi]'],,,,,,,,,,,,,
14925750,NLM,MEDLINE,20040215,20181201,,58,5,1951 Nov-Dec,"[Malignant histio-monocytic reticulosis; ulcerous cutaneous forms, terminal monocytemia].",544-7,"['MARGAROT, J', 'RIMBAUD, P', 'CAZAL, P', 'IZARN, P']","['MARGAROT J', 'RIMBAUD P', 'CAZAL P', 'IZARN P']",['und'],['Journal Article'],"Reticulose histio-monocytaire maligne; forme cutanee ulcereuse, monocytemie terminale.",France,Bull Soc Fr Dermatol Syphiligr,Bulletin de la Societe francaise de dermatologie et de syphiligraphie,7503407,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Lymphoma, Extranodal NK-T-Cell', '*Skin Ulcer']",['CLML: 5222:11738:252'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Bull Soc Fr Dermatol Syphiligr. 1951 Nov-Dec;58(5):544-7.,,,,,,,,,,,,,,
14925743,NLM,MEDLINE,20040215,20181201,,58,5,1951 Nov-Dec,[Erythrodermic and ulcerative forms of malignant histiocytary reticulosis].,537-8,"['DEGOS, R', 'RABUT, R', 'GARNIER, G', 'HEWITT, J', 'LEPERCQ, G']","['DEGOS R', 'RABUT R', 'GARNIER G', 'HEWITT J', 'LEPERCQ G']",['und'],['Journal Article'],Reticulose histiocytaire maligne a forme erythrodermique et ulcereuse.,France,Bull Soc Fr Dermatol Syphiligr,Bulletin de la Societe francaise de dermatologie et de syphiligraphie,7503407,,OM,"['*Histiocytic Sarcoma', '*Leukemia', '*Leukemia, Myeloid', '*Lymphoma, Extranodal NK-T-Cell']",['CLML: 5222:11731:252'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Bull Soc Fr Dermatol Syphiligr. 1951 Nov-Dec;58(5):537-8.,,,,,,,,,,,,,,
14925240,NLM,MEDLINE,20040215,20181201,0006-9248 (Print) 0006-9248 (Linking),31,9-10,1951,[Case of Letterer-Siwe disease].,870-3,"['SIRACKY, J']",['SIRACKY J'],['und'],['Journal Article'],Pripad choroby Letterer-Siwe.,Slovakia,Bratisl Lek Listy,Bratislavske lekarske listy,0065324,"['Familial Letterer-Siwe disease', 'Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', '*Histiocytosis, Langerhans-Cell', 'Humans', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5222:11228:398'],['NLM'],['*RETICULOENDOTHELIOSIS'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Bratisl Lek Listy. 1951;31(9-10):870-3.,,,,,,,,,,,,,,
14925156,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),7,6,1952 Jun,Transfer of myelogenous leukemia induced by gastric instillation of methylcholanthrene in Wistar rats.,613-22,"['SHAY, H', 'GRUENSTEIN, M', 'HARRIS, C', 'GLAZER, L']","['SHAY H', 'GRUENSTEIN M', 'HARRIS C', 'GLAZER L']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,['56-49-5 (Methylcholanthrene)'],OM,"['Animals', '*Leukemia', '*Leukemia, Myeloid', 'Methylcholanthrene/*pharmacology', 'Rats', 'Rats, Wistar', '*Stomach']",['CLML: 5222:11144:252:282'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/experimental', '*METHYLCHOLANTHRENE/effects']",1952/06/01 00:00,1952/06/01 00:01,['1952/06/01 00:00'],"['1952/06/01 00:00 [pubmed]', '1952/06/01 00:01 [medline]', '1952/06/01 00:00 [entrez]']",ppublish,Blood. 1952 Jun;7(6):613-22.,['S0006-4971(20)68118-6 [pii]'],,,,,,,,,,,,,
14925143,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),7,5,1952 May,Triethylene melamine in the treatment of neoplastic disease.,483-507,"['RUNDLES, R W', 'BARTON, W B']","['RUNDLES RW', 'BARTON WB']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,['F7IY6HZG9D (Triethylenemelamine)'],OM,"['Hodgkin Disease/*therapy', '*Leukemia', 'Leukemia, Lymphoid/*therapy', '*Lymphatic Vessels', '*Neoplasms', 'Triethylenemelamine/*therapeutic use']",['CLML: 5222:11131:212:252:467'],['NLM'],"[""*HODGKIN'S DISEASE/therapy"", '*LEUKEMIA, LYMPHATIC/therapy', '*TRIETHYLENE MELAMINE/therapeutic use']",1952/05/01 00:00,1952/05/01 00:01,['1952/05/01 00:00'],"['1952/05/01 00:00 [pubmed]', '1952/05/01 00:01 [medline]', '1952/05/01 00:00 [entrez]']",ppublish,Blood. 1952 May;7(5):483-507.,['S0006-4971(20)68128-9 [pii]'],,,,,,,,,,,,,
14924903,NLM,MEDLINE,20040215,20181201,0004-0061 (Print) 0004-0061 (Linking),17,2,1951 Nov,"[Rare gastric pathology: neurinoma, reticulosarcoma, primary lymphogranuloma, leukosis infiltration associated with peptic ulcer, multiple gastric ulcers in acute erythremic myelosis].",553-83,"['SMORLESI, L']",['SMORLESI L'],['und'],['Journal Article'],"Rara patologia gastrica; neurinoma, reticolosarcoma, linfogranuloma primitivo, infiltrazione leucosica associata ad ulcera peptica, ulcere gastriche multiple in mielosi acuta eritremica.",Italy,Arch De Vecchi Anat Patol,"Archivio ""de Vecchi"" per l'anatomia patologica e la medicina clinica",0372455,['Acute erythroleukemia'],OM,"['Humans', '*Leukemia, Erythroblastic, Acute', '*Lymphoma, Non-Hodgkin', '*Neurilemmoma', 'Otitis Media/*complications', 'Peptic Ulcer/*complications', '*Stomach Neoplasms', '*Stomach Ulcer']",['CLML: 5222:10891:322:339:436'],['NLM'],"['*OTITIS MEDIA/complications', '*PEPTIC ULCER/complications', '*STOMACH/neoplasms']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Arch De Vecchi Anat Patol. 1951 Nov;17(2):553-83.,,,,,,,,,,,,,,
14924893,NLM,MEDLINE,20040215,20181201,0004-0061 (Print) 0004-0061 (Linking),17,2,1951 Nov,[Blood serum as the cell liberation factor in normal hemopoiesis and leukemia].,329-58,"['COSTA, A', 'CIPRIANI, P L']","['COSTA A', 'CIPRIANI PL']",['und'],['Journal Article'],"E il siero sanguigno che costituisce il fattore della ""Zellausschwemmung"" nella emopoiesi normale e in quella leucemica.",Italy,Arch De Vecchi Anat Patol,"Archivio ""de Vecchi"" per l'anatomia patologica e la medicina clinica",0372455,,OM,"['*Hematopoiesis', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Serum']",['CLML: 5222:10881:205:252'],['NLM'],"['*HEMOPOIESIS', '*LEUKEMIA, MYELOCYTIC']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Arch De Vecchi Anat Patol. 1951 Nov;17(2):329-58.,,,,,,,,,,,,,,
14924864,NLM,MEDLINE,20040215,20181201,0004-010X (Print) 0004-010X (Linking),3,5,1951 Sep-Oct,[Variability of clinical picture of acute leukemia; pathogenic importance of insufficiency of the bone marrow; clinical study].,258-79,"['DOTTI, F', 'BONORA, G']","['DOTTI F', 'BONORA G']",['und'],['Journal Article'],Variabilita di quadri clinici della leucemia acuta; importanza patogenetica dell' insufficienza midollare; contributo clinico.,Italy,Arch Med Interna,Archivio di medicina interna,0421741,,OM,"['*Acute Disease', '*Biomedical Research', 'Bone Marrow/*pathology', 'Humans', 'Leukemia/*pathology']",['CLML: 5222:10852:72:252'],['NLM'],"['*BONE MARROW/pathology', '*LEUKEMIA/pathology']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Arch Med Interna. 1951 Sep-Oct;3(5):258-79.,,,,,,,,,,,,,,
14924488,NLM,MEDLINE,20040215,20190619,0003-4819 (Print) 0003-4819 (Linking),36,6,1952 Jun,Eosinophilic leukemia: report of a case with autopsy.,1541-7,"['HYMAN, H L', 'JARROLD, T']","['HYMAN HL', 'JARROLD T']",['eng'],['Journal Article'],,United States,Ann Intern Med,Annals of internal medicine,0372351,,OM,"['*Autopsy', '*Eosinophilia', 'Humans', '*Hypereosinophilic Syndrome', '*Leukemia']",['CLML: 5222:10468:156:251'],['NLM'],"['*EOSINOPHILIA', '*LEUKEMIA']",1952/06/01 00:00,1952/06/01 00:01,['1952/06/01 00:00'],"['1952/06/01 00:00 [pubmed]', '1952/06/01 00:01 [medline]', '1952/06/01 00:00 [entrez]']",ppublish,Ann Intern Med. 1952 Jun;36(6):1541-7. doi: 10.7326/0003-4819-36-6-1541.,['10.7326/0003-4819-36-6-1541 [doi]'],,,,,,,,,,,,,
14924122,NLM,MEDLINE,20040215,20181201,0002-9645 (Print) 0002-9645 (Linking),13,46,1952 Jan,Studies in avian leukosis. VI. Serial passage of highly malignant strain of visceral lymphomatosis in young chickens.,105-7,"['DAVIS, O S']",['DAVIS OS'],['eng'],['Journal Article'],,United States,Am J Vet Res,American journal of veterinary research,0375011,,OM,"['Animals', '*Avian Leukosis', '*Chickens', '*Disease', '*Meat', '*Poultry', '*Serial Passage']",['CLML: 5222:10102:178'],['NLM'],"['*FOWLS, DOMESTIC/diseases']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Am J Vet Res. 1952 Jan;13(46):105-7.,,,,,,,,,,,,,,
14923335,NLM,MEDLINE,20040215,20181201,0365-5555 (Print) 0365-5555 (Linking),29,4,1951,A transplantable plasma cell leukemia in mice preliminary report.,465-7,"['BICHEL, J']",['BICHEL J'],['eng'],['Journal Article'],,Denmark,Acta Pathol Microbiol Scand,Acta pathologica et microbiologica Scandinavica,7508471,,OM,"['Animals', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Plasma Cell', 'Mice', '*Monocytes', '*Neoplasms, Experimental', '*Transplants']",['CLML: 5222:9315:252:301'],['NLM'],"['*LEUKEMIA, MONOCYTIC/experimental', '*NEOPLASMS/experimental']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Pathol Microbiol Scand. 1951;29(4):465-7.,,,,,,,,,,,,,,
14923316,NLM,MEDLINE,20040215,20181201,0001-6535 (Print) 0001-6535 (Linking),6,1,1952,[Acute and chronic leukosis in childhood and adolescence].,5-52,"['MAURICE, P']",['MAURICE P'],['und'],['Journal Article'],Les leucoses aigues et chroniques de l'enfance et de l'adolescence.,Belgium,Acta Paediatr Belg,Acta paediatrica Belgica,0372635,,OM,['Leukemia/*therapy'],['CLML: 5222:9296:252'],['NLM'],['*LEUKEMIA/therapy'],1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Acta Paediatr Belg. 1952;6(1):5-52.,,,,,,,,,,,,,,
14923266,NLM,MEDLINE,20040215,20190812,0001-6101 (Print) 0001-6101 (Linking),141,6,1952 Feb 14,Monocytic leukemia with erythroblastosis.,451-7,"['HOEL, J']",['HOEL J'],['eng'],['Journal Article'],,Sweden,Acta Med Scand,Acta medica Scandinavica,0370330,,OM,"['*Hematologic Diseases', 'Humans', '*Leukemia', '*Leukemia, Monocytic, Acute', 'Leukemia, Myeloid/*complications']",['CLML: 5222:9246:252'],['NLM'],"['*LEUKEMIA, MONOCYTIC/complications']",1952/02/14 00:00,1952/02/14 00:01,['1952/02/14 00:00'],"['1952/02/14 00:00 [pubmed]', '1952/02/14 00:01 [medline]', '1952/02/14 00:00 [entrez]']",ppublish,Acta Med Scand. 1952 Feb 14;141(6):451-7. doi: 10.1111/j.0954-6820.1952.tb14235.x.,['10.1111/j.0954-6820.1952.tb14235.x [doi]'],,,,,,,,,,,,,
14923223,NLM,MEDLINE,20040215,20181201,0001-5660 (Print) 0001-5660 (Linking),1,2,1952 May,[The genetic problem of leukemia].,191-211,"['MORGANTI, G', 'CRESSERI, A']","['MORGANTI G', 'CRESSERI A']",['und'],['Journal Article'],Sul problema genetico delle leucemie.,Italy,Acta Genet Med Gemellol (Roma),Acta geneticae medicae et gemellologiae,0370314,,OM,"['*Heredity', 'Humans', 'Leukemia/*genetics']",['CLML: 5222:9203:252'],['NLM'],['*LEUKEMIA/heredity'],1952/05/01 00:00,1952/05/01 00:01,['1952/05/01 00:00'],"['1952/05/01 00:00 [pubmed]', '1952/05/01 00:01 [medline]', '1952/05/01 00:00 [entrez]']",ppublish,Acta Genet Med Gemellol (Roma). 1952 May;1(2):191-211.,,,,,,,,,,,,,,
14923186,NLM,MEDLINE,20040215,20190911,1784-3286 (Print) 1784-3286 (Linking),7,1,1952 Jan-Feb,[A case of reticulo-endotheliosis of the skin and lymph nodes improved by methyl-bis-beta-chloroethylamine hydrochloride].,81-7,"['CALLEBAUT, C M', 'ENDERLE, J']","['CALLEBAUT CM', 'ENDERLE J']",['und'],['Journal Article'],Un cas de reticulo-endotheliose cutanee et ganglionnaire ameliore par le chlorhydrate de methyl-bis-beta-chlorethylamine.,England,Acta Clin Belg,Acta clinica Belgica,0370306,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)', 'Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', 'Humans', 'Leukemia, Hairy Cell/*therapy', '*Lymph Nodes', 'Lymphatic Diseases/*therapy', '*Mechlorethamine', 'Nitrogen Mustard Compounds/*therapeutic use', '*Severe Combined Immunodeficiency']",['CLML: 5222:9166:313:398'],['NLM'],"['*NITROGEN MUSTARDS/therapeutic use', '*RETICULOENDOTHELIOSIS/therapy']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Acta Clin Belg. 1952 Jan-Feb;7(1):81-7. doi: 10.1080/17843286.1952.11717201.,['10.1080/17843286.1952.11717201 [doi]'],,,,,,,,,,,,,
14923071,NLM,MEDLINE,20040215,20181201,0096-6711 (Print) 0096-6711 (Linking),53,6,1952 Jun,Subleukemic plasma cell leukemia.,593-600,"['MAJERANOWSKI, J F']",['MAJERANOWSKI JF'],['eng'],['Journal Article'],,United States,AMA Arch Pathol,A.M.A. archives of pathology,14470150R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Plasma Cell', '*Monocytes']",['CLML: 5222:9051:252'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1952/06/01 00:00,1952/06/01 00:01,['1952/06/01 00:00'],"['1952/06/01 00:00 [pubmed]', '1952/06/01 00:01 [medline]', '1952/06/01 00:00 [entrez]']",ppublish,AMA Arch Pathol. 1952 Jun;53(6):593-600.,,,,,,,,,,,,,,
14922951,NLM,MEDLINE,20040215,20191108,2374-2941 (Print) 2374-2941 (Linking),83,6,1952 Jun,Acute neonatal myeloblastic leukemia.,788-93,"['CASILLI, A R', 'RUMSEY, W L', 'SATULSKY, E M']","['CASILLI AR', 'RUMSEY WL', 'SATULSKY EM']",['eng'],['Journal Article'],,United States,AMA Am J Dis Child,A.M.A. American journal of diseases of children,14470010R,,OM,"['Child', 'Humans', 'Infant', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Myeloid, Acute', 'Urticaria/*diagnosis']",['CLML: 5222:8931:252:485'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/in infant and child', '*URTICARIA/diagnosis']",1952/06/01 00:00,1952/06/01 00:01,['1952/06/01 00:00'],"['1952/06/01 00:00 [pubmed]', '1952/06/01 00:01 [medline]', '1952/06/01 00:00 [entrez]']",ppublish,AMA Am J Dis Child. 1952 Jun;83(6):788-93. doi: 10.1001/archpedi.1952.02040100086009.,['10.1001/archpedi.1952.02040100086009 [doi]'],,,,,,,,,,,,,
14922774,NLM,MEDLINE,20040215,20181201,0043-5325 (Print) 0043-5325 (Linking),64,10,1952 Mar 7,[ACTH in acute leukemia].,179-80,"['KEIBL, E']",['KEIBL E'],['und'],['Journal Article'],ACTH bei akuter Leukamie.,Austria,Wien Klin Wochenschr,Wiener klinische Wochenschrift,21620870R,['9002-60-2 (Adrenocorticotropic Hormone)'],OM,"['*Acute Disease', 'Adrenocorticotropic Hormone/*therapeutic use', '*Leukemia', 'Leukemia, Myeloid/*therapy']",['CLML: 5222:8713:8:252'],['NLM'],"['*ACTH/therapeutic use', '*LEUKEMIA, MYELOCYTIC/therapy']",1952/03/07 00:00,1952/03/07 00:01,['1952/03/07 00:00'],"['1952/03/07 00:00 [pubmed]', '1952/03/07 00:01 [medline]', '1952/03/07 00:00 [entrez]']",ppublish,Wien Klin Wochenschr. 1952 Mar 7;64(10):179-80.,,,,,,,,,,,,,,
14922451,NLM,MEDLINE,20040215,20181201,0066-0655 (Print) 0066-0655 (Linking),49,,1951,Fundus changes in leukemia.,445-73,"['CULLER, A M']",['CULLER AM'],['eng'],['Journal Article'],,United States,Trans Am Soc Ophthalmol Otolaryngol Allergy,Transactions - American Society of Ophthalmologic and Otolaryngologic Allergy,7506089,,OM,"['*Fundus Oculi', '*Hemorrhage', 'Humans', 'Leukemia/*complications', '*Retina', '*Retinal Hemorrhage']",['CLML: 5222:8357:251:399'],['NLM'],"['*LEUKEMIA/complications', '*RETINA/hemorrhage']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Trans Am Soc Ophthalmol Otolaryngol Allergy. 1951;49:445-73.,,,,,,,,,,,,,,
14922029,NLM,MEDLINE,20040215,20181201,0370-8179 (Print) 0370-8179 (Linking),49,10-11,1951 Oct-Nov,[Hemorrhagic syndrome in acute paramyeloblastic aleukemia].,834-8,"['POPOVIC, M', 'BORCIC, V']","['POPOVIC M', 'BORCIC V']",['und'],['Journal Article'],Hemoragi6cni sindrom u toku akutne paramijeloblastozne aleukemije.,Serbia,Srp Arh Celok Lek,Srpski arhiv za celokupno lekarstvo,0027440,,OM,"['*Hemorrhagic Disorders', 'Humans', 'Leukemia/*complications']",['CLML: 5222:7935:205:251'],['NLM'],"['*HEMORRHAGIC DIATHESIS', '*LEUKEMIA/complications']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Srp Arh Celok Lek. 1951 Oct-Nov;49(10-11):834-8.,,,,,,,,,,,,,,
14921767,NLM,MEDLINE,20040215,20181201,0035-6433 (Print) 0035-6433 (Linking),72,3,1951,[Facial diplegia caused by acute leukemia].,646-8,"['RADICCHI, M']",['RADICCHI M'],['und'],['Journal Article'],Diplegia facciale da leucemia acuta.,Italy,Riv Patol Nerv Ment,Rivista di patologia nervosa e mentale,0431335,,OM,"['*Acute Disease', 'Face/*innervation', '*Facial Paralysis', 'Leukemia/*complications', 'Paralysis/*innervation']",['CLML: 5222:7673:251:305'],['NLM'],"['*LEUKEMIA/complications', '*NERVES, FACIAL/paralysis']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Riv Patol Nerv Ment. 1951;72(3):646-8.,,,,,,,,,,,,,,
14921677,NLM,MEDLINE,20040215,20181201,0048-833X (Print),51,3-4,1951 Jul,[Use of naphthylamine in oil in the therapy of leukemia and malignant granuloma; further therapeutic attempts with aromatic derivatives of yperite].,388-99,"['SPIGLIATI, P']",['SPIGLIATI P'],['und'],['Journal Article'],L'impiego delle naftilamine oleose nella terapia delle leucemie e del granuloma maligno; ulteriori tentativi terapeutici con derivati aromatici dell'iprite.,Italy,Riv Crit Clin Med,Rivista critica di clinica medica,0436026,"['0 (Amines)', 'T8KEC9FH9P (Mustard Gas)']",OM,"['*Amines', 'Hodgkin Disease/*therapy', 'Leukemia/*therapy', 'Mustard Gas/*therapeutic use']",['CLML: 5222:7583:211:252:292'],['NLM'],"[""*HODGKIN'S DISEASE/therapy"", '*LEUKEMIA/therapy', '*MUSTARD GAS/therapeutic use']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Riv Crit Clin Med. 1951 Jul;51(3-4):388-99.,,,,,,,,,,,,,,
14921393,NLM,MEDLINE,20040215,20181201,0035-3787 (Print) 0035-3787 (Linking),85,4,1951,[Landry syndrome in a case of leukemia].,306-10,"['LORENTZ DE HAAS, A M']",['LORENTZ DE HAAS AM'],['und'],['Journal Article'],Syndrome de Landry dans un cas de leucemie.,France,Rev Neurol (Paris),Revue neurologique,2984779R,,OM,"['Humans', '*Leukemia', '*Paralysis', '*Syndrome']",['CLML: 5222:7280:251:330'],['NLM'],"['*LEUKEMIA', '*PARALYSIS']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Rev Neurol (Paris). 1951;85(4):306-10.,,,,,,,,,,,,,,
14920617,NLM,MEDLINE,20040215,20181201,0033-2240 (Print) 0033-2240 (Linking),7,11-12,1951,[A case of lymphatic leukemia with manifestations of hypersensitivity].,432-3,"['CETNAROWICZ, J']",['CETNAROWICZ J'],['und'],['Journal Article'],Przypadek przewleklej bialaczki limfatycznej z objawami uczulenia.,Poland,Przegl Lek,Przeglad lekarski,19840720R,,OM,"['Humans', '*Hypersensitivity', '*Leukemia', '*Leukemia, Lymphoid']",['CLML: 5222:6484:252'],['NLM'],"['*LEUKEMIA, LYMPHATIC/manifestations']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Przegl Lek. 1951;7(11-12):432-3.,,,,,,,,,,,,,,
14920569,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),8,2,1952 Jan 31,"[Lymphosarcoma with evolution into acute leukemia, possibly lymphatic].",38-42,"['PACIFICO, A', 'LOCASCIO, G']","['PACIFICO A', 'LOCASCIO G']",['und'],['Journal Article'],Linfosarcoma con evoluzione in leucemia acuta a probabile orientamento linfatico.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,,OM,"['Humans', 'Leukemia/*etiology', '*Lymphoma', '*Lymphoma, Non-Hodgkin']",['CLML: 5222:6436:252:268'],['NLM'],"['*LEUKEMIA/etiology and pathogenesis', '*LYMPHOSARCOMA']",1952/01/31 00:00,1952/01/31 00:01,['1952/01/31 00:00'],"['1952/01/31 00:00 [pubmed]', '1952/01/31 00:01 [medline]', '1952/01/31 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1952 Jan 31;8(2):38-42.,,,,,,,,,,,,,,
14920357,NLM,MEDLINE,20040215,20181201,0369-8394 (Print) 0369-8394 (Linking),41,4,1952 Jan 24,[Recurrence of leukemia treated by the association of cytostatics and cytophylactics].,57-64,"['DUBOIS-FERRIERE, H', 'SARASIN, R']","['DUBOIS-FERRIERE H', 'SARASIN R']",['und'],['Journal Article'],Remission de leucemies traitees par l'association de cytostatiques et de cytophylactiques.,Switzerland,Praxis,Praxis,0401230,"['0 (Cytostatic Agents)', '0 (Trace Elements)', 'F7IY6HZG9D (Triethylenemelamine)']",OM,"['*Cytostatic Agents', '*Leukemia', 'Leukemia, Myeloid/*therapy', '*Neoplasms', '*Recurrence', 'Trace Elements/*therapeutic use', 'Triethylenemelamine/*therapeutic use']",['CLML: 5222:6224:252:464:467'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/therapy', '*TRACE ELEMENTS/therapeutic use', '*TRIETHYLENE MELAMINE/therapeutic use']",1952/01/24 00:00,1952/01/24 00:01,['1952/01/24 00:00'],"['1952/01/24 00:00 [pubmed]', '1952/01/24 00:01 [medline]', '1952/01/24 00:00 [entrez]']",ppublish,Praxis. 1952 Jan 24;41(4):57-64.,,,,,,,,,,,,,,
14920233,NLM,MEDLINE,20040215,20181201,0048-4717 (Print) 0048-4717 (Linking),59,1,1952 Feb,[Certain clinico-statistical observations on 164 leukemia patients].,22-34,"['CAMPO, C', 'NUCCI, F']","['CAMPO C', 'NUCCI F']",['und'],['Journal Article'],Alcune osservazioni clinico-statistiche su 164 malati di leucemia.,Italy,Policlinico Med,Il Policlinico. Sezione medica,0401144,,OM,"['*Biometry', 'Humans', 'Leukemia/*epidemiology/*statistics & numerical data']",['CLML: 5222:6100:252'],['NLM'],['*LEUKEMIA/epidemiology and statistics'],1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,Policlinico Med. 1952 Feb;59(1):22-34.,,,,,,,,,,,,,,
14919893,NLM,MEDLINE,20040215,20181201,0028-4793 (Print) 0028-4793 (Linking),246,16,1952 Apr 17,WEEKLY clinicopathological exercise: myeloid metaplasia of spleen.,621-7,,,['eng'],['Journal Article'],,United States,N Engl J Med,The New England journal of medicine,0255562,,OM,"['*Disease', 'Humans', '*Leukemia', 'Leukemia, Myeloid/*etiology', '*Metaplasia', '*Myeloproliferative Disorders', '*Primary Myelofibrosis', '*Spleen', '*Splenic Diseases']",['CLML: 5222:5760:252:429'],['NLM'],"['*LEUKEMIA, MONOCYTIC/etiology and pathogenesis', '*SPLEEN/diseases']",1952/04/17 00:00,1952/04/17 00:01,['1952/04/17 00:00'],"['1952/04/17 00:00 [pubmed]', '1952/04/17 00:01 [medline]', '1952/04/17 00:00 [entrez]']",ppublish,N Engl J Med. 1952 Apr 17;246(16):621-7. doi: 10.1056/NEJM195204172461607.,['10.1056/NEJM195204172461607 [doi]'],,,,,,,,,,,,,
14919764,NLM,MEDLINE,20040215,20181201,0028-2162 (Print) 0028-2162 (Linking),96,3,1952 Jan 19,[The eosinophil granulomas of the skin with special eosinophil reference to reticulogranuloma].,140-7,"['WOERDEMAN, M J']",['WOERDEMAN MJ'],['und'],['Journal Article'],"De eosinophiele granulomen van de huid, in het bijzonder van de groep der reticulo-granulomen.",Netherlands,Ned Tijdschr Geneeskd,Nederlands tijdschrift voor geneeskunde,0400770,"['Reticuloendotheliosis, X-linked']",OM,"['*Eosinophilic Granuloma', '*Eosinophils', '*Genetic Diseases, X-Linked', 'Humans', '*Leukemia, Hairy Cell', '*Lipidoses', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency', '*Skin Diseases']",['CLML: 5222:5631:255:398:421'],['NLM'],"['*LIPOIDOSIS', '*RETICULOENDOTHELIOSIS', '*SKIN/diseases']",1952/01/19 00:00,1952/01/19 00:01,['1952/01/19 00:00'],"['1952/01/19 00:00 [pubmed]', '1952/01/19 00:01 [medline]', '1952/01/19 00:00 [entrez]']",ppublish,Ned Tijdschr Geneeskd. 1952 Jan 19;96(3):140-7.,,,,,,,,,,,,,,
14919426,NLM,MEDLINE,20040215,20181201,0027-2973 (Print) 0027-2973 (Linking),94,3,1952 Jan 18,[Critical observations on urethane therapy of chronic myelosis during the last 5 years].,117-23,"['MICHEL, H']",['MICHEL H'],['und'],['Journal Article'],Kritische Bemerkungen und Beobachtungen zur Urethantherapie der chronischen Myelose in den letzten 5 Jahren.,Germany,Munch Med Wochenschr,Munchener medizinische Wochenschrift (1950),7801802,['3IN71E75Z5 (Urethane)'],OM,"['Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'Leukemia, Myeloid/*therapy', 'Urethane/*therapeutic use']",['CLML: 5222:5293:252:482'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/therapy', '*URETHANE/therapeutic use']",1952/01/18 00:00,1952/01/18 00:01,['1952/01/18 00:00'],"['1952/01/18 00:00 [pubmed]', '1952/01/18 00:01 [medline]', '1952/01/18 00:00 [entrez]']",ppublish,Munch Med Wochenschr. 1952 Jan 18;94(3):117-23.,,,,,,,,,,,,,,
14919397,NLM,MEDLINE,20040215,20181201,,39-40,6,1951 Nov-Dec,[Cutaneous and mucous syndromes in monocytic leukemia].,635-8,"['GIRAUD, G', 'CAZAL, P', 'LATOUR, H', 'LEVY, A', 'PUECH, P']","['GIRAUD G', 'CAZAL P', 'LATOUR H', 'LEVY A', 'PUECH P']",['und'],['Journal Article'],Syndrome cutane et muqueux au cours de la leucemie a monocytes.,France,Montp Med,Montpellier medical,18820540R,,OM,"['*Administration, Cutaneous', 'Humans', '*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid', '*Mucous Membrane', 'Skin/*pathology', '*Syndrome']",['CLML: 5222:5264:252:288:423'],['NLM'],"['*LEUKEMIA, MONOCYTIC/manifestations', '*MUCOUS MEMBRANES', '*SKIN/pathology']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Montp Med. 1951 Nov-Dec;39-40(6):635-8.,,,,,,,,,,,,,,
14919228,NLM,MEDLINE,20040215,20181201,0026-4806 (Print) 0026-4806 (Linking),42,80,1951 Nov 24,[Aminopterin in 2 cases of acute leukemia].,871-7,"['MAUREA, C', 'ARCIELLO, G']","['MAUREA C', 'ARCIELLO G']",['und'],['Journal Article'],L'aminopterina in due casi di leucemia acuta.,Italy,Minerva Med,Minerva medica,0400732,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Acute Disease', '*Aminopterin', 'Folic Acid Antagonists/*therapeutic use', 'Humans', 'Leukemia/*therapy']",['CLML: 5222:5095:177:252'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1951/11/24 00:00,1951/11/24 00:01,['1951/11/24 00:00'],"['1951/11/24 00:00 [pubmed]', '1951/11/24 00:01 [medline]', '1951/11/24 00:00 [entrez]']",ppublish,Minerva Med. 1951 Nov 24;42(80):871-7.,,,,,,,,,,,,,,
14918943,NLM,MEDLINE,20040215,20181201,0025-8458 (Print) 0025-8458 (Linking),47,2,1952 Jan 11,[Monocytic leukosis in chronic roentgen and radium poisoning].,46-8,"['LEIBETSEDER, F']",['LEIBETSEDER F'],['und'],['Journal Article'],Monocytenleukose ais Folge chronischer Rontgen-Radium-Schadigung.,Germany,Med Klin,Medizinische Klinik,0376637,['W90AYD6R3Q (Radium)'],OM,"['Humans', '*Leukemia', 'Leukemia, Myeloid/*etiology', '*Monocytes', '*Radiation Effects', '*Radium']",['CLML: 5222:4810:252:389'],['NLM'],"['*LEUKEMIA, MONOCYTIC/etiology and pathogenesis', '*RADIATIONS/effects']",1952/01/11 00:00,1952/01/11 00:01,['1952/01/11 00:00'],"['1952/01/11 00:00 [pubmed]', '1952/01/11 00:01 [medline]', '1952/01/11 00:00 [entrez]']",ppublish,Med Klin. 1952 Jan 11;47(2):46-8.,,,,,,,,,,,,,,
14918534,NLM,MEDLINE,20040215,20181201,,7,2,1952 Jan 15,[Experiences with the treatment of leukemia].,38-42,"['KOLAR, V']",['KOLAR V'],['und'],['Journal Article'],Na6se zku6senosti s le6cenam leukemia.,Czech Republic,Lek List,Lekarske listy,18310680R,,OM,"['Humans', 'Leukemia/*therapy']",['CLML: 5222:4401:252'],['NLM'],['*LEUKEMIA/therapy'],1952/01/15 00:00,1952/01/15 00:01,['1952/01/15 00:00'],"['1952/01/15 00:00 [pubmed]', '1952/01/15 00:01 [medline]', '1952/01/15 00:00 [entrez]']",ppublish,Lek List. 1952 Jan 15;7(2):38-42.,,,,,,,,,,,,,,
14918519,NLM,MEDLINE,20040215,20181201,0023-9046 (Print) 0023-9046 (Linking),16,10,1951 Dec,[Acute tuberculosis during acute leukemia treated by ACTH (with autopsy report)].,1337-45,"['SAULNIER, G', 'BONENFANT, J L']","['SAULNIER G', 'BONENFANT JL']",['und'],['Journal Article'],Tuberculose aigue au cours d'une leucemie aigue traitee a l'A.C.T.H. (avec autopsie).,Canada,Laval Med,Laval medical,2985217R,['9002-60-2 (Adrenocorticotropic Hormone)'],OM,"['*Acute Disease', '*Adrenocorticotropic Hormone', '*Autopsy', 'Humans', '*Leukemia', 'Leukemia, Lymphoid/*therapy', 'Tuberculosis/*etiology']",['CLML: 5222:4386:252:470'],['NLM'],"['*LEUKEMIA, LYMPHATIC/therapy', '*TUBERCULOSIS/etiology and pathogenesis']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Laval Med. 1951 Dec;16(10):1337-45.,,,,,,,,,,,,,,
14918405,NLM,MEDLINE,20040215,20181201,0368-6132 (Print) 0368-6132 (Linking),7,1,1952 Jan 1,[ACTH treatment of leukemia].,20-4,"['KOLBL, H', 'ROSENKRANZ, A']","['KOLBL H', 'ROSENKRANZ A']",['und'],['Journal Article'],Ein Beitrag zur ACTH.-Behandlung der Leukamie.,Austria,Klin Med Osterr Z Wiss Prakt Med,Klinische Medizin; osterreichische Zeitschrift fur wissenschaftliche und praktische Medizin,18140020R,['9002-60-2 (Adrenocorticotropic Hormone)'],OM,"['Adrenocorticotropic Hormone/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5222:4272:8:252'],['NLM'],"['*ACTH/therapeutic use', '*LEUKEMIA/therapy']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Klin Med Osterr Z Wiss Prakt Med. 1952 Jan 1;7(1):20-4.,,,,,,,,,,,,,,
14917921,NLM,MEDLINE,20040215,20181201,0022-2143 (Print) 0022-2143 (Linking),39,4,1952 Apr,The effect of cortisone and ACTH in leukemia.,570-81,"['ADAMS, W S', 'VALENTINE, W N', 'BASSETT, S H', 'LAWRENCE, J S']","['ADAMS WS', 'VALENTINE WN', 'BASSETT SH', 'LAWRENCE JS']",['eng'],['Journal Article'],,United States,J Lab Clin Med,The Journal of laboratory and clinical medicine,0375375,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['Adrenocorticotropic Hormone/*therapeutic use', 'Cortisone/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5222:3788:8:120:252'],['NLM'],"['*ACTH/therapeutic use', '*CORTISONE/therapeutic use', '*LEUKEMIA/therapy']",1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,J Lab Clin Med. 1952 Apr;39(4):570-81.,,,,,,,,,,,,,,
14917876,NLM,MEDLINE,20040215,20181201,0019-5847 (Print) 0019-5847 (Linking),21,6,1952 Mar,A case of chronic myeloid leukaemia without hepatosplenic enlargement.,260-2,"['CHAKRABARTI, A']",['CHAKRABARTI A'],['eng'],['Journal Article'],,India,J Indian Med Assoc,Journal of the Indian Medical Association,7505608,,OM,"['Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Tuberculosis', 'Tuberculosis, Pulmonary/*complications']",['CLML: 5222:3743:252:475'],['NLM'],"['*LEUKEMIA, MYELOCYTIC', '*TUBERCULOSIS, PULMONARY/complications']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,J Indian Med Assoc. 1952 Mar;21(6):260-2.,,,,,,,,,,,,,,
14917361,NLM,MEDLINE,20040215,20181201,0018-5469 (Print) 0018-5469 (Linking),40,4,1951 Oct,[Chronic myeloid leukemia; clinico-therapeutic study in the light of modern knowledge].,573-87,"['DE SALLES FONSECA, A', 'DA COSTA, P D', 'DE CASTRO, A']","['DE SALLES FONSECA A', 'DA COSTA PD', 'DE CASTRO A']",['und'],['Journal Article'],Leucemia mieloide cronica; estudo clinico-terapeutico a luz das modernas aquisicoes.,Brazil,Hospital (Rio J),"Hospital (Rio de Janeiro, Brazil)",9427238,,OM,"['*Analgesia', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'Leukemia, Myeloid/*etiology', '*Pain Management']",['CLML: 5222:3215:23:252'],['NLM'],"['*ANALGESIA', '*LEUKEMIA, MYELOCYTIC/etiology and pathogenesis']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Hospital (Rio J). 1951 Oct;40(4):573-87.,,,,,,,,,,,,,,
14917265,NLM,MEDLINE,20040215,20181201,,92,6,1951 Nov-Dec,[Universal cutaneo-visceral reticulohistiocytosis].,429-42,"['ZICCARDI, M']",['ZICCARDI M'],['und'],['Journal Article'],Reticuloistiocitosi nodulare cutaneo-viscerale-universale.,Italy,Soc Ital Dermatol Sifilogr Sezioni Interprov Soc Ital Dermatol Sifilogr,Atti della Societa italiana di dermatologia e sifilografia e delle sezioni interprovinciali. Societa italiana di dermatologia e sifilografia,20820760R,"['Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', '*Histiocytosis', 'Humans', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5222:3119:398'],['NLM'],['*RETICULOENDOTHELIOSIS'],1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Soc Ital Dermatol Sifilogr Sezioni Interprov Soc Ital Dermatol Sifilogr. 1951 Nov-Dec;92(6):429-42.,,,,,,,,,,,,,,
14917209,NLM,MEDLINE,20040215,20181201,,4,4,1951,[Evolution of a case of acute leukemia in an adult treated with cortisone].,1185-92,"['ABECASIS, L']",['ABECASIS L'],['und'],['Journal Article'],Evolucao dum caso de leucemia aguda do adulto tratado com cortisona.,Portugal,Gaz Med Port,Gazeta medica portuguesa,17040250R,['V27W9254FZ (Cortisone)'],OM,"['*Acute Disease', '*Biological Evolution', 'Cortisone/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5222:3063:120:252'],['NLM'],"['*CORTISONE/therapeutic use', '*LEUKEMIA/therapy']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Gaz Med Port. 1951;4(4):1185-92.,,,,,,,,,,,,,,
14916985,NLM,MEDLINE,20040215,20181201,,75,5,1951 Nov,[Report on a case of osteomyeloreticulosis].,641-6,"['ROSIEN, I']",['ROSIEN I'],['und'],['Journal Article'],Bericht uber einen Fall von Osteomyeloretikulose.,Germany,Fortschr Geb Rontgenstr,Fortschritte auf dem Gebiete der Rontgenstrahlen,17010480R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5222:2839:252'],['NLM'],"['*LEUKEMIA, MYELOCYTIC']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Fortschr Geb Rontgenstr. 1951 Nov;75(5):641-6.,,,,,,,,,,,,,,
14916490,NLM,MEDLINE,20040215,20190922,0009-8787 (Print) 0009-8787 (Linking),19,2,1952 Apr,Treatment of acute lymphatic leukemia with aminopterin.,67-71,"['COTTLE, R I', 'BATTLE, J D Jr']","['COTTLE RI', 'BATTLE JD Jr']",['eng'],['Journal Article'],,United States,Cleve Clin Q,Cleveland Clinic quarterly,0373162,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Acute Disease', '*Aminopterin', 'Folic Acid Antagonists/*therapeutic use', '*Leukemia', 'Leukemia, Lymphoid/*therapy', '*Lymphatic Vessels']",['CLML: 5222:2344:177:252'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA, LYMPHATIC/therapy']",1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Cleve Clin Q. 1952 Apr;19(2):67-71. doi: 10.3949/ccjm.19.2.67.,['10.3949/ccjm.19.2.67 [doi]'],,,,,,,,,,,,,
14916353,NLM,MEDLINE,20040215,20181201,0008-4158 (Print) 0008-4158 (Linking),14,1,1952 Mar,The treatment of acute leukemia with cortisone and ACTH.,10-9,"['PEEL, M']",['PEEL M'],['eng'],['Journal Article'],,Canada,Can J Med Technol,Canadian journal of medical technology,0373141,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['*Acute Disease', 'Adrenocorticotropic Hormone/*therapeutic use', 'Cortisone/*therapeutic use', '*Leukemia', 'Leukemia, Lymphoid/*therapy', '*Lymphatic Vessels']",['CLML: 5222:2207:8:120:252'],['NLM'],"['*ACTH/therapeutic use', '*CORTISONE/therapeutic use', '*LEUKEMIA, LYMPHATIC/therapy']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Can J Med Technol. 1952 Mar;14(1):10-9.,,,,,,,,,,,,,,
14915990,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),7,4,1952 Apr,Erythroblastosis and leukemia: a case report illustrating variations in the clinical picture.,454-66,"['VERLOOP, M C', 'DEENSTRA, H', 'VAN DER HOEVEN, L H']","['VERLOOP MC', 'DEENSTRA H', 'VAN DER HOEVEN LH']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,,OM,"['*Hematologic Diseases', '*Leukemia', '*Leukemia, Myeloid', '*Polycythemia Vera']",['CLML: 5222:1844:252:364'],['NLM'],"['*LEUKEMIA, MYELOCYTIC', '*POLYCYTHEMIA VERA']",1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Blood. 1952 Apr;7(4):454-66.,['S0006-4971(20)68146-0 [pii]'],,,,,,,,,,,,,
14915902,NLM,MEDLINE,20040215,20181201,0365-0723 (Print) 0365-0723 (Linking),42,1-2,1952 Jan-Feb,[Clinico-pathological sessions: lymphatic leukemia with tuberculosis].,62-71,,,['und'],['Journal Article'],SESSOES clinico-patologicas; leucemia linfoide com tuberculose.,Brazil,Arq Bras Med,Arquivos brasileiros de medicina,15310420R,,OM,"['Humans', '*Leukemia', 'Leukemia, Lymphoid/*complications', '*Tuberculosis', 'Tuberculosis, Pulmonary/*complications']",['CLML: 5222:1756:252:475'],['NLM'],"['*LEUKEMIA, LYMPHATIC/complications', '*TUBERCULOSIS, PULMONARY/complications']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Arq Bras Med. 1952 Jan-Feb;42(1-2):62-71.,,,,,,,,,,,,,,
14915470,NLM,MEDLINE,20040215,20181201,,6,4,1952 Apr,"Papillary cystadenoma lymphomatosum of the parotid gland, associated with chronic lymphocytic lymphoblastoma.",226-8,"['REKERS, P E']",['REKERS PE'],['eng'],['Journal Article'],,United States,Ann West Med Surg,Annals of western medicine and surgery,15030120R,,OM,"['*Adenolymphoma', '*Leukemia', '*Leukemia, Lymphoid', '*Neoplasms', '*Parotid Gland', '*Parotid Neoplasms', '*Salivary Gland Neoplasms']",['CLML: 5222:1316:9:252:332'],['NLM'],"['*ADENOLYMPHOMA, SALIVARY', '*LEUKEMIA, LYMPHATIC', '*PAROTID GLAND/neoplasms']",1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,Ann West Med Surg. 1952 Apr;6(4):226-8.,,,,,,,,,,,,,,
14914620,NLM,MEDLINE,20040215,20181201,0365-3056 (Print) 0365-3056 (Linking),7,5,1952,Immunity in mice against leukemic cells of the same genetic constitution.,761-4,"['BRNCIC, D', 'HOECKER, G', 'GASIC, G']","['BRNCIC D', 'HOECKER G', 'GASIC G']",['eng'],['Journal Article'],,Belgium,Acta Unio Int Contra Cancrum,Acta - Unio Internationalis Contra Cancrum,7502506,,OM,"['Animals', '*Leukemia, Experimental', 'Mice']",['CLML: 5222:466:252'],['NLM'],['*LEUKEMIA/experimental'],1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Acta Unio Int Contra Cancrum. 1952;7(5):761-4.,,,,,,,,,,,,,,
14914046,NLM,MEDLINE,20040215,20181201,0044-3220 (Print) 0044-3220 (Linking),81,1,1951,[Bone changes in leukemia; unusual case of subleukemic myelosis in a 3 1/2 year old girl].,134-42,"['IDELBERGER, K']",['IDELBERGER K'],['und'],['Journal Article'],Knochenveranderungen bei Leukamien; uber einen ungewohnlichen Fall von subleukamischer Myelose bei einem 3 1/2 jahrigen Madchen.,Germany,Z Orthop Ihre Grenzgeb,Zeitschrift fur Orthopadie und ihre Grenzgebiete,1256465,,OM,"['*Bone and Bones', 'Female', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'Leukemia, Myeloid/*complications']",['CLML: 5221:44649:210'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/complications']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Z Orthop Ihre Grenzgeb. 1951;81(1):134-42.,,,,,,,,,,,,,,
14913959,NLM,MEDLINE,20040215,20181201,0043-5376 (Print) 0043-5376 (Linking),32,7,1951 Jul,[Differentiation of myeloid and lymphatic cells in fluorescence microscopy; vital staining with acridine orange].,320-3,"['BRAUNSTEINER, H', 'PAKESCH, F']","['BRAUNSTEINER H', 'PAKESCH F']",['und'],['Journal Article'],Differenzierung myeloischer und lymphatischer Zellen im Fluoreszenzmikroskop; Vitalfarbung mit Acidinorange.,Austria,Wien Z Inn Med,Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete,7502231,"['0 (Coloring Agents)', 'F30N4O6XVV (Acridine Orange)']",OM,"['*Acridine Orange', '*Coloring Agents', 'Humans', 'Leukemia/*diagnosis', '*Microscopy, Fluorescence', '*Staining and Labeling']",['CLML: 5221:44562:209:353'],['NLM'],"['*LEUKEMIA/diagnosis', '*STAINS AND STAINING']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Wien Z Inn Med. 1951 Jul;32(7):320-3.,,,,,,,,,,,,,,
14913930,NLM,MEDLINE,20040215,20181201,0043-5325 (Print) 0043-5325 (Linking),64,1,1952 Jan 4,[A simple method for cytoenzymatic examination of blood and bone marrow smears and its significance in the study of leukemic cells].,4-8,"['LAVES, W', 'THOMA, K', 'OBERDORFER, A']","['LAVES W', 'THOMA K', 'OBERDORFER A']",['und'],['Journal Article'],Ueber ein einfaches Verfahren zur zytoenzymatischen Untersuchung von Blut- und Knochenmarksausstrichen und seine Bedeutung fur das Studium leukamischer Zellen.,Austria,Wien Klin Wochenschr,Wiener klinische Wochenschrift,21620870R,,OM,"['*Bone Marrow', 'Humans', '*Leukemia']",['CLML: 5221:44533:209'],['NLM'],['*LEUKEMIA'],1952/01/04 00:00,1952/01/04 00:01,['1952/01/04 00:00'],"['1952/01/04 00:00 [pubmed]', '1952/01/04 00:01 [medline]', '1952/01/04 00:00 [entrez]']",ppublish,Wien Klin Wochenschr. 1952 Jan 4;64(1):4-8.,,,,,,,,,,,,,,
14913262,NLM,MEDLINE,20040215,20181201,0038-2310 (Print) 0038-2310 (Linking),16,3,1951 Nov,Leukopoiesis in trypan blue treated rats and its implications for the understanding of human leukaemias.,94,"['GILLMAN, T']",['GILLMAN T'],['eng'],['Journal Article'],,South Africa,S Afr J Med Sci,The South African journal of medical sciences,2984853R,['I2ZWO3LS3M (Trypan Blue)'],OM,"['Animals', 'Humans', '*Leukemia, Experimental', '*Leukocytes', '*Leukopoiesis', 'Rats', '*Trypan Blue']",['CLML: 5221:43854:210:211'],['NLM'],"['*LEUKEMIA/experimental', '*LEUKOCYTES']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,S Afr J Med Sci. 1951 Nov;16(3):94.,,,,,,,,,,,,,,
14913234,NLM,MEDLINE,20040215,20181201,,27,89,1951 Dec 2,"[A case of acute, histio-monocytic leukemia].",3562-7,"['OGAN, H', 'TOKTAMIS, F']","['OGAN H', 'TOKTAMIS F']",['und'],['Journal Article'],Un cas de leucemie histio-monocytaire aigue.,France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,,OM,"['Humans', '*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid', '*Monocytes']",['CLML: 5221:43826:210'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1951/12/02 00:00,1951/12/02 00:01,['1951/12/02 00:00'],"['1951/12/02 00:00 [pubmed]', '1951/12/02 00:01 [medline]', '1951/12/02 00:00 [entrez]']",ppublish,Sem Hop. 1951 Dec 2;27(89):3562-7.,,,,,,,,,,,,,,
14913232,NLM,MEDLINE,20040215,20181201,,27,89,1951 Dec 2,"[Acute, generalized proliferation of the lymph nodes in the terminal stage of chronic myeloid leukemia].",3551-7,"['FRANK, E']",['FRANK E'],['und'],['Journal Article'],Extreme proliferation ganglionnaire aigue generalisee comme terme final de la leucemie chronique myeloide.,France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,,OM,"['Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', 'Lymph Nodes/*pathology']",['CLML: 5221:43824:210:221'],['NLM'],"['*LEUKEMIA, MYELOCYTIC', '*LYMPH NODES/pathology']",1951/12/02 00:00,1951/12/02 00:01,['1951/12/02 00:00'],"['1951/12/02 00:00 [pubmed]', '1951/12/02 00:01 [medline]', '1951/12/02 00:00 [entrez]']",ppublish,Sem Hop. 1951 Dec 2;27(89):3551-7.,,,,,,,,,,,,,,
14913076,NLM,MEDLINE,20040215,20181201,0036-7672 (Print) 0036-7672 (Linking),81,50,1951 Dec 15,"[Therapy of malignant diseases of the blood with cortisone, triethylene melamine and the trace elements].",1235-7,"['DUBOIS-FERRIERE, H']",['DUBOIS-FERRIERE H'],['und'],['Journal Article'],"Essai de traitement des hemopathies malignes par la cortisone, le triethylene melamine et les oligometaux.",Switzerland,Schweiz Med Wochenschr,Schweizerische medizinische Wochenschrift,0404401,"['0 (Trace Elements)', 'F7IY6HZG9D (Triethylenemelamine)', 'V27W9254FZ (Cortisone)']",OM,"['Cortisone/*therapeutic use', 'Leukemia/*therapy', '*Lymphatic System', '*Neoplasms', '*Trace Elements', 'Triethylenemelamine/*therapeutic use']",['CLML: 5221:43668:97:210:222:381:383'],['NLM'],"['*CORTISONE/therapeutic use', '*LEUKEMIA/therapy', '*LYMPHATIC SYSTEM/neoplasms', '*TRACE ELEMENTS', '*TRIETHYLENE MELAMINE/therapeutic use']",1951/12/15 00:00,1951/12/15 00:01,['1951/12/15 00:00'],"['1951/12/15 00:00 [pubmed]', '1951/12/15 00:01 [medline]', '1951/12/15 00:00 [entrez]']",ppublish,Schweiz Med Wochenschr. 1951 Dec 15;81(50):1235-7.,,,,,,,,,,,,,,
14913074,NLM,MEDLINE,20040215,20181201,0036-7672 (Print) 0036-7672 (Linking),81,50,1951 Dec 15,[Problems in the treatment of acute leukemia].,1233-5,"['ALDER, A']",['ALDER A'],['und'],['Journal Article'],Das Problem der Behandlung akuter Leukamien.,Switzerland,Schweiz Med Wochenschr,Schweizerische medizinische Wochenschrift,0404401,,OM,"['*Acute Disease', 'Humans', 'Leukemia/*therapy']",['CLML: 5221:43666:210'],['NLM'],['*LEUKEMIA/therapy'],1951/12/15 00:00,1951/12/15 00:01,['1951/12/15 00:00'],"['1951/12/15 00:00 [pubmed]', '1951/12/15 00:01 [medline]', '1951/12/15 00:00 [entrez]']",ppublish,Schweiz Med Wochenschr. 1951 Dec 15;81(50):1233-5.,,,,,,,,,,,,,,
14913033,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),23,1,1952,[Nitrogen balance in leukemia treated with urethane; observations on elimination of 17-ketosteroids and on cellular maturation].,31-44,"['JAMRA, M A', 'GOMIDE, W']","['JAMRA MA', 'GOMIDE W']",['und'],['Journal Article'],Balance de l'azote chez des leucemiques traites avec l'urethane; observations sur l'elimination de 17-cetosteroides et sur la maturation cellulaire.,France,Sang,Le Sang,20540380R,"['0 (17-Ketosteroids)', '3IN71E75Z5 (Urethane)', 'N762921K75 (Nitrogen)']",OM,"['*17-Ketosteroids', 'Biological Transport', 'Leukemia/*therapy', '*Nitrogen', 'Urethane/*therapeutic use']",['CLML: 5221:43625:210:260:397'],['NLM'],"['*LEUKEMIA/therapy', '*NITROGEN', '*URETHANE/therapeutic use']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Sang. 1952;23(1):31-44.,,,,,,,,,,,,,,
14913031,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),23,1,1952,[Study on acute leukosis in children treated with associated folic acid antagonists and cortisone].,12-27,"['BERNARD, J', 'MATHE, G']","['BERNARD J', 'MATHE G']",['und'],['Journal Article'],Etude des leucoses aigues de l'enfance traitees par l'association antifoliques cortisone.,France,Sang,Le Sang,20540380R,"['0 (Folic Acid Antagonists)', 'V27W9254FZ (Cortisone)']",OM,"['Cortisone/*therapeutic use', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:43623:97:144:210'],['NLM'],"['*CORTISONE/therapeutic use', '*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Sang. 1952;23(1):12-27.,,,,,,,,,,,,,,
14913029,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,9,1951,[Systemic malignant reticulopathies or histio-monocytic reticulosis and its treatment; observation on six cases].,765-9,"['LEGER, H', 'MEYNARD, J', 'BIRABEN, J']","['LEGER H', 'MEYNARD J', 'BIRABEN J']",['und'],['Journal Article'],Note sur les reticulopathies malignes systematisees ou reticuloses histio-monocytaires et leur traitement; a propos de dix observations.,France,Sang,Le Sang,20540380R,,OM,"['Humans', '*Leukemia', 'Leukemia, Myeloid/*therapy', '*Monocytes']",['CLML: 5221:43621:210'],['NLM'],"['*LEUKEMIA, MONOCYTIC/therapy']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(9):765-9.,,,,,,,,,,,,,,
14913028,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,9,1951,[Morphological and experimental study on the pathogenesis of acute myeloid leukemia; blood disorders consecutive to experimental transmission of acute myeloid leukemia].,760-4,"['MAS Y MAGRO, F']",['MAS Y MAGRO F'],['und'],['Journal Article'],Recherches morphologiques et experimentales sur la pathogenie de la leucemie myeloide aigue. II. Les troubles du sang consecutifs a la transmission experimentale de la leucemie myeloide aigue.,France,Sang,Le Sang,20540380R,,OM,"['*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Myeloid, Acute', '*Leukocytes']",['CLML: 5221:43620:210:211'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/experimental', '*LEUKOCYTES']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(9):760-4.,,,,,,,,,,,,,,
14913027,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,9,1951,"[Morphological and experimental study on the pathogenesis of myeloid leukemia; heterologous experimental transmission of acute, human, myeloid leukemia].",756-60,"['MAS Y MAGRO, F']",['MAS Y MAGRO F'],['und'],['Journal Article'],Recherches morphologiques et experimentales sur la pathogenie de la leucemie myeloide. I. La transmission experimentale heterologue de la leucemie myeloide aigue humaine.,France,Sang,Le Sang,20540380R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5221:43619:210'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/experimental']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(9):756-60.,,,,,,,,,,,,,,
14913023,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,9,1951,[Cryptoleukoblastosis of prolonged evolution; discussion on therapeutic results].,736-44,"['MICHON, P', 'GAMALEIA, N', 'NOEL, B']","['MICHON P', 'GAMALEIA N', 'NOEL B']",['und'],['Journal Article'],Cryptoleucoblastoses d'evolution prolongee; discussion des resultats therapeutiques.,France,Sang,Le Sang,20540380R,,OM,"['Humans', 'Leukemia/*therapy']",['CLML: 5221:43615:210'],['NLM'],['*LEUKEMIA/therapy'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(9):736-44.,,,,,,,,,,,,,,
14913015,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,8,1951,[Observations on granulocytolysis in vitro in acute myeloid leukemias].,688-90,"['ALEKSANDROWICZ, J', 'MIKLASZEWSKA, J']","['ALEKSANDROWICZ J', 'MIKLASZEWSKA J']",['und'],['Journal Article'],Les observations sur la granulocytolyse in vitro dans les leucemies myeloides aigues.,France,Sang,Le Sang,20540380R,,OM,"['Humans', 'In Vitro Techniques', '*Leukemia', 'Leukemia, Myeloid/*blood', '*Leukemia, Myeloid, Acute']",['CLML: 5221:43607:210'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/blood in']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(8):688-90.,,,,,,,,,,,,,,
14912628,NLM,MEDLINE,20040215,20181201,0014-2565 (Print) 0014-2565 (Linking),43,5,1951 Dec 15,[Sarcoleukosis lenta with lymphoid goiter].,345-7,"['JIMENEZ-DIAZ, C', 'PANIAGUA, G']","['JIMENEZ-DIAZ C', 'PANIAGUA G']",['und'],['Journal Article'],Sarcoleucosis de evolucion lenta con bocio linfoide.,Spain,Rev Clin Esp,Revista clinica espanola,8608576,,OM,"['*Goiter', 'Humans', '*Leukemia']",['CLML: 5221:43220:211'],['NLM'],['*LEUKOSARCOMA'],1951/12/15 00:00,1951/12/15 00:01,['1951/12/15 00:00'],"['1951/12/15 00:00 [pubmed]', '1951/12/15 00:01 [medline]', '1951/12/15 00:00 [entrez]']",ppublish,Rev Clin Esp. 1951 Dec 15;43(5):345-7.,,,,,,,,,,,,,,
14912431,NLM,MEDLINE,20040215,20181201,,7,,1951,[Treatment of malignant lymphogranuloma and chronic leukemia with chloroethylnaphthylamine].,156-70,"['STORTI, E']",['STORTI E'],['und'],['Journal Article'],La terapia del linfogranuloma maligno e delle leucosi croniche con cloroetilnaftilamina.,Italy,Radioter Radiobiol Fis Medica,"Radioterapia, radiobiologia e fisica medica",20020080R,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Chronic Disease', 'Hodgkin Disease/*therapy', 'Leukemia/*therapy', '*Mechlorethamine', 'Nitrogen Mustard Compounds/*therapeutic use']",['CLML: 5221:43023:173:210:260'],['NLM'],"[""*HODGKIN'S DISEASE/therapy"", '*LEUKEMIA/therapy', '*NITROGEN MUSTARDS/therapeutic use']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Radioter Radiobiol Fis Medica. 1951;7:156-70.,,,,,,,,,,,,,,
14912031,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),78,3,1951 Dec,Further studies on formate incorporation by leukemic blood cells.,787-8,"['SKIPPER, H E', 'CHAPMAN, J B', 'BELL, M']","['SKIPPER HE', 'CHAPMAN JB', 'BELL M']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['0 (Formates)', '0YIW783RG1 (formic acid)']",OM,"['*Biochemical Phenomena', '*Blood Cells', 'Formates/*metabolism', 'Leukemia/*blood']",['CLML: 5221:42623:146:209'],['NLM'],"['*FORMATES/metabolism', '*LEUKEMIA/blood in']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1951 Dec;78(3):787-8. doi: 10.3181/00379727-78-19219.,['10.3181/00379727-78-19219 [doi]'],,,,,,,,,,,,,
14911930,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),78,2,1951 Nov,"Resistance in leukemic cells to a guanine analog, 8-azaguanine.",499-502,"['LAW, L W']",['LAW LW'],['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['0 (Purine Nucleosides)', '5Z93L87A1R (Guanine)', 'Q150359I72 (Azaguanine)']",OM,"['Animals', '*Azaguanine', '*Guanine', 'Humans', '*Leukemia, Experimental', '*Purine Nucleosides']",['CLML: 5221:42522:158:210'],['NLM'],"['*GUANINE', '*LEUKEMIA/experimental']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1951 Nov;78(2):499-502. doi: 10.3181/00379727-78-19118.,['10.3181/00379727-78-19118 [doi]'],,,,,,,,,,,,,
14911729,NLM,MEDLINE,20040215,20181201,0032-7867 (Print) 0032-7867 (Linking),60,5,1952 Jan 23,[Leukemia with tumors and Kahler's disease].,92-5,"['OLMER, J', 'ABIGNOLI, E']","['OLMER J', 'ABIGNOLI E']",['und'],['Journal Article'],Leucemies a tumeurs et maladie de Kahler.,France,Presse Med,La Presse medicale,0312556,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels', 'Multiple Myeloma/*diagnosis', '*Neoplasms', '*Plasma Cells']",['CLML: 5221:42321:210:247'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*MYELOMA, PLASMA CELL/diagnosis']",1952/01/23 00:00,1952/01/23 00:01,['1952/01/23 00:00'],"['1952/01/23 00:00 [pubmed]', '1952/01/23 00:01 [medline]', '1952/01/23 00:00 [entrez]']",ppublish,Presse Med. 1952 Jan 23;60(5):92-5.,,,,,,,,,,,,,,
14911619,NLM,MEDLINE,20040215,20181201,0032-745X (Print) 0032-745X (Linking),39,3,1952 Jan 18,[Hepatopancreatolienal calcinosis due to chronic recurrent pancreatitis complicated by chronic myeloid leukemia].,106-9,"['SCHAPOSNIK, F', 'BERGNA, L J']","['SCHAPOSNIK F', 'BERGNA LJ']",['und'],['Journal Article'],"Calcinosis hepatopancreaiolienal por pancreatitis cronica recidivante, complicada de leucemia mieloide cronica.",Argentina,Prensa Med Argent,Prensa medica argentina,0204056,,OM,"['Calcinosis/*etiology', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', 'Pancreatitis/*complications', '*Pancreatitis, Chronic']",['CLML: 5221:42211:67:210:273'],['NLM'],"['*CALCINOSIS/etiology and pathogenesis', '*LEUKEMIA, MYELOCYTIC', '*PANCREATITIS/complications']",1952/01/18 00:00,1952/01/18 00:01,['1952/01/18 00:00'],"['1952/01/18 00:00 [pubmed]', '1952/01/18 00:01 [medline]', '1952/01/18 00:00 [entrez]']",ppublish,Prensa Med Argent. 1952 Jan 18;39(3):106-9.,,,,,,,,,,,,,,
14911508,NLM,MEDLINE,20040215,20181201,0032-6518 (Print) 0032-6518 (Linking),168,1004,1952 Feb,The infective factor in asthma.,162-5,"['GUMPERT, T E']",['GUMPERT TE'],['eng'],['Journal Article'],,England,Practitioner,The Practitioner,0404245,,OM,"['Asthma/*etiology', 'Humans', '*Leukemia', 'Leukemia, Myeloid/*therapy']",['CLML: 5221:42100:39:210'],['NLM'],"['*ASTHMA/etiology and pathogenesis', '*LEUKEMIA, MONOCYTIC/therapy']",1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,Practitioner. 1952 Feb;168(1004):162-5.,,,,,,,,,,,,,,
14911302,NLM,MEDLINE,20040215,20181201,0031-4005 (Print) 0031-4005 (Linking),9,3,1952 Mar,Influence of ACTH and cortisone on leukemia.,339-41,"['FRANKLIN, J E']",['FRANKLIN JE'],['eng'],['Journal Article'],,United States,Pediatrics,Pediatrics,0376422,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['Adrenocorticotropic Hormone/*therapeutic use', 'Cortisone/*therapeutic use', '*Leadership', 'Leukemia/*therapy']",['CLML: 5221:41894:7:97:210'],['NLM'],"['*ACTH/therapeutic use', '*CORTISONE/therapeutic use', '*LEUKEMIA/therapy']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Pediatrics. 1952 Mar;9(3):339-41.,,,,,,,,,,,,,,
14911228,NLM,MEDLINE,20040215,20181201,,6,6,1951 Nov-Dec,[Roentgenography of osseous changes in leukemia in children].,331-5,"['SVAB, V', 'HORAK, B']","['SVAB V', 'HORAK B']",['und'],['Journal Article'],K rozpoznavani kostnach zmen u detskych leukemii pomoci roentgenu.,Czech Republic,Pediatr Listy,Pediatricke listy,0204303,,OM,"['Bone and Bones/*pathology', '*Leukemia']",['CLML: 5221:41820:59:210'],['NLM'],"['*BONES/pathology', '*LEUKEMIA/manifestations']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Pediatr Listy. 1951 Nov-Dec;6(6):331-5.,,,,,,,,,,,,,,
14911105,NLM,MEDLINE,20040215,20190214,0029-6643 (Print) 0029-6643 (Linking),10,2,1952 Feb,THERAPY of acute leukemia.,57-8,,,['eng'],['Journal Article'],,United States,Nutr Rev,Nutrition reviews,0376405,,OM,"['Humans', 'Leukemia/*therapy']",['CLML: 5221:41697:210'],['NLM'],['*LEUKEMIA/therapy'],1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,Nutr Rev. 1952 Feb;10(2):57-8. doi: 10.1111/j.1753-4887.1952.tb01065.x.,['10.1111/j.1753-4887.1952.tb01065.x [doi]'],,,,,,,,,,,,,
14910842,NLM,MEDLINE,20040215,20181201,0028-4793 (Print) 0028-4793 (Linking),246,13,1952 Mar 27,Splenectomy in leukemia and leukosarcoma.,477-84,"['FISHER, J H', 'WELCH, C S', 'DAMESHEK, W']","['FISHER JH', 'WELCH CS', 'DAMESHEK W']",['eng'],['Journal Article'],,United States,N Engl J Med,The New England journal of medicine,0255562,,OM,"['Humans', 'Leukemia/*therapy', 'Spleen/*surgery', '*Splenectomy']",['CLML: 5221:41434:210:211:352'],['NLM'],"['*LEUKEMIA/therapy', '*LEUKOSARCOMA/therapy', '*SPLEEN/surgery']",1952/03/27 00:00,1952/03/27 00:01,['1952/03/27 00:00'],"['1952/03/27 00:00 [pubmed]', '1952/03/27 00:01 [medline]', '1952/03/27 00:00 [entrez]']",ppublish,N Engl J Med. 1952 Mar 27;246(13):477-84. doi: 10.1056/NEJM195203272461301.,['10.1056/NEJM195203272461301 [doi]'],,,,,,,,,,,,,
14910783,NLM,MEDLINE,20040215,20181201,0028-1956 (Print) 0028-1956 (Linking),37,3,1952 Mar,The masking of clinical and hematological findings by cortisone and ACTH in acute leukemia in childhood.,67-8,"['MEHER, J E', 'TANNER, F H']","['MEHER JE', 'TANNER FH']",['eng'],['Journal Article'],,United States,Nebr State Med J,The Nebraska state medical journal,0326157,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['*Acute Disease', 'Adrenocorticotropic Hormone/*pharmacology', 'Cortisone/*pharmacology', 'Humans', '*Leukemia']",['CLML: 5221:41375:6:95:209'],['NLM'],"['*ACTH/effects', '*CORTISONE/effects', '*LEUKEMIA']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Nebr State Med J. 1952 Mar;37(3):67-8.,,,,,,,,,,,,,,
14910183,NLM,MEDLINE,20040215,20181201,0025-8105 (Print) 0025-8105 (Linking),11-12,,1951 Jul-Dec,[Leukemia; etiology and pathogenesis].,134-43,"['STAMENKOVIC, P']",['STAMENKOVIC P'],['und'],['Journal Article'],Leukemija; etiologija i patogeneza.,Serbia,Med Pregl,Medicinski pregled,2985249R,,OM,"['Humans', 'Leukemia/*etiology']",['CLML: 5221:40774:210'],['NLM'],['*LEUKEMIA/etiology and pathogenesis'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Med Pregl. 1951 Jul-Dec;11-12:134-43.,,,,,,,,,,,,,,
14909886,NLM,MEDLINE,20040215,20181201,0025-729X (Print) 0025-729X (Linking),1,2,1952 Jan 12,Chemotherapy in the reticuloses.,38-43,"['MELICK, R A']",['MELICK RA'],['eng'],['Journal Article'],,Australia,Med J Aust,The Medical journal of Australia,0400714,"['0 (Nitrogen Mustard Compounds)', '0 (Peptide Nucleic Acids)', '0 (Phosphorus Radioisotopes)', '0 (reticulose)', '27YLU75U4W (Phosphorus)', '3IN71E75Z5 (Urethane)', '50D9XSG0VR (Mechlorethamine)']",OM,"['Leukemia/*therapy', 'Lymphoma/*therapy', '*Mechlorethamine', 'Nitrogen Mustard Compounds/*therapeutic use', 'Peptide Nucleic Acids', '*Phosphorus', 'Phosphorus Radioisotopes/*therapeutic use', 'Urethane/*therapeutic use']",['CLML: 5221:40477:210:222:260:289:397'],['NLM'],"['*LEUKEMIA/therapy', '*LYMPHOMA/therapy', '*NITROGEN MUSTARDS/therapeutic use', '*PHOSPHORUS, RADIOACTIVE/therapeutic use', '*URETHANE/therapeutic use']",1952/01/12 00:00,1952/01/12 00:01,['1952/01/12 00:00'],"['1952/01/12 00:00 [pubmed]', '1952/01/12 00:01 [medline]', '1952/01/12 00:00 [entrez]']",ppublish,Med J Aust. 1952 Jan 12;1(2):38-43.,,,,,,,,,,,,,,
14909733,NLM,MEDLINE,20040215,20181201,,32,9,1951 Sep,"[Osteoarticular manifestations, first signs of acute leukemia in children].",6-8,"['MOURIQUAND, G', 'DECHAVANNE, D', 'ALLIGIER']","['MOURIQUAND G', 'DECHAVANNE D', 'ALLIGIER']",['und'],['Journal Article'],Manifestations osteo-articulaires premiers signes de leucemies aigues chez l'enfant.,France,Entret Bichat Med Entret Bichat,Les entretiens de Bichat. Medecine. Entretiens de Bichat,0241230,,OM,"['*Acute Disease', 'Bone and Bones/*pathology', 'Child', 'Humans', '*Leukemia']",['CLML: 5221:40324:59:210'],['NLM'],"['*BONES/pathology', '*LEUKEMIA/manifestations']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Entret Bichat Med Entret Bichat. 1951 Sep;32(9):6-8.,,,,,,,,,,,,,,
14909640,NLM,MEDLINE,20040215,20181201,0024-869X (Print) 0024-869X (Linking),19,8-9,1951 Oct,[Two cases of Letterer-Siwe's disease].,374-85,"['VAN BOLHUIS, J H', 'NOLEN, W']","['VAN BOLHUIS JH', 'NOLEN W']",['und'],['Journal Article'],Twee patienten met het syndroom van Letterer-Swie.,Netherlands,Maandschr Kindergeneeskd,Maandschrift voor kindergeneeskunde,7704293,"['Familial Letterer-Siwe disease', 'Reticuloendotheliosis, X-linked']",OM,"['Child', '*Genetic Diseases, X-Linked', 'Histiocytosis, Langerhans-Cell', 'Humans', 'Infant', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5221:40231:325'],['NLM'],['*RETICULOENDOTHELIOSIS/in infant and child'],1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Maandschr Kindergeneeskd. 1951 Oct;19(8-9):374-85.,,,,,,,,,,,,,,
14909010,NLM,MEDLINE,20040215,20181201,0368-394X (Print) 0368-394X (Linking),32,7-8,1951,[Case of pregnancy during leukemia].,657-8,"['PICOT, C']",['PICOT C'],['und'],['Journal Article'],Un cas de grossesse pendant une leucemie.,France,J Radiol Electrol Arch Electr Medicale,"Journal de radiologie, d'electrologie & archives d'electricite medicale",0013747,,OM,"['*Leukemia', '*Leukemia, Myeloid', 'Pregnancy']",['CLML: 5221:39601:210'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/in pregnancy']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,J Radiol Electrol Arch Electr Medicale. 1951;32(7-8):657-8.,,,,,,,,,,,,,,
14908834,NLM,MEDLINE,20040215,20190630,0022-3476 (Print) 0022-3476 (Linking),40,3,1952 Mar,The ameliorative effect of antibiotics on nonlipoid reticuloendotheliosis (Letterer-Siwe disease) in identical twins.,269-84,"['BIERMAN, H R', 'LANMAN, J T', 'DOD, K S', 'KELLY, K H', 'MILLER, E R', 'SHIMKIN, M B']","['BIERMAN HR', 'LANMAN JT', 'DOD KS', 'KELLY KH', 'MILLER ER', 'SHIMKIN MB']",['eng'],['Journal Article'],,United States,J Pediatr,The Journal of pediatrics,0375410,"['0 (Anti-Bacterial Agents)', '0 (Dermatologic Agents)', 'Familial Letterer-Siwe disease', 'Reticuloendotheliosis, X-linked']",OM,"['Anti-Bacterial Agents/*therapeutic use', 'Child', '*Dermatologic Agents', '*Genetic Diseases, X-Linked', '*Histiocytosis, Langerhans-Cell', 'Humans', 'Infant', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency', '*Twins, Monozygotic']",['CLML: 5221:39425:28:325'],['NLM'],"['*ANTIBIOTICS/therapeutic use', '*RETICULOENDOTHELIOSIS/in infant and child']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,J Pediatr. 1952 Mar;40(3):269-84. doi: 10.1016/s0022-3476(52)80256-2.,"['S0022-3476(52)80256-2 [pii]', '10.1016/s0022-3476(52)80256-2 [doi]']",,,,,,,,,,,,,
14908808,NLM,MEDLINE,20040215,20181201,0368-3494 (Print) 0368-3494 (Linking),64,1,1952 Jan,The role of the Leuconostoc citrovorum factor (LCF) in cell division and the mode of action of folic-acid antagonists on normal and leukaemic cells.,245-7,"['JACOBSON, W']",['JACOBSON W'],['eng'],['Journal Article'],,England,J Pathol Bacteriol,The Journal of pathology and bacteriology,0204750,"['0 (Folic Acid Antagonists)', 'Q573I9DVLP (Leucovorin)']",OM,"['*Cell Division', 'Folic Acid Antagonists/*therapeutic use', '*Leuconostoc', '*Leucovorin', 'Leukemia/*therapy']",['CLML: 5221:39399:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,J Pathol Bacteriol. 1952 Jan;64(1):245-7.,,,,,,,,,,,,,,
14908544,NLM,MEDLINE,20040215,20181201,0027-8874 (Print) 0027-8874 (Linking),12,4,1952 Feb,Increase in incidence of leukemia in hybrid mice bearing thymic transplants from a high leukemic strain.,789-805,"['LAW, L W']",['LAW LW'],['eng'],['Journal Article'],,United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,,OM,"['Animals', 'Incidence', '*Leukemia', '*Leukemia, Lymphoid', 'Mice', 'Thymus Gland/*physiology']",['CLML: 5221:39135:210:377'],['NLM'],"['*LEUKEMIA, LYMPHATIC/experimental', '*THYMUS/physiology']",1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,J Natl Cancer Inst. 1952 Feb;12(4):789-805.,,,,,,,,,,,,,,
14908348,NLM,MEDLINE,20040215,20181201,0025-0694 (Print) 0025-0694 (Linking),43,3,1952 Mar,"Leukemia, with special emphasis on ""leukemia in infants"".",65-7,"['BELIVEAU, R A']",['BELIVEAU RA'],['eng'],['Journal Article'],,United States,J Maine Med Assoc,The Journal of the Maine Medical Association,7505619,,OM,"['Humans', 'Infant', '*Leukemia']",['CLML: 5221:38939:209'],['NLM'],['*LEUKEMIA'],1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,J Maine Med Assoc. 1952 Mar;43(3):65-7.,,,,,,,,,,,,,,
14907601,NLM,MEDLINE,20040215,20181201,0004-1858 (Print) 0004-1858 (Linking),48,10,1952 Mar,Therapy of acute leukemia in children.,227-30,"['KLINGBERG, W G']",['KLINGBERG WG'],['eng'],['Journal Article'],,United States,J Ark Med Soc,The Journal of the Arkansas Medical Society,7503069,['0 (Folic Acid Antagonists)'],OM,"['*Acute Disease', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:38191:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,J Ark Med Soc. 1952 Mar;48(10):227-30.,,,,,,,,,,,,,,
14907357,NLM,MEDLINE,20040215,20190729,0002-9955 (Print) 0002-9955 (Linking),148,14,1952 Apr 5,Spontaneous venous thrombosis in the legs of tall men.,1202-3,"['NAIDE, M']",['NAIDE M'],['eng'],['Journal Article'],,United States,J Am Med Assoc,Journal of the American Medical Association,7507176,,OM,"['Humans', 'Leg/*blood supply', 'Male', '*Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', '*Thrombosis', '*Venous Thrombosis']",['CLML: 5221:37947:207:377'],['NLM'],"['*LEG/blood supply', '*THROMBOSIS']",1952/04/05 00:00,1952/04/05 00:01,['1952/04/05 00:00'],"['1952/04/05 00:00 [pubmed]', '1952/04/05 00:01 [medline]', '1952/04/05 00:00 [entrez]']",ppublish,J Am Med Assoc. 1952 Apr 5;148(14):1202-3. doi: 10.1001/jama.1952.02930140034009.,['10.1001/jama.1952.02930140034009 [doi]'],,,,,,,,,,,,,
14906896,NLM,MEDLINE,20040215,20181201,,4,3,1951 Dec,Chemotherapy of leukemia in adults.,91-113,"['WRIGHT, L T', 'WRIGHT, B P', 'WRIGHT, J C', 'HJELT, I', 'PRIGOT, A']","['WRIGHT LT', 'WRIGHT BP', 'WRIGHT JC', 'HJELT I', 'PRIGOT A']",['eng'],['Journal Article'],,United States,Harlem Hosp Bull,The Harlem Hospital bulletin,0234223,,OM,"['Adult', 'Humans', 'Leukemia/*therapy']",['CLML: 5221:37486:210'],['NLM'],['*LEUKEMIA/therapy'],1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Harlem Hosp Bull. 1951 Dec;4(3):91-113.,,,,,,,,,,,,,,
14906890,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),35,12,1951,Some investigations on the influence of cystin and cystein on the erythropoietic activity of the bone marrow cells with special regards to leukaemia.,1093-1109,"['PLUM, C M', 'GOLDBERG, L']","['PLUM CM', 'GOLDBERG L']",['eng'],['Journal Article'],,Italy,Haematologica,Haematologica,0417435,"['48TCX9A1VT (Cystine)', 'K848JZ4886 (Cysteine)']",OM,"['Bone Marrow/*drug effects', '*Bone Marrow Cells', 'Cysteine/*pharmacology', '*Cystine', 'Humans', '*Leukemia']",['CLML: 5221:37480:58:102'],['NLM'],"['*BONE MARROW/effect of drugs on', '*CYSTEINE/effects', '*CYSTINE']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Haematologica. 1951;35(12):1093-1109.,,,,,,,,,,,,,,
14906886,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),35,11,1951,[Chloroalkylamines and acute leukemia; clinical and histopathological study of methyl-bis (beta chloroethyl) amine hydrochloride in acute hemocytoblastic leukosis].,993-1041,"['MARINONE, G']",['MARINONE G'],['und'],['Journal Article'],Cloroalchilamine e leucemie acute; studio clinico ed istopatologico dell'azione del cloridrato di metil-bis (beta cloroetil) amina sulle leucosi emocitoblastiche acute.,Italy,Haematologica,Haematologica,0417435,"['0 (Amines)', '0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Amines', 'Humans', 'Leukemia/*therapy', '*Leukocytes', '*Mechlorethamine', 'Nitrogen Mustard Compounds/*therapeutic use']",['CLML: 5221:37476:210:260'],['NLM'],"['*LEUKEMIA/therapy', '*NITROGEN MUSTARDS/therapeutic use']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Haematologica. 1951;35(11):993-1041.,,,,,,,,,,,,,,
14906882,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),35,10,1951,"[Nitrogen mustard therapy of malignant granuloma, leukemia and neoplasms].",907-53,"['INGRASSIA, G', 'VASILE, B']","['INGRASSIA G', 'VASILE B']",['und'],['Journal Article'],La terapia aziopritica del granuloma maligno; delle leucemie e delle neoplasie.,Italy,Haematologica,Haematologica,0417435,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['Hodgkin Disease/*therapy', 'Leukemia/*therapy', '*Mechlorethamine', 'Neoplasms/*therapy', 'Nitrogen Mustard Compounds/*therapeutic use']",['CLML: 5221:37472:173:210:253:260'],['NLM'],"[""*HODGKIN'S DISEASE/therapy"", '*LEUKEMIA/therapy', '*NEOPLASMS/therapy', '*NITROGEN MUSTARDS/therapeutic use']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Haematologica. 1951;35(10):907-53.,,,,,,,,,,,,,,
14906880,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),35,10,1951,[Lymphosarcomatosis with leukemia evolution].,883-900,"['COTTI, L']",['COTTI L'],['und'],['Journal Article'],Linfosarcomatosi ad evoluzione leucemica.,Italy,Haematologica,Haematologica,0417435,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid']",['CLML: 5221:37470:210'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Haematologica. 1951;35(10):883-900.,,,,,,,,,,,,,,
14906724,NLM,MEDLINE,20040215,20181201,0016-5670 (Print) 0016-5670 (Linking),110,11,1951 Nov,[Therapy of leukemia with chloroethyl-naphthylamine compounds].,334-9,"['BERTOLA, A']",['BERTOLA A'],['und'],['Journal Article'],Sull'attivita terapeutica dei composti cloroetil-naftilaminici nelle leucemie.,Italy,Gazz Med Ital,Gazzetta medica italiana,0370730,['418M5916WG (Chloral Hydrate)'],OM,"['Chloral Hydrate/*therapeutic use', 'Humans', 'Leukemia/*therapy']",['CLML: 5221:37309:80:210'],['NLM'],"['*CHLORAL HYDRATE/therapeutic use', '*LEUKEMIA/therapy']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Gazz Med Ital. 1951 Nov;110(11):334-9.,,,,,,,,,,,,,,
14906723,NLM,MEDLINE,20040215,20181201,0016-5670 (Print) 0016-5670 (Linking),110,11,1951 Nov,[A case of promonocytic leukemia treated with ACTH].,332-4,"['GEROCARNI, B', 'GOUDAL, H']","['GEROCARNI B', 'GOUDAL H']",['ita'],['Journal Article'],Un caso di leucemia promonocitaria trattato con ACTH.,Italy,Gazz Med Ital,Gazzetta medica italiana,0370730,['9002-60-2 (Adrenocorticotropic Hormone)'],OM,"['Adrenocorticotropic Hormone/*therapeutic use', 'Humans', '*Leukemia', 'Leukemia, Myeloid/*therapy', '*Monocytes']",['CLML: 5221:37308:7:210'],['NLM'],"['*ACTH/therapeutic use', '*LEUKEMIA, MONOCYTIC/therapy']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Gazz Med Ital. 1951 Nov;110(11):332-4.,,,,,,,,,,,,,,
14906583,NLM,MEDLINE,20040215,20181201,0016-450X (Print) 0016-450X (Linking),42,2-4,1951 Dec,On a specific type and uterine metastasis of gastric cancer associated with leukemia-like reaction [Japanese text].,315-6,"['SASANO, N']",['SASANO N'],['eng'],['Journal Article'],,Japan,Gan,Gan,0151745,,OM,"['Female', 'Humans', '*Leukemia', 'Neoplasms/*blood', '*Stomach Neoplasms', '*Uterine Neoplasms']",['CLML: 5221:37167:251:357:400'],['NLM'],"['*NEOPLASMS/blood in', '*STOMACH/neoplasms', '*UTERUS/neoplasms']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Gan. 1951 Dec;42(2-4):315-6.,,,,,,,,,,,,,,
14906579,NLM,MEDLINE,20040215,20181201,0016-450X (Print) 0016-450X (Linking),42,2-4,1951 Dec,Precipitous leucopenia in a N-mustard treated leukemia; (an autopsy case).,302-7,"['TAZAKI, Y', 'FUCHIGAMI, A', 'OOTA, K']","['TAZAKI Y', 'FUCHIGAMI A', 'OOTA K']",['eng'],['Journal Article'],,Japan,Gan,Gan,0151745,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Autopsy', 'Humans', '*Leukemia', 'Leukemia, Myeloid/*therapy', '*Leukopenia', '*Mechlorethamine', '*Mustard Plant', 'Nitrogen Mustard Compounds/*pharmacology']",['CLML: 5221:37163:210:260'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/therapy', '*NITROGEN MUSTARDS/effects']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Gan. 1951 Dec;42(2-4):302-7.,,,,,,,,,,,,,,
14906511,NLM,MEDLINE,20040215,20211203,0016-450X (Print) 0016-450X (Linking),42,2-4,1951 Dec,Leukemic picture produced by transplantation of Yoshida sarcoma [Japanese text].,151-3,"['HONJO, O', 'TAGASHIRA, Y', 'OHARA, Y', 'MIYAKE, T', 'AMANO, S']","['HONJO O', 'TAGASHIRA Y', 'OHARA Y', 'MIYAKE T', 'AMANO S']",['eng'],['Journal Article'],,Japan,Gan,Gan,0151745,,OM,"['Animals', '*Asians', '*Diet', 'Humans', 'Leukemia/*etiology', '*Sarcoma, Experimental', '*Sarcoma, Yoshida']",['CLML: 5221:37095:111:210:335'],['NLM'],"['*DIETS', '*LEUKEMIA/etiology and pathogenesis', '*SARCOMA/experimental']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Gan. 1951 Dec;42(2-4):151-3.,,,,,,,,,,,,,,
14906484,NLM,MEDLINE,20040215,20181201,0016-3600 (Print) 0016-3600 (Linking),5,3,1952 Mar,Treatment of leukemia.,67-73,"['RAMBACH, W A', 'ALT, H L']","['RAMBACH WA', 'ALT HL']",['eng'],['Journal Article'],,United States,GP,GP,0230511,,OM,"['Humans', 'Leukemia/*therapy']",['CLML: 5221:37068:210'],['NLM'],['*LEUKEMIA/therapy'],1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,GP. 1952 Mar;5(3):67-73.,,,,,,,,,,,,,,
14906161,NLM,MEDLINE,20040215,20181201,0012-3714 (Print) 0012-3714 (Linking),12,12,1951 Dec,Neurological clinical conference; myelocytic leukemia with hematogenous tuberculosis and pyogenic septicemia.,376-9,"['BIEHL, J P', 'ARING, C', 'SHAVER, M']","['BIEHL JP', 'ARING C', 'SHAVER M']",['eng'],['Journal Article'],,United States,Dis Nerv Syst,Diseases of the nervous system,0370666,,OM,"['*Bacteremia', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Sepsis', '*Tuberculosis', 'Tuberculosis, Miliary/*complications']",['CLML: 5221:36745:210:340:388'],['NLM'],"['*LEUKEMIA, MYELOCYTIC', '*SEPTICEMIA AND BACTEREMIA', '*TUBERCULOSIS, MILIARY/complications']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Dis Nerv Syst. 1951 Dec;12(12):376-9.,,,,,,,,,,,,,,
14906038,NLM,MEDLINE,20040215,20181201,0012-0472 (Print) 0012-0472 (Linking),76,46,1951 Nov 16,[Chronic aleukemic myelosis].,1431,"['SANDKUHLER, S', 'STODTMEISTER, R']","['SANDKUHLER S', 'STODTMEISTER R']",['und'],['Journal Article'],Gibt es eine chronisch-aleukamische Myelose?,Germany,Dtsch Med Wochenschr,Deutsche medizinische Wochenschrift (1946),0006723,,OM,"['*Leukemia', '*Leukemia, Myeloid']",['CLML: 5221:36622:210'],['NLM'],"['*LEUKEMIA, MYELOCYTIC']",1951/11/16 00:00,1951/11/16 00:01,['1951/11/16 00:00'],"['1951/11/16 00:00 [pubmed]', '1951/11/16 00:01 [medline]', '1951/11/16 00:00 [entrez]']",ppublish,Dtsch Med Wochenschr. 1951 Nov 16;76(46):1431.,,,,,,,,,,,,,,
14906009,NLM,MEDLINE,20040215,20181201,0012-0219 (Print) 0012-0219 (Linking),7,5,1952 Jan 31,[Multiple transfusion in the treatment of chronic leukemia].,137-42,"['SCHULZ, F H', 'FISCHER, W']","['SCHULZ FH', 'FISCHER W']",['und'],['Journal Article'],Die Behandlung der chronischen Leukaemie mit gehauften Bluttransfusionen.,Germany,Dtsch Gesundheitsw,Das Deutsche Gesundheitswesen,0433572,,OM,"['Blood Transfusion/*therapeutic use', '*Chronic Disease', 'Humans', 'Leukemia/*therapy', '*Platelet Transfusion']",['CLML: 5221:36593:56:210'],['NLM'],"['*BLOOD TRANSFUSION/therapeutic use', '*LEUKEMIA/therapy']",1952/01/31 00:00,1952/01/31 00:01,['1952/01/31 00:00'],"['1952/01/31 00:00 [pubmed]', '1952/01/31 00:01 [medline]', '1952/01/31 00:00 [entrez]']",ppublish,Dtsch Gesundheitsw. 1952 Jan 31;7(5):137-42.,,,,,,,,,,,,,,
14905427,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),5,2,1952 Mar,Differential sulfate fixation in the spleen tissue of normal and leukemic mice.,403-4,"['DENKO, C W', 'LAYTON, L L']","['DENKO CW', 'LAYTON LL']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,['0 (Sulfates)'],OM,"['Animals', '*Leukemia, Experimental', 'Mice', '*Spleen', '*Sulfates']",['CLML: 5221:36011:210:362'],['NLM'],"['*LEUKEMIA/experimental', '*SULFATES']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Cancer. 1952 Mar;5(2):403-4. doi: 10.1002/1097-0142(195203)5:2<403::aid-cncr2820050230>3.0.co;2-v.,['10.1002/1097-0142(195203)5:2<403::aid-cncr2820050230>3.0.co;2-v [doi]'],,,,,,,,,,,,,
14905421,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),5,2,1952 Mar,Treatment of acute leukemia with anti-folic acid compounds (aninopterin and aminoanfol).,344-53,"['SAWITSKY, A', 'RITZ, N D', 'JACOBSON, J', 'MEYER, L M', 'SCHWARTZ, S O', 'KRIM, M', 'BOCK, G', 'BRAHIN, C M']","['SAWITSKY A', 'RITZ ND', 'JACOBSON J', 'MEYER LM', 'SCHWARTZ SO', 'KRIM M', 'BOCK G', 'BRAHIN CM']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Folic Acid Antagonists)', '935E97BOY8 (Folic Acid)']",OM,"['*Acute Disease', '*Folic Acid', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:36005:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Cancer. 1952 Mar;5(2):344-53. doi: 10.1002/1097-0142(195203)5:2<344::aid-cncr2820050224>3.0.co;2-g.,['10.1002/1097-0142(195203)5:2<344::aid-cncr2820050224>3.0.co;2-g [doi]'],,,,,,,,,,,,,
14905419,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),5,2,1952 Mar,The relative rates of formation of new leukocytes in patients with acute and chronic leukemias measured by the uptake of radioactive phosphorus in the isolated desoxyribosenucleic acid.,331-5,"['OSGOOD, E E', 'TIVEY, H', 'DAVISON, K B', 'SEAMAN, A J', 'LI, J G']","['OSGOOD EE', 'TIVEY H', 'DAVISON KB', 'SEAMAN AJ', 'LI JG']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,['27YLU75U4W (Phosphorus)'],OM,"['*Chronic Disease', 'Humans', 'Leukemia/*blood', '*Leukocytes', '*Phosphorus']",['CLML: 5221:36003:209:211'],['NLM'],"['*LEUKEMIA/blood in', '*LEUKOCYTES']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Cancer. 1952 Mar;5(2):331-5. doi: 10.1002/1097-0142(195203)5:2<331::aid-cncr2820050221>3.0.co;2-z.,['10.1002/1097-0142(195203)5:2<331::aid-cncr2820050221>3.0.co;2-z [doi]'],,,,,,,,,,,,,
14905246,NLM,MEDLINE,20040215,20181201,,44,11-12,1951,[Periorchitis and meningoencephalitis in guinea pigs after intraperitoneal injection of leukemic products; presence of intracellular bodies].,751-4,"['PETZETAKIS, M']",['PETZETAKIS M'],['und'],['Journal Article'],La periorchite et la meningoencephalite du cobaye apres injection intraperitoneale des produits leucemiques; presence de corpuscules intracellulaires.,France,Bull Soc Pathol Exot Filiales,Bulletin de la Societe de pathologie exotique et de ses filiales,7503399,,OM,"['Animals', '*Disease', '*Epididymitis', 'Guinea Pigs', 'Humans', '*Injections, Intraperitoneal', '*Leukemia, Experimental', 'Male', '*Meningoencephalitis', '*Orchitis', '*Testis']",['CLML: 5221:35830:210:233:372'],['NLM'],"['*LEUKEMIA/experimental', '*MENINGOENCEPHALITIS', '*TESTES/diseases']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Bull Soc Pathol Exot Filiales. 1951;44(11-12):751-4.,,,,,,,,,,,,,,
14905245,NLM,MEDLINE,20040215,20181201,,44,11-12,1951,[Keratoconjunctivitis in rabbits following inoculation with elements of human leukemia; presence of intracellular bodies; new test].,749-50,"['PETZETAKIS, M']",['PETZETAKIS M'],['und'],['Journal Article'],La kerato-conjonctivite du lapin consecutive a l'inoculation de produits leucemiques d'origine humaine; presence de corpuscules intracellulaires; nouveau test.,France,Bull Soc Pathol Exot Filiales,Bulletin de la Societe de pathologie exotique et de ses filiales,7503399,,OM,"['Animals', '*Conjunctivitis', 'Humans', '*Keratitis', '*Keratoconjunctivitis', '*Leukemia, Experimental', 'Rabbits']",['CLML: 5221:35829:91:199:210'],['NLM'],"['*CONJUNCTIVITIS/experimental', '*KERATITIS/experimental', '*LEUKEMIA/experimental']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Bull Soc Pathol Exot Filiales. 1951;44(11-12):749-50.,,,,,,,,,,,,,,
14905098,NLM,MEDLINE,20040215,20181201,,12,2,1951 Oct,Some observations on the morphologic basis for the roentgenographic changes in childhood leukemia.,67-73,"['FOLLIS, R H Jr', 'PARK, E A']","['FOLLIS RH Jr', 'PARK EA']",['eng'],['Journal Article'],,United States,Bull Hosp Joint Dis,Bulletin of the Hospital for Joint Diseases,7505376,,OM,"['Humans', '*Leukemia']",['CLML: 5221:35682:210'],['NLM'],['*LEUKEMIA/manifestations'],1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Bull Hosp Joint Dis. 1951 Oct;12(2):67-73.,,,,,,,,,,,,,,
14905068,NLM,MEDLINE,20040215,20181201,0068-3027 (Print) 0068-3027 (Linking),32,6,1952 Feb 10,[Therapeutic effect of ACTH and cortisone in acute and chronic leukemia].,282-5,"['MAURICE, P']",['MAURICE P'],['und'],['Journal Article'],L'action therapeutique de l'ACTH et cortisone dans les leucemies aigues et chroniques.,Belgium,Brux Med,Bruxelles medical,0372561,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['Adrenocorticotropic Hormone/*therapeutic use', '*Chronic Disease', 'Cortisone/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:35652:7:97:210'],['NLM'],"['*ACTH/therapeutic use', '*CORTISONE/therapeutic use', '*LEUKEMIA/therapy']",1952/02/10 00:00,1952/02/10 00:01,['1952/02/10 00:00'],"['1952/02/10 00:00 [pubmed]', '1952/02/10 00:01 [medline]', '1952/02/10 00:00 [entrez]']",ppublish,Brux Med. 1952 Feb 10;32(6):282-5.,,,,,,,,,,,,,,
14905037,NLM,MEDLINE,20040215,20190501,0007-1447 (Print) 0007-1447 (Linking),1,4760,1952 Mar 29,Spontaneous rupture of a leukaemic spleen.,693-4,"['COORAY, G H']",['COORAY GH'],['eng'],['Journal Article'],,England,Br Med J,British medical journal,0372673,,OM,"['Humans', 'Leukemia/*complications', 'Rupture', 'Rupture, Spontaneous', '*Spleen', '*Splenic Rupture']",['CLML: 5221:35621:209:352'],['NLM'],"['*LEUKEMIA/complications', '*SPLEEN/rupture']",1952/03/29 00:00,1952/03/29 00:01,['1952/03/29 00:00'],"['1952/03/29 00:00 [pubmed]', '1952/03/29 00:01 [medline]', '1952/03/29 00:00 [entrez]']",ppublish,Br Med J. 1952 Mar 29;1(4760):693-4. doi: 10.1136/bmj.1.4760.693.,['10.1136/bmj.1.4760.693 [doi]'],PMC2023133,,,,,,,,,,,,
14904772,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),27,9-10-11,1951 Sep-Nov,[Disease of guinea pig induced by intraperitoneal injection of a mash of chick embryo inoculated with leukemic material].,1469-73,"['SERAFINI, U M', 'BALDASSARRI, R']","['SERAFINI UM', 'BALDASSARRI R']",['und'],['Journal Article'],Malattia della cavia da iniezione intraperitoneale di poltiglia di embrioni di pollo inoculati con materiale leucemico.,Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,,OM,"['Animals', 'Guinea Pigs', '*Injections, Intraperitoneal', '*Leukemia, Experimental']",['CLML: 5221:35356:210'],['NLM'],['*LEUKEMIA/experimental'],1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1951 Sep-Nov;27(9-10-11):1469-73.,,,,,,,,,,,,,,
14904748,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),27,9-10-11,1951 Sep-Nov,[Demonstration of ultravirus in canine leukemia].,1430-2,"['VENDRAMINI, R', 'BRUNI, A', 'MAJORI, L']","['VENDRAMINI R', 'BRUNI A', 'MAJORI L']",['und'],['Journal Article'],Anche nella leucosi del cane puo essere dimostrata la presenza di un ultravirus.,Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,,OM,"['Animals', 'Dogs', 'Humans', 'Leukemia/*etiology']",['CLML: 5221:35332:210'],['NLM'],['*LEUKEMIA/etiology and pathogenesis'],1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1951 Sep-Nov;27(9-10-11):1430-2.,,,,,,,,,,,,,,
14904653,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),27,7-8,1951 Jul-Aug,[Further experimental contribution to demonstration of a viral agent of human leukemia; results of experiments conducted in 1950-51].,1247-9,"['NEGRONI, G', 'TOLU, A']","['NEGRONI G', 'TOLU A']",['und'],['Journal Article'],Ulteriore contributo sperimentale alla dimostrazione di un agente virale nelle leucemie umane: risultati delle esperienze condotte nell'anno 1950-51.,Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,,OM,"['Humans', 'Leukemia/*etiology', '*Viruses']",['CLML: 5221:35237:210:406'],['NLM'],"['*LEUKEMIA/etiology and pathogenesis', '*VIRUSES']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1951 Jul-Aug;27(7-8):1247-9.,,,,,,,,,,,,,,
14904652,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),27,7-8,1951 Jul-Aug,[Behavior of the guinea pig biological test in relation to inoculation of material corresponding to different phases of the disease from a subject with chronic myeloid leukemia].,1246-7,"['NEGRONI, G', 'TOLU, A']","['NEGRONI G', 'TOLU A']",['und'],['Journal Article'],"Comportamento dell ""test biologico cavia"" di fronte alla inoculazione di materiali corrispondenti a fasi diverse di malattia di un p. affetto da leucemia mieloide cronica.",Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,,OM,"['Animals', 'Guinea Pigs', '*Leukemia, Experimental', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Vaccination']",['CLML: 5221:35236:210'],['NLM'],['*LEUKEMIA/experimental'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1951 Jul-Aug;27(7-8):1246-7.,,,,,,,,,,,,,,
14904646,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),27,7-8,1951 Jul-Aug,[New experimental data in support of the possibility of demonstration of viral entities derivable from human leukemic material].,1234-6,"['MAGRASSI, F', 'LEONARDI, G', 'SCANU, A']","['MAGRASSI F', 'LEONARDI G', 'SCANU A']",['und'],['Journal Article'],Nuovi dati sperimentali in appoggio alla possibilita di dimostrazione di entita virali derivabili da materiali leucemici umani.,Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,,OM,"['Humans', 'Leukemia/*etiology', '*Viruses']",['CLML: 5221:35230:210:406'],['NLM'],"['*LEUKEMIA/etiology and pathogenesis', '*VIRUSES']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1951 Jul-Aug;27(7-8):1234-6.,,,,,,,,,,,,,,
14904514,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),7,3,1952 Mar,"Roles of prothrombin activity, heparin-protamine titer and platelet concentration in bleeding of leukemia.",311-25,"['FREEMAN, G', 'HYDE, J S']","['FREEMAN G', 'HYDE JS']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,"['0 (Protamines)', '9001-26-7 (Prothrombin)', '9005-49-6 (Heparin)']",OM,"['*Blood Coagulation', '*Blood Coagulation Tests', '*Blood Platelets', '*Heparin', 'Humans', '*Leukemia', '*Protamines', '*Prothrombin']",['CLML: 5221:35098:53:209'],['NLM'],"['*BLOOD COAGULATION', '*LEUKEMIA']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Blood. 1952 Mar;7(3):311-25.,['S0006-4971(20)65382-4 [pii]'],,,,,,,,,,,,,
14904513,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),7,3,1952 Mar,The nutritional status of folic acid in persons with leukemia and its possible relation to effects of aminopterin therapy.,307-10,"['SWENDSEID, M E', 'SWANSON, A L', 'MEYERS, M C', 'BETHELL, F H']","['SWENDSEID ME', 'SWANSON AL', 'MEYERS MC', 'BETHELL FH']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,"['935E97BOY8 (Folic Acid)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Aminopterin', '*Body Fluids', 'Folic Acid/*urine', 'Humans', 'Leukemia/*urine', '*Nutritional Status']",['CLML: 5221:35097:144:210'],['NLM'],"['*FOLIC ACID/in urine', '*LEUKEMIA/urine in']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Blood. 1952 Mar;7(3):307-10.,['S0006-4971(20)65381-2 [pii]'],,,,,,,,,,,,,
14904512,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),7,3,1952 Mar,The metabolic displacement of folic acid by aminopterin; studies in leukemia patients.,302-6,"['SWENDSEID, M E', 'SWANSON, A L', 'MILLER, S', 'BETHELL, F H']","['SWENDSEID ME', 'SWANSON AL', 'MILLER S', 'BETHELL FH']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,"['0 (Folic Acid Antagonists)', '935E97BOY8 (Folic Acid)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Aminopterin', '*Body Fluids', '*Folic Acid', 'Folic Acid Antagonists/*pharmacology', 'Leukemia/*urine']",['CLML: 5221:35096:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/effects', '*LEUKEMIA/urine in']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Blood. 1952 Mar;7(3):302-6.,['S0006-4971(20)65380-0 [pii]'],,,,,,,,,,,,,
14904103,NLM,MEDLINE,20040215,20190501,0003-9888 (Print) 0003-9888 (Linking),26,130,1951 Dec,Familial incidence of non-lipoid reticuloendotheliosis (Letterer-Siwe disease).,578-81,"['REESE, A J M', 'LEVY, E']","['REESE AJ', 'LEVY E']",['eng'],['Journal Article'],,England,Arch Dis Child,Archives of disease in childhood,0372434,"['Familial Letterer-Siwe disease', 'Reticuloendotheliosis, X-linked']",OM,"['Child', '*Genetic Diseases, X-Linked', '*Histiocytosis, Langerhans-Cell', 'Humans', 'Incidence', 'Infant', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5221:34687:325'],['NLM'],['*RETICULOENDOTHELIOSIS/in infant and child'],1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Arch Dis Child. 1951 Dec;26(130):578-81. doi: 10.1136/adc.26.130.578.,['10.1136/adc.26.130.578 [doi]'],PMC1988494,,,,,,,,,,,,
14903463,NLM,MEDLINE,20040215,20181201,,3,2,1952 Feb,Aminopterin in the treatment of acute leukemia of adults.,97-102,"['GENDEL, B R', 'KRAUS, A P', 'GREEN, F D']","['GENDEL BR', 'KRAUS AP', 'GREEN FD']",['eng'],['Journal Article'],,United States,Am Pract Dig Treat,American practitioner and digest of treatment,14840350R,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Acute Disease', '*Aminopterin', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:34033:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,Am Pract Dig Treat. 1952 Feb;3(2):97-102.,,,,,,,,,,,,,,
14903058,NLM,MEDLINE,20040215,20181201,0002-9467 (Print) 0002-9467 (Linking),123,11,1951 Nov,"Current trends in modern medicinals, II.",356-88,"['HOLLAND, M O']",['HOLLAND MO'],['eng'],['Journal Article'],,United States,Am J Pharm Sci Support Public Health,American journal of pharmacy and the sciences supporting public health,0416354,"['0 (Autonomic Agents)', '0 (Diuretics)', '0 (Hormones)', '0 (Organomercury Compounds)']",OM,"['*Autonomic Agents', '*Diuretics', '*Equipment and Supplies', 'Hormones/*therapeutic use', 'Leukemia/*therapy', 'Neoplasms/*therapy', '*Organomercury Compounds', 'Peptic Ulcer/*therapy', 'Pupil/*drug effects']",['CLML: 5221:33628:32:42:114:174:210:253:284:317'],['NLM'],"['*APPARATUS AND INSTRUMENTS', '*AUTONOMIC DRUGS', '*DIURETICS, MERCURIAL', '*HORMONES/therapeutic use', '*LEUKEMIA/therapy', '*NEOPLASMS/therapy', '*PEPTIC ULCER/therapy', '*PUPILS/effect of drugs on']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Am J Pharm Sci Support Public Health. 1951 Nov;123(11):356-88.,,,,,,,,,,,,,,
14902680,NLM,MEDLINE,20040215,20190626,0002-8703 (Print) 0002-8703 (Linking),43,3,1952 Mar,Pericarditis in patients with leukemia.,413-22,"['BIERMAN, H R', 'PERKINS, E K', 'ORTEGA, P']","['BIERMAN HR', 'PERKINS EK', 'ORTEGA P']",['eng'],['Journal Article'],,United States,Am Heart J,American heart journal,0370465,,OM,"['Humans', 'Leukemia/*complications', '*Pericarditis']",['CLML: 5221:33250:209:284'],['NLM'],"['*LEUKEMIA/complications', '*PERICARDITIS']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Am Heart J. 1952 Mar;43(3):413-22. doi: 10.1016/0002-8703(52)90084-7.,"['0002-8703(52)90084-7 [pii]', '10.1016/0002-8703(52)90084-7 [doi]']",,,,,,,,,,,,,
14902617,NLM,MEDLINE,20040215,20181201,0001-6985 (Print) 0001-6985 (Linking),56,5-6,1951,Congenital leukemia with megakaryocytosis in extramedullar foci.,233-40,"['SODERHJELM, L', 'RANSTROM, S']","['SODERHJELM L', 'RANSTROM S']",['eng'],['Journal Article'],,Sweden,Acta Soc Med Ups,Acta Societatis Medicorum Upsaliensis,0332127,,OM,"['*Blood Platelets', 'Humans', '*Leukemia']",['CLML: 5221:33187:53:209'],['NLM'],"['*BLOOD PLATELETS', '*LEUKEMIA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Soc Med Ups. 1951;56(5-6):233-40.,,,,,,,,,,,,,,
14902587,NLM,MEDLINE,20040215,20190917,0001-6926 (Print) 0001-6926 (Linking),36,6,1951 Dec,"Nitrogen mustard therapy in Hodgkin's disease, lympho-reticulosarcomatosis and lymphatic leukaemia.",461-8,"['KIELER, J']",['KIELER J'],['eng'],['Journal Article'],,Sweden,Acta radiol,Acta radiologica,0000221,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['Hodgkin Disease/*therapy', '*Leukemia', 'Leukemia, Lymphoid/*therapy', '*Lymphoma', 'Lymphoma, Non-Hodgkin/*therapy', '*Mechlorethamine', 'Nitrogen Mustard Compounds/*therapeutic use']",['CLML: 5221:33157:173:210:223:260'],['NLM'],"[""*HODGKIN'S DISEASE/therapy"", '*LEUKEMIA, LYMPHATIC/therapy', '*LYMPHOSARCOMA/therapy', '*NITROGEN MUSTARDS/therapeutic use']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Acta radiol. 1951 Dec;36(6):461-8. doi: 10.3109/00016925109176998.,['10.3109/00016925109176998 [doi]'],,,,,,,,,,,,,
14902343,NLM,MEDLINE,20040215,20190917,0365-463X (Print) 0365-463X (Linking),259,,1950,The effect of urethane in leukemia and multiple myeloma.,69-74,"['GULLBERG, B']",['GULLBERG B'],['eng'],['Journal Article'],,Sweden,Acta Med Scand Suppl,Acta medica Scandinavica. Supplementum,0370331,['3IN71E75Z5 (Urethane)'],OM,"['*Cell- and Tissue-Based Therapy', 'Humans', 'Leukemia/*therapy', 'Multiple Myeloma/*therapy', '*Plasma', '*Plasma Cells', 'Urethane/*therapeutic use']",['CLML: 5221:32913:210:247:397'],['NLM'],"['*LEUKEMIA/therapy', '*MYELOMA, PLASMA CELL/therapy', '*URETHANE/therapeutic use']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Acta Med Scand Suppl. 1950;259:69-74. doi: 10.1111/j.0954-6820.1951.tb13233.x.,['10.1111/j.0954-6820.1951.tb13233.x [doi]'],,,,,,,,,,,,,
14902315,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),6,6,1951 Dec,Experimental researches on the pathogenesis of leukaemias.,361-6,"['TORRIOLI, M', 'TORRIOLI, G']","['TORRIOLI M', 'TORRIOLI G']",['eng'],['Journal Article'],,Switzerland,Acta Haematol,Acta haematologica,0141053,,OM,"['Humans', 'Leukemia/*etiology']",['CLML: 5221:32885:210'],['NLM'],['*LEUKEMIA/etiology and pathogenesis'],1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Acta Haematol. 1951 Dec;6(6):361-6. doi: 10.1159/000203942.,['10.1159/000203942 [doi]'],,,,,,,,,,,,,
14902309,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),6,5,1951 Nov,[Histomorphology of monocytic leukemias].,290-309,"['FRESEN, O']",['FRESEN O'],['und'],['Journal Article'],Die Histomorphologie monozytarer Leukosen.,Switzerland,Acta Haematol,Acta haematologica,0141053,,OM,"['Humans', '*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid', '*Monocytes']",['CLML: 5221:32879:210'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Acta Haematol. 1951 Nov;6(5):290-309. doi: 10.1159/000203934.,['10.1159/000203934 [doi]'],,,,,,,,,,,,,
14902172,NLM,MEDLINE,20040215,20190917,0888-2479 (Print) 0888-2479 (Linking),89,4,1952 Apr,Follicular lymphoma with transient leukemic phase; brief review of literature and report of a case.,621-34,"['ANDAY, G J', 'SCHMITZ, H L']","['ANDAY GJ', 'SCHMITZ HL']",['eng'],['Journal Article'],,United States,AMA Arch Intern Med,A.M.A. archives of internal medicine,14470100R,,OM,"['Humans', '*Leukemia', '*Lymphoma', '*Lymphoma, Follicular', '*Lymphoma, Non-Hodgkin']",['CLML: 5221:32742:209:222'],['NLM'],"['*LEUKEMIA', '*LYMPHOSARCOMA']",1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,AMA Arch Intern Med. 1952 Apr;89(4):621-34. doi: 10.1001/archinte.1952.00240040100012.,['10.1001/archinte.1952.00240040100012 [doi]'],,,,,,,,,,,,,
14902100,NLM,MEDLINE,20040215,20191108,2374-2941 (Print) 2374-2941 (Linking),83,4,1952 Apr,Acute reticuloendotheliosis (Letterer-Siwe disease); report of a case in which several unusual features are combined.,475-80,"['NELSON, R A', 'STOFER, B E']","['NELSON RA', 'STOFER BE']",['eng'],['Journal Article'],,United States,AMA Am J Dis Child,A.M.A. American journal of diseases of children,14470010R,"['Familial Letterer-Siwe disease', 'Reticuloendotheliosis, X-linked']",OM,"['Child', '*Genetic Diseases, X-Linked', '*Histiocytosis, Langerhans-Cell', 'Humans', 'Infant', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5221:32670:325'],['NLM'],['*RETICULOENDOTHELIOSIS/in infant and child'],1952/04/01 00:00,1952/04/01 00:01,['1952/04/01 00:00'],"['1952/04/01 00:00 [pubmed]', '1952/04/01 00:01 [medline]', '1952/04/01 00:00 [entrez]']",ppublish,AMA Am J Dis Child. 1952 Apr;83(4):475-80. doi: 10.1001/archpedi.1952.02040080071006.,['10.1001/archpedi.1952.02040080071006 [doi]'],,,,,,,,,,,,,
14901940,NLM,MEDLINE,20040215,20181201,0044-2542 (Print) 0044-2542 (Linking),6,19-20,1951 Oct,[Blood iron in leukemias].,611-6,"['SCHULZ, F H', 'MORCZEK, A']","['SCHULZ FH', 'MORCZEK A']",['und'],['Journal Article'],Das Serumeisen bei Leukamien.,Germany,Z Gesamte Inn Med,Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,21730470R,"['0 (Iron Compounds)', 'E1UOL152H7 (Iron)']",OM,"['Humans', '*Iron', 'Iron Compounds/*metabolism', 'Leukemia/*blood']",['CLML: 5221:32462:195:209'],['NLM'],"['*IRON COMPOUNDS/metabolism', '*LEUKEMIA/blood in']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Z Gesamte Inn Med. 1951 Oct;6(19-20):611-6.,,,,,,,,,,,,,,
14901918,NLM,MEDLINE,20040215,20181201,0044-2542 (Print) 0044-2542 (Linking),6,15-16,1951 Aug,"[Typhoid-like intestinal ulceration in myeloblastic leukemia; a comment on F. W. Scheibe's article, A case of typhoid in a child simulating acute paramyeloblastic leukemial].",493-6,"['KOHN, K']",['KOHN K'],['und'],['Journal Article'],"Typhusahnliche Darmgeschwure bei Myeloblastenleukamie; eine Stellungnahme zu einem in dieser Zeitschrift veroffentlichten Aufsatz, Ein Fall von Typhus abdominalis beim Kleinkind unter dem klinischen Bild einer akuten Paramyeloblastenleukamie von F. W. Scheibe.",Germany,Z Gesamte Inn Med,Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,21730470R,['0 (Typhoid-Paratyphoid Vaccines)'],OM,"['Child', 'Humans', '*Leukemia', 'Leukemia, Myeloid/*complications', '*Leukemia, Myelomonocytic, Acute', 'Typhoid Fever/*diagnosis', '*Typhoid-Paratyphoid Vaccines']",['CLML: 5221:32440:210:395'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/complications', '*TYPHOID FEVER/diagnosis']",1951/08/01 00:00,1951/08/01 00:01,['1951/08/01 00:00'],"['1951/08/01 00:00 [pubmed]', '1951/08/01 00:01 [medline]', '1951/08/01 00:00 [entrez]']",ppublish,Z Gesamte Inn Med. 1951 Aug;6(15-16):493-6.,,,,,,,,,,,,,,
14901581,NLM,MEDLINE,20040215,20181201,0566-0777 (Print) 0566-0777 (Linking),3,3,1952 Mar,Treatment of leukemia in children.,461-8,"['BRUTON, O C', 'PRICE, W S']","['BRUTON OC', 'PRICE WS']",['eng'],['Journal Article'],,United States,U S Armed Forces Med J,United States Armed Forces medical journal,21410750R,['0 (Folic Acid Antagonists)'],OM,"['Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:32091:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,U S Armed Forces Med J. 1952 Mar;3(3):461-8.,,,,,,,,,,,,,,
14901045,NLM,MEDLINE,20040215,20181201,0370-9590 (Print) 0370-9590 (Linking),99,20,1951 Nov 15,[Treatment of histomonocytic reticulosis with cortisone].,940,"['MAGGI, A', 'HOJMAN, D', 'ROSEMBLIT, E']","['MAGGI A', 'HOJMAN D', 'ROSEMBLIT E']",['und'],['Journal Article'],Tratamiento con cortisona en una reticulosis histiomonocatica.,Argentina,Sem Med,La Semana medica,0404403,['V27W9254FZ (Cortisone)'],OM,"['Cortisone/*therapeutic use', '*Leukemia', 'Leukemia, Myeloid/*therapy', '*Monocytes']",['CLML: 5221:31554:97:210'],['NLM'],"['*CORTISONE/therapeutic use', '*LEUKEMIA, MONOCYTIC/therapy']",1951/11/15 00:00,1951/11/15 00:01,['1951/11/15 00:00'],"['1951/11/15 00:00 [pubmed]', '1951/11/15 00:01 [medline]', '1951/11/15 00:00 [entrez]']",ppublish,Sem Med. 1951 Nov 15;99(20):940.,,,,,,,,,,,,,,
14900995,NLM,MEDLINE,20040215,20181201,0036-7672 (Print) 0036-7672 (Linking),81,46,1951 Nov 17,[Two cases of successfully treated hemolytic anemia].,1121-4,"['BREMY, P']",['BREMY P'],['und'],['Journal Article'],Zwei besondere Falle erfolgreich behandelter hamolytischer Anamie.,Switzerland,Schweiz Med Wochenschr,Schweizerische medizinische Wochenschrift,0404401,"['Reticuloendotheliosis, X-linked']",OM,"['Anemia, Hemolytic/*etiology', '*Genetic Diseases, X-Linked', 'Humans', '*Leukemia, Hairy Cell', '*Severe Combined Immunodeficiency']",['CLML: 5221:31504:21:325'],['NLM'],"['*ANEMIA, HEMOLYTIC/etiology and pathogenesis', '*RETICULOENDOTHELIOSIS/manifestations']",1951/11/17 00:00,1951/11/17 00:01,['1951/11/17 00:00'],"['1951/11/17 00:00 [pubmed]', '1951/11/17 00:01 [medline]', '1951/11/17 00:00 [entrez]']",ppublish,Schweiz Med Wochenschr. 1951 Nov 17;81(46):1121-4.,,,,,,,,,,,,,,
14900786,NLM,MEDLINE,20040215,20181201,0370-632X (Print) 0370-632X (Linking),8,4,1951 Oct-Dec,[Priapism of leukemic origin; cure by radiotherapy of the spleen].,494-5,"['PONTHUS, P', 'BOUSTANY, F']","['PONTHUS P', 'BOUSTANY F']",['und'],['Journal Article'],Priapisme d'origine leucemique; guerison par radiotherapie splenique.,Lebanon,Rev Med Moyen Orient,Revue medicale du Moyen-Orient,20340240R,,OM,"['Humans', 'Leukemia/*complications', 'Male', '*Priapism', '*Spleen']",['CLML: 5221:31284:209:304'],['NLM'],"['*LEUKEMIA/complications', '*PRIAPISM']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Rev Med Moyen Orient. 1951 Oct-Dec;8(4):494-5.,,,,,,,,,,,,,,
14900396,NLM,MEDLINE,20040215,20181201,,20,6,1951 Nov,[Simultaneous occurrence of malignant tumors and systemic diseases].,405-12,"['WALTHER, H E']",['WALTHER HE'],['und'],['Journal Article'],Gleichzeitiges Vorkommen von bosartigen Geschwulsten und Systemerkrankungen.,Switzerland,Radiol Clin,Radiologia clinica,0024237,,OM,"['Humans', 'Leukemia/*complications', '*Neoplasms']",['CLML: 5221:30870:209:251'],['NLM'],"['*LEUKEMIA/complications', '*NEOPLASMS']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Radiol Clin. 1951 Nov;20(6):405-12.,,,,,,,,,,,,,,
14900250,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),7,19,1951 Oct 15,[Resistance of hemoglobin to alkaline denaturation in acute erythremic myelosis in man and in fowl].,592-3,"['IANNACCONE, A', 'RUSSO, N']","['IANNACCONE A', 'RUSSO N']",['und'],['Journal Article'],La resistenza dell'emoglobina alla denaturazione alcalina nella mielosi eritremica acuta dell-uomo e nella mielosi eritremica dei polli.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,"['0 (Hemoglobins)', 'Acute erythroleukemia']",OM,"['Animals', '*Biochemical Phenomena', '*Birds', '*Hemoglobins', '*Leukemia, Erythroblastic, Acute', '*Meat', '*Polycythemia Vera']",['CLML: 5221:30724:166:299'],['NLM'],"['*HEMOGLOBIN', '*POLYCYTHEMIA VERA']",1951/10/15 00:00,1951/10/15 00:01,['1951/10/15 00:00'],"['1951/10/15 00:00 [pubmed]', '1951/10/15 00:01 [medline]', '1951/10/15 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1951 Oct 15;7(19):592-3.,,,,,,,,,,,,,,
14900245,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),7,18,1951 Sep 30,[Aplastic myelosis and tuberculosis; clinical and hematologic aspects].,557-61,"['POLOSA, P', 'CURCIO, R']","['POLOSA P', 'CURCIO R']",['und'],['Journal Article'],Mielosi aplastica e tubercolosi; contributo clinicoematologico.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,,OM,"['*Anemia', '*Anemia, Aplastic', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Tuberculosis', '*Tuberculosis, Pulmonary']",['CLML: 5221:30719:20:391'],['NLM'],"['*ANEMIA, APLASTIC', '*TUBERCULOSIS, PULMONARY/manifestations']",1951/09/30 00:00,1951/09/30 00:01,['1951/09/30 00:00'],"['1951/09/30 00:00 [pubmed]', '1951/09/30 00:01 [medline]', '1951/09/30 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1951 Sep 30;7(18):557-61.,,,,,,,,,,,,,,
14900235,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),7,16,1951 Aug 31,[Acute leukemia and tuberculosis].,495-6,"['CONSOLINI, M']",['CONSOLINI M'],['und'],['Journal Article'],Leucemia acuta e tubercolosi; contributo clinico.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,,OM,"['*Acute Disease', 'Humans', 'Leukemia/*complications', '*Tuberculosis', '*Tuberculosis, Pulmonary']",['CLML: 5221:30709:209:389'],['NLM'],"['*LEUKEMIA/complications', '*TUBERCULOSIS, PULMONARY']",1951/08/31 00:00,1951/08/31 00:01,['1951/08/31 00:00'],"['1951/08/31 00:00 [pubmed]', '1951/08/31 00:01 [medline]', '1951/08/31 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1951 Aug 31;7(16):495-6.,,,,,,,,,,,,,,
14899973,NLM,MEDLINE,20040215,20181201,0031-403X (Print) 0031-403X (Linking),5,,1951 Sep-Oct,[Blood picture in myeloid leukemia in children].,44-9,"['KAPLAN, E M']",['KAPLAN EM'],['und'],['Journal Article'],Kartina krovi pri mieloidnom leikoze v detskom vozraste.,Russia (Federation),Pediatriia,Pediatriia,0405563,,OM,"['*Leukemia', 'Leukemia, Myeloid/*blood']",['CLML: 5221:30447:210'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/blood in']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Pediatriia. 1951 Sep-Oct;5:44-9.,,,,,,,,,,,,,,
14899892,NLM,MEDLINE,20040215,20181201,0030-6002 (Print) 0030-6002 (Linking),92,52,1951 Dec 30,[New data on the therapy and pathogenesis of pernicious anemia and leukemia].,1667-83,"['BARTA, I']",['BARTA I'],['und'],['Journal Article'],Ujabb szempontok az anaemia perniciosa es a leukaemiak pathogenesiseben es therapiajaban.,Hungary,Orv Hetil,Orvosi hetilap,0376412,"['0 (Hematinics)', '935E97BOY8 (Folic Acid)', 'P6YC3EG204 (Vitamin B 12)']",OM,"['*Anemia', 'Anemia, Pernicious/*therapy', 'Folic Acid/*therapeutic use', '*Hematinics', 'Leukemia/*therapy', 'Vitamin B 12/*therapeutic use']",['CLML: 5221:30366:21:144:210:410'],['NLM'],"['*ANEMIA, PERNICIOUS/therapy', '*FOLIC ACID/therapeutic use', '*LEUKEMIA/therapy', '*VITAMIN B 12/therapeutic use']",1951/12/30 00:00,1951/12/30 00:01,['1951/12/30 00:00'],"['1951/12/30 00:00 [pubmed]', '1951/12/30 00:01 [medline]', '1951/12/30 00:00 [entrez]']",ppublish,Orv Hetil. 1951 Dec 30;92(52):1667-83.,,,,,,,,,,,,,,
14899713,NLM,MEDLINE,20040215,20181201,0028-7628 (Print) 0028-7628 (Linking),52,5,1952 Mar 1,Radiophosphorus (P32) in diagnosis and treatment.,551-4,"['DUFFY, B J Jr', 'HOWLAND, J W']","['DUFFY BJ Jr', 'HOWLAND JW']",['eng'],['Journal Article'],,United States,N Y State J Med,New York state journal of medicine,0401064,"['0 (Phosphorus Radioisotopes)', '0 (Phosphorus, Dietary)', '27YLU75U4W (Phosphorus)']",OM,"['Humans', 'Leukemia/*therapy', '*Phosphorus', '*Phosphorus Radioisotopes', '*Phosphorus, Dietary', 'Polycythemia Vera/*therapy', '*Radioactivity']",['CLML: 5221:30185:210:289:299'],['NLM'],"['*LEUKEMIA/therapy', '*PHOSPHORUS, RADIOACTIVE', '*POLYCYTHEMIA VERA/therapy']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,N Y State J Med. 1952 Mar 1;52(5):551-4.,,,,,,,,,,,,,,
14899065,NLM,MEDLINE,20040215,20181201,0025-6749 (Print) 0025-6749 (Linking),9,208,1951 Dec 15,[Thiouracil therapy of chronic myeloid leukemia].,477,,,['und'],['Journal Article'],ESSAI de traitement de la leucemie myeloide chronique par le thiouracile.,Switzerland,Med Hyg (Geneve),Medecine et hygiene,9427226,['59X161SCYL (Thiouracil)'],OM,"['*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'Leukemia, Myeloid/*therapy', 'Thiouracil/*therapeutic use']",['CLML: 5221:29537:210:375'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/therapy', '*THIOURACIL/therapeutic use']",1951/12/15 00:00,1951/12/15 00:01,['1951/12/15 00:00'],"['1951/12/15 00:00 [pubmed]', '1951/12/15 00:01 [medline]', '1951/12/15 00:00 [entrez]']",ppublish,Med Hyg (Geneve). 1951 Dec 15;9(208):477.,,,,,,,,,,,,,,
14899021,NLM,MEDLINE,20040215,20181201,0025-6749 (Print) 0025-6749 (Linking),9,206,1951 Nov 15,[Therapy of acute leukemia].,429,"['ALDER, A']",['ALDER A'],['und'],['Journal Article'],Le probleme du traitement de la leucemie aigue.,Switzerland,Med Hyg (Geneve),Medecine et hygiene,9427226,,OM,"['*Acute Disease', 'Humans', 'Leukemia/*therapy']",['CLML: 5221:29493:210'],['NLM'],['*LEUKEMIA/therapy'],1951/11/15 00:00,1951/11/15 00:01,['1951/11/15 00:00'],"['1951/11/15 00:00 [pubmed]', '1951/11/15 00:01 [medline]', '1951/11/15 00:00 [entrez]']",ppublish,Med Hyg (Geneve). 1951 Nov 15;9(206):429.,,,,,,,,,,,,,,
14898899,NLM,MEDLINE,20040215,20181201,0025-021X (Print) 0025-021X (Linking),14,12,1951 Dec,[Pregnancy and leukemia].,369-72,"['SZINNYAI, M']",['SZINNYAI M'],['und'],['Journal Article'],Terhesseg es leukaemia.,Hungary,Magy Noorv Lapja,Magyar noorvosok lapja,0016262,,OM,"['Female', '*Leukemia', '*Leukemia, Myeloid', 'Pregnancy', '*Pregnancy Complications']",['CLML: 5221:29371:210:302'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/in pregnancy', '*PREGNANCY/complications']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Magy Noorv Lapja. 1951 Dec;14(12):369-72.,,,,,,,,,,,,,,
14897721,NLM,MEDLINE,20040215,20181201,0091-7427 (Print) 0091-7427 (Linking),6,11,1951 Nov,Leukemia research with laboratory mice.,411-8,"['DUNN, T B']",['DUNN TB'],['eng'],['Journal Article'],,United States,J Am Med Womens Assoc,Journal of the American Medical Women's Association,9810653,,OM,"['Animals', '*Leukemia', '*Leukemia, Experimental', 'Mice', '*Research']",['CLML: 5221:28175:210'],['NLM'],['*LEUKEMIA/experimental'],1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,J Am Med Womens Assoc. 1951 Nov;6(11):411-8.,,,,,,,,,,,,,,
14897704,NLM,MEDLINE,20040215,20190729,0002-9955 (Print) 0002-9955 (Linking),148,12,1952 Mar 22,Use of triethylene melamine in treatment of leukemia and leukosarcoma.,1015-21,"['SILVERBERG, J H', 'DAMESHEK, W']","['SILVERBERG JH', 'DAMESHEK W']",['eng'],['Journal Article'],,United States,J Am Med Assoc,Journal of the American Medical Association,7507176,['F7IY6HZG9D (Triethylenemelamine)'],OM,"['Leukemia/*therapy', 'Triethylenemelamine/*therapeutic use']",['CLML: 5221:28158:210:211:383'],['NLM'],"['*LEUKEMIA/therapy', '*LEUKOSARCOMA/therapy', '*TRIETHYLENE MELAMINE/therapeutic use']",1952/03/22 00:00,1952/03/22 00:01,['1952/03/22 00:00'],"['1952/03/22 00:00 [pubmed]', '1952/03/22 00:01 [medline]', '1952/03/22 00:00 [entrez]']",ppublish,J Am Med Assoc. 1952 Mar 22;148(12):1015-21. doi: 10.1001/jama.1952.02930120037009.,['10.1001/jama.1952.02930120037009 [doi]'],,,,,,,,,,,,,
14897698,NLM,MEDLINE,20040215,20190729,0002-9955 (Print) 0002-9955 (Linking),148,12,1952 Mar 22,"Resistance to corticotropin, cortisone, and folic acid antagonists in leukemia.",987-94,"['PILLERS, E M K', 'BURCHENAL, J H', 'ELIEL, L P', 'PEARSON, O H']","['PILLERS EM', 'BURCHENAL JH', 'ELIEL LP', 'PEARSON OH']",['eng'],['Journal Article'],,United States,J Am Med Assoc,Journal of the American Medical Association,7507176,"['0 (Folic Acid Antagonists)', '9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['Adrenocorticotropic Hormone/*therapeutic use', '*Biochemical Phenomena', 'Cortisone/*therapeutic use', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:28152:7:97:144:210'],['NLM'],"['*ACTH/therapeutic use', '*CORTISONE/therapeutic use', '*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/03/22 00:00,1952/03/22 00:01,['1952/03/22 00:00'],"['1952/03/22 00:00 [pubmed]', '1952/03/22 00:01 [medline]', '1952/03/22 00:00 [entrez]']",ppublish,J Am Med Assoc. 1952 Mar 22;148(12):987-94. doi: 10.1001/jama.1952.02930120009003.,['10.1001/jama.1952.02930120009003 [doi]'],,,,,,,,,,,,,
14897649,NLM,MEDLINE,20040215,20190729,0002-9955 (Print) 0002-9955 (Linking),148,9,1952 Mar 1,TRANSMISSIBLE leukemia in mice.,746,,,['eng'],['Journal Article'],,United States,J Am Med Assoc,Journal of the American Medical Association,7507176,,OM,"['Animals', '*Leukemia', '*Leukemia, Experimental', 'Mice']",['CLML: 5221:28103:210'],['NLM'],['*LEUKEMIA/experimental'],1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,J Am Med Assoc. 1952 Mar 1;148(9):746. doi: 10.1001/jama.1952.02930090056015.,['10.1001/jama.1952.02930090056015 [doi]'],,,,,,,,,,,,,
14897236,NLM,MEDLINE,20040215,20181201,0017-0364 (Print) 0017-0364 (Linking),101,5,1951 Sep-Oct,[Medicolegal evaluation of leukemic diseases in compensation].,383-8,"['REITANO, U']",['REITANO U'],['und'],['Journal Article'],Ancora sulla valutazione medico-legale ai fini della pensionistica di privilegio delle malattie leucemiche.,Italy,G Med Mil,Giornale di medicina militare,0417723,,OM,"['*Defense Mechanisms', '*Disease', '*Leukemia', '*Military Personnel']",['CLML: 5221:27690:33:209'],['NLM'],"['*ARMED FORCES PERSONNEL/diseases', '*LEUKEMIA']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,G Med Mil. 1951 Sep-Oct;101(5):383-8.,,,,,,,,,,,,,,
14897133,NLM,MEDLINE,20040215,20181201,,4,3,1951,[A case of eosinophilic leukemia].,911-20,"['TRINCAO, C', 'ESTEVES, V', 'DE AGUIAR, F']","['TRINCAO C', 'ESTEVES V', 'DE AGUIAR F']",['und'],['Journal Article'],Um caso de leucemia eosinofila.,Portugal,Gaz Med Port,Gazeta medica portuguesa,17040250R,,OM,"['Humans', '*Hypereosinophilic Syndrome', '*Leukemia']",['CLML: 5221:27587:209'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Gaz Med Port. 1951;4(3):911-20.,,,,,,,,,,,,,,
14897118,NLM,MEDLINE,20040215,20181201,,4,3,1951,[Acute decalcifying leukemia].,736-49,"['PIMENTEL, J C']",['PIMENTEL JC'],['und'],['Journal Article'],Leucemia aguda descalcificante.,Portugal,Gaz Med Port,Gazeta medica portuguesa,17040250R,,OM,"['*Acute Disease', 'Humans', '*Leukemia']",['CLML: 5221:27572:209'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Gaz Med Port. 1951;4(3):736-49.,,,,,,,,,,,,,,
14896406,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),12,2,1952 Feb,"The effects of freezing storage, and thawing upon the transplantability of mouse leukemic cells.",117-23,"['GABRIELSON, R M', 'SYVERTON, J T', 'KIRSCHBAUM, A']","['GABRIELSON RM', 'SYVERTON JT', 'KIRSCHBAUM A']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,,OM,"['Animals', '*Freezing', '*Leukemia, Experimental', 'Mice']",['CLML: 5221:26859:210'],['NLM'],['*LEUKEMIA/experimental'],1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,Cancer Res. 1952 Feb;12(2):117-23.,,,,,,,,,,,,,,
14896341,NLM,MEDLINE,20040215,20181201,,58,4,1951 Jul-Oct,[Mast cell reticulosis].,435-40,"['DEGOS, R', 'LORTAT JACOB', 'MALLARME, J', 'SAUVAN, R']","['DEGOS R', 'LORTAT JACOB', 'MALLARME J', 'SAUVAN R']",['und'],['Journal Article'],Reticulose a mastocytes.,France,Bull Soc Fr Dermatol Syphiligr,Bulletin de la Societe francaise de dermatologie et de syphiligraphie,7503407,"['Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', 'Humans', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Mast Cells', '*Severe Combined Immunodeficiency']",['CLML: 5221:26794:325'],['NLM'],['*RETICULOENDOTHELIOSIS'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Bull Soc Fr Dermatol Syphiligr. 1951 Jul-Oct;58(4):435-40.,,,,,,,,,,,,,,
14896310,NLM,MEDLINE,20040215,20181201,,58,4,1951 Jul-Oct,[Malignant cutaneous and pulmonary histiocytic reticulosis].,381-3,"['DEGOS, R', 'DESBUQUOIS, G', 'GARNIER, G', 'LEGRAIN, M']","['DEGOS R', 'DESBUQUOIS G', 'GARNIER G', 'LEGRAIN M']",['und'],['Journal Article'],Reticulose histiocytaire maligne cutanee et pulmonaire.,France,Bull Soc Fr Dermatol Syphiligr,Bulletin de la Societe francaise de dermatologie et de syphiligraphie,7503407,"['Reticuloendotheliosis, X-linked']",OM,"['*Administration, Cutaneous', '*Genetic Diseases, X-Linked', 'Humans', '*Leukemia, Hairy Cell', '*Severe Combined Immunodeficiency']",['CLML: 5221:26763:325'],['NLM'],['*RETICULOENDOTHELIOSIS/manifestations'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Bull Soc Fr Dermatol Syphiligr. 1951 Jul-Oct;58(4):381-3.,,,,,,,,,,,,,,
14896201,NLM,MEDLINE,20040215,20181201,0007-1447 (Print) 0007-1447 (Linking),1,4756,1952 Mar 1,EPIDEMIC haemorrhagic disease in Korea.,477-8,,,['eng'],['Journal Article'],,England,Br Med J,British medical journal,0372673,,OM,"['Animals', '*Epidemics', '*Hemorrhagic Disorders', '*Hemorrhagic Fever with Renal Syndrome', 'Humans', '*Leukemia, Experimental', 'Republic of Korea']",['CLML: 5221:26654:127:210'],['NLM'],"['*EPIDEMIC HEMORRHAGIC FEVER', '*LEUKEMIA/experimental']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,Br Med J. 1952 Mar 1;1(4756):477-8.,,,,,,,,,,,,,,
14896058,NLM,MEDLINE,20040215,20190501,0007-1447 (Print) 0007-1447 (Linking),1,4750,1952 Jan 19,Bullous lesions in leukaemia.,139-40,"['SCUTT, R']",['SCUTT R'],['eng'],['Journal Article'],,England,Br Med J,British medical journal,0372673,,OM,"['*Blister', 'Humans', '*Leukemia', '*Skin Diseases']",['CLML: 5221:26511:210:344'],['NLM'],"['*LEUKEMIA/manifestations', '*SKIN/diseases']",1952/01/19 00:00,1952/01/19 00:01,['1952/01/19 00:00'],"['1952/01/19 00:00 [pubmed]', '1952/01/19 00:01 [medline]', '1952/01/19 00:00 [entrez]']",ppublish,Br Med J. 1952 Jan 19;1(4750):139-40. doi: 10.1136/bmj.1.4750.139.,['10.1136/bmj.1.4750.139 [doi]'],PMC2022268,,,,,,,,,,,,
14896020,NLM,MEDLINE,20040215,20190501,0007-1447 (Print) 0007-1447 (Linking),1,4748,1952 Jan 5,Leukaemia with primary gynaecological manifestations.,30-1,"['WHEATON, C E']",['WHEATON CE'],['eng'],['Journal Article'],,England,Br Med J,British medical journal,0372673,,OM,"['Female', '*Gynecology', '*Hemorrhage', 'Humans', 'Leukemia/*complications', '*Uterine Hemorrhage', '*Uterus']",['CLML: 5221:26473:209:400'],['NLM'],"['*LEUKEMIA/complications', '*UTERUS/hemorrhage']",1952/01/05 00:00,1952/01/05 00:01,['1952/01/05 00:00'],"['1952/01/05 00:00 [pubmed]', '1952/01/05 00:01 [medline]', '1952/01/05 00:00 [entrez]']",ppublish,Br Med J. 1952 Jan 5;1(4748):30-1. doi: 10.1136/bmj.1.4748.30.,['10.1136/bmj.1.4748.30 [doi]'],PMC2022231,,,,,,,,,,,,
14895910,NLM,MEDLINE,20040215,20181201,0007-1285 (Print) 0007-1285 (Linking),25,289,1952 Jan,A case of extremely long survival in chronic myelogenous leukemia.,52-3,"['VAN DER WERFF, J T']",['VAN DER WERFF JT'],['eng'],['Journal Article'],,England,Br J Radiol,The British journal of radiology,0373125,,OM,"['Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid']",['CLML: 5221:26363:210'],['NLM'],"['*LEUKEMIA, MYELOCYTIC']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Br J Radiol. 1952 Jan;25(289):52-3. doi: 10.1259/0007-1285-25-289-52.,['10.1259/0007-1285-25-289-52 [doi]'],,,,,,,,,,,,,
14895252,NLM,MEDLINE,20040215,20181201,0004-0061 (Print) 0004-0061 (Linking),17,1,1951 Jul,"[Unusual concomitants of liver cirrhosis (leukemia, Addison's disease, hepatic tuberculosis, gastric polyposis, hepatic echinococcosis, rupture of the liver in cancrocirrhosis)].",151-76,"['TAROCCHI, B']",['TAROCCHI B'],['und'],['Journal Article'],"Rare concomitanze della cirrosi epatica (leucemia, morbo di Addison, tubercolosi epatica, poliposi gastrica, echinococco epatico, rottura del fegato in corso di cancrocirrosi).",Italy,Arch De Vecchi Anat Patol,"Archivio ""de Vecchi"" per l'anatomia patologica e la medicina clinica",0372455,"['Polyposis, Gastric']",OM,"['*Addison Disease', 'Adenomatous Polyps', '*Echinococcosis, Hepatic', 'Humans', '*Leukemia', '*Liver Cirrhosis', '*Stomach Neoplasms', '*Tuberculosis, Hepatic']",['CLML: 5221:25704:216'],['NLM'],['*LIVER CIRRHOSIS'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Arch De Vecchi Anat Patol. 1951 Jul;17(1):151-76.,,,,,,,,,,,,,,
14894796,NLM,MEDLINE,20040215,20181201,0365-3307 (Print) 0365-3307 (Linking),8,1,1951 Mar,[Di Guglielmo's disease; 2 cases].,7-25,"['TRINCAO, C', 'SOARES, A D']","['TRINCAO C', 'SOARES AD']",['und'],['Journal Article'],Doenca de Di Guglielmo; consideracoes a proposito de dois casos.,Portugal,An Inst Med Trop (Lisb),Anais do Instituto de Medicina Tropical,7502512,,OM,"['*Leukemia, Erythroblastic, Acute', '*Polycythemia Vera']",['CLML: 5221:25237:299'],['NLM'],['*POLYCYTHEMIA VERA'],1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,An Inst Med Trop (Lisb). 1951 Mar;8(1):7-25.,,,,,,,,,,,,,,
14894560,NLM,MEDLINE,20040215,20190616,0002-9378 (Print) 0002-9378 (Linking),63,2,1952 Feb,Acute myelogenous leucemia in pregnancy.,445-8,"['AUER, J']",['AUER J'],['eng'],['Journal Article'],,United States,Am J Obstet Gynecol,American journal of obstetrics and gynecology,0370476,,OM,"['Female', '*Leukemia', '*Leukemia, Myeloid', 'Pregnancy', '*Pregnancy Complications']",['CLML: 5221:25001:210:302'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/in pregnancy', '*PREGNANCY/complications']",1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,Am J Obstet Gynecol. 1952 Feb;63(2):445-8. doi: 10.1016/s0002-9378(15)32844-1.,"['S0002-9378(15)32844-1 [pii]', '10.1016/s0002-9378(15)32844-1 [doi]']",,,,,,,,,,,,,
14894466,NLM,MEDLINE,20040215,20190627,0002-9343 (Print) 0002-9343 (Linking),11,5,1951 Nov,Disseminated visceral torulosis without nervous system involvement with clinical appearance of granulocytic leukemia.,658-64,"['ZELMAN, S', ""O'NEIL, R H"", 'PLAUT, A']","['ZELMAN S', ""O'NEIL RH"", 'PLAUT A']",['eng'],['Journal Article'],,United States,Am J Med,The American journal of medicine,0267200,,OM,"['*Cryptococcosis', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Nervous System']",['CLML: 5221:24907:101:209'],['NLM'],"['*CRYPTOCOCCOSIS', '*LEUKEMIA']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Am J Med. 1951 Nov;11(5):658-64. doi: 10.1016/0002-9343(51)90098-8.,"['0002-9343(51)90098-8 [pii]', '10.1016/0002-9343(51)90098-8 [doi]']",,,,,,,,,,,,,
14894309,NLM,MEDLINE,20040215,20181201,,5,3-4,1951 Dec,[Radiodiagnosis of osseous modifications in infantile leukemia].,50-65,"['SVAB, V', 'HORAK, B']","['SVAB V', 'HORAK B']",['und'],['Journal Article'],Radiodiagnostic des modifications osseuses dans les leucemies infantiles.,Czech Republic,Acta Radiol Cancerol,Acta radiologica et cancerologica. Bohemoslovencia,14610230R,,OM,"['Bone and Bones/*pathology', '*Diagnostic Techniques and Procedures', '*Leukemia']",['CLML: 5221:24750:59:210'],['NLM'],"['*BONES/pathology', '*LEUKEMIA/manifestations']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Acta Radiol Cancerol. 1951 Dec;5(3-4):50-65.,,,,,,,,,,,,,,
14894307,NLM,MEDLINE,20040215,20190917,0001-6926 (Print) 0001-6926 (Linking),36,5,1951 Nov,Roentgen therapy in chronic leukemia.,417-31,"['MULLER, C', 'POPPE, E']","['MULLER C', 'POPPE E']",['eng'],['Journal Article'],,Sweden,Acta radiol,Acta radiologica,0000221,,OM,"['*Chronic Disease', 'Leukemia/*therapy']",['CLML: 5221:24748:210'],['NLM'],['*LEUKEMIA/therapy'],1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Acta radiol. 1951 Nov;36(5):417-31. doi: 10.3109/00016925109176993.,['10.3109/00016925109176993 [doi]'],,,,,,,,,,,,,
14893972,NLM,MEDLINE,20040215,20181201,0096-5979 (Print) 0096-5979 (Linking),65,3,1952 Mar,Acute leukemia with leukemic ulcers of the thigh and ulcers of the mouth due to aminopterin.,369-70,"['WEBSTER, J', 'BLUEFARB, S', 'SICKLEY, J F']","['WEBSTER J', 'BLUEFARB S', 'SICKLEY JF']",['eng'],['Journal Article'],,United States,AMA Arch Derm Syphilol,A.M.A. archives of dermatology and syphilology,14470040R,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Aminopterin', '*Face', 'Folic Acid Antagonists/*therapeutic use', '*Gastrointestinal Tract', 'Humans', '*Leukemia', 'Leukemia, Myeloid/*therapy', '*Mouth', '*Thigh', '*Ulcer']",['CLML: 5221:24413:144:210:395'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA, MYELOCYTIC/therapy', '*ULCER']",1952/03/01 00:00,1952/03/01 00:01,['1952/03/01 00:00'],"['1952/03/01 00:00 [pubmed]', '1952/03/01 00:01 [medline]', '1952/03/01 00:00 [entrez]']",ppublish,AMA Arch Derm Syphilol. 1952 Mar;65(3):369-70.,,,,,,,,,,,,,,
14893731,NLM,MEDLINE,20040215,20181201,0042-8450 (Print) 0042-8450 (Linking),8,9-10,1951 Sep-Oct,[Case of nodular reticuloendotheliosis in kala-azar].,332-4,"['TAVCAR, D']",['TAVCAR D'],['srp'],['Journal Article'],Slucaj cvoraste retikuloendotelioze kod kala-azara.,Serbia,Vojnosanit Pregl,Vojnosanitetski pregled,21530700R,"['Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', 'Humans', 'Leishmaniasis/*complications', '*Leishmaniasis, Visceral', 'Leukemia, Hairy Cell/*etiology', '*Severe Combined Immunodeficiency']",['CLML: 5221:24108:208:325'],['NLM'],"['*LEISHMANIASIS/complications', '*RETICULOENDOTHELIOSIS/etiology and pathogenesis']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Vojnosanit Pregl. 1951 Sep-Oct;8(9-10):332-4.,,,,,,,,,,,,,,
14893569,NLM,MEDLINE,20040215,20181201,0041-5782 (Print) 0041-5782 (Linking),113,38,1951 Sep 20,[Length of survival in chronic leukemia of childhood].,1304-6,"['ANDERSEN, P', 'KRINGELBACH, J']","['ANDERSEN P', 'KRINGELBACH J']",['und'],['Journal Article'],Om levetiden ved chronisk leucaemi i barnealderen.,Denmark,Ugeskr Laeger,Ugeskrift for laeger,0141730,,OM,"['*Chronic Disease', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5221:23946:210'],['NLM'],"['*LEUKEMIA, MYELOCYTIC']",1951/09/20 00:00,1951/09/20 00:01,['1951/09/20 00:00'],"['1951/09/20 00:00 [pubmed]', '1951/09/20 00:01 [medline]', '1951/09/20 00:00 [entrez]']",ppublish,Ugeskr Laeger. 1951 Sep 20;113(38):1304-6.,,,,,,,,,,,,,,
14892805,NLM,MEDLINE,20040215,20181201,,27,76,1951 Oct 14,[Clinical notes on hypochromic anemia in early infancy].,2994-9,"['BERNARD, J', 'GRENET, P', 'OSSIPOVSKI, B']","['BERNARD J', 'GRENET P', 'OSSIPOVSKI B']",['und'],['Journal Article'],Notes cliniques sur l'anemie hypochrome du petit enfant.,France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,"['E1UOL152H7 (Iron)', 'X-linked sideroblastic anemia']",OM,"['*Anemia', '*Anemia, Hypochromic', '*Anemia, Iron-Deficiency', '*Anemia, Sideroblastic', '*Genetic Diseases, X-Linked', 'Humans', '*Iron', '*Leukemia']",['CLML: 5221:23181:21:309'],['NLM'],"['*ANEMIA, IRON DEFICIENCY', '*PSEUDOLEUKEMIA INFANTUM']",1951/10/14 00:00,1951/10/14 00:01,['1951/10/14 00:00'],"['1951/10/14 00:00 [pubmed]', '1951/10/14 00:01 [medline]', '1951/10/14 00:00 [entrez]']",ppublish,Sem Hop. 1951 Oct 14;27(76):2994-9.,,,,,,,,,,,,,,
14892778,NLM,MEDLINE,20040215,20190619,0036-8075 (Print) 0036-8075 (Linking),114,2967,1951 Nov 9,An elevated excretion of creatine associated with leukemia in mice.,502-3,"['DINNING, J S', 'SEAGER, L D']","['DINNING JS', 'SEAGER LD']",['eng'],['Journal Article'],,United States,Science,"Science (New York, N.Y.)",0404511,['MU72812GK0 (Creatine)'],OM,"['Animals', 'Biological Transport', '*Body Fluids', 'Creatine/*urine', '*Leukemia', '*Leukemia, Experimental', 'Mice']",['CLML: 5221:23153:100:210'],['NLM'],"['*CREATINE/in urine', '*LEUKEMIA/experimental']",1951/11/09 00:00,1951/11/09 00:01,['1951/11/09 00:00'],"['1951/11/09 00:00 [pubmed]', '1951/11/09 00:01 [medline]', '1951/11/09 00:00 [entrez]']",ppublish,Science. 1951 Nov 9;114(2967):502-3. doi: 10.1126/science.114.2967.502.,['10.1126/science.114.2967.502 [doi]'],,,,,,,,,,,,,
14892439,NLM,MEDLINE,20040215,20181201,0034-947X (Print) 0034-947X (Linking),7,5,1951 Sep-Oct,[Modern treatment of infantile leukemias with folic acid antagonists].,729-30,"['BADOSA, O']",['BADOSA O'],['und'],['Journal Article'],"El moderno tratamiento de las leucemias infantiles, con los antagonistas de acido folico.",Spain,Rev Esp Pediatr,Revista espanola de pediatria,0404303,['0 (Folic Acid Antagonists)'],OM,"['*Folic Acid Antagonists', 'Humans', '*Leukemia']",['CLML: 5221:22808:144'],['NLM'],['*FOLIC ACID ANTAGONISTS'],1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Rev Esp Pediatr. 1951 Sep-Oct;7(5):729-30.,,,,,,,,,,,,,,
14892239,NLM,MEDLINE,20040215,20191026,0033-5541 (Print) 0033-5541 (Linking),36,4,1951,Measurement of the visceral blood volume in dogs.,219-31,"['DELORME, E J', 'MacPHERSON, A I S', 'MUKHERJEE, S R', 'ROWLANDS, S']","['DELORME EJ', 'MacPHERSON AI', 'MUKHERJEE SR', 'ROWLANDS S']",['eng'],['Journal Article'],,England,Q J Exp Physiol Cogn Med Sci,Quarterly journal of experimental physiology and cognate medical sciences,0404466,,OM,"['Animals', '*Blood Circulation', '*Blood Volume', 'Dogs', 'Leukemia/*therapy']",['CLML: 5221:22608:52:210'],['NLM'],"['*BLOOD CIRCULATION', '*LEUKEMIA/therapy']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Q J Exp Physiol Cogn Med Sci. 1951;36(4):219-31. doi: 10.1113/expphysiol.1951.sp000975.,['10.1113/expphysiol.1951.sp000975 [doi]'],,,,,,,,,,,,,
14892016,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),78,1,1951 Oct,Mechanisms of amethopterin resistance in leukemia. II. Effect of cortisone on sensitive and resistant mouse leukemias.,352-4,"['BURCHENAL, J H', 'WEBBER, L F', 'JOHNSTON, S F']","['BURCHENAL JH', 'WEBBER LF', 'JOHNSTON SF']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['V27W9254FZ (Cortisone)', 'YL5FZ2Y5U1 (Methotrexate)']",OM,"['Animals', 'Cortisone/*pharmacology', '*Leukemia', '*Leukemia, Experimental', '*Methotrexate', 'Mice']",['CLML: 5221:22385:95:210'],['NLM'],"['*CORTISONE/effects', '*LEUKEMIA/experimental']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1951 Oct;78(1):352-4. doi: 10.3181/00379727-78-19070.,['10.3181/00379727-78-19070 [doi]'],,,,,,,,,,,,,
14892015,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),78,1,1951 Oct,Mechanisms of amethopterin resistance in leukemia. I. Effects of weak folic acid antagonists on mouse leukemias.,348-51,"['BURCHENAL, J H', 'JOHNSTON, S F', 'WARING, G B']","['BURCHENAL JH', 'JOHNSTON SF', 'WARING GB']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['0 (Folic Acid Antagonists)', 'YL5FZ2Y5U1 (Methotrexate)']",OM,"['Animals', '*Biochemical Phenomena', 'Folic Acid Antagonists/*pharmacology', '*Leukemia', '*Leukemia, Experimental', '*Methotrexate']",['CLML: 5221:22384:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/effects', '*LEUKEMIA/experimental']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1951 Oct;78(1):348-51. doi: 10.3181/00379727-78-19069.,['10.3181/00379727-78-19069 [doi]'],,,,,,,,,,,,,
14892014,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),78,1,1951 Oct,"Pathogenic properties, and ""vertical"" transmission of the mouse leukemia agent.",342-8,"['GROSS, L']",['GROSS L'],['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,,OM,"['Animals', '*Infectious Disease Transmission, Vertical', '*Leukemia', '*Leukemia, Experimental']",['CLML: 5221:22383:210'],['NLM'],['*LEUKEMIA/experimental'],1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1951 Oct;78(1):342-8. doi: 10.3181/00379727-78-19068.,['10.3181/00379727-78-19068 [doi]'],,,,,,,,,,,,,
14891892,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),77,4,1951 Aug,Preferential incorporation of formate carbon into leukemic blood cells as indicated by autoradiography.,849-54,"['SKIPPER, H E', 'CHAPMAN, J B', 'BOYD, G A', 'RISER, W H Jr', 'BELL, M']","['SKIPPER HE', 'CHAPMAN JB', 'BOYD GA', 'RISER WH Jr', 'BELL M']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['0 (Formates)', '0YIW783RG1 (formic acid)', '7440-44-0 (Carbon)']",OM,"['Animals', '*Autoradiography', '*Blood Cells', '*Carbon', '*Formates', '*Leukemia, Experimental']",['CLML: 5221:22261:210'],['NLM'],['*LEUKEMIA/experimental'],1951/08/01 00:00,1951/08/01 00:01,['1951/08/01 00:00'],"['1951/08/01 00:00 [pubmed]', '1951/08/01 00:01 [medline]', '1951/08/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1951 Aug;77(4):849-54. doi: 10.3181/00379727-77-18946.,['10.3181/00379727-77-18946 [doi]'],,,,,,,,,,,,,
14891555,NLM,MEDLINE,20040215,20181201,0032-6518 (Print) 0032-6518 (Linking),167,1002,1951 Dec,The treatment of chronic leukaemia.,657-60,"['CHALMERS, J N M']",['CHALMERS JN'],['eng'],['Journal Article'],,England,Practitioner,The Practitioner,0404245,,OM,"['*Chronic Disease', 'Leukemia/*therapy']",['CLML: 5221:21924:210'],['NLM'],['*LEUKEMIA/therapy'],1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Practitioner. 1951 Dec;167(1002):657-60.,,,,,,,,,,,,,,
14891329,NLM,MEDLINE,20040215,20181201,0031-4005 (Print) 0031-4005 (Linking),8,5,1951 Nov,Leukemia and neuroblastoma.,730-3,"['DARGEON, H', 'BURCHENAL, J H']","['DARGEON H', 'BURCHENAL JH']",['eng'],['Journal Article'],,United States,Pediatrics,Pediatrics,0376422,,OM,"['*Coronary Disease', 'Humans', 'Leukemia/*therapy', '*Neuroblastoma']",['CLML: 5221:21698:93:210:257'],['NLM'],"['*CORONARY DISEASE', '*LEUKEMIA/therapy', '*NEUROBLASTOMA']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Pediatrics. 1951 Nov;8(5):730-3.,,,,,,,,,,,,,,
14891288,NLM,MEDLINE,20040215,20181201,0031-3890 (Print) 0031-3890 (Linking),59,7-8,1951 Jul-Aug,[Two cases of Jaksch-Hayem-Luzet anemia in two sets of twins].,565-76,"['SAGGESE, M', 'CROCCO, G']","['SAGGESE M', 'CROCCO G']",['und'],['Journal Article'],Su due casi di anemia di Jaksch-Hayem-Luzet in due coppie di gemelli.,Italy,Pediatria (Napoli),La Pediatria,0401207,,OM,"['*Anemia', '*Leukemia', '*Twins']",['CLML: 5221:21657:309'],['NLM'],['*PSEUDOLEUKEMIA INFANTUM'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Pediatria (Napoli). 1951 Jul-Aug;59(7-8):565-76.,,,,,,,,,,,,,,
14890798,NLM,MEDLINE,20040215,20181201,0028-2162 (Print) 0028-2162 (Linking),95,39,1951 Sep 29,[Reticuloses].,2871-7,"['DEELMAN, H T']",['DEELMAN HT'],['und'],['Journal Article'],De reticuloses.,Netherlands,Ned Tijdschr Geneeskd,Nederlands tijdschrift voor geneeskunde,0400770,"['0 (Peptide Nucleic Acids)', '0 (reticulose)', 'Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', 'Peptide Nucleic Acids', '*Severe Combined Immunodeficiency']",['CLML: 5221:21167:325'],['NLM'],['*RETICULOENDOTHELIOSIS'],1951/09/29 00:00,1951/09/29 00:01,['1951/09/29 00:00'],"['1951/09/29 00:00 [pubmed]', '1951/09/29 00:01 [medline]', '1951/09/29 00:00 [entrez]']",ppublish,Ned Tijdschr Geneeskd. 1951 Sep 29;95(39):2871-7.,,,,,,,,,,,,,,
14890788,NLM,MEDLINE,20040215,20181201,0028-2162 (Print) 0028-2162 (Linking),95,37,1951 Sep 15,[Megakaryocytes in peripheral blood].,2704-7,"['BEUKEMA, W']",['BEUKEMA W'],['und'],['Journal Article'],Megacaryocyten in het periphere bloed.,Netherlands,Ned Tijdschr Geneeskd,Nederlands tijdschrift voor geneeskunde,0400770,,OM,"['*Blood Platelets', 'Humans', '*Leukemia', 'Leukemia, Myeloid/*blood', '*Megakaryocytes']",['CLML: 5221:21157:53:210'],['NLM'],"['*BLOOD PLATELETS', '*LEUKEMIA, MYELOCYTIC/blood in']",1951/09/15 00:00,1951/09/15 00:01,['1951/09/15 00:00'],"['1951/09/15 00:00 [pubmed]', '1951/09/15 00:01 [medline]', '1951/09/15 00:00 [entrez]']",ppublish,Ned Tijdschr Geneeskd. 1951 Sep 15;95(37):2704-7.,,,,,,,,,,,,,,
14890591,NLM,MEDLINE,20040215,20181201,0026-4806 (Print) 0026-4806 (Linking),42,66,1951 Oct 6,[Appearance of leukemic myelosis following thiouracil therapy].,508-9,"['FUA, C']",['FUA C'],['und'],['Journal Article'],Insorgenza di mielosi leucemica in seguito a terapia tiouracilica.,Italy,Minerva Med,Minerva medica,0400732,['59X161SCYL (Thiouracil)'],OM,"['Humans', 'Hyperthyroidism/*therapy', '*Leukemia', 'Leukemia, Myeloid/*etiology', 'Thiouracil/*toxicity']",['CLML: 5221:20960:182:210:375'],['NLM'],"['*HYPERTHYROIDISM/therapy', '*LEUKEMIA, MYELOCYTIC/etiology and pathogenesis', '*THIOURACIL/toxicity']",1951/10/06 00:00,1951/10/06 00:01,['1951/10/06 00:00'],"['1951/10/06 00:00 [pubmed]', '1951/10/06 00:01 [medline]', '1951/10/06 00:00 [entrez]']",ppublish,Minerva Med. 1951 Oct 6;42(66):508-9.,,,,,,,,,,,,,,
14890432,NLM,MEDLINE,20040215,20181201,0025-7818 (Print) 0025-7818 (Linking),42,10,1951 Oct,"[Grave plastrinopenic hemorrhagic syndrome, manifestation of onset of chronic leukemic lymphadenosis].",295-8,"['SAITA, G']",['SAITA G'],['und'],['Journal Article'],"Grave sindrome emorragica piastrinopenica, manifestazione d'esordio di linfoadenosi leucemica cronica.",Italy,Med Lav,La Medicina del lavoro,0401176,,OM,"['*Leukemia', '*Leukemia, Lymphoid']",['CLML: 5221:20801:210'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Med Lav. 1951 Oct;42(10):295-8.,,,,,,,,,,,,,,
14889974,NLM,MEDLINE,20040215,20181201,0024-7790 (Print) 0024-7790 (Linking),185,42,1951 Oct 21,[Therapy of acute leukemias by auto-transfusion of x-irradiated blood].,271-4,"['CROIZAT, P', 'REVOL, L', 'PAPILLON, J', 'PINET', 'BUSSY']","['CROIZAT P', 'REVOL L', 'PAPILLON J', 'PINET', 'BUSSY']",['und'],['Journal Article'],Essais de traitement des leucoses aigues par reinjection au malade de son propre sang irradie par rayons x.,France,Lyon Med,Lyon medical,0335015,,OM,"['*Acute Disease', '*Blood Transfusion', 'Humans', 'Leukemia/*therapy', '*Platelet Transfusion']",['CLML: 5221:20343:210'],['NLM'],['*LEUKEMIA/therapy'],1951/10/21 00:00,1951/10/21 00:01,['1951/10/21 00:00'],"['1951/10/21 00:00 [pubmed]', '1951/10/21 00:01 [medline]', '1951/10/21 00:00 [entrez]']",ppublish,Lyon Med. 1951 Oct 21;185(42):271-4.,,,,,,,,,,,,,,
14889701,NLM,MEDLINE,20040215,20181201,0368-6132 (Print) 0368-6132 (Linking),6,9,1951 Sep 1,[Effective therapy of leukemias].,405-9,"['FLEISCHHACKER, H']",['FLEISCHHACKER H'],['und'],['Journal Article'],Der Einfluss der Therapie bei Leukamien.,Austria,Klin Med Osterr Z Wiss Prakt Med,Klinische Medizin; osterreichische Zeitschrift fur wissenschaftliche und praktische Medizin,18140020R,,OM,"['Humans', 'Leukemia/*therapy']",['CLML: 5221:20070:210'],['NLM'],['*LEUKEMIA/therapy'],1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Klin Med Osterr Z Wiss Prakt Med. 1951 Sep 1;6(9):405-9.,,,,,,,,,,,,,,
14889492,NLM,MEDLINE,20040215,20181201,0368-394X (Print) 0368-394X (Linking),32,5-6,1951,"[Case of leukosis with sarcomatous outset, discovered accidentally during a pleuro-pulmonary examination; acute evolution].",527-9,"['LE BIHAN, R', 'GUENNEC', 'TEXIER', 'BOISOT']","['LE BIHAN R', 'GUENNEC', 'TEXIER', 'BOISOT']",['und'],['Journal Article'],"Sur un cas de leucose, a debut sarcomateux, decouvert fortuitement a la suite d'un examen pleuro-pulmonaire; evolution aigue.",France,J Radiol Electrol Arch Electr Medicale,"Journal de radiologie, d'electrologie & archives d'electricite medicale",0013747,,OM,"['*Biological Evolution', 'Humans', '*Leukemia', '*Mediastinal Neoplasms', '*Mediastinum', '*Pleura']",['CLML: 5221:19861:211:228'],['NLM'],"['*LEUKOSARCOMA', '*MEDIASTINUM/neoplasms']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,J Radiol Electrol Arch Electr Medicale. 1951;32(5-6):527-9.,,,,,,,,,,,,,,
14889398,NLM,MEDLINE,20040215,20190630,0022-3476 (Print) 0022-3476 (Linking),39,5,1951 Nov,Citrovorum factor in leucemia; two cases with autopsy findings.,560-4,"['EARLE, A M', 'REILLY, W A', 'LAWSON, W G']","['EARLE AM', 'REILLY WA', 'LAWSON WG']",['eng'],['Journal Article'],,United States,J Pediatr,The Journal of pediatrics,0375410,"['935E97BOY8 (Folic Acid)', 'Q573I9DVLP (Leucovorin)']",OM,"['*Autopsy', 'Folic Acid/analogs & derivatives', '*Leucovorin', '*Leukemia']",['CLML: 5221:19767:144:209'],['NLM'],"['*FOLIC ACID/derivatives', '*LEUKEMIA']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,J Pediatr. 1951 Nov;39(5):560-4. doi: 10.1016/s0022-3476(51)80177-x.,"['S0022-3476(51)80177-X [pii]', '10.1016/s0022-3476(51)80177-x [doi]']",,,,,,,,,,,,,
14889264,NLM,MEDLINE,20040215,20181201,0027-8874 (Print) 0027-8874 (Linking),12,3,1951 Dec,Myelogenous leukemia in the cat.,599-613,"['EYESTONE, W H']",['EYESTONE WH'],['eng'],['Journal Article'],,United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,,OM,"['Animals', '*Cat Diseases', 'Cats', '*Leukemia', 'Leukemia, Myeloid/*diagnosis']",['CLML: 5221:19633:74:210'],['NLM'],"['*CATS/diseases', '*LEUKEMIA, MYELOCYTIC/diagnosis']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,J Natl Cancer Inst. 1951 Dec;12(3):599-613.,,,,,,,,,,,,,,
14889247,NLM,MEDLINE,20040215,20181201,0027-8874 (Print) 0027-8874 (Linking),12,2,1951 Oct,Electrophoretically determined blood-protein levels in a case of acute myelogenous leukemia under exchange transfusion treatment.,323-35,"['GUTTER, F J', 'KREVANS, J R', 'MOULTON, G A', 'KEGELES, G']","['GUTTER FJ', 'KREVANS JR', 'MOULTON GA', 'KEGELES G']",['eng'],['Journal Article'],,United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,"['0 (Blood Proteins)', '0 (Hemoglobins)']",OM,"['*Blood Proteins', '*Hemoglobins', 'Humans', '*Leukemia', 'Leukemia, Myeloid/*therapy', '*Leukemia, Myeloid, Acute']",['CLML: 5221:19616:54:166:210'],['NLM'],"['*BLOOD PROTEINS', '*HEMOGLOBIN', '*LEUKEMIA, MYELOCYTIC/therapy']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,J Natl Cancer Inst. 1951 Oct;12(2):323-35.,,,,,,,,,,,,,,
14889161,NLM,MEDLINE,20040215,20181201,0021-7883 (Print) 0021-7883 (Linking),32,763,1951 Oct 20,[Results of therapy of various diseases of the blood by radioactive phosphorus].,919-28,"['CROIZAT, P', 'BERGER, M', 'CREYSSEL, R']","['CROIZAT P', 'BERGER M', 'CREYSSEL R']",['und'],['Journal Article'],Resultats du traitement de diverses hemopathies par le phosphore radioactif; une experience de 16 mois.,France,J Med Lyon,Journal de medecine de Lyon,2985084R,"['0 (Phosphorus Radioisotopes)', '0 (Phosphorus, Dietary)', '27YLU75U4W (Phosphorus)']",OM,"['Leukemia/*therapy', '*Phosphorus', 'Phosphorus Radioisotopes/*therapeutic use', '*Phosphorus, Dietary', '*Radioactivity']",['CLML: 5221:19530:210:289'],['NLM'],"['*LEUKEMIA/therapy', '*PHOSPHORUS, RADIOACTIVE/therapeutic use']",1951/10/20 00:00,1951/10/20 00:01,['1951/10/20 00:00'],"['1951/10/20 00:00 [pubmed]', '1951/10/20 00:01 [medline]', '1951/10/20 00:00 [entrez]']",ppublish,J Med Lyon. 1951 Oct 20;32(763):919-28.,,,,,,,,,,,,,,
14888031,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),35,7,1951,[Chronic erythremic myelosis terminating in hemocytoblastic myelosis].,661-77,"['BUSSI, L', 'FRANZINI, P']","['BUSSI L', 'FRANZINI P']",['und'],['Journal Article'],Mielosi eritremica cronica con evoluzione terminale in mielosi emocitoblastica.,Italy,Haematologica,Haematologica,0417435,,OM,"['*Death', '*Leukemia, Erythroblastic, Acute', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Leukocytes', '*Polycythemia Vera']",['CLML: 5221:18400:299'],['NLM'],['*POLYCYTHEMIA VERA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Haematologica. 1951;35(7):661-77.,,,,,,,,,,,,,,
14888027,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),35,7,1951,[Old and recent unsolved questions on basophil leukopoiesis in man; morphological and microchemical characteristics of basophil granuloblasts in so-called basophil leukosis].,589-612,"['MARINONE, G']",['MARINONE G'],['und'],['Journal Article'],Questioni insolute antiche e recenti sulla leucopoiesi basofila del-l'uomo; le caratteristiche morfologiche e micro chimiche dei granuloblasti basofili nelle cosiddette leucosi a basofili.,Italy,Haematologica,Haematologica,0417435,,OM,"['*Basophils', 'Humans', '*Leukemia', '*Leukopoiesis', 'Male']",['CLML: 5221:18396:209'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Haematologica. 1951;35(7):589-612.,,,,,,,,,,,,,,
14888025,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),35,6,1951,[Contribution to case reports of eosinophil leukemia].,557-68,"['DONATI, G', 'LOVISETTO, P']","['DONATI G', 'LOVISETTO P']",['und'],['Journal Article'],Contributo alla casistica della leucemia eosinofila.,Italy,Haematologica,Haematologica,0417435,,OM,"['Eosinophilia/*complications', '*Eosinophils', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5221:18394:126:210'],['NLM'],"['*EOSINOPHILIA/complications', '*LEUKEMIA, MYELOCYTIC']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Haematologica. 1951;35(6):557-68.,,,,,,,,,,,,,,
14888024,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),35,6,1951,[Effect of estrogens and testosterone on hemopoiesis in leukemia; contribution to the study of the therapy of leukemia with sex hormones].,493-555,"['STORTI, E', 'MAURI, C', 'MOCCHI, N']","['STORTI E', 'MAURI C', 'MOCCHI N']",['und'],['Journal Article'],L'azione degli estrogeni e del testosterone sull'emopoiesi dei leucemici; contributo allo studio della terapia delle leucemie con ormoni sessuali.,Italy,Haematologica,Haematologica,0417435,"['0 (Androgens)', '0 (Estrogens)', '0 (Gonadal Steroid Hormones)', '3XMK78S47O (Testosterone)']",OM,"['Androgens/*therapeutic use', 'Estrogens/*therapeutic use', '*Gonadal Steroid Hormones', '*Hematopoiesis', 'Humans', 'Leukemia/*therapy', '*Testosterone']",['CLML: 5221:18393:20:133:210'],['NLM'],"['*ANDROGENS/therapeutic use', '*ESTROGENS/therapeutic use', '*LEUKEMIA/therapy']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Haematologica. 1951;35(6):493-555.,,,,,,,,,,,,,,
14886950,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,12,1951 Dec,The effect of high levels of certain steroids on induced lymphocytic leukemia in the rat.,937-42,"['DONALD, T C Jr', 'HIGGINS, G M']","['DONALD TC Jr', 'HIGGINS GM']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,"['0 (Steroids)', '9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['Adrenocorticotropic Hormone/*pharmacology', 'Animals', 'Cortisone/*pharmacology', '*Leukemia, Lymphoid', 'Rats', '*Steroids']",['CLML: 5221:17319:5:95'],['NLM'],"['*ACTH/effects', '*CORTISONE/effects']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Dec;11(12):937-42.,,,,,,,,,,,,,,
14886936,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,11,1951 Nov,The concentration of folic acid in leukocytes; observations on normal subjects and persons with leukemia.,864-7,"['SWENDSEID, M E', 'BETHELL, F H', 'BIRD, O D']","['SWENDSEID ME', 'BETHELL FH', 'BIRD OD']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,['935E97BOY8 (Folic Acid)'],OM,"['*Folic Acid', 'Leukemia/*blood', '*Leukocytes']",['CLML: 5221:17305:209'],['NLM'],['*LEUKEMIA/blood in'],1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Nov;11(11):864-7.,,,,,,,,,,,,,,
14886919,NLM,MEDLINE,20040215,20181201,0008-5448 (Print) 0008-5448 (Linking),3,5,1951 Sep-Oct,TUMOR clinic conference.,112-3; passim,,,['eng'],['Journal Article'],,United States,Cancer Bull,"Cancer bulletin (Houston, Tex.)",0373142,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', 'Neoplasms/*metabolism']",['CLML: 5221:17288:210:252'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*NEOPLASMS/metabolism']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Cancer Bull. 1951 Sep-Oct;3(5):112-3; passim.,,,,,,,,,,,,,,
14886918,NLM,MEDLINE,20040215,20181201,0008-5448 (Print) 0008-5448 (Linking),3,5,1951 Sep-Oct,OFFICE clinic.,107-10,,,['eng'],['Journal Article'],,United States,Cancer Bull,"Cancer bulletin (Houston, Tex.)",0373142,,OM,"['*Ambulatory Care Facilities', 'Humans', 'Leukemia/*diagnosis']",['CLML: 5221:17287:209'],['NLM'],['*LEUKEMIA/diagnosis'],1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Cancer Bull. 1951 Sep-Oct;3(5):107-10.,,,,,,,,,,,,,,
14886917,NLM,MEDLINE,20040215,20181201,0008-5448 (Print) 0008-5448 (Linking),3,5,1951 Sep-Oct,BEYOND the bright searchlights.,104-6,,,['eng'],['Journal Article'],,United States,Cancer Bull,"Cancer bulletin (Houston, Tex.)",0373142,,OM,"['Humans', 'Leukemia/*therapy']",['CLML: 5221:17286:210'],['NLM'],['*LEUKEMIA/therapy'],1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Cancer Bull. 1951 Sep-Oct;3(5):104-6.,,,,,,,,,,,,,,
14886915,NLM,MEDLINE,20040215,20181201,0008-5448 (Print) 0008-5448 (Linking),3,5,1951 Sep-Oct,"RADIATION, remission, relief.",100-1; passim,,,['eng'],['Journal Article'],,United States,Cancer Bull,"Cancer bulletin (Houston, Tex.)",0373142,,OM,"['Humans', 'Leukemia/*therapy']",['CLML: 5221:17284:210'],['NLM'],['*LEUKEMIA/therapy'],1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Cancer Bull. 1951 Sep-Oct;3(5):100-1; passim.,,,,,,,,,,,,,,
14886914,NLM,MEDLINE,20040215,20181201,0008-5448 (Print) 0008-5448 (Linking),3,5,1951 Sep-Oct,MALIGNANT blood dyscrasias.,98; passim,,,['eng'],['Journal Article'],,United States,Cancer Bull,"Cancer bulletin (Houston, Tex.)",0373142,,OM,"['*Hematologic Diseases', 'Humans', 'Leukemia/*diagnosis']",['CLML: 5221:17283:51:209'],['NLM'],"['*BLOOD/diseases', '*LEUKEMIA/diagnosis']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Cancer Bull. 1951 Sep-Oct;3(5):98; passim.,,,,,,,,,,,,,,
14886910,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),5,1,1952 Jan,Studies on the mechanism of action of chemotherapeutic agents in cancer. VI. Synergistic (additive) action of drugs on a transplantable leukemia in mice.,153-60,"['GOLDIN, A', 'GREENSPAN, E M', 'SCHOENBACH, E B']","['GOLDIN A', 'GREENSPAN EM', 'SCHOENBACH EB']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,['0 (Antineoplastic Agents)'],OM,"['Animals', '*Antineoplastic Agents', '*Leukemia', '*Leukemia, Experimental', 'Mice', '*Neoplasms']",['CLML: 5221:17279:210'],['NLM'],['*LEUKEMIA/experimental'],1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Cancer. 1952 Jan;5(1):153-60. doi: 10.1002/1097-0142(195201)5:1<153::aid-cncr2820050121>3.0.co;2-8.,['10.1002/1097-0142(195201)5:1<153::aid-cncr2820050121>3.0.co;2-8 [doi]'],,,,,,,,,,,,,
14886906,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),5,1,1952 Jan,Differentiation of plasmocytic responses from myelomatous diseases on the basis of bone-marrow findings.,128-37,"['FADEM, R S']",['FADEM RS'],['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,,OM,"['*Bone Marrow', '*Cell Differentiation', 'Humans', '*Leukemia', 'Multiple Myeloma/*diagnosis', '*Plasma Cells']",['CLML: 5221:17275:209:247'],['NLM'],"['*LEUKEMIA', '*MYELOMA, PLASMA CELL/diagnosis']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Cancer. 1952 Jan;5(1):128-37. doi: 10.1002/1097-0142(195201)5:1<128::aid-cncr2820050117>3.0.co;2-g.,['10.1002/1097-0142(195201)5:1<128::aid-cncr2820050117>3.0.co;2-g [doi]'],,,,,,,,,,,,,
14886851,NLM,MEDLINE,20040215,20181201,0008-4409 (Print) 0008-4409 (Linking),65,6,1951 Dec,ACTH and cortisone in the treatment of acute leukaemia.,552-5,"['CAMERON, D G', 'TOWNSEND, S R', 'MILLS, E S', 'MATHEWS, W H']","['CAMERON DG', 'TOWNSEND SR', 'MILLS ES', 'MATHEWS WH']",['eng'],['Journal Article'],,Canada,Can Med Assoc J,Canadian Medical Association journal,0414110,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['*Acute Disease', 'Adrenocorticotropic Hormone/*therapeutic use', 'Cortisone/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:17220:7:97:210'],['NLM'],"['*ACTH/therapeutic use', '*CORTISONE/therapeutic use', '*LEUKEMIA/therapy']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Can Med Assoc J. 1951 Dec;65(6):552-5.,,PMC1822309,,,,,,,,,,,,
14886850,NLM,MEDLINE,20040215,20181201,0008-4409 (Print) 0008-4409 (Linking),65,6,1951 Dec,Leukaemia in children.,548-52,"['RODGERS, C L', 'DONOHUE, W L', 'SNELLING, C E']","['RODGERS CL', 'DONOHUE WL', 'SNELLING CE']",['eng'],['Journal Article'],,Canada,Can Med Assoc J,Canadian Medical Association journal,0414110,,OM,"['Child', 'Humans', 'Leukemia/*therapy']",['CLML: 5221:17219:210'],['NLM'],['*LEUKEMIA/therapy'],1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Can Med Assoc J. 1951 Dec;65(6):548-52.,,PMC1822293,,,,,,,,,,,,
14886821,NLM,MEDLINE,20040215,20181201,0008-4158 (Print) 0008-4158 (Linking),13,4,1951 Dec,The use of cortisone therapy in two cases of lymphatic leukemia.,185-91,"['MATHESON, J']",['MATHESON J'],['eng'],['Journal Article'],,Canada,Can J Med Technol,Canadian journal of medical technology,0373141,['V27W9254FZ (Cortisone)'],OM,"['Cortisone/*therapeutic use', '*Leukemia', 'Leukemia, Lymphoid/*therapy', '*Lymphatic Vessels']",['CLML: 5221:17190:97:210'],['NLM'],"['*CORTISONE/therapeutic use', '*LEUKEMIA, LYMPHATIC/therapy']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Can J Med Technol. 1951 Dec;13(4):185-91.,,,,,,,,,,,,,,
14886757,NLM,MEDLINE,20040215,20181201,0008-1264 (Print) 0008-1264 (Linking),76,1,1952 Jan,Malignant tumors of childhood.,27-9,"['KNUTTI, R E']",['KNUTTI RE'],['eng'],['Journal Article'],,United States,Calif Med,California medicine,0410260,,OM,"['Child', 'Humans', 'Infant', '*Leukemia', '*Neoplasms']",['CLML: 5221:17126:252'],['NLM'],['*NEOPLASMS/in infant and child'],1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Calif Med. 1952 Jan;76(1):27-9.,,PMC1521197,"In the past 20 years, cancer in the age group, 0-14 years has become the second leading cause of death by disease. At some ages, notably between 5 and 14, it may be the leading cause of death by disease. Leukemia is the most frequent form of cancer in childhood, and tumors of the brain are in second place. An attempt should be made to categorize more accurately tumors stated in reports as ""miscellaneous,"" since in the reports analyzed herein, 15.8 per cent of all malignant lesions were so classified.",,,,,,,,,,,
14886645,NLM,MEDLINE,20040215,20190501,0007-1447 (Print) 0007-1447 (Linking),2,4746,1951 Dec 22,Leukaemia. I. Clinical features and diagnosis.,1513-5,"['WHITBY, L']",['WHITBY L'],['eng'],['Journal Article'],,England,Br Med J,British medical journal,0372673,,OM,"['Humans', 'Leukemia/*diagnosis']",['CLML: 5221:17014:209'],['NLM'],['*LEUKEMIA/diagnosis'],1951/12/22 00:00,1951/12/22 00:01,['1951/12/22 00:00'],"['1951/12/22 00:00 [pubmed]', '1951/12/22 00:01 [medline]', '1951/12/22 00:00 [entrez]']",ppublish,Br Med J. 1951 Dec 22;2(4746):1513-5. doi: 10.1136/bmj.2.4746.1513.,['10.1136/bmj.2.4746.1513 [doi]'],PMC2070835,,,,,,,,,,,,
14886641,NLM,MEDLINE,20040215,20181201,0007-1447 (Print) 0007-1447 (Linking),2,4746,1951 Dec 22,EFFECTS of injury.,1509-10,,,['eng'],['Journal Article'],,England,Br Med J,British medical journal,0372673,,OM,"['Blood Transfusion/*therapeutic use', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5221:17010:56:210'],['NLM'],"['*BLOOD TRANSFUSION/therapeutic use', '*LEUKEMIA, LYMPHATIC/experimental']",1951/12/22 00:00,1951/12/22 00:01,['1951/12/22 00:00'],"['1951/12/22 00:00 [pubmed]', '1951/12/22 00:01 [medline]', '1951/12/22 00:00 [entrez]']",ppublish,Br Med J. 1951 Dec 22;2(4746):1509-10.,,PMC2070887,,,,,,,,,,,,
14886417,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),7,2,1952 Feb,The anticoagulant effect of bacterial polysaccharides in normal and thrombocytopenic plasma of leukemia.,235-42,"['FREEMAN, G']",['FREEMAN G'],['eng'],['Journal Article'],,United States,Blood,Blood,7603509,"['0 (Anticoagulants)', '0 (Polysaccharides, Bacterial)']",OM,"['*Anticoagulants', 'Humans', 'Leukemia/*blood', '*Polysaccharides, Bacterial']",['CLML: 5221:16786:28:209'],['NLM'],"['*ANTICOAGULANTS', '*LEUKEMIA/blood in']",1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,Blood. 1952 Feb;7(2):235-42.,['S0006-4971(20)65397-6 [pii]'],,,,,,,,,,,,,
14886412,NLM,MEDLINE,20040215,20181201,0006-4971 (Print) 0006-4971 (Linking),7,Suppl.,1952 Jan,PROCEEDINGS of the Second Conference on Folic Acid Antagonists in the treatment of leukemia.,97-190,,,['eng'],['Journal Article'],,United States,Blood,Blood,7603509,['0 (Folic Acid Antagonists)'],OM,"['Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:16781:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Blood. 1952 Jan;7(Suppl.):97-190.,,,,,,,,,,,,,,
14886408,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),7,1,1952 Jan,Multiple spontaneous remissions in a child with acute leukemia. The occurrence of agranulocytosis and aplastic anemia in acute leukemia and their relationship to remissions.,37-46,"['BASSEN, F A', 'KOHN, J L']","['BASSEN FA', 'KOHN JL']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,,OM,"['*Agranulocytosis', '*Anemia, Aplastic', 'Child', 'Humans', '*Leukemia', '*Neoplasms', '*Remission, Spontaneous']",['CLML: 5221:16777:209'],['NLM'],['*LEUKEMIA'],1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,Blood. 1952 Jan;7(1):37-46.,['S0006-4971(20)64298-7 [pii]'],,,,,,,,,,,,,
14885633,NLM,MEDLINE,20040215,20181201,,2,10,1951 Oct,Clinical experiences in the use of radioactive phosphorus.,852-4,"['COOPER, W M']",['COOPER WM'],['eng'],['Journal Article'],,United States,Am Pract Dig Treat,American practitioner and digest of treatment,14840350R,"['0 (Phosphorus Radioisotopes)', '0 (Phosphorus, Dietary)', '27YLU75U4W (Phosphorus)']",OM,"['Leukemia/*therapy', '*Phosphorus', 'Phosphorus Radioisotopes/*therapeutic use', '*Phosphorus, Dietary', 'Polycythemia Vera/*therapy', '*Radioactivity']",['CLML: 5221:15983:210:289:299'],['NLM'],"['*LEUKEMIA/therapy', '*PHOSPHORUS, RADIOACTIVE/therapeutic use', '*POLYCYTHEMIA VERA/therapy']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Am Pract Dig Treat. 1951 Oct;2(10):852-4.,,,,,,,,,,,,,,
14885300,NLM,MEDLINE,20040215,20190616,0002-9378 (Print) 0002-9378 (Linking),62,5,1951 Nov,Leucemia and pregnancy.,1143-7,"['FIRST, A', 'WELLENBACH, B L']","['FIRST A', 'WELLENBACH BL']",['eng'],['Journal Article'],,United States,Am J Obstet Gynecol,American journal of obstetrics and gynecology,0370476,,OM,"['*Leukemia', 'Pregnancy']",['CLML: 5221:15650:209'],['NLM'],['*LEUKEMIA'],1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Am J Obstet Gynecol. 1951 Nov;62(5):1143-7. doi: 10.1016/0002-9378(51)91038-1.,"['0002-9378(51)91038-1 [pii]', '10.1016/0002-9378(51)91038-1 [doi]']",,,,,,,,,,,,,
14885146,NLM,MEDLINE,20040215,20190827,0002-9211 (Print) 0002-9211 (Linking),18,12,1951 Dec,Diabetes mellitus and concomitant leukemia.,349-51,"['PAUL, J T', 'BEST, W R', 'LIMARZI, L R']","['PAUL JT', 'BEST WR', 'LIMARZI LR']",['eng'],['Journal Article'],,United States,Am J Dig Dis,The American journal of digestive diseases,0404011,,OM,"['*Diabetes Mellitus', 'Humans', 'Leukemia/*complications']",['CLML: 5221:15496:109:209'],['NLM'],"['*DIABETES MELLITUS', '*LEUKEMIA/complications']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,Am J Dig Dis. 1951 Dec;18(12):349-51. doi: 10.1007/BF02876284.,['10.1007/BF02876284 [doi]'],,,,,,,,,,,,,
14884928,NLM,MEDLINE,20040215,20181201,0001-6071 (Print) 0001-6071 (Linking),8,1,1951 Jul-Sep,Lymphosarcoma cell leukemia (leukosarcoma Sternberg).,21-34,"['STRANSKY, E', 'FLORENTIN, A A']","['STRANSKY E', 'FLORENTIN AA']",['eng'],['Journal Article'],,Philippines,Acta Med Philipp,Acta medica Philippina,0312677,,OM,"['Humans', '*Leukemia', '*Lymphoma, Non-Hodgkin']",['CLML: 5221:15278:211'],['NLM'],['*LEUKOSARCOMA'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Acta Med Philipp. 1951 Jul-Sep;8(1):21-34.,,,,,,,,,,,,,,
14884793,NLM,MEDLINE,20040215,20190917,0888-2479 (Print) 0888-2479 (Linking),89,2,1952 Feb,Conversion of lymphocytic leukemia to Hodgkin's disease.,297-302,"['KRIM, M', 'MEYER, L M', 'ROSENTHAL, J', 'RITZ, N D']","['KRIM M', 'MEYER LM', 'ROSENTHAL J', 'RITZ ND']",['eng'],['Journal Article'],,United States,AMA Arch Intern Med,A.M.A. archives of internal medicine,14470100R,,OM,"['*Hodgkin Disease', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5221:15143:173:210'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA, LYMPHATIC']",1952/02/01 00:00,1952/02/01 00:01,['1952/02/01 00:00'],"['1952/02/01 00:00 [pubmed]', '1952/02/01 00:01 [medline]', '1952/02/01 00:00 [entrez]']",ppublish,AMA Arch Intern Med. 1952 Feb;89(2):297-302. doi: 10.1001/archinte.1952.00240020129009.,['10.1001/archinte.1952.00240020129009 [doi]'],,,,,,,,,,,,,
14884329,NLM,MEDLINE,20040215,20181201,0566-0777 (Print) 0566-0777 (Linking),2,12,1951 Dec,Treatment of leukemia and similar disorders.,1787-94,"['SMITH, R H']",['SMITH RH'],['eng'],['Journal Article'],,United States,U S Armed Forces Med J,United States Armed Forces medical journal,21410750R,,OM,"['Humans', 'Leukemia/*therapy']",['CLML: 5221:14607:210'],['NLM'],['*LEUKEMIA/therapy'],1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,U S Armed Forces Med J. 1951 Dec;2(12):1787-94.,,,,,,,,,,,,,,
14884311,NLM,MEDLINE,20040215,20181201,0041-5782 (Print) 0041-5782 (Linking),113,35,1951 Aug 30,Transplantation of leukaemia into mice and its genetic aspects.,1168-9,"['HOGREFFE, G']",['HOGREFFE G'],['eng'],['Journal Article'],,Denmark,Ugeskr Laeger,Ugeskrift for laeger,0141730,,OM,"['Animals', '*Leukemia', '*Leukemia, Experimental', 'Mice']",['CLML: 5221:14589:210'],['NLM'],['*LEUKEMIA/experimental'],1951/08/30 00:00,1951/08/30 00:01,['1951/08/30 00:00'],"['1951/08/30 00:00 [pubmed]', '1951/08/30 00:01 [medline]', '1951/08/30 00:00 [entrez]']",ppublish,Ugeskr Laeger. 1951 Aug 30;113(35):1168-9.,,,,,,,,,,,,,,
14883866,NLM,MEDLINE,20040215,20190619,0036-8075 (Print) 0036-8075 (Linking),114,2963,1951 Oct 12,The life span of the red blood cell in chronic leukemia and polycythemia.,385-7,"['BERLIN, N I', 'LAWRENCE, J H', 'LEE, H C']","['BERLIN NI', 'LAWRENCE JH', 'LEE HC']",['eng'],['Journal Article'],,United States,Science,"Science (New York, N.Y.)",0404511,,OM,"['*Chronic Disease', '*Erythrocytes', 'Humans', 'Leukemia/*blood', '*Polycythemia', 'Polycythemia Vera/*blood']",['CLML: 5221:14143:130:209:299'],['NLM'],"['*ERYTHROCYTES', '*LEUKEMIA/blood in', '*POLYCYTHEMIA VERA/blood in']",1951/10/12 00:00,1951/10/12 00:01,['1951/10/12 00:00'],"['1951/10/12 00:00 [pubmed]', '1951/10/12 00:01 [medline]', '1951/10/12 00:00 [entrez]']",ppublish,Science. 1951 Oct 12;114(2963):385-7. doi: 10.1126/science.114.2963.385.,['10.1126/science.114.2963.385 [doi]'],,,,,,,,,,,,,
14883541,NLM,MEDLINE,20040215,20181201,0120-0011 (Print) 0120-0011 (Linking),20,2,1951 Aug,[Hematoderma in the light of a case of leukemia cutis].,41-60,"['CARRIZOSA ARGAEZ, R']",['CARRIZOSA ARGAEZ R'],['und'],['Journal Article'],Las hematodermias a la luz de un caso de leucemia cutis.,Colombia,Rev Fac Med Univ Nac Colomb,"Revista de la Facultad de Medicina, Universidad Nacional de Colombia",7507464,,OM,"['Humans', '*Leukemia', '*Skin Neoplasms']",['CLML: 5221:13813:210'],['NLM'],['*LEUKEMIA/manifestations'],1951/08/01 00:00,1951/08/01 00:01,['1951/08/01 00:00'],"['1951/08/01 00:00 [pubmed]', '1951/08/01 00:01 [medline]', '1951/08/01 00:00 [entrez]']",ppublish,Rev Fac Med Univ Nac Colomb. 1951 Aug;20(2):41-60.,,,,,,,,,,,,,,
14883342,NLM,MEDLINE,20040215,20181201,0033-8419 (Print) 0033-8419 (Linking),57,5,1951 Nov,Reticulo-endotheliosis (Hand-Schuller-Christian disease).,642-52,"['HODGSON, J R', 'KENNEDY, R L J', 'CAMP, J D']","['HODGSON JR', 'KENNEDY RL', 'CAMP JD']",['eng'],['Journal Article'],,United States,Radiology,Radiology,0401260,"['Reticuloendotheliosis, X-linked']",OM,"['Child', '*Genetic Diseases, X-Linked', '*Histiocytosis, Langerhans-Cell', 'Humans', 'Infant', '*Leukemia, Hairy Cell', 'Lipidoses/*diagnosis', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5221:13614:213:325'],['NLM'],"['*LIPOIDOSIS/diagnosis', '*RETICULOENDOTHELIOSIS/in infant and child']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Radiology. 1951 Nov;57(5):642-52. doi: 10.1148/57.5.642.,['10.1148/57.5.642 [doi]'],,,,,,,,,,,,,
14883243,NLM,MEDLINE,20040215,20190911,0033-2720 (Print) 0033-2720 (Linking),25,4,1951 Oct,WHEN do we eat?,697-700,,,['eng'],['Journal Article'],,United States,Psychiatr Q,The Psychiatric quarterly,0376465,"['Reticuloendotheliosis, X-linked']",OM,"['Child', '*Genetic Diseases, X-Linked', 'Humans', 'Infant', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', 'Obesity/*therapy', '*Severe Combined Immunodeficiency']",['CLML: 5221:13515:264:325'],['NLM'],"['*OBESITY/therapy', '*RETICULOENDOTHELIOSIS/in infant and child']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Psychiatr Q. 1951 Oct;25(4):697-700. doi: 10.1007/BF01584315.,['10.1007/BF01584315 [doi]'],,,,,,,,,,,,,
14882562,NLM,MEDLINE,20040215,20181201,0028-7628 (Print) 0028-7628 (Linking),51,20,1951 Oct 15,Prolonged spontaneous remission in acute leukemia.,2413-5,"['SCHWARZ, A', 'LEVINE, L H']","['SCHWARZ A', 'LEVINE LH']",['eng'],['Journal Article'],,United States,N Y State J Med,New York state journal of medicine,0401064,,OM,"['*Acute Disease', '*Colonic Neoplasms', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Remission, Spontaneous']",['CLML: 5221:12834:88:210'],['NLM'],"['*COLON/neoplasms', '*LEUKEMIA, MYELOCYTIC']",1951/10/15 00:00,1951/10/15 00:01,['1951/10/15 00:00'],"['1951/10/15 00:00 [pubmed]', '1951/10/15 00:01 [medline]', '1951/10/15 00:00 [entrez]']",ppublish,N Y State J Med. 1951 Oct 15;51(20):2413-5.,,,,,,,,,,,,,,
14882542,NLM,MEDLINE,20040215,20181201,0028-7628 (Print) 0028-7628 (Linking),51,19,1951 Oct 1,Effect of insulin and glucose in chronic lymphatic leukemia.,2257-9,"['GITMAN, L', 'LEVINE, E A', 'APPELMAN, D H', 'JACOBI, M']","['GITMAN L', 'LEVINE EA', 'APPELMAN DH', 'JACOBI M']",['eng'],['Journal Article'],,United States,N Y State J Med,New York state journal of medicine,0401064,"['0 (Insulin)', 'IY9XDZ35W2 (Glucose)']",OM,"['*Glucose', 'Humans', 'Insulin/*therapeutic use', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', 'Leukemia, Lymphoid/*therapy', '*Lymphatic Vessels', '*Shoes']",['CLML: 5221:12814:191:210:342'],['NLM'],"['*INSULIN/therapeutic use', '*LEUKEMIA, LYMPHATIC/therapy', '*SHOES']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,N Y State J Med. 1951 Oct 1;51(19):2257-9.,,,,,,,,,,,,,,
14882241,NLM,MEDLINE,20040215,20181201,0096-5480 (Print) 0096-5480 (Linking),73,6,1951 Nov,"Radiation treatment of leukemias, Hodgkin's disease and lymphosarcoma.",189-92,"['PEAKE, J D', 'ESKRIDGE, M']","['PEAKE JD', 'ESKRIDGE M']",['eng'],['Journal Article'],,United States,Miss Valley Med J,"Mississippi Valley medical journal (Quincy, Ill)",18730540R,,OM,"['Hodgkin Disease/*therapy', 'Humans', 'Leukemia/*therapy', '*Lymphoma', 'Lymphoma, Non-Hodgkin/*therapy', '*Radiation']",['CLML: 5221:12513:173:210:223'],['NLM'],"[""*HODGKIN'S DISEASE/therapy"", '*LEUKEMIA/therapy', '*LYMPHOSARCOMA/therapy']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Miss Valley Med J. 1951 Nov;73(6):189-92.,,,,,,,,,,,,,,
14881966,NLM,MEDLINE,20040215,20181201,0025-777X (Print) 0025-777X (Linking),69,9,1951 Sep,[Use of leukocyte concentration in the diagnosis of aleukemic leukemia].,463-70,"['PARREIRA, F', 'PARREIRA, M']","['PARREIRA F', 'PARREIRA M']",['und'],['Journal Article'],O emprego do enriquecimento dos leucocitos no diagnostico dos leucemias aleucemicas.,Portugal,Med Contemp,"Medicina contemporanea (Lisbon, Portugal)",0400720,,OM,"['Leukemia/*diagnosis', '*Leukocytes']",['CLML: 5221:12238:210'],['NLM'],"['*LEUKEMIA, ALEUKEMIC/diagnosis']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Med Contemp. 1951 Sep;69(9):463-70.,,,,,,,,,,,,,,
14881566,NLM,MEDLINE,20040215,20181201,0140-6736 (Print) 0140-6736 (Linking),2,6693,1951 Dec 8,VIRUSES in cancer and leukaemia.,1076-7,,,['eng'],['Journal Article'],,England,Lancet,"Lancet (London, England)",2985213R,,OM,"['*Breast Neoplasms', 'Humans', 'Leukemia/*etiology', '*Neoplasms', '*Viruses']",['CLML: 5221:11837:63:210'],['NLM'],"['*BREAST/neoplasms', '*LEUKEMIA/etiology and pathogenesis']",1951/12/08 00:00,1951/12/08 00:01,['1951/12/08 00:00'],"['1951/12/08 00:00 [pubmed]', '1951/12/08 00:01 [medline]', '1951/12/08 00:00 [entrez]']",ppublish,Lancet. 1951 Dec 8;2(6693):1076-7.,,,,,,,,,,,,,,
14881510,NLM,MEDLINE,20040215,20190612,0140-6736 (Print) 0140-6736 (Linking),2,6690,1951 Nov 17,Low plasma-potassium levels in acute leukaemia.,912-3,"['VIDEBAEK, A']",['VIDEBAEK A'],['eng'],['Journal Article'],,England,Lancet,"Lancet (London, England)",2985213R,['RWP5GA015D (Potassium)'],OM,"['*Acute Disease', 'Humans', 'Leukemia/*blood', 'Potassium/*blood']",['CLML: 5221:11781:209:300'],['NLM'],"['*LEUKEMIA/blood in', '*POTASSIUM/in blood']",1951/11/17 00:00,1951/11/17 00:01,['1951/11/17 00:00'],"['1951/11/17 00:00 [pubmed]', '1951/11/17 00:01 [medline]', '1951/11/17 00:00 [entrez]']",ppublish,Lancet. 1951 Nov 17;2(6690):912-3. doi: 10.1016/s0140-6736(51)91874-0.,"['S0140-6736(51)91874-0 [pii]', '10.1016/s0140-6736(51)91874-0 [doi]']",,,,,,,,,,,,,
14881376,NLM,MEDLINE,20040215,20181201,0023-2149 (Print) 0023-2149 (Linking),29,10,1951 Oct,"[Differential diagnosis of agranulocytosis, aleukia and acute leukopenic leukosis; clinico-anatomic parallels].",36-42,"['DASHTAIANTS, G A']",['DASHTAIANTS GA'],['und'],['Journal Article'],"K diferentsial'noi diagnostike agranulotsitoza, aleiki i ostrogo leikopenicheskogo leikoza; kliniko-anatomicheskie paralleli.",Russia (Federation),Klin Med (Mosk),Klinicheskaia meditsina,2985204R,,OM,"['Agranulocytosis/*diagnosis', '*Diagnosis, Differential', 'Humans', 'Leukemia/*diagnosis']",['CLML: 5221:11647:13:209'],['NLM'],"['*AGRANULOCYTOSIS/diagnosis', '*LEUKEMIA/diagnosis']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Klin Med (Mosk). 1951 Oct;29(10):36-42.,,,,,,,,,,,,,,
14881142,NLM,MEDLINE,20040215,20181201,0035-9033 (Print) 0035-9033 (Linking),37,4,1951,A case of acute monocytic leukaemia.,215-6,"['CLEAVE, T L']",['CLEAVE TL'],['eng'],['Journal Article'],,England,J R Nav Med Serv,Journal of the Royal Naval Medical Service,7503111,,OM,"['Humans', '*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid']",['CLML: 5221:11413:210'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,J R Nav Med Serv. 1951;37(4):215-6.,,,,,,,,,,,,,,
14881041,NLM,MEDLINE,20040215,20190630,0022-3476 (Print) 0022-3476 (Linking),39,4,1951 Oct,Treatment of leucemia in childhood.,442-7,"['MICKLE, K C', 'MUSCATO, G V', 'LEMANSKI, A', 'CLAUDON, D B']","['MICKLE KC', 'MUSCATO GV', 'LEMANSKI A', 'CLAUDON DB']",['eng'],['Journal Article'],,United States,J Pediatr,The Journal of pediatrics,0375410,['0 (Folic Acid Antagonists)'],OM,"['Folic Acid Antagonists/*therapeutic use', 'Humans', '*Leukemia', 'Leukemia, Lymphoid/*therapy']",['CLML: 5221:11312:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA, LYMPHATIC/therapy']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,J Pediatr. 1951 Oct;39(4):442-7. doi: 10.1016/s0022-3476(51)80203-8.,"['S0022-3476(51)80203-8 [pii]', '10.1016/s0022-3476(51)80203-8 [doi]']",,,,,,,,,,,,,
14880784,NLM,MEDLINE,20040215,20190724,0022-2151 (Print) 0022-2151 (Linking),65,9,1951 Sep,Diseases of the blood connected with oto-rhino-laryngology.,629-37,"['WHITBY, L']",['WHITBY L'],['eng'],['Journal Article'],,England,J Laryngol Otol,The Journal of laryngology and otology,8706896,,OM,"['*Agranulocytosis', 'Ear/*pathology', '*Hemorrhagic Disorders', 'Humans', '*Leukemia', '*Nose Diseases', '*Otolaryngology']",['CLML: 5221:11055:13:117:167:210:261'],['NLM'],"['*AGRANULOCYTOSIS/manifestations', '*EAR/pathology', '*HEMORRHAGIC DIATHESIS/manifestations', '*LEUKEMIA/manifestations', '*NOSE/diseases']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,J Laryngol Otol. 1951 Sep;65(9):629-37. doi: 10.1017/s0022215100010550.,['10.1017/s0022215100010550 [doi]'],,,,,,,,,,,,,
14879893,NLM,MEDLINE,20040215,20181201,0016-5085 (Print) 0016-5085 (Linking),19,2,1951 Oct,"Abdominal masses. V. Systemic diseases and diseases of special regions: chronic myelogenous leukemia, chronic lymphatic leukemia, lymphosarcoma, polycythemia vera, tumors of the abdominal wall, and retroperitoneal tumors.",303-19,"['BUTLER, D B', 'BARGEN, J A']","['BUTLER DB', 'BARGEN JA']",['eng'],['Journal Article'],,United States,Gastroenterology,Gastroenterology,0374630,,OM,"['*Abdomen', '*Abdominal Wall', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Lymphoma', '*Lymphoma, Non-Hodgkin', '*Neoplasms', '*Polycythemia Vera']",['CLML: 5221:10164:1:210:222:299'],['NLM'],"['*ABDOMEN', '*LEUKEMIA, LYMPHATIC', '*LEUKEMIA, MYELOCYTIC', '*LYMPHOSARCOMA', '*POLYCYTHEMIA VERA/manifestations']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Gastroenterology. 1951 Oct;19(2):303-19.,,,,,,,,,,,,,,
14879605,NLM,MEDLINE,20040215,20181201,0012-1762 (Print) 0012-1762 (Linking),23,58,1951 Sep 3,[Lymphatic acute aleukemic leukemia].,2595-8,"['KLEIMANS, M']",['KLEIMANS M'],['und'],['Journal Article'],Leucemia linfatica aguda aleucemica.,Argentina,Dia Med,El Dia medico,0370663,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5221:9876:210'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1951/09/03 00:00,1951/09/03 00:01,['1951/09/03 00:00'],"['1951/09/03 00:00 [pubmed]', '1951/09/03 00:01 [medline]', '1951/09/03 00:00 [entrez]']",ppublish,Dia Med. 1951 Sep 3;23(58):2595-8.,,,,,,,,,,,,,,
14879561,NLM,MEDLINE,20040215,20181201,0366-8940 (Print) 0366-8940 (Linking),124,37,1951,[Lupus erythematodes acutus with reticulosis and involvement of the reticular cells in formation of the LE cells].,906-9,"['HAUSER, W']",['HAUSER W'],['und'],['Journal Article'],Lupus erythematodes acutus mit Begleitretikulose und mit eteiligung von Retikulumzellen an der L. E.-Zellenbildung.,Germany,Dermatol Wochenschr,Dermatologische Wochenschrift,0232054,"['Reticuloendotheliosis, X-linked']",OM,"['*Collagen Diseases', '*Genetic Diseases, X-Linked', 'Humans', '*Leukemia, Hairy Cell', '*Lupus Erythematosus, Systemic', '*Lymphatic Diseases', '*Neutrophils', '*Severe Combined Immunodeficiency']",['CLML: 5221:9832:221:325'],['NLM'],"['*LUPUS ERYTHEMATOSUS', '*RETICULOENDOTHELIOSIS']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Dermatol Wochenschr. 1951;124(37):906-9.,,,,,,,,,,,,,,
14879423,NLM,MEDLINE,20040215,20181201,0008-7335 (Print) 0008-7335 (Linking),90,40,1951 Sep 5,[Simultaneous appearance of Hodgkin's disease and leukemic reticulosis].,1191-3,"['SOYKA, O']",['SOYKA O'],['und'],['Journal Article'],Pozorovani sou6casneho vyskytu Hodgkinovy choroby s leukemickou retikulosou.,Czech Republic,Cas Lek Cesk,Casopis lekaru ceskych,0004743,,OM,"['Hodgkin Disease/*complications', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5221:9694:173:210'],['NLM'],"[""*HODGKIN'S DISEASE/complications"", '*LEUKEMIA, MONOCYTIC']",1951/09/05 00:00,1951/09/05 00:01,['1951/09/05 00:00'],"['1951/09/05 00:00 [pubmed]', '1951/09/05 00:01 [medline]', '1951/09/05 00:00 [entrez]']",ppublish,Cas Lek Cesk. 1951 Sep 5;90(40):1191-3.,,,,,,,,,,,,,,
14879373,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,5,1951 Sep,An unusual case of acute plasma-cell leukemia treated with a folic acid antagonist and urethane.,1043-51,"['MEYER, L M', 'RUTZKY, J']","['MEYER LM', 'RUTZKY J']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Folic Acid Antagonists)', '3IN71E75Z5 (Urethane)', '935E97BOY8 (Folic Acid)']",OM,"['*Folic Acid', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy', '*Leukemia, Plasma Cell', 'Urethane/*therapeutic use']",['CLML: 5221:9644:144:210:397'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy', '*URETHANE/therapeutic use']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Cancer. 1951 Sep;4(5):1043-51. doi: 10.1002/1097-0142(195109)4:5<1043::aid-cncr2820040522>3.0.co;2-f.,['10.1002/1097-0142(195109)4:5<1043::aid-cncr2820040522>3.0.co;2-f [doi]'],,,,,,,,,,,,,
14879369,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,5,1951 Sep,Over-all tracer studies with C14 labeled nitrogen mustard in normal and leukemic mice.,1025-7,"['SKIPPER, H E', 'BENNETT, L L Jr', 'LANGHAM, W H']","['SKIPPER HE', 'BENNETT LL Jr', 'LANGHAM WH']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['Animals', '*Leukemia, Experimental', '*Mechlorethamine', 'Mice', 'Nitrogen Mustard Compounds/*pharmacology', '*Research']",['CLML: 5221:9640:210:260'],['NLM'],"['*LEUKEMIA/experimental', '*NITROGEN MUSTARDS/effects']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Cancer. 1951 Sep;4(5):1025-7. doi: 10.1002/1097-0142(195109)4:5<1025::aid-cncr2820040518>3.0.co;2-v.,['10.1002/1097-0142(195109)4:5<1025::aid-cncr2820040518>3.0.co;2-v [doi]'],,,,,,,,,,,,,
14879367,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,5,1951 Sep,The metabolism of leukocytes taken from peripheral blood of leukemic patients.,1009-14,"['BIRD, R M', 'CLEMENTS, J A', 'BECKER, L M']","['BIRD RM', 'CLEMENTS JA', 'BECKER LM']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,,OM,"['Humans', 'Leukemia/*blood', 'Leukocytes/*metabolism']",['CLML: 5221:9638:209:211'],['NLM'],"['*LEUKEMIA/blood in', '*LEUKOCYTES/metabolism']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Cancer. 1951 Sep;4(5):1009-14. doi: 10.1002/1097-0142(195109)4:5<1009::aid-cncr2820040516>3.0.co;2-r.,['10.1002/1097-0142(195109)4:5<1009::aid-cncr2820040516>3.0.co;2-r [doi]'],,,,,,,,,,,,,
14879366,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,5,1951 Sep,Radioactive phosphorus. II. In the treatment of myeloid leukemia.,999-1008,"['DIAMOND, H D', 'CRAVER, L F']","['DIAMOND HD', 'CRAVER LF']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Phosphorus Radioisotopes)', '27YLU75U4W (Phosphorus)']",OM,"['Humans', '*Leukemia', 'Leukemia, Myeloid/*therapy', '*Phosphorus', 'Phosphorus Radioisotopes/*therapeutic use']",['CLML: 5221:9637:210:289'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/therapy', '*PHOSPHORUS, RADIOACTIVE/therapeutic use']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Cancer. 1951 Sep;4(5):999-1008. doi: 10.1002/1097-0142(195109)4:5<999::aid-cncr2820040515>3.0.co;2-n.,['10.1002/1097-0142(195109)4:5<999::aid-cncr2820040515>3.0.co;2-n [doi]'],,,,,,,,,,,,,
14879157,NLM,MEDLINE,20040215,20190501,0007-1447 (Print) 0007-1447 (Linking),2,4747,1951 Dec 29,Leukaemia. II. Treatment.,1573-5,"['WHITBY, L']",['WHITBY L'],['eng'],['Journal Article'],,England,Br Med J,British medical journal,0372673,,OM,['Leukemia/*therapy'],['CLML: 5221:9428:210'],['NLM'],['*LEUKEMIA/therapy'],1951/12/29 00:00,1951/12/29 00:01,['1951/12/29 00:00'],"['1951/12/29 00:00 [pubmed]', '1951/12/29 00:01 [medline]', '1951/12/29 00:00 [entrez]']",ppublish,Br Med J. 1951 Dec 29;2(4747):1573-5. doi: 10.1136/bmj.2.4747.1573.,['10.1136/bmj.2.4747.1573 [doi]'],PMC2070514,,,,,,,,,,,,
14879128,NLM,MEDLINE,20040215,20190501,0007-1447 (Print) 0007-1447 (Linking),2,4745,1951 Dec 15,Monocytic leukaemia and pulmonary tuberculosis complicating pregnancy.,1442-3,"['BEVEN, G']",['BEVEN G'],['eng'],['Journal Article'],,England,Br Med J,British medical journal,0372673,,OM,"['Humans', '*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid', 'Pregnancy', '*Pregnancy Complications', '*Tuberculosis', '*Tuberculosis, Pulmonary']",['CLML: 5221:9399:210:301:391'],['NLM'],"['*LEUKEMIA, MONOCYTIC', '*PREGNANCY/complications', '*TUBERCULOSIS, PULMONARY/in pregnancy']",1951/12/15 00:00,1951/12/15 00:01,['1951/12/15 00:00'],"['1951/12/15 00:00 [pubmed]', '1951/12/15 00:01 [medline]', '1951/12/15 00:00 [entrez]']",ppublish,Br Med J. 1951 Dec 15;2(4745):1442-3. doi: 10.1136/bmj.2.4745.1442.,['10.1136/bmj.2.4745.1442 [doi]'],PMC2070671,,,,,,,,,,,,
14878703,NLM,MEDLINE,20040215,20181201,0366-368X (Print),7,17,1951 Sep 1,[Cortisone and aminopterin therapy of acute leukemia].,789-92,"['VAN GOIDSENHOVEN', 'BROEKAERT, R']","['VAN GOIDSENHOVEN', 'BROEKAERT R']",['und'],['Journal Article'],Acute leukaemie behandeld met cortisone en aminopterine.,Belgium,Belg Tijdschr Geneesk,Belgisch tijdschrift voor geneeskunde,15510370R,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)', 'V27W9254FZ (Cortisone)']",OM,"['*Acute Disease', '*Aminopterin', 'Cortisone/*therapeutic use', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:8974:97:144:210'],['NLM'],"['*CORTISONE/therapeutic use', '*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Belg Tijdschr Geneesk. 1951 Sep 1;7(17):789-92.,,,,,,,,,,,,,,
14877543,NLM,MEDLINE,20040215,20181201,0365-5504 (Print) 0365-5504 (Linking),4,4,1951 Jul-Aug,[Cytometry of leukemic cells; cytometric character of staminal cells in microhemocytoblastic and acute lymphoblastic leukemia].,361-6,"['COSSANDI, E', 'CASTELLOTTI, P E']","['COSSANDI E', 'CASTELLOTTI PE']",['und'],['Journal Article'],Contributo alla citometria delle cellule leucemiche; caratteri citometrici delle cellule staminali nelle leucemie microemocitoblastiche e linfoblastiche acute.,Italy,Acta Paediatr Lat,Acta paediatrica Latina,0370360,,OM,"['Humans', 'Leukemia/*blood', '*Precursor Cell Lymphoblastic Leukemia-Lymphoma']",['CLML: 5221:7778:209'],['NLM'],['*LEUKEMIA/blood in'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Acta Paediatr Lat. 1951 Jul-Aug;4(4):361-6.,,,,,,,,,,,,,,
14877521,NLM,MEDLINE,20040215,20190812,0001-6101 (Print) 0001-6101 (Linking),140,5,1951,Histioleukaemias and acute leukaemias.,381-94,"['MONASTERIO, G', 'GIGLI, G']","['MONASTERIO G', 'GIGLI G']",['eng'],['Journal Article'],,Sweden,Acta Med Scand,Acta medica Scandinavica,0370330,,OM,"['*Acute Disease', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5221:7756:210'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Med Scand. 1951;140(5):381-94. doi: 10.1111/j.0954-6820.1951.tb09665.x.,['10.1111/j.0954-6820.1951.tb09665.x [doi]'],,,,,,,,,,,,,
14877516,NLM,MEDLINE,20040215,20181201,0001-6101 (Print) 0001-6101 (Linking),140,5,1951,"Pathogenetic problems in ""acute leukemic conditions"".",349-54,"['NORDENSON, N G']",['NORDENSON NG'],['eng'],['Journal Article'],,Sweden,Acta Med Scand,Acta medica Scandinavica,0370330,,OM,"['*Acute Disease', 'Leukemia/*etiology', '*Mononuclear Phagocyte System']",['CLML: 5221:7751:210:325'],['NLM'],"['*LEUKEMIA/etiology and pathogenesis', '*RETICULOENDOTHELIAI, SYSTEM']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Med Scand. 1951;140(5):349-54.,,,,,,,,,,,,,,
14877327,NLM,MEDLINE,20040215,20190917,0888-2479 (Print) 0888-2479 (Linking),89,1,1952 Jan,Late lymphatic leukemia complicating hypersplenic syndrome.,82-9,"['COCHRANE, H A', 'GROSS, L']","['COCHRANE HA', 'GROSS L']",['eng'],['Journal Article'],,United States,AMA Arch Intern Med,A.M.A. archives of internal medicine,14470100R,,OM,"['*Disease', 'Humans', '*Hypersplenism', '*Leukemia', '*Leukemia, Lymphoid', '*Spleen', '*Splenic Diseases']",['CLML: 5221:7562:210:352'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*SPLEEN/diseases']",1952/01/01 00:00,1952/01/01 00:01,['1952/01/01 00:00'],"['1952/01/01 00:00 [pubmed]', '1952/01/01 00:01 [medline]', '1952/01/01 00:00 [entrez]']",ppublish,AMA Arch Intern Med. 1952 Jan;89(1):82-9. doi: 10.1001/archinte.1952.00240010092008.,['10.1001/archinte.1952.00240010092008 [doi]'],,,,,,,,,,,,,
14877227,NLM,MEDLINE,20040215,20181201,0044-2917 (Print) 0044-2917 (Linking),70,1,1951,[On the pathogenesis of myeloid leukemia].,26-32,"['LI, M S']",['LI MS'],['und'],['Journal Article'],Beitrage zur Pathogenese der myeloischen Leukamie.,Germany,Z Kinderheilkd,Zeitschrift fur Kinderheilkunde,7604363,,OM,"['Bronchiectasis/*complications', 'Humans', '*Leukemia', 'Leukemia, Myeloid/*etiology', 'Pneumonia/*complications']",['CLML: 5221:7377:64:210:296'],['NLM'],"['*BRONCHIECTASIS/complications', '*LEUKEMIA, MYELOCYTIC/etiology and pathogenesis', '*PNEUMONIA/complications']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Z Kinderheilkd. 1951;70(1):26-32.,,,,,,,,,,,,,,
14877173,NLM,MEDLINE,20040215,20181201,0043-5325 (Print) 0043-5325 (Linking),63,35-36,1951 Sep 7,[Treatment of acute leukemias with the adrenocorticotropic hormone of the anterior pituitary].,652-7,"['GEYER, G', 'HEIN, M', 'KEIBL, E']","['GEYER G', 'HEIN M', 'KEIBL E']",['und'],['Journal Article'],Die Behandlung akuter Leukamien mit adrenocorticotropem Hypophysenvorderlappenhormon.,Austria,Wien Klin Wochenschr,Wiener klinische Wochenschrift,21620870R,['9002-60-2 (Adrenocorticotropic Hormone)'],OM,"['*Acute Disease', 'Adrenocorticotropic Hormone/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:7323:7:210'],['NLM'],"['*ACTH/therapeutic use', '*LEUKEMIA/therapy']",1951/09/07 00:00,1951/09/07 00:01,['1951/09/07 00:00'],"['1951/09/07 00:00 [pubmed]', '1951/09/07 00:01 [medline]', '1951/09/07 00:00 [entrez]']",ppublish,Wien Klin Wochenschr. 1951 Sep 7;63(35-36):652-7.,,,,,,,,,,,,,,
14877142,NLM,MEDLINE,20040215,20181201,0043-5325 (Print) 0043-5325 (Linking),63,32,1951 Aug 10,[New studies on roentgenotherapy of blood diseases].,569-72,"['PAPE, R']",['PAPE R'],['und'],['Journal Article'],Neue Studien zur Rontgentherapie der Blutkrankheiten.,Austria,Wien Klin Wochenschr,Wiener klinische Wochenschrift,21620870R,,OM,"['Anemia/*therapy', '*Hematologic Diseases', 'Humans', 'Leukemia/*therapy', '*X-Ray Therapy']",['CLML: 5221:7292:20:52:210'],['NLM'],"['*ANEMIA/therapy', '*BLOOD/diseases', '*LEUKEMIA/therapy']",1951/08/10 00:00,1951/08/10 00:01,['1951/08/10 00:00'],"['1951/08/10 00:00 [pubmed]', '1951/08/10 00:01 [medline]', '1951/08/10 00:00 [entrez]']",ppublish,Wien Klin Wochenschr. 1951 Aug 10;63(32):569-72.,,,,,,,,,,,,,,
14876928,NLM,MEDLINE,20040215,20181201,0042-4668 (Print) 0042-4668 (Linking),13,4,1951 Jul-Aug,[Case of acute myeloblastic leukemia].,84-5,"['KROL, I S']",['KROL IS'],['und'],['Journal Article'],Sluchai ostrogo mieloblasticheskogo leikoza.,Russia (Federation),Vestn Otorinolaringol,Vestnik otorinolaringologii,0416577,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Myeloid, Acute']",['CLML: 5221:7076:210'],['NLM'],"['*LEUKEMIA, MYELOCYTIC']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Vestn Otorinolaringol. 1951 Jul-Aug;13(4):84-5.,,,,,,,,,,,,,,
14876647,NLM,MEDLINE,20040215,20181201,0491-1377 (Print) 0491-1377 (Linking),2,7,1951 Jul,[Lymphoid leukemia with predominant abdominal manifestation].,438-40,"['WARTER, J', 'KURTZEMANN, G']","['WARTER J', 'KURTZEMANN G']",['und'],['Journal Article'],Leucemie lymphoide d'expression abdominale predominante.,France,Strasb Med,Strasbourg medical,21020030R,,OM,"['Gastrointestinal Tract/*pathology', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5221:6795:151:210'],['NLM'],"['*GASTROINTESTINAL SYSTEM/pathology', '*LEUKEMIA, LYMPHATIC']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Strasb Med. 1951 Jul;2(7):438-40.,,,,,,,,,,,,,,
14876316,NLM,MEDLINE,20040215,20181201,,24,3,1951 May-Jun,[Therapeutic value of massive transfusions in the treatment of reticuloses of slow evolution with progressive bone marrow destruction].,117-8,"['MARINONE, G']",['MARINONE G'],['und'],['Journal Article'],Sur la valeur therapeutique des transfusions massives dans le traitement des reticuloses a evolution lente avec destruction medullaire progressive.,Spain,Sangue,Il Sangue,20540400R,"['0 (Peptide Nucleic Acids)', '0 (reticulose)']",OM,"['*Bone Marrow', '*Bone Marrow Diseases', 'Humans', 'Leukemia/*therapy', 'Peptide Nucleic Acids', '*Spleen']",['CLML: 5221:6464:210'],['NLM'],"['*LEUKEMIA, ALEUKEMIC/therapy']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Sangue. 1951 May-Jun;24(3):117-8.,,,,,,,,,,,,,,
14876306,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,7,1951,[Histio-plasmoblastic leukosarcomatosis].,592-5,"['BENAZET', 'LANGUILLON', 'RAOULT']","['BENAZET', 'LANGUILLON', 'RAOULT']",['und'],['Journal Article'],Leucosarcomatose histio-plasmoblastique.,France,Sang,Le Sang,20540380R,,OM,"['*Blood Cell Count', '*Leukemia', '*Plasma Cells']",['CLML: 5221:6454:211'],['NLM'],['*LEUKOSARCOMA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(7):592-5.,,,,,,,,,,,,,,
14876304,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,7,1951,"[Hematologic onset of malignant leukemias. II. A second mode of onset, the erythroblastic onset; relations with Di Guglielmo's acute erythroblastosis].",586-8,"['MALLARME, J', 'BOUREL']","['MALLARME J', 'BOUREL']",['und'],['Journal Article'],"Des debuts hematologiques des leucoses malignes. II. Sur un deuxieme mode de debut, le debut erythroblastique; rapport avec l'erythroblastose aigue de Di Guglielmo.",France,Sang,Le Sang,20540380R,,OM,"['*Erythroblasts', '*Hematologic Diseases', 'Humans', '*Leukemia']",['CLML: 5221:6452:209'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(7):586-8.,,,,,,,,,,,,,,
14876182,NLM,MEDLINE,20040215,20181201,0370-632X (Print) 0370-632X (Linking),8,3,1951 Jul-Sep,[Two cases of acute leukosis treated by aminopterin].,357-65,"['TACHOYAN, S']",['TACHOYAN S'],['und'],['Journal Article'],Deux cas de leucose aigue traites par l'aminopterine.,Lebanon,Rev Med Moyen Orient,Revue medicale du Moyen-Orient,20340240R,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Aminopterin', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:6322:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Rev Med Moyen Orient. 1951 Jul-Sep;8(3):357-65.,,,,,,,,,,,,,,
14876003,NLM,MEDLINE,20040215,20181201,0034-7264 (Print) 0034-7264 (Linking),8,7,1951 Jul,[Etiopathogenesis of funicular myelosis].,477-80,"['NERY, O']",['NERY O'],['und'],['Journal Article'],Etiopathogenia das mieloses funiculares.,Brazil,Rev Bras Med,Revista brasileira de medicina,0401324,,OM,"['Humans', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Spinal Cord Diseases']",['CLML: 5221:6115:351'],['NLM'],['*SPINAL CORD/diseases'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Rev Bras Med. 1951 Jul;8(7):477-80.,,,,,,,,,,,,,,
14875527,NLM,MEDLINE,20040215,20181201,0860-8857 (Print) 0860-8857 (Linking),6,18-19,1951 May 7,"[Preliminary results of combined urethane, nitrogen mustard and Delbet's vaccine therapy of chronic myelocytic leukemias].",620-4,"['SZREDER, W', 'MIGDALSKA, Z']","['SZREDER W', 'MIGDALSKA Z']",['und'],['Journal Article'],"Tymczasowe wyniki leczenia przewleklych bialaczek szpikowych rownoczesnie uretanem, iperytem azotowym i szczepionka Delbeta.",Poland,Pol Tyg Lek (Wars),Polski tygodnik lekarski,9706227,"['0 (Nitrogen Mustard Compounds)', '3IN71E75Z5 (Urethane)', '50D9XSG0VR (Mechlorethamine)']",OM,"['Humans', '*Immunotherapy, Active', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'Leukemia, Myeloid/*therapy', '*Mechlorethamine', 'Nitrogen Mustard Compounds/*therapeutic use', 'Urethane/*therapeutic use']",['CLML: 5221:5639:210:260:397'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/therapy', '*NITROGEN MUSTARDS/therapeutic use', '*URETHANE/therapeutic use']",1951/05/07 00:00,1951/05/07 00:01,['1951/05/07 00:00'],"['1951/05/07 00:00 [pubmed]', '1951/05/07 00:01 [medline]', '1951/05/07 00:00 [entrez]']",ppublish,Pol Tyg Lek (Wars). 1951 May 7;6(18-19):620-4.,,,,,,,,,,,,,,
14875405,NLM,MEDLINE,20040215,20181201,0031-3939 (Print) 0031-3939 (Linking),26,5,1951 May,[Problem of leukemic reactions of the bone marrow during tuberculosis in children].,534-9,"['GODLEWSKI, J', 'PAWLAK, M']","['GODLEWSKI J', 'PAWLAK M']",['und'],['Journal Article'],Przyczynek do zagadnienia odczynow szpikowych blalaczkowych w przebiegu gru1zlicy u dzicci.,Poland,Pediatr Pol,Pediatria polska,2985039R,,OM,"['*Bone Marrow', 'Child', 'Humans', '*Leukemia', 'Leukemia, Myeloid/*diagnosis', 'Tuberculosis/*diagnosis']",['CLML: 5221:5517:210:385'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/diagnosis', '*TUBERCULOSIS/diagnosis']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Pediatr Pol. 1951 May;26(5):534-9.,,,,,,,,,,,,,,
14874721,NLM,MEDLINE,20040215,20181201,0025-729X (Print) 0025-729X (Linking),2,4,1951 Jul 28,Treatment of acute leucaemia by folic acid antagonists.,119-21,"['McLEAN, J A']",['McLEAN JA'],['eng'],['Journal Article'],,Australia,Med J Aust,The Medical journal of Australia,0400714,['0 (Folic Acid Antagonists)'],OM,"['*Acute Disease', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:4833:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1951/07/28 00:00,1951/07/28 00:01,['1951/07/28 00:00'],"['1951/07/28 00:00 [pubmed]', '1951/07/28 00:01 [medline]', '1951/07/28 00:00 [entrez]']",ppublish,Med J Aust. 1951 Jul 28;2(4):119-21.,,,,,,,,,,,,,,
14874709,NLM,MEDLINE,20040215,20201218,0025-729X (Print) 0025-729X (Linking),2,3,1951 Jul 21,Chloroma.,83-5,"['FENTON, F G', 'RYAN, H']","['FENTON FG', 'RYAN H']",['eng'],['Journal Article'],,Australia,Med J Aust,The Medical journal of Australia,0400714,,OM,"['Humans', '*Leukemia', '*Neoplasms', '*Orbit', '*Sarcoma, Myeloid']",['CLML: 5221:4821:211:266'],['NLM'],"['*LEUKOSARCOMA', '*ORBIT/neoplasms']",1951/07/21 00:00,1951/07/21 00:01,['1951/07/21 00:00'],"['1951/07/21 00:00 [pubmed]', '1951/07/21 00:01 [medline]', '1951/07/21 00:00 [entrez]']",ppublish,Med J Aust. 1951 Jul 21;2(3):83-5. doi: 10.5694/j.1326-5377.1951.tb68104.x.,['10.5694/j.1326-5377.1951.tb68104.x [doi]'],,,,,,,,,,,,,
14874291,NLM,MEDLINE,20040215,20181201,0021-8111 (Print) 0021-8111 (Linking),69,17,1951 Aug 19,[Acute malignant reticulosis in a sixteen months old infant].,441-6,"['DEHERRIPON, H', 'FOURNIER, A', 'DENIS DU PEAGE, J']","['DEHERRIPON H', 'FOURNIER A', 'DENIS DU PEAGE J']",['und'],['Journal Article'],Reticulose aigue maligne chez un enfant de seize mois.,France,J Sci Med Lille,Journal des sciences medicales de Lille,0413413,"['Reticuloendotheliosis, X-linked']",OM,"['Child', '*Genetic Diseases, X-Linked', '*Histiocytic Sarcoma', 'Humans', 'Infant', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5221:4403:325'],['NLM'],['*RETICULOENDOTHELIOSIS/in infant and child'],1951/08/19 00:00,1951/08/19 00:01,['1951/08/19 00:00'],"['1951/08/19 00:00 [pubmed]', '1951/08/19 00:01 [medline]', '1951/08/19 00:00 [entrez]']",ppublish,J Sci Med Lille. 1951 Aug 19;69(17):441-6.,,,,,,,,,,,,,,
14874162,NLM,MEDLINE,20040215,20190917,0368-3494 (Print) 0368-3494 (Linking),63,3,1951 Jul,"Quantitative studies on the content of nucleic acids in normal and leukaemic cells, from blood and bone marrow.",471-83,"['DAVIDSON, J N', 'LESLIE, I', 'WHITE, J C']","['DAVIDSON JN', 'LESLIE I', 'WHITE JC']",['eng'],['Journal Article'],,England,J Pathol Bacteriol,The Journal of pathology and bacteriology,0204750,['0 (Nucleic Acids)'],OM,"['*Bone Marrow', 'Humans', 'Leukemia/*blood', '*Nucleic Acids']",['CLML: 5221:4274:209:261'],['NLM'],"['*LEUKEMIA/blood in', '*NUCLEIC ACIDS']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,J Pathol Bacteriol. 1951 Jul;63(3):471-83. doi: 10.1002/path.1700630314.,['10.1002/path.1700630314 [doi]'],,,,,,,,,,,,,
14874155,NLM,MEDLINE,20040215,20190917,0368-3494 (Print) 0368-3494 (Linking),63,3,1951 Jul,Erythraemic myelosis in a girl aged 13 years.,395-402,"['EMERY, J L']",['EMERY JL'],['eng'],['Journal Article'],,England,J Pathol Bacteriol,The Journal of pathology and bacteriology,0204750,,OM,"['*Leukemia, Erythroblastic, Acute', '*Polycythemia Vera']",['CLML: 5221:4267:299'],['NLM'],['*POLYCYTHEMIA VERA'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,J Pathol Bacteriol. 1951 Jul;63(3):395-402. doi: 10.1002/path.1700630305.,['10.1002/path.1700630305 [doi]'],,,,,,,,,,,,,
14874051,NLM,MEDLINE,20040215,20181201,0368-3001 (Print) 0368-3001 (Linking),128,9,1951 Sep,[Generalized malignant reticulopathies or histio-monocytic reticulosis].,829-39,"['LEGER', 'MEYNARD', 'BIRABEN']","['LEGER', 'MEYNARD', 'BIRABEN']",['und'],['Journal Article'],Les reticulopathies malignes systematisees ou reticulose histio-monocytaire.,France,J Med Bord,Journal de medecine de Bordeaux et du Sud-Ouest,0161067,,OM,"['Humans', '*Leukemia', 'Leukemia, Myeloid/*therapy', '*Monocytes']",['CLML: 5221:4163:210'],['NLM'],"['*LEUKEMIA, MONOCYTIC/therapy']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,J Med Bord. 1951 Sep;128(9):829-39.,,,,,,,,,,,,,,
14873985,NLM,MEDLINE,20040215,20181201,0022-8699 (Print) 0022-8699 (Linking),52,9,1951 Sep,The leukemias; their therapy and prognosis.,448-58,"['AGEE, L G']",['AGEE LG'],['eng'],['Journal Article'],,United States,J Kans Med Soc,The Journal of the Kansas Medical Society,7505612,,OM,"['Humans', 'Leukemia/*therapy', 'Prognosis']",['CLML: 5221:4097:210'],['NLM'],['*LEUKEMIA/therapy'],1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,J Kans Med Soc. 1951 Sep;52(9):448-58.,,,,,,,,,,,,,,
14873587,NLM,MEDLINE,20040215,20190729,0002-9955 (Print) 0002-9955 (Linking),147,9,1951 Oct 27,Leukemia and other malignant diseases in physicians.,893-4,"['PELLER, S', 'PICK, P']","['PELLER S', 'PICK P']",['eng'],['Journal Article'],,United States,J Am Med Assoc,Journal of the American Medical Association,7507176,,OM,"['*Disease', 'Humans', '*Leukemia', '*Neoplasms', '*Physicians', '*Syndrome']",['CLML: 5221:3699:209:290'],['NLM'],"['*LEUKEMIA', '*PHYSICIANS/diseases']",1951/10/27 00:00,1951/10/27 00:01,['1951/10/27 00:00'],"['1951/10/27 00:00 [pubmed]', '1951/10/27 00:01 [medline]', '1951/10/27 00:00 [entrez]']",ppublish,J Am Med Assoc. 1951 Oct 27;147(9):893-4. doi: 10.1001/jama.1951.03670260095031.,['10.1001/jama.1951.03670260095031 [doi]'],,,,,,,,,,,,,
14873321,NLM,MEDLINE,20040215,20181201,,27,446,1951 Feb,[Lymphatic reaction in relatives of leukemic subjects].,41-5,"['ARDACHNIKOV, C N']",['ARDACHNIKOV CN'],['und'],['Journal Article'],Reacao linfatica nos parentes dos leucemicos.,Brazil,Imprensa Medica,Imprensa medica,17530180R,,OM,"['*Communicable Diseases', 'Humans', '*Infectious Mononucleosis', '*Leukemia', '*Leukemia, Lymphoid']",['CLML: 5221:3433:210:240'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*MONONUCLEOSIS, INFECTIOUS']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,Imprensa Medica. 1951 Feb;27(446):41-5.,,,,,,,,,,,,,,
14872812,NLM,MEDLINE,20040215,20181201,0367-1038 (Print) 0367-1038 (Linking),58,10,1951 Oct,Lymphosarcoma terminating with leukaemia.,507-13,"['GAULD, W R']",['GAULD WR'],['eng'],['Journal Article'],,Scotland,Edinb Med J,Edinburgh medical journal,0007305,,OM,"['*Death', 'Humans', 'Leukemia/*etiology', '*Lymphoma', '*Lymphoma, Non-Hodgkin']",['CLML: 5221:2922:210:222'],['NLM'],"['*LEUKEMIA/etiology and pathogenesis', '*LYMPHOSARCOMA']",1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Edinb Med J. 1951 Oct;58(10):507-13.,,PMC5288044,,,,,,,,,,,,
14872273,NLM,MEDLINE,20040429,20181130,0941-293X (Print) 0941-293X (Linking),101,1,2004 Jan,[Ocular hypotonia in leukemia].,80-2,"['Hackethal, U', 'Holzapfel, C', 'Husstedt, I', 'Gerding, H']","['Hackethal U', 'Holzapfel C', 'Husstedt I', 'Gerding H']",['ger'],"['Case Reports', 'Journal Article']",Hypotonia bulbi bei Leukamie.,Germany,Ophthalmologe,Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft,9206148,"['0 (Antineoplastic Agents)', '0 (Organophosphonates)', '0 (Organophosphorus Compounds)', '8J337D1HZY (Cytosine)', 'JIL713Q00N (Cidofovir)']",IM,"['Antineoplastic Agents/adverse effects/therapeutic use', 'Cidofovir', 'Cytosine/*adverse effects/*analogs & derivatives/*therapeutic use', 'Diagnosis, Differential', 'Humans', 'Leukemia, B-Cell/*drug therapy', 'Male', 'Middle Aged', 'Ocular Hypertension/*chemically induced/*diagnosis', '*Organophosphonates', 'Organophosphorus Compounds/*adverse effects/*therapeutic use', 'Uveitis, Anterior/*chemically induced/*diagnosis']",,,,2004/02/12 05:00,2004/04/30 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/04/30 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Ophthalmologe. 2004 Jan;101(1):80-2. doi: 10.1007/s00347-003-0816-0.,['10.1007/s00347-003-0816-0 [doi]'],,,"['Klinik und Poliklinik fur Augenheilkunde, Universitatsklinikum Munster, Munster. hacketu@mednet.uni-muenster.de']",,,,,,,,,,
14872093,NLM,MEDLINE,20040701,20061115,0022-3565 (Print) 0022-3565 (Linking),309,3,2004 Jun,Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep.,1085-92,"['Segrave, Alicia M', 'Mager, Donald E', 'Charman, Susan A', 'Edwards, Glenn A', 'Porter, Christopher J H']","['Segrave AM', 'Mager DE', 'Charman SA', 'Edwards GA', 'Porter CJ']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,J Pharmacol Exp Ther,The Journal of pharmacology and experimental therapeutics,0376362,"['0 (Interleukin-6)', '0 (LIF protein, human)', '0 (Leukemia Inhibitory Factor)', '0 (Recombinant Proteins)']",IM,"['Animals', 'Area Under Curve', 'Biological Availability', 'Humans', 'Interleukin-6/*pharmacokinetics', 'Leukemia Inhibitory Factor', 'Models, Biological', 'Recombinant Proteins/pharmacokinetics', 'Sheep']",,,,2004/02/12 05:00,2004/07/02 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/07/02 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,J Pharmacol Exp Ther. 2004 Jun;309(3):1085-92. doi: 10.1124/jpet.103.063289. Epub 2004 Feb 10.,"['10.1124/jpet.103.063289 [doi]', 'jpet.103.063289 [pii]']",,"The pharmacokinetics of recombinant human leukemia inhibitory factor (rhLIF) were investigated following i.v. and s.c. administration of a wide range of dose levels. Parallel studies were conducted where single i.v. bolus doses of 12.5, 25, 100, 250, 500, or 750 microg/kg rhLIF (n = 2) or s.c. doses of 10, 20, or 50 microg/kg rhLIF (n = 4) were administered to sheep. Blood samples were collected for up to 24 h postdosing, and the plasma concentrations of rhLIF were analyzed by enzyme-linked immunosorbent assay. Noncompartmental analysis demonstrated an increase in the terminal elimination half-life (from 0.27 to 2.29 h) and a decrease in systemic clearance (from 5.18 to 1.09 ml/min/kg) with increasing i.v. doses of rhLIF, suggesting nonlinear pharmacokinetic behavior. A greater than proportional increase in the area under the plasma concentration-time curve with dose also indicated significantly nonlinear pharmacokinetics after s.c. administration. A mechanistic compartmental model was developed to characterize the pharmacokinetics of rhLIF. The key feature of the model accounting for the nonlinear pharmacokinetic behavior of rhLIF was high-affinity, saturable receptor binding and subsequent cellular internalization and degradation. The apparent total density of LIF cell surface receptors and receptor turnover dynamics were included in the model, along with nonspecific binding and linear elimination from the systemic circulation. The absorption of rhLIF from the s.c. injection site into the systemic circulation was characterized by a first-order absorption process via a delay compartment. The proposed model satisfactorily captured the complex pharmacokinetic profiles of rhLIF following both i.v. and s.c. administration.","['Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.']",20040210,,,,,,,,,
14871997,NLM,MEDLINE,20040928,20191108,1078-0432 (Print) 1078-0432 (Linking),10,3,2004 Feb 1,Multiple myeloma regression mediated by bruceantin.,1170-9,"['Cuendet, Muriel', 'Christov, Konstantin', 'Lantvit, Daniel D', 'Deng, Yunfan', 'Hedayat, Samad', 'Helson, Lawrence', 'McChesney, James D', 'Pezzuto, John M']","['Cuendet M', 'Christov K', 'Lantvit DD', 'Deng Y', 'Hedayat S', 'Helson L', 'McChesney JD', 'Pezzuto JM']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Clin Cancer Res,Clinical cancer research : an official journal of the American Association for Cancer Research,9502500,"['0 (BH3 Interacting Domain Death Agonist Protein)', '0 (BID protein, human)', '0 (Bid protein, mouse)', '0 (Carbocyanines)', '0 (Carrier Proteins)', '0 (Fluorescent Dyes)', '0 (Proto-Oncogene Proteins c-myc)', '0 (Quassins)', '36015-30-2 (Propidium)', ""54501-79-0 (3,3'-dihexyl-2,2'-oxacarbocyanine)"", 'EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)', 'EC 3.4.22.- (CASP3 protein, human)', 'EC 3.4.22.- (CASP7 protein, human)', 'EC 3.4.22.- (CASP8 protein, human)', 'EC 3.4.22.- (CASP9 protein, human)', 'EC 3.4.22.- (Casp3 protein, mouse)', 'EC 3.4.22.- (Casp7 protein, mouse)', 'EC 3.4.22.- (Casp8 protein, mouse)', 'EC 3.4.22.- (Casp9 protein, mouse)', 'EC 3.4.22.- (Caspase 3)', 'EC 3.4.22.- (Caspase 7)', 'EC 3.4.22.- (Caspase 8)', 'EC 3.4.22.- (Caspase 9)', 'EC 3.4.22.- (Caspases)', 'S3NW88DI4T (bruceantin)']",IM,"['Animals', 'Apoptosis', 'BH3 Interacting Domain Death Agonist Protein', 'Carbocyanines/pharmacology', 'Carrier Proteins/metabolism', 'Caspase 3', 'Caspase 7', 'Caspase 8', 'Caspase 9', 'Caspases/metabolism', 'Cell Differentiation', 'Cell Line, Tumor', 'Dose-Response Relationship, Drug', 'Down-Regulation', 'Enzyme Activation', 'Fluorescent Dyes/pharmacology', 'Humans', 'Immunoblotting', 'Immunohistochemistry', 'In Situ Nick-End Labeling', 'Membrane Potentials', 'Mice', 'Mice, SCID', 'Mitochondria/pathology', 'Models, Chemical', 'Multiple Myeloma/*drug therapy', 'Neoplasm Transplantation', 'Poly(ADP-ribose) Polymerases/metabolism', 'Propidium/pharmacology', 'Proto-Oncogene Proteins c-myc/metabolism', 'Quassins/chemistry/*pharmacology']",,,,2004/02/12 05:00,2004/09/29 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/09/29 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Clin Cancer Res. 2004 Feb 1;10(3):1170-9. doi: 10.1158/1078-0432.ccr-0362-3.,['10.1158/1078-0432.ccr-0362-3 [doi]'],,"PURPOSE: Bruceantin has been shown to induce cell differentiation in a number of leukemia and lymphoma cell lines. It also down-regulated c-MYC, suggesting a correlation of down-regulation with induction of cell differentiation or cell death. In the present study, we focused on multiple myeloma, using the RPMI 8226 cell line as a model. EXPERIMENTAL DESIGN: The effects of bruceantin on c-MYC levels and apoptosis were examined by immunoblotting, 4',6-diamidino-2-phenylindole staining, evaluation of caspase-like activity, and 3,3'-dihexyloxacarbocyanine iodide staining. The potential of bruceantin to inhibit primary tumor growth was assessed with RPMI 8226 xenografts in SCID mice, and apoptosis in the tumors was evaluated by the terminal deoxynucleotidyl transferase-mediated nick end labeling assay. RESULTS: c-MYC was strongly down-regulated in cultured RPMI 8226 cells by treatment with bruceantin for 24 h. With U266 and H929 cells, bruceantin did not regulate c-MYC in this manner. Apoptosis was induced in the three cell lines. In RPMI 8226 cells, apoptosis occurred through proteolytic processing of procaspases and degradation of poly(ADP-ribose) polymerase. The mitochondrial pathway was also involved. Because RPMI 8226 cells were the most sensitive, they were used in a xenograft model. Bruceantin treatment (2.5-5 mg/kg) resulted in a significant regression of tumors without overt toxicity. Apoptosis was significantly elevated in tumors derived from animals treated with bruceantin (37%) as compared with the control tumors (14%). CONCLUSIONS: Bruceantin interferes with the growth of RPMI 8226 cells in cell culture and xenograft models. These results suggest that bruceantin should be reinvestigated for clinical efficacy against multiple myeloma and other hematological malignancies.","['Program for Collaborative Research in the Pharmaceutical Sciences, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, IL, USA.']",,['P01 CA 48112/CA/NCI NIH HHS/United States'],,,,,,,,
14871984,NLM,MEDLINE,20040928,20191108,1078-0432 (Print) 1078-0432 (Linking),10,3,2004 Feb 1,"Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.",1047-56,"['Grube, Matthias', 'Rezvani, Katayoun', 'Wiestner, Adrian', 'Fujiwara, Hiroshi', 'Sconocchia, Giuseppe', 'Melenhorst, Jan J', 'Hensel, Nancy', 'Marti, Gerald E', 'Kwak, Larry W', 'Wilson, Wyndham', 'Barrett, John A']","['Grube M', 'Rezvani K', 'Wiestner A', 'Fujiwara H', 'Sconocchia G', 'Melenhorst JJ', 'Hensel N', 'Marti GE', 'Kwak LW', 'Wilson W', 'Barrett JA']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Clin Cancer Res,Clinical cancer research : an official journal of the American Association for Cancer Research,9502500,"['0 (Antigens)', '0 (Antigens, CD19)', '0 (Antigens, CD20)', '0 (Antigens, Differentiation, B-Lymphocyte)', '0 (CD40 Antigens)', '0 (DNA, Complementary)', '0 (HLA-A Antigens)', '0 (HLA-A*02:01 antigen)', '0 (HLA-A2 Antigen)', '0 (Peptides)', '0 (RNA, Messenger)', '63231-63-0 (RNA)', '82115-62-6 (Interferon-gamma)']",IM,"['Adult', 'Aged', 'Aged, 80 and over', 'Antigens/chemistry', 'Antigens, CD19/biosynthesis/metabolism', 'Antigens, CD20/biosynthesis/metabolism', 'Antigens, Differentiation, B-Lymphocyte/*immunology/metabolism', 'B-Lymphocytes/immunology/*metabolism', 'CD40 Antigens/metabolism', 'CD8-Positive T-Lymphocytes/metabolism', 'Cell Line, Tumor', 'DNA, Complementary/metabolism', 'Female', 'Flow Cytometry', 'HLA-A Antigens/metabolism', 'HLA-A2 Antigen', 'Humans', 'Interferon-gamma/metabolism', 'Lymphoma, B-Cell/immunology/*metabolism', 'Male', 'Middle Aged', 'Peptides/*chemistry', 'Polymerase Chain Reaction', 'Protein Binding', 'RNA/chemistry', 'RNA, Messenger/metabolism', 'Reverse Transcriptase Polymerase Chain Reaction', 'T-Lymphocytes, Cytotoxic/*metabolism']",,,,2004/02/12 05:00,2004/09/29 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/09/29 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Clin Cancer Res. 2004 Feb 1;10(3):1047-56. doi: 10.1158/1078-0432.ccr-03-0075.,['10.1158/1078-0432.ccr-03-0075 [doi]'],,"PURPOSE: To investigate potential immunotherapeutic strategies in B lymphocytic malignancies we looked for CTLs recognizing CD19 and CD20 epitopes. EXPERIMENTAL DESIGN: Three CD19 and CD20 peptides binding to HLA-A*0201 were identified and used to detect peptide specific CTLs by a quantitative real-time PCR to measure IFN-gamma mRNA expression in 23 healthy individuals and 28 patients (18 chronic lymphocytic leukemia (CLL), 7 follicular lymphoma, 2 acute lymphocytic leukemia, and 1 large cell lymphoma). Peptide-specific CTLs were expanded in culture with CD40-activated B cells to test lytic activity in three patients. RESULTS: In healthy individuals, CD8+ T-cell responses were detected in one to CD19(74-82), in three to CD20(127-135), and three to CD20(188-196). Seven of 27 patients (6 with CLL) had CD8+ T cells recognizing CD19(74-82). Seven patients responded to CD20(127-135) and three to CD20(188-196). All were CLL patients. CD19(74-82)-specific CTLs from three patients were expanded over 4 weeks. These cells were HLA-A*0201 specific and lytic for peptide-loaded antigen-presenting cells but not to malignant or unpulsed B cells. CONCLUSIONS: CTLs that recognize CD19 and CD20 epitopes exist in healthy individuals and may be increased in CLL patients. They are of low avidity and require high doses of peptide for activation. Strategies to increase T-cell avidity would be necessary for T-cell immunotherapeutic approaches using the peptides studied.","['Hematology Branch, National Heart-Lung-Blood Institute/NIH, 9000 Rockville Pike, Building 10, Bethesda, MD 20892, USA.']",,,,,,,,,,
14871978,NLM,MEDLINE,20040928,20191108,1078-0432 (Print) 1078-0432 (Linking),10,3,2004 Feb 1,Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia.,994-1002,"['Wong, Ivy H N', 'Chan, Jacqueline', 'Wong, Joyce', 'Tam, Paul K H']","['Wong IH', 'Chan J', 'Wong J', 'Tam PK']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Clin Cancer Res,Clinical cancer research : an official journal of the American Association for Cancer Research,9502500,"['0 (RASSF1 protein, human)', '0 (Tumor Suppressor Proteins)', '136601-57-5 (Cyclin D1)', '63231-63-0 (RNA)']",IM,"['Adolescent', 'Alleles', 'Cell Line', 'Cell Line, Tumor', 'Child', 'Child, Preschool', 'Cyclin D1/biosynthesis', '*DNA Methylation', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Neoplasm Metastasis', 'Neoplasms/*genetics', 'Promoter Regions, Genetic', 'RNA/metabolism', 'Reverse Transcriptase Polymerase Chain Reaction', 'Tumor Suppressor Proteins/*genetics']",,,,2004/02/12 05:00,2004/09/29 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/09/29 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Clin Cancer Res. 2004 Feb 1;10(3):994-1002. doi: 10.1158/1078-0432.ccr-0378-3.,['10.1158/1078-0432.ccr-0378-3 [doi]'],,"PURPOSE AND EXPERIMENTAL DESIGN: The role of RASSF1A has been elucidated recently in regulating apoptosis and cell cycle progression by inhibiting cyclin D1 accumulation. Aberrant RASSF1A promoter methylation has been found frequently in multiple adult cancer types. Using methylation-specific PCR and reverse transcription-PCR, we investigated epigenetic deregulation of RASSF1A in primary tumors, adjacent nontumor tissues, secondary metastases, peripheral blood cells, and plasma samples from children with 18 different cancer types, in association with their clinicopathologic features. RESULTS: Regardless of the tumor size, ubiquitous RASSF1A promoter methylation was found in 67% (16 of 24) of pediatric tumors, including neuroblastoma, thyroid carcinoma, hepatocellular carcinoma, pancreatoblastoma, adrenocortical carcinoma, Wilms' tumor, Burkitt's lymphoma, and T-cell lymphoma. A majority (75%) of pediatric cancer patients with tumoral RASSF1A methylation was male. Methylated RASSF1A alleles were also detected in 4 of 13 adjacent nontumor tissues, suggesting that this epigenetic change is potentially an early and critical event in childhood neoplasia. RASSF1A promoter methylation found in 92% (11 of 12) of cell lines largely derived from pediatric cancer patients was significantly associated with transcriptional silencing/repression. After demethylation treatment with 5-aza-2'-deoxycytidine, transcriptional reactivation was shown in KELLY, RD, and Namalwa cell lines as analyzed by reverse transcription-PCR. For the first time, RASSF1A methylation was detected in 54% (7 of 13), 40% (4 of 10), and 9% (1 of 11) of buffy coat samples collected before, during, and after treatment, correspondingly, from pediatric patients with neuroblastoma, thyroid carcinoma, hepatocellular carcinoma, rhabdomyosarcoma, Burkitt's lymphoma, T-cell lymphoma, or acute lymphoblastic leukemia. Concordantly, RASSF1A methylation was found during treatment in plasma of the same patients, suggesting cell death and good response to chemotherapy. CONCLUSIONS: RASSF1A methylation in tumor or buffy coat did not correlate strongly with age, tumor size, recurrence/metastasis, or overall survival in this cohort of pediatric cancer patients. Of importance, epigenetic inactivation of RASSF1A may potentially be crucial in pediatric tumor initiation.","['Department of Biochemistry, 3/F Laboratory Block, Faculty of Medicine Building, 21 Sassoon Road, The University of Hong Kong, Hong Kong Special Administrative Region. ihnwong@hkucc.hku.hk']",,,,,,,,,,
14871853,NLM,MEDLINE,20040409,20201219,0008-5472 (Print) 0008-5472 (Linking),64,3,2004 Feb 1,Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.,1164-70,"['Schmidt, Susanne M', 'Schag, Kerstin', 'Muller, Martin R', 'Weinschenk, Toni', 'Appel, Silke', 'Schoor, Oliver', 'Weck, Markus M', 'Grunebach, Frank', 'Kanz, Lothar', 'Stevanovic, Stefan', 'Rammensee, Hans-Georg', 'Brossart, Peter']","['Schmidt SM', 'Schag K', 'Muller MR', 'Weinschenk T', 'Appel S', 'Schoor O', 'Weck MM', 'Grunebach F', 'Kanz L', 'Stevanovic S', 'Rammensee HG', 'Brossart P']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Cancer Res,Cancer research,2984705R,"['0 (Epitopes, T-Lymphocyte)', '0 (HLA-A Antigens)', '0 (HLA-A*02:01 antigen)', '0 (HLA-A2 Antigen)', '0 (Membrane Proteins)', '0 (PLIN2 protein, human)', '0 (Peptides)', '0 (Perilipin-2)', '63231-63-0 (RNA)']",IM,"['Antigen Presentation/immunology', 'Cell Line, Tumor', 'Dendritic Cells/immunology', 'Epitopes, T-Lymphocyte/immunology', 'HLA-A Antigens/*immunology/metabolism', 'HLA-A2 Antigen', 'Humans', 'Membrane Proteins', 'Neoplasms/*immunology/metabolism', 'Peptides/genetics/*immunology/metabolism', 'Perilipin-2', 'RNA/genetics', 'T-Lymphocytes, Cytotoxic/*immunology', 'Transfection']",,,,2004/02/12 05:00,2004/04/10 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/04/10 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Cancer Res. 2004 Feb 1;64(3):1164-70. doi: 10.1158/0008-5472.can-03-2538.,['10.1158/0008-5472.can-03-2538 [doi]'],,"Identification of tumor-associated antigens and advances in tumor immunology resulted in the development of vaccination strategies to treat patients with malignant diseases. Using a novel approach that combines DNA chip analysis of tumor samples with isolation of peptides on the surface of tumor cells, a HLA-A*0201-binding peptide derived from the adipophilin protein was identified. Adipophilin is involved in lipid storage and was thought to be expressed only in adipocytes, but it can be found in other cell types such as macrophages or tumor cells. In the present study, we analyzed the possible use of this peptide as a T-cell epitope presented by malignant cells. To accomplish this, we induced CTL responses using this HLA-A*0201-binding peptide. The in vitro-induced CTLs efficiently lysed cells pulsed with the adipophilin peptide and HLA-matched tumor cell lines in an antigen-specific and HLA-restricted manner. Finally, the induced CTLs recognized autologous dendritic cells (DCs) pulsed with the antigenic peptide or transfected with tumor RNA purified from an adipophilin-expressing tumor cell line. To further analyze the possible use of this peptide in immunotherapies of human malignancies, we induced adipophilin-specific CTLs using peripheral blood mononuclear cells and DCs from HLA-A*0201-positive patients with chronic lymphatic leukemia and plasma cell leukemia. The in vitro-generated CTLs recognized autologous chronic lymphatic leukemia cells and malignant plasma cells, whereas they spared nonmalignant resting or activated B and T lymphocytes, monocytes, or DCs. Our results demonstrate that this peptide might represent an interesting candidate for the development of cancer vaccines designed to target adipophilin-derived epitopes in a wide range of malignancies.","['University of Tubingen, Department of Hematology, Tuebingen, Germany.']",,,,,,,,,,
14871852,NLM,MEDLINE,20040409,20201215,0008-5472 (Print) 0008-5472 (Linking),64,3,2004 Feb 1,Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.,1157-63,"['Hogan, Kevin T', 'Coppola, Michael A', 'Gatlin, Christine L', 'Thompson, Lee W', 'Shabanowitz, Jeffrey', 'Hunt, Donald F', 'Engelhard, Victor H', 'Ross, Mark M', 'Slingluff, Craig L Jr']","['Hogan KT', 'Coppola MA', 'Gatlin CL', 'Thompson LW', 'Shabanowitz J', 'Hunt DF', 'Engelhard VH', 'Ross MM', 'Slingluff CL Jr']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Cancer Res,Cancer research,2984705R,"['0 (Antigens, Neoplasm)', '0 (Epitopes, T-Lymphocyte)', '0 (HLA-A3 Antigen)', '0 (Oligopeptides)', '0 (Protein Isoforms)']",IM,"['Amino Acid Sequence', 'Antigens, Neoplasm/genetics/*immunology', 'Base Sequence', 'Cell Line, Tumor', 'Epitopes, T-Lymphocyte/immunology', 'HLA-A3 Antigen/immunology', 'Humans', 'Melanoma/genetics/*immunology/metabolism', 'Molecular Sequence Data', 'Oligopeptides/immunology', 'Protein Isoforms', 'T-Lymphocytes, Cytotoxic/*immunology']",,,,2004/02/12 05:00,2004/04/10 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/04/10 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Cancer Res. 2004 Feb 1;64(3):1157-63. doi: 10.1158/0008-5472.can-03-2209.,['10.1158/0008-5472.can-03-2209 [doi]'],,"Multiple isoforms (TAG-1, TAG-2a, TAG-2b, and TAG-2c) of a novel cancer/testis antigen gene have been identified and are expressed in 84-88% of melanoma cell lines tested. The tumor antigen (TAG) genes are also expressed in K562, a myelogenous leukemia cell line, and they have homology to two chronic myelogenous leukemia-derived clones and a hepatocellular carcinoma clone in the human expressed sequence tags (EST) database, thus indicating that their expression is not restricted to melanomas. In contrast to the fact that many cancer/testis antigens are poorly immunogenic, the TAG-derived peptide, RLSNRLLLR, is recognized by HLA-A3-restricted, melanoma-specific CTLs that were obtained from a melanoma patient with spontaneous reactivity to the peptide. Unlike most cancer/testis antigen genes which are located on the X chromosome, the TAG genes are located on chromosome 5. The genes have the additional unusual features of being coded for in an open reading frame that is initiated by one of three nonstandard initiation codons, and the sequence coding the RLSNRLLLR peptide crosses an exon-exon boundary. The properties of the TAG antigens indicate that they are excellent vaccine candidates for the treatment of melanoma and perhaps other cancers.","['Department of Surgery, University of Virginia, and Argonex, Inc., Charlottesville, Virginia, USA.']",,"['F32CA72166/CA/NCI NIH HHS/United States', 'R01CA57653/CA/NCI NIH HHS/United States', 'R01CA90815/CA/NCI NIH HHS/United States']",,,,,,,,
14871840,NLM,MEDLINE,20040409,20191108,0008-5472 (Print) 0008-5472 (Linking),64,3,2004 Feb 1,"Induction of apoptosis in leukemic cells by homovanillic acid derivative, capsaicin, through oxidative stress: implication of phosphorylation of p53 at Ser-15 residue by reactive oxygen species.",1071-8,"['Ito, Keisuke', 'Nakazato, Tomonori', 'Yamato, Kenji', 'Miyakawa, Yoshitaka', 'Yamada, Taketo', 'Hozumi, Nobumichi', 'Segawa, Kaoru', 'Ikeda, Yasuo', 'Kizaki, Masahiro']","['Ito K', 'Nakazato T', 'Yamato K', 'Miyakawa Y', 'Yamada T', 'Hozumi N', 'Segawa K', 'Ikeda Y', 'Kizaki M']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Cancer Res,Cancer research,2984705R,"['0 (Reactive Oxygen Species)', '0 (Tumor Suppressor Protein p53)', '452VLY9402 (Serine)', 'S07O44R1ZM (Capsaicin)']",IM,"['Apoptosis/*drug effects', 'Capsaicin/*pharmacology', 'Cell Division/drug effects', 'Cell Line, Tumor', 'G1 Phase/drug effects', 'Humans', 'Leukemia/*drug therapy/metabolism/pathology', 'Mitochondria/drug effects/physiology', 'Oxidative Stress/physiology', 'Phosphorylation', 'Reactive Oxygen Species/metabolism', 'Resting Phase, Cell Cycle/drug effects', 'Serine/metabolism', 'Signal Transduction/drug effects', 'Tumor Suppressor Protein p53/*metabolism']",,,,2004/02/12 05:00,2004/04/10 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/04/10 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Cancer Res. 2004 Feb 1;64(3):1071-8. doi: 10.1158/0008-5472.can-03-1670.,['10.1158/0008-5472.can-03-1670 [doi]'],,"Capsaicin (N-vanillyl-8-methyl-1-nonenamide) is a homovanillic acid derivative found in pungent fruits. Several investigators have reported the ability of capsaicin to inhibit events associated with the promotion of cancer. However, the effects of capsaicin on human leukemic cells have never been investigated. We investigated the effects of capsaicin on leukemic cells in vitro and in vivo and further examined the molecular mechanisms of capsaicin-induced apoptosis in myeloid leukemic cells. Capsaicin suppressed the growth of leukemic cells, but not normal bone marrow mononuclear cells, via induction of G(0)-G(1) phase cell cycle arrest and apoptosis. Capsaicin-induced apoptosis was in association with the elevation of intracellular reactive oxygen species production. Interestingly, capsaicin-sensitive leukemic cells were possessed of wild-type p53, resulting in the phosphorylation of p53 at the Ser-15 residue by the treatment of capsaicin. Abrogation of p53 expression by the antisense oligonucleotides significantly attenuated capsaicin-induced cell cycle arrest and apoptosis. Pretreatment with the antioxidant N-acetyl-L-cystein and catalase, but not superoxide dismutase, completely inhibited capsaicin-induced apoptosis by inhibiting phosphorylation of Ser-15 residue of p53. Moreover, capsaicin effectively inhibited tumor growth and induced apoptosis in vivo using NOD/SCID mice with no toxic effects. We conclude that capsaicin has potential as a novel therapeutic agent for the treatment of leukemia.","['Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.']",,,,,,,,,,
14871835,NLM,MEDLINE,20040409,20191108,0008-5472 (Print) 0008-5472 (Linking),64,3,2004 Feb 1,Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils.,1037-43,"['Koga, Yuhki', 'Matsuzaki, Akinobu', 'Suminoe, Aiko', 'Hattori, Hiroyoshi', 'Hara, Toshiro']","['Koga Y', 'Matsuzaki A', 'Suminoe A', 'Hattori H', 'Hara T']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,"['0 (Apoptosis Regulatory Proteins)', '0 (Membrane Glycoproteins)', '0 (RNA, Messenger)', '0 (TNF-Related Apoptosis-Inducing Ligand)', '0 (TNFSF10 protein, human)', '0 (Tumor Necrosis Factor-alpha)']",IM,"['Apoptosis Regulatory Proteins', 'Blotting, Western', 'Cells, Cultured', 'Enzyme-Linked Immunosorbent Assay', 'Flow Cytometry', 'Gene Expression Profiling', 'Humans', 'Jurkat Cells', 'Leukemia, T-Cell/drug therapy', 'Leukocytes, Mononuclear/metabolism/physiology', 'Membrane Glycoproteins/*biosynthesis/blood/genetics/pharmacology', 'Neutrophils/immunology/metabolism/*physiology', 'Oligonucleotide Array Sequence Analysis', 'RNA, Messenger/blood/genetics', 'TNF-Related Apoptosis-Inducing Ligand', 'Tumor Necrosis Factor-alpha/*biosynthesis/genetics/pharmacology']",,,,2004/02/12 05:00,2004/04/10 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/04/10 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Cancer Res. 2004 Feb 1;64(3):1037-43. doi: 10.1158/0008-5472.can-03-1808.,['10.1158/0008-5472.can-03-1808 [doi]'],,"To detect the novel genes expressed uniquely in neutrophils and elucidate their function, the gene expression pattern was compared by using cDNA microarray containing 240 cytokine genes between the neutrophils and peripheral blood mononuclear cells (PBMCs) obtained from healthy human donors. Twenty-six genes, including tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), were expressed in neutrophils at a level >10 times higher than that seen in phytohemagglutinin-stimulated PBMCs. The amounts of mRNA and protein of TRAIL were quantified by real-time reverse transcription-PCR and ELISA, respectively. TRAIL was expressed in resting neutrophils at the mRNA and protein levels, and its expression was enhanced after stimulation with IFN-gamma. Neutrophils expressed TRAIL on the cell surface and released it into the culture media. The cytotoxicity of neutrophil-derived TRAIL against Jurkat cells was determined by flow cytometry using FITC-conjugated annexin V. When Jurkat cells were cultured with neutrophils in the presence of IFN-gamma, the number of Jurkat cells undergoing apoptosis increased, and such increase depended on the effector:target ratio. This cytotoxicity was suppressed partially by adding anti-TRAIL antibody to the media. Neutrophils may exert their own antitumor effect by TRAIL. A microarray analysis was found to be a useful tool for detecting novel genes that are suggested to play unknown roles in the neutrophil function.","['Department of Pediatrics, Graduate School of Medical Sciences, School of Health Sciences, Kyushu University, Fukuoka, Japan. yuuki-k@pediatr.med.kyushu-u.ac.jp']",,,,,,,,,,
14871822,NLM,MEDLINE,20040409,20191108,0008-5472 (Print) 0008-5472 (Linking),64,3,2004 Feb 1,Restoration of promyelocytic leukemia protein-nuclear bodies in neuroblastoma cells enhances retinoic acid responsiveness.,928-33,"['Yu, Jiang Hong', 'Nakajima, Ayako', 'Nakajima, Hiroshi', 'Diller, Lisa R', 'Bloch, Kenneth D', 'Bloch, Donald B']","['Yu JH', 'Nakajima A', 'Nakajima H', 'Diller LR', 'Bloch KD', 'Bloch DB']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Cancer Res,Cancer research,2984705R,"['0 (Antineoplastic Agents)', '0 (Neoplasm Proteins)', '0 (Nuclear Proteins)', '0 (Promyelocytic Leukemia Protein)', '0 (Transcription Factors)', '0 (Tumor Suppressor Proteins)', '143220-95-5 (PML protein, human)', '5688UTC01R (Tretinoin)']",IM,"['Antineoplastic Agents/*pharmacology', 'Cell Differentiation/drug effects/physiology', 'Cell Line, Tumor', 'Cell Nucleus Structures/*metabolism', 'HL-60 Cells', 'Humans', 'Immunohistochemistry', 'Neoplasm Proteins/*biosynthesis/deficiency', 'Neuroblastoma/*drug therapy/*metabolism/pathology/ultrastructure', '*Nuclear Proteins', 'Promyelocytic Leukemia Protein', 'Transcription Factors/*biosynthesis/deficiency', 'Tretinoin/*pharmacology', 'Tumor Suppressor Proteins']",,,,2004/02/12 05:00,2004/04/10 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/04/10 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Cancer Res. 2004 Feb 1;64(3):928-33. doi: 10.1158/0008-5472.can-03-1199.,['10.1158/0008-5472.can-03-1199 [doi]'],,"Neuroblastoma is the most common solid tumor of infancy and is believed to result from impaired differentiation of neuronal crest embryonal cells. The promyelocytic leukemia protein (PML)-nuclear body is a cellular structure that is disrupted during the pathogenesis of acute promyelocytic leukemia, a disease characterized by impaired myeloid cell differentiation. During the course of studies to examine the composition and function of PML-nuclear bodies, we observed that the human neuroblastoma cell line SH-SY5Y lacked these structures and that the absence of PML-nuclear bodies was a feature of N- and I-type, but not S-type, neuroblastoma cell lines. Induction of neuroblastoma cell differentiation with 5-bromo-2'deoxyuridine, all-trans-retinoic acid, or IFN-gamma induced PML-nuclear body formation. PML-nuclear bodies were not detected in tissue sections prepared from undifferentiated neuroblastomas but were present in neuroblasts in differentiating tumors. Expression of PML in neuroblastoma cells restored PML-nuclear bodies, enhanced responsiveness to all-trans-retinoic acid, and induced cellular differentiation. Pharmacological therapies that increase PML expression may prove to be important components of combined modalities for the treatment of neuroblastoma.","['Department of Medicine, Harvard Medical School, USA.']",,"['DK-051179/DK/NIDDK NIH HHS/United States', 'DK-40561/DK/NIDDK NIH HHS/United States', 'HL-57172/HL/NHLBI NIH HHS/United States']",,,,,,,,
14871251,NLM,MEDLINE,20040510,20190705,0007-1048 (Print) 0007-1048 (Linking),124,5,2004 Mar,Chemotherapy plus G-CSF mobilized peripheral blood stem cell harvests from acute myeloid leukaemia patients contain large amounts of polyclonal myeloid linnegCD11cpos dendritic precursor cells.,636-44,"['Sanchez, Joaquin', 'Herrera, Concepcion', 'Torres, Antonio', 'Roman-Gomez, Jose', 'Alvarez, Miguel A']","['Sanchez J', 'Herrera C', 'Torres A', 'Roman-Gomez J', 'Alvarez MA']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,England,Br J Haematol,British journal of haematology,0372544,"['0 (CD11 Antigens)', '143011-72-7 (Granulocyte Colony-Stimulating Factor)']",IM,"['Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'CD11 Antigens/analysis', 'Clone Cells', 'Dendritic Cells/*pathology', 'Feasibility Studies', 'Female', 'Flow Cytometry', 'Granulocyte Colony-Stimulating Factor/*therapeutic use', 'Hematopoietic Stem Cell Mobilization/*methods', 'Hematopoietic Stem Cells/*pathology', 'Humans', 'Leukemia, Myeloid, Acute/pathology/*therapy', 'Male', 'Myeloid Cells/*pathology', 'Phenotype']",,,,2004/02/12 05:00,2004/05/11 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/05/11 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Br J Haematol. 2004 Mar;124(5):636-44. doi: 10.1111/j.1365-2141.2004.04818.x.,"['4818 [pii]', '10.1111/j.1365-2141.2004.04818.x [doi]']",,"Dendritic cells (DC) are potent antigen-presenting cells that can induce effective tumour-specific T-cell responses. This study investigated leucapheresis products as source of DC precursors in 48 patients undergoing autologous peripheral blood stem cell (PBSC) transplantation for haematological malignancies. Strikingly, high-dose cytarabine and etoposide plus granulocyte colony stimulating factor (G-CSF) mobilized PBSC harvests from acute myeloid leukaemia (AML) patients containing the highest number of myeloid lin(neg)CD11c(pos) DC (mean: 7.04 x 106/kg, range: 1.46-19.67) which was 18.1-fold higher than in non-AML patients mobilized using chemotherapy (CT) regimens plus G-CSF. Clonality of purified lin(neg)CD11c(pos) DC from CT plus G-CSF mobilized AML patients (n = 8 ) was assessed using the human androgen-receptor locus methylation, disclosing a polyclonal pattern in five female patients. These cells displayed morphological and phenotypic features of myeloid DC precursors with expression of HLA-DR, HLA-ABC, CD86, CCR5 and CD54 molecules but lacking CD80, CD83, CD1a and CD40 antigens. Short-term culture with autologous leukaemic cell lysates plus tumour necrosis factor-alpha yielded maturated myeloid DC capable of triggering interleukin-2 and interferon-gamma production by autologous T-lymphocytes. These findings suggest that the use of post-remission CT and G-CSF as mobilizing regimen in AML patients generates PBSC containing high doses of polyclonal myeloid lin(neg)CD11c(pos) DC precursors, which could be used to design feasible immunotherapy protocols.","['Hematology and Bone Marrow Transplantation Department, University Hospital Reina Sofia, Avda. Menendez Pidal s/n, 14004 Cordoba, Spain. joaquin.sanchez@cheerful.com']",,,,,,,,,,
14871250,NLM,MEDLINE,20040510,20190705,0007-1048 (Print) 0007-1048 (Linking),124,5,2004 Mar,"Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant.",629-35,"['Nishida, Tetsuya', 'Akatsuka, Yoshiki', 'Morishima, Yasuo', 'Hamajima, Nobuyuki', 'Tsujimura, Kunio', 'Kuzushima, Kiyotaka', 'Kodera, Yoshihisa', 'Takahashi, Toshitada']","['Nishida T', 'Akatsuka Y', 'Morishima Y', 'Hamajima N', 'Tsujimura K', 'Kuzushima K', 'Kodera Y', 'Takahashi T']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,England,Br J Haematol,British journal of haematology,0372544,"['0 (Epitopes)', '0 (HLA-A Antigens)', '0 (HLA-A24 Antigen)', '0 (Minor Histocompatibility Antigens)']",IM,"['Adolescent', 'Adult', 'Bone Marrow Transplantation/*immunology', 'Child', 'Child, Preschool', 'Epitopes', 'Female', '*Genes, BRCA2', 'Graft vs Host Disease/genetics', 'Graft vs Leukemia Effect/genetics', 'HLA-A Antigens/*genetics', 'HLA-A24 Antigen', 'Hematologic Neoplasms/therapy', 'Humans', 'Infant', 'Male', 'Middle Aged', 'Minor Histocompatibility Antigens', 'Polymorphism, Genetic', 'Retrospective Studies', 'Risk Factors', 'T-Lymphocytes/immunology']",,,,2004/02/12 05:00,2004/05/11 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/05/11 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Br J Haematol. 2004 Mar;124(5):629-35. doi: 10.1111/j.1365-2141.2004.04823.x.,"['4823 [pii]', '10.1111/j.1365-2141.2004.04823.x [doi]']",,"Minor histocompatibility antigens (mHAs) are major histocompatibility complex (MHC)-associated peptides, which trigger T-cell responses that mediate graft versus host disease (GVHD) and graft versus leukaemia effects. We recently identified a new mHA epitope, termed ACC-1, which is presented by HLA-A*2402 and encoded by BCL2A1, whose expression is restricted to haematopoietic cells including leukaemic cells. HLA-A24/ACC-1 tetramer detected the presence of ACC-1-specific CD8+ cells in the peripheral blood of a patient up to 7 months following transplantation, and these tetramer-positive cells were expandable in vitro by ACC-1 peptide stimulation. A retrospective analysis of 320 patients with HLA-A*2402 who had received a human leucocyte antigen (HLA) genotypically matched unrelated donor through the Japan Marrow Donor Programme was conducted to determine whether ACC-1 disparity is associated with adverse clinical outcomes such as GVHD. Among these patients, ACC-1 disparity was detected in 55 (17.2%) donor/recipient pairs. After adjusting for known risk factors, the hazard ratios or odds ratios of acute and chronic GVHD, relapse and disease-free survival were not statistically different between patients receiving ACC-1 compatible and incompatible transplantation. These data suggest that disparity of haematopoietic cell-specific mHA, ACC-1, is unlikely at least to augment GVHD, and that T cells specific for ACC-1 may also be used for immunotherapy of recurring leukaemia without GVHD.","['Division of Immunology, Aichi Cancer Centre Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.']",,,,,,,,,,
14871247,NLM,MEDLINE,20040510,20190705,0007-1048 (Print) 0007-1048 (Linking),124,5,2004 Mar,Cardiac monitoring of patients receiving arsenic trioxide therapy.,610-7,"['Unnikrishnan, Dilip', 'Dutcher, Janice P', 'Garl, Susan', 'Varshneya, Nikita', 'Lucariello, Richard', 'Wiernik, Peter H']","['Unnikrishnan D', 'Dutcher JP', 'Garl S', 'Varshneya N', 'Lucariello R', 'Wiernik PH']",['eng'],"['Clinical Trial', 'Clinical Trial, Phase II', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,England,Br J Haematol,British journal of haematology,0372544,"['0 (Antineoplastic Agents)', '0 (Arsenicals)', '0 (Oxides)', 'S7V92P67HO (Arsenic Trioxide)']",IM,"['Adult', 'Aged', 'Antineoplastic Agents/*adverse effects', 'Arrhythmias, Cardiac/*chemically induced', 'Arsenic Trioxide', 'Arsenicals/*adverse effects', 'Edema/*chemically induced', 'Electrocardiography, Ambulatory', 'Female', 'Hematologic Neoplasms/*drug therapy', 'Humans', 'Male', 'Middle Aged', 'Oxides/*adverse effects', 'Prospective Studies']",,,,2004/02/12 05:00,2004/05/11 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/05/11 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Br J Haematol. 2004 Mar;124(5):610-7. doi: 10.1111/j.1365-2141.2003.04817.x.,"['4817 [pii]', '10.1111/j.1365-2141.2003.04817.x [doi]']",,"Arsenic trioxide (ATO) is approved for the treatment of acute promyelocytic leukaemia and is under investigation for other malignancies. We report the cardiac findings in 18 patients with haematologic malignancies treated with ATO and assess the role of cardiac factors in fluid retention syndrome observed during ATO therapy. Based on initial observations in 10 patients treated with ATO, cardiac functions in the subsequent eight patients were evaluated prospectively. Evaluation included pre- and during-treatment electrocardiograms, Holter monitoring, echocardiograms, multigated acquisition scan and cardiac stress tests if indicated. All eight patients developed fluid retention during ATO, evidenced by pulmonary congestion, oedema and pleural/pericardial effusions. No cardiac factors were identified that contributed to fluid retention. Six patients had prolonged corrected QT (QTc) compared with baseline, three developed ventricular tachycardia. Sinus tachycardia, ventricular premature contractions, and non-sustained ventricular/supraventricular tachycardia were seen during ATO treatment. Fluid retention and cardiac events did not correlate with the dose or total amount of ATO or prior anthracycline therapy. In summary, fluid overload during ATO therapy does not appear to be cardiac in origin but appears to be drug-related, and may reflect cytokine-induced capillary leak. QTc prolongation, transient arrhythmias and clinically significant arrhythmias were seen with therapeutic doses of ATO.","['Our Lady of Mercy Cancer Center, 600 East 233rd Street, Bronx, NY, USA.']",,,,,,,,,,
14871222,NLM,MEDLINE,20040413,20190906,1076-0512 (Print) 1076-0512 (Linking),30,2 Pt 2,2004 Feb,Cutaneous leukemia inhibitory factor and its potential role in the development of skin tumors.,279-90,"['McKenzie, Roddie C', 'Szepietowski, Jacek']","['McKenzie RC', 'Szepietowski J']",['eng'],"['Journal Article', 'Review']",,United States,Dermatol Surg,Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],9504371,"['0 (Interleukin-6)', '0 (LIF protein, human)', '0 (Leukemia Inhibitory Factor)']",IM,"['Cell Transformation, Neoplastic/immunology', 'Humans', 'Inflammation/immunology', 'Interleukin-6/*biosynthesis/genetics/*immunology', 'Leukemia Inhibitory Factor', 'Mast Cells/immunology', 'Neoplasms/immunology', 'Signal Transduction/*immunology', 'Skin/*immunology', 'Skin Diseases/immunology', 'Skin Neoplasms/*immunology']",,,,2004/02/12 05:00,2004/04/14 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/04/14 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Dermatol Surg. 2004 Feb;30(2 Pt 2):279-90. doi: 10.1111/j.1524-4725.2004.30087.x.,"['30087 [pii]', '10.1111/j.1524-4725.2004.30087.x [doi]']",,"Leukemia inhibitory factor (LIF) is a polyfunctional cytokine with a variety and a diverse range of biological activities. However, this is a reflection of the fact that the cytokine is expressed in many different tissues, has a wide target cell range, and fulfills different functions in different tissues. The purpose of this article is to examine what is known about LIF expression in the skin and to consider whether LIF plays a role in inflammatory and hyperplastic events in the skin. LIF is strongly expressed in skin tumors, and recent studies indicate that it may affect tumor growth by several different mechanisms. The biological activities of LIF relevant to carcinogenesis, its expression, and signal transduction by the LIF receptor are described. Expression of LIF in normal skin by skin tumors and its induction by ultraviolet radiation and proinflammatory stimuli are discussed, as are possible interactions between LIF, mast cells, and tumor growth. We consider what role LIF and other members of the hemopoietin family of cytokines play in healthy and diseased skin and whether LIF could play a role in hyperplastic skin disorders. LIF appears to be an important cytokine for normal keratinocyte growth and wound healing and may be involved in regulating the proliferation of skin tumors. Accordingly, LIF may be a useful target for anticancer therapy and as a growth factor for normal skin during reconstructive surgery.","['Epidermal Inflammation and Protection Group, Laboratory for Clinical and Molecular Virology, Royal (Dick) Veterinary College, University of Edinburgh, Edinburgh, Scotland, United Kingdom. roddie.mckenzie@ed.ac.uk']",,,84,,,,,,,
14871103,NLM,MEDLINE,20040525,20151119,0002-7863 (Print) 0002-7863 (Linking),126,6,2004 Feb 18,Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2.,1726-31,"['Shamis, Marina', 'Lode, Holger N', 'Shabat, Doron']","['Shamis M', 'Lode HN', 'Shabat D']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,J Am Chem Soc,Journal of the American Chemical Society,7503056,"['0 (Antibodies, Catalytic)', '0 (Drug Carriers)', '0 (Prodrugs)', '6D4M1DAL6O (cremophor EL)', '80168379AG (Doxorubicin)', 'PDC6A3C0OX (Glycerol)']",IM,"['Antibodies, Catalytic/chemistry/*metabolism', 'Biotransformation', 'Cell Line, Tumor', 'Doxorubicin/analogs & derivatives/chemical synthesis/pharmacokinetics', 'Drug Carriers/*chemical synthesis/chemistry/*pharmacokinetics', 'Drug Design', 'Glycerol/*analogs & derivatives/chemical synthesis/pharmacokinetics/toxicity', 'Humans', 'Inhibitory Concentration 50', 'Prodrugs/*chemical synthesis/chemistry/*pharmacokinetics']",,,,2004/02/12 05:00,2004/05/27 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/05/27 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,J Am Chem Soc. 2004 Feb 18;126(6):1726-31. doi: 10.1021/ja039052p.,['10.1021/ja039052p [doi]'],,"Self-immolative dendrimers have recently been developed and introduced as a potential platform for a multi-prodrug. These unique structural dendrimers can release all of their tail units, through a self-immolative chain fragmentation, which is initiated by a single cleavage at the dendrimer's core. Incorporation of drug molecules as the tail units and an enzyme substrate as the trigger can generate a multi-prodrug unit that will be activated with a single enzymatic cleavage. We have synthesized the first generation of dendritic prodrugs with doxorubicin and camptothecin as tail units and a retro-aldol retro-Michael focal trigger, which can be cleaved by catalytic antibody 38C2. The bioactivation of the dendritic prodrugs was evaluated in cell-growth inhibition assay with the Molt-3 leukemia cell line in the presence and the absence of antibody 38C2. The dendritic unit was applied as a platform for a heterodimeric prodrug, which achieved a remarkable increase in toxicity with its bioactivation.","['School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel-Aviv University, Tel Aviv 69978, Israel.']",,,,,,,,,,
14870901,NLM,MEDLINE,20040519,20191108,1397-3142 (Print) 1397-3142 (Linking),7,6,2003 Dec,"Successful treatment of primary refractory acute myeloid leukemia with megadose stem cell transplantation, bone marrow boost and reduced intensity conditioning avoiding chronic graft vs. host disease and severe late toxicity.",494-6,"['Langer, Thorsten', 'Beck, Joern-Dirk', 'Gravou-Apostulatou, Chara', 'Lang, Peter', 'Handgretinger, Rupert', 'Greil, Johann']","['Langer T', 'Beck JD', 'Gravou-Apostulatou C', 'Lang P', 'Handgretinger R', 'Greil J']",['eng'],"['Case Reports', 'Journal Article']",,Denmark,Pediatr Transplant,Pediatric transplantation,9802574,,IM,"['Acute Disease', '*Bone Marrow Transplantation', 'Child', 'Graft vs Host Disease/*prevention & control', 'Humans', 'Leukemia, Myeloid/*therapy', 'Male', 'Remission Induction', '*Stem Cell Transplantation', 'Transplantation Conditioning/*methods', 'Transplantation, Homologous']",,,,2004/02/12 05:00,2004/05/20 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/05/20 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Pediatr Transplant. 2003 Dec;7(6):494-6. doi: 10.1046/j.1399-3046.2003.00095.x.,['10.1046/j.1399-3046.2003.00095.x [doi]'],,"We report on a 9-yr-old boy suffering from primary refractory AML. Remission was not achieved after two courses of induction therapy, leading to prolonged aplasia for more than 3 months and severe infection. Therefore, the boy was treated with a reduced intensity conditioning regimen consisting of fludarabine, cyclophosphamide and OKT3. Megadose transplantation of highly enriched CD34+ peripheral stem cells from his HLA-identical brother, followed on day +11 by a boost of unmanipulated bone marrow, was performed. Regeneration of donor hematopoiesis was rapid and led to resolution of infection. No additional donor lymphocyte infusions were necessary. More than 4 1/2 yr after the transplant the boy remains in complete continuous remission with no evidence for chronic GvHD or other late effects. Therefore, we conclude that reduced intensity conditioning in combination with allogeneic megadose stem cell transplantation and bone marrow boost may have helped to achieve cure from primary refractory AML as well as a good quality of life for this boy.","['Division of Pediatric Oncology, Hospital for Children and Adolescents, University of Erlangen, Germany.']",,,,['Pediatr Transplant. 2003 Dec;7(6):422-5. PMID: 14870888'],,,,,,
14870891,NLM,MEDLINE,20040519,20191108,1397-3142 (Print) 1397-3142 (Linking),7,6,2003 Dec,Adoptive immunotherapy as consolidation of remission in pediatric AML relapsing post-transplant.,446-9,"['Vettenranta, Kim', 'Hovi, Liisa', 'Saarinen-Pihkala, Ulla M']","['Vettenranta K', 'Hovi L', 'Saarinen-Pihkala UM']",['eng'],"['Case Reports', 'Journal Article']",,Denmark,Pediatr Transplant,Pediatric transplantation,9802574,,IM,"['Adolescent', '*Bone Marrow Transplantation', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Immunotherapy, Adoptive/*methods', 'Leukemia, Myeloid, Acute/drug therapy/*therapy', 'Recurrence', 'Remission Induction', 'T-Lymphocytes/transplantation', 'Treatment Outcome']",,,,2004/02/12 05:00,2004/05/20 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/05/20 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Pediatr Transplant. 2003 Dec;7(6):446-9. doi: 10.1046/j.1399-3046.2003.00082.x.,['10.1046/j.1399-3046.2003.00082.x [doi]'],,"Treatment of acute leukemia relapse following an allogeneic transplantation is a challenge. We reinduced three pediatric patients with acute myeloid leukemia (AML) relapsing after a marrow transplantation from a sibling donor into remission with chemotherapy and used donor lymphocyte infusions (DLIs) as consolidation. In two of the cases, the allogeneic recognition was enhanced through the use of interferon in the absence of clinical graft vs. host disease (GVHD). Subsequently, all the three developed (acute grade III-IV or chronic extensive) GVHD and remain in remission with a good quality of life 19, 15 and 14 months post-relapse. We consider an active approach in the treatment of pediatric AML relapsing post-transplant justified.","['Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, University of Helsinki, Finland. kim.vettenranta@hus.fi']",,,,['Pediatr Transplant. 2003 Dec;7(6):419-21. PMID: 14870887'],,,,,,
14870888,NLM,MEDLINE,20040519,20191108,1397-3142 (Print) 1397-3142 (Linking),7,6,2003 Dec,Novel treatment for refractory acute myeloid leukemia.,422-5,"['Ringden, Olle']",['Ringden O'],['eng'],"['Comment', 'Editorial']",,Denmark,Pediatr Transplant,Pediatric transplantation,9802574,,IM,"['Acute Disease', 'Animals', 'Graft vs Host Disease/prevention & control', 'Graft vs Leukemia Effect/immunology', 'Humans', 'Immunotherapy, Adoptive/*methods', 'Leukemia, Myeloid/*therapy', 'Pediatrics', 'Remission Induction', 'Stem Cell Transplantation/*methods']",,,,2004/02/12 05:00,2004/05/20 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/05/20 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Pediatr Transplant. 2003 Dec;7(6):422-5. doi: 10.1046/j.1397-3142.2003.00106.x.,['10.1046/j.1397-3142.2003.00106.x [doi]'],,,,,,,,['Pediatr Transplant. 2003 Dec;7(6):494-6. PMID: 14870901'],,,,,
14870887,NLM,MEDLINE,20040519,20191108,1397-3142 (Print) 1397-3142 (Linking),7,6,2003 Dec,Treatment of relapsing AML following hematopoietic stem cell transplantation.,419-21,"['Atlas, Mark P', 'Lipton, Jeffrey M']","['Atlas MP', 'Lipton JM']",['eng'],"['Comment', 'Editorial']",,Denmark,Pediatr Transplant,Pediatric transplantation,9802574,,IM,"['*Hematopoietic Stem Cell Transplantation', 'Humans', '*Immunotherapy, Adoptive', 'Leukemia, Myeloid, Acute/drug therapy/*therapy', 'Pediatrics', 'Recurrence', 'Remission Induction', 'T-Lymphocytes/transplantation', 'Transplantation, Homologous']",,,,2004/02/12 05:00,2004/05/20 05:00,['2004/02/12 05:00'],"['2004/02/12 05:00 [pubmed]', '2004/05/20 05:00 [medline]', '2004/02/12 05:00 [entrez]']",ppublish,Pediatr Transplant. 2003 Dec;7(6):419-21. doi: 10.1046/j.1397-3142.2003.00119.x.,['10.1046/j.1397-3142.2003.00119.x [doi]'],,,,,,,,['Pediatr Transplant. 2003 Dec;7(6):446-9. PMID: 14870891'],,,,,
14870181,NLM,MEDLINE,20040215,20181201,0008-7335 (Print) 0008-7335 (Linking),90,34,1951 Aug 24,[Remission of acute leukemia treated with exsanguination transfusion].,1020-3,"['CHVAPIL, J', 'KOHN, E']","['CHVAPIL J', 'KOHN E']",['und'],['Journal Article'],Remise akutna leukemie le6cene exsanguina6cna transfusa.,Czech Republic,Cas Lek Cesk,Casopis lekaru ceskych,0004743,,OM,"['*Acute Disease', '*Blood Transfusion', '*Exsanguination', 'Humans', '*Leukemia', 'Leukemia, Myeloid/*therapy']",['CLML: 5221:2399:56:210'],['NLM'],"['*BLOOD TRANSFUSION', '*LEUKEMIA, MYELOCYTIC/therapy']",1951/08/24 00:00,1951/08/24 00:01,['1951/08/24 00:00'],"['1951/08/24 00:00 [pubmed]', '1951/08/24 00:01 [medline]', '1951/08/24 00:00 [entrez]']",ppublish,Cas Lek Cesk. 1951 Aug 24;90(34):1020-3.,,,,,,,,,,,,,,
14870141,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,10,1951 Oct,Rodent leukemia: Recent biological studies. A review.,741-52,"['KIRSCHBAUM, A']",['KIRSCHBAUM A'],['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,,OM,"['Animals', 'Humans', '*Leukemia', '*Leukemia, Experimental']",['CLML: 5221:2359:210'],['NLM'],['*LEUKEMIA/experimental'],1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Oct;11(10):741-52.,,,,,,,,,,,,,,
14870132,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,9,1951 Sep,Sterilization of leukemic cells in vivo and in vitro.,700-5,"['BURCHENAL, J H', 'CREMER, M A', 'WILLIAMS, B S', 'ARMSTRONG, R A']","['BURCHENAL JH', 'CREMER MA', 'WILLIAMS BS', 'ARMSTRONG RA']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,,OM,"['Animals', 'Humans', 'In Vitro Techniques', '*Leukemia, Experimental', '*Sterilization']",['CLML: 5221:2350:210'],['NLM'],['*LEUKEMIA/experimental'],1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Sep;11(9):700-5.,,,,,,,,,,,,,,
14870127,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,9,1951 Sep,Effect of West Nile and Ilheus viruses on mouse leukemias.,669-75,"['SOUTHAM, C M', 'BRONSTEIN, B', 'WEBBER, L F']","['SOUTHAM CM', 'BRONSTEIN B', 'WEBBER LF']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,,OM,"['Animals', '*Leukemia', '*Leukemia, Experimental', 'Mice', '*Viruses']",['CLML: 5221:2345:210'],['NLM'],['*LEUKEMIA/experimental'],1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Sep;11(9):669-75.,,,,,,,,,,,,,,
14870028,NLM,MEDLINE,20040215,20181201,0366-1334 (Print) 0366-1334 (Linking),67,23-24,1951 Jun 29-Jul 6,[Attempted treatment of chronic myeloid leukemia by thiouracil; remarkable remission of blood disorders].,1024-9,"['BERNARD, J', 'DELTOUR, G', 'CHRISTOL, D', 'VELEZ, E', 'COLVEZ, P']","['BERNARD J', 'DELTOUR G', 'CHRISTOL D', 'VELEZ E', 'COLVEZ P']",['und'],['Journal Article'],Essai de traitement de la leucemie myeloide chronique par le thiouracile; remarquable remission des desordres sanguins.,France,Bull Mem Soc Med Hop Paris,Bulletins et memoires de la Societe medicale des hopitaux de Paris,7503472,['59X161SCYL (Thiouracil)'],OM,"['*Hematologic Diseases', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'Leukemia, Myeloid/*therapy', 'Thiouracil/*therapeutic use']",['CLML: 5221:2246:210:375'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/therapy', '*THIOURACIL/therapeutic use']",1951/06/29 00:00,1951/06/29 00:01,['1951/06/29 00:00'],"['1951/06/29 00:00 [pubmed]', '1951/06/29 00:01 [medline]', '1951/06/29 00:00 [entrez]']",ppublish,Bull Mem Soc Med Hop Paris. 1951 Jun 29-Jul 6;67(23-24):1024-9.,,,,,,,,,,,,,,
14869902,NLM,MEDLINE,20040215,20181201,0004-5497 (Print) 0004-5497 (Linking),38,3,1951,[Factors determining the transformation of a transplantable myeloma of the rat into myeloid leukemia].,284-93,"['LACOUR, F', 'OBERLING, C', 'GAGNE, F', 'GUERIN, M']","['LACOUR F', 'OBERLING C', 'GAGNE F', 'GUERIN M']",['und'],['Journal Article'],Etude des facteurs qui determinent la transformation d'un myelome greffable du rat en leucemie myeloide.,France,Bull Assoc Fr Etud Cancer,Bulletin de l'Association francaise pour l'etude du cancer,7503389,,OM,"['Animals', '*Leukemia', '*Leukemia, Myeloid', '*Multiple Myeloma', '*Plasma Cells', 'Rats']",['CLML: 5221:2120:210:247'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/experimental', '*MYELOMA, PLASMA CELL/experimental']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Bull Assoc Fr Etud Cancer. 1951;38(3):284-93.,,,,,,,,,,,,,,
14869559,NLM,MEDLINE,20040215,20181201,0006-9248 (Print) 0006-9248 (Linking),31,3-4,1951,[Profuse ovarian hemorrhage in chronic myelocytic leukemia].,416-21,"['VALENTSIK, F']",['VALENTSIK F'],['und'],['Journal Article'],Profuzne krvacanie z ovaria pri chronickej myeloickej leukemii.,Slovakia,Bratisl Lek Listy,Bratislavske lekarske listy,0065324,,OM,"['Female', '*Hemorrhage', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'Leukemia, Myeloid/*complications', '*Ovarian Diseases', '*Ovary']",['CLML: 5221:1777:210:269'],['NLM'],"['*LEUKEMIA, MYELOCYTIC/complications', '*OVARIES/hemorrhage']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Bratisl Lek Listy. 1951;31(3-4):416-21.,,,,,,,,,,,,,,
14869382,NLM,MEDLINE,20040215,20181201,,26,191,1950 Oct-Dec,"[Results of splenectomy in splenic anemia, hemorrhagic purpura, hemolytic jaundice and chronic myeloid leukemia].",247-63,"['MARTIARENA, L H', 'SUARES, D Z']","['MARTIARENA LH', 'SUARES DZ']",['und'],['Journal Article'],"Resultados de la esplenectomaa en la anemia esplenica purpura hemorragica, ictericia hemolatica y leucemia mieloide cronica.",Argentina,Bol Univ B Aires,Boletin. Universidad de Buenos Aires. Instituto de Clinica Quirurgica,15750790R,,OM,"['Humans', '*Hypersplenism', '*Jaundice', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Purpura', 'Spleen/*surgery', '*Splenectomy']",['CLML: 5221:1600:352'],['NLM'],['*SPLEEN/surgery'],1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Bol Univ B Aires. 1950 Oct-Dec;26(191):247-63.,,,,,,,,,,,,,,
14869363,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),6,11,1951 Nov,The average volume of leukemic leukocytes.,1013-20,"['TIVEY, H', 'LI, J G', 'OSGOOD, E E', 'DUERST, M', 'KLOBUCHER, V', 'PETERSON, E', 'HUGHES, M E']","['TIVEY H', 'LI JG', 'OSGOOD EE', 'DUERST M', 'KLOBUCHER V', 'PETERSON E', 'HUGHES ME']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,,OM,"['Leukemia/*blood', '*Leukocytes']",['CLML: 5221:1581:209'],['NLM'],['*LEUKEMIA/blood in'],1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Blood. 1951 Nov;6(11):1013-20.,['S0006-4971(20)84676-X [pii]'],,,,,,,,,,,,,
14869362,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),6,11,1951 Nov,Observations on the effect of various folic acid antagonists on acute leukemia.,1002-12,"['WILSON, S J']",['WILSON SJ'],['eng'],['Journal Article'],,United States,Blood,Blood,7603509,['0 (Folic Acid Antagonists)'],OM,"['*Acute Disease', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:1580:144:210'],['NLM'],"['*FOLIC ACID ANTAGONISTS/therapeutic use', '*LEUKEMIA/therapy']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Blood. 1951 Nov;6(11):1002-12.,['S0006-4971(20)84675-8 [pii]'],,,,,,,,,,,,,
14869361,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),6,11,1951 Nov,Congenital leukemia.,990-1001,"['BERNHARD, W G', 'GORE, I', 'KILBY, R A']","['BERNHARD WG', 'GORE I', 'KILBY RA']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,,OM,"['Humans', '*Leukemia']",['CLML: 5221:1579:209'],['NLM'],['*LEUKEMIA'],1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Blood. 1951 Nov;6(11):990-1001.,['S0006-4971(20)84674-6 [pii]'],,,,,,,,,,,,,
14869360,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),6,11,1951 Nov,Influence of age and sex upon frequency and cytologic types of human leukemias; evidence of a myeloid: lymphoid antagonism.,976-89,"['DAUSSET, J', 'SCHWARZMAN, V']","['DAUSSET J', 'SCHWARZMAN V']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,['0 (Liver Extracts)'],OM,"['Humans', 'Leukemia/*etiology', 'Liver Extracts/*pharmacology']",['CLML: 5221:1578:210:216'],['NLM'],"['*LEUKEMIA/etiology and pathogenesis', '*LIVER EXTRACTS/effects']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Blood. 1951 Nov;6(11):976-89.,['S0006-4971(20)84673-4 [pii]'],,,,,,,,,,,,,
14869359,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),6,11,1951 Nov,Recent studies on the etiology and nature of leukemia.,964-75,"['FURTH, J']",['FURTH J'],['eng'],['Journal Article'],,United States,Blood,Blood,7603509,,OM,"['Humans', 'Leukemia/*etiology']",['CLML: 5221:1577:210'],['NLM'],['*LEUKEMIA/etiology and pathogenesis'],1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,Blood. 1951 Nov;6(11):964-75.,['S0006-4971(20)84672-2 [pii]'],,,,,,,,,,,,,
14869344,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),6,9,1951 Sep,The use of adrenocorticotropic hormone and cortisone in the treatment of leukemia and leukosarcoma.,804-23,"['ROSENTHAL, M C', 'SAUNDERS, R H', 'SCHWARTZ, L I', 'ZANNOS, L', 'PEREZ SANTIAGO, E', 'DAMESHEK, W']","['ROSENTHAL MC', 'SAUNDERS RH', 'SCHWARTZ LI', 'ZANNOS L', 'PEREZ SANTIAGO E', 'DAMESHEK W']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['Adrenocorticotropic Hormone/*therapeutic use', 'Cortisone/*therapeutic use', 'Leukemia/*therapy']",['CLML: 5221:1562:7:97:210:211'],['NLM'],"['*ACTH/therapeutic use', '*CORTISONE/therapeutic use', '*LEUKEMIA/therapy', '*LEUKOSARCOMA/therapy']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Blood. 1951 Sep;6(9):804-23.,['S0006-4971(20)61046-1 [pii]'],,,,,,,,,,,,,
14869093,NLM,MEDLINE,20040215,20181201,,213,1-2,1951,[Leukocyte metabolism. I. Leukocyte respiration and glycolysis in the normal state and in leukemia].,162-74,"['KEIBL, E', 'SPITZY, K H']","['KEIBL E', 'SPITZY KH']",['und'],['Journal Article'],Zum Problem des Leukozytenstoffwechsels. I. Atmung und Glykolyse normaler und leukamischer weisser Blutzellen.,Germany,Naunyn Schmiedebergs Arch Exp Pathol Pharmakol,Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie,0054224,['IY9XDZ35W2 (Glucose)'],OM,"['*Carbohydrate Metabolism', 'Glucose/*metabolism', '*Glycolysis', 'Humans', 'Leukemia/*blood', 'Leukocytes/*metabolism', '*Respiration']",['CLML: 5221:1311:154:209:211'],['NLM'],"['*GLUCOSE/metabolism', '*LEUKEMIA/blood in', '*LEUKOCYTES/metabolism']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1951;213(1-2):162-74.,,,,,,,,,,,,,,
14868605,NLM,MEDLINE,20040215,20181201,0365-3056 (Print) 0365-3056 (Linking),7,4,1951,[Electron microscopy of normal and leukemic leukocytes].,646-59,"['BESSIS, M']",['BESSIS M'],['und'],['Journal Article'],Etudes au microscope electronique des leucocytes normaux et leucemiques.,Belgium,Acta Unio Int Contra Cancrum,Acta - Unio Internationalis Contra Cancrum,7502506,,OM,"['Leukemia/*blood', '*Leukocytes', '*Microscopy, Electron']",['CLML: 5221:823:209:211'],['NLM'],"['*LEUKEMIA/blood in', '*LEUKOCYTES']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Unio Int Contra Cancrum. 1951;7(4):646-59.,,,,,,,,,,,,,,
14868571,NLM,MEDLINE,20040215,20181201,0365-3056 (Print) 0365-3056 (Linking),7,3,1951,Mechanism of resistance in leukemia.,436-42,"['BURCHENAL, J H', 'BABCOCK, G M', 'ARMSTRONG, R A', 'ROBINSON, E']","['BURCHENAL JH', 'BABCOCK GM', 'ARMSTRONG RA', 'ROBINSON E']",['eng'],['Journal Article'],,Belgium,Acta Unio Int Contra Cancrum,Acta - Unio Internationalis Contra Cancrum,7502506,,OM,"['Animals', '*Biochemical Phenomena', 'Humans', '*Leukemia', '*Leukemia, Experimental']",['CLML: 5221:789:210'],['NLM'],['*LEUKEMIA/experimental'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Unio Int Contra Cancrum. 1951;7(3):436-42.,,,,,,,,,,,,,,
14868377,NLM,MEDLINE,20040215,20181201,0001-6063 (Print),12,7,1951,[Chronic erythremic myelosis].,275-304,"['TAGLIONI, V']",['TAGLIONI V'],['und'],['Journal Article'],Sulla mielosi eritremica cronica.,Italy,Acta Med Patav,Acta medica Patavina,0376306,,OM,"['*Chronic Disease', '*Leukemia, Erythroblastic, Acute', '*Polycythemia Vera']",['CLML: 5221:595:299'],['NLM'],['*POLYCYTHEMIA VERA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Med Patav. 1951;12(7):275-304.,,,,,,,,,,,,,,
14868232,NLM,MEDLINE,20040215,20190911,0096-6908 (Print) 0096-6908 (Linking),63,5,1951 Nov,Failure of thymectomy in lymphatic leukemia.,695-7,"['DEAN, G O', 'EARLE, A M', 'REILLY, W A']","['DEAN GO', 'EARLE AM', 'REILLY WA']",['eng'],['Journal Article'],,United States,AMA Arch Surg,A.M.A. archives of surgery,14470160R,,OM,"['Humans', '*Leukemia', 'Leukemia, Lymphoid/*therapy', '*Lymphatic Vessels', '*Thoracic Surgical Procedures', '*Thymectomy', 'Thymus Gland/*surgery']",['CLML: 5221:450:210:377'],['NLM'],"['*LEUKEMIA, LYMPHATIC/therapy', '*THYMUS/surgery']",1951/11/01 00:00,1951/11/01 00:01,['1951/11/01 00:00'],"['1951/11/01 00:00 [pubmed]', '1951/11/01 00:01 [medline]', '1951/11/01 00:00 [entrez]']",ppublish,AMA Arch Surg. 1951 Nov;63(5):695-7. doi: 10.1001/archsurg.1951.01250040709018.,['10.1001/archsurg.1951.01250040709018 [doi]'],,,,,,,,,,,,,
14868167,NLM,MEDLINE,20040215,20181201,0096-6711 (Print) 0096-6711 (Linking),52,4,1951 Oct,Acute plasma leukemia without localized bone lesions; report of a case with autopsy observations.,384-9,"['LAWRENCE, S H', 'FORTNER, H C']","['LAWRENCE SH', 'FORTNER HC']",['eng'],['Journal Article'],,United States,AMA Arch Pathol,A.M.A. archives of pathology,14470150R,,OM,"['*Acute Disease', '*Autopsy', '*Bone Diseases', '*Cartilage Diseases', 'Humans', '*Leukemia']",['CLML: 5221:385:209'],['NLM'],['*LEUKEMIA'],1951/10/01 00:00,1951/10/01 00:01,['1951/10/01 00:00'],"['1951/10/01 00:00 [pubmed]', '1951/10/01 00:01 [medline]', '1951/10/01 00:00 [entrez]']",ppublish,AMA Arch Pathol. 1951 Oct;52(4):384-9.,,,,,,,,,,,,,,
14867984,NLM,MEDLINE,20040215,20190917,0888-2479 (Print) 0888-2479 (Linking),88,6,1951 Dec,Hypocellular marrow in acute leukemia; report of two cases.,803-11,"['BEYERS, M R', 'MEYER, L M', 'LOWENTHAL, M', 'OEHRIG, R J', 'SAWITSKY, A']","['BEYERS MR', 'MEYER LM', 'LOWENTHAL M', 'OEHRIG RJ', 'SAWITSKY A']",['eng'],['Journal Article'],,United States,AMA Arch Intern Med,A.M.A. archives of internal medicine,14470100R,,OM,"['*Acute Disease', 'Bone Marrow/*pathology', 'Humans', '*Leukemia', '*Pancytopenia']",['CLML: 5221:202:58:209'],['NLM'],"['*BONE MARROW/pathology', '*LEUKEMIA']",1951/12/01 00:00,1951/12/01 00:01,['1951/12/01 00:00'],"['1951/12/01 00:00 [pubmed]', '1951/12/01 00:01 [medline]', '1951/12/01 00:00 [entrez]']",ppublish,AMA Arch Intern Med. 1951 Dec;88(6):803-11. doi: 10.1001/archinte.1951.03810120104010.,['10.1001/archinte.1951.03810120104010 [doi]'],,,,,,,,,,,,,
14867781,NLM,MEDLINE,20040215,20181201,0096-5480 (Print) 0096-5480 (Linking),73,2,1951 Mar,"Treatment of the leukemias, polycythemia vera and the malignant lymphomas.",54-6,"['REINHARD, E H']",['REINHARD EH'],['eng'],['Journal Article'],,United States,Miss Valley Med J,"Mississippi Valley medical journal (Quincy, Ill)",18730540R,,OM,"['*Hematopoietic System', '*Hodgkin Disease', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphoma', '*Polycythemia Vera']",['CLML: 5120:86052A:177:429:444:547'],['NLM'],"['*HEMOPOIETIC SYSTEM', ""*HODGKIN'S DISEASE"", '*LEUKEMIA, LYMPHATIC', '*POLYCYTHEMIA VERA']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Miss Valley Med J. 1951 Mar;73(2):54-6.,,,,,,,,,,,,,,
14867213,NLM,MEDLINE,20040215,20181201,0372-7025 (Print) 0372-7025 (Linking),20,1,1951 Jan-Feb,[Problem of tuberculosis and myelogenous leukemia].,13-5,"[""HAL'AK, O""]","[""HAL'AK O""]",['und'],['Journal Article'],Ku problemu tuberkulozy a chron. myeloidnej leukemie.,Czech Republic,Vojen Zdrav Listy,Vojenske zdravotnicke listy,0230326,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Tuberculosis', '*Tuberculosis, Pulmonary']",['CLML: 5120:100878:395:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*TUBERCULOSIS, PULMONARY']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Vojen Zdrav Listy. 1951 Jan-Feb;20(1):13-5.,,,,,,,,,,,,,,
14867011,NLM,MEDLINE,20040215,20181201,0041-5782 (Print) 0041-5782 (Linking),113,31,1951 Aug 2,[Adaptation of the virus of avian leukosis for culture in chick embryo].,1023-4,"['ATANASIU, P', 'VIEUCHANGE, J', 'STRUNGE, B']","['ATANASIU P', 'VIEUCHANGE J', 'STRUNGE B']",['und'],['Journal Article'],Adaptation af honseleukosens virus til dyrkning pa honseaeg.,Denmark,Ugeskr Laeger,Ugeskrift for laeger,0141730,,OM,"['*Adaptation, Physiological', 'Animals', '*Avian Leukosis', 'Chick Embryo', '*Erythroblastosis, Fetal', '*Hematologic Diseases', '*Wounds and Injuries']",['CLML: 5120:100676:314:470'],['NLM'],"['*ERYTHROBLASTOSIS', '*WOUNDS']",1951/08/02 00:00,1951/08/02 00:01,['1951/08/02 00:00'],"['1951/08/02 00:00 [pubmed]', '1951/08/02 00:01 [medline]', '1951/08/02 00:00 [entrez]']",ppublish,Ugeskr Laeger. 1951 Aug 2;113(31):1023-4.,,,,,,,,,,,,,,
14865897,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,6,1951,[Action of different antileukemic products on transmissible erythroblastosis of fowls].,446-50,"['BESSIS, M', 'ELY, Z', 'FREIXA, P']","['BESSIS M', 'ELY Z', 'FREIXA P']",['und'],['Journal Article'],Action de differents produits antileucemiques sur l'erythroblastose transmissible des poules.,France,Sang,Le Sang,20540380R,,OM,"['*Erythroblastosis, Fetal', '*Hematologic Diseases', 'Humans', '*Leukemia', '*Meat']",['CLML: 5120:99558:314:546'],['NLM'],"['*ERYTHROBLASTOSIS', '*LEUKEMIA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(6):446-50.,,,,,,,,,,,,,,
14865891,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,5,1951,[Acute basophilic leukosis].,374-85,"['CHEVALLIER, P', 'MARINONE, G']","['CHEVALLIER P', 'MARINONE G']",['und'],['Journal Article'],La leucose aigue a basoblastes.,France,Sang,Le Sang,20540380R,,OM,"['Humans', '*Leukemia']",['CLML: 5120:99552:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(5):374-85.,,,,,,,,,,,,,,
14865887,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,4,1951,[Value of the cadmium test in the clinical diagnosis of diseases of the blood].,336-40,"['ITELSON, I']",['ITELSON I'],['und'],['Journal Article'],La valeur de la reaction au cadmium pour la clinique dans les maladies du sang.,France,Sang,Le Sang,20540380R,"['0 (Blood Proteins)', '00BH33GNGH (Cadmium)']",OM,"['*Blood Proteins', '*Cadmium', 'Humans', '*Leukemia']",['CLML: 5120:99548:120:156:546'],['NLM'],"['*BLOOD PROTEINS', '*CADMIUM', '*LEUKEMIA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(4):336-40.,,,,,,,,,,,,,,
14865871,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,3,1951,[Case of multiple myeloma of bone with plasmocytic leukosis and with characteristic renal alterations].,192-202,"['MARCHAL, G', 'DUHAMEL, G', 'NORY', 'BOUSQUET']","['MARCHAL G', 'DUHAMEL G', 'NORY', 'BOUSQUET']",['und'],['Journal Article'],Sur un cas de myelome multiple des os avec leucose a plasmocytes et avec alterations renales caracteristiques.,France,Sang,Le Sang,20540380R,,OM,"['*Bone and Bones', 'Humans', '*Leukemia', '*Multiple Myeloma', '*Neoplasms', '*Plasma Cells']",['CLML: 5120:99532:407:546'],['NLM'],"['*LEUKEMIA', '*TUMORS, MULTIPLE MYELOMA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(3):192-202.,,,,,,,,,,,,,,
14865492,NLM,MEDLINE,20040215,20181201,,76,,1951 May,"[Evolutive modalities of acute leukemia, especially in relation to therapy].",233-48,"['MICHON, P', 'NOEL, B']","['MICHON P', 'NOEL B']",['und'],['Journal Article'],Modalites evolutives des leucoses aigues notamment en fonction des therapeutiques.,France,Rev Med Nancy,Revue medicale de Nancy,0204063,,OM,"['*Acute Disease', 'Humans', '*Leukemia']",['CLML: 5120:99126:546'],['NLM'],['*LEUKEMIA'],1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Rev Med Nancy. 1951 May;76:233-48.,,,,,,,,,,,,,,
14865490,NLM,MEDLINE,20040215,20181201,0370-632X (Print) 0370-632X (Linking),8,2,1951 Apr-Jun,[Malignant lymphogranulomatosis in a young child].,252-5,"['MAROUN, T', 'GUERGUERIAN, G', 'GUERGUERIAN, S']","['MAROUN T', 'GUERGUERIAN G', 'GUERGUERIAN S']",['und'],['Journal Article'],Lymphogranulomatose maligne chez un tout jeune enfant.,Lebanon,Rev Med Moyen Orient,Revue medicale du Moyen-Orient,20340240R,,OM,"['Child', '*Hodgkin Disease', 'Humans', '*Leukemia']",['CLML: 5120:99124:196'],['NLM'],['*PSEUDOLEUKEMIA'],1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,Rev Med Moyen Orient. 1951 Apr-Jun;8(2):252-5.,,,,,,,,,,,,,,
14865105,NLM,MEDLINE,20040215,20181201,0014-2565 (Print) 0014-2565 (Linking),41,4,1951 May 31,[Generalized tumor with leukanemia].,277-9,"['RODA-CASO', 'FERNANDEZ-CRIADO']","['RODA-CASO', 'FERNANDEZ-CRIADO']",['und'],['Journal Article'],"Tumor generalizado, con leucanemia.",Spain,Rev Clin Esp,Revista clinica espanola,8608576,,OM,"['*Carcinoma', 'Humans', '*Leukemia', '*Neoplasms']",['CLML: 5120:98706:171:546'],['NLM'],"['*CARCINOMA', '*LEUKEMIA']",1951/05/31 00:00,1951/05/31 00:01,['1951/05/31 00:00'],"['1951/05/31 00:00 [pubmed]', '1951/05/31 00:01 [medline]', '1951/05/31 00:00 [entrez]']",ppublish,Rev Clin Esp. 1951 May 31;41(4):277-9.,,,,,,,,,,,,,,
14865084,NLM,MEDLINE,20040215,20181201,0014-2565 (Print) 0014-2565 (Linking),41,3,1951 May 15,[Considerations on sarco-leukosis; lymphosarcomatous cell leukemia].,153-76,"['PANIAGUA, G', 'MORALES PLEGUEZUELO, M', 'JIMENEZ DIAZ, C']","['PANIAGUA G', 'MORALES PLEGUEZUELO M', 'JIMENEZ DIAZ C']",['und'],['Journal Article'],Consideraciones sobre la sarcoleucosis. (Leucemia de celulas linfosarcomatosas).,Spain,Rev Clin Esp,Revista clinica espanola,8608576,"['EC 1.5.8.3 (Sarcosine Dehydrogenase)', 'Sarcosinemia']",OM,"['*Amino Acid Metabolism, Inborn Errors', '*Leukemia', '*Lymphoma, Non-Hodgkin', '*Mitochondrial Diseases', '*Neoplasms', '*Sarcoma', '*Sarcosine Dehydrogenase']",['CLML: 5120:98685:267:546'],['NLM'],"['*LEUKEMIA', '*SARCOMA, LYMPHOSARCOMA']",1951/05/15 00:00,1951/05/15 00:01,['1951/05/15 00:00'],"['1951/05/15 00:00 [pubmed]', '1951/05/15 00:01 [medline]', '1951/05/15 00:00 [entrez]']",ppublish,Rev Clin Esp. 1951 May 15;41(3):153-76.,,,,,,,,,,,,,,
14865064,NLM,MEDLINE,20040215,20181201,0014-2565 (Print) 0014-2565 (Linking),41,1,1951 Apr 15,[Erythro-sarco-leukemia].,56-9,"['CENTENERA FONDON, D']",['CENTENERA FONDON D'],['und'],['Journal Article'],Eritro-sarco-leucemia.,Spain,Rev Clin Esp,Revista clinica espanola,8608576,"['EC 1.5.8.3 (Sarcosine Dehydrogenase)', 'Sarcosinemia']",OM,"['*Amino Acid Metabolism, Inborn Errors', 'Humans', '*Leukemia', '*Mitochondrial Diseases', '*Sarcosine Dehydrogenase']",['CLML: 5120:98665:546'],['NLM'],['*LEUKEMIA'],1951/04/15 00:00,1951/04/15 00:01,['1951/04/15 00:00'],"['1951/04/15 00:00 [pubmed]', '1951/04/15 00:01 [medline]', '1951/04/15 00:00 [entrez]']",ppublish,Rev Clin Esp. 1951 Apr 15;41(1):56-9.,,,,,,,,,,,,,,
14864691,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),7,10,1951 May 31,[Allergic reaction induced in leukemic subjects by intradermal injections of a mixture of chorion and allantois of chick embryos inoculated with human leukemic matter].,296-7,"['RIGGIO-TORRIOLI, G', 'CARDINALI, G']","['RIGGIO-TORRIOLI G', 'CARDINALI G']",['und'],['Journal Article'],Reazione allergica ottenuta in soggetti leucemici mediante iniezione intradermica di poltiglia di membrane corion-allantoidee di embrioni di pollo inoculati con materiale leucemico umano.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,,OM,"['*Allantois', 'Animals', 'Chick Embryo', '*Chorion', 'Humans', '*Hypersensitivity', '*Injections, Intradermal', '*Leukemia']",['CLML: 5120:98292:545'],['NLM'],['*LEUKEMIA'],1951/05/31 00:00,1951/05/31 00:01,['1951/05/31 00:00'],"['1951/05/31 00:00 [pubmed]', '1951/05/31 00:01 [medline]', '1951/05/31 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1951 May 31;7(10):296-7.,,,,,,,,,,,,,,
14864000,NLM,MEDLINE,20040215,20181201,0031-4005 (Print) 0031-4005 (Linking),8,2,1951 Aug,Idiopathic aplastic anemia in children; its early differentiation from aleukemic leukemia by bone marrow aspiration.,216-26,"['STURGEON, P']",['STURGEON P'],['eng'],['Journal Article'],,United States,Pediatrics,Pediatrics,0376422,"['Aplastic anemia, idiopathic']",OM,"['*Anemia, Aplastic', '*Bone Marrow', 'Child', 'Humans', '*Leukemia']",['CLML: 5120:97582:38:130:546'],['NLM'],"['*ANEMIA, APLASTIC', '*BONE MARROW', '*LEUKEMIA, ALEUKEMIC']",1951/08/01 00:00,1951/08/01 00:01,['1951/08/01 00:00'],"['1951/08/01 00:00 [pubmed]', '1951/08/01 00:01 [medline]', '1951/08/01 00:00 [entrez]']",ppublish,Pediatrics. 1951 Aug;8(2):216-26.,,,,,,,,,,,,,,
14863187,NLM,MEDLINE,20040215,20181201,0026-4806 (Print) 0026-4806 (Linking),42,35,1951 Jun 16,[Chronic myeloid leukemia with pseudotumoral localizations in the bones].,1165-9,"['MININNI, G', 'SCARDIGLI, G']","['MININNI G', 'SCARDIGLI G']",['und'],['Journal Article'],Mielosi leucemica cronica con localizzazione ossea pseudotumorale.,Italy,Minerva Med,Minerva medica,0400732,,OM,"['*Bone Neoplasms', '*Bone and Bones', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Neoplasms']",['CLML: 5120:96766:130:547'],['NLM'],"['*BONE, TUMORS', '*LEUKEMIA, MYELOGENOUS']",1951/06/16 00:00,1951/06/16 00:01,['1951/06/16 00:00'],"['1951/06/16 00:00 [pubmed]', '1951/06/16 00:01 [medline]', '1951/06/16 00:00 [entrez]']",ppublish,Minerva Med. 1951 Jun 16;42(35):1165-9.,,,,,,,,,,,,,,
14862772,NLM,MEDLINE,20040215,20181201,0375-9342 (Print) 0375-9342 (Linking),5,5,1951 May,[Possibilities of the treatment of acute leukemias with blood transfusion].,101-3,"['STEFANOVIC, S']",['STEFANOVIC S'],['und'],['Journal Article'],Mogucnosti lecenja akutnih leukemja transfuzijama krvi.,Serbia,Med Glas,Medicinski glasnik,0400723,,OM,"['*Acute Disease', '*Blood Transfusion', 'Humans', '*Leukemia']",['CLML: 5120:96351:123:546'],['NLM'],"['*BLOOD TRANSFUSION', '*LEUKEMIA']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Med Glas. 1951 May;5(5):101-3.,,,,,,,,,,,,,,
14862563,NLM,MEDLINE,20040215,20181201,0025-7125 (Print) 0025-7125 (Linking),35,5,1951 Sep,Current trends in the management of the leukemias and the malignant lymphomas.,1381-1401,"['ROSS, J F', 'EBAUGH, F G Jr']","['ROSS JF', 'EBAUGH FG Jr']",['eng'],['Journal Article'],,United States,Med Clin North Am,The Medical clinics of North America,2985236R,,OM,"['*Disease Management', '*Hodgkin Disease', 'Humans', '*Leukemia', '*Lymphoma']",['CLML: 5120:96128:444:546'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA']",1951/09/01 00:00,1951/09/01 00:01,['1951/09/01 00:00'],"['1951/09/01 00:00 [pubmed]', '1951/09/01 00:01 [medline]', '1951/09/01 00:00 [entrez]']",ppublish,Med Clin North Am. 1951 Sep;35(5):1381-1401.,['S0025-7125(16)35230-0 [pii]'],,,,,,,,,,,,,
14862311,NLM,MEDLINE,20040215,20181201,0024-869X (Print) 0024-869X (Linking),19,5,1951 Jul,"[Atrophy of the bone marrow, a new cause of the Jaksch-Hayem-Luzet syndrome].",145-53,"['VEENEKLAAS, G M H']",['VEENEKLAAS GM'],['und'],['Journal Article'],"Beenmerg-atrophie, een nieuwe oorzaak van het syndroom van von Jaksch-Hayem-Luzet.",Netherlands,Maandschr Kindergeneeskd,Maandschrift voor kindergeneeskunde,7704293,['Meyenburg-Altherr-Uehlinger syndrome'],OM,"['*Arthritis', '*Atrophy', '*Bone Marrow', '*Deafness', '*Leukemia', '*Polychondritis, Relapsing']",['CLML: 5120:95876:130:196'],['NLM'],"['*BONE MARROW', '*PSEUDOLEUKEMIA']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Maandschr Kindergeneeskd. 1951 Jul;19(5):145-53.,,,,,,,,,,,,,,
14862288,NLM,MEDLINE,20040215,20181201,0024-7790 (Print) 0024-7790 (Linking),184,25,1951 Jun 24,[Aleukemic megakaryocytic myelosis. Possible effect of massive ingestion of aspirin during ten years].,426-8,"['LEVRAT, M', 'MOREL, P', 'DEVIC, M', 'BRUN, F']","['LEVRAT M', 'MOREL P', 'DEVIC M', 'BRUN F']",['und'],['Journal Article'],Myelose aleucemique megacariocytaire. Role possible de l'ingestion massive d'aspirine pendant dix ans.,France,Lyon Med,Lyon medical,0335015,['R16CO5Y76E (Aspirin)'],OM,"['*Aspirin', '*Eating', '*Leukemia', '*Primary Myelofibrosis']",['CLML: 5120:95853:65:546'],['NLM'],"['*ASPIRIN', '*LEUKEMIA, ALEUKEMIC']",1951/06/24 00:00,1951/06/24 00:01,['1951/06/24 00:00'],"['1951/06/24 00:00 [pubmed]', '1951/06/24 00:01 [medline]', '1951/06/24 00:00 [entrez]']",ppublish,Lyon Med. 1951 Jun 24;184(25):426-8.,,,,,,,,,,,,,,
14862154,NLM,MEDLINE,20040215,20181201,0368-6698 (Print) 0368-6698 (Linking),6,7-8,1951 Aug 1,[Investigation of folic acid antagonist therapy in cancer of hemopoietic organs and leukemia].,266-7,"['BASERGA, A']",['BASERGA A'],['und'],['Journal Article'],Untersuchungen uber die Therapie mit Antifolsaure bei Neubildungen der blutbildenden Organe und der Leukamie.,Austria,Krebsarzt,Der Krebsarzt,0251004,"['0 (Folic Acid Antagonists)', '935E97BOY8 (Folic Acid)']",OM,"['*Folic Acid', '*Folic Acid Antagonists', '*Hematopoietic System', '*Leukemia', '*Neoplasms']",['CLML: 5120:95713:349:429:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*HEMOPOIETIC SYSTEM', '*LEUKEMIA']",1951/08/01 00:00,1951/08/01 00:01,['1951/08/01 00:00'],"['1951/08/01 00:00 [pubmed]', '1951/08/01 00:01 [medline]', '1951/08/01 00:00 [entrez]']",ppublish,Krebsarzt. 1951 Aug 1;6(7-8):266-7.,,,,,,,,,,,,,,
14862066,NLM,MEDLINE,20040215,20181201,0023-2149 (Print) 0023-2149 (Linking),29,8,1951 Aug,[On the penicillin therapy of acute myeloblastic leukosis].,91,"['MISHCHENKO, P I']",['MISHCHENKO PI'],['und'],['Journal Article'],I voprosu o penitsillinoterapii ostrogo mieloblasticheskogo leikoza.,Russia (Federation),Klin Med (Mosk),Klinicheskaia meditsina,2985204R,['0 (Penicillins)'],OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Penicillins']",['CLML: 5120:95625:138:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*PENICILLIN']",1951/08/01 00:00,1951/08/01 00:01,['1951/08/01 00:00'],"['1951/08/01 00:00 [pubmed]', '1951/08/01 00:01 [medline]', '1951/08/01 00:00 [entrez]']",ppublish,Klin Med (Mosk). 1951 Aug;29(8):91.,,,,,,,,,,,,,,
14861882,NLM,MEDLINE,20040215,20181201,0013-2411 (Print) 0013-2411 (Linking),34,5,1951,The principles of radiation therapy of lymphoblastoma.,13-8,"['ABOU SINNA, I']",['ABOU SINNA I'],['eng'],['Journal Article'],,Egypt,J Egypt Med Assoc,The Journal of the Egyptian Medical Association,0417734,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Hodgkin Disease', '*Leukemia', '*Lymphoma, Non-Hodgkin', '*Mechlorethamine', '*Nitrogen Mustard Compounds', '*Sarcoma']",['CLML: 5120:95437:88:267:444:546'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA', '*NITROGEN MUSTARDS', '*SARCOMA, LYMPHOSARCOMA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,J Egypt Med Assoc. 1951;34(5):13-8.,,,,,,,,,,,,,,
14861559,NLM,MEDLINE,20040215,20181201,0368-3001 (Print) 0368-3001 (Linking),128,7,1951 Jul,[New treatment of acute leukosis].,726-7,"['AUBERTIN, R']",['AUBERTIN R'],['und'],['Journal Article'],Les nouveaux traitements des leucoses aigues.,France,J Med Bord,Journal de medecine de Bordeaux et du Sud-Ouest,0161067,,OM,"['Humans', '*Leukemia']",['CLML: 5120:95114:546'],['NLM'],['*LEUKEMIA'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,J Med Bord. 1951 Jul;128(7):726-7.,,,,,,,,,,,,,,
14861523,NLM,MEDLINE,20040215,20181201,0022-2143 (Print) 0022-2143 (Linking),38,2,1951 Aug,"Biochemical studies on leucocytes. II. Phosphatase activity in chronic lymphatic leucemia, acute leucemia, and miscellaneous hematologic conditions.",245-53,"['BECK, W S', 'VALENTINE, W N']","['BECK WS', 'VALENTINE WN']",['eng'],['Journal Article'],,United States,J Lab Clin Med,The Journal of laboratory and clinical medicine,0375375,['EC 3.1.3.2 (Phosphoric Monoester Hydrolases)'],OM,"['*Hematologic Diseases', 'Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', '*Leukocytes', '*Phosphoric Monoester Hydrolases']",['CLML: 5120:95078:546'],['NLM'],['*LEUKEMIA'],1951/08/01 00:00,1951/08/01 00:01,['1951/08/01 00:00'],"['1951/08/01 00:00 [pubmed]', '1951/08/01 00:01 [medline]', '1951/08/01 00:00 [entrez]']",ppublish,J Lab Clin Med. 1951 Aug;38(2):245-53.,['0022-2143(51)90054-6 [pii]'],,,,,,,,,,,,,
14861004,NLM,MEDLINE,20040215,20190729,0002-9955 (Print) 0002-9955 (Linking),146,17,1951 Aug 25,Uremia complicating leukemia chemotherapy; report of a case treated with triethylene melamine.,1595-7,"['KRAVITZ, S C', 'DIAMOND, H D', 'CRAVER, L F']","['KRAVITZ SC', 'DIAMOND HD', 'CRAVER LF']",['eng'],['Journal Article'],,United States,J Am Med Assoc,Journal of the American Medical Association,7507176,['F7IY6HZG9D (Triethylenemelamine)'],OM,"['Humans', '*Leukemia', '*Triethylenemelamine', '*Uremia', '*Urologic Diseases']",['CLML: 5120:94553:416:546'],['NLM'],"['*LEUKEMIA', '*UREMIA']",1951/08/25 00:00,1951/08/25 00:01,['1951/08/25 00:00'],"['1951/08/25 00:00 [pubmed]', '1951/08/25 00:01 [medline]', '1951/08/25 00:00 [entrez]']",ppublish,J Am Med Assoc. 1951 Aug 25;146(17):1595-7. doi: 10.1001/jama.1951.63670170004011c.,['10.1001/jama.1951.63670170004011c [doi]'],,,,,,,,,,,,,
14860646,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),35,4,1951,[Comparative research on the behavior of eosinophils and neutrophils in bone marrow in leukemia].,339-73,"['SACCHETTI, C', 'SACCHETTI-LEATI, M F']","['SACCHETTI C', 'SACCHETTI-LEATI MF']",['und'],['Journal Article'],Ricerche comparative sul comportamento degli eosinofili e dei neutrofili nel midollo osseo nelle leucemie.,Italy,Haematologica,Haematologica,0417435,,OM,"['*Bone Marrow', '*Eosinophils', 'Humans', '*Leukemia', '*Leukocyte Count', '*Leukocytes', '*Neutrophils']",['CLML: 5120:94195:130:309:546:547'],['NLM'],"['*BONE MARROW', '*EOSINOPHILS', '*LEUKEMIA', '*LEUKOCYTES']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Haematologica. 1951;35(4):339-73.,,,,,,,,,,,,,,
14860566,NLM,MEDLINE,20040215,20181201,,92,3,1951 May-Jun,[Therapeutic efficacy of nitrogen mustard in a case of chronic lymphatic leukemia with diffuse cutaneous leukemia].,179-87,"['GIANOTTI, F', 'LEVI, L']","['GIANOTTI F', 'LEVI L']",['und'],['Journal Article'],Efficacia terapeutica dell'azotoiprite in un caso di leucemia linfatica cronica con leucemide cutanea diffusa.,Italy,Soc Ital Dermatol Sifilogr Sezioni Interprov Soc Ital Dermatol Sifilogr,Atti della Societa italiana di dermatologia e sifilografia e delle sezioni interprovinciali. Societa italiana di dermatologia e sifilografia,20820760R,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', '*Leukemia, Lymphoid', '*Mechlorethamine', '*Nitrogen Mustard Compounds']",['CLML: 5120:94097:88:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*NITROGEN MUSTARDS']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Soc Ital Dermatol Sifilogr Sezioni Interprov Soc Ital Dermatol Sifilogr. 1951 May-Jun;92(3):179-87.,,,,,,,,,,,,,,
14860546,NLM,MEDLINE,20040215,20181201,0017-0275 (Print) 0017-0275 (Linking),32,7,1951 Jul,"[Multiphasic hemopathy; aplastic anemia, remission, lymphatic leukemia].",741-59,"['MIRCOLI, D', 'CAVAZZUTI, F']","['MIRCOLI D', 'CAVAZZUTI F']",['und'],['Journal Article'],"Emopatia plurifasica: anemia aplastica, remissione, leucemia linfatica.",Italy,G Clin Med,Giornale di clinica medica,0413411,,OM,"['*Anemia', '*Anemia, Aplastic', 'Humans', '*Leukemia', '*Leukemia, Lymphoid']",['CLML: 5120:94077:38:546'],['NLM'],"['*ANEMIA, APLASTIC', '*LEUKEMIA, LYMPHATIC']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,G Clin Med. 1951 Jul;32(7):741-59.,,,,,,,,,,,,,,
14859099,NLM,MEDLINE,20040215,20181201,0366-1334 (Print) 0366-1334 (Linking),67,17-18,1951 May 18-25,[Septicemia due to Pseudomonas aeruginosa (Bacillus pyocyaneus) detected by agranulocytosis and ending in malignant leukemia].,705-10,"['MOREAU, R', 'CLER, R', 'NATIVELLE, R', 'ETIENNE']","['MOREAU R', 'CLER R', 'NATIVELLE R', 'ETIENNE']",['und'],['Journal Article'],Septicemie a Pseudomonas aeruginosa (bacille pyocyanique) revelee par une agranulocytose et terminee par une leucose maligne.,France,Bull Mem Soc Med Hop Paris,Bulletins et memoires de la Societe medicale des hopitaux de Paris,7503472,,OM,"['*Agranulocytosis', '*Bacillus', 'Humans', '*Leukemia', '*Pseudomonas aeruginosa', '*Sepsis']",['CLML: 5120:92585:196:286:395'],['NLM'],"['*GRANULOCYTOPENIA', '*PSEUDOMONAS AERUGINOSA', '*SEPTICEMIA']",1951/05/18 00:00,1951/05/18 00:01,['1951/05/18 00:00'],"['1951/05/18 00:00 [pubmed]', '1951/05/18 00:01 [medline]', '1951/05/18 00:00 [entrez]']",ppublish,Bull Mem Soc Med Hop Paris. 1951 May 18-25;67(17-18):705-10.,,,,,,,,,,,,,,
14859087,NLM,MEDLINE,20040215,20181201,0366-1334 (Print) 0366-1334 (Linking),67,15-16,1951 May 4-11,[Acute leukosis with leukoblasts in cerebrospinal fluid and meningeal syndrome; possible role of pregnancy].,633-6,"['GELIN, G', 'ROSAN, H']","['GELIN G', 'ROSAN H']",['und'],['Journal Article'],Leucose aigue avec leucoblastorachie et syndrome meninge; role eventuel de grossesse.,France,Bull Mem Soc Med Hop Paris,Bulletins et memoires de la Societe medicale des hopitaux de Paris,7503472,,OM,"['Humans', '*Leukemia', '*Meninges', '*Meningism', 'Pregnancy']",['CLML: 5120:92573:28:546'],['NLM'],"['*LEUKEMIA', '*MENINGES']",1951/05/04 00:00,1951/05/04 00:01,['1951/05/04 00:00'],"['1951/05/04 00:00 [pubmed]', '1951/05/04 00:01 [medline]', '1951/05/04 00:00 [entrez]']",ppublish,Bull Mem Soc Med Hop Paris. 1951 May 4-11;67(15-16):633-6.,,,,,,,,,,,,,,
14859086,NLM,MEDLINE,20040215,20181201,0366-1334 (Print) 0366-1334 (Linking),67,15-16,1951 May 4-11,[Trials of combined aminopterin-cortisone therapy of acute leukoses in children].,621-32,"['MARIE, J', 'BERNARD, J', 'SALET, J', 'CRUCIANI']","['MARIE J', 'BERNARD J', 'SALET J', 'CRUCIANI']",['und'],['Journal Article'],Essais de traitement des leucoses aigues de l'enfant par l'association aminopterine-cortisone.,France,Bull Mem Soc Med Hop Paris,Bulletins et memoires de la Societe medicale des hopitaux de Paris,7503472,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)', 'V27W9254FZ (Cortisone)']",OM,"['*Aminopterin', '*Cortisone', '*Folic Acid Antagonists', '*Leukemia', '*Psychotherapy, Multiple']",['CLML: 5120:92572:226:349:546'],['NLM'],"['*CORTISONE', '*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/05/04 00:00,1951/05/04 00:01,['1951/05/04 00:00'],"['1951/05/04 00:00 [pubmed]', '1951/05/04 00:01 [medline]', '1951/05/04 00:00 [entrez]']",ppublish,Bull Mem Soc Med Hop Paris. 1951 May 4-11;67(15-16):621-32.,,,,,,,,,,,,,,
14859024,NLM,MEDLINE,20040215,20181201,0020-3955 (Print) 0020-3955 (Linking),4,1,1951 Jan-Mar,Considerations on sarcoleucosis (leukemia of lympho-sarcomatous cells).,15-63,"['PANIAGUA, G', 'MORALES PLEGUEZUELO, M', 'JIMENEZ DIAZ, C']","['PANIAGUA G', 'MORALES PLEGUEZUELO M', 'JIMENEZ DIAZ C']",['eng'],['Journal Article'],,Spain,Bull Inst Med Res Univ Madr,"Bulletin of the Institute for Medical Research, University of Madrid",7505378,,OM,"['Humans', '*Leukemia']",['CLML: 5120:92510:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Bull Inst Med Res Univ Madr. 1951 Jan-Mar;4(1):15-63.,,,,,,,,,,,,,,
14858470,NLM,MEDLINE,20040215,20181201,0539-6115 (Print) 0539-6115 (Linking),8,1,1951 Feb,[Treatment of leukemia in pediatrics].,32-53,"['SOTO ALLANDE, R', 'TORREGROSA, L', 'TORROELLA, J M']","['SOTO ALLANDE R', 'TORREGROSA L', 'TORROELLA JM']",['und'],['Journal Article'],Tratamiento de las leucemias en pediatria.,Mexico,Bol Med Hosp Infant Mex,Boletin medico del Hospital Infantil de Mexico,0414106,['0 (Folic Acid Antagonists)'],OM,"['*Folic Acid Antagonists', '*Leukemia', '*Pediatrics']",['CLML: 5120:91951:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,Bol Med Hosp Infant Mex. 1951 Feb;8(1):32-53.,,,,,,,,,,,,,,
14858201,NLM,MEDLINE,20040215,20181201,,12,5,1951 May,[Nitrogen balance in leukemia treated with urethane; observations on 17-ketosteroid elimination and on cell maturation].,469-88,"['JAMRA, M A', 'GOMIDE, W']","['JAMRA MA', 'GOMIDE W']",['und'],['Journal Article'],Balanco nitrogenado de leucemicos tratados con uretana; observacoes sobre a eliminacao de 17-cetosteroides e sobre a maturacao celular.,Brazil,Arq Clin (Rio De J),Arquivos de clinica,15310570R,"['0 (17-Ketosteroids)', '0 (Steroids)', '3IN71E75Z5 (Urethane)', 'N762921K75 (Nitrogen)']",OM,"['*17-Ketosteroids', '*Cell Growth Processes', '*Leukemia', '*Nitrogen', '*Steroids', '*Urethane']",['CLML: 5120:91657:88:326:417:546'],['NLM'],"['*LEUKEMIA', '*NITROGEN', '*STEROIDS', '*URETHANE']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Arq Clin (Rio De J). 1951 May;12(5):469-88.,,,,,,,,,,,,,,
14858199,NLM,MEDLINE,20040215,20181201,,12,5,1951 May,[A case of monocytic leukemia].,454-63,"['de FIGUEIREDO, L H']",['de FIGUEIREDO LH'],['und'],['Journal Article'],Sobre um caso de leucemia de monocitos.,Brazil,Arq Clin (Rio De J),Arquivos de clinica,15310570R,,OM,"['*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid', '*Monocytes']",['CLML: 5120:91655:547'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Arq Clin (Rio De J). 1951 May;12(5):454-63.,,,,,,,,,,,,,,
14858091,NLM,MEDLINE,20040215,20181201,,9,10-12,1950 Oct-Dec,[Plasma cell leukemia; report of a case].,323-31,"['BIDOT PERALTA, C']",['BIDOT PERALTA C'],['und'],['Journal Article'],Leucemia a celulas plasmaticas; reporte de un caso.,Cuba,Arch Cuba Cancerol,Archivos cubanos de cancerologia,15230090R,,OM,"['Humans', '*Leukemia', '*Leukemia, Plasma Cell']",['CLML: 5120:91547:546'],['NLM'],['*LEUKEMIA'],1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Arch Cuba Cancerol. 1950 Oct-Dec;9(10-12):323-31.,,,,,,,,,,,,,,
14858001,NLM,MEDLINE,20040215,20181201,,24,3,1951,[Leukemia with skin and lymph node manifestations].,201-8,"['CERRI, B']",['CERRI B'],['und'],['Journal Article'],Istioleucemia con manifestazioni cutanee e linfoghiandolari.,Italy,Arch Ital Dermatol Sifilogr Venereol,"Archivio italiano di dermatologia, sifilografia, e venereologia",15220190R,,OM,"['Humans', '*Leukemia', '*Lymph Nodes', '*Skin']",['CLML: 5120:91453:300:546:573'],['NLM'],"['*LEUKEMIA', '*LYMPH NODES', '*SKIN']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Arch Ital Dermatol Sifilogr Venereol. 1951;24(3):201-8.,,,,,,,,,,,,,,
14857489,NLM,MEDLINE,20040215,20181201,0365-4362 (Print) 0365-4362 (Linking),39,3,1950,Urethane derivatives in leukemia.,205-10,"['VARTIAINEN, I', 'VARTIAINEN, O']","['VARTIAINEN I', 'VARTIAINEN O']",['eng'],['Journal Article'],,Finland,Ann Med Intern Fenn,Annales medicinae internae Fenniae,0221122,['3IN71E75Z5 (Urethane)'],OM,"['*Leukemia', '*Urethane']",['CLML: 5120:90906:417:546'],['NLM'],"['*LEUKEMIA', '*URETHANE']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Ann Med Intern Fenn. 1950;39(3):205-10.,,,,,,,,,,,,,,
14857288,NLM,MEDLINE,20040215,20181201,0365-3307 (Print) 0365-3307 (Linking),7,Suppl,1950 Sep,"[The treatment of leukemia, with notes on other severe hematic diseases].",177-91,"['FIESCHI, A']",['FIESCHI A'],['und'],['Journal Article'],"Terapia delle leucemie, con un accenno anche alle altre gravi emopatie.",Portugal,An Inst Med Trop (Lisb),Anais do Instituto de Medicina Tropical,7502512,,OM,"['*Hematopoietic System', '*Leukemia']",['CLML: 5120:90705:429:546'],['NLM'],"['*HEMOPOIETIC SYSTEM', '*LEUKEMIA']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,An Inst Med Trop (Lisb). 1950 Sep;7(Suppl):177-91.,,,,,,,,,,,,,,
14857182,NLM,MEDLINE,20040215,20181201,0002-9513 (Print) 0002-9513 (Linking),166,2,1951 Aug,Hematology of the dog following intravenous administration of radioactive colloidal gold.,323-7,"['WHEELER, B', 'JACKSON, M A', 'HAHN, P F']","['WHEELER B', 'JACKSON MA', 'HAHN PF']",['eng'],['Journal Article'],,United States,Am J Physiol,The American journal of physiology,0370511,"['0 (Gold Colloid, Radioactive)', '0 (Gold Radioisotopes)']",OM,"['*Administration, Intravenous', 'Animals', '*Blood', 'Dogs', '*Gold Colloid, Radioactive', '*Gold Radioisotopes', '*Hematology', '*Leukemia', '*Radioactivity']",['CLML: 5120:90599:111:388:546'],['NLM'],"['*BLOOD', '*GOLD, RADIOACTIVE', '*LEUKEMIA']",1951/08/01 00:00,1951/08/01 00:01,['1951/08/01 00:00'],"['1951/08/01 00:00 [pubmed]', '1951/08/01 00:01 [medline]', '1951/08/01 00:00 [entrez]']",ppublish,Am J Physiol. 1951 Aug;166(2):323-7. doi: 10.1152/ajplegacy.1951.166.2.323.,['10.1152/ajplegacy.1951.166.2.323 [doi]'],,,,,,,,,,,,,
14856626,NLM,MEDLINE,20040215,20190812,0001-6101 (Print) 0001-6101 (Linking),140,2,1951 Jul 15,The changes in the bone marrow differential in chronic leukemia treated with P32 and Y90.,99-118,"['BERLIN, N I', 'LAWRENCE, J H']","['BERLIN NI', 'LAWRENCE JH']",['eng'],['Journal Article'],,Sweden,Acta Med Scand,Acta medica Scandinavica,0370330,"['0 (Isotopes)', '0 (Radioisotopes)']",OM,"['*Bone Marrow', 'Humans', '*Isotopes', '*Leukemia', '*Radioactivity', '*Radioisotopes']",['CLML: 5120:90028:130:487:546'],['NLM'],"['*BONE MARROW', '*ISOTOPES, RADIOACTIVE', '*LEUKEMIA']",1951/07/15 00:00,1951/07/15 00:01,['1951/07/15 00:00'],"['1951/07/15 00:00 [pubmed]', '1951/07/15 00:01 [medline]', '1951/07/15 00:00 [entrez]']",ppublish,Acta Med Scand. 1951 Jul 15;140(2):99-118. doi: 10.1111/j.0954-6820.1951.tb10160.x.,['10.1111/j.0954-6820.1951.tb10160.x [doi]'],,,,,,,,,,,,,
14856607,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),6,1,1951,Experimental studies on the aetiology of human leukaemias.,38-50,"['MAGRASSI, F', 'LEONARDI, G', 'NEGRONI, G', 'TOLU, A']","['MAGRASSI F', 'LEONARDI G', 'NEGRONI G', 'TOLU A']",['eng'],['Journal Article'],,Switzerland,Acta Haematol,Acta haematologica,0141053,,OM,"['Humans', '*Leukemia']",['CLML: 5120:90009:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Haematol. 1951;6(1):38-50. doi: 10.1159/000203902.,['10.1159/000203902 [doi]'],,,,,,,,,,,,,
14856595,NLM,MEDLINE,20040215,20181201,0001-5555 (Print) 0001-5555 (Linking),31,4,1951,Case of chronic lymphatic leucaemia with unusual cutaneous manifestations.,488-93,"['BAFVERSTEDT, V B']",['BAFVERSTEDT VB'],['eng'],['Journal Article'],,Sweden,Acta Derm Venereol,Acta dermato-venereologica,0370310,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5120:89997:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Derm Venereol. 1951;31(4):488-93.,,,,,,,,,,,,,,
14856409,NLM,MEDLINE,20040215,20191108,0096-5979 (Print) 0096-5979 (Linking),64,2,1951 Aug,Generalized herpes zoster encephalitis and lymphatic leukemia. a case report.,192-4,"['FRANK, L']",['FRANK L'],['eng'],['Journal Article'],,United States,AMA Arch Derm Syphilol,A.M.A. archives of dermatology and syphilology,14470040R,,OM,"['*Encephalitis', '*Encephalitis, Varicella Zoster', '*Herpes Zoster', '*Herpesvirus 3, Human', 'Humans', '*Leukemia', '*Leukemia, Lymphoid']",['CLML: 5120:89811:303:435:546'],['NLM'],"['*ENCEPHALITIS', '*HERPES ZOSTER', '*LEUKEMIA, LYMPHATIC']",1951/08/01 00:00,1951/08/01 00:01,['1951/08/01 00:00'],"['1951/08/01 00:00 [pubmed]', '1951/08/01 00:01 [medline]', '1951/08/01 00:00 [entrez]']",ppublish,AMA Arch Derm Syphilol. 1951 Aug;64(2):192-4. doi: 10.1001/archderm.1951.01570080076010.,['10.1001/archderm.1951.01570080076010 [doi]'],,,,,,,,,,,,,
14856151,NLM,MEDLINE,20040215,20181201,0044-2542 (Print) 0044-2542 (Linking),6,9-10,1951 May,[Hematological and clinical polymorphism of acute leukemia].,311-20,"['HAAS, W']",['HAAS W'],['und'],['Journal Article'],Uber die hamatologische und klinische Polymorphie akuter Leukamien.,Germany,Z Gesamte Inn Med,Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,21730470R,,OM,"['*Acute Disease', 'Humans', '*Leukemia', '*Leukocytes']",['CLML: 5120:89519:546:547'],['NLM'],"['*LEUKEMIA', '*LEUKOCYTES']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Z Gesamte Inn Med. 1951 May;6(9-10):311-20.,,,,,,,,,,,,,,
14856131,NLM,MEDLINE,20040215,20181201,0044-2542 (Print) 0044-2542 (Linking),6,7-8,1951 Apr,[Multiple myeloma with atypical blood protein changes].,228-33,"['von BRAND, V', 'GOETZE, E']","['von BRAND V', 'GOETZE E']",['und'],['Journal Article'],Multiples Myelom mit atypischen Serumeiweissveranderungen.,Germany,Z Gesamte Inn Med,Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,21730470R,['0 (Blood Proteins)'],OM,"['*Blood Proteins', 'Humans', '*Leukemia', '*Multiple Myeloma', '*Neoplasms']",['CLML: 5120:89499:407:546'],['NLM'],"['*LEUKEMIA', '*TUMORS, MULTIPLE MYELOMA']",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,Z Gesamte Inn Med. 1951 Apr;6(7-8):228-33.,,,,,,,,,,,,,,
14855943,NLM,MEDLINE,20040215,20181201,0372-5588 (Print) 0372-5588 (Linking),46,8,1951 Aug,"The effect of 4-aminopteroylglutamic acid (aminopterin), a folic acid antagonist on experimentally produced avian leukosis.",312-4,"['JOHNSON, E P']",['JOHNSON EP'],['eng'],['Journal Article'],,United States,Vet Med,Veterinary medicine,21520030R,"['0 (Folic Acid Antagonists)', '935E97BOY8 (Folic Acid)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Aminopterin', 'Animals', '*Avian Leukosis', '*Bird Diseases', '*Birds', '*Folic Acid', '*Folic Acid Antagonists', '*Leukemia', '*Meat', '*Poultry']",['CLML: 5120:89310:349:354:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*FOWLS', '*LEUKEMIA, AVIAN']",1951/08/01 00:00,1951/08/01 00:01,['1951/08/01 00:00'],"['1951/08/01 00:00 [pubmed]', '1951/08/01 00:01 [medline]', '1951/08/01 00:00 [entrez]']",ppublish,Vet Med. 1951 Aug;46(8):312-4.,,,,,,,,,,,,,,
14855663,NLM,MEDLINE,20040215,20181201,0041-5782 (Print) 0041-5782 (Linking),112,47,1950 Nov 23,[Urinary tyrosine in pernicious anemia and leukemia in comparison with normal conditions].,1634-7,"['MUNK PLUM, C']",['MUNK PLUM C'],['und'],['Journal Article'],Undersogelser over tyrosinudskillelse i urin hos patienter med anaemia perniciosa og leukaemi sammenlignet med normale forhold.,Denmark,Ugeskr Laeger,Ugeskrift for laeger,0141730,['42HK56048U (Tyrosine)'],OM,"['*Anemia', '*Anemia, Pernicious', 'Humans', '*Leukemia', '*Tyrosine', '*Urinary Tract']",['CLML: 5120:89030:40:412:546'],['NLM'],"['*ANEMIA, PERNICIOUS', '*LEUKEMIA', '*TYROSINE']",1950/11/23 00:00,1950/11/23 00:01,['1950/11/23 00:00'],"['1950/11/23 00:00 [pubmed]', '1950/11/23 00:01 [medline]', '1950/11/23 00:00 [entrez]']",ppublish,Ugeskr Laeger. 1950 Nov 23;112(47):1634-7.,,,,,,,,,,,,,,
14855158,NLM,MEDLINE,20040215,20181201,0370-8179 (Print) 0370-8179 (Linking),49,3-4,1951 Mar-Apr,[Remission of subacute lymphatic leukemia due to frequent small transfusions].,284-8,"['ZAMUROVIC, R']",['ZAMUROVIC R'],['und'],['Journal Article'],Uspela klini6cka remisija kod subakutne limfati6cne leukemije pod deistvom malih cestih transfuzija.,Serbia,Srp Arh Celok Lek,Srpski arhiv za celokupno lekarstvo,0027440,,OM,"['*Blood Transfusion', 'Humans', '*Leukemia', '*Leukemia, Lymphoid']",['CLML: 5120:88519:123:546'],['NLM'],"['*BLOOD TRANSFUSION', '*LEUKEMIA, LYMPHATIC']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Srp Arh Celok Lek. 1951 Mar-Apr;49(3-4):284-8.,,,,,,,,,,,,,,
14854915,NLM,MEDLINE,20040215,20190619,0036-8075 (Print) 0036-8075 (Linking),114,2952,1951 Jul 27,Growth of human leukemic leucocytes in vitro and in vivo as measured by uptake of p32 in desoxyribose nucleic acid.,95-8,"['OSGOOD, E E', 'LI, J G', 'TIVEY, H', 'DUERST, M L', 'SEAMAN, A J']","['OSGOOD EE', 'LI JG', 'TIVEY H', 'DUERST ML', 'SEAMAN AJ']",['eng'],['Journal Article'],,United States,Science,"Science (New York, N.Y.)",0404511,['0 (Nucleic Acids)'],OM,"['Humans', 'In Vitro Techniques', '*Leukemia', '*Leukocytes', '*Nucleic Acids', '*Physiological Phenomena']",['CLML: 5120:88276:546:547'],['NLM'],"['*LEUKEMIA', '*LEUKOCYTES']",1951/07/27 00:00,1951/07/27 00:01,['1951/07/27 00:00'],"['1951/07/27 00:00 [pubmed]', '1951/07/27 00:01 [medline]', '1951/07/27 00:00 [entrez]']",ppublish,Science. 1951 Jul 27;114(2952):95-8. doi: 10.1126/science.114.2952.95.,['10.1126/science.114.2952.95 [doi]'],,,,,,,,,,,,,
14854706,NLM,MEDLINE,20040215,20181201,0300-9904 (Print) 0300-9904 (Linking),26,2,1951 Mar-Apr,[Seasonal evolution of disease induced in the guinea pig by inoculation of leukemic matter].,165-72,"['NEGRONI, G', 'TOLU, A']","['NEGRONI G', 'TOLU A']",['und'],['Journal Article'],Osservazioni sull'andamento stagionale della malattia indotta nella cavia con l'inoculazione di materiali leucemici.,Italy,Riv Ist Sieroter Ital,Rivista dell'Istituto sieroterapico italiano,7505994,,OM,"['Animals', '*Biological Evolution', 'Guinea Pigs', '*Leukemia', '*Seasons', '*Vaccination']",['CLML: 5120:88067:546'],['NLM'],['*LEUKEMIA'],1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Riv Ist Sieroter Ital. 1951 Mar-Apr;26(2):165-72.,,,,,,,,,,,,,,
14854702,NLM,MEDLINE,20040215,20181201,0300-9904 (Print) 0300-9904 (Linking),26,2,1951 Mar-Apr,[Experimental immunization of the rabbit with human leukemic leukocytes].,131-44,"['CAJANO, A', 'MAUREA, C']","['CAJANO A', 'MAUREA C']",['und'],['Journal Article'],Immunizzazione sperimentale del coniglio con leucociti leucemici umani.,Italy,Riv Ist Sieroter Ital,Rivista dell'Istituto sieroterapico italiano,7505994,,OM,"['Animals', 'Humans', '*Immunization', '*Leukemia', '*Leukocytes', 'Rabbits', '*Vaccination']",['CLML: 5120:88063:546'],['NLM'],['*LEUKEMIA'],1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Riv Ist Sieroter Ital. 1951 Mar-Apr;26(2):131-44.,,,,,,,,,,,,,,
14854654,NLM,MEDLINE,20040215,20181201,0048-8364 (Print) 0048-8364 (Linking),4,1,1951 Jan,[A case of cutaneous leukosarcomatosis].,13-8,"['MENOZZI, L']",['MENOZZI L'],['und'],['Journal Article'],"Su un caso di ""leucosarcomatosi"" cutanea.",Italy,Riv Anat Patol Oncol,Rivista di anatomia patologica e di oncologia,0404350,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', '*Neoplasms', '*Sarcoma', '*Skin']",['CLML: 5120:88008:267:300'],['NLM'],"['*SARCOMA, LEUKOSARCOMA', '*SKIN']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Riv Anat Patol Oncol. 1951 Jan;4(1):13-8.,,,,,,,,,,,,,,
14854478,NLM,MEDLINE,20040215,20181201,0048-7791 (Print) 0048-7791 (Linking),4,1,1951 Jan,[Results of roentgenological examination of the skeleton in 24 cases of leukemia personally observed].,1-9,"['FARRERAS VALENTI, P', 'VILASECA SABATER, J M']","['FARRERAS VALENTI P', 'VILASECA SABATER JM']",['und'],['Journal Article'],Resultados de la exploracion roentgenological del esqueleto en veinticuatro leucemicos personalmente observados.,Spain,Rev Esp Reum Enferm Osteoartic,Revista espanola de reumatismo y enfermedades osteoarticulares,0404304,,OM,"['*Bone and Bones', 'Humans', '*Leukemia', '*Musculoskeletal System', '*Skeleton']",['CLML: 5120:87828:129:546'],['NLM'],"['*BONE', '*LEUKEMIA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Rev Esp Reum Enferm Osteoartic. 1951 Jan;4(1):1-9.,,,,,,,,,,,,,,
14854043,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),77,2,1951 Jun,Response of a resistant variant of leukemic cells to an antagonist of pteroylglutamic acid.,340-4,"['LAW, L W']",['LAW LW'],['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['0 (Folic Acid Antagonists)', '935E97BOY8 (Folic Acid)']",OM,"['*Folic Acid', '*Folic Acid Antagonists', '*Leukemia', '*Musculoskeletal Physiological Phenomena']",['CLML: 5120:87384:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/06/01 00:00,1951/06/01 00:01,['1951/06/01 00:00'],"['1951/06/01 00:00 [pubmed]', '1951/06/01 00:01 [medline]', '1951/06/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1951 Jun;77(2):340-4. doi: 10.3181/00379727-77-18773.,['10.3181/00379727-77-18773 [doi]'],,,,,,,,,,,,,
14853766,NLM,MEDLINE,20040215,20181201,0048-5128 (Print) 0048-5128 (Linking),5,49,1951 Jun 15,[Therapy of acute leukemias].,1043-50,"['KEIBL, E']",['KEIBL E'],['und'],['Journal Article'],Zur Therapie der akuten Leukamien.,Austria,Prakt Arzt,Der Praktische Arzt,0060366,,OM,"['*Acute Disease', 'Humans', '*Leukemia']",['CLML: 5120:87103:546'],['NLM'],['*LEUKEMIA'],1951/06/15 00:00,1951/06/15 00:01,['1951/06/15 00:00'],"['1951/06/15 00:00 [pubmed]', '1951/06/15 00:01 [medline]', '1951/06/15 00:00 [entrez]']",ppublish,Prakt Arzt. 1951 Jun 15;5(49):1043-50.,,,,,,,,,,,,,,
14853616,NLM,MEDLINE,20040215,20181201,0031-4005 (Print) 0031-4005 (Linking),8,1,1951 Jul,Effects of ACTH and cortisone on leukemia in childhood.,34-52,"['SCHULMAN, I', 'LANMAN, J T', 'LAXDAL, O E', 'HOLT, L E Jr']","['SCHULMAN I', 'LANMAN JT', 'LAXDAL OE', 'HOLT LE Jr']",['eng'],['Journal Article'],,United States,Pediatrics,Pediatrics,0376422,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['*Adrenocorticotropic Hormone', '*Child', '*Cortisone', '*Leukemia']",['CLML: 5120:86945:8:195:227:545'],['NLM'],"['*ACTH', '*CHILD', '*CORTISONE', '*LEUKEMIA']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Pediatrics. 1951 Jul;8(1):34-52.,,,,,,,,,,,,,,
14853615,NLM,MEDLINE,20040215,20181201,0031-4005 (Print) 0031-4005 (Linking),8,1,1951 Jul,Pituitary adrenocorticotropic hormone (ACTH) and 11-dehydro-17 hydroxy corticosterone (cortisone) therapy in the leukemias and lymphomas of children.,26-33,"['SNELLING, C E', 'DONOHUE, W L', 'LASKI, B', 'JACKSON, S H']","['SNELLING CE', 'DONOHUE WL', 'LASKI B', 'JACKSON SH']",['eng'],['Journal Article'],,United States,Pediatrics,Pediatrics,0376422,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)', 'W980KJ009P (Corticosterone)']",OM,"['*Adrenocorticotropic Hormone', '*Corticosterone', '*Cortisone', '*Leukemia', '*Lymphoma', '*Pituitary Gland']",['CLML: 5120:86944'],,,1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Pediatrics. 1951 Jul;8(1):26-33.,,,,,,,,,,,,,,
14853614,NLM,MEDLINE,20040215,20181201,0031-4005 (Print) 0031-4005 (Linking),8,1,1951 Jul,Pituitary adrenocorticotropic hormone (ACTH) and 11-dehydro-17 hydroxy corticosterone (cortisone) therapy in the leukemias and lymphomas of children.,22-5,"['SNELLING, C E', 'DONOHUE, W L', 'LASKI, B', 'JACKSON, S H']","['SNELLING CE', 'DONOHUE WL', 'LASKI B', 'JACKSON SH']",['eng'],['Journal Article'],,United States,Pediatrics,Pediatrics,0376422,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)', 'W980KJ009P (Corticosterone)']",OM,"['*Adrenocorticotropic Hormone', 'Child', '*Corticosterone', '*Cortisone', '*Leukemia', '*Lymphoma', '*Lymphoma, Non-Hodgkin', '*Neoplasms', '*Pituitary Gland', '*Sarcoma']",['CLML: 5120:86943:8:195:227:267:545'],['NLM'],"['*ACTH', '*CHILD', '*CORTISONE', '*LEUKEMIA', '*SARCOMA, LYMPHOSARCOMA']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Pediatrics. 1951 Jul;8(1):22-5.,,,,,,,,,,,,,,
14853584,NLM,MEDLINE,20040215,20181201,0369-8300 (Print) 0369-8300 (Linking),41,20,1951 May 26,"[New therapy of acute leucoses (folic acid antagonists, cortisone, ACTH, aminopterine-cortisone combined)].",285-7,"['BERNARD, J']",['BERNARD J'],['und'],['Journal Article'],"Les nouveaux traitements des leucoses aigues (antifoliques, cortisone, A.C.T.H. association aminopterine-cortisone).",France,Paris Med,Paris medical,19520510R,"['0 (Folic Acid Antagonists)', '9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['*Adrenocorticotropic Hormone', '*Cortisone', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:86913:8:349:546'],['NLM'],"['*ACTH', '*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/05/26 00:00,1951/05/26 00:01,['1951/05/26 00:00'],"['1951/05/26 00:00 [pubmed]', '1951/05/26 00:01 [medline]', '1951/05/26 00:00 [entrez]']",ppublish,Paris Med. 1951 May 26;41(20):285-7.,,,,,,,,,,,,,,
14853453,NLM,MEDLINE,20040215,20181201,0030-3755 (Print) 0030-3755 (Linking),122,1,1951 Jul,[Hypertensive leucemic uveitis].,1-9,"['WEEKERS, R', 'PRIJOT, E']","['WEEKERS R', 'PRIJOT E']",['und'],['Journal Article'],Uveite leucemique hypertensive.,Switzerland,Ophthalmologica,Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde,0054655,,OM,"['Humans', '*Hypertension', '*Leukemia', '*Leukemia, Lymphoid', '*Uveitis']",['CLML: 5120:86782:425:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*UVEITIS']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Ophthalmologica. 1951 Jul;122(1):1-9. doi: 10.1159/000301028.,['10.1159/000301028 [doi]'],,,,,,,,,,,,,
14853094,NLM,MEDLINE,20040215,20181201,0028-7571 (Print) 0028-7571 (Linking),17,6,1951 Jun-Jul,Monocytic leukemia.,278-9,"['KWAPIS, H J']",['KWAPIS HJ'],['eng'],['Journal Article'],,United States,N Y State Dent J,The New York state dental journal,0414634,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Tooth']",['CLML: 5120:86406:357:547'],['NLM'],"['*LEUKEMIA, MONOCYTIC', '*TEETH']",1951/06/01 00:00,1951/06/01 00:01,['1951/06/01 00:00'],"['1951/06/01 00:00 [pubmed]', '1951/06/01 00:01 [medline]', '1951/06/01 00:00 [entrez]']",ppublish,N Y State Dent J. 1951 Jun-Jul;17(6):278-9.,,,,,,,,,,,,,,
14852349,NLM,MEDLINE,20040215,20181201,0025-7648 (Print) 0025-7648 (Linking),9,199,1951 May 1,[A case of acute leukemia and 2 cases of agranulocytosis with prior angina].,304-5,"['GARCIA RAMIRO, D']",['GARCIA RAMIRO D'],['und'],['Journal Article'],"Un caso de leucemia aguda y dos de agranulocitosis, todos ellos con angina previa.",Spain,Medicamenta (Madr),Medicamenta,0400716,,OM,"['*Acute Disease', '*Agranulocytosis', '*Angina Pectoris', '*Leukemia']",['CLML: 5120:85631:395:545'],['NLM'],"['*GRANULOCYTOPENIA', '*LEUKEMIA']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Medicamenta (Madr). 1951 May 1;9(199):304-5.,,,,,,,,,,,,,,
14852199,NLM,MEDLINE,20040215,20201230,0025-729X (Print) 0025-729X (Linking),1,23,1951 Jun 9,A case of monocytic leuchaemia with chloroma-like tumours.,835-9,"['BONNIN, J A']",['BONNIN JA'],['eng'],['Journal Article'],,Australia,Med J Aust,The Medical journal of Australia,0400714,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Neoplasms', '*Sarcoma, Myeloid']",['CLML: 5120:85481:547'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1951/06/09 00:00,1951/06/09 00:01,['1951/06/09 00:00'],"['1951/06/09 00:00 [pubmed]', '1951/06/09 00:01 [medline]', '1951/06/09 00:00 [entrez]']",ppublish,Med J Aust. 1951 Jun 9;1(23):835-9. doi: 10.5694/j.1326-5377.1951.tb88469.x.,['10.5694/j.1326-5377.1951.tb88469.x [doi]'],,,,,,,,,,,,,
14852071,NLM,MEDLINE,20040215,20181201,0025-6749 (Print) 0025-6749 (Linking),9,194,1951 May 15,[Importance of the terrain in pathology and the role of biological catalyzers in therapy of malignant hemopathies; leukemia and malignant lymphogranuloma].,177-8,"['DUBOIS-FERRIERE, H']",['DUBOIS-FERRIERE H'],['und'],['Journal Article'],"L'importance du terrain en pathologie et le role des catalyseurs biologiques dans le traitement des hemopathies malignes, (leucemie et lymphogranulome malin).",Switzerland,Med Hyg (Geneve),Medecine et hygiene,9427226,,OM,"['*Catalysis', '*Hodgkin Disease', '*Leukemia']",['CLML: 5120:85353:444:546'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA']",1951/05/15 00:00,1951/05/15 00:01,['1951/05/15 00:00'],"['1951/05/15 00:00 [pubmed]', '1951/05/15 00:01 [medline]', '1951/05/15 00:00 [entrez]']",ppublish,Med Hyg (Geneve). 1951 May 15;9(194):177-8.,,,,,,,,,,,,,,
14850967,NLM,MEDLINE,20040215,20181201,0027-8874 (Print) 0027-8874 (Linking),11,5,1951 Apr,"Effects of a filtrable, self-propagating contaminant on a transplantable acute lymphoid leukemia in mice.",1037-55,"['LAW, L W', 'DUNN, T B']","['LAW LW', 'DUNN TB']",['eng'],['Journal Article'],,United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,,OM,"['*Acute Disease', 'Animals', '*Leukemia', '*Leukemia, Lymphoid', 'Mice', '*Precursor Cell Lymphoblastic Leukemia-Lymphoma']",['CLML: 5120:84243:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,J Natl Cancer Inst. 1951 Apr;11(5):1037-55.,,,,,,,,,,,,,,
14850887,NLM,MEDLINE,20040215,20181201,0368-3001 (Print) 0368-3001 (Linking),128,6,1951 Jun,[Aspects of pseudo-myeloid leukemia in acute pulmonary tuberculosis].,673-6,"['CREYX', 'LENG-LEVY, J', 'DUBREUIL, J', 'MALINEAU, R']","['CREYX', 'LENG-LEVY J', 'DUBREUIL J', 'MALINEAU R']",['und'],['Journal Article'],Sur un aspect de pseudo-leucemie myeloide au cours d'une tuberculose pulmonaire aigue.,France,J Med Bord,Journal de medecine de Bordeaux et du Sud-Ouest,0161067,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Tuberculosis', '*Tuberculosis, Pulmonary']",['CLML: 5120:84153:396:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*TUBERCULOSIS, PULMONARY']",1951/06/01 00:00,1951/06/01 00:01,['1951/06/01 00:00'],"['1951/06/01 00:00 [pubmed]', '1951/06/01 00:01 [medline]', '1951/06/01 00:00 [entrez]']",ppublish,J Med Bord. 1951 Jun;128(6):673-6.,,,,,,,,,,,,,,
14850836,NLM,MEDLINE,20040215,20181201,0022-2143 (Print) 0022-2143 (Linking),38,1,1951 Jul,"Biochemical studies on leucocytes. I. Phosphatase activity in health, leucocytosis, and myelocytic leucemia.",39-55,"['VALENTINE, W N', 'BECK, W S']","['VALENTINE WN', 'BECK WS']",['eng'],['Journal Article'],,United States,J Lab Clin Med,The Journal of laboratory and clinical medicine,0375375,['EC 3.1.3.2 (Phosphoric Monoester Hydrolases)'],OM,"['*Leukemia', '*Leukemia, Myeloid', '*Leukocytes', '*Leukocytosis', '*Phosphoric Monoester Hydrolases']",['CLML: 5120:84102:154:546:547:548'],['NLM'],"['*LEUKEMIA', '*LEUKEMIA, MYELOGENOUS', '*LEUKOCYTOSIS', '*PHOSPHATASE']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,J Lab Clin Med. 1951 Jul;38(1):39-55.,['0022-2143(51)90114-X [pii]'],,,,,,,,,,,,,
14849907,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),35,3,1951,[Chronic erythremic myelosis].,255-86,"['FRADA, G']",['FRADA G'],['und'],['Journal Article'],Mielosi eritremica cronica.,Italy,Haematologica,Haematologica,0417435,,OM,"['*Chronic Disease', '*Convulsive Therapy', 'Humans', '*Leukemia, Erythroblastic, Acute', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid']",['CLML: 5120:83128:68:293'],['NLM'],"['*MYELOSIS, ERYTHREMIC', '*SHOCK THERAPY']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Haematologica. 1951;35(3):255-86.,,,,,,,,,,,,,,
14849906,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),35,3,1951,[Hemocytoblastic leukemia with subacute and chronic course].,227-54,"['AUSTONI, M', 'GHEZZO, F']","['AUSTONI M', 'GHEZZO F']",['und'],['Journal Article'],Leucemie emocitoblastiche a decorso subacuto e cronico.,Italy,Haematologica,Haematologica,0417435,,OM,['*Leukemia'],['CLML: 5120:83127:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Haematologica. 1951;35(3):227-54.,,,,,,,,,,,,,,
14849292,NLM,MEDLINE,20040215,20181201,0011-9075 (Print) 0011-9075 (Linking),102,4-6,1951,[Regression of cutaneous lymphatic leukemia under penicillin therapy].,371-2,"['MIESCHER, G', 'STORCK, H']","['MIESCHER G', 'STORCK H']",['und'],['Journal Article'],Lymphatische Leukamie der Haut durch Penicillin zur Ruckbildung gebracht.,Switzerland,Dermatologica,Dermatologica,0211607,['0 (Penicillins)'],OM,"['*Administration, Cutaneous', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels', '*Penicillins', '*Skin']",['CLML: 5120:82499:138:301:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*PENICILLIN', '*SKIN']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Dermatologica. 1951;102(4-6):371-2.,,,,,,,,,,,,,,
14848829,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,7,1951 Jul,The effect of visible light on the development in mice of skin tumors and leukemia induced by carcinogens.,559-61,"['MORTON, J J', 'MIDER, G B', 'LUCECLAUSEN, E M', 'MAHONEY, E B']","['MORTON JJ', 'MIDER GB', 'LUCECLAUSEN EM', 'MAHONEY EB']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,['0 (Carcinogens)'],OM,"['Animals', '*Carcinogens', '*Leukemia', '*Light', 'Mice', '*Neoplasms', '*Skin Neoplasms']",['CLML: 5120:82020:401:546:552'],['NLM'],"['*LEUKEMIA', '*LIGHT', '*TUMORS']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Jul;11(7):559-61.,,,,,,,,,,,,,,
14848815,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,7,1951 Jul,Nuclei from normal and leukemic mouse spleen. II. The nucleic acid content of normal and leukemic nuclei.,485-9,"['PETERMANN, M L', 'SCHNEIDER, R M']","['PETERMANN ML', 'SCHNEIDER RM']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,['0 (Nucleic Acids)'],OM,"['*Cell Nucleus', '*Leukemia', '*Nucleic Acids', '*Spleen']",['CLML: 5120:82006:92:318:546'],['NLM'],"['*LEUKEMIA', '*NUCLEIC ACIDS', '*SPLEEN']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Jul;11(7):485-9.,,,,,,,,,,,,,,
14848718,NLM,MEDLINE,20040215,20181201,0008-1264 (Print) 0008-1264 (Linking),75,1,1951 Jul,Trisethylene-imino-s-triazine (triethylene melamine or TEM) in the treatment of neoplastic diseases.,26-34,"['SHIMKIN, M B', 'BIERMAN, H R', 'KELLY, K H', 'LOWENHAUPT, E', 'FURST, A']","['SHIMKIN MB', 'BIERMAN HR', 'KELLY KH', 'LOWENHAUPT E', 'FURST A']",['eng'],['Journal Article'],,United States,Calif Med,California medicine,0410260,"['0 (Nitrogen Mustard Compounds)', '0 (Triazines)', '50D9XSG0VR (Mechlorethamine)', 'F7IY6HZG9D (Triethylenemelamine)']",OM,"['Animals', '*Hodgkin Disease', 'Humans', '*Lung Neoplasms', '*Lymphoma', '*Mechlorethamine', 'Mice', '*Neoplasms', '*Nitrogen Mustard Compounds', '*Triazines', '*Triethylenemelamine']",['CLML: 5120:81909:88:167'],['NLM'],"['*CANCER', '*NITROGEN MUSTARDS']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Calif Med. 1951 Jul;75(1):26-34.,,PMC1520923,"Trisethylene-imino-s-triazine (triethylene melamine or TEM) produced minimal effects in inhibiting transplantable lymphoma and mammary adenocarcinoma in mice. In strain A mice, injection of the compound induced pulmonary tumors.TEM was tried on 32 patients with neoplastic disease, including nine patients with Hodgkin's disease and five with lymphosarcoma and lymphatic leukemia. The therapeutic and toxic effects were similar to those observed with nitrogen mustard (HN2). Satisfactory remissions of up to three months were observed in Hodgkin's disease and lymphosarcoma following parenteral administration of TEM. It is the authors' impression that the remissions obtained with TEM were not as complete and did not last as long as those obtained with HN2.TEM is effective by the oral route as well as parenterally, and produces much less emetic reaction than HN2. On the other hand, the chemotherapeutic range is narrower than that of HN2. Patients who do not respond to HN2 show no response to TEM.TEM is a drug of some clinical usefulness in the same conditions and with the same general limitations and toxic effects as HN2. The ease of administration of TEM increases its hazards, and close clinical and hematologic observations are essential on patients receiving the agent.",,,,,,,,,,,
14847899,NLM,MEDLINE,20040215,20181201,,12,3,1951 Mar,[Recent acquisitions in the treatment of acute leukemia].,162-77,"['de MENDONCA, J M']",['de MENDONCA JM'],['und'],['Journal Article'],Recentes aquisicoes no tratamento das leucemias agudas.,Brazil,Arq Clin (Rio De J),Arquivos de clinica,15310570R,,OM,"['*Acute Disease', 'Humans', '*Leukemia']",['CLML: 5120:81027:546'],['NLM'],['*LEUKEMIA'],1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Arq Clin (Rio De J). 1951 Mar;12(3):162-77.,,,,,,,,,,,,,,
14847898,NLM,MEDLINE,20040215,20181201,,12,3,1951 Mar,"[Nitrogen mustard in the treatment of Hodgkin's disease, lymphosarcoma, leukemia and related diseases].",141-61,"['de LORENZO, J', 'JANNINI, P']","['de LORENZO J', 'JANNINI P']",['und'],['Journal Article'],"A mustarda nitrogenada no tratamento do mal de Hodgkin, linfosarcoma, leucemia e molestias afins.",Brazil,Arq Clin (Rio De J),Arquivos de clinica,15310570R,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Hodgkin Disease', '*Leukemia', '*Lymphoma', '*Lymphoma, Non-Hodgkin', '*Mechlorethamine', '*Nitrogen Mustard Compounds', '*Sarcoma']",['CLML: 5120:81026:88:267:444:546'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA', '*NITROGEN MUSTARDS', '*SARCOMA, LYMPHOSARCOMA']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Arq Clin (Rio De J). 1951 Mar;12(3):141-61.,,,,,,,,,,,,,,
14847864,NLM,MEDLINE,20040215,20181201,,3,3,1951 May-Jun,[Splenic metaplasia with medullary fibrosis; concept regarding this disease; case report].,303-14,"['BARQUET CHEDIAK, A', 'CHEDIAK, M']","['BARQUET CHEDIAK A', 'CHEDIAK M']",['und'],['Journal Article'],Metaplasia esplenica con fibrosis medular; concepto sobre esta afeccion; presentacion de un caso.,Cuba,Arch Hosp Univ,Archivos. Hospital Universitario General Calixto Garcia,17240430R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Metaplasia', '*Spleen']",['CLML: 5120:80985:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Arch Hosp Univ. 1951 May-Jun;3(3):303-14.,,,,,,,,,,,,,,
14847763,NLM,MEDLINE,20040215,20181201,0003-9691 (Print) 0003-9691 (Linking),12,4,1951,[Three cases of chronic myeloid leukemia caused by benzol].,399-404,"['BOUSSER, J', 'TARA, S']","['BOUSSER J', 'TARA S']",['und'],['Journal Article'],A propos de trois cas de leucemie myeloide chronique provoques par le benzol.,France,Arch Mal Prof,Archives des maladies professionnelles de medecine du travail et de securite sociale,2985157R,['J64922108F (Benzene)'],OM,"['*Benzene', 'Humans', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive']",['CLML: 5120:80875:94'],['NLM'],['*BENZENE'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Arch Mal Prof. 1951;12(4):399-404.,,,,,,,,,,,,,,
14847705,NLM,MEDLINE,20040215,20181201,0003-9764 (Print) 0003-9764 (Linking),8,4,1951,[Di Guglielmo's acute erythroblastic myelosis].,404-7,"['CLEMENT, R', 'DUPERRAT, B', 'GERBEAUX, J', 'CHAVELET, F']","['CLEMENT R', 'DUPERRAT B', 'GERBEAUX J', 'CHAVELET F']",['und'],['Journal Article'],Myelose erythroblastique aigue de Di Guglielmo.,France,Arch Fr Pediatr,Archives francaises de pediatrie,0372421,,OM,"['*Erythroblasts', 'Humans', '*Leukemia, Erythroblastic, Acute', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid']",['CLML: 5120:80815:68'],['NLM'],"['*MYELOSIS, ERYTHREMIC']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Arch Fr Pediatr. 1951;8(4):404-7.,,,,,,,,,,,,,,
14847462,NLM,MEDLINE,20040215,20190619,0003-4819 (Print) 0003-4819 (Linking),35,1,1951 Jul,Blood cell changes in leukemia during aminopterin therapy.,236-9,"['ISAACS, R', 'TRIMMER, R W']","['ISAACS R', 'TRIMMER RW']",['eng'],['Journal Article'],,United States,Ann Intern Med,Annals of internal medicine,0372351,['JYB41CTM2Q (Aminopterin)'],OM,"['*Aminopterin', '*Blood', '*Blood Cells', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:80554:109:547'],['NLM'],"['*BLOOD', '*LEUKEMIA, MYELOGENOUS']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Ann Intern Med. 1951 Jul;35(1):236-9. doi: 10.7326/0003-4819-35-1-236.,['10.7326/0003-4819-35-1-236 [doi]'],,,,,,,,,,,,,
14847457,NLM,MEDLINE,20040215,20190619,0003-4819 (Print) 0003-4819 (Linking),35,1,1951 Jul,"Myelocytic leukemia: an analysis of incidence, distribution and fatality, 1910-1948.",194-212,"['SHIMKIN, M B', 'METTIER, S R', 'BIERMAN, H R']","['SHIMKIN MB', 'METTIER SR', 'BIERMAN HR']",['eng'],['Journal Article'],,United States,Ann Intern Med,Annals of internal medicine,0372351,,OM,"['Incidence', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:80549:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Ann Intern Med. 1951 Jul;35(1):194-212. doi: 10.7326/0003-4819-35-1-194.,['10.7326/0003-4819-35-1-194 [doi]'],,,,,,,,,,,,,
14847449,NLM,MEDLINE,20040215,20190619,0003-4819 (Print) 0003-4819 (Linking),35,1,1951 Jul,Leukemia and pregnancy: report of four cases and review of the literature.,59-68,"['SLENTZ, W A']",['SLENTZ WA'],['eng'],['Journal Article'],,United States,Ann Intern Med,Annals of internal medicine,0372351,,OM,"['Female', 'Humans', '*Leukemia', 'Pregnancy']",['CLML: 5120:80541:185:546'],['NLM'],"['*LEUKEMIA', '*PREGNANCY']",1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,Ann Intern Med. 1951 Jul;35(1):59-68. doi: 10.7326/0003-4819-35-1-59.,['10.7326/0003-4819-35-1-59 [doi]'],,,,,,,,,,,,,
14846763,NLM,MEDLINE,20040215,20190513,0002-9173 (Print) 0002-9173 (Linking),21,6,1951 Jun,"Simultaneous occurrence of Kaposi's sarcoma, leukemia and diabetes mellitus; report of a case.",586-9,"['FISCHER, J W', 'COHEN, D M']","['FISCHER JW', 'COHEN DM']",['eng'],['Journal Article'],,England,Am J Clin Pathol,American journal of clinical pathology,0370470,,OM,"['*Diabetes Mellitus', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Neoplasms', '*Sarcoma', '*Sarcoma, Kaposi']",['CLML: 5120:79850:263:267:546'],['NLM'],"['*DIABETES MELLITUS', '*LEUKEMIA, LYMPHATIC', ""*SARCOMA, KAPOSI'S""]",1951/06/01 00:00,1951/06/01 00:01,['1951/06/01 00:00'],"['1951/06/01 00:00 [pubmed]', '1951/06/01 00:01 [medline]', '1951/06/01 00:00 [entrez]']",ppublish,Am J Clin Pathol. 1951 Jun;21(6):586-9. doi: 10.1093/ajcp/21.6.586.,['10.1093/ajcp/21.6.586 [doi]'],,,,,,,,,,,,,
14846516,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),5,6,1951 Jun,Unusual anemia associated with chronic myeloid leukemia.,345-59,"['YOUNG, L E', 'PLATZER, R F', 'LAWRENCE, J S']","['YOUNG LE', 'PLATZER RF', 'LAWRENCE JS']",['eng'],['Journal Article'],,Switzerland,Acta Haematol,Acta haematologica,0141053,,OM,"['*Anemia', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid']",['CLML: 5120:79598:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1951/06/01 00:00,1951/06/01 00:01,['1951/06/01 00:00'],"['1951/06/01 00:00 [pubmed]', '1951/06/01 00:01 [medline]', '1951/06/01 00:00 [entrez]']",ppublish,Acta Haematol. 1951 Jun;5(6):345-59. doi: 10.1159/000203843.,['10.1159/000203843 [doi]'],,,,,,,,,,,,,
14845538,NLM,MEDLINE,20040215,20181201,0035-6077 (Print) 0035-6077 (Linking),49,3,1951 Mar,[Case of lymphatic leukemia in a pair of dichorial twins (false twins)].,161-70,"['BIEBER, A']",['BIEBER A'],['und'],['Journal Article'],Sopra un caso di emopatia (leucemia linfatica) in una coppia di gemelli bicori (falsi gemelli).,Italy,Riv Clin Pediatr,Rivista di clinica pediatrica,0404503,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Twins', '*Twins, Dizygotic']",['CLML: 5120:78541:410:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*TWINS']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Riv Clin Pediatr. 1951 Mar;49(3):161-70.,,,,,,,,,,,,,,
14845520,NLM,MEDLINE,20040215,20181201,0035-5259 (Print) 0035-5259 (Linking),65,8,1951 Feb 24,[Polyphasic myelosis; so-called refractory pernicious anemia; myelosis erythremic; hemocytoblastemis].,210-5,"['QUATTRIN, N']",['QUATTRIN N'],['und'],['Journal Article'],Mielosi polifasica anemia perniciosa cosidetta refrattaria; mielosi eritremica; emocitoblastemia.,Italy,Riforma Med,La Riforma medica,0404345,,OM,"['*Anemia, Pernicious', 'Humans', '*Leukemia, Erythroblastic, Acute', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid']",['CLML: 5120:78523:68'],['NLM'],"['*MYELOSIS, ERYTHREMIC']",1951/02/24 00:00,1951/02/24 00:01,['1951/02/24 00:00'],"['1951/02/24 00:00 [pubmed]', '1951/02/24 00:01 [medline]', '1951/02/24 00:00 [entrez]']",ppublish,Riforma Med. 1951 Feb 24;65(8):210-5.,,,,,,,,,,,,,,
14845189,NLM,MEDLINE,20040215,20181201,0370-4386 (Print) 0370-4386 (Linking),6,2,1951,[Primary carcinoma of the liver in myelogenous leukemia treated with urethane].,148-56,"['EVANS, T S', 'WATERS, L', 'HARDIN, B', 'MATOSSIAN, N', 'GOLTRA, E', 'DE LUCA, V']","['EVANS TS', 'WATERS L', 'HARDIN B', 'MATOSSIAN N', 'GOLTRA E', 'DE LUCA V']",['und'],['Journal Article'],"Carcinome primitif du foie, apparu chez un sujet atteint de leucemie myeloide traitee par l'urethane.",France,Rev Hematol,Revue d'hematologie,20330240R,['3IN71E75Z5 (Urethane)'],OM,"['*Carcinoma', '*Leukemia', '*Leukemia, Myeloid', '*Liver Neoplasms', '*Urethane']",['CLML: 5120:78182:173:417:547:560'],['NLM'],"['*CARCINOMA', '*LEUKEMIA, MYELOGENOUS', '*LIVER NEOPLASMS', '*URETHANE']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Rev Hematol. 1951;6(2):148-56.,,,,,,,,,,,,,,
14845080,NLM,MEDLINE,20040215,20181201,,61,12,1950 Dec,[Plasma-cell leukemia; case report].,796-804,"['BIDOT PERALTA, C']",['BIDOT PERALTA C'],['und'],['Journal Article'],Leucemia a celulas plasmaticas; (reporte de un caso).,Cuba,Rev Med Cubana,Revista medica cubana,20240100R,,OM,"['Humans', '*Leukemia', '*Leukemia, Plasma Cell']",['CLML: 5120:78063:546'],['NLM'],['*LEUKEMIA'],1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Rev Med Cubana. 1950 Dec;61(12):796-804.,,,,,,,,,,,,,,
14844964,NLM,MEDLINE,20040215,20181201,0034-9143 (Print),43,3,1951 Mar,[Changes in the dental pulp in leucemia].,98-100,"['BEHN, F', 'VIVALDI de MUNOZ, L']","['BEHN F', 'VIVALDI de MUNOZ L']",['spa'],['Journal Article'],Alteraciones de la pulpa dentaria en las leucemias.,Chile,Rev Dent Chile,Revista dental de Chile,0407205,,OM,"['*Dental Pulp', 'Humans', '*Leukemia']",['CLML: 5120:77947:254:546'],['NLM'],"['*DENTAL PULP', '*LEUKEMIA']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Rev Dent Chile. 1951 Mar;43(3):98-100.,,,,,,,,,,,,,,
14844922,NLM,MEDLINE,20040215,20181201,0014-2565 (Print) 0014-2565 (Linking),40,2,1951 Jan 31,[Chronic myelogenous leukemia in a girl].,124-5,"['PALACIOS', 'MINON, R']","['PALACIOS', 'MINON R']",['und'],['Journal Article'],Leucumia mieloide cronica en una nina.,Spain,Rev Clin Esp,Revista clinica espanola,8608576,,OM,"['Female', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid']",['CLML: 5120:77905:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1951/01/31 00:00,1951/01/31 00:01,['1951/01/31 00:00'],"['1951/01/31 00:00 [pubmed]', '1951/01/31 00:01 [medline]', '1951/01/31 00:00 [entrez]']",ppublish,Rev Clin Esp. 1951 Jan 31;40(2):124-5.,,,,,,,,,,,,,,
14844913,NLM,MEDLINE,20040215,20181201,0014-2565 (Print) 0014-2565 (Linking),40,2,1951 Jan 31,[Leukemias in old age].,93-7,"['FARRERAS VALENTI, P']",['FARRERAS VALENTI P'],['und'],['Journal Article'],Las leucemias en la vejez.,Spain,Rev Clin Esp,Revista clinica espanola,8608576,,OM,"['Aged', 'Humans', '*Leukemia']",['CLML: 5120:77896:18:546'],['NLM'],"['*AGED', '*LEUKEMIA']",1951/01/31 00:00,1951/01/31 00:01,['1951/01/31 00:00'],"['1951/01/31 00:00 [pubmed]', '1951/01/31 00:01 [medline]', '1951/01/31 00:00 [entrez]']",ppublish,Rev Clin Esp. 1951 Jan 31;40(2):93-7.,,,,,,,,,,,,,,
14844717,NLM,MEDLINE,20040215,20181201,0033-9695 (Print) 0033-9695 (Linking),31,2,1951 Jan 31,[Leukemic aspects of transplantable fowl lymphosarcoma].,33-9,"['LA MANNA, N']",['LA MANNA N'],['und'],['Journal Article'],Aspetti leucemici del linfosarcoma trapiantabile del pollo.,Italy,Rass Int Clin Ter,Rassegna internazionale di clinica e terapia,0401266,,OM,"['Humans', '*Leukemia', '*Lymphoma', '*Lymphoma, Non-Hodgkin', '*Sarcoma']",['CLML: 5120:77700:267:546'],['NLM'],"['*LEUKEMIA', '*SARCOMA, LYMPHOSARCOMA']",1951/01/31 00:00,1951/01/31 00:01,['1951/01/31 00:00'],"['1951/01/31 00:00 [pubmed]', '1951/01/31 00:01 [medline]', '1951/01/31 00:00 [entrez]']",ppublish,Rass Int Clin Ter. 1951 Jan 31;31(2):33-9.,,,,,,,,,,,,,,
14844709,NLM,MEDLINE,20040215,20181201,0370-4165 (Print) 0370-4165 (Linking),27,3,1951 Mar,[Constitutional hemolytic anemia and anemia of hemolytic character from reticuloendotheliosis].,72-7,"['GASBARRINI, A']",['GASBARRINI A'],['und'],['Journal Article'],Anemia emolitica costituzionale ed anemia a carattere emolitico da reticolo endoteliosi.,Italy,Rass Clin Sci,Rassegna clinico-scientifica,0422562,"['Reticuloendotheliosis, X-linked']",OM,"['*Anemia', '*Anemia, Hemolytic', '*Genetic Diseases, X-Linked', 'Humans', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5120:77692:39:232'],['NLM'],"['*ANEMIA, HEMOLYTIC', '*RETICULOENDOTHELIOSIS']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Rass Clin Sci. 1951 Mar;27(3):72-7.,,,,,,,,,,,,,,
14844500,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),7,8,1951 Apr 30,[Experimental study on leukemia; existence of a filtrable virus].,228-30,"['PETZETAKIS, M']",['PETZETAKIS M'],['und'],['Journal Article'],Studi sperimentali sulle leucemie; sull'esistenza di un virus filtrabile.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,,OM,"['*Filtration', '*Leukemia', '*Viruses']",['CLML: 5120:77476:439:546'],['NLM'],"['*LEUKEMIA', '*VIRUSES']",1951/04/30 00:00,1951/04/30 00:01,['1951/04/30 00:00'],"['1951/04/30 00:00 [pubmed]', '1951/04/30 00:01 [medline]', '1951/04/30 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1951 Apr 30;7(8):228-30.,,,,,,,,,,,,,,
14844498,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),7,8,1951 Apr 30,[Multiple successive and simultaneous treatment in a case of chronic myeloid leukemia].,217,"['CAPPELLO, F']",['CAPPELLO F'],['und'],['Journal Article'],Trattamento multiplo successivo e trattamento multiplo simultaneo in un caso di leucemia mieloide cronica.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,"['0 (Chloramines)', '3IN71E75Z5 (Urethane)', '50D9XSG0VR (Mechlorethamine)', 'KW8K411A1P (chloramine)']",OM,"['*Chloramines', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Mechlorethamine', '*Urethane', '*X-Ray Therapy']",['CLML: 5120:77474:199:248:417:547'],['NLM'],"['*CHLORAMINE', '*LEUKEMIA, MYELOGENOUS', '*ROENTGENOTHERAPY', '*URETHANE']",1951/04/30 00:00,1951/04/30 00:01,['1951/04/30 00:00'],"['1951/04/30 00:00 [pubmed]', '1951/04/30 00:01 [medline]', '1951/04/30 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1951 Apr 30;7(8):217.,,,,,,,,,,,,,,
14844493,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),7,7,1951 Apr 15,[Morphological and experimental research on the pathogenesis of acute myelogenous leukemia; experimental transmission of acute human myelosis].,193-5,['MAS y MAGRO'],['MAS y MAGRO'],['und'],['Journal Article'],Ricerche morfologiche e sperimentali sulla patogenesi della leucemia mieloide acuta. I. La trasmissione sperimentale della mielosi acuta umana.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Myeloid, Acute', '*Leukemia, Myelomonocytic, Acute']",['CLML: 5120:77469:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1951/04/15 00:00,1951/04/15 00:01,['1951/04/15 00:00'],"['1951/04/15 00:00 [pubmed]', '1951/04/15 00:01 [medline]', '1951/04/15 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1951 Apr 15;7(7):193-5.,,,,,,,,,,,,,,
14844486,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),7,6,1951 Mar 31,[Unusual observation of histiocytic leukemia].,163-5,"['MONASTERIO, G', 'GIGLI, G', 'LAMI, G']","['MONASTERIO G', 'GIGLI G', 'LAMI G']",['und'],['Journal Article'],Sopra una singolare osservazione di istio-leucemia.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,['WCK1KIQ23Q (Chlortetracycline)'],OM,"['*Chlortetracycline', 'Humans', '*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid', '*Monocytes']",['CLML: 5120:77462:70:547'],['NLM'],"['*AUREOMYCIN', '*LEUKEMIA, MONOCYTIC']",1951/03/31 00:00,1951/03/31 00:01,['1951/03/31 00:00'],"['1951/03/31 00:00 [pubmed]', '1951/03/31 00:01 [medline]', '1951/03/31 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1951 Mar 31;7(6):163-5.,,,,,,,,,,,,,,
14844477,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),7,3,1951 Feb 15,[Folic acid antagonists in the treatment of acute leukemia].,79-86,"['MAUREA, C', 'BISSANTI, A']","['MAUREA C', 'BISSANTI A']",['und'],['Journal Article'],Gli antifolici nella terapia delle leucemie acute.,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,['0 (Folic Acid Antagonists)'],OM,"['*Acute Disease', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:77453:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/02/15 00:00,1951/02/15 00:01,['1951/02/15 00:00'],"['1951/02/15 00:00 [pubmed]', '1951/02/15 00:01 [medline]', '1951/02/15 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1951 Feb 15;7(3):79-86.,,,,,,,,,,,,,,
14844202,NLM,MEDLINE,20040215,20181201,0091-746X (Print) 0091-746X (Linking),18,14,1951 May 15,The effect of therapy on the life history and biologic behavior of leukemia.,311-25,"['FARBER, S']",['FARBER S'],['eng'],['Journal Article'],,United States,Proc Inst Med Chic,The Proceedings of the Institute of Medicine of Chicago,7505869,['0 (Biological Products)'],OM,"['*Biological Products', 'Humans', '*Leukemia']",['CLML: 5120:77178:546'],['NLM'],['*LEUKEMIA'],1951/05/15 00:00,1951/05/15 00:01,['1951/05/15 00:00'],"['1951/05/15 00:00 [pubmed]', '1951/05/15 00:01 [medline]', '1951/05/15 00:00 [entrez]']",ppublish,Proc Inst Med Chic. 1951 May 15;18(14):311-25.,,,,,,,,,,,,,,
14844138,NLM,MEDLINE,20040215,20181201,0032-7867 (Print) 0032-7867 (Linking),59,23,1951 Apr 7,[Association of leukemia with polycythemia vera].,461-3,"['DE BACKER, J', 'LAWRENCE, J H']","['DE BACKER J', 'LAWRENCE JH']",['und'],['Journal Article'],L'association de la leucemie a la polycythemie vraie.,France,Presse Med,La Presse medicale,0312556,,OM,"['*Leukemia', '*Leukemia, Myeloid', '*Polycythemia Vera']",['CLML: 5120:77114:177:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*POLYCYTHEMIA VERA']",1951/04/07 00:00,1951/04/07 00:01,['1951/04/07 00:00'],"['1951/04/07 00:00 [pubmed]', '1951/04/07 00:01 [medline]', '1951/04/07 00:00 [entrez]']",ppublish,Presse Med. 1951 Apr 7;59(23):461-3.,,,,,,,,,,,,,,
14844011,NLM,MEDLINE,20040215,20181201,0369-8394 (Print) 0369-8394 (Linking),40,21,1951 May 24,"[Clinical use of cytophylaxis, a biological therapeutic method].",443-5,"['DUBOIS-FERRIERE, H']",['DUBOIS-FERRIERE H'],['und'],['Journal Article'],"Quelques applications cliniques de la cytophylaxie, methode biologique de traitement.",Switzerland,Praxis,Praxis,0401230,,OM,"['*Ion Exchange', '*Leukemia']",['CLML: 5120:76987:485:546'],['NLM'],"['*ION TRANSFER', '*LEUKEMIA']",1951/05/24 00:00,1951/05/24 00:01,['1951/05/24 00:00'],"['1951/05/24 00:00 [pubmed]', '1951/05/24 00:01 [medline]', '1951/05/24 00:00 [entrez]']",ppublish,Praxis. 1951 May 24;40(21):443-5.,,,,,,,,,,,,,,
14843990,NLM,MEDLINE,20040215,20181201,0369-8394 (Print) 0369-8394 (Linking),40,16,1951 Apr 19,"[Effect of cortisone, triethylene melamine and oligo-elements in a case of acute leukemia in a child].",327-30,"['BOVET-DU BOIS, N', 'DUBOIS-FERRIERE, H', 'BLANC, W', 'VOGT, A']","['BOVET-DU BOIS N', 'DUBOIS-FERRIERE H', 'BLANC W', 'VOGT A']",['und'],['Journal Article'],"Action de la cortisone, du triethylene melamine et des oligo-elements dans un cas de leucemie aigue chez l'enfant.",Switzerland,Praxis,Praxis,0401230,"['0 (Adenine Nucleotides)', '0 (Oligoribonucleotides)', ""61172-40-5 (2',5'-oligoadenylate)"", '9002-60-2 (Adrenocorticotropic Hormone)', 'F7IY6HZG9D (Triethylenemelamine)', 'V27W9254FZ (Cortisone)']",OM,"['*Adenine Nucleotides', '*Adrenocorticotropic Hormone', '*Cortisone', '*Leukemia', '*Oligoribonucleotides', '*Triethylenemelamine']",['CLML: 5120:76966:8:545'],['NLM'],"['*ACTH', '*LEUKEMIA']",1951/04/19 00:00,1951/04/19 00:01,['1951/04/19 00:00'],"['1951/04/19 00:00 [pubmed]', '1951/04/19 00:01 [medline]', '1951/04/19 00:00 [entrez]']",ppublish,Praxis. 1951 Apr 19;40(16):327-30.,,,,,,,,,,,,,,
14843687,NLM,MEDLINE,20040215,20190214,0029-6643 (Print) 0029-6643 (Linking),9,5,1951 May,FOLACIN antagonists in the treatment of acute leukemia.,143-5,,,['eng'],['Journal Article'],,United States,Nutr Rev,Nutrition reviews,0376405,"['0 (Folic Acid Antagonists)', '935E97BOY8 (Folic Acid)']",OM,"['*Folic Acid', '*Folic Acid Antagonists', 'Humans', '*Leukemia']",['CLML: 5120:76650:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Nutr Rev. 1951 May;9(5):143-5. doi: 10.1111/j.1753-4887.1951.tb02599.x.,['10.1111/j.1753-4887.1951.tb02599.x [doi]'],,,,,,,,,,,,,
14843209,NLM,MEDLINE,20040215,20181201,0028-1956 (Print) 0028-1956 (Linking),36,6,1951 Jun,Treatment of leukemia.,203-9,"['REED, E B']",['REED EB'],['eng'],['Journal Article'],,United States,Nebr State Med J,The Nebraska state medical journal,0326157,,OM,"['*Blood Transfusion', '*Leukemia']",['CLML: 5120:76172:123:546'],['NLM'],"['*BLOOD TRANSFUSION', '*LEUKEMIA']",1951/06/01 00:00,1951/06/01 00:01,['1951/06/01 00:00'],"['1951/06/01 00:00 [pubmed]', '1951/06/01 00:01 [medline]', '1951/06/01 00:00 [entrez]']",ppublish,Nebr State Med J. 1951 Jun;36(6):203-9.,,,,,,,,,,,,,,
14842889,NLM,MEDLINE,20040215,20181201,0026-4806 (Print) 0026-4806 (Linking),42,18,1951 Apr 7,[Acute leukemia and non-myelogenous preliminary stage and remission; terminal cerebellar hemorrhage].,594-8,"['SCHIAVINA, M']",['SCHIAVINA M'],['und'],['Journal Article'],Leucemia acuta e prestadio amielico e remissione; emorragia cerebellare terminale.,Italy,Minerva Med,Minerva medica,0400732,,OM,"['*Acute Disease', '*Cerebellum', 'Humans', '*Leukemia']",['CLML: 5120:75852:187:546'],['NLM'],"['*CEREBELLUM', '*LEUKEMIA']",1951/04/07 00:00,1951/04/07 00:01,['1951/04/07 00:00'],"['1951/04/07 00:00 [pubmed]', '1951/04/07 00:01 [medline]', '1951/04/07 00:00 [entrez]']",ppublish,Minerva Med. 1951 Apr 7;42(18):594-8.,,,,,,,,,,,,,,
14842856,NLM,MEDLINE,20040215,20181201,0026-4806 (Print) 0026-4806 (Linking),42,12,1951 Mar 3,[Reservations on the analogy between the various leukemic diseases and their cumulative inclusion in the chapter of neoplasms].,370-3,"['FERRARI, E']",['FERRARI E'],['und'],['Journal Article'],Riserve sull'analogia tra le varie affezioni leucemiche e sul loro cumulative incasellamento nel capitolo dei neoplasmi.,Italy,Minerva Med,Minerva medica,0400732,,OM,"['Humans', '*Leukemia', '*Neoplasms']",['CLML: 5120:75819:546'],['NLM'],['*LEUKEMIA'],1951/03/03 00:00,1951/03/03 00:01,['1951/03/03 00:00'],"['1951/03/03 00:00 [pubmed]', '1951/03/03 00:01 [medline]', '1951/03/03 00:00 [entrez]']",ppublish,Minerva Med. 1951 Mar 3;42(12):370-3.,,,,,,,,,,,,,,
14842432,NLM,MEDLINE,20040215,20181201,0025-7842 (Print) 0025-7842 (Linking),25,143,1951 Feb,[Myelogenous leukemia without splenomegaly].,125-8,"['GUILLEN, J A', 'BALLESTER, A D']","['GUILLEN JA', 'BALLESTER AD']",['und'],['Journal Article'],Leucemia mieloide sin esplenomegalia.,Spain,Med Esp,Medicina espanola,2985243R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Splenomegaly']",['CLML: 5120:75390:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,Med Esp. 1951 Feb;25(143):125-8.,,,,,,,,,,,,,,
14841727,NLM,MEDLINE,20040215,20181201,0368-394X (Print) 0368-394X (Linking),32,1-2,1951,[Stem-cell leukemia].,119-20,"['BRU', 'POUTANSANT', 'PLANEL']","['BRU', 'POUTANSANT', 'PLANEL']",['und'],['Journal Article'],Un cas de leucemie chronique a cellules souches.,France,J Radiol Electrol Arch Electr Medicale,"Journal de radiologie, d'electrologie & archives d'electricite medicale",0013747,,OM,"['*Acute Disease', 'Humans', '*Leukemia', '*Leukemia, Myeloid, Acute']",['CLML: 5120:74683:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,J Radiol Electrol Arch Electr Medicale. 1951;32(1-2):119-20.,,,,,,,,,,,,,,
14841523,NLM,MEDLINE,20040215,20181201,0027-8874 (Print) 0027-8874 (Linking),11,4,1951 Feb,Observations on properties of leukemic cells resistant to folic acid antagonists.,849-65,"['LAW, L W', 'BOYLE, P J']","['LAW LW', 'BOYLE PJ']",['eng'],['Journal Article'],,United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,['0 (Folic Acid Antagonists)'],OM,"['*Folic Acid Antagonists', '*Leukemia', '*Leukemia, Lymphoid']",['CLML: 5120:74474:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA, LYMPHATIC']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,J Natl Cancer Inst. 1951 Feb;11(4):849-65.,,,,,,,,,,,,,,
14841063,NLM,MEDLINE,20040215,20190729,0002-9955 (Print) 0002-9955 (Linking),146,11,1951 Jul 14,Jaundice in acute subleukemic lymphocytic leukemia due to obstruction of the common duct by portal nodes.,987-8,"['BOWER, J S', 'COCA-MIR, R']","['BOWER JS', 'COCA-MIR R']",['eng'],['Journal Article'],,United States,J Am Med Assoc,Journal of the American Medical Association,7507176,,OM,"['*Bile Ducts', 'Humans', '*Jaundice', '*Jaundice, Obstructive', '*Leukemia', '*Leukemia, Lymphoid', '*Lymph Nodes']",['CLML: 5120:74014:101:492:546:573'],['NLM'],"['*BILE DUCTS', '*JAUNDICE, OBSTRUCTIVE', '*LEUKEMIA', '*LYMPH NODES']",1951/07/14 00:00,1951/07/14 00:01,['1951/07/14 00:00'],"['1951/07/14 00:00 [pubmed]', '1951/07/14 00:01 [medline]', '1951/07/14 00:00 [entrez]']",ppublish,J Am Med Assoc. 1951 Jul 14;146(11):987-8. doi: 10.1001/jama.1951.03670110007002.,['10.1001/jama.1951.03670110007002 [doi]'],,,,,,,,,,,,,
14840637,NLM,MEDLINE,20040215,20181201,0016-6456 (Print) 0016-6456 (Linking),44,12,1951,[Systemic diseases].,355-400,"['DEENSTRA, H', 'BUIJS, H']","['DEENSTRA H', 'BUIJS H']",['und'],['Journal Article'],Over systeemziekten.,Netherlands,Geneeskd Bl,Geneeskundige bladen uit kliniek en laboratorium voor de praktijk,0370734,,OM,"['Humans', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Lymphatic System', '*Mononuclear Phagocyte System', '*Primary Myelofibrosis']",['CLML: 5120:73550:68:232:573'],['NLM'],"['*LYMPHATIC SYSTEM', '*MYELOSIS', '*RETICULOENDOTHELIAL SYSTEM']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Geneeskd Bl. 1951;44(12):355-400.,,,,,,,,,,,,,,
14839618,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,3,1951 May,"The effect of radioactive colloidal metallic gold in the treatment of ""acute"" AK-4 leukemia in mice.",634-6,"['HAHN, P F', 'SKIPPER, H E', 'CAROTHERS, E L', 'BERNARD, L J']","['HAHN PF', 'SKIPPER HE', 'CAROTHERS EL', 'BERNARD LJ']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,['0 (Gold Radioisotopes)'],OM,"['*Acute Disease', 'Animals', '*Gold Radioisotopes', '*Leukemia', 'Mice']",['CLML: 5120:72507:388:546'],['NLM'],"['*GOLD, RADIOACTIVE', '*LEUKEMIA']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Cancer. 1951 May;4(3):634-6. doi: 10.1002/1097-0142(195105)4:3<634::aid-cncr2820040315>3.0.co;2-3.,['10.1002/1097-0142(195105)4:3<634::aid-cncr2820040315>3.0.co;2-3 [doi]'],,,,,,,,,,,,,
14839617,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,3,1951 May,"The ""vertical"" transmission of mouse mammary carcinoma and chicken leukemia; its possible implications for human pathology.",626-33,"['GROSS, L']",['GROSS L'],['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,,OM,"['Animals', '*Breast', '*Breast Neoplasms', '*Carcinoma', '*Chickens', 'Humans', '*Leukemia', 'Mice']",['CLML: 5120:72506:174:546'],['NLM'],"['*CARCINOMA', '*LEUKEMIA']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Cancer. 1951 May;4(3):626-33. doi: 10.1002/1097-0142(195105)4:3<626::aid-cncr2820040314>3.0.co;2-1.,['10.1002/1097-0142(195105)4:3<626::aid-cncr2820040314>3.0.co;2-1 [doi]'],,,,,,,,,,,,,
14839612,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,3,1951 May,Blood histamine in myelogenous leukemia.,570-8,"['SHIMKIN, M B', 'BIERMAN, H R', 'LOWBEER, B V A', 'WHEELER, P M', 'GOETZL, F R']","['SHIMKIN MB', 'BIERMAN HR', 'LOWBEER BV', 'WHEELER PM', 'GOETZL FR']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,['820484N8I3 (Histamine)'],OM,"['*Blood', '*Histamine', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:72501:111:440:547'],['NLM'],"['*BLOOD', '*HISTAMINE', '*LEUKEMIA, MYELOGENOUS']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Cancer. 1951 May;4(3):570-8. doi: 10.1002/1097-0142(195105)4:3<570::aid-cncr2820040309>3.0.co;2-3.,['10.1002/1097-0142(195105)4:3<570::aid-cncr2820040309>3.0.co;2-3 [doi]'],,,,,,,,,,,,,
14839611,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,3,1951 May,"The effects of the folic acid antagonists and 2,6-diaminopurine on neoplastic disease, with special reference to acute leukemia.",549-69,"['BURCHENAL, J H', 'KARNOFSKY, D A', 'KINGSLEY-PILLERS, E M', 'SOUTHAM, C M', 'MYERS, W P L', 'ESCHER, G C', 'CRAVER, L F', 'DARGEON, H W', 'RHOADS, C P']","['BURCHENAL JH', 'KARNOFSKY DA', 'KINGSLEY-PILLERS EM', 'SOUTHAM CM', 'MYERS WP', 'ESCHER GC', 'CRAVER LF', 'DARGEON HW', 'RHOADS CP']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Folic Acid Antagonists)', '0 (Purines)', '452-06-2 (2-Aminopurine)', '49P95BAU4Z (2,6-diaminopurine)', 'W60KTZ3IZY (purine)']",OM,"['2-Aminopurine/analogs & derivatives', '*Folic Acid Antagonists', '*Leukemia', '*Neoplasms', '*Purines']",['CLML: 5120:72500:209:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA', '*PURINES']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Cancer. 1951 May;4(3):549-69. doi: 10.1002/1097-0142(195105)4:3<549::aid-cncr2820040308>3.0.co;2-j.,['10.1002/1097-0142(195105)4:3<549::aid-cncr2820040308>3.0.co;2-j [doi]'],,,,,,,,,,,,,
14839289,NLM,MEDLINE,20040215,20190501,0007-1447 (Print) 0007-1447 (Linking),1,4720,1951 Jun 23,Aleukaemic myeloid leukaemia presenting as aplastic anaemia.,1430-1,"['BLACK, A B', 'MEYNELL, M J']","['BLACK AB', 'MEYNELL MJ']",['eng'],['Journal Article'],,England,Br Med J,British medical journal,0372673,,OM,"['*Anemia', '*Anemia, Aplastic', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:72138:38:547'],['NLM'],"['*ANEMIA, APLASTIC', '*LEUKEMIA, MYELOGENOUS']",1951/06/23 00:00,1951/06/23 00:01,['1951/06/23 00:00'],"['1951/06/23 00:00 [pubmed]', '1951/06/23 00:01 [medline]', '1951/06/23 00:00 [entrez]']",ppublish,Br Med J. 1951 Jun 23;1(4720):1430-1. doi: 10.1136/bmj.1.4720.1430.,['10.1136/bmj.1.4720.1430 [doi]'],PMC2069473,,,,,,,,,,,,
14839100,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),26,11-12,1950 Nov-Dec,[Research on blood coagulation in roentgenotherapy of leukemia. III. Action of irradiated leukemic plasma on plasma coagulation in normal and hemophilic subjects].,1550-1,"['TROPEANO, L', 'DI GUGLIELMO, L']","['TROPEANO L', 'DI GUGLIELMO L']",['und'],['Journal Article'],Ricerche sulla coagulazione del sangue nei leucemici sottoposti a roentgenterapia. III. Azione del plasma di leucemici irradiati sulla coagulazione del plasma di soggetti normali ed emofilici.,Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,,OM,"['*Blood Coagulation', '*Hemophilia A', 'Humans', '*Leukemia', '*Plasma', '*Research', '*X-Ray Therapy']",['CLML: 5120:71949:115:428:546'],['NLM'],"['*BLOOD COAGULATION', '*HEMOPHILIA', '*LEUKEMIA']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1950 Nov-Dec;26(11-12):1550-1.,,,,,,,,,,,,,,
14839099,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),26,11-12,1950 Nov-Dec,"[Research on blood coagulation in roentgenotherapy of leukemia. II. Coagulation of recalcified plasma after centrifugation at various velocities, according to Quick].",1548-9,"['DI GUGLIELMO, L', 'TROPEANO, L']","['DI GUGLIELMO L', 'TROPEANO L']",['und'],['Journal Article'],"Ricerche sulla coagulazione del sangue nei leucemici sottoposti a roentgenterapia. II. Coagulazione del plasma ricalcificato dopo centrifugazione del plasma ricalcificato dopo centrifugazione a differenti velocita, secondo Quick.",Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,,OM,"['*Blood Coagulation', '*Centrifugation', 'Humans', '*Leukemia', '*Plasma', '*X-Ray Therapy']",['CLML: 5120:71948:115:546'],['NLM'],"['*BLOOD COAGULATION', '*LEUKEMIA']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1950 Nov-Dec;26(11-12):1548-9.,,,,,,,,,,,,,,
14839098,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),26,11-12,1950 Nov-Dec,[Research on blood coagulation in roentgenotherapy of leukemia. I. Behavior of total blood coagulation].,1546-8,"['TROPEANO, L', 'DI GUGLIELMO, L']","['TROPEANO L', 'DI GUGLIELMO L']",['und'],['Journal Article'],Ricerche sulla coagulazione del sangue nei leucemici sottoposti a roentgenterapia. I. Comportamento della coagulazione del sangue totale.,Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,,OM,"['*Blood Coagulation', 'Humans', '*Leukemia', '*Research', '*X-Ray Therapy']",['CLML: 5120:71947:115:546'],['NLM'],"['*BLOOD COAGULATION', '*LEUKEMIA']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1950 Nov-Dec;26(11-12):1546-8.,,,,,,,,,,,,,,
14838961,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),6,6,1951 Jun,The effects of triethylene melamine and related compounds on the leukocytes of mouse leukemia.,504-12,"['BURCHENAL, J H', 'WEBBER, L F', 'BIEDLER, J L', 'MEIGS, G M', 'STOBBE, G D']","['BURCHENAL JH', 'WEBBER LF', 'BIEDLER JL', 'MEIGS GM', 'STOBBE GD']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,"['0 (Triazines)', 'F7IY6HZG9D (Triethylenemelamine)', 'N3GP2YSD88 (melamine)']",OM,"['*Leukemia', '*Leukocytes', '*Triazines', '*Triethylenemelamine']",['CLML: 5120:71800:27:546'],['NLM'],"['*LEUKEMIA', '*MELAMINE']",1951/06/01 00:00,1951/06/01 00:01,['1951/06/01 00:00'],"['1951/06/01 00:00 [pubmed]', '1951/06/01 00:01 [medline]', '1951/06/01 00:00 [entrez]']",ppublish,Blood. 1951 Jun;6(6):504-12.,['S0006-4971(20)68234-9 [pii]'],,,,,,,,,,,,,
14838740,NLM,MEDLINE,20040215,20181201,,3,2,1951 Mar-Apr,[Concepts on erythremic diseases; case report on erythroleukemia].,279-92,"['BARQUET CHEDIAK, A']",['BARQUET CHEDIAK A'],['und'],['Journal Article'],Conceptos sobre enfermedades eritremicas; presentacion de un caso de eritroleucemia.,Cuba,Arch Hosp Univ,Archivos. Hospital Universitario General Calixto Garcia,17240430R,,OM,"['Humans', '*Leukemia', '*Leukemia, Erythroblastic, Acute', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Polycythemia Vera']",['CLML: 5120:71571:68:546'],['NLM'],"['*LEUKEMIA', '*MYELOSIS, ERYTHREMIC']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Arch Hosp Univ. 1951 Mar-Apr;3(2):279-92.,,,,,,,,,,,,,,
14837960,NLM,MEDLINE,20040215,20181201,0002-936X (Print) 0002-936X (Linking),51,6,1951 Jun,Chronic lymphatic leukemia; a nursing care study.,345-6,"['YURA, H']",['YURA H'],['eng'],['Journal Article'],,United States,Am J Nurs,The American journal of nursing,0372646,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', '*Leukemia, Lymphoid', '*Nursing']",['CLML: 5120:70752:93:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*NURSING']",1951/06/01 00:00,1951/06/01 00:01,['1951/06/01 00:00'],"['1951/06/01 00:00 [pubmed]', '1951/06/01 00:01 [medline]', '1951/06/01 00:00 [entrez]']",ppublish,Am J Nurs. 1951 Jun;51(6):345-6.,,,,,,,,,,,,,,
14837805,NLM,MEDLINE,20040215,20181201,0365-3056 (Print) 0365-3056 (Linking),7,2,1951,[Adaptation of the virus of avian leukosis to the chick embryo].,213-5,"['ATANASIU, P', 'VIEUCHANGE, J', 'STRUNGE, B']","['ATANASIU P', 'VIEUCHANGE J', 'STRUNGE B']",['und'],['Journal Article'],Adaptation du virus de la leucose aviaire a l'embryon de poulet.,Belgium,Acta Unio Int Contra Cancrum,Acta - Unio Internationalis Contra Cancrum,7502506,,OM,"['*Acclimatization', 'Animals', '*Avian Leukosis', '*Bird Diseases', '*Birds', 'Chick Embryo', '*Leukemia']",['CLML: 5120:70587:546'],['NLM'],"['*LEUKEMIA, AVIAN']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Unio Int Contra Cancrum. 1951;7(2):213-5.,,,,,,,,,,,,,,
14837789,NLM,MEDLINE,20040215,20181201,,5,1-2,1951 Apr,Two cases of lymhatic leukemia and cancer.,40-4,"['SVEJDA, J', 'SVOBODA, K', 'MRKOS, D', 'KOSTELNIK, K']","['SVEJDA J', 'SVOBODA K', 'MRKOS D', 'KOSTELNIK K']",['eng'],['Journal Article'],,Czech Republic,Acta Radiol Cancerol,Acta radiologica et cancerologica. Bohemoslovencia,14610230R,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels', '*Neoplasms']",['CLML: 5120:70571:164:546'],['NLM'],"['*CANCER', '*LEUKEMIA, LYMPHATIC']",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,Acta Radiol Cancerol. 1951 Apr;5(1-2):40-4.,,,,,,,,,,,,,,
14837705,NLM,MEDLINE,20040215,20181201,0365-463X (Print) 0365-463X (Linking),252,,1951,Red cell survival studies in normal and leukaemic subjects.,1-141,"['BERLIN, R']",['BERLIN R'],['eng'],['Journal Article'],,Sweden,Acta Med Scand Suppl,Acta medica Scandinavica. Supplementum,0370331,,OM,"['*Cell Survival', '*Erythrocyte Aging', '*Erythrocytes', 'Humans', '*Leukemia']",['CLML: 5120:70485:316:546'],['NLM'],"['*ERYTHROCYTES', '*LEUKEMIA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Med Scand Suppl. 1951;252:1-141.,,,,,,,,,,,,,,
14837680,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),5,5,1951 May,SUMMARY o papers on leukaemia and allied conditions.,307-11,,,['eng'],['Journal Article'],,Switzerland,Acta Haematol,Acta haematologica,0141053,,OM,"['Humans', '*Leukemia']",['CLML: 5120:70460:546'],['NLM'],['*LEUKEMIA'],1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Acta Haematol. 1951 May;5(5):307-11.,,,,,,,,,,,,,,
14837608,NLM,MEDLINE,20040215,20181201,,66,1,1951 Jan,[New experiments in the treatment of leukemia].,1-2,"['INTROZZI, P']",['INTROZZI P'],['und'],['Journal Article'],Nuovi tentativi di cura delle leucemie.,Italy,Accad Medica,Accademia medica,14510510R,,OM,"['Humans', '*Leukemia']",['CLML: 5120:70387:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Accad Medica. 1951 Jan;66(1):1-2.,,,,,,,,,,,,,,
14837503,NLM,MEDLINE,20040215,20181201,0096-5979 (Print) 0096-5979 (Linking),64,1,1951 Jul,Leukemia cutis?,70-1,"['TWINING, H E']",['TWINING HE'],['eng'],['Journal Article'],,United States,AMA Arch Derm Syphilol,A.M.A. archives of dermatology and syphilology,14470040R,,OM,"['Humans', '*Leukemia', '*Skin Diseases', '*Skin Neoplasms']",['CLML: 5120:70282:258'],['NLM'],['*DERMATOSES'],1951/07/01 00:00,1951/07/01 00:01,['1951/07/01 00:00'],"['1951/07/01 00:00 [pubmed]', '1951/07/01 00:01 [medline]', '1951/07/01 00:00 [entrez]']",ppublish,AMA Arch Derm Syphilol. 1951 Jul;64(1):70-1.,,,,,,,,,,,,,,
14836973,NLM,MEDLINE,20040215,20181201,0044-2844 (Print) 0044-2844 (Linking),10,10,1951 May 15,[On so-called reticulosarcomatosis of the skin].,391-2,['GOTTRON'],['GOTTRON'],['und'],['Journal Article'],Sogenannte Reticulosarkomatose der Haut.,Germany,Z Haut Geschlechtskr,Zeitschrift fur Haut- und Geschlechtskrankheiten,0367575,"['Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', 'Humans', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Lymphoma, Non-Hodgkin', '*Sarcoma', '*Severe Combined Immunodeficiency', '*Skin']",['CLML: 5120:69697:232:268:301'],['NLM'],"['*RETICULOENDOTHELIOSIS', '*SARCOMA, RETICULOSARCOMA', '*SKIN']",1951/05/15 00:00,1951/05/15 00:01,['1951/05/15 00:00'],"['1951/05/15 00:00 [pubmed]', '1951/05/15 00:01 [medline]', '1951/05/15 00:00 [entrez]']",ppublish,Z Haut Geschlechtskr. 1951 May 15;10(10):391-2.,,,,,,,,,,,,,,
14836718,NLM,MEDLINE,20040215,20181201,0043-5376 (Print) 0043-5376 (Linking),32,3,1951 Mar,[Therapy of acute leukoses].,117-21,"['REIMER, E E', 'VINAZZER, H']","['REIMER EE', 'VINAZZER H']",['und'],['Journal Article'],Die Therapie akut verlaufender Leukosen.,Austria,Wien Z Inn Med,Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete,7502231,,OM,['*Leukemia'],['CLML: 5120:69442:546'],['NLM'],['*LEUKEMIA'],1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Wien Z Inn Med. 1951 Mar;32(3):117-21.,,,,,,,,,,,,,,
14836574,NLM,MEDLINE,20040215,20181201,,59,4,1951 Apr,The present position regarding leukaemia.,178-87,"['WHITBY, L']",['WHITBY L'],['eng'],['Journal Article'],,United States,West J Surg Obstet Gynecol,"Western journal of surgery, obstetrics, and gynecology",0031306,,OM,"['Humans', '*Leukemia']",['CLML: 5120:69294:546'],['NLM'],['*LEUKEMIA'],1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,West J Surg Obstet Gynecol. 1951 Apr;59(4):178-87.,,,,,,,,,,,,,,
14836430,NLM,MEDLINE,20040215,20191108,0376-0081 (Print) 0376-0081 (Linking),320,1,1951,[Degenerative processes in the liver in leukemia].,86-92,"['PRINZ, F']",['PRINZ F'],['und'],['Journal Article'],Ueber Abbauvorgange in der Leber bei Leukamie.,Germany,Virchows Arch Pathol Anat Physiol Klin Med,Virchows Archiv fur pathologische Anatomie und Physiologie und fur klinische Medizin,0217007,,OM,"['Humans', '*Leukemia', '*Liver']",['CLML: 5120:69137:546:560'],['NLM'],"['*LEUKEMIA', '*LIVER, IN VARIOUS CONDITIONS']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Virchows Arch Pathol Anat Physiol Klin Med. 1951;320(1):86-92. doi: 10.1007/BF00957132.,['10.1007/BF00957132 [doi]'],,,,,,,,,,,,,
14835938,NLM,MEDLINE,20040215,20181201,0041-5782 (Print) 0041-5782 (Linking),113,7,1951 Feb 15,[Leukemia in Danish children during the years 1942-1949].,205-8,"['ANDERSEN, P E']",['ANDERSEN PE'],['und'],['Journal Article'],Leucaemi hos born i Danmark I arene 1942-1949.,Denmark,Ugeskr Laeger,Ugeskrift for laeger,0141730,,OM,"['Child', 'Humans', '*Leukemia']",['CLML: 5120:68639:546'],['NLM'],['*LEUKEMIA'],1951/02/15 00:00,1951/02/15 00:01,['1951/02/15 00:00'],"['1951/02/15 00:00 [pubmed]', '1951/02/15 00:01 [medline]', '1951/02/15 00:00 [entrez]']",ppublish,Ugeskr Laeger. 1951 Feb 15;113(7):205-8.,,,,,,,,,,,,,,
14835892,NLM,MEDLINE,20040215,20181201,0494-2736 (Print) 0494-2736 (Linking),17,3,1951 Mar,[Aleukemic leukemia in a case of osteosclerosis myelofibrosis].,94-102,"['YENER, M S', 'ERGUN, S', 'KUTSOY, S']","['YENER MS', 'ERGUN S', 'KUTSOY S']",['und'],['Journal Article'],Alosemik bir osteomiyeloskleroz vak'asi.,Turkey,Turk Tip Cemiy Mecm,Turk Tip Cemiyeti mecmuasi,7600196,,OM,"['Humans', '*Leukemia', '*Osteosclerosis', '*Primary Myelofibrosis', '*Splenomegaly']",['CLML: 5120:68593:111:318:546'],['NLM'],"['*LEUKEMIA, ALEUKEMIC', '*OSTEOSCLEROSIS', '*SPLENOMEGALY']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Turk Tip Cemiy Mecm. 1951 Mar;17(3):94-102.,,,,,,,,,,,,,,
14835890,NLM,MEDLINE,20040215,20181201,0494-2736 (Print) 0494-2736 (Linking),17,2,1951 Feb,[The relationship between agranulocytosis with leukemoid reaction and leukemia; report of a case].,80-8,"['KULEY, M', 'ULAGAY, I', 'TEKUL, N']","['KULEY M', 'ULAGAY I', 'TEKUL N']",['und'],['Journal Article'],Agranulositozla lokemoid reaksiyon ve losemi arasinda munasebet; bir vak's munasebetiyle.,Turkey,Turk Tip Cemiy Mecm,Turk Tip Cemiyeti mecmuasi,7600196,,OM,"['*Agranulocytosis', 'Humans', '*Leukemia', '*Leukemoid Reaction']",['CLML: 5120:68591:395:546'],['NLM'],"['*GRANULOCYTOPENIA', '*LEUKEMIA, ALEUKEMIC']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,Turk Tip Cemiy Mecm. 1951 Feb;17(2):80-8.,,,,,,,,,,,,,,
14835816,NLM,MEDLINE,20040215,20181201,,6,6,1951 Jun,Acute monocytic leukaemia.,272-6,"['DAVIS, W J', 'ALWAY, A E', 'ENGLAND, N J']","['DAVIS WJ', 'ALWAY AE', 'ENGLAND NJ']",['eng'],['Journal Article'],,Canada,Treat Serv Bull,Treatment services bulletin. Canada. Department of Veterans' Affairs,16020690R,,OM,"['Humans', '*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid', '*Monocytes']",['CLML: 5120:68517:547'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1951/06/01 00:00,1951/06/01 00:01,['1951/06/01 00:00'],"['1951/06/01 00:00 [pubmed]', '1951/06/01 00:01 [medline]', '1951/06/01 00:00 [entrez]']",ppublish,Treat Serv Bull. 1951 Jun;6(6):272-6.,,,,,,,,,,,,,,
14835610,NLM,MEDLINE,20040215,20181201,0029-2001 (Print) 0029-2001 (Linking),71,10,1951 May 15,[Aminopterin therapy of acute leukemia in children].,322-3,"['IMERSLUND, O']",['IMERSLUND O'],['und'],['Journal Article'],Akutt levkemi hos barn behandlet med aminopterin.,Norway,Tidsskr Nor Laegeforen,"Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke",0413423,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Acute Disease', '*Aminopterin', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:68302:349:545'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/05/15 00:00,1951/05/15 00:01,['1951/05/15 00:00'],"['1951/05/15 00:00 [pubmed]', '1951/05/15 00:01 [medline]', '1951/05/15 00:00 [entrez]']",ppublish,Tidsskr Nor Laegeforen. 1951 May 15;71(10):322-3.,,,,,,,,,,,,,,
14835609,NLM,MEDLINE,20040215,20181201,0029-2001 (Print) 0029-2001 (Linking),71,10,1951 May 15,[Aminopterin therapy in acute leukemia].,319-21; passim,"['RINVIK, R']",['RINVIK R'],['und'],['Journal Article'],Akutt levkemi behandlet med aminopterin.,Norway,Tidsskr Nor Laegeforen,"Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke",0413423,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Acute Disease', '*Aminopterin', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:68301:349:545'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/05/15 00:00,1951/05/15 00:01,['1951/05/15 00:00'],"['1951/05/15 00:00 [pubmed]', '1951/05/15 00:01 [medline]', '1951/05/15 00:00 [entrez]']",ppublish,Tidsskr Nor Laegeforen. 1951 May 15;71(10):319-21; passim.,,,,,,,,,,,,,,
14835443,NLM,MEDLINE,20040215,20181201,0040-3660 (Print) 0040-3660 (Linking),23,1,1951 Jan-Feb,"[Etiology, pathogenesis and clinical aspects of alimentary-toxic aleukia (septic angina)].",88-94,"['NESTEROV, V S']",['NESTEROV VS'],['und'],['Journal Article'],"Etiologiia, patogenez i klinika alimentarno-toksicheskoi aleiki (sopticheskoi anginy).",Russia (Federation),Ter Arkh,Terapevticheskii arkhiv,2984818R,,OM,"['*Angina Pectoris', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:68135:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Ter Arkh. 1951 Jan-Feb;23(1):88-94.,,,,,,,,,,,,,,
14835149,NLM,MEDLINE,20040215,20181201,0039-6060 (Print) 0039-6060 (Linking),29,4,1951 Apr,"Vertebral manifestations of malignant lymphoma, myeloid leucemia, and multiple myeloma.",545-54,"['MAZET, R Jr']",['MAZET R Jr'],['eng'],['Journal Article'],,United States,Surgery,Surgery,0417347,,OM,"['Humans', '*Leukemia', '*Lymphoma', '*Multiple Myeloma', '*Neoplasms', '*Spine']",['CLML: 5120:67841:316:406:407:546'],['NLM'],"['*LEUKEMIA', '*SPINE', '*TUMORS, LYMPHOMA', '*TUMORS, MULTIPLE MYELOMA']",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,Surgery. 1951 Apr;29(4):545-54.,['0039-6060(51)90113-4 [pii]'],,,,,,,,,,,,,
14834844,NLM,MEDLINE,20040215,20181201,,14,1,1951,[Pathology of the histiomonocytic system; histiocyte reactions and monocytic leukemia].,81-92,"['JASINSKI, B']",['JASINSKI B'],['und'],['Journal Article'],Zur Pathologie des histiomonocytaren Systems; Histiocytare Reaktion und Monocytenleukamie.,Switzerland,Schweiz Z Pathol Bakteriol,Schweizerische Zeitschrift fur Pathologie und Bakteriologie. Revue suisse de pathologie et de bacteriologie,20630440R,,OM,"['*Histiocytes', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukocytes', '*Monocytes', '*Mononuclear Phagocyte System']",['CLML: 5120:67525:231:547'],['NLM'],"['*LEUKEMIA, MONOCYTIC', '*LEUKOCYTES', '*RETICULOENDOTHELIAL SYSTEM']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Schweiz Z Pathol Bakteriol. 1951;14(1):81-92.,,,,,,,,,,,,,,
14834735,NLM,MEDLINE,20040215,20181201,0035-6417 (Print) 0035-6417 (Linking),6,1,1951 Jan,"[Effect of methyl-bis (beta-chloroethyl)amine hydrochloride on Hodgkin's disease, lymphosarcoma, leukemia and neoplasms].",1-58,"['LEVI, M', 'MENE, G', 'FERRI, A']","['LEVI M', 'MENE G', 'FERRI A']",['und'],['Journal Article'],"Sull'azione del cloridrato di metil-bis (beta-cloroetil)-amina nel morbo di Hodgkin, nel linfosarcoma, nelle leucemie e neoplasie.",Italy,Riv Patol Clin,Rivista di patologia e clinica,0404504,"['0 (Amines)', '0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Amines', '*Hodgkin Disease', 'Humans', '*Leukemia', '*Lymphoma', '*Lymphoma, Non-Hodgkin', '*Mechlorethamine', '*Neoplasms', '*Nitrogen Mustard Compounds', '*Sarcoma']",['CLML: 5120:67416:88:267:444:546'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA', '*NITROGEN MUSTARDS', '*SARCOMA, LYMPHOSARCOMA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Riv Patol Clin. 1951 Jan;6(1):1-58.,,,,,,,,,,,,,,
14834397,NLM,MEDLINE,20040215,20181201,0033-8362 (Print) 0033-8362 (Linking),37,2,1951 Feb,"[Chemotherapy and radiotherapy of lymphosarcoma, lymphogranuloma and chronic leukemic myelosis].",56,['TONIOLO'],['TONIOLO'],['und'],['Journal Article'],"Chemioterapia e radioterapia nel linfosarcoma, nel linfogranuloma e nella mielosi leucemica cronica.",Italy,Radiol Med,La Radiologia medica,0177625,,OM,"['*Hodgkin Disease', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Lymphoma', '*Lymphoma, Non-Hodgkin', '*Neoplasms', '*Sarcoma']",['CLML: 5120:67049:267:444:547'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA, MYELOGENOUS', '*SARCOMA, LYMPHOSARCOMA']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,Radiol Med. 1951 Feb;37(2):56.,,,,,,,,,,,,,,
14834118,NLM,MEDLINE,20040215,20181201,0032-7867 (Print) 0032-7867 (Linking),59,20,1951 Mar 28,"[Experimental meningoencephalitis in rabbit, induced by intracerebral injection of leukemic material after filtration. Presence of intracellular corpuscles in the brain].",388-9,"['PETZERAKIS, M']",['PETZERAKIS M'],['und'],['Journal Article'],Meningo-encephalite experimentale du lapin apres injection intracerebrale de produits leucemiques apres filtration; presence de corpuscules intracellulaires dans le cerveau.,France,Presse Med,La Presse medicale,0312556,,OM,"['Animals', '*Brain', '*Cytoplasm', '*Leukemia', '*Meningoencephalitis', 'Rabbits']",['CLML: 5120:66770:31:546'],['NLM'],"['*LEUKEMIA', '*MENINGOENCEPHALITIS']",1951/03/28 00:00,1951/03/28 00:01,['1951/03/28 00:00'],"['1951/03/28 00:00 [pubmed]', '1951/03/28 00:01 [medline]', '1951/03/28 00:00 [entrez]']",ppublish,Presse Med. 1951 Mar 28;59(20):388-9.,,,,,,,,,,,,,,
14833946,NLM,MEDLINE,20040215,20190713,0032-5481 (Print) 0032-5481 (Linking),9,5,1951 May,Treatment and prognosis in the leukemias and allied disorders.,375-82,"['STURGIS, C C']",['STURGIS CC'],['eng'],['Journal Article'],,England,Postgrad Med,Postgraduate medicine,0401147,,OM,"['Humans', '*Leukemia', 'Prognosis']",['CLML: 5120:66598:546'],['NLM'],['*LEUKEMIA'],1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,Postgrad Med. 1951 May;9(5):375-82. doi: 10.1080/00325481.1951.11694138.,['10.1080/00325481.1951.11694138 [doi]'],,,,,,,,,,,,,
14833002,NLM,MEDLINE,20040215,20190612,0140-6736 (Print) 0140-6736 (Linking),1,6665,1951 May 26,Streptomyces fermentation derivatives in acute leukaemia.,1157-9,"['BARNARD, R D']",['BARNARD RD'],['eng'],['Journal Article'],,England,Lancet,"Lancet (London, England)",2985213R,['9002-60-2 (Adrenocorticotropic Hormone)'],OM,"['*Acute Disease', '*Adrenocorticotropic Hormone', '*Fermentation', 'Humans', '*Leukemia', '*Streptomyces']",['CLML: 5120:65644:8:546'],['NLM'],"['*ACTH', '*LEUKEMIA']",1951/05/26 00:00,1951/05/26 00:01,['1951/05/26 00:00'],"['1951/05/26 00:00 [pubmed]', '1951/05/26 00:01 [medline]', '1951/05/26 00:00 [entrez]']",ppublish,Lancet. 1951 May 26;1(6665):1157-9. doi: 10.1016/s0140-6736(51)92663-3.,['10.1016/s0140-6736(51)92663-3 [doi]'],,,,,,,,,,,,,
14832892,NLM,MEDLINE,20040215,20181201,0013-2411 (Print) 0013-2411 (Linking),34,3,1951,A case of chloroma.,202-5,"['FAHMI, T', 'KINAWI, M']","['FAHMI T', 'KINAWI M']",['eng'],['Journal Article'],,Egypt,J Egypt Med Assoc,The Journal of the Egyptian Medical Association,0417734,,OM,"['Humans', '*Neoplasms', '*Sarcoma, Myeloid']",['CLML: 5120:65524:404'],['NLM'],"['*TUMORS, CHLOROMA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,J Egypt Med Assoc. 1951;34(3):202-5.,,,,,,,,,,,,,,
14831939,NLM,MEDLINE,20040215,20181201,0019-5863 (Print) 0019-5863 (Linking),86,1,1951 Jan,Cutaneous lesions following inoculation of live culture of Leishmania donovani in man.,6,"['SEN GUPTA, P C', 'DAS GUPTA, C R']","['SEN GUPTA PC', 'DAS GUPTA CR']",['eng'],['Journal Article'],,India,Ind Med Gaz,The Indian medical gazette,7501544,,OM,"['Humans', '*Leishmania donovani', '*Leishmaniasis', '*Leukemia', 'Male', '*Vaccination']",['CLML: 5120:64507:541:546'],['NLM'],"['*LEISHMANIASIS', '*LEUKEMIA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Ind Med Gaz. 1951 Jan;86(1):6.,,PMC5191673,,,,,,,,,,,,
14831834,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),34,10,1950,[Hemocytoblastic leukosis of spontaneous protracted evolution; clinical and hematological study].,1057-72,"['NINNI, M']",['NINNI M'],['und'],['Journal Article'],La leucosi emocitoblastica a decorso spontaneamente protratto; studio clinico ed ematologico.,Italy,Haematologica,Haematologica,0417435,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukocytes', '*Stem Cells']",['CLML: 5120:64392:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Haematologica. 1950;34(10):1057-72.,,,,,,,,,,,,,,
14831830,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),34,10,1950,[Chloronaphthylamine in the treatment of malignant lymphogranuloma and chronic leukemia].,925-63,"['INTROZZI, P', 'NINNI, M']","['INTROZZI P', 'NINNI M']",['und'],['Journal Article'],La cloronaftilamina nel trattamento del linfogranuloma maligno e delle leucemie croniche.,Italy,Haematologica,Haematologica,0417435,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Chronic Disease', '*Hodgkin Disease', '*Leukemia', '*Mechlorethamine', '*Nitrogen Mustard Compounds']",['CLML: 5120:64388:88:444:546'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA', '*NITROGEN MUSTARDS']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Haematologica. 1950;34(10):925-63.,,,,,,,,,,,,,,
14831825,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),34,10,1950,[Further hematological and clinical contribution to chronic myelosis with basophil metachromatic granuloblasts].,837-50,"['CATTANEO, I']",['CATTANEO I'],['und'],['Journal Article'],Ulteriore contributo ematologico e clinico alla conoscenza della mielosi cronica a granuloblasti metacromatici basofili.,Italy,Haematologica,Haematologica,0417435,,OM,"['*Basophils', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid']",['CLML: 5120:64383:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Haematologica. 1950;34(10):837-50.,,,,,,,,,,,,,,
14831128,NLM,MEDLINE,20040215,20181201,0008-7335 (Print) 0008-7335 (Linking),90,18,1951 May 4,[Clinical experiences with nitrogen mustards].,543-50,"['SIEBEROVA-KLIMOVA, R']",['SIEBEROVA-KLIMOVA R'],['und'],['Journal Article'],Klinicke zku6senosti s ho6r6ci6cnymi dusaky.,Czech Republic,Cas Lek Cesk,Casopis lekaru ceskych,0004743,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Erythema', '*Leukemia', '*Mechlorethamine', '*Neoplasms', '*Nitrogen Mustard Compounds']",['CLML: 5120:63651:88:164:314:546'],['NLM'],"['*CANCER', '*ERYTHEMA', '*LEUKEMIA', '*NITROGEN MUSTARDS']",1951/05/04 00:00,1951/05/04 00:01,['1951/05/04 00:00'],"['1951/05/04 00:00 [pubmed]', '1951/05/04 00:01 [medline]', '1951/05/04 00:00 [entrez]']",ppublish,Cas Lek Cesk. 1951 May 4;90(18):543-50.,,,,,,,,,,,,,,
14830992,NLM,MEDLINE,20040215,20181201,0366-1334 (Print) 0366-1334 (Linking),67,5-6,1951 Feb 9-16,[Acute familial leukosis; parallel course of acute leukosis of the same type in child and father].,183-94,"['DEBRE, R', 'BERNARD, J', 'BUHOT, S']","['DEBRE R', 'BERNARD J', 'BUHOT S']",['und'],['Journal Article'],Leucose aigue familiale; evolution rapprochee d'une leucose aigue du meme type chez une enfant et chez son pere.,France,Bull Mem Soc Med Hop Paris,Bulletins et memoires de la Societe medicale des hopitaux de Paris,7503472,,OM,"['Child', '*Fathers', 'Humans', '*Leukemia']",['CLML: 5120:63515:545'],['NLM'],['*LEUKEMIA'],1951/02/09 00:00,1951/02/09 00:01,['1951/02/09 00:00'],"['1951/02/09 00:00 [pubmed]', '1951/02/09 00:01 [medline]', '1951/02/09 00:00 [entrez]']",ppublish,Bull Mem Soc Med Hop Paris. 1951 Feb 9-16;67(5-6):183-94.,,,,,,,,,,,,,,
14830086,NLM,MEDLINE,20040215,20190619,0003-4819 (Print) 0003-4819 (Linking),34,4,1951 Apr,Cortone in lymphoblastoma: a case report.,1062-65,"['SULMAN, W R']",['SULMAN WR'],['eng'],['Journal Article'],,United States,Ann Intern Med,Annals of internal medicine,0372351,['V27W9254FZ (Cortisone)'],OM,"['*Cortisone', 'Humans', '*Leukemia', '*Lymphoma, Non-Hodgkin']",['CLML: 5120:62549:196:227'],['NLM'],"['*CORTISONE', '*PSEUDOLEUKEMIA']",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,Ann Intern Med. 1951 Apr;34(4):1062-65. doi: 10.7326/0003-4819-34-4-1062.,['10.7326/0003-4819-34-4-1062 [doi]'],,,,,,,,,,,,,
14829310,NLM,MEDLINE,20040215,20181201,0001-6748 (Print) 0001-6748 (Linking),1,4,1950,On a cause of haemorrhages during treatment with aminopterin.,651-55,"['van CREVELD, S', 'PAULSSEN, M M P', 'TENG, S K']","['van CREVELD S', 'PAULSSEN MM', 'TENG SK']",['eng'],['Journal Article'],,Netherlands,Acta Physiol Pharmacol Neerl,Acta physiologica et pharmacologica Neerlandica,14610130R,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Aminopterin', '*Folic Acid Antagonists', '*Hemorrhage', '*Leukemia']",['CLML: 5120:61743:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Acta Physiol Pharmacol Neerl. 1950;1(4):651-55.,,,,,,,,,,,,,,
14829308,NLM,MEDLINE,20040215,20181201,0001-6748 (Print) 0001-6748 (Linking),1,4,1950,On some chemotherapeutic experiments with podophyllotoxin.,638-44,"['WATERMAN, N']",['WATERMAN N'],['eng'],['Journal Article'],,Netherlands,Acta Physiol Pharmacol Neerl,Acta physiologica et pharmacologica Neerlandica,14610130R,"['9000-55-9 (Podophyllin)', 'L36H50F353 (Podophyllotoxin)']",OM,"['Humans', '*Leukemia', '*Neoplasms', '*Podophyllin', '*Podophyllotoxin']",['CLML: 5120:61741:162:174:546'],['NLM'],"['*CANCER', '*LEUKEMIA', '*PODOPHYLLIN']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Acta Physiol Pharmacol Neerl. 1950;1(4):638-44.,,,,,,,,,,,,,,
14829285,NLM,MEDLINE,20040215,20190911,0365-5555 (Print) 0365-5555 (Linking),28,2,1951,Influence of the sex hormones upon the development of leukemia in mice.,201-6,"['ARENTSEN, K', 'HOGREFFE, G']","['ARENTSEN K', 'HOGREFFE G']",['eng'],['Journal Article'],,Denmark,Acta Pathol Microbiol Scand,Acta pathologica et microbiologica Scandinavica,7508471,['0 (Gonadal Steroid Hormones)'],OM,"['Animals', '*Gonadal Steroid Hormones', '*Leukemia', 'Mice']",['CLML: 5120:61718:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Pathol Microbiol Scand. 1951;28(2):201-6. doi: 10.1111/j.1699-0463.1951.tb03687.x.,['10.1111/j.1699-0463.1951.tb03687.x [doi]'],,,,,,,,,,,,,
14829258,NLM,MEDLINE,20040215,20191026,0365-1436 (Print) 0365-1436 (Linking),40,2,1951 Mar,Aminopterin therapy in leukemia in childhood.,127-42,"['JERSILD, T', 'MEHLSEN, S']","['JERSILD T', 'MEHLSEN S']",['eng'],['Journal Article'],,Sweden,Acta Paediatr,Acta paediatrica,0000213,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Aminopterin', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:61691:349:545'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Acta Paediatr. 1951 Mar;40(2):127-42. doi: 10.1111/j.1651-2227.1951.tb15791.x.,['10.1111/j.1651-2227.1951.tb15791.x [doi]'],,,,,,,,,,,,,
14829228,NLM,MEDLINE,20040215,20190812,0001-6101 (Print) 0001-6101 (Linking),139,5,1951,The latent hemolytic syndrome in leukemia with splenomegaly.,331-40,"['BERLIN, R']",['BERLIN R'],['eng'],['Journal Article'],,Sweden,Acta Med Scand,Acta medica Scandinavica,0370330,,OM,"['*Anemia', '*Anemia, Hemolytic', '*Leukemia', '*Splenomegaly', '*Syndrome']",['CLML: 5120:61661:39:318:546'],['NLM'],"['*ANEMIA, HEMOLYTIC', '*LEUKEMIA', '*SPLENOMEGALY']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Med Scand. 1951;139(5):331-40. doi: 10.1111/j.0954-6820.1951.tb17172.x.,['10.1111/j.0954-6820.1951.tb17172.x [doi]'],,,,,,,,,,,,,
14829061,NLM,MEDLINE,20040215,20191108,0096-5979 (Print) 0096-5979 (Linking),63,6,1951 Jun,"Generalized herpes zoster: report of a case following roentgen ray therapy, associated with chronic lymphatic leukemia, leukemia cutis and Mikulicz's syndrome.",772-6,"['BOSWORTH, E L']",['BOSWORTH EL'],['eng'],['Journal Article'],,United States,AMA Arch Derm Syphilol,A.M.A. archives of dermatology and syphilology,14470040R,,OM,"['*Herpes Zoster', '*Herpesvirus 3, Human', 'Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', '*Leukemia, Lymphoid', 'X-Rays']",['CLML: 5120:61494:435:546'],['NLM'],"['*HERPES ZOSTER', '*LEUKEMIA, LYMPHATIC']",1951/06/01 00:00,1951/06/01 00:01,['1951/06/01 00:00'],"['1951/06/01 00:00 [pubmed]', '1951/06/01 00:01 [medline]', '1951/06/01 00:00 [entrez]']",ppublish,AMA Arch Derm Syphilol. 1951 Jun;63(6):772-6. doi: 10.1001/archderm.1951.01570060100013.,['10.1001/archderm.1951.01570060100013 [doi]'],,,,,,,,,,,,,
14828222,NLM,MEDLINE,20040215,20181201,0048-8364 (Print) 0048-8364 (Linking),3,11,1950 Nov,"[Cerebral changes and microglioblastic reactions in leukemia, with several considerations on the histogenesis of microglia].",1060-88,"['MEO, L']",['MEO L'],['und'],['Journal Article'],Le alterazioni encefaliche e la reazione microglioblastica nelle leucemie con alcune considerazioni sulla istogenesi della microglia.,Italy,Riv Anat Patol Oncol,Rivista di anatomia patologica e di oncologia,0404350,,OM,"['Humans', '*Leukemia', '*Microglia', '*Neuroglia']",['CLML: 5120:60514:83:546'],['NLM'],"['*LEUKEMIA', '*NEUROGLIA']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Riv Anat Patol Oncol. 1950 Nov;3(11):1060-88.,,,,,,,,,,,,,,
14827884,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),76,2,1951 Feb,Serum anti-hyaluronidase in human leukemia and lymphosarcoma. Effects of cortisone and ACTH.,239-42,"['HENSTELL, H H', 'FREEDMAN, R I']","['HENSTELL HH', 'FREEDMAN RI']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['9002-60-2 (Adrenocorticotropic Hormone)', 'EC 3.2.1.35 (Hyaluronoglucosaminidase)', 'V27W9254FZ (Cortisone)']",OM,"['*Adrenocorticotropic Hormone', '*Blood', '*Cortisone', '*Hyaluronoglucosaminidase', '*Leukemia', '*Lymphoma', '*Lymphoma, Non-Hodgkin', '*Neoplasms', '*Sarcoma']",['CLML: 5120:60156:8:109:227:267:461:546'],['NLM'],"['*ACTH', '*BLOOD', '*CORTISONE', '*HYALURONIDASE', '*LEUKEMIA', '*SARCOMA, LYMPHOSARCOMA']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1951 Feb;76(2):239-42. doi: 10.3181/00379727-76-18448.,['10.3181/00379727-76-18448 [doi]'],,,,,,,,,,,,,
14827608,NLM,MEDLINE,20040215,20181201,,6,1,1951 Jan-Feb,[Hemoblastosis in child].,38-42,"['MATHESIUS, J']",['MATHESIUS J'],['und'],['Journal Article'],Haemoblastosa v detskem veku.,Czech Republic,Pediatr Listy,Pediatricke listy,0204303,,OM,"['Child', 'Humans', '*Leukemia']",['CLML: 5120:59878:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Pediatr Listy. 1951 Jan-Feb;6(1):38-42.,,,,,,,,,,,,,,
14827544,NLM,MEDLINE,20040215,20181201,0030-6002 (Print) 0030-6002 (Linking),91,28,1950 Jul 9,[Experimental monocytosis].,876-78,"['RONA, G', 'BEREGI, E']","['RONA G', 'BEREGI E']",['und'],['Journal Article'],Kaserleti monocytosis.,Hungary,Orv Hetil,Orvosi hetilap,0376412,['9007-58-3 (Elastin)'],OM,"['*Elastin', '*Leukemia', '*Leukemia, Myeloid', '*Monocytes']",['CLML: 5120:59814:294:547'],['NLM'],"['*ELASTIN', '*LEUKEMIA, MONOCYTIC']",1950/07/09 00:00,1950/07/09 00:01,['1950/07/09 00:00'],"['1950/07/09 00:00 [pubmed]', '1950/07/09 00:01 [medline]', '1950/07/09 00:00 [entrez]']",ppublish,Orv Hetil. 1950 Jul 9;91(28):876-78.,,,,,,,,,,,,,,
14827314,NLM,MEDLINE,20040215,20181201,0029-2303 (Print) 0029-2303 (Linking),61,2,1951 Feb,[Leukemia].,61-3,"['KRAMER, T']",['KRAMER T'],['und'],['Journal Article'],Leukemier.,Norway,Nor Tannlaegeforen Tid,Den Norske tannlaegeforenings tidende,0414136,,OM,"['*Face', '*Gastrointestinal Tract', 'Humans', '*Leukemia', '*Mouth']",['CLML: 5120:59572:59:546'],['NLM'],"['*LEUKEMIA', '*MOUTH']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,Nor Tannlaegeforen Tid. 1951 Feb;61(2):61-3.,,,,,,,,,,,,,,
14827107,NLM,MEDLINE,20040215,20181201,0097-1790 (Print) 0097-1790 (Linking),103,9,1951 Mar,Acute myelogenous leukemia. Report of a case receiving 214 blood transfusions and with the development of hemosiderosis.,393-7,"['JOHNSON, P B', 'SIGNORELLI, J J', 'PIZZOLATO, P']","['JOHNSON PB', 'SIGNORELLI JJ', 'PIZZOLATO P']",['eng'],['Journal Article'],,United States,New Orleans Med Surg J,The New Orleans medical and surgical journal,19030340R,,OM,"['*Blood Transfusion', '*Hemosiderosis', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Myeloid, Acute']",['CLML: 5120:59356:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,New Orleans Med Surg J. 1951 Mar;103(9):393-7.,,,,,,,,,,,,,,
14827068,NLM,MEDLINE,20040215,20181201,0028-3878 (Print) 0028-3878 (Linking),1,2,1951 Mar-Apr,CLINICAL pathologic conference: severe generalized arteriosclerosis; myeloid leukemia with myelofibrosis; large glioblastoma of the right temporal lobe and island of Reil.,163-6,,,['eng'],['Journal Article'],,United States,Neurology,Neurology,0401060,,OM,"['*Arteriosclerosis', '*Brain Neoplasms', '*Glioblastoma', '*Glioma', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Neoplasms', '*Primary Myelofibrosis', '*Temporal Lobe']",['CLML: 5120:59317:61:139:405:547'],['NLM'],"['*ARTERIOSCLEROSIS', '*BRAIN TUMOR', '*LEUKEMIA, MYELOGENOUS', '*TUMORS, GLIOMA']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Neurology. 1951 Mar-Apr;1(2):163-6.,,,,,,,,,,,,,,
14826571,NLM,MEDLINE,20040215,20181201,0026-4806 (Print) 0026-4806 (Linking),42,3,1951 Jan 20,[Action of naphthylamine compound (chloronaphthene) in a case of chronic lymphatic leukemia].,75-9,"['DE RITIS, F', 'NEGRONI, G']","['DE RITIS F', 'NEGRONI G']",['und'],['Journal Article'],Attivita di un composto naftilaminico (cloronaftina) in um caso di leucemia linfatica cronica.,Italy,Minerva Med,Minerva medica,0400732,['0 (Naphthols)'],OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Naphthols']",['CLML: 5120:58820:71:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*NAPHTHOL AND COMPOUNDS']",1951/01/20 00:00,1951/01/20 00:01,['1951/01/20 00:00'],"['1951/01/20 00:00 [pubmed]', '1951/01/20 00:01 [medline]', '1951/01/20 00:00 [entrez]']",ppublish,Minerva Med. 1951 Jan 20;42(3):75-9.,,,,,,,,,,,,,,
14826091,NLM,MEDLINE,20040215,20181201,0025-6749 (Print) 0025-6749 (Linking),9,188,1951 Feb 15,[Modern therapy of leukemia].,66,,,['und'],['Journal Article'],TRAITEMENT moderne de la leucemie.,Switzerland,Med Hyg (Geneve),Medecine et hygiene,9427226,,OM,"['Humans', '*Leukemia']",['CLML: 5120:58320:546'],['NLM'],['*LEUKEMIA'],1951/02/15 00:00,1951/02/15 00:01,['1951/02/15 00:00'],"['1951/02/15 00:00 [pubmed]', '1951/02/15 00:01 [medline]', '1951/02/15 00:00 [entrez]']",ppublish,Med Hyg (Geneve). 1951 Feb 15;9(188):66.,,,,,,,,,,,,,,
14825999,NLM,MEDLINE,20040215,20181201,0024-7790 (Print) 0024-7790 (Linking),184,11,1951 Mar 18,[Importance of aureomycin in the treatment of leukemia].,184-6,"['PLAUCHU', 'REVOL', 'MOREL', 'CHAVANIS', 'MOURIQUAND']","['PLAUCHU', 'REVOL', 'MOREL', 'CHAVANIS', 'MOURIQUAND']",['und'],['Journal Article'],Interet l'aureomycine dans le traitement des leucemies.,France,Lyon Med,Lyon medical,0335015,['WCK1KIQ23Q (Chlortetracycline)'],OM,"['*Chlortetracycline', '*Leukemia']",['CLML: 5120:58228:70:546'],['NLM'],"['*AUREOMYCIN', '*LEUKEMIA']",1951/03/18 00:00,1951/03/18 00:01,['1951/03/18 00:00'],"['1951/03/18 00:00 [pubmed]', '1951/03/18 00:01 [medline]', '1951/03/18 00:00 [entrez]']",ppublish,Lyon Med. 1951 Mar 18;184(11):184-6.,,,,,,,,,,,,,,
14825876,NLM,MEDLINE,20040215,20190612,0140-6736 (Print) 0140-6736 (Linking),1,6662,1951 May 5,"Myeloid reticulosis, its diagnosis and course.",978-81,"['ISRAELS, M C G']",['ISRAELS MC'],['eng'],['Journal Article'],,England,Lancet,"Lancet (London, England)",2985213R,,OM,"['Humans', '*Leukemia', '*Mononuclear Phagocyte System']",['CLML: 5120:58105:232:546'],['NLM'],"['*LEUKEMIA', '*RETICULOENDOTHELIAL SYSTEM']",1951/05/05 00:00,1951/05/05 00:01,['1951/05/05 00:00'],"['1951/05/05 00:00 [pubmed]', '1951/05/05 00:01 [medline]', '1951/05/05 00:00 [entrez]']",ppublish,Lancet. 1951 May 5;1(6662):978-81. doi: 10.1016/s0140-6736(51)92496-8.,"['S0140-6736(51)92496-8 [pii]', '10.1016/s0140-6736(51)92496-8 [doi]']",,,,,,,,,,,,,
14825342,NLM,MEDLINE,20040215,20181201,0368-394X (Print) 0368-394X (Linking),31,11-12,1950,[Subtotal radiotherapy in the treatment of leukemias].,730-1,"['BETOULIERES, P', 'POULIQUEN, J']","['BETOULIERES P', 'POULIQUEN J']",['und'],['Journal Article'],La radiotherapie sub-totale dans le traitement des leucemies.,France,J Radiol Electrol Arch Electr Medicale,"Journal de radiologie, d'electrologie & archives d'electricite medicale",0013747,,OM,"['Humans', '*Leukemia']",['CLML: 5120:57562:546'],['NLM'],['*LEUKEMIA'],1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,J Radiol Electrol Arch Electr Medicale. 1950;31(11-12):730-1.,,,,,,,,,,,,,,
14824967,NLM,MEDLINE,20040215,20181201,0022-3018 (Print) 0022-3018 (Linking),113,4,1951 Apr,Leukemia with a clinical syndrome stimulating poliomyelitis.,360-2,"['FRIEDMAN, E D']",['FRIEDMAN ED'],['eng'],['Journal Article'],,United States,J Nerv Ment Dis,The Journal of nervous and mental disease,0375402,,OM,"['Humans', '*Leukemia', '*Poliomyelitis']",['CLML: 5120:57182:175:546'],['NLM'],"['*LEUKEMIA', '*POLIOMYELITIS']",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,J Nerv Ment Dis. 1951 Apr;113(4):360-2.,,,,,,,,,,,,,,
14824799,NLM,MEDLINE,20040215,20181201,0025-7028 (Print) 0025-7028 (Linking),40,4,1951 Apr,Folic acid antagonists in the treatment of acute and subacute leukemia.,177-80,"['FREEDMAN, M H']",['FREEDMAN MH'],['eng'],['Journal Article'],,United States,J Med Assoc Ga,Journal of the Medical Association of Georgia,7505620,['0 (Folic Acid Antagonists)'],OM,"['*Acute Disease', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:57014:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,J Med Assoc Ga. 1951 Apr;40(4):177-80.,,,,,,,,,,,,,,
14824753,NLM,MEDLINE,20040215,20181201,0368-3001 (Print) 0368-3001 (Linking),128,3,1951 Mar,[Plasmocytic leukemias; (case report)].,398-402,"['CREYX, M', 'LENG-LEVY, J', 'DUBREUIL, J', 'DAVID-CHAUSSE, J', 'AUBERT, L']","['CREYX M', 'LENG-LEVY J', 'DUBREUIL J', 'DAVID-CHAUSSE J', 'AUBERT L']",['und'],['Journal Article'],Les leucemies a plasmocytes; (a propos d'un cas).,France,J Med Bord,Journal de medecine de Bordeaux et du Sud-Ouest,0161067,,OM,"['Humans', '*Leukemia', '*Leukemia, Plasma Cell']",['CLML: 5120:56959:546'],['NLM'],['*LEUKEMIA'],1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,J Med Bord. 1951 Mar;128(3):398-402.,,,,,,,,,,,,,,
14824620,NLM,MEDLINE,20040215,20181201,0096-6983 (Print) 0096-6983 (Linking),41,3,1951 Mar,Folic acid antagonists in the treatment of leukemia.,84-6,"['HENDRICKS, A B', 'FOWLER, W M']","['HENDRICKS AB', 'FOWLER WM']",['eng'],['Journal Article'],,United States,J Iowa State Med Soc,Journal. Iowa State Medical Society,17710080R,['0 (Folic Acid Antagonists)'],OM,"['*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:56826:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,J Iowa State Med Soc. 1951 Mar;41(3):84-6.,,,,,,,,,,,,,,
14822489,NLM,MEDLINE,20040215,20181201,0010-5309 (Print) 0010-5309 (Linking),73,14,1951 Apr 7,[Myeloid leukemia and radiotherapy].,1285,"['SOULIER, J P']",['SOULIER JP'],['und'],['Journal Article'],Leucemie myeloide et radiotherapie.,France,Concours Med,Concours medical,2984731R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Radiotherapy']",['CLML: 5120:54607:216:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*RADIOTHERAPY']",1951/04/07 00:00,1951/04/07 00:01,['1951/04/07 00:00'],"['1951/04/07 00:00 [pubmed]', '1951/04/07 00:01 [medline]', '1951/04/07 00:00 [entrez]']",ppublish,Concours Med. 1951 Apr 7;73(14):1285.,,,,,,,,,,,,,,
14821995,NLM,MEDLINE,20040215,20181201,0008-7335 (Print) 0008-7335 (Linking),90,9,1951 Mar 2,[Chloroleukemia].,278-84,"['DONNER, L', 'STREDA, A', 'VANEK, J']","['DONNER L', 'STREDA A', 'VANEK J']",['und'],['Journal Article'],Chloroleukemie.,Czech Republic,Cas Lek Cesk,Casopis lekaru ceskych,0004743,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:54111:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1951/03/02 00:00,1951/03/02 00:01,['1951/03/02 00:00'],"['1951/03/02 00:00 [pubmed]', '1951/03/02 00:01 [medline]', '1951/03/02 00:00 [entrez]']",ppublish,Cas Lek Cesk. 1951 Mar 2;90(9):278-84.,,,,,,,,,,,,,,
14821967,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,3,1951 Mar,The nucleic acid inhibiting action of 4-amino-N10-methylpteroylglutamic acid in mice with a sensitive and resistant strain of leukemia.,229-31,"['SKIPPER, H E', 'BURCHENAL, J H']","['SKIPPER HE', 'BURCHENAL JH']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,"['0 (Amino Acids)', '0 (Folic Acid Antagonists)', '0 (Nucleic Acids)']",OM,"['*Amino Acids', 'Animals', '*Folic Acid Antagonists', '*Leukemia', 'Mice', '*Nucleic Acids']",['CLML: 5120:54083:92:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA', '*NUCLEIC ACIDS']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Mar;11(3):229-31.,,,,,,,,,,,,,,
14821954,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,3,1951 Mar,Partial reversal of the anti-leukemic action of folic acid antagonists by vitamin B12.,161-3,"['SKIPPER, H E', 'CHAPMAN, J B', 'BELL, M']","['SKIPPER HE', 'CHAPMAN JB', 'BELL M']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,"['0 (Folic Acid Antagonists)', 'P6YC3EG204 (Vitamin B 12)']",OM,"['*Folic Acid Antagonists', 'Humans', '*Leukemia', '*Vitamin B 12']",['CLML: 5120:54070:349:444:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA', '*VITAMIN B12']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Mar;11(3):161-3.,,,,,,,,,,,,,,
14821946,NLM,MEDLINE,20040215,20181201,0008-5448 (Print) 0008-5448 (Linking),3,2,1951 Mar-Apr,LEUKEMIA.,32-3; passim,,,['eng'],['Journal Article'],,United States,Cancer Bull,"Cancer bulletin (Houston, Tex.)",0373142,,OM,"['Humans', '*Leukemia']",['CLML: 5120:54062:546'],['NLM'],['*LEUKEMIA'],1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Cancer Bull. 1951 Mar-Apr;3(2):32-3; passim.,,,,,,,,,,,,,,
14821937,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,2,1951 Mar,Spontaneous and induced plasma-cell neoplasia in a strain of mice.,387-97,"['RASK-NIELSEN, R', 'GORMSEN, H']","['RASK-NIELSEN R', 'GORMSEN H']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,,OM,"['Animals', '*Leukemia', 'Mice', '*Multiple Myeloma', '*Plasmacytoma']",['CLML: 5120:54053:546'],['NLM'],['*LEUKEMIA'],1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Cancer. 1951 Mar;4(2):387-97. doi: 10.1002/1097-0142(195103)4:2<387::aid-cncr2820040229>3.0.co;2-y.,['10.1002/1097-0142(195103)4:2<387::aid-cncr2820040229>3.0.co;2-y [doi]'],,,,,,,,,,,,,
14821932,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,2,1951 Mar,Screening of a diverse series of candidate antileukemic agents.,360-2,"['SKIPPER, H E', 'BELL, M', 'CHAPMAN, J B']","['SKIPPER HE', 'BELL M', 'CHAPMAN JB']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,['0 (Antineoplastic Agents)'],OM,"['*Antineoplastic Agents', 'Humans', '*Leukemia']",['CLML: 5120:54048:546'],['NLM'],['*LEUKEMIA'],1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Cancer. 1951 Mar;4(2):360-2. doi: 10.1002/1097-0142(195103)4:2<360::aid-cncr2820040224>3.0.co;2-z.,['10.1002/1097-0142(195103)4:2<360::aid-cncr2820040224>3.0.co;2-z [doi]'],,,,,,,,,,,,,
14821931,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,2,1951 Mar,Partial reversal of the antileukemic action of folic acid antagonists by nucleic acids.,357-9,"['SKIPPER, H E', 'BELL, M', 'CHAPMAN, J B']","['SKIPPER HE', 'BELL M', 'CHAPMAN JB']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Folic Acid Antagonists)', '0 (Nucleic Acids)']",OM,"['*Folic Acid Antagonists', '*Leukemia', '*Nucleic Acids']",['CLML: 5120:54047:92:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA', '*NUCLEIC ACIDS']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Cancer. 1951 Mar;4(2):357-9. doi: 10.1002/1097-0142(195103)4:2<357::aid-cncr2820040223>3.0.co;2-i.,['10.1002/1097-0142(195103)4:2<357::aid-cncr2820040223>3.0.co;2-i [doi]'],,,,,,,,,,,,,
14821930,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,2,1951 Mar,Chemotherapy of leukemia. III. Further studies on the effect of nitrogen mustards and related compounds on transmitted mouse leukemia.,353-6,"['BURCHENAL, J H', 'BURCHENAL, J R', 'JOHNSTON, S F']","['BURCHENAL JH', 'BURCHENAL JR', 'JOHNSTON SF']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Leukemia', '*Mechlorethamine', '*Nitrogen Mustard Compounds']",['CLML: 5120:54046:88:546'],['NLM'],"['*LEUKEMIA', '*NITROGEN MUSTARDS']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Cancer. 1951 Mar;4(2):353-6. doi: 10.1002/1097-0142(195103)4:2<353::aid-cncr2820040222>3.0.co;2-x.,['10.1002/1097-0142(195103)4:2<353::aid-cncr2820040222>3.0.co;2-x [doi]'],,,,,,,,,,,,,
14821800,NLM,MEDLINE,20040215,20181201,0366-1334 (Print) 0366-1334 (Linking),67,3-4,1951 Jan 26-Feb 2,[Four observations on Sternberg type leukosarcomatosis].,133-4,"['de GRAILLY, R', 'LACHAPELE, A P', 'FAURE, L', 'LEGER, H', 'BIRABEN, J']","['de GRAILLY R', 'LACHAPELE AP', 'FAURE L', 'LEGER H', 'BIRABEN J']",['und'],['Journal Article'],A propos de quatre observations de leucosarcomatose de type Sternberg.,France,Bull Mem Soc Med Hop Paris,Bulletins et memoires de la Societe medicale des hopitaux de Paris,7503472,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', '*Sarcoma']",['CLML: 5120:53916:267'],['NLM'],"['*SARCOMA, LEUKOSARCOMA']",1951/01/26 00:00,1951/01/26 00:01,['1951/01/26 00:00'],"['1951/01/26 00:00 [pubmed]', '1951/01/26 00:01 [medline]', '1951/01/26 00:00 [entrez]']",ppublish,Bull Mem Soc Med Hop Paris. 1951 Jan 26-Feb 2;67(3-4):133-4.,,,,,,,,,,,,,,
14821725,NLM,MEDLINE,20040215,20181201,,57,5,1950 Nov-Dec,"[Mycosis fungoides with leukemic evolution, failure of nitrogen mustard].",538-9,"['LONGCHAMPT', 'DUPERRAT, B', 'BELLONNE']","['LONGCHAMPT', 'DUPERRAT B', 'BELLONNE']",['und'],['Journal Article'],"Mycosis fongoide a evolution leucemique, echec de la moutarde a l'azote.",France,Bull Soc Fr Dermatol Syphiligr,Bulletin de la Societe francaise de dermatologie et de syphiligraphie,7503407,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Biological Evolution', 'Humans', '*Leukemia', '*Mechlorethamine', '*Mycosis Fungoides', '*Nitrogen Mustard Compounds']",['CLML: 5120:53841:67:88:546'],['NLM'],"['*LEUKEMIA', '*MYCOSIS FUNGOIDES', '*NITROGEN MUSTARDS']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Bull Soc Fr Dermatol Syphiligr. 1950 Nov-Dec;57(5):538-9.,,,,,,,,,,,,,,
14821624,NLM,MEDLINE,20040215,20181201,0046-3515 (Print) 0046-3515 (Linking),3,1,1951,[Case of myelosarcoma of the uterine cervix].,106-7,"['CAILLOT, J', 'CHARVET']","['CAILLOT J', 'CHARVET']",['und'],['Journal Article'],Un cas de myelosarcome du col uterin.,France,Bull Fed Soc Gynecol Obstet Lang Fr,Bulletin de la Federation des societes de gynecologie et dobstetrique de langue francaise,7503396,,OM,"['*Cervix Uteri', 'Female', 'Humans', '*Neoplasms', '*Sarcoma', '*Sarcoma, Myeloid', '*Uterus']",['CLML: 5120:53735:268:424'],['NLM'],"['*SARCOMA, MYELOPLAXOMA', '*UTERUS, CERVIX']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Bull Fed Soc Gynecol Obstet Lang Fr. 1951;3(1):106-7.,,,,,,,,,,,,,,
14821585,NLM,MEDLINE,20040215,20181201,0004-5497 (Print) 0004-5497 (Linking),38,1,1951,[Production of tumors by injection of avian leukemia into the chorio-allantoic membrane of the egg].,72-85,"['VIGIER, P', 'GUERIN, M']","['VIGIER P', 'GUERIN M']",['und'],['Journal Article'],Productions tumorales par passage de la leucemie de la poule sur la membrane chorio-allantoidienne de l'oeuf.,France,Bull Assoc Fr Etud Cancer,Bulletin de l'Association francaise pour l'etude du cancer,7503389,,OM,"['*Allantois', 'Animals', '*Bird Diseases', '*Birds', '*Chorion', '*Leukemia', '*Neoplasms']",['CLML: 5120:53696:204:546'],['NLM'],"['*CHORION', '*LEUKEMIA, AVIAN']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Bull Assoc Fr Etud Cancer. 1951;38(1):72-85.,,,,,,,,,,,,,,
14821530,NLM,MEDLINE,20040215,20190501,0007-1447 (Print) 0007-1447 (Linking),1,4710,1951 Apr 14,Acute leukaemia treated with a-methopterin.,784-92,"['DACIE, J V', 'DRESNER, E', 'MOLLIN, D L', 'WHITE, J C']","['DACIE JV', 'DRESNER E', 'MOLLIN DL', 'WHITE JC']",['eng'],['Journal Article'],,England,Br Med J,British medical journal,0372673,['0 (Folic Acid Antagonists)'],OM,"['*Acute Disease', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:53641:349:545'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/04/14 00:00,1951/04/14 00:01,['1951/04/14 00:00'],"['1951/04/14 00:00 [pubmed]', '1951/04/14 00:01 [medline]', '1951/04/14 00:00 [entrez]']",ppublish,Br Med J. 1951 Apr 14;1(4710):784-92. doi: 10.1136/bmj.1.4710.784.,['10.1136/bmj.1.4710.784 [doi]'],PMC2068725,,,,,,,,,,,,
14821172,NLM,MEDLINE,20040215,20181201,0007-0610 (Print) 0007-0610 (Linking),90,4,1951 Feb 20,A pitfall for the dental practitioner.,100,"['BOWLER, A']",['BOWLER A'],['eng'],['Journal Article'],,England,Br Dent J,British dental journal,7513219,,OM,"['*Dentists', 'Humans', '*Leukemia', '*Tooth Extraction']",['CLML: 5120:53283:358:546'],['NLM'],"['*LEUKEMIA', '*TEETH EXTRACTION']",1951/02/20 00:00,1951/02/20 00:01,['1951/02/20 00:00'],"['1951/02/20 00:00 [pubmed]', '1951/02/20 00:01 [medline]', '1951/02/20 00:00 [entrez]']",ppublish,Br Dent J. 1951 Feb 20;90(4):100.,,,,,,,,,,,,,,
14820986,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),6,4,1951 Apr,"A comparison of the effects of 4-amino-N10-methyl-pteroylglutamic acid and 2,6-diaminopurine upon sensitive and resistant sublines of a strain of mouse leukemia.",337-43,"['BURCHENAL, J H', 'WEBBER, L F', 'MEIGS, G M', 'BIEDLER, J L']","['BURCHENAL JH', 'WEBBER LF', 'MEIGS GM', 'BIEDLER JL']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,"['0 (Amino Acids)', '452-06-2 (2-Aminopurine)', '49P95BAU4Z (2,6-diaminopurine)', '935E97BOY8 (Folic Acid)']",OM,"['2-Aminopurine/analogs & derivatives', '*Amino Acids', 'Animals', '*Folic Acid', '*Leukemia', 'Mice']",['CLML: 5120:53071:546'],['NLM'],['*LEUKEMIA'],1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,Blood. 1951 Apr;6(4):337-43.,['S0006-4971(20)64317-8 [pii]'],,,,,,,,,,,,,
14820985,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),6,4,1951 Apr,Serum anti-proteases in the leukemias.,330-6,"['WEST, P M', 'SMITH, B W']","['WEST PM', 'SMITH BW']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,"['EC 3.- (Hydrolases)', 'EC 3.4.- (Endopeptidases)', 'EC 3.4.- (Peptide Hydrolases)']",OM,"['*Blood', '*Endopeptidases', 'Humans', '*Hydrolases', '*Leukemia', '*Peptide Hydrolases']",['CLML: 5120:53070:109:546'],['NLM'],"['*BLOOD', '*LEUKEMIA']",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,Blood. 1951 Apr;6(4):330-6.,['S0006-4971(20)64316-6 [pii]'],,,,,,,,,,,,,
14820467,NLM,MEDLINE,20040215,20191210,0096-6630 (Print) 0096-6630 (Linking),68,3,1951 Mar,Infectious origin of acute leukemia.,110-9,"['BROWN, E E']",['BROWN EE'],['eng'],['Journal Article'],,United States,Arch Pediatr,Archives of pediatrics,15210180R,,OM,"['*Acute Disease', '*Communicable Diseases', 'Humans', '*Infections', '*Leukemia']",['CLML: 5120:52497:474:546'],['NLM'],"['*INFECTION', '*LEUKEMIA']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Arch Pediatr. 1951 Mar;68(3):110-9.,,,,,,,,,,,,,,
14820451,NLM,MEDLINE,20040215,20181201,0003-9691 (Print) 0003-9691 (Linking),12,1,1951,[Plasmocytic leukosarcomatosis in a worker from inhalation of tar vapors].,48-50,"['ROCHE, L', 'MOREL, S', 'GUILLERMET, J']","['ROCHE L', 'MOREL S', 'GUILLERMET J']",['und'],['Journal Article'],Leucosarcomatose plasmocytaire chez un ouvrier expose a inhaler des vapeur de brai.,France,Arch Mal Prof,Archives des maladies professionnelles de medecine du travail et de securite sociale,2985157R,['0 (Tars)'],OM,"['Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', '*Neoplasms', '*Occupational Health', '*Sarcoma', '*Tars']",['CLML: 5120:52481:267:353:468'],['NLM'],"['*INDUSTRIAL HYGIENE', '*SARCOMA, LEUKOSARCOMA', '*TAR']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Arch Mal Prof. 1951;12(1):48-50.,,,,,,,,,,,,,,
14819611,NLM,MEDLINE,20040215,20181201,0365-3307 (Print) 0365-3307 (Linking),7,,1950 Jul,[Atypical cellular fractionation in a case of acute leukemia].,131-4,"['GOUVEIA, E']",['GOUVEIA E'],['und'],['Journal Article'],In vulgar fragmentacao celular num caso de leucemia aguda.,Portugal,An Inst Med Trop (Lisb),Anais do Instituto de Medicina Tropical,7502512,,OM,"['*Acute Disease', '*Dose Fractionation, Radiation', 'Humans', '*Leukemia']",['CLML: 5120:51619:546'],['NLM'],['*LEUKEMIA'],1950/07/01 00:00,1950/07/01 00:01,['1950/07/01 00:00'],"['1950/07/01 00:00 [pubmed]', '1950/07/01 00:01 [medline]', '1950/07/01 00:00 [entrez]']",ppublish,An Inst Med Trop (Lisb). 1950 Jul;7:131-4.,,,,,,,,,,,,,,
14819058,NLM,MEDLINE,20040215,20190627,0002-9343 (Print) 0002-9343 (Linking),10,4,1951 Apr,Lymphocytic leukemoid reaction associated with primary carcinoma of the breast.,522-7,"['KLEEMAN, C R']",['KLEEMAN CR'],['eng'],['Journal Article'],,United States,Am J Med,The American journal of medicine,0267200,,OM,"['*Breast', '*Carcinoma', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Leukemoid Reaction']",['CLML: 5120:51066:142:173:546'],['NLM'],"['*BREAST', '*CARCINOMA', '*LEUKEMIA, LYMPHATIC']",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,Am J Med. 1951 Apr;10(4):522-7. doi: 10.1016/0002-9343(51)90323-3.,"['0002-9343(51)90323-3 [pii]', '10.1016/0002-9343(51)90323-3 [doi]']",,,,,,,,,,,,,
14819051,NLM,MEDLINE,20040215,20190627,0002-9343 (Print) 0002-9343 (Linking),10,4,1951 Apr,Treatment of leukemia with aminopterin.,452-8,"['MEYER, L M', 'NEWMAN, A']","['MEYER LM', 'NEWMAN A']",['eng'],['Journal Article'],,United States,Am J Med,The American journal of medicine,0267200,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Aminopterin', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:51059:349:545'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,Am J Med. 1951 Apr;10(4):452-8. doi: 10.1016/0002-9343(51)90290-2.,"['0002-9343(51)90290-2 [pii]', '10.1016/0002-9343(51)90290-2 [doi]']",,,,,,,,,,,,,
14818794,NLM,MEDLINE,20040215,20181201,0365-5504 (Print) 0365-5504 (Linking),4,1,1951 Jan-Feb,[Lymphosarcomatosis with clinical characteristics of a chloroma revealed during total remission of acute leukemia].,1-25,"['COLARIZI, A', 'SORAGNI, E']","['COLARIZI A', 'SORAGNI E']",['und'],['Journal Article'],Linfosarcomatosi con caratteri clinici di cloroma rivelatasi durante remissone totale di una leucemia acuta.,Italy,Acta Paediatr Lat,Acta paediatrica Latina,0370360,,OM,"['Humans', '*Leukemia', '*Lymphoma', '*Lymphoma, Non-Hodgkin', '*Neoplasms', '*Sarcoma', '*Sarcoma, Myeloid']",['CLML: 5120:50802:267:546'],['NLM'],"['*LEUKEMIA', '*SARCOMA, LYMPHOSARCOMA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Paediatr Lat. 1951 Jan-Feb;4(1):1-25.,,,,,,,,,,,,,,
14818745,NLM,MEDLINE,20040215,20190812,0001-6101 (Print) 0001-6101 (Linking),139,4,1951,"Relations between pernicious anaemia, myeloid leukaemia and lymphatic leukaemia.",275-91,"['PLUM, C M']",['PLUM CM'],['eng'],['Journal Article'],,Sweden,Acta Med Scand,Acta medica Scandinavica,0370330,,OM,"['*Anemia', '*Anemia, Pernicious', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Leukemia, Myeloid']",['CLML: 5120:50753:39:546:547'],['NLM'],"['*ANEMIA, PERNICIOUS', '*LEUKEMIA, LYMPHATIC', '*LEUKEMIA, MYELOGENOUS']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Med Scand. 1951;139(4):275-91. doi: 10.1111/j.0954-6820.1951.tb17167.x.,['10.1111/j.0954-6820.1951.tb17167.x [doi]'],,,,,,,,,,,,,
14818709,NLM,MEDLINE,20040215,20181201,0001-5989 (Print) 0001-5989 (Linking),2,1,1951,[On acute asymptomatic hyperlymphocytosis].,21-58,"['HAVAS, A']",['HAVAS A'],['und'],['Journal Article'],Uber die Hyperlymphocytosis acuta asymptomatica.,Hungary,Acta Med Acad Sci Hung,Acta medica Academiae Scientiarum Hungaricae,0370323,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5120:50709:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Med Acad Sci Hung. 1951;2(1):21-58.,,,,,,,,,,,,,,
14818690,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),5,2,1951 Feb,Chronic lymphatic leukemia associated with Hodgkin's disease.,65-74,"['SEIFE, M', 'REICH, C', 'LISA, J R']","['SEIFE M', 'REICH C', 'LISA JR']",['eng'],['Journal Article'],,Switzerland,Acta Haematol,Acta haematologica,0141053,['0 (Anti-Bacterial Agents)'],OM,"['*Anti-Bacterial Agents', '*Hodgkin Disease', 'Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', '*Leukemia, Lymphoid']",['CLML: 5120:50690:48:443:546'],['NLM'],"['*ANTIBIOTICS', ""*HODGKIN'S DISEASE"", '*LEUKEMIA, LYMPHATIC']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,Acta Haematol. 1951 Feb;5(2):65-74. doi: 10.1159/000203813.,['10.1159/000203813 [doi]'],,,,,,,,,,,,,
14818525,NLM,MEDLINE,20040215,20181201,0096-6711 (Print) 0096-6711 (Linking),51,5,1951 May,Histochemical distribution of glycogen. III. In kidneys of leukemic patients.,494-7,"['MENTEN, M L', 'CARPENTER, A M']","['MENTEN ML', 'CARPENTER AM']",['eng'],['Journal Article'],,United States,AMA Arch Pathol,A.M.A. archives of pathology,14470150R,['9005-79-2 (Glycogen)'],OM,"['*Glycogen', 'Humans', '*Kidney', '*Leukemia']",['CLML: 5120:50517:386:509:546'],['NLM'],"['*GLYCOGEN', '*KIDNEYS', '*LEUKEMIA']",1951/05/01 00:00,1951/05/01 00:01,['1951/05/01 00:00'],"['1951/05/01 00:00 [pubmed]', '1951/05/01 00:01 [medline]', '1951/05/01 00:00 [entrez]']",ppublish,AMA Arch Pathol. 1951 May;51(5):494-7.,,,,,,,,,,,,,,
14818090,NLM,MEDLINE,20040215,20181201,0043-5376 (Print) 0043-5376 (Linking),32,1,1951 Jan,[Effect of roentgen rays on the action of urethane].,31-6,"['FOCHEM, K', 'REIMER, E', 'SCHMID, J']","['FOCHEM K', 'REIMER E', 'SCHMID J']",['und'],['Journal Article'],Einfluss der Rontgenstrahlen auf die Urethanwirkung.,Austria,Wien Z Inn Med,Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete,7502231,['3IN71E75Z5 (Urethane)'],OM,"['*Leukemia', '*Urethane', '*X-Rays']",['CLML: 5120:49988:245:417:546'],['NLM'],"['*LEUKEMIA', '*ROENTGEN RAYS', '*URETHANE']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Wien Z Inn Med. 1951 Jan;32(1):31-6.,,,,,,,,,,,,,,
14817166,NLM,MEDLINE,20040215,20190823,0036-5513 (Print) 0036-5513 (Linking),2,4,1950,Effects of ACTH in human leukemia.,276-83,"['VIDEBAEK, AA']",['VIDEBAEK A'],['eng'],['Journal Article'],,England,Scand J Clin Lab Invest,Scandinavian journal of clinical and laboratory investigation,0404375,['9002-60-2 (Adrenocorticotropic Hormone)'],OM,"['*Adrenocorticotropic Hormone', '*Leukemia']",['CLML: 5120:49010:8:545'],['NLM'],"['*ACTH', '*LEUKEMIA']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Scand J Clin Lab Invest. 1950;2(4):276-83. doi: 10.3109/00365515009056673.,['10.3109/00365515009056673 [doi]'],,,,,,,,,,,,,
14817138,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,1,1951,[A case of myelogenous leukemia without splenomegaly with rapidly fatal evolution].,76-7,"['BETHOUX, L', 'SEIGNEURIN, R', 'CAU, G']","['BETHOUX L', 'SEIGNEURIN R', 'CAU G']",['und'],['Journal Article'],Un cas de leucemie myelogene sans splenomeglie a evolution rapidement mortelle.,France,Sang,Le Sang,20540380R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Splenomegaly']",['CLML: 5120:48982:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(1):76-7.,,,,,,,,,,,,,,
14817128,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),22,1,1951,[Lesions of the fundus oculi in acute leucosis].,1-11,"['DOLLFUS, M A', 'CAT, N D']","['DOLLFUS MA', 'CAT ND']",['und'],['Journal Article'],Les lesions du fond de l'oeil dans la leucose aigue.,France,Sang,Le Sang,20540380R,,OM,"['*Fundus Oculi', 'Humans', '*Leukemia']",['CLML: 5120:48972:362:546'],['NLM'],"['*FUNDUS OCULI', '*LEUKEMIA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Sang. 1951;22(1):1-11.,,,,,,,,,,,,,,
14816904,NLM,MEDLINE,20040215,20181201,0035-3787 (Print) 0035-3787 (Linking),83,4,1950 Oct,[Sensorimotor polyneuritis of the extremities in a case of lympho-histiocytary hyperplasia].,294-7,"['ALAJOUANINE, T', 'CASTAIGNE, P', 'LHERMITTE, F', 'GRAVELEAU, J']","['ALAJOUANINE T', 'CASTAIGNE P', 'LHERMITTE F', 'GRAVELEAU J']",['und'],['Journal Article'],Polynevrite sensitivo-motrice des quatre membres chez un malade atteint d'hyperplasie lympho-histiocytaire.,France,Rev Neurol (Paris),Revue neurologique,2984779R,,OM,"['*Extremities', 'Humans', '*Hyperplasia', '*Leukemia', '*Neuritis', '*Polyneuropathies']",['CLML: 5120:48712:83:325:546'],['NLM'],"['*EXTREMITIES', '*LEUKEMIA', '*NEURITIS, MULTIPLE']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Rev Neurol (Paris). 1950 Oct;83(4):294-7.,,,,,,,,,,,,,,
14816884,NLM,MEDLINE,20040215,20181201,0370-632X (Print) 0370-632X (Linking),7,4,1950 Oct-Dec,[Myeloid leukemia treated by localized radiotherapy; survival for six years after beginning irradiation].,495-7,"['PONTHUS, P', 'BERBIR, A', 'HAJJAR, J']","['PONTHUS P', 'BERBIR A', 'HAJJAR J']",['und'],['Journal Article'],Leucemie myeloide traitee par radiotherapie localisee; survie de six ans apres le debut des irradiations.,Lebanon,Rev Med Moyen Orient,Revue medicale du Moyen-Orient,20340240R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Radiotherapy']",['CLML: 5120:48692:217:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*RADIOTHERAPY']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Rev Med Moyen Orient. 1950 Oct-Dec;7(4):495-7.,,,,,,,,,,,,,,
14816851,NLM,MEDLINE,20040215,20181201,0370-4386 (Print) 0370-4386 (Linking),5,5-6,1950,[Morphology of leukemic cells in electron microscopy].,746-63,"['BERNHARD, W', 'BRAUNSTEINER, H', 'FEBVRE, H L', 'HAREL, J', 'KLEIN, R', 'OBERLING, C']","['BERNHARD W', 'BRAUNSTEINER H', 'FEBVRE HL', 'HAREL J', 'KLEIN R', 'OBERLING C']",['und'],['Journal Article'],Morphologie des cellules leucemiques au microscope electronique.,France,Rev Hematol,Revue d'hematologie,20330240R,,OM,"['*Leukemia', '*Microscopy, Electron']",['CLML: 5120:48659:546'],['NLM'],['*LEUKEMIA'],1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Rev Hematol. 1950;5(5-6):746-63.,,,,,,,,,,,,,,
14816775,NLM,MEDLINE,20040215,20181201,,21,263,1950 Nov,[Lymphatic aleukemic chronic leukemia].,687-90,"['VERAU, J M']",['VERAU JM'],['und'],['Journal Article'],"Leucemia aleucemica linfoide cronica (Un caso referido en el Hospital de Belen, sala Sta. Luisa, Trujillo).",Peru,Rev Med Peru,Revista medica peruana,20240510R,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5120:48579:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Rev Med Peru. 1950 Nov;21(263):687-90.,,,,,,,,,,,,,,
14816382,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),76,1,1951 Jan,"""Spontaneous"" leukemia developing in C3H mice following inoculation in infancy, with AK-leukemic extracts, or AK-embrvos.",27-32,"['GROSS, L']",['GROSS L'],['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,,OM,"['Animals', '*Leukemia', 'Mice', 'Mice, Inbred C3H', '*Vaccination']",['CLML: 5120:48149:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1951 Jan;76(1):27-32.,,,,,,,,,,,,,,
14815980,NLM,MEDLINE,20040215,20181201,0031-3939 (Print) 0031-3939 (Linking),24,9,1950 Sep,[Differential diagnosis of leukemia in children].,831-3,"['MIKULOWSKI, W']",['MIKULOWSKI W'],['und'],['Journal Article'],Przyczynki do trudnosci rozniczkowo rozpoznawczych bialaczki w'wieku dzieciecym.,Poland,Pediatr Pol,Pediatria polska,2985039R,,OM,"['Child', '*Diagnosis, Differential', 'Humans', '*Leukemia']",['CLML: 5120:47742:546'],['NLM'],['*LEUKEMIA'],1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Pediatr Pol. 1950 Sep;24(9):831-3.,,,,,,,,,,,,,,
14815917,NLM,MEDLINE,20040215,20181201,0369-7606 (Print) 0369-7606 (Linking),3,4,1950,[Two cases of bilateral sarcoma of the adrenals with central nervous symptoms].,219-32,"['DA RUGNA, D']",['DA RUGNA D'],['und'],['Journal Article'],Uber 2 Falle doppelseitiger Nebennieren-Sarkome mit zentralnervosen Symptomen.,Switzerland,Oncologia,Oncologia,0134456,,OM,"['*Adrenal Glands', 'Humans', '*Leukemia, Myeloid', '*Primary Myelofibrosis', '*Sarcoma', '*Spinal Cord']",['CLML: 5120:47675:16:68:266:315'],['NLM'],"['*ADRENALS', '*MYELOSIS', '*SARCOMA', '*SPINAL CORD']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Oncologia. 1950;3(4):219-32.,,,,,,,,,,,,,,
14815768,NLM,MEDLINE,20040215,20181201,0028-7628 (Print) 0028-7628 (Linking),51,5,1951 Mar 1,Gaucher's disease and giant follicular lymphoblastoma.,645-7,"['FRIEDMAN, I S', 'GRAYZEL, D M']","['FRIEDMAN IS', 'GRAYZEL DM']",['eng'],['Journal Article'],,United States,N Y State J Med,New York state journal of medicine,0401064,,OM,"['*Anemia', '*Gaucher Disease', '*Hypersplenism', '*Leukemia', '*Lymphoma, Non-Hodgkin']",['CLML: 5120:47526:40:196'],['NLM'],"['*ANEMIA, SPLENIC', '*PSEUDOLEUKEMIA']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,N Y State J Med. 1951 Mar 1;51(5):645-7.,,,,,,,,,,,,,,
14815397,NLM,MEDLINE,20040215,20181201,0025-8628 (Print) 0025-8628 (Linking),6,11,1950 Nov,[Observations on the course of leukemic syndrome in chickens].,648,['DOMANSKI'],['DOMANSKI'],['und'],['Journal Article'],Obserwacje nad przebiegiem kompleksu bialaczkowego u kur.,Poland,Med Weter,Medycyna weterynaryjna,0413416,,OM,"['Animals', '*Chickens', 'Humans', '*Leukemia', '*Meat', '*Syndrome']",['CLML: 5120:47155:546'],['NLM'],['*LEUKEMIA'],1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Med Weter. 1950 Nov;6(11):648.,,,,,,,,,,,,,,
14814860,NLM,MEDLINE,20040215,20190612,0140-6736 (Print) 0140-6736 (Linking),1,6658,1951 Apr 7,Cortisone in acute lymphoblastic leukemia.,760-2,"['SUZMAN, M M', 'GOLDBERG, B', 'HIRSCH, H']","['SUZMAN MM', 'GOLDBERG B', 'HIRSCH H']",['eng'],['Journal Article'],,England,Lancet,"Lancet (London, England)",2985213R,['V27W9254FZ (Cortisone)'],OM,"['*Acute Disease', '*Cortisone', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Precursor Cell Lymphoblastic Leukemia-Lymphoma']",['CLML: 5120:46574:227:546'],['NLM'],"['*CORTISONE', '*LEUKEMIA, LYMPHATIC']",1951/04/07 00:00,1951/04/07 00:01,['1951/04/07 00:00'],"['1951/04/07 00:00 [pubmed]', '1951/04/07 00:01 [medline]', '1951/04/07 00:00 [entrez]']",ppublish,Lancet. 1951 Apr 7;1(6658):760-2. doi: 10.1016/s0140-6736(51)92184-8.,"['S0140-6736(51)92184-8 [pii]', '10.1016/s0140-6736(51)92184-8 [doi]']",,,,,,,,,,,,,
14814794,NLM,MEDLINE,20040215,20181201,0023-1495 (Print) 0023-1495 (Linking),18,11-12,1950 Nov-Dec,[Spontaneous remission of acute leukemia].,532-5,"['HUTH, E']",['HUTH E'],['und'],['Journal Article'],Spontanremission einer akuten Leukamie.,Germany,Kinderarztl Prax,Kinderarztliche Praxis,0376356,,OM,"['*Acute Disease', 'Humans', '*Leukemia', '*Remission, Spontaneous']",['CLML: 5120:46508:546'],['NLM'],['*LEUKEMIA'],1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Kinderarztl Prax. 1950 Nov-Dec;18(11-12):532-5.,,,,,,,,,,,,,,
14814792,NLM,MEDLINE,20040215,20181201,0023-1495 (Print) 0023-1495 (Linking),18,11-12,1950 Nov-Dec,"[Leukemia misdiagnoses as articular rheumatism, with observations on the pathomorphism of leukosis].",526-30,"['OPITZ, H']",['OPITZ H'],['und'],['Journal Article'],Gelenkrheumatismus-Leukamie Zugleich ein Beitrag zur Frage der Pathomorphose der Leukosen.,Germany,Kinderarztl Prax,Kinderarztliche Praxis,0376356,,OM,"['*Arthritis', '*Arthritis, Rheumatoid', '*Diagnostic Errors', 'Humans', '*Joint Diseases', '*Leukemia']",['CLML: 5120:46506:63:546'],['NLM'],"['*ARTHRITIS, RHEUMATOID', '*LEUKEMIA']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Kinderarztl Prax. 1950 Nov-Dec;18(11-12):526-30.,,,,,,,,,,,,,,
14814205,NLM,MEDLINE,20040215,20181201,0021-9738 (Print) 0021-9738 (Linking),30,2,1951 Feb,The haemolytic factor in the anaemia of lymphatic leukaemia.,130-6,"['BROWN, G M', 'ELLIOTT, S M', 'YOUNG, W A']","['BROWN GM', 'ELLIOTT SM', 'YOUNG WA']",['eng'],['Journal Article'],,United States,J Clin Invest,The Journal of clinical investigation,7802877,,OM,"['*Anemia', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5120:45887:38:546'],['NLM'],"['*ANEMIA', '*LEUKEMIA, LYMPHATIC']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,J Clin Invest. 1951 Feb;30(2):130-6. doi: 10.1172/JCI102425.,['10.1172/JCI102425 [doi]'],PMC436238,,,,,,,,,,,,
14813938,NLM,MEDLINE,20040215,20181201,0098-6151 (Print) 0098-6151 (Linking),50,6,1951 Feb,The present status of radiation therapy of the leukemias.,309-10; passim,"['PORIAS, J A']",['PORIAS JA'],['eng'],['Journal Article'],,United States,J Am Osteopath Assoc,The Journal of the American Osteopathic Association,7503065,,OM,"['Humans', '*Leukemia', '*Radiotherapy']",['CLML: 5120:45620:216:546'],['NLM'],"['*LEUKEMIA', '*RADIOTHERAPY']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,J Am Osteopath Assoc. 1951 Feb;50(6):309-10; passim.,,,,,,,,,,,,,,
14812435,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,2,1951 Feb,The anti-leukemic action of combinations of certain known anti-leukemic agents.,109-12,"['SKIPPER, H E', 'CHAPMAN, J B', 'BELL, M']","['SKIPPER HE', 'CHAPMAN JB', 'BELL M']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,,OM,"['Humans', '*Leukemia']",['CLML: 5120:44035:546'],['NLM'],['*LEUKEMIA'],1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Feb;11(2):109-12.,,,,,,,,,,,,,,
14811962,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),26,7,1950 Jul,[Ribosuria in normal subjects and in leukemic and neoplastic subjects].,1051-4,"['LEONARDI, G', 'AMALFI, M']","['LEONARDI G', 'AMALFI M']",['und'],['Journal Article'],La ribosuria in soggetti normali e in soggetti leucemici e neoplastici.,Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,['681HV46001 (Ribose)'],OM,"['Humans', '*Leukemia', '*Neoplasms', '*Ribose']",['CLML: 5120:43535:166:237:546'],['NLM'],"['*CANCER', '*LEUKEMIA', '*RIBOSE']",1950/07/01 00:00,1950/07/01 00:01,['1950/07/01 00:00'],"['1950/07/01 00:00 [pubmed]', '1950/07/01 00:01 [medline]', '1950/07/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1950 Jul;26(7):1051-4.,,,,,,,,,,,,,,
14811961,NLM,MEDLINE,20040215,20181201,0037-8771 (Print) 0037-8771 (Linking),26,7,1950 Jul,[Etiopathogenetic problem of leukemia. II. Conditioning factors in the hemopathic evolution of the viral infection induced in the guineapig with the viruses isolated from human leukemia].,1048-51,"['MAGRASSI, F', 'NEGRONI, G', 'TOLU, A', 'MARRAS, G']","['MAGRASSI F', 'NEGRONI G', 'TOLU A', 'MARRAS G']",['und'],['Journal Article'],Contributo allo studio del problema eziopatogenetico delle leucemie. II. Fattori condizionanti nella evoluzione emopatica della infezione virale indotta nella cavia con i virus isolati da leucemie umane.,Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,['9001-26-7 (Prothrombin)'],OM,"['*Biological Evolution', 'Guinea Pigs', 'Humans', '*Leukemia', '*Prothrombin', '*Virus Diseases', '*Viruses']",['CLML: 5120:43534:546'],['NLM'],['*LEUKEMIA'],1950/07/01 00:00,1950/07/01 00:01,['1950/07/01 00:00'],"['1950/07/01 00:00 [pubmed]', '1950/07/01 00:01 [medline]', '1950/07/01 00:00 [entrez]']",ppublish,Boll Soc Ital Biol Sper. 1950 Jul;26(7):1048-51.,,,,,,,,,,,,,,
14811915,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),6,3,1951 Mar,Erythroleukemia.,261-9,"['BLACKBURN, E K', 'LAJTHA, L G']","['BLACKBURN EK', 'LAJTHA LG']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,,OM,"['*Hematopoietic System', 'Humans', '*Leukemia, Erythroblastic, Acute']",['CLML: 5120:43488:429'],['NLM'],['*HEMOPOIETIC SYSTEM'],1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Blood. 1951 Mar;6(3):261-9.,['S0006-4971(20)64404-4 [pii]'],,,,,,,,,,,,,
14811908,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),6,2,1951 Feb,Chemical studies of normal and leukemic bone marrow.,175-82,"['DIETZ, A A', 'STEINBERG, B']","['DIETZ AA', 'STEINBERG B']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,,OM,"['*Bone Marrow', 'Humans', '*Leukemia']",['CLML: 5120:43481:130:546'],['NLM'],"['*BONE MARROW', '*LEUKEMIA']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,Blood. 1951 Feb;6(2):175-82.,['S0006-4971(20)64412-3 [pii]'],,,,,,,,,,,,,
14811804,NLM,MEDLINE,20040215,20181201,0004-1556 (Print) 0004-1556 (Linking),8,3,1951 Mar,Chloroma (a case report).,33-6,"['LOPEZ QUINONES, E G', 'GARCIA, R', 'CONTRERAS, E']","['LOPEZ QUINONES EG', 'GARCIA R', 'CONTRERAS E']",['eng'],['Journal Article'],,United States,Ariz Med,Arizona medicine,0372465,,OM,"['*Contracture', 'Humans', '*Ischemic Contracture', '*Leukemia', '*Leukemia, Myeloid', '*Monocytes', '*Neoplasms', '*Sarcoma, Myeloid']",['CLML: 5120:43362:221:404:547'],['NLM'],"['*CONTRACTURE, ISCHEMIC', '*LEUKEMIA, MONOCYTIC', '*TUMORS, CHLOROMA']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,Ariz Med. 1951 Mar;8(3):33-6.,,,,,,,,,,,,,,
14811711,NLM,MEDLINE,20040215,20181201,0004-0312 (Print) 0004-0312 (Linking),90,6,1950 Dec,"[Quantitative evaluation of asynchronisms of nucleo-cytoplasmatic maturation of bone marrow cells. II. Research on granuloblasts under normal conditions, in leukocytes and in chronic leukemia].",502-5,"['ASTALDI, G', 'GALLO, V', 'SACCHETTI, C']","['ASTALDI G', 'GALLO V', 'SACCHETTI C']",['und'],['Journal Article'],"Valutazione quantitativa degli asincronismi di maturazione nucleocitoplasmatica delle cellule midollari. II. Ricerche sui granuloblasti nella norma, nelle leucocitosi e nelle leucemie croniche.",Italy,Arch Sci Med (Torino),Archivio per le scienze mediche,0372451,,OM,"['*Bone Marrow Cells', 'Humans', '*Leukemia', '*Leukocytes']",['CLML: 5120:43267:545:547'],['NLM'],"['*LEUKEMIA', '*LEUKOCYTES']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Arch Sci Med (Torino). 1950 Dec;90(6):502-5.,,,,,,,,,,,,,,
14811658,NLM,MEDLINE,20040215,20181201,0004-0061 (Print) 0004-0061 (Linking),16,1,1951 Jan,[Hyperplastic follicle splenomegaly; pure splenic form of Brill-Symmers disease].,305-37,"['BELLUCCI, G']",['BELLUCCI G'],['und'],['Journal Article'],Splenomegalia follicolo iperplastica (forma splenica pura del morbo di Brill Symmers).,Italy,Arch De Vecchi Anat Patol,"Archivio ""de Vecchi"" per l'anatomia patologica e la medicina clinica",0372455,,OM,"['Female', 'Humans', '*Hyperplasia', '*Leukemia', '*Lymphoma', '*Lymphoma, Follicular', '*Lymphoma, Non-Hodgkin', '*Neoplasms', '*Ovarian Follicle', '*Spleen', '*Splenomegaly']",['CLML: 5120:43210:196:317:406'],['NLM'],"['*PSEUDOLEUKEMIA', '*SPLEEN', '*TUMORS, LYMPHOBLASTOMA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Arch De Vecchi Anat Patol. 1951 Jan;16(1):305-37.,,,,,,,,,,,,,,
14811623,NLM,MEDLINE,20040215,20181201,,1,1,1951 Jan,Atypical abdominal tuberculosis simulating myeloid leukemia.,19-25,"['FRIEND, J', 'STEWART, J W', 'THACKRAY, A C']","['FRIEND J', 'STEWART JW', 'THACKRAY AC']",['eng'],['Journal Article'],,Scotland,Arch Middx Hosp,Archives. Middlesex Hospital,18340010R,,OM,"['*Abdomen', '*Abdominal Cavity', 'Humans', '*Leukemia, Myeloid', '*Leukocytosis', 'Tuberculosis/*diagnosis']",['CLML: 5120:43175:2:393:548'],['NLM'],"['*ABDOMEN', '*LEUKOCYTOSIS', '*TUBERCULOSIS, DIAGNOSIS']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Arch Middx Hosp. 1951 Jan;1(1):19-25.,,,,,,,,,,,,,,
14811171,NLM,MEDLINE,20040215,20181201,0365-4931 (Print) 0365-4931 (Linking),67,11-12,1950 Nov-Dec,[Mikulicz' syndrome and leukemia].,835-40,"['CHATELLIER, H P', 'FRONTEAU']","['CHATELLIER HP', 'FRONTEAU']",['und'],['Journal Article'],Syndrome de Mikulicz et leucemie.,France,Ann Otolaryngol,Les Annales d'oto-laryngologie,15010150R,,OM,"['Humans', '*Leukemia', ""*Mikulicz' Disease""]",['CLML: 5120:42712:42:546'],['NLM'],"['*LEUKEMIA', ""*MIKULICZ'S DISEASE""]",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Ann Otolaryngol. 1950 Nov-Dec;67(11-12):835-40.,,,,,,,,,,,,,,
14810515,NLM,MEDLINE,20040215,20190812,0001-6101 (Print) 0001-6101 (Linking),139,2,1951,Eosinophilic leukemia infiltrating the gasserian ganglion.,146-52,"['NORDLANDER, N B']",['NORDLANDER NB'],['eng'],['Journal Article'],,Sweden,Acta Med Scand,Acta medica Scandinavica,0370330,,OM,"['Humans', '*Hypereosinophilic Syndrome', '*Leukemia', '*Trigeminal Ganglion']",['CLML: 5120:42025:369:546'],['NLM'],"['*GASSERIAN GANGLION', '*LEUKEMIA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Acta Med Scand. 1951;139(2):146-52. doi: 10.1111/j.0954-6820.1951.tb17154.x.,['10.1111/j.0954-6820.1951.tb17154.x [doi]'],,,,,,,,,,,,,
14810259,NLM,MEDLINE,20040215,20190917,0888-2479 (Print) 0888-2479 (Linking),87,3,1951 Mar,"Titrated, regularly spaced radioactive phosphorus or spray roentgen therapy of leukemias.",329-48,"['OSGOOD, E E']",['OSGOOD EE'],['eng'],['Journal Article'],,United States,AMA Arch Intern Med,A.M.A. archives of internal medicine,14470100R,"['0 (Phosphorus Radioisotopes)', '0 (Phosphorus, Dietary)', '27YLU75U4W (Phosphorus)']",OM,"['*Leukemia', '*Phosphorus', '*Phosphorus Radioisotopes', '*Phosphorus, Dietary', '*Radioactivity']",['CLML: 5120:41756:156:546'],['NLM'],"['*LEUKEMIA', '*PHOSPHORUS AND COMPOUNDS, RADIOACTIVE']",1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,AMA Arch Intern Med. 1951 Mar;87(3):329-48. doi: 10.1001/archinte.1951.03810030002001.,['10.1001/archinte.1951.03810030002001 [doi]'],,,,,,,,,,,,,
14810237,NLM,MEDLINE,20040215,20181201,0096-5979 (Print) 0096-5979 (Linking),63,4,1951 Apr,A case for diagnosis: lymphatic leukemia? Kaposi's sarcoma?,513-4,"['SACHS, W']",['SACHS W'],['eng'],['Journal Article'],,United States,AMA Arch Derm Syphilol,A.M.A. archives of dermatology and syphilology,14470040R,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels', '*Sarcoma', '*Sarcoma, Kaposi']",['CLML: 5120:41734:267:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', ""*SARCOMA, KAPOSI'S""]",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,AMA Arch Derm Syphilol. 1951 Apr;63(4):513-4.,,,,,,,,,,,,,,
14810232,NLM,MEDLINE,20040215,20191108,0096-5979 (Print) 0096-5979 (Linking),63,4,1951 Apr,Leukemia as a possible complication of radiodermatitis.,503,"['LYNCH, F W']",['LYNCH FW'],['eng'],['Journal Article'],,United States,AMA Arch Derm Syphilol,A.M.A. archives of dermatology and syphilology,14470040R,,OM,"['*Dermatitis', '*Leukemia', '*Radiodermatitis', '*X-Ray Therapy']",['CLML: 5120:41729:248:257:546'],['NLM'],"['*DERMATITIS', '*LEUKEMIA', '*ROENTGENOTHERAPY']",1951/04/01 00:00,1951/04/01 00:01,['1951/04/01 00:00'],"['1951/04/01 00:00 [pubmed]', '1951/04/01 00:01 [medline]', '1951/04/01 00:00 [entrez]']",ppublish,AMA Arch Derm Syphilol. 1951 Apr;63(4):503. doi: 10.1001/archderm.1951.01570040097019.,['10.1001/archderm.1951.01570040097019 [doi]'],,,,,,,,,,,,,
14810167,NLM,MEDLINE,20040215,20191108,2374-2941 (Print) 2374-2941 (Linking),81,3,1951 Mar,"Familial leukemia; a report of leukemia in five siblings, with a brief review of the genetic aspects of this disease.",313-22,"['ANDERSON, R C']",['ANDERSON RC'],['eng'],['Journal Article'],,United States,AMA Am J Dis Child,A.M.A. American journal of diseases of children,14470010R,,OM,"['Humans', '*Leukemia', '*Siblings']",['CLML: 5120:41664:546'],['NLM'],['*LEUKEMIA'],1951/03/01 00:00,1951/03/01 00:01,['1951/03/01 00:00'],"['1951/03/01 00:00 [pubmed]', '1951/03/01 00:01 [medline]', '1951/03/01 00:00 [entrez]']",ppublish,AMA Am J Dis Child. 1951 Mar;81(3):313-22. doi: 10.1001/archpedi.1951.02040030323001.,['10.1001/archpedi.1951.02040030323001 [doi]'],,,,,,,,,,,,,
14809848,NLM,MEDLINE,20040215,20181201,0196-5336 (Print) 0196-5336 (Linking),17,1,1951 Jan,"An evaluation of the nature, treatment, and prognosis of leukemia.",22-3,"['STURGIS, C C']",['STURGIS CC'],['eng'],['Journal Article'],,United States,Med Bull (Ann Arbor),"Medical bulletin (Ann Arbor, Mich.)",9427052,,OM,"['Humans', '*Leukemia', 'Prognosis']",['CLML: 5120:41235:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Med Bull (Ann Arbor). 1951 Jan;17(1):22-3.,,,,,,,,,,,,,,
14809522,NLM,MEDLINE,20040215,20181201,0039-2073 (Print) 0039-2073 (Linking),83,2,1950,"[Advances in the treatment of tumors, leukemia and granuloma].",183-97,"['GANSSLEN, M']",['GANSSLEN M'],['und'],['Journal Article'],"Fortschritte in der Behandlung von Tumoren, Leukamien und Granulomen.",Germany,Strahlentherapie,Strahlentherapie,1260024,"['0 (Sulfathiazoles)', 'N91BDP6H0X (Choline)', 'Y7FKS2XWQH (Sulfathiazole)']",OM,"['*Anura', '*Choline', '*Granuloma', '*Hodgkin Disease', '*Leukemia', '*Leukemia, Lymphoid', '*Leukemia, Myeloid', '*Neoplasms', 'Sulfathiazole', '*Sulfathiazoles']",['CLML: 5120:40900:203:341:360:444:547'],['NLM'],"['*CHOLINE', '*FROGS', ""*HODGKIN'S DISEASE"", '*LEUKEMIA, LYMPHATIC', '*LEUKEMIA, MYELOGENOUS', '*SULFATHIAZOLE']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Strahlentherapie. 1950;83(2):183-97.,,,,,,,,,,,,,,
14809323,NLM,MEDLINE,20040215,20181201,,26,92,1950 Dec 14,[Is there an infra-clinical stage of leukemia?].,4747-9,"['OLMER, J']",['OLMER J'],['und'],['Journal Article'],Existe-t-il un stade infraclinique des leucemies?,France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,,OM,"['Humans', '*Leukemia']",['CLML: 5120:40700:546'],['NLM'],['*LEUKEMIA'],1950/12/14 00:00,1950/12/14 00:01,['1950/12/14 00:00'],"['1950/12/14 00:00 [pubmed]', '1950/12/14 00:01 [medline]', '1950/12/14 00:00 [entrez]']",ppublish,Sem Hop. 1950 Dec 14;26(92):4747-9.,,,,,,,,,,,,,,
14809230,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),21,9,1950,[Relapse and fatal evolution of acute leukemia after complete remission for three years and seven months].,833-8,"['ANDRE, R']",['ANDRE R'],['und'],['Journal Article'],Rechute et evolution fatale d'une leucemie aigue apres une remission complete de trois ans et sept mois.,France,Sang,Le Sang,20540380R,,OM,"['*Acute Disease', 'Humans', '*Leukemia', '*Recurrence', '*Remission Induction']",['CLML: 5120:40607:546'],['NLM'],['*LEUKEMIA'],1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Sang. 1950;21(9):833-8.,,,,,,,,,,,,,,
14809227,NLM,MEDLINE,20040215,20181201,0370-8721 (Print) 0370-8721 (Linking),21,9,1950,[Anerythremic form of malignant subacute erythromyelosis; (Di Guglielmo's disease)].,823-6,"['AUBRY, M', 'PORTIER', 'VOLLENWEIDER']","['AUBRY M', 'PORTIER', 'VOLLENWEIDER']",['und'],['Journal Article'],Erythromyelose maligne subaique a forme anerythremique; (maladie de Di Guglielmo).,France,Sang,Le Sang,20540380R,,OM,"['*Erythroblastosis, Fetal', '*Hematologic Diseases', 'Humans', '*Leukemia, Erythroblastic, Acute', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Primary Myelofibrosis']",['CLML: 5120:40604:68:314'],['NLM'],"['*ERYTHROBLASTOSIS', '*MYELOSIS']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Sang. 1950;21(9):823-6.,,,,,,,,,,,,,,
14809178,NLM,MEDLINE,20040215,20181201,0035-6077 (Print) 0035-6077 (Linking),48,12,1950 Dec,[Considerations on an atypical case of infectious mononucleosis in a six year old child].,773-84,"['ROSSI, R', 'LOTTINI, A']","['ROSSI R', 'LOTTINI A']",['und'],['Journal Article'],Considerazioni su di un caso di mononucleosi infettiva a decorso atipico in un bambino di sei anni.,Italy,Riv Clin Pediatr,Rivista di clinica pediatrica,0404503,,OM,"['Child', '*Communicable Diseases', 'Humans', '*Infectious Mononucleosis', '*Leukemia']",['CLML: 5120:40555:52:546'],['NLM'],"['*LEUKEMIA', '*MONONUCLEOSIS, INFECTIOUS']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Riv Clin Pediatr. 1950 Dec;48(12):773-84.,,,,,,,,,,,,,,
14808860,NLM,MEDLINE,20040215,20181201,0034-7531 (Print) 0034-7531 (Linking),22,12,1950 Dec,[Case report of chronic myeloid leukemia in an infant treated with urethane].,751-64,"['PADRON RUIZ, E']",['PADRON RUIZ E'],['und'],['Journal Article'],Reporte de un caso de leucemia mieloide cronica en un lactante tratado con uretano.,Cuba,Rev Cubana Pediatr,Revista cubana de pediatria,0417464,['3IN71E75Z5 (Urethane)'],OM,"['*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Urethane']",['CLML: 5120:40199:417:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*URETHANE']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Rev Cubana Pediatr. 1950 Dec;22(12):751-64.,,,,,,,,,,,,,,
14808458,NLM,MEDLINE,20040215,20181201,0370-1514 (Print) 0370-1514 (Linking),6,23,1950 Dec 15,[Current therapy of chronic leukemia and malignant lymphogranuloma; clinical contribution].,775-6,"['TIMPANO, P']",['TIMPANO P'],['und'],['Journal Article'],Le terapia attuale delle leucemie croniche e del linfogranuloma maligno; (contributo clinico).,Italy,Prog Med (Napoli),Il Progresso medico,2984827R,,OM,"['*Chronic Disease', '*Hodgkin Disease', '*Leukemia']",['CLML: 5120:39789:444:546'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA']",1950/12/15 00:00,1950/12/15 00:01,['1950/12/15 00:00'],"['1950/12/15 00:00 [pubmed]', '1950/12/15 00:01 [medline]', '1950/12/15 00:00 [entrez]']",ppublish,Prog Med (Napoli). 1950 Dec 15;6(23):775-6.,,,,,,,,,,,,,,
14808392,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),75,3,1950 Dec,Uniform transfer to random bred rats of lymphatic leukemia induced by gastric instillation of methylcholanthrene.,753-4,"['SHAY, H', 'GRUENSTEIN, M', 'GLAZER, L']","['SHAY H', 'GRUENSTEIN M', 'GLAZER L']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['0 (Benz(a)Anthracenes)', '429L45KABE (cholanthrene)', '56-49-5 (Methylcholanthrene)']",OM,"['Animals', '*Benz(a)Anthracenes', '*Leukemia', '*Leukemia, Lymphoid', '*Methylcholanthrene', 'Rats']",['CLML: 5120:39723:201:546'],['NLM'],"['*CHOLANTHRENE', '*LEUKEMIA, LYMPHATIC']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1950 Dec;75(3):753-4. doi: 10.3181/00379727-75-18331.,['10.3181/00379727-75-18331 [doi]'],,,,,,,,,,,,,
14808356,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),75,3,1950 Dec,"Similarity of hematologic effect of pyridoxine deficiency, cortisone, and myeloid metaplasia factor of human urine.",655-8,"['WEIR, D R', 'HEINLE, R W']","['WEIR DR', 'HEINLE RW']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['8059-24-3 (Vitamin B 6)', 'V27W9254FZ (Cortisone)']",OM,"['*Blood', '*Cortisone', 'Humans', '*Leukemia', '*Metaplasia', '*Myeloproliferative Disorders', '*Primary Myelofibrosis', '*Splenic Diseases', '*Vitamin B 6', '*Vitamin B 6 Deficiency']",['CLML: 5120:39687:110:227:444:546'],['NLM'],"['*BLOOD', '*CORTISONE', '*LEUKEMIA', '*VITAMIN B6']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1950 Dec;75(3):655-8. doi: 10.3181/00379727-75-18295.,['10.3181/00379727-75-18295 [doi]'],,,,,,,,,,,,,
14808349,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),75,3,1950 Dec,Presence of myelokentric and lymphokentric acid in sera of patients with lymphomatoid diseases.,633-6,"['FOSTER, C G', 'MILLER, F R']","['FOSTER CG', 'MILLER FR']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,['0 (Acids)'],OM,"['*Acids', 'Humans', '*Leukemia', '*Oxidation-Reduction']",['CLML: 5120:39680:546'],['NLM'],['*LEUKEMIA'],1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1950 Dec;75(3):633-6. doi: 10.3181/00379727-75-18288.,['10.3181/00379727-75-18288 [doi]'],,,,,,,,,,,,,
14808316,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),75,2,1950 Nov,Particulate component of plasma from fowls with avian erythro-myeloblastic leucosis.,533-6,"['BEARD, D', 'ECKERT, E A', 'CSAKY, T Z', 'SHARP, D G', 'BEARD, J W']","['BEARD D', 'ECKERT EA', 'CSAKY TZ', 'SHARP DG', 'BEARD JW']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,,OM,"['*Granulocyte Precursor Cells', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Plasma']",['CLML: 5120:39647:117:547'],['NLM'],"['*BLOOD PLASMA', '*LEUKEMIA, MYELOGENOUS']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1950 Nov;75(2):533-6. doi: 10.3181/00379727-75-18255.,['10.3181/00379727-75-18255 [doi]'],,,,,,,,,,,,,
14808302,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),75,2,1950 Nov,Effect of aminopterin on animals receiving myelokentric or lymphokentric acid.,490-2,"['MAROTTA, R C', 'MILLER, F R']","['MAROTTA RC', 'MILLER FR']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['0 (Acids)', '0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Acids', '*Aminopterin', 'Animals', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:39633:68:349:545:573'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA', '*LYMPHOKENTRIC ACID', '*MYELOKENTRIC ACID']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1950 Nov;75(2):490-2. doi: 10.3181/00379727-75-18241.,['10.3181/00379727-75-18241 [doi]'],,,,,,,,,,,,,
14808254,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),75,2,1950 Nov,Studies on urinary histamine in chronic myelocytic leukemia.,348-9,"['PEARCE, M L', 'VALENTINE, W N']","['PEARCE ML', 'VALENTINE WN']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,['820484N8I3 (Histamine)'],OM,"['*Histamine', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive']",['CLML: 5120:39585:441:546'],['NLM'],"['*HISTAMINE', '*LEUKEMIA']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1950 Nov;75(2):348-9. doi: 10.3181/00379727-75-18193.,['10.3181/00379727-75-18193 [doi]'],,,,,,,,,,,,,
14808250,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),75,2,1950 Nov,Hyperpigmentation in acute leukemia treated with folic acid antagonists.,332-4,"['WAISMAN, H A', 'RICHMOND, J B', 'ZIMMERMAN, A A']","['WAISMAN HA', 'RICHMOND JB', 'ZIMMERMAN AA']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,['0 (Folic Acid Antagonists)'],OM,"['*Acute Disease', '*Folic Acid Antagonists', '*Hyperpigmentation', '*Leukemia', '*Pigmentation']",['CLML: 5120:39581:161:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA', '*PIGMENTATION']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1950 Nov;75(2):332-4. doi: 10.3181/00379727-75-18189.,['10.3181/00379727-75-18189 [doi]'],,,,,,,,,,,,,
14808234,NLM,MEDLINE,20040215,20181201,0035-9157 (Print) 0035-9157 (Linking),44,1,1951 Jan,Subacute aleukaemic lymphatic leukemia presenting as compression fracture of the dorsal spine.,74-5,"['METCALFE, R H']",['METCALFE RH'],['eng'],['Journal Article'],,England,Proc R Soc Med,Proceedings of the Royal Society of Medicine,7505890,,OM,"['*Fractures, Compression', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels', '*Spine']",['CLML: 5120:39565:316:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*SPINE']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Proc R Soc Med. 1951 Jan;44(1):74-5.,,PMC2081583,,,,,,,,,,,,
14807968,NLM,MEDLINE,20040215,20181201,0032-745X (Print) 0032-745X (Linking),37,51,1950 Dec 22,[Treatment of myelogenous leukemia with cortisone].,3116-26,"['PASQUALINI, R Q']",['PASQUALINI RQ'],['und'],['Journal Article'],Tratamiento de la leucemia mieloide aguda con cortisona.,Argentina,Prensa Med Argent,Prensa medica argentina,0204056,['V27W9254FZ (Cortisone)'],OM,"['*Cortisone', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:39276:227:547'],['NLM'],"['*CORTISONE', '*LEUKEMIA, MYELOGENOUS']",1950/12/22 00:00,1950/12/22 00:01,['1950/12/22 00:00'],"['1950/12/22 00:00 [pubmed]', '1950/12/22 00:01 [medline]', '1950/12/22 00:00 [entrez]']",ppublish,Prensa Med Argent. 1950 Dec 22;37(51):3116-26.,,,,,,,,,,,,,,
14807836,NLM,MEDLINE,20040215,20181201,0860-8857 (Print) 0860-8857 (Linking),5,45,1950 Nov 6,[Studies on pathogenesis of myelogenous leukemia in relation to investigations on granulocytolysis].,1556-8,"['ALEKSANDROWICZ, J']",['ALEKSANDROWICZ J'],['und'],['Journal Article'],Rozwazania nad patogeneza bialaczki szpikowej ostrej w swietle badan nad granulocytoliza (doniesienie tymczasowe).,Poland,Pol Tyg Lek (Wars),Polski tygodnik lekarski,9706227,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:39139:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1950/11/06 00:00,1950/11/06 00:01,['1950/11/06 00:00'],"['1950/11/06 00:00 [pubmed]', '1950/11/06 00:01 [medline]', '1950/11/06 00:00 [entrez]']",ppublish,Pol Tyg Lek (Wars). 1950 Nov 6;5(45):1556-8.,,,,,,,,,,,,,,
14807804,NLM,MEDLINE,20040215,20181201,0860-8857 (Print) 0860-8857 (Linking),5,37-38,1950 Sep 18,[Difficulties in differential diagnosis of leukemia in children].,1313-8,"['MIKULOWSKI, W']",['MIKULOWSKI W'],['und'],['Journal Article'],Trudnosci roznicoworozpoznawcze bialaczki w wieku dzieciecym.,Poland,Pol Tyg Lek (Wars),Polski tygodnik lekarski,9706227,,OM,"['Child', '*Diagnosis, Differential', 'Humans', '*Leukemia']",['CLML: 5120:39107:546'],['NLM'],['*LEUKEMIA'],1950/09/18 00:00,1950/09/18 00:01,['1950/09/18 00:00'],"['1950/09/18 00:00 [pubmed]', '1950/09/18 00:01 [medline]', '1950/09/18 00:00 [entrez]']",ppublish,Pol Tyg Lek (Wars). 1950 Sep 18;5(37-38):1313-8.,,,,,,,,,,,,,,
14807570,NLM,MEDLINE,20040215,20181201,0031-3890 (Print) 0031-3890 (Linking),58,9-10,1950 Sep-Oct 1,[A new criterion for differential diagnosis between Cooley's anemia and Jaksch-Hayne-Luzet anemia].,645-54,"['VECCHIO, F']",['VECCHIO F'],['und'],['Journal Article'],Sun un nuovo criterio diagnostico differenziale fra anemia di Cooley e anemia di Jaksch-Hayem-Luzet.,Italy,Pediatria (Napoli),La Pediatria,0401207,,OM,"['*Anemia', '*Diagnosis, Differential', '*Erythroblasts', '*Leukemia', '*beta-Thalassemia']",['CLML: 5120:38871:38:196'],['NLM'],"['*ANEMIA, ERYTHROBLASTIC', '*PSEUDOLEUKEMIA']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Pediatria (Napoli). 1950 Sep-Oct 1;58(9-10):645-54.,,,,,,,,,,,,,,
14807079,NLM,MEDLINE,20040215,20181201,,38,6,1950 Nov-Dec,[Acute congenital leukemia in the newborn].,270-86,"['GRISLAIN, J R', 'HARROUSSEAU, H']","['GRISLAIN JR', 'HARROUSSEAU H']",['und'],['Journal Article'],"Les leucemies aigues ""congenitales"" du nouveau-ne.",France,Nourrisson,Le Nourrisson,0070765,,OM,"['*Acute Disease', 'Humans', 'Infant', 'Infant, Newborn', '*Leukemia']",['CLML: 5120:38363:471:546'],['NLM'],"['*INFANT, NEWBORN', '*LEUKEMIA']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Nourrisson. 1950 Nov-Dec;38(6):270-86.,,,,,,,,,,,,,,
14806944,NLM,MEDLINE,20040215,20181201,0029-1420 (Print) 0029-1420 (Linking),44,37,1950 Sep 15,[Acute myeloid leukemia with complete remission].,1482-3,"['BERGSTROM, I', 'LJUNGGREN, H']","['BERGSTROM I', 'LJUNGGREN H']",['und'],['Journal Article'],Akut myeloisk leukemi med fullstandig remission.,Sweden,Nord Med,Nordisk medicin,0401001,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Myeloid, Acute', '*Remission Induction']",['CLML: 5120:38228:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1950/09/15 00:00,1950/09/15 00:01,['1950/09/15 00:00'],"['1950/09/15 00:00 [pubmed]', '1950/09/15 00:01 [medline]', '1950/09/15 00:00 [entrez]']",ppublish,Nord Med. 1950 Sep 15;44(37):1482-3.,,,,,,,,,,,,,,
14806941,NLM,MEDLINE,20040215,20181201,0029-1420 (Print) 0029-1420 (Linking),44,37,1950 Sep 15,[Herpes zoster and leukemia].,1475-8,"['HALLGREN, B E']",['HALLGREN BE'],['und'],['Journal Article'],Herpes zoster och leukami.,Sweden,Nord Med,Nordisk medicin,0401001,,OM,"['*Herpes Zoster', '*Herpesvirus 3, Human', '*Leukemia', '*Leukemia, Lymphoid']",['CLML: 5120:38225:435:546'],['NLM'],"['*HERPES ZOSTER', '*LEUKEMIA, LYMPHATIC']",1950/09/15 00:00,1950/09/15 00:01,['1950/09/15 00:00'],"['1950/09/15 00:00 [pubmed]', '1950/09/15 00:01 [medline]', '1950/09/15 00:00 [entrez]']",ppublish,Nord Med. 1950 Sep 15;44(37):1475-8.,,,,,,,,,,,,,,
14805489,NLM,MEDLINE,20040215,20181201,0025-682X (Print) 0025-682X (Linking),10,5,1950 Sep-Oct,[Treatment of myeloid leukemia with urethane; one personal case].,846-50,"['LANGUILLON, J']",['LANGUILLON J'],['und'],['Journal Article'],Le traitement de la leucemie myeloide par l'urethane; (a propos d'un cas personnel).,France,Med Trop (Mars),Medecine tropicale : revue du Corps de sante colonial,8710146,['3IN71E75Z5 (Urethane)'],OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Urethane']",['CLML: 5120:36748:417:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*URETHANE']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Med Trop (Mars). 1950 Sep-Oct;10(5):846-50.,,,,,,,,,,,,,,
14805339,NLM,MEDLINE,20040215,20181201,0373-2746 (Print) 0373-2746 (Linking),28,10,1950 Oct,[Leucosis].,405-11,"['BROCHNER-MORTENSEN, K']",['BROCHNER-MORTENSEN K'],['dan'],['Journal Article'],Leukose.,Denmark,Manedsskr Prakt Laegegern,Maanedsskrift for praktisk laegegerning og social Medicin,18410260R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:36598:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Manedsskr Prakt Laegegern. 1950 Oct;28(10):405-11.,,,,,,,,,,,,,,
14805317,NLM,MEDLINE,20040215,20181201,0024-7790 (Print) 0024-7790 (Linking),183,52,1950 Dec 24,[Cryptogenic aplastic myelosis terminating in acute leukosis].,423-7,"['RAVAULT, P', 'FRAISSE, H', 'DENIS']","['RAVAULT P', 'FRAISSE H', 'DENIS']",['und'],['Journal Article'],Myelose aplasique cryptogenetique terminee par leucose aigue.,France,Lyon Med,Lyon medical,0335015,,OM,"['*Anemia', '*Anemia, Aplastic', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid']",['CLML: 5120:36576:38:546'],['NLM'],"['*ANEMIA, APLASTIC', '*LEUKEMIA']",1950/12/24 00:00,1950/12/24 00:01,['1950/12/24 00:00'],"['1950/12/24 00:00 [pubmed]', '1950/12/24 00:01 [medline]', '1950/12/24 00:00 [entrez]']",ppublish,Lyon Med. 1950 Dec 24;183(52):423-7.,,,,,,,,,,,,,,
14805059,NLM,MEDLINE,20040215,20190612,0140-6736 (Print) 0140-6736 (Linking),1,6650,1951 Feb 10,Treatment of acute leukemia with aminopterin.,325-7,"['WILKINSON, J F', 'GARDIKAS, C']","['WILKINSON JF', 'GARDIKAS C']",['eng'],['Journal Article'],,England,Lancet,"Lancet (London, England)",2985213R,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Acute Disease', '*Aminopterin', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:36318:349:545'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1951/02/10 00:00,1951/02/10 00:01,['1951/02/10 00:00'],"['1951/02/10 00:00 [pubmed]', '1951/02/10 00:01 [medline]', '1951/02/10 00:00 [entrez]']",ppublish,Lancet. 1951 Feb 10;1(6650):325-7. doi: 10.1016/s0140-6736(51)92298-2.,"['S0140-6736(51)92298-2 [pii]', '10.1016/s0140-6736(51)92298-2 [doi]']",,,,,,,,,,,,,
14804902,NLM,MEDLINE,20040215,20181201,0023-2149 (Print) 0023-2149 (Linking),29,1,1951 Jan,[Treatment of chronic leukosis with urethane].,77-9,"['GEIRO, S B']",['GEIRO SB'],['und'],['Journal Article'],Lechenie khronicheskikh leikozov uretanom.,Russia (Federation),Klin Med (Mosk),Klinicheskaia meditsina,2985204R,['3IN71E75Z5 (Urethane)'],OM,"['*Leukemia', '*Urethane']",['CLML: 5120:36156:417:546'],['NLM'],"['*LEUKEMIA', '*URETHANE']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Klin Med (Mosk). 1951 Jan;29(1):77-9.,,,,,,,,,,,,,,
14804854,NLM,MEDLINE,20040215,20181201,0023-2149 (Print) 0023-2149 (Linking),18,11,1950 Nov,[Acute liver dystrophy in a case of leukosis treated with urethane].,87-8,"['RUBINSHTEIN, B A']",['RUBINSHTEIN BA'],['und'],['Journal Article'],"Ostraia distrofia pecheni u bol'noi leikozom, lechennoi uretanom.",Russia (Federation),Klin Med (Mosk),Klinicheskaia meditsina,2985204R,['3IN71E75Z5 (Urethane)'],OM,"['*Feeding and Eating Disorders', '*Leukemia', '*Liver', '*Urethane']",['CLML: 5120:36108:417:546:557'],['NLM'],"['*LEUKEMIA', '*LIVER', '*URETHANE']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Klin Med (Mosk). 1950 Nov;18(11):87-8.,,,,,,,,,,,,,,
14804842,NLM,MEDLINE,20040215,20181201,0023-2149 (Print) 0023-2149 (Linking),18,11,1950 Nov,[Chemotherapy of leukosis (Review of recent literature)].,11-21,"['KASSIRSKII, I A']",['KASSIRSKII IA'],['und'],['Journal Article'],O khimioterapii leikozov (Obzor novoi literatury).,Russia (Federation),Klin Med (Mosk),Klinicheskaia meditsina,2985204R,,OM,"['Humans', '*Leukemia']",['CLML: 5120:36096:546'],['NLM'],['*LEUKEMIA'],1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Klin Med (Mosk). 1950 Nov;18(11):11-21.,,,,,,,,,,,,,,
14804659,NLM,MEDLINE,20040215,20181201,0021-8111 (Print) 0021-8111 (Linking),69,3,1951 Feb 4,[Urethane in myeloid leukemia therapy].,119-22,"['BERNARD, A']",['BERNARD A'],['und'],['Journal Article'],Le traitement des leucemies myeloides par l'urethane.,France,J Sci Med Lille,Journal des sciences medicales de Lille,0413413,['3IN71E75Z5 (Urethane)'],OM,"['*Leukemia', '*Leukemia, Myeloid', '*Urethane', '*X-Ray Therapy']",['CLML: 5120:35892:248:417:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*ROENTGENOTHERAPY', '*URETHANE']",1951/02/04 00:00,1951/02/04 00:01,['1951/02/04 00:00'],"['1951/02/04 00:00 [pubmed]', '1951/02/04 00:01 [medline]', '1951/02/04 00:00 [entrez]']",ppublish,J Sci Med Lille. 1951 Feb 4;69(3):119-22.,,,,,,,,,,,,,,
14804649,NLM,MEDLINE,20040215,20181201,0021-8111 (Print) 0021-8111 (Linking),68,26,1950 Dec 24,[Acute leucosis in an eight year old child].,467-70,"['BUISINE, A', 'HENNINOT, E']","['BUISINE A', 'HENNINOT E']",['und'],['Journal Article'],Leucose aigue chez un enfant de huit ans.,France,J Sci Med Lille,Journal des sciences medicales de Lille,0413413,,OM,"['Child', 'Humans', '*Leukemia']",['CLML: 5120:35882:546'],['NLM'],['*LEUKEMIA'],1950/12/24 00:00,1950/12/24 00:01,['1950/12/24 00:00'],"['1950/12/24 00:00 [pubmed]', '1950/12/24 00:01 [medline]', '1950/12/24 00:00 [entrez]']",ppublish,J Sci Med Lille. 1950 Dec 24;68(26):467-70.,,,,,,,,,,,,,,
14804490,NLM,MEDLINE,20040215,20181201,0368-394X (Print) 0368-394X (Linking),31,7-8,1950,[Two cases of leukosis with cutaneous incipience].,440-2,"['MARQUES, P', 'BASEX, A']","['MARQUES P', 'BASEX A']",['und'],['Journal Article'],A propos de deux cas de leucose a debut clinique cutane.,France,J Radiol Electrol Arch Electr Medicale,"Journal de radiologie, d'electrologie & archives d'electricite medicale",0013747,,OM,"['*Administration, Cutaneous', 'Humans', '*Leukemia', '*Skin']",['CLML: 5120:35720:301:546'],['NLM'],"['*LEUKEMIA', '*SKIN']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,J Radiol Electrol Arch Electr Medicale. 1950;31(7-8):440-2.,,,,,,,,,,,,,,
14804489,NLM,MEDLINE,20040215,20181201,0368-394X (Print) 0368-394X (Linking),31,7-8,1950,[Determination of radiosensitivity of leukemic patients].,439-40,"['RATTI, A']",['RATTI A'],['und'],['Journal Article'],L'evaluation de la radiosensibilite des leucemiques.,France,J Radiol Electrol Arch Electr Medicale,"Journal de radiologie, d'electrologie & archives d'electricite medicale",0013747,,OM,"['Humans', '*Leukemia', '*Radiation Tolerance', '*Radiotherapy']",['CLML: 5120:35719:217:546'],['NLM'],"['*LEUKEMIA', '*RADIOTHERAPY']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,J Radiol Electrol Arch Electr Medicale. 1950;31(7-8):439-40.,,,,,,,,,,,,,,
14804488,NLM,MEDLINE,20040215,20181201,0368-394X (Print) 0368-394X (Linking),31,7-8,1950,[Case of crypto-leukosarcomatosis and its relation to leukemia and sarcoma].,438-9,"['LACHAPELE, A P', 'BIRABEN, J']","['LACHAPELE AP', 'BIRABEN J']",['und'],['Journal Article'],Su un cas de crypto-leucosarcomatose et les rapports entre leucemie et sarcome.,France,J Radiol Electrol Arch Electr Medicale,"Journal de radiologie, d'electrologie & archives d'electricite medicale",0013747,,OM,"['Animals', '*Cryptosporidiosis', 'Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', '*Leukemia, Lymphoid', '*Sarcoma']",['CLML: 5120:35718:267:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*SARCOMA, LEUKOSARCOMA']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,J Radiol Electrol Arch Electr Medicale. 1950;31(7-8):438-9.,,,,,,,,,,,,,,
14804463,NLM,MEDLINE,20040215,20181201,0368-394X (Print) 0368-394X (Linking),31,7-8,1950,[Leukemias; present position of radiotherapy].,407-11,"['MARQUES, P', 'BETOULIERES, P']","['MARQUES P', 'BETOULIERES P']",['und'],['Journal Article'],Les leucemies; (position actuelle de la radiotherapie).,France,J Radiol Electrol Arch Electr Medicale,"Journal de radiologie, d'electrologie & archives d'electricite medicale",0013747,,OM,"['Humans', '*Leukemia', '*Radiotherapy']",['CLML: 5120:35693:216:546'],['NLM'],"['*LEUKEMIA', '*RADIOTHERAPY']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,J Radiol Electrol Arch Electr Medicale. 1950;31(7-8):407-11.,,,,,,,,,,,,,,
14804256,NLM,MEDLINE,20040215,20190630,0022-3476 (Print) 0022-3476 (Linking),38,1,1951 Jan,Thymectomy and ACTH in lymphatic leukemia.,63-8,"['EARLE, A M', 'REILLY, W A', 'DEAN, G O']","['EARLE AM', 'REILLY WA', 'DEAN GO']",['eng'],['Journal Article'],,United States,J Pediatr,The Journal of pediatrics,0375410,['9002-60-2 (Adrenocorticotropic Hormone)'],OM,"['*Adrenocorticotropic Hormone', '*Leukemia', '*Leukemia, Lymphoid', '*Thymectomy']",['CLML: 5120:35486:9:371:547'],['NLM'],"['*ACTH', '*LEUKEMIA, LYMPHATIC', '*THYMECTOMY']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,J Pediatr. 1951 Jan;38(1):63-8. doi: 10.1016/s0022-3476(51)80089-1.,"['S0022-3476(51)80089-1 [pii]', '10.1016/s0022-3476(51)80089-1 [doi]']",,,,,,,,,,,,,
14804075,NLM,MEDLINE,20040215,20181201,0026-6620 (Print) 0026-6620 (Linking),48,2,1951 Feb,CLINICAL pathologic conference: leukosarcoma.,129-31,,,['eng'],['Journal Article'],,United States,Mo Med,Missouri medicine,0400744,,OM,"['Humans', '*Leukemia, Lymphocytic, Chronic, B-Cell', 'Male', '*Neoplasms', '*Sarcoma', '*Testis']",['CLML: 5120:35299:267:361'],['NLM'],"['*SARCOMA, LEUKOSARCOMA', '*TESTES']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,Mo Med. 1951 Feb;48(2):129-31.,,,,,,,,,,,,,,
14802922,NLM,MEDLINE,20040215,20211203,0017-7768 (Print) 0017-7768 (Linking),39,12,1950 Dec 15,Folic acid antagonists in the treatment of acute leukemia [Hebrew text; English summary].,150-4,"['MATOTH, Y']",['MATOTH Y'],['eng'],['Journal Article'],,Israel,Harefuah,Harefuah,0034351,['0 (Folic Acid Antagonists)'],OM,"['*Acute Disease', '*Ethnicity', '*Folic Acid Antagonists', 'Humans', '*Language', '*Leukemia']",['CLML: 5120:34088:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/12/15 00:00,1950/12/15 00:01,['1950/12/15 00:00'],"['1950/12/15 00:00 [pubmed]', '1950/12/15 00:01 [medline]', '1950/12/15 00:00 [entrez]']",ppublish,Harefuah. 1950 Dec 15;39(12):150-4.,,,,,,,,,,,,,,
14802898,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),34,8,1950,[Clinical and anatomo-histologic contribution to the study of histiocytomatosis (hyperplastic-dysplastic-neoplastiform histiocytomatosis; histiocytomatosis with evolution into hemocytoblastic leukemia)].,639-91,"['MERLI, A', 'BRUSCA, A']","['MERLI A', 'BRUSCA A']",['und'],['Journal Article'],Contributo clinico ed anatomo-istologico allo studio delle istiocitomatosi (I. iperplastico-displastico-neoplastiforme: I. ad evoluzione in leucemia emocitobalstica).,Italy,Haematologica,Haematologica,0417435,,OM,"['*Brain Neoplasms', 'Humans', '*Hyperplasia', '*Leukemia', '*Neoplasms']",['CLML: 5120:34064:408'],['NLM'],"['*TUMORS, RETICULOENDOTHELIOMA']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Haematologica. 1950;34(8):639-91.,,,,,,,,,,,,,,
14802809,NLM,MEDLINE,20040215,20181201,0017-0275 (Print) 0017-0275 (Linking),31,11,1950 Nov,[Case of myeloid leukemia in an infant treated with ethyl urethane and roentgen therapy].,1402-30,"['GIUSEPPE, M']",['GIUSEPPE M'],['und'],['Journal Article'],Sopra un caso di leucemia mieloide in un bambino trattato con etiluretano e roentgen-terapia.,Italy,G Clin Med,Giornale di clinica medica,0413411,['3IN71E75Z5 (Urethane)'],OM,"['*Leukemia', '*Leukemia, Myeloid', '*Urethane']",['CLML: 5120:33975:417:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*URETHANE']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,G Clin Med. 1950 Nov;31(11):1402-30.,,,,,,,,,,,,,,
14802624,NLM,MEDLINE,20040215,20181201,0016-450X (Print) 0016-450X (Linking),41,2-4,1950 Dec,Histological change of the liver and muscle of chicken and of the liver and lung of mice by means of the injection of the blood of the patient of chronic myelogenous leukemia.,213-4,"['WATANABE, F', 'KITAGAWA, Y']","['WATANABE F', 'KITAGAWA Y']",['eng'],['Journal Article'],,Japan,Gan,Gan,0151745,,OM,"['Animals', '*Chickens', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Liver', '*Lung', 'Mice', '*Muscles']",['CLML: 5120:33770:64:547:556:569'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*LIVER', '*LUNGS', '*MUSCLES']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Gan. 1950 Dec;41(2-4):213-4.,,,,,,,,,,,,,,
14802207,NLM,MEDLINE,20040215,20181201,0366-8576 (Print) 0366-8576 (Linking),197,5,1950,[Genuine reticuloendotheliosis (reticulosis vera). I].,602-19,"['MUNDT, E']",['MUNDT E'],['und'],['Journal Article'],Die genuine Reticulo-Endotheliose (Reticulose pure).,Germany,Dtsch Arch Klin Med,Deutsches Archiv fur klinische Medizin,0060760,"['Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5120:33345:232'],['NLM'],['*RETICULOENDOTHELIOSIS'],1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Dtsch Arch Klin Med. 1950;197(5):602-19.,,,,,,,,,,,,,,
14802206,NLM,MEDLINE,20040215,20181201,0366-8576 (Print) 0366-8576 (Linking),197,5,1950,[Lung modifications in chronic leukemia].,596-601,"['HEROLD, K', 'MICHEL, W']","['HEROLD K', 'MICHEL W']",['und'],['Journal Article'],Pulmonale Veranderungen bei chronischer Leukamie.,Germany,Dtsch Arch Klin Med,Deutsches Archiv fur klinische Medizin,0060760,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lung', '*Lymphatic Vessels']",['CLML: 5120:33344:546:569'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*LUNGS']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Dtsch Arch Klin Med. 1950;197(5):596-601.,,,,,,,,,,,,,,
14802153,NLM,MEDLINE,20040215,20181201,0012-0472 (Print) 0012-0472 (Linking),75,51,1950 Dec 22,[The pathologic anatomy of chronic myelosis as effected by urethane therapy].,1722-6,"['MASSHOFF, W', 'HEINZEL, W']","['MASSHOFF W', 'HEINZEL W']",['und'],['Journal Article'],Das pathologisch-anatomische Bild der urethanbehandelten chronischen Myelose.,Germany,Dtsch Med Wochenschr,Deutsche medizinische Wochenschrift (1946),0006723,['3IN71E75Z5 (Urethane)'],OM,"['*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Urethane']",['CLML: 5120:33291:417:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*URETHANE']",1950/12/22 00:00,1950/12/22 00:01,['1950/12/22 00:00'],"['1950/12/22 00:00 [pubmed]', '1950/12/22 00:01 [medline]', '1950/12/22 00:00 [entrez]']",ppublish,Dtsch Med Wochenschr. 1950 Dec 22;75(51):1722-6. doi: 10.1055/s-0028-1117762.,['10.1055/s-0028-1117762 [doi]'],,,,,,,,,,,,,
14802117,NLM,MEDLINE,20040215,20181201,0011-9075 (Print) 0011-9075 (Linking),101,4-5,1950,[Demonstration of spirochetes in disease of doubtful etiology; a study on the findings of Dr. C. Lennhoff].,193-212,"['SCHUPPLI, R']",['SCHUPPLI R'],['und'],['Journal Article'],Zur Frage des Nachweises von Spirochaten bei atiologisch unabgeklarten Krankheiten; nachuntersuchungen zu den Befunden von Dr. C Lannhoff.,Switzerland,Dermatologica,Dermatologica,0211607,,OM,"['*Bacteria', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels', '*Psoriasis', '*Skin Diseases', '*Spirochaeta', '*Spirochaetales']",['CLML: 5120:33251:197:259:317:547'],['NLM'],"['*DERMATOSES', '*LEUKEMIA, LYMPHATIC', '*PSORIASIS', '*SPIROCHAETA']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Dermatologica. 1950;101(4-5):193-212.,,,,,,,,,,,,,,
14801847,NLM,MEDLINE,20040215,20181201,,10,18,1950 May 6,[Neoplastiform leukemia].,753-70,"['SPOSITO, M', 'NAVA, G']","['SPOSITO M', 'NAVA G']",['und'],['Journal Article'],Contributo alla conoscenza delle leucemie neoplastiformi.,Italy,Clin Nuova Rass Prog Med Int,Clinica nuova; rassegna del progresso medico internazionale,16230300R,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels', '*Neoplasms']",['CLML: 5120:32964:401:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*TUMORS']",1950/05/06 00:00,1950/05/06 00:01,['1950/05/06 00:00'],"['1950/05/06 00:00 [pubmed]', '1950/05/06 00:01 [medline]', '1950/05/06 00:00 [entrez]']",ppublish,Clin Nuova Rass Prog Med Int. 1950 May 6;10(18):753-70.,,,,,,,,,,,,,,
14801771,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),4,1,1951 Jan,A study of the natural history of acute leukemia with special reference to the duration of the disease and the occurrence of remissions.,39-59,"['SOUTHAM, C M', 'CRAVER, L F', 'DARGEON, H W', 'BURCHENAL, J H']","['SOUTHAM CM', 'CRAVER LF', 'DARGEON HW', 'BURCHENAL JH']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,,OM,"['*Acute Disease', 'Humans', '*Leukemia', '*Neoplasms']",['CLML: 5120:32885:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Cancer. 1951 Jan;4(1):39-59. doi: 10.1002/1097-0142(195101)4:1<39::aid-cncr2820040105>3.0.co;2-g.,['10.1002/1097-0142(195101)4:1<39::aid-cncr2820040105>3.0.co;2-g [doi]'],,,,,,,,,,,,,
14801041,NLM,MEDLINE,20040215,20181201,0366-0486 (Print) 0366-0486 (Linking),31,3-4,1951 Jan,[Experimental leukemia].,261-73,"['UHER, V']",['UHER V'],['und'],['Journal Article'],P6raspevek k otazce experimentalnach leukemia.,Czech Republic,Biol Listy,Biologicke listy,0234431,,OM,"['Animals', '*Leukemia', '*Leukemia, Experimental']",['CLML: 5120:32092:546'],['NLM'],['*LEUKEMIA'],1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Biol Listy. 1951 Jan;31(3-4):261-73.,,,,,,,,,,,,,,
14800018,NLM,MEDLINE,20040215,20181201,0366-1334 (Print) 0366-1334 (Linking),51,7,1950,[Case of chloroma].,673-84,"['SECRETAN, P']",['SECRETAN P'],['und'],['Journal Article'],A propos d'un cas de chlorome.,France,Bull Mem Soc Med Hop Paris,Bulletins et memoires de la Societe medicale des hopitaux de Paris,7503472,,OM,"['Humans', '*Neoplasms', '*Sarcoma, Myeloid']",['CLML: 5120:31051:404'],['NLM'],"['*TUMORS, CHLOROMA']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Bull Mem Soc Med Hop Paris. 1950;51(7):673-84.,,,,,,,,,,,,,,
14799239,NLM,MEDLINE,20040215,20181201,0001-6640 (Print) 0001-6640 (Linking),8,96,1950 Dec,[Clinical history of leukemia in an infant of 2 1/2 months of age].,1473-98,"['DOMINGUEZ, E', 'MANZANARES, A']","['DOMINGUEZ E', 'MANZANARES A']",['und'],['Journal Article'],Comentarios a la historia clanica de una leucemia aguda en un lactante de dos meses y medio.,Spain,Acta Pediatr Esp,Acta pediatrica espanola,0405466,,OM,"['Humans', 'Infant', '*Leukemia']",['CLML: 5120:30259:546'],['NLM'],['*LEUKEMIA'],1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Acta Pediatr Esp. 1950 Dec;8(96):1473-98.,,,,,,,,,,,,,,
14799158,NLM,MEDLINE,20040215,20190812,0001-6101 (Print) 0001-6101 (Linking),139,1,1951,Urethane tolerance tests in leukemia patients.,7-14,"['HALLGREN, B E']",['HALLGREN BE'],['eng'],['Journal Article'],,Sweden,Acta Med Scand,Acta medica Scandinavica,0370330,['3IN71E75Z5 (Urethane)'],OM,"['*Leukemia', '*Urethane']",['CLML: 5120:30163:417:546'],['NLM'],"['*LEUKEMIA', '*URETHANE']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Acta Med Scand. 1951;139(1):7-14. doi: 10.1111/j.0954-6820.1950.tb17140.x.,['10.1111/j.0954-6820.1950.tb17140.x [doi]'],,,,,,,,,,,,,
14798864,NLM,MEDLINE,20040215,20181201,0043-5376 (Print) 0043-5376 (Linking),31,11,1950 Nov,[Differentiation of myeloblastoses].,422-6,"['PAKESCH, F', 'REIMER, E E']","['PAKESCH F', 'REIMER EE']",['und'],['Journal Article'],Zur Differenzierung der Myeloblastosen.,Austria,Wien Z Inn Med,Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete,7502231,,OM,"['*Cell Differentiation', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:29837:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Wien Z Inn Med. 1950 Nov;31(11):422-6.,,,,,,,,,,,,,,
14797771,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),75,1,1950 Oct,Blood urethane levels achieved with entero-coated tablets.,173-4,"['ROSENTHAL, M C', 'SAUNDERS, R H Jr']","['ROSENTHAL MC', 'SAUNDERS RH Jr']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['0 (Tablets)', '3IN71E75Z5 (Urethane)']",OM,"['Humans', '*Leukemia', '*Multiple Myeloma', '*Neoplasms', '*Tablets', '*Urethane']",['CLML: 5120:28671:407:417:546'],['NLM'],"['*LEUKEMIA', '*TUMORS, MULTIPLE MYELOMA', '*URETHANE']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1950 Oct;75(1):173-4. doi: 10.3181/00379727-75-18135.,['10.3181/00379727-75-18135 [doi]'],,,,,,,,,,,,,
14796954,NLM,MEDLINE,20040215,20181201,0029-1420 (Print) 0029-1420 (Linking),43,17,1950 Apr 28,[Aplastic anemia].,712-3,"['BERG, A H']",['BERG AH'],['und'],['Journal Article'],Aplastisk anemi.,Sweden,Nord Med,Nordisk medicin,0401001,,OM,"['*Anemia', '*Anemia, Aplastic', 'Humans', '*Leukemia', '*Tracheophyta', 'X-Rays']",['CLML: 5120:27844:38:244:546'],['NLM'],"['*ANEMIA, APLASTIC', '*LEUKEMIA', '*ROENTGEN RAYS']",1950/04/28 00:00,1950/04/28 00:01,['1950/04/28 00:00'],"['1950/04/28 00:00 [pubmed]', '1950/04/28 00:01 [medline]', '1950/04/28 00:00 [entrez]']",ppublish,Nord Med. 1950 Apr 28;43(17):712-3.,,,,,,,,,,,,,,
14796416,NLM,MEDLINE,20040215,20181201,0025-8474 (Print) 0025-8474 (Linking),4,10,1950 Oct,[Remittent acute leukemia].,768-73,"['GRUNKE, W']",['GRUNKE W'],['und'],['Journal Article'],Remittierende akute Leukamie.,Germany,Med Monatsschr,Medizinische Monatsschrift,0375265,['3IN71E75Z5 (Urethane)'],OM,"['*Acute Disease', '*Leukemia', '*Leukemia, Myeloid', '*Urethane']",['CLML: 5120:27281:417:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*URETHANE']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Med Monatsschr. 1950 Oct;4(10):768-73.,,,,,,,,,,,,,,
14796157,NLM,MEDLINE,20040215,20201114,0025-729X (Print) 0025-729X (Linking),2,25,1950 Dec 16,Should we treat leuchaemia in childhood?,892-5,"['COLEBATCH, J H', 'WILLIAMS, A L']","['COLEBATCH JH', 'WILLIAMS AL']",['eng'],['Journal Article'],,Australia,Med J Aust,The Medical journal of Australia,0400714,['0 (Folic Acid Antagonists)'],OM,"['*Folic Acid Antagonists', 'Humans', '*Leukemia']",['CLML: 5120:27009:349:545'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/12/16 00:00,1950/12/16 00:01,['1950/12/16 00:00'],"['1950/12/16 00:00 [pubmed]', '1950/12/16 00:01 [medline]', '1950/12/16 00:00 [entrez]']",ppublish,Med J Aust. 1950 Dec 16;2(25):892-5. doi: 10.5694/j.1326-5377.1950.tb107023.x.,['10.5694/j.1326-5377.1950.tb107023.x [doi]'],,,,,,,,,,,,,
14795794,NLM,MEDLINE,20040215,20190612,0140-6736 (Print) 0140-6736 (Linking),1,6647,1951 Jan 20,"Trial of beta-naphthyl-di-2-chloroethylamine in leukaemia, Hodgkin's disease, and allied disorders.",137-9,"['GARDIKAS, C', 'WILKINSON, J F']","['GARDIKAS C', 'WILKINSON JF']",['eng'],['Journal Article'],,England,Lancet,"Lancet (London, England)",2985213R,"['0 (Arylsulfonates)', '0 (Ethylamines)', '0 (Nitrogen Mustard Compounds)', '2589ET7417 (metsulfuron methyl)', '50D9XSG0VR (Mechlorethamine)', 'P7YLY3O329 (2-chloroethylamine)']",OM,"['*Arylsulfonates', 'Ethylamines', '*Hodgkin Disease', '*Leukemia', '*Mechlorethamine', '*Nitrogen Mustard Compounds']",['CLML: 5120:26611:88:444:546'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA', '*NITROGEN MUSTARDS']",1951/01/20 00:00,1951/01/20 00:01,['1951/01/20 00:00'],"['1951/01/20 00:00 [pubmed]', '1951/01/20 00:01 [medline]', '1951/01/20 00:00 [entrez]']",ppublish,Lancet. 1951 Jan 20;1(6647):137-9. doi: 10.1016/s0140-6736(51)91214-7.,"['S0140-6736(51)91214-7 [pii]', '10.1016/s0140-6736(51)91214-7 [doi]']",,,,,,,,,,,,,
14795600,NLM,MEDLINE,20040215,20181201,0023-2149 (Print) 0023-2149 (Linking),18,10,1950 Oct,[Acute leukosis].,11-9,"['KRAEVSKII, N A', 'NEMENOVA, N M']","['KRAEVSKII NA', 'NEMENOVA NM']",['und'],['Journal Article'],K ucheniiu ob ostrom leikoze.,Russia (Federation),Klin Med (Mosk),Klinicheskaia meditsina,2985204R,,OM,['*Leukemia'],['CLML: 5120:26417:546'],['NLM'],['*LEUKEMIA'],1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Klin Med (Mosk). 1950 Oct;18(10):11-9.,,,,,,,,,,,,,,
14795196,NLM,MEDLINE,20040215,20181201,0027-8874 (Print) 0027-8874 (Linking),11,2,1950 Oct,The influence of thymectomy on the incidence of carcinogen-induced leukemia in strain DBA mice.,425-37,"['LAW, L W', 'MILLER, J H']","['LAW LW', 'MILLER JH']",['eng'],['Journal Article'],,United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,['0 (Carcinogens)'],OM,"['Animals', '*Carcinogens', 'Incidence', '*Leukemia', 'Mice', 'Mice, Inbred DBA', '*Thymectomy']",['CLML: 5120:26007:546'],['NLM'],['*LEUKEMIA'],1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,J Natl Cancer Inst. 1950 Oct;11(2):425-37.,,,,,,,,,,,,,,
14795182,NLM,MEDLINE,20040215,20181201,0027-8874 (Print) 0027-8874 (Linking),11,2,1950 Oct,"Observations on the effect of thymectomy on spontaneous leukemias in mice of the highleukemic strains, RIL and C 58.",253-62,"['LAW, L W', 'MILLER, J H']","['LAW LW', 'MILLER JH']",['eng'],['Journal Article'],,United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,,OM,"['Animals', '*Leukemia', 'Mice', '*Thymectomy']",['CLML: 5120:25993:546'],['NLM'],['*LEUKEMIA'],1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,J Natl Cancer Inst. 1950 Oct;11(2):253-62.,,,,,,,,,,,,,,
14795056,NLM,MEDLINE,20040215,20181201,0022-2143 (Print) 0022-2143 (Linking),36,6,1950 Dec,Diabetes mellitus and concomitant leukemia.,972,"['PAUL, J T', 'BEST, W R', 'LIMARZI, L R']","['PAUL JT', 'BEST WR', 'LIMARZI LR']",['eng'],['Journal Article'],,United States,J Lab Clin Med,The Journal of laboratory and clinical medicine,0375375,,OM,"['*Diabetes Mellitus', 'Humans', '*Leukemia']",['CLML: 5120:25854:263:546'],['NLM'],"['*DIABETES MELLITUS', '*LEUKEMIA']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,J Lab Clin Med. 1950 Dec;36(6):972.,,,,,,,,,,,,,,
14795026,NLM,MEDLINE,20040215,20181201,0022-2143 (Print) 0022-2143 (Linking),36,6,1950 Dec,Sulfhydryl content of blood cells in dyscrasias.,929-41,"['CONTOPOULOS, A N', 'ANDERSON, H H']","['CONTOPOULOS AN', 'ANDERSON HH']",['eng'],['Journal Article'],,United States,J Lab Clin Med,The Journal of laboratory and clinical medicine,0375375,['0 (Sulfhydryl Compounds)'],OM,"['*Blood', '*Blood Cells', '*Hyperplasia', '*Leukemia', '*Sulfhydryl Compounds']",['CLML: 5120:25824:113:221:341:546'],['NLM'],"['*BLOOD', '*CONTINENCE', '*LEUKEMIA', '*SULFHYDRYL COMPOUNDS']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,J Lab Clin Med. 1950 Dec;36(6):929-41.,,,,,,,,,,,,,,
14795021,NLM,MEDLINE,20040215,20181201,0022-2143 (Print) 0022-2143 (Linking),36,6,1950 Dec,The urinary excretion of 17-ketosteroids and corticosteroids in leukemia; the effects of aminopterin (4-amino-pteroylglutamic acid) on the excretion of corticosteroids in acute leukemia.,877-86,"['HANLON, D G', 'MASON, H L', 'STICKNEY, J M']","['HANLON DG', 'MASON HL', 'STICKNEY JM']",['eng'],['Journal Article'],,United States,J Lab Clin Med,The Journal of laboratory and clinical medicine,0375375,"['0 (17-Ketosteroids)', '0 (Adrenal Cortex Hormones)', '0 (Androgens)', '0 (Dermatologic Agents)', '0 (Folic Acid Antagonists)', '0 (Glucocorticoids)', '935E97BOY8 (Folic Acid)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*17-Ketosteroids', '*Adrenal Cortex Hormones', '*Aminopterin', '*Androgens', '*Dermatologic Agents', '*Folic Acid', '*Folic Acid Antagonists', '*Glucocorticoids', '*Leukemia']",['CLML: 5120:25819:14:37:349:546'],['NLM'],"['*ADRENAL CORTEX HORMONES', '*ANDROGENS', '*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,J Lab Clin Med. 1950 Dec;36(6):877-86.,,,,,,,,,,,,,,
14794487,NLM,MEDLINE,20040215,20190729,0002-9955 (Print) 0002-9955 (Linking),145,8,1951 Feb 24,Herpes zoster with a varicelliform eruption and parotitis in chronic leukemia.,560-1,"['GELFAND, M L']",['GELFAND ML'],['eng'],['Journal Article'],,United States,J Am Med Assoc,Journal of the American Medical Association,7507176,,OM,"['*Exanthema', '*Herpes Zoster', '*Herpesvirus 3, Human', '*Leukemia', '*Parotitis']",['CLML: 5120:25265:435:546'],['NLM'],"['*HERPES ZOSTER', '*LEUKEMIA']",1951/02/24 00:00,1951/02/24 00:01,['1951/02/24 00:00'],"['1951/02/24 00:00 [pubmed]', '1951/02/24 00:01 [medline]', '1951/02/24 00:00 [entrez]']",ppublish,J Am Med Assoc. 1951 Feb 24;145(8):560-1. doi: 10.1001/jama.1951.72920260003008a.,['10.1001/jama.1951.72920260003008a [doi]'],,,,,,,,,,,,,
14793829,NLM,MEDLINE,20040215,20181201,0018-0203 (Print) 0018-0203 (Linking),17,4-5,1950 Oct,[Biermer's anemia; folic acid therapy; funicular myelosis].,423-36,"['BARRELET, J']",['BARRELET J'],['und'],['Journal Article'],Anemie de Biermer; traitement a l'acide folique; myelose funiculaire.,Switzerland,Helv Med Acta,Helvetica medica acta,0401174,['935E97BOY8 (Folic Acid)'],OM,"['*Anemia', '*Anemia, Pernicious', '*Folic Acid', 'Humans', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Myelitis']",['CLML: 5120:24605:40:68:349'],['NLM'],"['*ANEMIA, PERNICIOUS', '*FOLIC ACID', '*MYELITIS, FUNICULAR']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Helv Med Acta. 1950 Oct;17(4-5):423-36.,,,,,,,,,,,,,,
14793783,NLM,MEDLINE,20040215,20181201,0367-4800 (Print) 0367-4800 (Linking),31,12,1950 Dec,Monocytic leukemia: report of four cases.,442-54,"['KENNEDY, A C', 'SMITH, M D']","['KENNEDY AC', 'SMITH MD']",['eng'],['Journal Article'],,Scotland,Glasgow Med J,Glasgow medical journal,17140140R,,OM,"['Humans', '*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid', '*Monocytes']",['CLML: 5120:24559:547'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Glasgow Med J. 1950 Dec;31(12):442-54.,,PMC5970867,,,,,,,,,,,,
14793761,NLM,MEDLINE,20040215,20181201,0017-0364 (Print) 0017-0364 (Linking),97,5,1950 Sep-Oct,[Case of acute hemocytoblastic leukemia with positive Paul-Bunnell-Davidsohn reaction].,457-64,"['PANTE, D', 'LAZZARA, F']","['PANTE D', 'LAZZARA F']",['und'],['Journal Article'],Su un caso di leucemia emocitoblastica acute con reazione di Paul-Bunnell-Davidsohn positiva.,Italy,G Med Mil,Giornale di medicina militare,0417723,,OM,"['*Communicable Diseases', 'Humans', '*Infectious Mononucleosis', '*Leukemia']",['CLML: 5120:24537:52:546'],['NLM'],"['*LEUKEMIA', '*MONONUCLEOSIS, INFECTIOUS']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,G Med Mil. 1950 Sep-Oct;97(5):457-64.,,,,,,,,,,,,,,
14793711,NLM,MEDLINE,20040215,20181201,0017-0275 (Print) 0017-0275 (Linking),31,8,1950 Aug,[Hematic crasis and planimetry of leukocytes in members of the family of leukemia patients].,961-77,"['POSTIGLIONE, F']",['POSTIGLIONE F'],['und'],['Journal Article'],Crasi ematica e planimetria dei leucociti nei familiari di leucemici.,Italy,G Clin Med,Giornale di clinica medica,0413411,,OM,"['Humans', '*Leukemia', '*Leukocytes']",['CLML: 5120:24487:546'],['NLM'],['*LEUKEMIA'],1950/08/01 00:00,1950/08/01 00:01,['1950/08/01 00:00'],"['1950/08/01 00:00 [pubmed]', '1950/08/01 00:01 [medline]', '1950/08/01 00:00 [entrez]']",ppublish,G Clin Med. 1950 Aug;31(8):961-77.,,,,,,,,,,,,,,
14793275,NLM,MEDLINE,20040215,20181201,0012-1762 (Print) 0012-1762 (Linking),22,66,1950 Oct 16,[Human leukemia in the framework of conditioned infectious disease with viral etiology].,2767-72,"['MAGRASSI, F']",['MAGRASSI F'],['und'],['Journal Article'],La leucemia humana en el cuadro de la enfermedad infectiva condicionada a una etiologia viral.,Argentina,Dia Med,El Dia medico,0370663,,OM,"['*Communicable Diseases', 'Humans', '*Leukemia']",['CLML: 5120:24046:546'],['NLM'],['*LEUKEMIA'],1950/10/16 00:00,1950/10/16 00:01,['1950/10/16 00:00'],"['1950/10/16 00:00 [pubmed]', '1950/10/16 00:01 [medline]', '1950/10/16 00:00 [entrez]']",ppublish,Dia Med. 1950 Oct 16;22(66):2767-72.,,,,,,,,,,,,,,
14793092,NLM,MEDLINE,20040215,20181201,0012-0219 (Print) 0012-0219 (Linking),5,48,1950 Nov 30,[Nitrogen mustard therapy of malignant tumors].,1506-15,"['LINDEMANN, M', 'GUMMEL, H']","['LINDEMANN M', 'GUMMEL H']",['und'],['Journal Article'],Losttherapie bei bosartigen Geschwulsten.,Germany,Dtsch Gesundheitsw,Das Deutsche Gesundheitswesen,0433572,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Carcinoma', '*Hodgkin Disease', '*Leukemia', '*Mechlorethamine', '*Neoplasms', '*Nitrogen Mustard Compounds']",['CLML: 5120:23863:88:173:444:546'],['NLM'],"['*CARCINOMA', ""*HODGKIN'S DISEASE"", '*LEUKEMIA', '*NITROGEN MUSTARDS']",1950/11/30 00:00,1950/11/30 00:01,['1950/11/30 00:00'],"['1950/11/30 00:00 [pubmed]', '1950/11/30 00:01 [medline]', '1950/11/30 00:00 [entrez]']",ppublish,Dtsch Gesundheitsw. 1950 Nov 30;5(48):1506-15.,,,,,,,,,,,,,,
14792813,NLM,MEDLINE,20040215,20181201,0037-9026 (Print) 0037-9026 (Linking),144,13-14,1950 Jul,[Electric charge of leukocytes; leukocytes of normal human circulating blood and of blood of chronic leukemia (agranulocytes)].,959-62,"['BAZIN, S', 'ROBINEAUX, R']","['BAZIN S', 'ROBINEAUX R']",['und'],['Journal Article'],Etude de la charge electrique des leucocytes. Leucocytes humains du sang circulant normal et du sang de leucemies chroniques (agranulocytes).,France,C R Seances Soc Biol Fil,Comptes rendus des seances de la Societe de biologie et de ses filiales,7505439,,OM,"['Humans', '*Leukemia', '*Leukocytes', '*Leukocytes, Mononuclear']",['CLML: 5120:23563:547'],['NLM'],['*LEUKOCYTES'],1950/07/01 00:00,1950/07/01 00:01,['1950/07/01 00:00'],"['1950/07/01 00:00 [pubmed]', '1950/07/01 00:01 [medline]', '1950/07/01 00:00 [entrez]']",ppublish,C R Seances Soc Biol Fil. 1950 Jul;144(13-14):959-62.,,,,,,,,,,,,,,
14792781,NLM,MEDLINE,20040215,20181201,0037-9026 (Print) 0037-9026 (Linking),144,13-14,1950 Jul,[Effect of two folic acid antagonists on fowl leukemia].,885-7,"['BESSIS, M', 'FREIXA, P']","['BESSIS M', 'FREIXA P']",['und'],['Journal Article'],Action de deux antagonistes de l'acide folique sur la leucemie des poules.,France,C R Seances Soc Biol Fil,Comptes rendus des seances de la Societe de biologie et de ses filiales,7505439,['0 (Folic Acid Antagonists)'],OM,"['Animals', '*Birds', '*Folic Acid Antagonists', '*Leukemia', '*Meat', '*Poultry']",['CLML: 5120:23531:349:354:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*FOWLS', '*LEUKEMIA']",1950/07/01 00:00,1950/07/01 00:01,['1950/07/01 00:00'],"['1950/07/01 00:00 [pubmed]', '1950/07/01 00:01 [medline]', '1950/07/01 00:00 [entrez]']",ppublish,C R Seances Soc Biol Fil. 1950 Jul;144(13-14):885-7.,,,,,,,,,,,,,,
14792744,NLM,MEDLINE,20040215,20211203,0009-8787 (Print) 0009-8787 (Linking),18,1,1951 Jan,Lymphatic leukemia occurring simultaneously in Negro brother and sister.,33-4,"['PORTMANN, U V', 'ROBINSON, W H']","['PORTMANN UV', 'ROBINSON WH']",['eng'],['Journal Article'],,United States,Cleve Clin Q,Cleveland Clinic quarterly,0373162,,OM,"['*Blacks', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels', '*Siblings']",['CLML: 5120:23490:74:547'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*NEGROES']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Cleve Clin Q. 1951 Jan;18(1):33-4. doi: 10.3949/ccjm.18.1.33.,['10.3949/ccjm.18.1.33 [doi]'],,,,,,,,,,,,,
14792619,NLM,MEDLINE,20040215,20181201,0008-7335 (Print) 0008-7335 (Linking),89,46,1950 Nov 17,[Failure of exsanguination transfusion in acute leukemias].,1291-4,"['JANELE, J', 'HLOUSKOVA, Z']","['JANELE J', 'HLOUSKOVA Z']",['und'],['Journal Article'],Neuspechy exsanguina6cnach transfusa u akutnach leukemia.,Czech Republic,Cas Lek Cesk,Casopis lekaru ceskych,0004743,,OM,"['*Acute Disease', '*Blood Transfusion', '*Exsanguination', 'Humans', '*Leukemia']",['CLML: 5120:23340:123:546'],['NLM'],"['*BLOOD TRANSFUSION', '*LEUKEMIA']",1950/11/17 00:00,1950/11/17 00:01,['1950/11/17 00:00'],"['1950/11/17 00:00 [pubmed]', '1950/11/17 00:01 [medline]', '1950/11/17 00:00 [entrez]']",ppublish,Cas Lek Cesk. 1950 Nov 17;89(46):1291-4.,,,,,,,,,,,,,,
14792613,NLM,MEDLINE,20040215,20181201,0008-7335 (Print) 0008-7335 (Linking),89,45,1950 Nov 10,[Familial leukosis].,1264-8,"['WIEDERMANN, B']",['WIEDERMANN B'],['und'],['Journal Article'],Rodovy vyskyt leukos.,Czech Republic,Cas Lek Cesk,Casopis lekaru ceskych,0004743,,OM,"['*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:23334:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1950/11/10 00:00,1950/11/10 00:01,['1950/11/10 00:00'],"['1950/11/10 00:00 [pubmed]', '1950/11/10 00:01 [medline]', '1950/11/10 00:00 [entrez]']",ppublish,Cas Lek Cesk. 1950 Nov 10;89(45):1264-8.,,,,,,,,,,,,,,
14792554,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,1,1951 Jan,"Carbamates in the chemotherapy of leukemia. VIII. Overall tracer studies on carbonyl-labeled urethan, methylene-labeled urethan, and methylene-labeled ethyl alcohol.",46-51,"['SKIPPER, H E', 'BENNETT, L L Jr', 'BRYAN, C E', 'WHITE, L Jr', 'NEWTON, M A', 'SIMPSON, L']","['SKIPPER HE', 'BENNETT LL Jr', 'BRYAN CE', 'WHITE L Jr', 'NEWTON MA', 'SIMPSON L']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,"['0 (Carbamates)', '0 (Esters)', '2465-56-7 (carbene)', '3IN71E75Z5 (Urethane)', '3K9958V90M (Ethanol)', 'OP0UW79H66 (Methane)']",OM,"['*Carbamates', '*Esters', '*Ethanol', '*Leukemia', '*Methane', '*Urethane']",['CLML: 5120:23275:417:546'],['NLM'],"['*LEUKEMIA', '*URETHANE']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Jan;11(1):46-51.,,,,,,,,,,,,,,
14792551,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),11,1,1951 Jan,The development of lymphatic and myelogenous leukemia in Wistar rats following gastric instillation of methylcholanthrene.,29-34,"['SHAY, H', 'GRUENSTEIN, M', 'MARX, H E', 'GLAZER, L']","['SHAY H', 'GRUENSTEIN M', 'MARX HE', 'GLAZER L']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,['56-49-5 (Methylcholanthrene)'],OM,"['Animals', '*Leukemia', '*Leukemia, Myeloid', '*Lymphatic Vessels', '*Methylcholanthrene', 'Rats', 'Rats, Wistar', '*Stomach']",['CLML: 5120:23272:38:546'],['NLM'],"['*LEUKEMIA', '*METHYLCHOLANTHRENE']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Cancer Res. 1951 Jan;11(1):29-34.,,,,,,,,,,,,,,
14792542,NLM,MEDLINE,20040215,20181201,0008-5472 (Print) 0008-5472 (Linking),10,12,1950 Dec,Effect of certain folic acid antagonists on transplanted myeloid and lymphoid leukemias of the F strain of mice.,762-8,"['KIRSCHBAUM, A', 'GEISSE, N C', 'SISTER T JUDD', 'MEYER, L M']","['KIRSCHBAUM A', 'GEISSE NC', 'SISTER T JUDD', 'MEYER LM']",['eng'],['Journal Article'],,United States,Cancer Res,Cancer research,2984705R,['0 (Folic Acid Antagonists)'],OM,"['Animals', '*Folic Acid Antagonists', '*Leukemia', '*Leukemia, Lymphoid', 'Mice']",['CLML: 5120:23263:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Cancer Res. 1950 Dec;10(12):762-8.,,,,,,,,,,,,,,
14792463,NLM,MEDLINE,20040215,20181201,0008-4409 (Print) 0008-4409 (Linking),64,1,1951 Jan,Treatment of leukemia with cortisone.,44-7,"['BELL, R E', 'THOMSON, R K']","['BELL RE', 'THOMSON RK']",['eng'],['Journal Article'],,Canada,Can Med Assoc J,Canadian Medical Association journal,0414110,['V27W9254FZ (Cortisone)'],OM,"['*Cortisone', '*Leukemia']",['CLML: 5120:23184:227:546'],['NLM'],"['*CORTISONE', '*LEUKEMIA']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Can Med Assoc J. 1951 Jan;64(1):44-7.,,,,,,,,,,,,,,
14792462,NLM,MEDLINE,20040215,20181201,0008-4409 (Print) 0008-4409 (Linking),64,1,1951 Jan,Cortisone in the treatment of leukemia.,39-42,"['WEDER, C', 'BECKER, A']","['WEDER C', 'BECKER A']",['eng'],['Journal Article'],,Canada,Can Med Assoc J,Canadian Medical Association journal,0414110,['V27W9254FZ (Cortisone)'],OM,"['*Cortisone', '*Leukemia', '*Leukemia, Lymphoid', '*Leukemia, Myeloid', '*Lymphatic Vessels']",['CLML: 5120:23183:227:546:547'],['NLM'],"['*CORTISONE', '*LEUKEMIA, LYMPHATIC', '*LEUKEMIA, MYELOGENOUS']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,Can Med Assoc J. 1951 Jan;64(1):39-42.,,PMC1821431,,,,,,,,,,,,
14791593,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),5,12,1950 Dec,The effect of desoxycorticosterone acetate and vitamin C on chronic leukemia.,1156-60,"['METTIER, S R', 'ELLENHORN, M J', 'GORDAN, G']","['METTIER SR', 'ELLENHORN MJ', 'GORDAN G']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,"['0 (Adrenal Cortex Hormones)', '0 (Vitamins)', '6E0A168OB8 (Desoxycorticosterone Acetate)', 'PQ6CK8PD0R (Ascorbic Acid)']",OM,"['*Adrenal Cortex Hormones', '*Ascorbic Acid', '*Chronic Disease', '*Desoxycorticosterone Acetate', '*Leukemia', '*Vitamins']",['CLML: 5120:22246:13:446:546'],['NLM'],"['*ADRENAL CORTEX HORMONES', '*LEUKEMIA', '*VITAMIN C']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Blood. 1950 Dec;5(12):1156-60.,['S0006-4971(20)66294-2 [pii]'],,,,,,,,,,,,,
14791091,NLM,MEDLINE,20040215,20181201,0004-0312 (Print) 0004-0312 (Linking),90,4,1950 Oct,[Leukemic reticulo-endotheliosis; a case of hyperplastic reticulo-endotheliosis with a peripheral picture of lymphatic leukemia].,241-58,"['ARAGONA, F']",['ARAGONA F'],['und'],['Journal Article'],Le reticolo-endoteliosi leucemiche; studio su di un caso di reticolo-endoteliosi iperplastica con quadro periferico di leucemia linfatica.,Italy,Arch Sci Med (Torino),Archivio per le scienze mediche,0372451,"['Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', 'Humans', '*Leukemia', '*Leukemia, Hairy Cell', '*Leukemia, Lymphoid', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5120:21736:232:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*RETICULOENDOTHELIOSIS']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Arch Sci Med (Torino). 1950 Oct;90(4):241-58.,,,,,,,,,,,,,,
14791037,NLM,MEDLINE,20040215,20181201,0004-0231 (Print) 0004-0231 (Linking),23,4,1950,[Unusual finding of systematic leukemic localization in the esophagus in an individual with acute hemocytoblastic leukemia].,241-9,"['CRISTIANI, M']",['CRISTIANI M'],['und'],['Journal Article'],Eccezionale reperto di sistematica localizzazione leucemica nell'esofago di un individuo affetto da leucemia emocitoblastica acuta.,Italy,Arch Ital Anat Istol Patol,Archivio italiano di anatomia e istologia patologica,0372443,,OM,"['*Biological Phenomena', '*Esophagus', 'Humans', '*Leukemia', '*Physiological Phenomena']",['CLML: 5120:21666:318:546'],['NLM'],"['*ESOPHAGUS', '*LEUKEMIA']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Arch Ital Anat Istol Patol. 1950;23(4):241-9.,,,,,,,,,,,,,,
14790996,NLM,MEDLINE,20040215,20181201,0096-6630 (Print) 0096-6630 (Linking),67,10,1950 Oct,Acute leukemia; report of case.,483-91,"['BLACKADER, A D', 'GILLIES, B D']","['BLACKADER AD', 'GILLIES BD']",['eng'],['Journal Article'],,United States,Arch Pediatr,Archives of pediatrics,15210180R,,OM,"['*Acute Disease', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5120:21625:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Arch Pediatr. 1950 Oct;67(10):483-91.,,,,,,,,,,,,,,
14790846,NLM,MEDLINE,20040215,20181201,0003-9764 (Print) 0003-9764 (Linking),7,6,1950,"[Von Jaksch-Luzet disease with tuberculosis, treated with streptomycin; results].",609-11,"['BENMUSSA, S', 'CARUANA, M', 'COHEN, H', 'GALES, Y']","['BENMUSSA S', 'CARUANA M', 'COHEN H', 'GALES Y']",['und'],['Journal Article'],Maladie de Von Jaksch-Luzet avec tuberculose traitee par la streptomycine; resultats.,France,Arch Fr Pediatr,Archives francaises de pediatrie,0372421,"['0 (Anti-Bacterial Agents)', 'Y45QSO73OB (Streptomycin)']",OM,"['*Anti-Bacterial Agents', '*Leukemia', '*Streptomycin', '*Tuberculosis', 'Tuberculosis, Pulmonary/*therapy']",['CLML: 5120:21470:196:336:397'],['NLM'],"['*PSEUDOLEUKEMIA', '*STREPTOMYCIN', '*TUBERCULOSIS, PULMONARY-ANTIBIOTIC AND CHEMOTHERAPY']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Arch Fr Pediatr. 1950;7(6):609-11.,,,,,,,,,,,,,,
14790700,NLM,MEDLINE,20040215,20181201,0365-6020 (Print) 0365-6020 (Linking),191,,1950,[Lymphatic leukemia].,716,['WEYHBRECHT'],['WEYHBRECHT'],['und'],['Journal Article'],Lymphatische Leukamie (illustration).,Germany,Arch Dermatol Syph,Archiv fur Dermatologie und Syphilis,15130110R,,OM,"['*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5120:21294:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Arch Dermatol Syph. 1950;191:716.,,,,,,,,,,,,,,
14789619,NLM,MEDLINE,20040215,20181201,0365-6403 (Print) 0365-6403 (Linking),5,32,1950 Aug 18,[Urethane therapy of leukemia].,597-9,"['EBERHARD, H']",['EBERHARD H'],['und'],['Journal Article'],Beitrag zur Urethanbehandlung der Leukamien.,Germany,Arztl Wochensch,Arztliche Wochenschrift,14640350R,['3IN71E75Z5 (Urethane)'],OM,"['*Leukemia', '*Urethane']",['CLML: 5120:20179:417:546'],['NLM'],"['*LEUKEMIA', '*URETHANE']",1950/08/18 00:00,1950/08/18 00:01,['1950/08/18 00:00'],"['1950/08/18 00:00 [pubmed]', '1950/08/18 00:01 [medline]', '1950/08/18 00:00 [entrez]']",ppublish,Arztl Wochensch. 1950 Aug 18;5(32):597-9.,,,,,,,,,,,,,,
14789510,NLM,MEDLINE,20040215,20181201,0365-463X (Print) 0365-463X (Linking),246,,1950,Three cases of megakaryocytic leukemia.,234-9,"['STENSTROM, N M']",['STENSTROM NM'],['eng'],['Journal Article'],,Sweden,Acta Med Scand Suppl,Acta medica Scandinavica. Supplementum,0370331,,OM,"['Humans', '*Leukemia', '*Leukemia, Megakaryoblastic, Acute']",['CLML: 5120:20041:546'],['NLM'],['*LEUKEMIA'],1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Acta Med Scand Suppl. 1950;246:234-9.,,,,,,,,,,,,,,
14789451,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),4,5,1950 Nov,[Four cases of plasma-cell leukemia].,291-300,"['SCHERRER, M']",['SCHERRER M'],['und'],['Journal Article'],Vier Falle von Plasmazell-Leukamie.,Switzerland,Acta Haematol,Acta haematologica,0141053,,OM,"['Humans', '*Leukemia', '*Leukemia, Plasma Cell', '*Neoplasms', '*Plasmacytoma']",['CLML: 5120:19982:167:546'],['NLM'],"['*LEUKEMIA', '*PLASMACYTOSIS']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Acta Haematol. 1950 Nov;4(5):291-300. doi: 10.1159/000203764.,['10.1159/000203764 [doi]'],,,,,,,,,,,,,
14789336,NLM,MEDLINE,20040215,20181201,0096-6711 (Print) 0096-6711 (Linking),51,1,1951 Jan,Acute myelogenous leukemia with giant cell carcinoma of thyroid.,72-5,"['DARON, P', 'PIZZOLATO, P']","['DARON P', 'PIZZOLATO P']",['eng'],['Journal Article'],,United States,AMA Arch Pathol,A.M.A. archives of pathology,14470150R,,OM,"['*Carcinoma', '*Carcinoma, Giant Cell', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Myeloid, Acute', '*Thyroid Gland']",['CLML: 5120:19866:174:372:547'],['NLM'],"['*CARCINOMA', '*LEUKEMIA, MYELOGENOUS', '*THYROID']",1951/01/01 00:00,1951/01/01 00:01,['1951/01/01 00:00'],"['1951/01/01 00:00 [pubmed]', '1951/01/01 00:01 [medline]', '1951/01/01 00:00 [entrez]']",ppublish,AMA Arch Pathol. 1951 Jan;51(1):72-5.,,,,,,,,,,,,,,
14789283,NLM,MEDLINE,20040215,20190917,0888-2479 (Print) 0888-2479 (Linking),87,2,1951 Feb,Eosinophilic leukemia with report of a case.,280-6,"['CARMEL, W J', 'MINNO, A M', 'COOK, W L Jr']","['CARMEL WJ', 'MINNO AM', 'COOK WL Jr']",['eng'],['Journal Article'],,United States,AMA Arch Intern Med,A.M.A. archives of internal medicine,14470100R,,OM,"['*Eosinophils', 'Humans', '*Hypereosinophilic Syndrome', '*Leukemia', '*Leukemia, Myeloid', '*Leukocyte Count']",['CLML: 5120:19813:309:547'],['NLM'],"['*EOSINOPHILS', '*LEUKEMIA, MYELOGENOUS']",1951/02/01 00:00,1951/02/01 00:01,['1951/02/01 00:00'],"['1951/02/01 00:00 [pubmed]', '1951/02/01 00:01 [medline]', '1951/02/01 00:00 [entrez]']",ppublish,AMA Arch Intern Med. 1951 Feb;87(2):280-6. doi: 10.1001/archinte.1951.03810020102010.,['10.1001/archinte.1951.03810020102010 [doi]'],,,,,,,,,,,,,
14788987,NLM,MEDLINE,20040215,20181201,0044-2542 (Print) 0044-2542 (Linking),5,17-18,1950 Sep,[Two cases of plasmocytoma].,546,"['SCHENNETTEN, F']",['SCHENNETTEN F'],['und'],['Journal Article'],Klinischer Beitrag zur Frage des Plasmozytoms.,Germany,Z Gesamte Inn Med,Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,21730470R,,OM,"['Humans', '*Leukemia', '*Multiple Myeloma', '*Neoplasms', '*Neoplasms, Plasma Cell', '*Plasmacytoma']",['CLML: 5120:19477:407:546'],['NLM'],"['*LEUKEMIA', '*TUMORS, MULTIPLE MYELOMA']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Z Gesamte Inn Med. 1950 Sep;5(17-18):546.,,,,,,,,,,,,,,
14788979,NLM,MEDLINE,20040215,20181201,0044-2542 (Print) 0044-2542 (Linking),5,15-16,1950 Aug,[Clinical aspects of reticuloendotheliosis and monocytosis].,506-20,"['SCHILLING, V']",['SCHILLING V'],['und'],['Journal Article'],Klinik der Retikuloendotheliosen und Monozytosen.,Germany,Z Gesamte Inn Med,Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,21730470R,"['Reticuloendotheliosis, X-linked']",OM,"['*Genetic Diseases, X-Linked', '*Leukemia', '*Leukemia, Myeloid', '*Monocytes', '*Mononuclear Phagocyte System', '*Severe Combined Immunodeficiency']",['CLML: 5120:19469:232:547'],['NLM'],"['*LEUKEMIA, MONOCYTIC', '*RETICULOENDOTHELIAL SYSTEM']",1950/08/01 00:00,1950/08/01 00:01,['1950/08/01 00:00'],"['1950/08/01 00:00 [pubmed]', '1950/08/01 00:01 [medline]', '1950/08/01 00:00 [entrez]']",ppublish,Z Gesamte Inn Med. 1950 Aug;5(15-16):506-20.,,,,,,,,,,,,,,
14788622,NLM,MEDLINE,20040215,20191108,0376-0081 (Print) 0376-0081 (Linking),318,5,1950,[Terminal stages of myeloid leukemia and their diagnosis by liver biopsy].,619-30,"['LENNERT, K']",['LENNERT K'],['und'],['Journal Article'],Uber die Endstadien der myeloischen Leukamie und ihre Diagnose aus dem Leberschnittbild.,Germany,Virchows Arch Pathol Anat Physiol Klin Med,Virchows Archiv fur pathologische Anatomie und Physiologie und fur klinische Medizin,0217007,,OM,"['*Biopsy', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Liver']",['CLML: 5120:19095:547:560'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*LIVER, IN VARIOUS CONDITIONS']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Virchows Arch Pathol Anat Physiol Klin Med. 1950;318(5):619-30. doi: 10.1007/BF00947941.,['10.1007/BF00947941 [doi]'],,,,,,,,,,,,,
14788365,NLM,MEDLINE,20040215,20181201,0041-5782 (Print) 0041-5782 (Linking),112,39,1950 Sep 28,[Remission of leukemia in childhood].,1359-60,"['MEHLSEN, S', 'JERSILD, T']","['MEHLSEN S', 'JERSILD T']",['und'],['Journal Article'],Remissioner ved leukaemi i barnealderen.,Denmark,Ugeskr Laeger,Ugeskrift for laeger,0141730,,OM,"['Humans', '*Leukemia']",['CLML: 5120:18838:546'],['NLM'],['*LEUKEMIA'],1950/09/28 00:00,1950/09/28 00:01,['1950/09/28 00:00'],"['1950/09/28 00:00 [pubmed]', '1950/09/28 00:01 [medline]', '1950/09/28 00:00 [entrez]']",ppublish,Ugeskr Laeger. 1950 Sep 28;112(39):1359-60.,,,,,,,,,,,,,,
14788364,NLM,MEDLINE,20040215,20181201,0041-5782 (Print) 0041-5782 (Linking),112,39,1950 Sep 28,[Aminopterin therapy of leukemia in childhood].,1354-9,"['JERSILD, T', 'MEHLSEN, S']","['JERSILD T', 'MEHLSEN S']",['und'],['Journal Article'],Aminopterinbehandling af leukaemi i barnealderen.,Denmark,Ugeskr Laeger,Ugeskrift for laeger,0141730,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Aminopterin', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:18837:349:545'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/09/28 00:00,1950/09/28 00:01,['1950/09/28 00:00'],"['1950/09/28 00:00 [pubmed]', '1950/09/28 00:01 [medline]', '1950/09/28 00:00 [entrez]']",ppublish,Ugeskr Laeger. 1950 Sep 28;112(39):1354-9.,,,,,,,,,,,,,,
14788345,NLM,MEDLINE,20040215,20181201,0041-5782 (Print) 0041-5782 (Linking),112,36,1950 Sep 7,"[Cholinesterase in the plasma, erythrocytes and whole blood in pernicious anemia and leukemia].",1250-2,"['PLUM, C M']",['PLUM CM'],['und'],['Journal Article'],"Cholinesterase i plasma, erytrocyter og fuldblod ved pernicios anaemi og leukaemi.",Denmark,Ugeskr Laeger,Ugeskrift for laeger,0141730,['EC 3.1.1.8 (Cholinesterases)'],OM,"['*Anemia', '*Anemia, Pernicious', '*Cholinesterases', '*Erythrocytes', 'Humans', '*Leukemia', '*Plasma']",['CLML: 5120:18818:40:203:546'],['NLM'],"['*ANEMIA, PERNICIOUS', '*CHOLINESTERASE', '*LEUKEMIA']",1950/09/07 00:00,1950/09/07 00:01,['1950/09/07 00:00'],"['1950/09/07 00:00 [pubmed]', '1950/09/07 00:01 [medline]', '1950/09/07 00:00 [entrez]']",ppublish,Ugeskr Laeger. 1950 Sep 7;112(36):1250-2.,,,,,,,,,,,,,,
14787986,NLM,MEDLINE,20040215,20181201,0040-5957 (Print) 0040-5957 (Linking),5,5,1950,[Favorable effect of testosterone in 2 cases of acute myeloid leukemia].,227-35,"['LAROCHE, G', 'TREMOLIERES, J', 'BOURGIN, M', 'RATHERY, M']","['LAROCHE G', 'TREMOLIERES J', 'BOURGIN M', 'RATHERY M']",['und'],['Journal Article'],Action favorable de la testosterone dans deux cas de leucose aigue myeloide.,France,Therapie,Therapie,0420544,"['0 (Androgens)', '3XMK78S47O (Testosterone)']",OM,"['*Androgens', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Leukemia, Myeloid, Acute', '*Testosterone']",['CLML: 5120:18459:37:547'],['NLM'],"['*ANDROGENS', '*LEUKEMIA, MYELOGENOUS']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Therapie. 1950;5(5):227-35.,,,,,,,,,,,,,,
14787392,NLM,MEDLINE,20040215,20181201,0036-7672 (Print) 0036-7672 (Linking),80,41,1950 Oct 14,[Pernicious anemia as the initial phase of an acute erythro-leukemia].,1122-4,"['HEILMEYER, L']",['HEILMEYER L'],['und'],['Journal Article'],Perniciose Anamie als Initialphase einer akuten Erythro-leukamie.,Switzerland,Schweiz Med Wochenschr,Schweizerische medizinische Wochenschrift,0404401,,OM,"['*Acute Disease', '*Anemia', '*Anemia, Pernicious', 'Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:17859:39:547'],['NLM'],"['*ANEMIA, PERNICIOUS', '*LEUKEMIA, MYELOGENOUS']",1950/10/14 00:00,1950/10/14 00:01,['1950/10/14 00:00'],"['1950/10/14 00:00 [pubmed]', '1950/10/14 00:01 [medline]', '1950/10/14 00:00 [entrez]']",ppublish,Schweiz Med Wochenschr. 1950 Oct 14;80(41):1122-4.,,,,,,,,,,,,,,
14787391,NLM,MEDLINE,20040215,20181201,0036-7672 (Print) 0036-7672 (Linking),80,41,1950 Oct 14,[Case of congenital leukemia].,1121-2,"['BAUMANN, T']",['BAUMANN T'],['und'],['Journal Article'],Ueber einen Fall von angeborener Leukamie.,Switzerland,Schweiz Med Wochenschr,Schweizerische medizinische Wochenschrift,0404401,,OM,"['Humans', '*Leukemia']",['CLML: 5120:17858:546'],['NLM'],['*LEUKEMIA'],1950/10/14 00:00,1950/10/14 00:01,['1950/10/14 00:00'],"['1950/10/14 00:00 [pubmed]', '1950/10/14 00:01 [medline]', '1950/10/14 00:00 [entrez]']",ppublish,Schweiz Med Wochenschr. 1950 Oct 14;80(41):1121-2.,,,,,,,,,,,,,,
14786662,NLM,MEDLINE,20040215,20181201,0014-2565 (Print) 0014-2565 (Linking),38,2,1950 Jul 31,[Monocytic leukemia; comments on 7 cases].,89-113,"['JIMENEZ DIAZ, C', 'MORALES PLEGUEZUELO, A', 'PANIAGUA RODRIGUEZ, G']","['JIMENEZ DIAZ C', 'MORALES PLEGUEZUELO A', 'PANIAGUA RODRIGUEZ G']",['und'],['Journal Article'],La leucemia monocatica (comentarios a proposito de siete observaciones).,Spain,Rev Clin Esp,Revista clinica espanola,8608576,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:17073:547'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1950/07/31 00:00,1950/07/31 00:01,['1950/07/31 00:00'],"['1950/07/31 00:00 [pubmed]', '1950/07/31 00:01 [medline]', '1950/07/31 00:00 [entrez]']",ppublish,Rev Clin Esp. 1950 Jul 31;38(2):89-113.,,,,,,,,,,,,,,
14786627,NLM,MEDLINE,20040215,20181201,0014-2565 (Print) 0014-2565 (Linking),37,4,1950 May 31,[Osteosclerotic hepatosplenomegalic leukaemia and glioblastoma].,281-3,"['GILSANZ', 'PANIAGUA']","['GILSANZ', 'PANIAGUA']",['und'],['Journal Article'],Leucanemia osteoesclerotica hepato-esplenomegalica y glioblastoma.,Spain,Rev Clin Esp,Revista clinica espanola,8608576,,OM,"['*Brain Neoplasms', '*Glioblastoma', 'Humans', '*Leukemia', '*Neoplasms', '*Neoplasms, Neuroepithelial', '*Neuroectodermal Tumors, Primitive', '*Splenomegaly']",['CLML: 5120:17038:139:318:408:546'],['NLM'],"['*BRAIN TUMOR', '*LEUKEMIA', '*SPLENOMEGALY', '*TUMORS, SPONGIOBLASTOMA']",1950/05/31 00:00,1950/05/31 00:01,['1950/05/31 00:00'],"['1950/05/31 00:00 [pubmed]', '1950/05/31 00:01 [medline]', '1950/05/31 00:00 [entrez]']",ppublish,Rev Clin Esp. 1950 May 31;37(4):281-3.,,,,,,,,,,,,,,
14786604,NLM,MEDLINE,20040215,20181201,0370-4106 (Print) 0370-4106 (Linking),21,7,1950 Jul,[Osseous lesions in leukemia in children].,289-97,"['HASBUN, J', 'EBERHARD, R']","['HASBUN J', 'EBERHARD R']",['und'],['Journal Article'],Lesiones oseas en la leucemia del nino.,Chile,Rev Chil Pediatr,Revista chilena de pediatria,0404261,,OM,"['*Bone and Bones', 'Child', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5120:17015:129:547'],['NLM'],"['*BONE', '*LEUKEMIA, LYMPHATIC']",1950/07/01 00:00,1950/07/01 00:01,['1950/07/01 00:00'],"['1950/07/01 00:00 [pubmed]', '1950/07/01 00:01 [medline]', '1950/07/01 00:00 [entrez]']",ppublish,Rev Chil Pediatr. 1950 Jul;21(7):289-97.,,,,,,,,,,,,,,
14786488,NLM,MEDLINE,20040215,20181201,0033-9776 (Print) 0033-9776 (Linking),52,5,1950 May,[Leukemia with remissions].,293-304,"['PORRAZZO, F']",['PORRAZZO F'],['und'],['Journal Article'],Sulle leucemie a remissione.,Italy,Rass Med Sarda,Rassegna medica sarda,0413553,,OM,"['Humans', '*Leukemia', '*Neoplasms']",['CLML: 5120:16876:546'],['NLM'],['*LEUKEMIA'],1950/05/01 00:00,1950/05/01 00:01,['1950/05/01 00:00'],"['1950/05/01 00:00 [pubmed]', '1950/05/01 00:01 [medline]', '1950/05/01 00:00 [entrez]']",ppublish,Rass Med Sarda. 1950 May;52(5):293-304.,,,,,,,,,,,,,,
14786487,NLM,MEDLINE,20040215,20181201,0033-9776 (Print) 0033-9776 (Linking),52,5,1950 May,[Study of osmotic erythrocyte resistance in erythremic myelosis].,290-2,"['CASULA, D']",['CASULA D'],['und'],['Journal Article'],Lo studio della resistenza globulare osmotica nelle mielosi eritremiche.,Italy,Rass Med Sarda,Rassegna medica sarda,0413553,,OM,"['*Erythrocytes', 'Humans', '*Leukemia, Erythroblastic, Acute', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Osmosis']",['CLML: 5120:16875:68:315'],['NLM'],"['*ERYTHROCYTES', '*MYELOSIS, ERYTHREMIC']",1950/05/01 00:00,1950/05/01 00:01,['1950/05/01 00:00'],"['1950/05/01 00:00 [pubmed]', '1950/05/01 00:01 [medline]', '1950/05/01 00:00 [entrez]']",ppublish,Rass Med Sarda. 1950 May;52(5):290-2.,,,,,,,,,,,,,,
14786026,NLM,MEDLINE,20040215,20181201,0096-0667 (Print) 0096-0667 (Linking),53,11,1950 Nov,"Human leukemia, with emphasis upon recent therapeutic experiences.",1172-81,"['ERF, L A']",['ERF LA'],['eng'],['Journal Article'],,United States,Pa Med J,Pennsylvania medical journal (1928),101245788,,OM,"['Humans', '*Leukemia']",['CLML: 5120:16386:546'],['NLM'],['*LEUKEMIA'],1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Pa Med J. 1950 Nov;53(11):1172-81.,,,,,,,,,,,,,,
14785872,NLM,MEDLINE,20040215,20181201,0029-3385 (Print) 0029-3385 (Linking),49,11,1950 Nov,Mikulicz's syndrome in chronic leukemia.,772-4,"['RADDING, J']",['RADDING J'],['eng'],['Journal Article'],,United States,Northwest Med,Northwest medicine,0407175,,OM,"['*Chronic Disease', 'Humans', '*Leukemia', ""*Mikulicz' Disease""]",['CLML: 5120:16232:42:546'],['NLM'],"['*LEUKEMIA', ""*MIKULICZ'S DISEASE""]",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Northwest Med. 1950 Nov;49(11):772-4.,,,,,,,,,,,,,,
14785624,NLM,MEDLINE,20040215,20181201,,37-38,3,1950 May-Jun,[Lymphoblastosis associated with cancer of the lung; use of lung puncture biopsy in diagnosis].,200-2,"['CAZAL, P', 'LATOUR, H', 'SALVAING, J', 'LEVY, A', 'GIRAUD, G']","['CAZAL P', 'LATOUR H', 'SALVAING J', 'LEVY A', 'GIRAUD G']",['und'],['Journal Article'],Association d'une lymphoblastose et d'un cancer du poumon; utilite de la ponction-biopsie pulmonaire pour la determination du diagnostic.,France,Montp Med,Montpellier medical,18820540R,,OM,"['*Biopsy, Needle', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lung', '*Lung Neoplasms', '*Neoplasms']",['CLML: 5120:15980:165:546:569'],['NLM'],"['*CANCER', '*LEUKEMIA, LYMPHATIC', '*LUNGS, NEOPLASMS']",1950/05/01 00:00,1950/05/01 00:01,['1950/05/01 00:00'],"['1950/05/01 00:00 [pubmed]', '1950/05/01 00:01 [medline]', '1950/05/01 00:00 [entrez]']",ppublish,Montp Med. 1950 May-Jun;37-38(3):200-2.,,,,,,,,,,,,,,
14785487,NLM,MEDLINE,20040215,20181201,,175,,1950 Nov,[Recent acquisitions in the treatment of acute leukemia].,494-509,"['de MENDONCA, J M']",['de MENDONCA JM'],['und'],['Journal Article'],Recentes aquisicoes no tratamento das leucemias agudas.,Brazil,Med Cir Farm,"Medicina, cirurgia, farmacia",18540370R,,OM,"['*Acute Disease', 'Humans', '*Leukemia']",['CLML: 5120:15827:546'],['NLM'],['*LEUKEMIA'],1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Med Cir Farm. 1950 Nov;175:494-509.,,,,,,,,,,,,,,
14785320,NLM,MEDLINE,20040215,20181201,0024-869X (Print) 0024-869X (Linking),18,9,1950 Sep,[Experiences with aminopterin in the treatment of leukemia].,325-40,"['HAVERKAMP BEGEMANN, N', 'van WIJHE, M']","['HAVERKAMP BEGEMANN N', 'van WIJHE M']",['und'],['Journal Article'],Ervaringen over de behandeling der leucaemie met aminopterine.,Netherlands,Maandschr Kindergeneeskd,Maandschrift voor kindergeneeskunde,7704293,"['0 (Folic Acid Antagonists)', 'JYB41CTM2Q (Aminopterin)']",OM,"['*Aminopterin', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:15659:349:545'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Maandschr Kindergeneeskd. 1950 Sep;18(9):325-40.,,,,,,,,,,,,,,
14785133,NLM,MEDLINE,20040215,20181201,0023-1495 (Print) 0023-1495 (Linking),18,,1950,"[Efficacy and limitations of karyoklastic therapy of leukosis, lymphogranulomatosis, and malignant tumors in childhood].",143-50,"['WEICKER, H']",['WEICKER H'],['und'],['Journal Article'],"Leistungsfahigkeit und Grenzen der Mitosegift-Therapie bei den Leukosen, Lymphogranulomatosen und malignen Geschwulsten des Kindesalters.",Germany,Kinderarztl Prax,Kinderarztliche Praxis,0376356,"['0 (Nitrogen Mustard Compounds)', '3IN71E75Z5 (Urethane)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Hodgkin Disease', '*Leukemia', '*Mechlorethamine', '*Neoplasms', '*Nitrogen Mustard Compounds', '*Sarcoidosis', '*Urethane']",['CLML: 5120:15467:88:164:417:444:546'],['NLM'],"['*CANCER', ""*HODGKIN'S DISEASE"", '*LEUKEMIA', '*NITROGEN MUSTARDS', '*URETHANE']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Kinderarztl Prax. 1950;18:143-50.,,,,,,,,,,,,,,
14784656,NLM,MEDLINE,20040215,20181201,0022-2143 (Print) 0022-2143 (Linking),36,5,1950 Nov,Erythrocyte values in the leucemias.,798-9,"['BEST, W R', 'LIMARZI, L R', 'PONCHER, H G']","['BEST WR', 'LIMARZI LR', 'PONCHER HG']",['eng'],['Journal Article'],,United States,J Lab Clin Med,The Journal of laboratory and clinical medicine,0375375,,OM,"['*Erythrocytes', 'Humans', '*Leukemia']",['CLML: 5120:14962:316:546'],['NLM'],"['*ERYTHROCYTES', '*LEUKEMIA']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,J Lab Clin Med. 1950 Nov;36(5):798-9.,,,,,,,,,,,,,,
14784620,NLM,MEDLINE,20040215,20181201,0096-6983 (Print) 0096-6983 (Linking),50,11,1950 Nov,Multiple myeloma and plasma cell leukemia: Case report.,527-9,"['BICKFORD, R H', 'FOWLER, W M']","['BICKFORD RH', 'FOWLER WM']",['eng'],['Journal Article'],,United States,J Iowa State Med Soc,Journal. Iowa State Medical Society,17710080R,,OM,"['Humans', '*Leukemia', '*Leukemia, Plasma Cell', '*Multiple Myeloma', '*Neoplasms']",['CLML: 5120:14926:407:546'],['NLM'],"['*LEUKEMIA', '*TUMORS, MULTIPLE MYELOMA']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,J Iowa State Med Soc. 1950 Nov;50(11):527-9.,,,,,,,,,,,,,,
14784270,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),34,5,1950,[Principal varieties of Di Guglielmo's disease; personal contribution to the acute erythremic manifestations of peculiar aspect].,357-92,"['DI LOLLO, F']",['DI LOLLO F'],['und'],['Journal Article'],Le principali varieta della malattia di Di Guglielmo.,Italy,Haematologica,Haematologica,0417435,,OM,"['Humans', '*Leukemia, Erythroblastic, Acute', '*Polycythemia']",['CLML: 5120:14544:177'],['NLM'],['*POLYCYTHEMIA'],1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Haematologica. 1950;34(5):357-92.,,,,,,,,,,,,,,
14784265,NLM,MEDLINE,20040215,20181201,0390-6078 (Print) 0390-6078 (Linking),34,4,1950,"[Case of acute erythremic myelosis, clinical and hemato-histological study].",281-305,"['ROMEO, F']",['ROMEO F'],['und'],['Journal Article'],Su un caso di mielosi eritremica acuta (studio clinico ed ematoistologico).,Italy,Haematologica,Haematologica,0417435,['Acute erythroleukemia'],OM,"['*Leukemia, Erythroblastic, Acute', '*Polycythemia']",['CLML: 5120:14539:177'],['NLM'],['*POLYCYTHEMIA'],1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Haematologica. 1950;34(4):281-305.,,,,,,,,,,,,,,
14783755,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),3,6,1950 Nov,"Susceptibility of suckling-infant, and resistance of adult, mice of the C3H and of the C57 lines to inoculation with Ak leukemia.",1073-87,"['GROSS, L']",['GROSS L'],['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,,OM,"['Animals', '*Disease Susceptibility', '*Leukemia', 'Mice', 'Mice, Inbred C3H', '*Vaccination']",['CLML: 5120:13997:546'],['NLM'],['*LEUKEMIA'],1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Cancer. 1950 Nov;3(6):1073-87. doi: 10.1002/1097-0142(1950)3:6<1073::aid-cncr2820030618>3.0.co;2-5.,['10.1002/1097-0142(1950)3:6<1073::aid-cncr2820030618>3.0.co;2-5 [doi]'],,,,,,,,,,,,,
14783748,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),3,6,1950 Nov,The biological half-life of radioactive phosphorus in the blood of patients with leukemia. IV. Leukocytes; radioactive phosphorus content and the relation to plasma-P32 levels.,1014-7,"['OSGOOD, E E', 'TIVEY, H', 'KLINK, E', 'McKENZIE, M', 'HUGHES, M E', 'ORT, J', 'GUSTAFSON, I', 'FULLER, M', 'KLOBUCHER, V', 'STODDARD, H']","['OSGOOD EE', 'TIVEY H', 'KLINK E', 'McKENZIE M', 'HUGHES ME', 'ORT J', 'GUSTAFSON I', 'FULLER M', 'KLOBUCHER V', 'STODDARD H']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Phosphorus Radioisotopes)', '27YLU75U4W (Phosphorus)']",OM,"['Half-Life', 'Humans', '*Leukemia', '*Leukocytes', '*Phosphorus', '*Phosphorus Radioisotopes', '*Plasma']",['CLML: 5120:13990:156:546:547'],['NLM'],"['*LEUKEMIA', '*LEUKOCYTES', '*PHOSPHORUS AND COMPOUNDS, RADIOACTIVE']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Cancer. 1950 Nov;3(6):1014-7. doi: 10.1002/1097-0142(1950)3:6<1014::aid-cncr2820030610>3.0.co;2-w.,['10.1002/1097-0142(1950)3:6<1014::aid-cncr2820030610>3.0.co;2-w [doi]'],,,,,,,,,,,,,
14783747,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),3,6,1950 Nov,The biological half-life of radioactive phosphorus in the blood of patients with leukemia. III. Erythrocytes; with deviations of observations from predicted values.,1010-13,"['TIVEY, H', 'OSGOOD, E E', 'KLINK, E', 'McKENZIE, M', 'HUGHES, M E', 'ORT, J', 'GUSTAFSON, I', 'FULLER, M', 'KLOBUCHER, V', 'STODDARD, H']","['TIVEY H', 'OSGOOD EE', 'KLINK E', 'McKENZIE M', 'HUGHES ME', 'ORT J', 'GUSTAFSON I', 'FULLER M', 'KLOBUCHER V', 'STODDARD H']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Phosphorus Radioisotopes)', '27YLU75U4W (Phosphorus)']",OM,"['*Erythrocytes', 'Half-Life', 'Humans', '*Leukemia', '*Phosphorus', '*Phosphorus Radioisotopes']",['CLML: 5120:13989:156:316:546'],['NLM'],"['*ERYTHROCYTES', '*LEUKEMIA', '*PHOSPHORUS AND COMPOUNDS, RADIOACTIVE']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Cancer. 1950 Nov;3(6):1010-13. doi: 10.1002/1097-0142(1950)3:6<1010::aid-cncr2820030609>3.0.co;2-i.,['10.1002/1097-0142(1950)3:6<1010::aid-cncr2820030609>3.0.co;2-i [doi]'],,,,,,,,,,,,,
14783746,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),3,6,1950 Nov,The biological half-life of radioactive phosphorus in the blood of patients with leukemia. II. Plasma; with deviations of observations from predicted values and an estimate of total-phosphorus turnover rate.,1003-9,"['OSGOOD, E E', 'TIVEY, H', 'KLINK, E', 'McKENZIE, M', 'HUGHES, M E', 'ORT, J', 'GUSTAFSON, I', 'FULLER, M', 'KLOBUCHER, V', 'STODDARD, H']","['OSGOOD EE', 'TIVEY H', 'KLINK E', 'McKENZIE M', 'HUGHES ME', 'ORT J', 'GUSTAFSON I', 'FULLER M', 'KLOBUCHER V', 'STODDARD H']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Phosphorus Radioisotopes)', '27YLU75U4W (Phosphorus)']",OM,"['Half-Life', '*Leukemia', '*Phosphorus', '*Phosphorus Radioisotopes', '*Plasma']",['CLML: 5120:13988:116:156:546'],['NLM'],"['*BLOOD PLASMA', '*LEUKEMIA', '*PHOSPHORUS AND COMPOUNDS, RADIOACTIVE']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Cancer. 1950 Nov;3(6):1003-9. doi: 10.1002/1097-0142(1950)3:6<1003::aid-cncr2820030608>3.0.co;2-d.,['10.1002/1097-0142(1950)3:6<1003::aid-cncr2820030608>3.0.co;2-d [doi]'],,,,,,,,,,,,,
14783745,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),3,6,1950 Nov,"The biological half-life of radioactive phosphorus in the blood of patients with leukemia. I. Whole blood, with deviations of observations from predicted values and an estimate of total-phosphorus turnover rate.",992-1002,"['TIVEY, H', 'OSGOOD, E E', 'KLINK, E', 'McKENZIE, M', 'HUGHES, M E', 'ORT, J', 'GUSTAFSON, I', 'FULLER, M', 'KLOBUCHER, V', 'STODDARD, H']","['TIVEY H', 'OSGOOD EE', 'KLINK E', 'McKENZIE M', 'HUGHES ME', 'ORT J', 'GUSTAFSON I', 'FULLER M', 'KLOBUCHER V', 'STODDARD H']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Phosphorus Radioisotopes)', '27YLU75U4W (Phosphorus)']",OM,"['*Blood', 'Half-Life', 'Humans', '*Leukemia', '*Phosphorus', '*Phosphorus Radioisotopes']",['CLML: 5120:13987:111:156:546'],['NLM'],"['*BLOOD', '*LEUKEMIA', '*PHOSPHORUS AND COMPOUNDS, RADIOACTIVE']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Cancer. 1950 Nov;3(6):992-1002. doi: 10.1002/1097-0142(1950)3:6<992::aid-cncr2820030607>3.0.co;2-w.,['10.1002/1097-0142(1950)3:6<992::aid-cncr2820030607>3.0.co;2-w [doi]'],,,,,,,,,,,,,
14783271,NLM,MEDLINE,20040215,20181201,0002-9645 (Print) 0002-9645 (Linking),11,41,1950 Oct,Studies in avian leucosis. V. An investigation of the possible relationship of sex hormones to visceral lymphonatosis.,428-36,"['DAVIS, O S', 'ANDREWS, F N', 'DOYLE, L P']","['DAVIS OS', 'ANDREWS FN', 'DOYLE LP']",['eng'],['Journal Article'],,United States,Am J Vet Res,American journal of veterinary research,0375011,"['0 (Androgens)', '0 (Contraceptive Agents, Female)', '0 (Estrogens)', '0 (Gonadal Steroid Hormones)']",OM,"['*Androgens', 'Animals', '*Bird Diseases', '*Contraceptive Agents, Female', '*Estrogens', 'Female', '*Gonadal Steroid Hormones', '*Leukemia', '*Viscera']",['CLML: 5120:13464:37:321:440:546'],['NLM'],"['*ANDROGENS', '*ESTROGENS', '*LEUKEMIA, AVIAN', '*VISCERA']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Am J Vet Res. 1950 Oct;11(41):428-36.,,,,,,,,,,,,,,
14783241,NLM,MEDLINE,20040215,20181201,0092-5632 (Print) 0092-5632 (Linking),64,6,1950 Dec,Diagnosis and treatment of lymphoblastoma and leukemia from the standpoint of the radiologist.,919-28,"['MORTON, J L']",['MORTON JL'],['eng'],['Journal Article'],,United States,Am J Roentgenol Radium Ther,The American journal of roentgenology and radium therapy,0404014,,OM,"['*Hodgkin Disease', 'Humans', '*Leukemia', '*Lymphoma', '*Lymphoma, Non-Hodgkin', '*Neoplasms']",['CLML: 5120:13434:406:444:546'],['NLM'],"[""*HODGKIN'S DISEASE"", '*LEUKEMIA', '*TUMORS, LYMPHOBLASTOMA']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Am J Roentgenol Radium Ther. 1950 Dec;64(6):919-28.,,,,,,,,,,,,,,
14783239,NLM,MEDLINE,20040215,20181201,0092-5632 (Print) 0092-5632 (Linking),64,6,1950 Dec,"Leukemia, polycythemia and related diseases.",907-12,"['WRIGHT, C S']",['WRIGHT CS'],['eng'],['Journal Article'],,United States,Am J Roentgenol Radium Ther,The American journal of roentgenology and radium therapy,0404014,,OM,"['Humans', '*Leukemia', '*Polycythemia', '*Polycythemia Vera']",['CLML: 5120:13432:177:546'],['NLM'],"['*LEUKEMIA', '*POLYCYTHEMIA VERA']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,Am J Roentgenol Radium Ther. 1950 Dec;64(6):907-12.,,,,,,,,,,,,,,
14782680,NLM,MEDLINE,20040215,20191108,2374-2941 (Print) 2374-2941 (Linking),80,6,1950 Dec,Duration of acute leukemia in children. Review of the literature and report of a case of unusually long survival.,955-62,"['MOODY, E A', 'DAVIS, R W']","['MOODY EA', 'DAVIS RW']",['eng'],['Journal Article'],,United States,AMA Am J Dis Child,A.M.A. American journal of diseases of children,14470010R,,OM,"['*Acute Disease', 'Child', 'Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5120:12853:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1950/12/01 00:00,1950/12/01 00:01,['1950/12/01 00:00'],"['1950/12/01 00:00 [pubmed]', '1950/12/01 00:01 [medline]', '1950/12/01 00:00 [entrez]']",ppublish,AMA Am J Dis Child. 1950 Dec;80(6):955-62. doi: 10.1001/archpedi.1950.04040020970008.,['10.1001/archpedi.1950.04040020970008 [doi]'],,,,,,,,,,,,,
14782491,NLM,MEDLINE,20040215,20181201,0043-5376 (Print) 0043-5376 (Linking),31,9,1950 Sep,[Electron microscope studies of the thrombocytes in essential thrombopenia and acute leukemia].,321-7,"['BRAUNSTEINER, H', 'FEBVRE, H']","['BRAUNSTEINER H', 'FEBVRE H']",['und'],['Journal Article'],Elektronenmikroskopische Untersuchungen der Thrombozyten bei essentiellen Thrombopenien und akuten Leukamien.,Austria,Wien Z Inn Med,Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete,7502231,,OM,"['*Blood Platelets', '*Electrons', '*Leukemia', '*Purpura', '*Purpura, Thrombocytopenic', '*Thrombocytopenia']",['CLML: 5120:12587:210:546'],['NLM'],"['*LEUKEMIA', '*PURPURA, THROMBOPENIC']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Wien Z Inn Med. 1950 Sep;31(9):321-7.,,,,,,,,,,,,,,
14782395,NLM,MEDLINE,20040215,20190702,0042-4900 (Print) 0042-4900 (Linking),62,45,1950 Nov 11,Studies on the avian leukosis complex.,621-2,"['DARCEL, C Le Q']",['DARCEL Cle Q'],['eng'],['Journal Article'],,England,Vet Rec,The Veterinary record,0031164,,OM,"['Animals', '*Avian Leukosis', '*Bird Diseases', '*Birds', '*Leukemia', '*Poultry']",['CLML: 5120:12490:354:546'],['NLM'],"['*FOWLS', '*LEUKEMIA, AVIAN']",1950/11/11 00:00,1950/11/11 00:01,['1950/11/11 00:00'],"['1950/11/11 00:00 [pubmed]', '1950/11/11 00:01 [medline]', '1950/11/11 00:00 [entrez]']",ppublish,Vet Rec. 1950 Nov 11;62(45):621-2. doi: 10.1136/vr.62.45.621.,['10.1136/vr.62.45.621 [doi]'],,,,,,,,,,,,,
14781937,NLM,MEDLINE,20040215,20181201,,26,70,1950 Sep 22,[The hemorrhagic syndrome of acute leukemias].,3676-80,"['TZANCK, A', 'SOULIER, J P', 'DAUSSET, J']","['TZANCK A', 'SOULIER JP', 'DAUSSET J']",['und'],['Journal Article'],Le syndrome hemorragique des leucemies aigues.,France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,,OM,"['*Acute Disease', 'Humans', '*Leukemia', '*Syndrome']",['CLML: 5120:12015:546'],['NLM'],['*LEUKEMIA'],1950/09/22 00:00,1950/09/22 00:01,['1950/09/22 00:00'],"['1950/09/22 00:00 [pubmed]', '1950/09/22 00:01 [medline]', '1950/09/22 00:00 [entrez]']",ppublish,Sem Hop. 1950 Sep 22;26(70):3676-80.,,,,,,,,,,,,,,
14781887,NLM,MEDLINE,20040215,20181201,,26,65,1950 Sep 2,[Trials on treatment of acute leukemias].,3322-35,"['BERNARD, J']",['BERNARD J'],['und'],['Journal Article'],Les essais de traitement des leucoses aigues.,France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,,OM,"['*Acute Disease', 'Humans', '*Leukemia']",['CLML: 5120:11965:546'],['NLM'],['*LEUKEMIA'],1950/09/02 00:00,1950/09/02 00:01,['1950/09/02 00:00'],"['1950/09/02 00:00 [pubmed]', '1950/09/02 00:01 [medline]', '1950/09/02 00:00 [entrez]']",ppublish,Sem Hop. 1950 Sep 2;26(65):3322-35.,,,,,,,,,,,,,,
14781886,NLM,MEDLINE,20040215,20181201,,26,65,1950 Sep 2,[Human leukemias in the class of virus diseases].,3318-21,"['MAGRASSI, F']",['MAGRASSI F'],['und'],['Journal Article'],Les leucemies humaines dans le cadre des maladies infectieuses conditionnees a virus.,France,Sem Hop,La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,9410059,,OM,"['Humans', '*Leukemia', '*Virus Diseases']",['CLML: 5120:11964:546'],['NLM'],['*LEUKEMIA'],1950/09/02 00:00,1950/09/02 00:01,['1950/09/02 00:00'],"['1950/09/02 00:00 [pubmed]', '1950/09/02 00:01 [medline]', '1950/09/02 00:00 [entrez]']",ppublish,Sem Hop. 1950 Sep 2;26(65):3318-21.,,,,,,,,,,,,,,
14781165,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),74,4,1950 Aug,Prevention of chemotherapeutic effects of 4-amino-N10-methyl-pteroylglutamic acid on mouse leukemia by citrovorum factor.,735-7,"['BURCHENAL, J H', 'BABCOCK, G M', 'BROQUIST, H P', 'JUKES, T H']","['BURCHENAL JH', 'BABCOCK GM', 'BROQUIST HP', 'JUKES TH']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,"['0 (Amino Acids)', '0 (Folic Acid Antagonists)', 'Q573I9DVLP (Leucovorin)']",OM,"['*Amino Acids', '*Biomedical Research', '*Folic Acid Antagonists', '*Leucovorin', '*Leukemia']",['CLML: 5120:11198:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/08/01 00:00,1950/08/01 00:01,['1950/08/01 00:00'],"['1950/08/01 00:00 [pubmed]', '1950/08/01 00:01 [medline]', '1950/08/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1950 Aug;74(4):735-7. doi: 10.3181/00379727-74-18031.,['10.3181/00379727-74-18031 [doi]'],,,,,,,,,,,,,
14781156,NLM,MEDLINE,20040215,20200930,0037-9727 (Print) 0037-9727 (Linking),74,4,1950 Aug,"Chemotherapy of leukemia. V. Effects of 2,4,6-triethylenimino-S-triazine and related compounds on transplanted mouse leukemia.",708-12,"['BURCHENAL, J H', 'JOHNSTON, S F', 'CREMER, M A', 'WEBBER, L F', 'STOCK, C C']","['BURCHENAL JH', 'JOHNSTON SF', 'CREMER MA', 'WEBBER LF', 'STOCK CC']",['eng'],['Journal Article'],,United States,Proc Soc Exp Biol Med,"Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)",7505892,['0 (Triazines)'],OM,"['Animals', '*Leukemia', 'Mice', '*Triazines']",['CLML: 5120:11189:385:546'],['NLM'],"['*LEUKEMIA', '*TRIAZINE']",1950/08/01 00:00,1950/08/01 00:01,['1950/08/01 00:00'],"['1950/08/01 00:00 [pubmed]', '1950/08/01 00:01 [medline]', '1950/08/01 00:00 [entrez]']",ppublish,Proc Soc Exp Biol Med. 1950 Aug;74(4):708-12. doi: 10.3181/00379727-74-18022.,['10.3181/00379727-74-18022 [doi]'],,,,,,,,,,,,,
14780993,NLM,MEDLINE,20040215,20181201,0032-745X (Print) 0032-745X (Linking),37,34,1950 Aug 25,[Folic acid antagonists in the treatment of leukemia].,1992-6,"['FUSTINONI, O', 'LASCALEA, M C']","['FUSTINONI O', 'LASCALEA MC']",['und'],['Journal Article'],Los antagonistas del acido folico en el tratamiento de las leucemias.,Argentina,Prensa Med Argent,Prensa medica argentina,0204056,['0 (Folic Acid Antagonists)'],OM,"['*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:11026:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/08/25 00:00,1950/08/25 00:01,['1950/08/25 00:00'],"['1950/08/25 00:00 [pubmed]', '1950/08/25 00:01 [medline]', '1950/08/25 00:00 [entrez]']",ppublish,Prensa Med Argent. 1950 Aug 25;37(34):1992-6.,,,,,,,,,,,,,,
14780952,NLM,MEDLINE,20040215,20190713,0032-5481 (Print) 0032-5481 (Linking),8,5,1950 Nov,Treatment of leukemia.,414-6,"['BURCHENAL, J H', 'KARNOFSKY, D A']","['BURCHENAL JH', 'KARNOFSKY DA']",['eng'],['Journal Article'],,England,Postgrad Med,Postgraduate medicine,0401147,,OM,"['Humans', '*Leukemia']",['CLML: 5120:10982:546'],['NLM'],['*LEUKEMIA'],1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Postgrad Med. 1950 Nov;8(5):414-6. doi: 10.1080/00325481.1950.11694033.,['10.1080/00325481.1950.11694033 [doi]'],,,,,,,,,,,,,
14780878,NLM,MEDLINE,20040215,20181201,0048-4717 (Print) 0048-4717 (Linking),57,4,1950 Aug,[Research on the osmotic resistance of the erythrocytes in leukemia].,218-29,"['SILVESTRONI, E', 'SERAFINI, U M']","['SILVESTRONI E', 'SERAFINI UM']",['und'],['Journal Article'],Ricerche sulla resistenza osmotica delle emazie nelle leucemie.,Italy,Policlinico Med,Il Policlinico. Sezione medica,0401144,,OM,"['*Biochemical Phenomena', '*Erythrocytes', 'Humans', '*Leukemia', '*Osmosis']",['CLML: 5120:10908:316:546'],['NLM'],"['*ERYTHROCYTES', '*LEUKEMIA']",1950/08/01 00:00,1950/08/01 00:01,['1950/08/01 00:00'],"['1950/08/01 00:00 [pubmed]', '1950/08/01 00:01 [medline]', '1950/08/01 00:00 [entrez]']",ppublish,Policlinico Med. 1950 Aug;57(4):218-29.,,,,,,,,,,,,,,
14780712,NLM,MEDLINE,20040215,20181201,0369-8300 (Print) 0369-8300 (Linking),40,36,1950 Sep 23,[Bone tumors and acute monocytic leukemia].,501-4,"['COCHEZ, P', 'GLAUNES, J P', 'DURAND, A']","['COCHEZ P', 'GLAUNES JP', 'DURAND A']",['und'],['Journal Article'],Tumeurs osseuses et leucose aigue monocytaire.,France,Paris Med,Paris medical,19520510R,,OM,"['*Bone Neoplasms', 'Humans', '*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid', '*Neoplasms']",['CLML: 5120:10731:130:547'],['NLM'],"['*BONE, TUMORS', '*LEUKEMIA, MONOCYTIC']",1950/09/23 00:00,1950/09/23 00:01,['1950/09/23 00:00'],"['1950/09/23 00:00 [pubmed]', '1950/09/23 00:01 [medline]', '1950/09/23 00:00 [entrez]']",ppublish,Paris Med. 1950 Sep 23;40(36):501-4.,,,,,,,,,,,,,,
14780661,NLM,MEDLINE,20040215,20190712,0030-4220 (Print) 0030-4220 (Linking),3,9,1950 Sep,Aleucemic leucemia.,1142-4,"['KROGH, H W']",['KROGH HW'],['eng'],['Journal Article'],,United States,Oral Surg Oral Med Oral Pathol,"Oral surgery, oral medicine, and oral pathology",0376406,,OM,"['Humans', '*Leukemia']",['CLML: 5120:10676:546'],['NLM'],"['*LEUKEMIA, ALEUKEMIC']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Oral Surg Oral Med Oral Pathol. 1950 Sep;3(9):1142-4. doi: 10.1016/0030-4220(50)90008-9.,['10.1016/0030-4220(50)90008-9 [doi]'],,,,,,,,,,,,,
14780368,NLM,MEDLINE,20040215,20181201,0028-4793 (Print) 0028-4793 (Linking),243,20,1950 Nov 16,Plasmacytic leukemia; report of a case.,769-73,"['HILL, N P', 'HAWN, C V Z']","['HILL NP', 'HAWN CV']",['eng'],['Journal Article'],,United States,N Engl J Med,The New England journal of medicine,0255562,,OM,"['Humans', '*Leukemia', '*Leukemia, Plasma Cell']",['CLML: 5120:10380:546'],['NLM'],['*LEUKEMIA'],1950/11/16 00:00,1950/11/16 00:01,['1950/11/16 00:00'],"['1950/11/16 00:00 [pubmed]', '1950/11/16 00:01 [medline]', '1950/11/16 00:00 [entrez]']",ppublish,N Engl J Med. 1950 Nov 16;243(20):769-73. doi: 10.1056/NEJM195011162432002.,['10.1056/NEJM195011162432002 [doi]'],,,,,,,,,,,,,
14780035,NLM,MEDLINE,20040215,20181201,0026-556X (Print) 0026-556X (Linking),33,10,1950 Oct,Chronic leukemic infiltration of the gastric wall simulating peptic ulcer.,1004-8,"['CONLEY, R H', 'WILSON, J A']","['CONLEY RH', 'WILSON JA']",['eng'],['Journal Article'],,United States,Minn Med,Minnesota medicine,8000173,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Leukemic Infiltration', 'Minnesota', '*Peptic Ulcer', '*Stomach']",['CLML: 5120:10047:142:331:547'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*PEPTIC ULCER', '*STOMACH']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Minn Med. 1950 Oct;33(10):1004-8.,,,,,,,,,,,,,,
14780017,NLM,MEDLINE,20040215,20181201,0026-4946 (Print) 0026-4946 (Linking),2,8,1950 Aug,[Clinical contribution to the study of leukemoid reaction in children].,367-73,"['COSSANDI, E']",['COSSANDI E'],['und'],['Journal Article'],Contributo clinico allo studio delle reazioni leucemoidi nell'infanzia.,Italy,Minerva Pediatr,Minerva pediatrica,0400740,,OM,"['*Blood', 'Humans', '*Leukemia', '*Leukemoid Reaction']",['CLML: 5120:10029:111:546'],['NLM'],"['*BLOOD', '*LEUKEMIA']",1950/08/01 00:00,1950/08/01 00:01,['1950/08/01 00:00'],"['1950/08/01 00:00 [pubmed]', '1950/08/01 00:01 [medline]', '1950/08/01 00:00 [entrez]']",ppublish,Minerva Pediatr. 1950 Aug;2(8):367-73.,,,,,,,,,,,,,,
14779983,NLM,MEDLINE,20040215,20181201,0026-4806 (Print) 0026-4806 (Linking),41,46,1950 Sep 22,[Naphthylamine compounds in the treatment of severe hemolymph diseases; a further clinical contribution].,490-7,"['SPIGLIATI, P']",['SPIGLIATI P'],['und'],['Journal Article'],I composti naftilaminici nella terapia di alcune gravi emolinfopatie; ulteriore contributo clinico.,Italy,Minerva Med,Minerva medica,0400732,['0 (Naphthols)'],OM,"['Animals', '*Hemolymph', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Naphthols']",['CLML: 5120:9995:71:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*NAPHTHOL AND COMPOUNDS']",1950/09/22 00:00,1950/09/22 00:01,['1950/09/22 00:00'],"['1950/09/22 00:00 [pubmed]', '1950/09/22 00:01 [medline]', '1950/09/22 00:00 [entrez]']",ppublish,Minerva Med. 1950 Sep 22;41(46):490-7.,,,,,,,,,,,,,,
14779965,NLM,MEDLINE,20040215,20181201,0026-4806 (Print) 0026-4806 (Linking),41,44,1950 Sep 8,[Activity of progesterone in large doses in chronic lymphadenosis].,405-7,"['VILLA, L']",['VILLA L'],['und'],['Journal Article'],Attivita del progesterone in elevato dosaggio nella linfadenosi cronica.,Italy,Minerva Med,Minerva medica,0400732,['4G7DS2Q64Y (Progesterone)'],OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Progesterone']",['CLML: 5120:9977:191:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*PROGESTERONE']",1950/09/08 00:00,1950/09/08 00:01,['1950/09/08 00:00'],"['1950/09/08 00:00 [pubmed]', '1950/09/08 00:01 [medline]', '1950/09/08 00:00 [entrez]']",ppublish,Minerva Med. 1950 Sep 8;41(44):405-7.,,,,,,,,,,,,,,
14779668,NLM,MEDLINE,20040215,20181201,0025-7583 (Print) 0025-7583 (Linking),78,11,1950 Nov,The control of spleen size. Preliminary note in chronic myelogenous leukemia.,534-5,"['BOYERS, L M']",['BOYERS LM'],['eng'],['Journal Article'],,United States,Med Times,Medical times,0406055,['0CPP32S55X (Dimercaprol)'],OM,"['*Dimercaprol', 'Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Spleen']",['CLML: 5120:9676:79:317:547'],['NLM'],"['*BAL', '*LEUKEMIA, MYELOGENOUS', '*SPLEEN']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,Med Times. 1950 Nov;78(11):534-5.,,,,,,,,,,,,,,
14779491,NLM,MEDLINE,20040215,20181201,0024-7790 (Print) 0024-7790 (Linking),183,39,1950 Sep 24,"[Case of acute leukosis with beginning symptoms of Biermer's anemia (hyperchromic anemia, medullary megaloblastosis, achylia)].",204-7,"['BERTOYE, P', 'MONNET, P', 'MOREL, P', 'CARRON, R']","['BERTOYE P', 'MONNET P', 'MOREL P', 'CARRON R']",['und'],['Journal Article'],"Un cas de leucose aigue avec episode de debut pseudobiermerien (anemie hyperchrome, megaloblastose medullaire achylie).",France,Lyon Med,Lyon medical,0335015,,OM,"['*Achlorhydria', '*Adrenal Medulla', '*Anemia', '*Anemia, Pernicious', 'Humans', '*Leukemia']",['CLML: 5120:9496:6:39:545'],['NLM'],"['*ACHYLIA GASTRICA', '*ANEMIA, PERNICIOUS', '*LEUKEMIA']",1950/09/24 00:00,1950/09/24 00:01,['1950/09/24 00:00'],"['1950/09/24 00:00 [pubmed]', '1950/09/24 00:01 [medline]', '1950/09/24 00:00 [entrez]']",ppublish,Lyon Med. 1950 Sep 24;183(39):204-7.,,,,,,,,,,,,,,
14779245,NLM,MEDLINE,20040215,20190630,0022-3476 (Print) 0022-3476 (Linking),37,4,1950 Oct,The effect of transfusions and antibiotics upon the duration of life in children with lymphogenous leucemia.,455-62,"['BIERMAN, H R', 'COHEN, P', 'McCLELLAND, J N', 'SHIMKIN, M B']","['BIERMAN HR', 'COHEN P', 'McCLELLAND JN', 'SHIMKIN MB']",['eng'],['Journal Article'],,United States,J Pediatr,The Journal of pediatrics,0375410,"['0 (Anti-Bacterial Agents)', '0 (Dermatologic Agents)']",OM,"['*Anti-Bacterial Agents', '*Blood Transfusion', 'Child', '*Dermatologic Agents', 'Humans', '*Leukemia', '*Leukemia, Lymphoid']",['CLML: 5120:9238:48:123:546'],['NLM'],"['*ANTIBIOTICS', '*BLOOD TRANSFUSION', '*LEUKEMIA, LYMPHATIC']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,J Pediatr. 1950 Oct;37(4):455-62. doi: 10.1016/s0022-3476(50)80254-8.,"['S0022-3476(50)80254-8 [pii]', '10.1016/s0022-3476(50)80254-8 [doi]']",,,,,,,,,,,,,
14778746,NLM,MEDLINE,20040215,20190729,0002-9955 (Print) 0002-9955 (Linking),144,16,1950 Dec 16,Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias.,1349-53,"['PEARSON, O H', 'ELIEL, L P']","['PEARSON OH', 'ELIEL LP']",['eng'],['Journal Article'],,United States,J Am Med Assoc,Journal of the American Medical Association,7507176,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['*Adrenocorticotropic Hormone', '*Cortisone', '*Cushing Syndrome', '*Hodgkin Disease', 'Humans', '*Leukemia', '*Lymphoma', '*Pituitary Diseases', '*Pituitary Gland']",['CLML: 5120:8710:7:239:443:545'],['NLM'],"['*ACTH', '*CUSHING SYNDROME', ""*HODGKIN'S DISEASE"", '*LEUKEMIA']",1950/12/16 00:00,1950/12/16 00:01,['1950/12/16 00:00'],"['1950/12/16 00:00 [pubmed]', '1950/12/16 00:01 [medline]', '1950/12/16 00:00 [entrez]']",ppublish,J Am Med Assoc. 1950 Dec 16;144(16):1349-53. doi: 10.1001/jama.1950.02920160023005.,['10.1001/jama.1950.02920160023005 [doi]'],,,,,,,,,,,,,
14778495,NLM,MEDLINE,20040215,20181201,,3,3,1950,[Non-leukemic periods in acute leukosis in children].,563-91,"['GUASCH, J', 'RAICHS, A']","['GUASCH J', 'RAICHS A']",['und'],['Journal Article'],Los periodos no leucemicos de las leucosis agudas en la infancia.,Portugal,Gaz Med Port,Gazeta medica portuguesa,17040250R,,OM,"['Child', 'Humans', '*Leukemia']",['CLML: 5120:8447:546'],['NLM'],['*LEUKEMIA'],1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Gaz Med Port. 1950;3(3):563-91.,,,,,,,,,,,,,,
14778439,NLM,MEDLINE,20040215,20181201,0016-1535 (Print) 0016-1535 (Linking),5,4,1950 Jul-Aug,[Therapeutic effects of nitrogen mustards (chloramine Simes)].,351-402,"['BISARO, A', 'BUTTO, M']","['BISARO A', 'BUTTO M']",['und'],['Journal Article'],Effetti terapeutici delle azotoipriti.,Italy,Friuli Med,Il Friuli medico,0421045,"['0 (Chloramines)', '0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)', 'KW8K411A1P (chloramine)']",OM,"['*Chloramines', '*Hodgkin Disease', 'Humans', '*Leukemia', '*Mechlorethamine', '*Nitrogen Mustard Compounds']",['CLML: 5120:8383:199:443:546'],['NLM'],"['*CHLORAMINE', ""*HODGKIN'S DISEASE"", '*LEUKEMIA']",1950/07/01 00:00,1950/07/01 00:01,['1950/07/01 00:00'],"['1950/07/01 00:00 [pubmed]', '1950/07/01 00:01 [medline]', '1950/07/01 00:00 [entrez]']",ppublish,Friuli Med. 1950 Jul-Aug;5(4):351-402.,,,,,,,,,,,,,,
14778368,NLM,MEDLINE,20040215,20181201,0367-004X (Print) 0367-004X (Linking),164,4,1950,"[Primary reticuloendotheliosis of the brain, with special reference to a peculiar, hitherto unknown granulomatous process in the brain].",332-80,"['WILKE, G']",['WILKE G'],['und'],['Journal Article'],"Uber primare Reticuloendotheliosen des Gehirns, mit besonderer Berucksichtigung bisher unbekannter eigenartiger granulomatoser Hirnprozesse.",Germany,Dtsch Z Nervenheilkd,Deutsche Zeitschrift fur Nervenheilkunde,0266603,"['Reticuloendotheliosis, X-linked']",OM,"['*Blood Vessels', '*Brain', '*Cerebral Arteries', '*Cerebral Veins', '*Encephalitis', '*Genetic Diseases, X-Linked', 'Humans', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5120:8303:124:188:232:303'],['NLM'],"['*BLOOD VESSELS', '*CEREBRAL ARTERIES AND VEINS', '*ENCEPHALITIS', '*RETICULOENDOTHELIOSIS']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Dtsch Z Nervenheilkd. 1950;164(4):332-80.,,,,,,,,,,,,,,
14777572,NLM,MEDLINE,20040215,20181201,0003-956X (Print) 0003-956X (Linking),6,3,1950 Sep,[Histiomonocytic reticulosis with cutaneous localizations; rapid death from visceral generalization].,189-96,"['CRAPS, M', 'van der MEIREN, L', 'DELCOURT, R']","['CRAPS M', 'van der MEIREN L', 'DELCOURT R']",['und'],['Journal Article'],Reticulose histiomonocytaire a localisations cutanees; mort rapide par generalisation viscerale.,Belgium,Arch Belg Dermatol Syphiligr,Archives belges de dermatologie et de syphiligraphie,0412670,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Neoplasms', '*Skull', '*Skull Neoplasms']",['CLML: 5120:7486:233:547'],['NLM'],"['*CRANIUM, TUMORS', '*LEUKEMIA, MONOCYTIC']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Arch Belg Dermatol Syphiligr. 1950 Sep;6(3):189-96.,,,,,,,,,,,,,,
14777571,NLM,MEDLINE,20040215,20181201,0003-956X (Print) 0003-956X (Linking),6,3,1950 Sep,[Case of leukemids].,181-8,"['REYNAERS, H']",['REYNAERS H'],['und'],['Journal Article'],Un cas de leucemides.,Belgium,Arch Belg Dermatol Syphiligr,Archives belges de dermatologie et de syphiligraphie,0412670,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid', '*Monocytes']",['CLML: 5120:7485:547'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Arch Belg Dermatol Syphiligr. 1950 Sep;6(3):181-8.,,,,,,,,,,,,,,
14777509,NLM,MEDLINE,20040215,20181201,,210,4-5,1950,[Affinity of urethane for different blood cells in the normal state and in leukemia].,473-8,"['BEICKERT, A']",['BEICKERT A'],['und'],['Journal Article'],Uber die Affinitat des Urethans zu verschiedenen Zellformen des normalen und leukamischen Blutes.,Germany,Naunyn Schmiedebergs Arch Exp Pathol Pharmakol,Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie,0054224,['3IN71E75Z5 (Urethane)'],OM,"['*Blood Cells', '*Leukemia', '*Urethane']",['CLML: 5120:7417:417'],['NLM'],['*URETHANE'],1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1950;210(4-5):473-8.,,,,,,,,,,,,,,
14777428,NLM,MEDLINE,20040215,20181201,0392-9418 (Print) 0392-9418 (Linking),55,4,1950 Jul-Aug,[Case of acute leukemia].,510-21,"['TATARELLI, G']",['TATARELLI G'],['und'],['Journal Article'],Considerazioni su di un caso di leucemia acuta.,Italy,Ann Med Nav (Roma),Annali di medicina navale,0373072,,OM,"['*Acute Disease', 'Humans', '*Leukemia']",['CLML: 5120:7336:545'],['NLM'],['*LEUKEMIA'],1950/07/01 00:00,1950/07/01 00:01,['1950/07/01 00:00'],"['1950/07/01 00:00 [pubmed]', '1950/07/01 00:01 [medline]', '1950/07/01 00:00 [entrez]']",ppublish,Ann Med Nav (Roma). 1950 Jul-Aug;55(4):510-21.,,,,,,,,,,,,,,
14777272,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),4,3,1950 Sep,"Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid).",157-67,"['MEYER, L M', 'MILLER, F R', 'ROWEN, M J', 'BOCK, G', 'RUTZKY, J']","['MEYER LM', 'MILLER FR', 'ROWEN MJ', 'BOCK G', 'RUTZKY J']",['eng'],['Journal Article'],,Switzerland,Acta Haematol,Acta haematologica,0141053,"['0 (Folic Acid Antagonists)', '0 (Glutamates)', '935E97BOY8 (Folic Acid)', 'YL5FZ2Y5U1 (Methotrexate)']",OM,"['*Acute Disease', '*Folic Acid', '*Folic Acid Antagonists', '*Glutamates', '*Leukemia', '*Methotrexate']",['CLML: 5120:7137:349:545'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Acta Haematol. 1950 Sep;4(3):157-67. doi: 10.1159/000203749.,['10.1159/000203749 [doi]'],,,,,,,,,,,,,
14777270,NLM,MEDLINE,20040215,20181201,0001-5792 (Print) 0001-5792 (Linking),4,3,1950 Sep,The relationship of polycythemia vera to leukemia; a critical review.,129-47,"['SCHWARTZ, S O', 'EHRLICH, L']","['SCHWARTZ SO', 'EHRLICH L']",['eng'],['Journal Article'],,Switzerland,Acta Haematol,Acta haematologica,0141053,,OM,"['Humans', '*Leukemia', '*Polycythemia', '*Polycythemia Vera']",['CLML: 5120:7135:177:546'],['NLM'],"['*LEUKEMIA', '*POLYCYTHEMIA']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Acta Haematol. 1950 Sep;4(3):129-47. doi: 10.1159/000203745.,['10.1159/000203745 [doi]'],,,,,,,,,,,,,
14777160,NLM,MEDLINE,20040215,20181201,2374-2941 (Print) 2374-2941 (Linking),80,5,1950 Nov,Congenital lymphatic leukemia.,800-2,"['HEEN, R C']",['HEEN RC'],['eng'],['Journal Article'],,United States,AMA Am J Dis Child,A.M.A. American journal of diseases of children,14470010R,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5120:7025:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1950/11/01 00:00,1950/11/01 00:01,['1950/11/01 00:00'],"['1950/11/01 00:00 [pubmed]', '1950/11/01 00:01 [medline]', '1950/11/01 00:00 [entrez]']",ppublish,AMA Am J Dis Child. 1950 Nov;80(5):800-2.,,,,,,,,,,,,,,
14776610,NLM,MEDLINE,20040215,20181201,0370-8179 (Print) 0370-8179 (Linking),48,7-8,1950 Jul-Aug,[New methods in treatment of acute leukemias].,534-8,"['STEFANOVIC, S']",['STEFANOVIC S'],['und'],['Journal Article'],Novosti u le6cenju akutnih leukemija.,Serbia,Srp Arh Celok Lek,Srpski arhiv za celokupno lekarstvo,0027440,,OM,"['*Acute Disease', '*Blood Transfusion', 'Humans', '*Leukemia']",['CLML: 5120:6413:123:546'],['NLM'],"['*BLOOD TRANSFUSION', '*LEUKEMIA']",1950/07/01 00:00,1950/07/01 00:01,['1950/07/01 00:00'],"['1950/07/01 00:00 [pubmed]', '1950/07/01 00:01 [medline]', '1950/07/01 00:00 [entrez]']",ppublish,Srp Arh Celok Lek. 1950 Jul-Aug;48(7-8):534-8.,,,,,,,,,,,,,,
14775480,NLM,MEDLINE,20040215,20181201,0025-8628 (Print) 0025-8628 (Linking),6,5,1950 May,[Case of leukosis in a heifer].,298-9,"['CHWOJNOWSKI, A']",['CHWOJNOWSKI A'],['und'],['Journal Article'],Przypadek leucosis u jalowicy.,Poland,Med Weter,Medycyna weterynaryjna,0413416,,OM,"['Animals', 'Cattle', 'Female', '*Leukemia']",['CLML: 5120:5220:546'],['NLM'],['*LEUKEMIA'],1950/05/01 00:00,1950/05/01 00:01,['1950/05/01 00:00'],"['1950/05/01 00:00 [pubmed]', '1950/05/01 00:01 [medline]', '1950/05/01 00:00 [entrez]']",ppublish,Med Weter. 1950 May;6(5):298-9.,,,,,,,,,,,,,,
14774775,NLM,MEDLINE,20040215,20181201,0146-1575 (Print) 0146-1575 (Linking),8,3,1950 Jul,Osteomyelitis in fatal lymphatic leukemia; report of case.,245-7,"['BROWN, C J Jr']",['BROWN CJ Jr'],['eng'],['Journal Article'],,United States,J Oral Surg (Chic),Journal of oral surgery,0234121,,OM,"['Humans', '*Leukemia, Lymphoid', '*Mandible', '*Osteomyelitis']",['CLML: 5120:4493:10:111:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*MANDIBLE', '*OSTEOMYELITIS']",1950/07/01 00:00,1950/07/01 00:01,['1950/07/01 00:00'],"['1950/07/01 00:00 [pubmed]', '1950/07/01 00:01 [medline]', '1950/07/01 00:00 [entrez]']",ppublish,J Oral Surg (Chic). 1950 Jul;8(3):245-7.,,,,,,,,,,,,,,
14774623,NLM,MEDLINE,20040215,20181201,0022-2143 (Print) 0022-2143 (Linking),36,3,1950 Sep,The blood volume in chronic leukemia as determined by p32 labeled red blood cells.,435-9,"['BERLIN, N I', 'LAWRENCE, J H', 'GARTLAND, J']","['BERLIN NI', 'LAWRENCE JH', 'GARTLAND J']",['eng'],['Journal Article'],,United States,J Lab Clin Med,The Journal of laboratory and clinical medicine,0375375,,OM,"['*Blood Volume', '*Chronic Disease', '*Erythrocytes', '*Leukemia']",['CLML: 5120:4340:315:546'],['NLM'],"['*ERYTHROCYTES', '*LEUKEMIA']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,J Lab Clin Med. 1950 Sep;36(3):435-9.,['0022-2143(50)90181-8 [pii]'],,,,,,,,,,,,,
14774146,NLM,MEDLINE,20040215,20190729,0002-9955 (Print) 0002-9955 (Linking),144,8,1950 Oct 21,Monocytic leukemia treated with pituitary adrenocorticotropic hormone (ACTH).,617-8,"['KINSELL, L W', 'ROGERS, H', 'BAKER, C', 'JENKINS, B J']","['KINSELL LW', 'ROGERS H', 'BAKER C', 'JENKINS BJ']",['eng'],['Journal Article'],,United States,J Am Med Assoc,Journal of the American Medical Association,7507176,['9002-60-2 (Adrenocorticotropic Hormone)'],OM,"['*Adrenocorticotropic Hormone', '*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid', '*Pituitary Diseases', '*Pituitary Gland']",['CLML: 5120:3858:9:547'],['NLM'],"['*ACTH', '*LEUKEMIA, MONOCYTIC']",1950/10/21 00:00,1950/10/21 00:01,['1950/10/21 00:00'],"['1950/10/21 00:00 [pubmed]', '1950/10/21 00:01 [medline]', '1950/10/21 00:00 [entrez]']",ppublish,J Am Med Assoc. 1950 Oct 21;144(8):617-8. doi: 10.1001/jama.1950.62920080003006b.,['10.1001/jama.1950.62920080003006b [doi]'],,,,,,,,,,,,,
14773598,NLM,MEDLINE,20040215,20181201,0014-9772 (Print) 0014-9772 (Linking),8,,1950 Aug,[Lymphatic leukemia].,27-9,"['VEKSLER, M I']",['VEKSLER MI'],['und'],['Journal Article'],Limfaticheskaia leikemiia.,Russia (Federation),Feldsher Akush,Fel'dsher i akusherka,16930040R,,OM,"['*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels']",['CLML: 5120:3299:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1950/08/01 00:00,1950/08/01 00:01,['1950/08/01 00:00'],"['1950/08/01 00:00 [pubmed]', '1950/08/01 00:01 [medline]', '1950/08/01 00:00 [entrez]']",ppublish,Feldsher Akush. 1950 Aug;8:27-9.,,,,,,,,,,,,,,
14773277,NLM,MEDLINE,20040215,20181201,0012-0472 (Print) 0012-0472 (Linking),75,31-32,1950 Aug 11,[Hematologic and anatomopathologic findings in leukemic and reactive myeloblastosis].,1015-6,"['REMY, R', 'HINZ, W']","['REMY R', 'HINZ W']",['und'],['Journal Article'],Hamatologische und pathologisch-anatomische Befunde bei leukamischen und reaktiven Myeloblastosen.,Germany,Dtsch Med Wochenschr,Deutsche medizinische Wochenschrift (1946),0006723,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:2978:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1950/08/11 00:00,1950/08/11 00:01,['1950/08/11 00:00'],"['1950/08/11 00:00 [pubmed]', '1950/08/11 00:01 [medline]', '1950/08/11 00:00 [entrez]']",ppublish,Dtsch Med Wochenschr. 1950 Aug 11;75(31-32):1015-6. doi: 10.1055/s-0028-1117594.,['10.1055/s-0028-1117594 [doi]'],,,,,,,,,,,,,
14772720,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),3,5,1950 Sep,Studies on the role of folic acid in the leukemic process.,871-3,"['SKIPPER, H E', 'CHAPMAN, J B', 'BELL, M']","['SKIPPER HE', 'CHAPMAN JB', 'BELL M']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Folic Acid Antagonists)', '935E97BOY8 (Folic Acid)']",OM,"['*Folic Acid', '*Folic Acid Antagonists', 'Humans', '*Leukemia']",['CLML: 5120:2405:348:349:546'],['NLM'],"['*FOLIC ACID', '*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Cancer. 1950 Sep;3(5):871-3. doi: 10.1002/1097-0142(1950)3:5<871::aid-cncr2820030514>3.0.co;2-h.,['10.1002/1097-0142(1950)3:5<871::aid-cncr2820030514>3.0.co;2-h [doi]'],,,,,,,,,,,,,
14772710,NLM,MEDLINE,20040215,20190620,0008-543X (Print) 0008-543X (Linking),3,5,1950 Sep,Radioactive phosphorus. I. In the treatment of lymphatic leukemia.,779-88,"['DIAMOND, H D', 'CRAVER, L F', 'WOODARD, H Q', 'PARKS, G H']","['DIAMOND HD', 'CRAVER LF', 'WOODARD HQ', 'PARKS GH']",['eng'],['Journal Article'],,United States,Cancer,Cancer,0374236,"['0 (Phosphorus Radioisotopes)', '27YLU75U4W (Phosphorus)']",OM,"['*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels', '*Phosphorus', '*Phosphorus Radioisotopes']",['CLML: 5120:2395:156:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*PHOSPHORUS AND COMPOUNDS, RADIOACTIVE']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Cancer. 1950 Sep;3(5):779-88. doi: 10.1002/1097-0142(1950)3:5<779::aid-cncr2820030504>3.0.co;2-y.,['10.1002/1097-0142(1950)3:5<779::aid-cncr2820030504>3.0.co;2-y [doi]'],,,,,,,,,,,,,
14772702,NLM,MEDLINE,20040215,20181201,0008-5448 (Print) 0008-5448 (Linking),2,4,1950 Jul-Aug,LEUKEMIA.,82,,,['eng'],['Journal Article'],,United States,Cancer Bull,"Cancer bulletin (Houston, Tex.)",0373142,,OM,"['Humans', '*Leukemia']",['CLML: 5120:2387:545'],['NLM'],['*LEUKEMIA'],1950/07/01 00:00,1950/07/01 00:01,['1950/07/01 00:00'],"['1950/07/01 00:00 [pubmed]', '1950/07/01 00:01 [medline]', '1950/07/01 00:00 [entrez]']",ppublish,Cancer Bull. 1950 Jul-Aug;2(4):82.,,,,,,,,,,,,,,
14772666,NLM,MEDLINE,20040215,20181201,0008-1264 (Print) 0008-1264 (Linking),73,4,1950 Oct,Familial occurrence of polycythemia and leukemia.,361-4,"['LAWRENCE, J H', 'GOETSCH, A T']","['LAWRENCE JH', 'GOETSCH AT']",['eng'],['Journal Article'],,United States,Calif Med,California medicine,0410260,,OM,"['Humans', '*Leukemia', '*Polycythemia']",['CLML: 5120:2344:177:546'],['NLM'],"['*LEUKEMIA', '*POLYCYTHEMIA']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Calif Med. 1950 Oct;73(4):361-4.,,PMC1520474,,,,,,,,,,,,
14772579,NLM,MEDLINE,20040215,20181201,0020-3955 (Print) 0020-3955 (Linking),3,2,1950 Apr-Jun,Monocytic leukaemia; concerning seven observations.,69-118,"['JIMENEZ DIAZ, C', 'MORALES PLEGUEZUELO, M', 'PANIAGUA RODRIGUEZ, G']","['JIMENEZ DIAZ C', 'MORALES PLEGUEZUELO M', 'PANIAGUA RODRIGUEZ G']",['eng'],['Journal Article'],,Spain,Bull Inst Med Res Univ Madr,"Bulletin of the Institute for Medical Research, University of Madrid",7505378,,OM,"['Humans', '*Leukemia', '*Leukemia, Monocytic, Acute', '*Leukemia, Myeloid', '*Monocytes']",['CLML: 5120:2253:547'],['NLM'],"['*LEUKEMIA, MONOCYTIC']",1950/04/01 00:00,1950/04/01 00:01,['1950/04/01 00:00'],"['1950/04/01 00:00 [pubmed]', '1950/04/01 00:01 [medline]', '1950/04/01 00:00 [entrez]']",ppublish,Bull Inst Med Res Univ Madr. 1950 Apr-Jun;3(2):69-118.,,,,,,,,,,,,,,
14772266,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),5,10,1950 Oct,"The sedimentation differential agglutination test. I. Method of the test. II. Observations on the destruction and production of red cells, with special reference to myeloblastic leukemia and comparison with the results of the radioactive phosphorus method.",950-63,"['STATS, D']",['STATS D'],['eng'],['Journal Article'],,United States,Blood,Blood,7603509,['27YLU75U4W (Phosphorus)'],OM,"['*Agglutination', '*Agglutination Tests', '*Blood Sedimentation', '*Erythrocytes', 'Humans', '*Leukemia, Myeloid', '*Phosphorus']",['CLML: 5120:1877:18:122'],['NLM'],"['*AGGLUTINATION', '*BLOOD SEDIMENTATION']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Blood. 1950 Oct;5(10):950-63.,['S0006-4971(20)73605-0 [pii]'],,,,,,,,,,,,,
14772263,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),5,10,1950 Oct,Hemolytic anemia in myelogenous leukemia with splenectomy.,920-4,"['JONSSON, U', 'HANSEN-PRUSS, O C', 'RUNDLES, R W']","['JONSSON U', 'HANSEN-PRUSS OC', 'RUNDLES RW']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,,OM,"['*Anemia', '*Anemia, Hemolytic', 'Humans', '*Leukemia', '*Leukemia, Myeloid', '*Splenectomy']",['CLML: 5120:1874:39:547'],['NLM'],"['*ANEMIA, HEMOLYTIC', '*LEUKEMIA, MYELOGENOUS']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Blood. 1950 Oct;5(10):920-4.,['S0006-4971(20)73602-5 [pii]'],,,,,,,,,,,,,
14772262,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),5,10,1950 Oct,Benign pericardial effusion in the course of chronic myelogenous leukemia.,916-9,"['FRIEDMAN, N H', 'SILVERMAN, J J']","['FRIEDMAN NH', 'SILVERMAN JJ']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,,OM,"['Humans', '*Leukemia', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive', '*Leukemia, Myeloid', '*Pericardial Effusion', '*Pericarditis']",['CLML: 5120:1873:145:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS', '*PERICARDITIS']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Blood. 1950 Oct;5(10):916-9.,['S0006-4971(20)73601-3 [pii]'],,,,,,,,,,,,,
14772261,NLM,MEDLINE,20040215,20210216,0006-4971 (Print) 0006-4971 (Linking),5,10,1950 Oct,Folic acid antagonists in the treatment of acute and subacute leukemia.,898-915,"['DAMESHEK, W', 'FREEDMAN, M H', 'STEINBERG, L']","['DAMESHEK W', 'FREEDMAN MH', 'STEINBERG L']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,['0 (Folic Acid Antagonists)'],OM,"['*Acute Disease', '*Folic Acid Antagonists', '*Leukemia']",['CLML: 5120:1872:349:546'],['NLM'],"['*FOLIC ACID ANTAGONISTS', '*LEUKEMIA']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,Blood. 1950 Oct;5(10):898-915.,['S0006-4971(20)73600-1 [pii]'],,,,,,,,,,,,,
14771996,NLM,MEDLINE,20040215,20181201,0004-0193 (Print) 0004-0193 (Linking),5,3,1950 May-Jun,[Nosology of neoplastiform leukemias].,467-79,"['MARTELLI, C F']",['MARTELLI CF'],['und'],['Journal Article'],Nosolgia delle leucemie neoplastiformi.,Italy,Arch Maragliano Patol Clin,"Archivio ""E. Maragliano"" di patologia e clinica",2985161R,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphocytic, Chronic, B-Cell', '*Sarcoma']",['CLML: 5120:1577:267:546'],['NLM'],"['*LEUKEMIA', '*SARCOMA, LEUKOSARCOMA']",1950/05/01 00:00,1950/05/01 00:01,['1950/05/01 00:00'],"['1950/05/01 00:00 [pubmed]', '1950/05/01 00:01 [medline]', '1950/05/01 00:00 [entrez]']",ppublish,Arch Maragliano Patol Clin. 1950 May-Jun;5(3):467-79.,,,,,,,,,,,,,,
14771748,NLM,MEDLINE,20040215,20190619,0003-4819 (Print) 0003-4819 (Linking),33,3,1950 Sep,Extremely high lymphocyte count in lymphatic leukemia: report of a case.,717-8,"['HADEN, R L', 'PORTMANN, U V']","['HADEN RL', 'PORTMANN UV']",['eng'],['Journal Article'],,United States,Ann Intern Med,Annals of internal medicine,0372351,,OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphocyte Count']",['CLML: 5120:1321:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Ann Intern Med. 1950 Sep;33(3):717-8. doi: 10.7326/0003-4819-33-3-717.,['10.7326/0003-4819-33-3-717 [doi]'],,,,,,,,,,,,,
14771060,NLM,MEDLINE,20040215,20190717,0002-9629 (Print) 0002-9629 (Linking),220,3,1950 Sep,Periarteritis nodosa simulating eosinophilic leukemia; a case report.,313-5,"['BLACKBURN, C R']",['BLACKBURN CR'],['eng'],['Journal Article'],,United States,Am J Med Sci,The American journal of the medical sciences,0370506,,OM,"['*Eosinophilia', '*Hypereosinophilic Syndrome', '*Leukemia', '*Polyarteritis Nodosa']",['CLML: 5120:633:145:308:546'],['NLM'],"['*EOSINOPHILIA', '*LEUKEMIA', '*PERIARTERITIS NODOSA']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Am J Med Sci. 1950 Sep;220(3):313-5. doi: 10.1097/00000441-195022030-00014.,['10.1097/00000441-195022030-00014 [doi]'],,,,,,,,,,,,,
14771053,NLM,MEDLINE,20040215,20190717,0002-9629 (Print) 0002-9629 (Linking),220,3,1950 Sep,Leukemia in radiologists in a 20 year period.,282-6,"['MARCH, H C']",['MARCH HC'],['eng'],['Journal Article'],,United States,Am J Med Sci,The American journal of the medical sciences,0370506,,OM,"['Humans', '*Leukemia']",['CLML: 5120:626:546'],['NLM'],['*LEUKEMIA'],1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Am J Med Sci. 1950 Sep;220(3):282-6. doi: 10.1097/00000441-195022030-00007.,['10.1097/00000441-195022030-00007 [doi]'],,,,,,,,,,,,,
14771052,NLM,MEDLINE,20040215,20211203,0002-9629 (Print) 0002-9629 (Linking),220,3,1950 Sep,Subacute erythremic myelosis; report of a case in a Filipino.,276-81,"['de la FUENTE, V']",['de la FUENTE V'],['eng'],['Journal Article'],,United States,Am J Med Sci,The American journal of the medical sciences,0370506,,OM,"['*Asians', '*Hematopoietic System', 'Humans', '*Leukemia, Erythroblastic, Acute', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive']",['CLML: 5120:625:68:428'],['NLM'],"['*HEMOPOIETIC SYSTEM', '*MYELOSIS, ERYTHREMIC']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,Am J Med Sci. 1950 Sep;220(3):276-81.,,,,,,,,,,,,,,
14770961,NLM,MEDLINE,20040215,20181201,0065-2822 (Print) 0065-2822 (Linking),4,,1950,Nitrogen mustards in the treatment of neoplastic disease.,1-75,"['KARNOFSKY, D A']",['KARNOFSKY DA'],['eng'],['Journal Article'],,United States,Adv Intern Med,Advances in internal medicine,0370427,"['0 (Nitrogen Mustard Compounds)', '50D9XSG0VR (Mechlorethamine)']",OM,"['*Hodgkin Disease', '*Leukemia', '*Lung Neoplasms', '*Lymphoma', '*Lymphoma, Non-Hodgkin', '*Mechlorethamine', '*Mycosis Fungoides', '*Neoplasms', '*Nitrogen Mustard Compounds', '*Polycythemia', '*Sarcoma']",['CLML: 5120:529:68:88:164:177:267:444:546:570'],['NLM'],"['*CANCER', ""*HODGKIN'S DISEASE"", '*LEUKEMIA', '*LUNGS, NEOPLASMS', '*MYCOSIS FUNGOIDES', '*NITROGEN MUSTARDS', '*POLYCYTHEMIA', '*SARCOMA, LYMPHOSARCOMA']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Adv Intern Med. 1950;4:1-75.,,,,,,,,,,,,,,
14770845,NLM,MEDLINE,20040215,20190911,0365-5555 (Print) 0365-5555 (Linking),27,4,1950,A case of hyper- and macroglobulinemia accompanied by atypical lymphatic hyperplasia.,506-18,"['DALGAARD, E B']",['DALGAARD EB'],['eng'],['Journal Article'],,Denmark,Acta Pathol Microbiol Scand,Acta pathologica et microbiologica Scandinavica,7508471,,OM,"['*Hyperplasia', '*Leukemia', '*Leukemia, Lymphoid', '*Lymphatic Vessels', '*Precancerous Conditions', '*Waldenstrom Macroglobulinemia']",['CLML: 5120:412:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC']",1950/01/01 00:00,1950/01/01 00:01,['1950/01/01 00:00'],"['1950/01/01 00:00 [pubmed]', '1950/01/01 00:01 [medline]', '1950/01/01 00:00 [entrez]']",ppublish,Acta Pathol Microbiol Scand. 1950;27(4):506-18. doi: 10.1111/j.1699-0463.1950.tb04922.x.,['10.1111/j.1699-0463.1950.tb04922.x [doi]'],,,,,,,,,,,,,
14770501,NLM,MEDLINE,20040215,20181201,0096-5979 (Print) 0096-5979 (Linking),62,4,1950 Oct,LIPOMELANOTIC reticuloendotheliosis of Pautrier.,590-2,,,['eng'],['Journal Article'],,United States,AMA Arch Derm Syphilol,A.M.A. archives of dermatology and syphilology,14470040R,"['Reticuloendotheliosis, X-linked']",OM,"['*Education, Nursing', '*Genetic Diseases, X-Linked', '*Leukemia, Hairy Cell', '*Lymphatic Diseases', '*Severe Combined Immunodeficiency']",['CLML: 5120:51:94:232'],['NLM'],"['*NURSING EDUCATION', '*RETICULOENDOTHELIOSIS']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,AMA Arch Derm Syphilol. 1950 Oct;62(4):590-2.,,,,,,,,,,,,,,
14770490,NLM,MEDLINE,20040215,20191108,0096-5979 (Print) 0096-5979 (Linking),62,4,1950 Oct,Lymphadenosis cutis circumscripta treated with radioactive phosphorus.,556-61,"['BARNES, S S', 'MOFFATT, T W']","['BARNES SS', 'MOFFATT TW']",['eng'],['Journal Article'],,United States,AMA Arch Derm Syphilol,A.M.A. archives of dermatology and syphilology,14470040R,"['0 (Phosphorus Radioisotopes)', '27YLU75U4W (Phosphorus)']",OM,"['Humans', '*Leukemia', '*Leukemia, Lymphoid', '*Phosphorus', '*Phosphorus Radioisotopes', '*Radioactivity', '*Skin']",['CLML: 5120:40:156:301:546'],['NLM'],"['*LEUKEMIA, LYMPHATIC', '*PHOSPHORUS AND COMPOUNDS, RADIOACTIVE', '*SKIN']",1950/10/01 00:00,1950/10/01 00:01,['1950/10/01 00:00'],"['1950/10/01 00:00 [pubmed]', '1950/10/01 00:01 [medline]', '1950/10/01 00:00 [entrez]']",ppublish,AMA Arch Derm Syphilol. 1950 Oct;62(4):556-61. doi: 10.1001/archderm.1950.01530170082010.,['10.1001/archderm.1950.01530170082010 [doi]'],,,,,,,,,,,,,
14770469,NLM,MEDLINE,20040215,20181201,2374-2941 (Print) 2374-2941 (Linking),80,3,1950 Sep,The treatment of leukemia with ACTH and cortisone.,521-2,"['SCHULMAN, I']",['SCHULMAN I'],['eng'],['Journal Article'],,United States,AMA Am J Dis Child,A.M.A. American journal of diseases of children,14470010R,"['9002-60-2 (Adrenocorticotropic Hormone)', 'V27W9254FZ (Cortisone)']",OM,"['*Adrenocorticotropic Hormone', '*Cortisone', '*Leukemia']",['CLML: 5120:19:8:226:545'],['NLM'],"['*ACTH', '*CORTISONE', '*LEUKEMIA']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,AMA Am J Dis Child. 1950 Sep;80(3):521-2.,,,,,,,,,,,,,,
14770458,NLM,MEDLINE,20040215,20191108,2374-2941 (Print) 2374-2941 (Linking),80,3,1950 Sep,Congenital myelogenous leukemia.,417-22,"['TAYLOR, F M', 'GEPPERT, L J']","['TAYLOR FM', 'GEPPERT LJ']",['eng'],['Journal Article'],,United States,AMA Am J Dis Child,A.M.A. American journal of diseases of children,14470010R,,OM,"['Humans', '*Leukemia', '*Leukemia, Myeloid']",['CLML: 5120:8:547'],['NLM'],"['*LEUKEMIA, MYELOGENOUS']",1950/09/01 00:00,1950/09/01 00:01,['1950/09/01 00:00'],"['1950/09/01 00:00 [pubmed]', '1950/09/01 00:01 [medline]', '1950/09/01 00:00 [entrez]']",ppublish,AMA Am J Dis Child. 1950 Sep;80(3):417-22. doi: 10.1001/archpedi.1950.04040020428008.,['10.1001/archpedi.1950.04040020428008 [doi]'],,,,,,,,,,,,,
14770434,NLM,MEDLINE,20040309,20131121,0008-543X (Print) 0008-543X (Linking),100,4,2004 Feb 15,Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.,773-82,"['Kaufman, Yotam', 'Drori, Stavit', 'Cole, Peter D', 'Kamen, Barton A', 'Sirota, Jenny', 'Ifergan, Ilan', 'Arush, Myriam Weyl Ben', 'Elhasid, Ronit', 'Sahar, Dvora', 'Kaspers, Gert Jan L', 'Jansen, Gerrit', 'Matherly, Larry H', 'Rechavi, Gideon', 'Toren, Amos', 'Assaraf, Yehuda G']","['Kaufman Y', 'Drori S', 'Cole PD', 'Kamen BA', 'Sirota J', 'Ifergan I', 'Arush MW', 'Elhasid R', 'Sahar D', 'Kaspers GJ', 'Jansen G', 'Matherly LH', 'Rechavi G', 'Toren A', 'Assaraf YG']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Cancer,Cancer,0374236,"['0 (Antimetabolites, Antineoplastic)', '0 (Carrier Proteins)', '0 (Membrane Transport Proteins)', '0 (Reduced Folate Carrier Protein)', '0 (SLC19A1 protein, human)', 'YL5FZ2Y5U1 (Methotrexate)']",IM,"['Antimetabolites, Antineoplastic/*pharmacology', 'Blotting, Northern', 'Carrier Proteins/*genetics/*pharmacology', 'Child', 'DNA Mutational Analysis', 'Drug Resistance, Neoplasm', 'Humans', '*Membrane Transport Proteins', 'Methotrexate/*pharmacology', 'Osteosarcoma/drug therapy/genetics', 'Polymerase Chain Reaction', 'Polymorphism, Genetic', 'Polymorphism, Single-Stranded Conformational', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/*genetics', 'Reduced Folate Carrier Protein', 'Tumor Cells, Cultured']",,,,2004/02/11 05:00,2004/03/10 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Cancer. 2004 Feb 15;100(4):773-82. doi: 10.1002/cncr.20018.,['10.1002/cncr.20018 [doi]'],,"BACKGROUND: Although the majority of children with acute lymphoblastic leukemia (ALL) are cured with combination chemotherapy containing methotrexate (MTX), drug resistance contributes to treatment failure for a substantial fraction of patients. The primary transporter for folates and MTX is the reduced folate carrier (RFC). Impaired drug transport is a documented mechanism of MTX resistance in patients with ALL; however, to the authors' knowledge it is not known whether inactivating RFC mutations are a contributing factor. METHODS: The authors devised a genomic polymerase chain reaction-single strand conformational polymorphism assay followed by sequencing and screened the entire RFC coding region for sequence alterations in DNA from 246 leukemia specimens from patients with diverse ethnic variation, 24 at the time of recurrence and the rest at the time of diagnosis. This cohort was comprised of 203 B-precursor ALL specimens (82.5%), 32 T-lineage ALL specimens (13%), and 11 acute myeloblastic leukemia specimens (4.5%). RESULTS: Of 246 DNA samples, only 3 diagnosis B-precursor ALL specimens (1.2%) were found to harbor alterations in the RFC gene, including heterozygous single nucleotide changes resulting in D56H and D522N substitutions in the first extracellular loop and the C-terminus of this transporter, respectively. The third sample had a sequence alteration in exon 3 that could not be identified because of the lack of availability of DNA. CONCLUSIONS: Whereas inactivating RFC mutations are a frequent mechanism of MTX resistance in human leukemia cell lines and in patients with osteosarcoma, they are not common and do not appear to play any significant role in intrinsic or acquired resistance to MTX in childhood leukemia. This is the first study of RFC mutations in multiple pediatric leukemia specimens.","['Department of Biology, The Technion, Haifa, Israel.']",,,,,,['Copyright 2003 American Cancer Society.'],,,,
14770421,NLM,MEDLINE,20040309,20061115,0008-543X (Print) 0008-543X (Linking),100,4,2004 Feb 15,"Children, cancer, and nutrition--A dynamic triangle in review.",677-87,"['Sala, Alessandra', 'Pencharz, Paul', 'Barr, Ronald D']","['Sala A', 'Pencharz P', 'Barr RD']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']",,United States,Cancer,Cancer,0374236,,IM,"['Child', '*Child Welfare', 'Child, Preschool', '*Developing Countries', 'Health Status', 'Humans', 'Incidence', 'Infant', 'Infant, Newborn', 'Malnutrition/epidemiology/physiopathology', 'Neoplasms/*complications/*therapy', 'Nutrition Assessment', '*Nutritional Status', '*Nutritional Support', 'Prognosis', 'Survival Analysis']",,,,2004/02/11 05:00,2004/03/10 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Cancer. 2004 Feb 15;100(4):677-87. doi: 10.1002/cncr.11833.,['10.1002/cncr.11833 [doi]'],,"The overall cure rate for cancer in childhood now exceeds 70% and is projected to reach 85% by the year 2010 in industrialized countries. Therefore, major attention is being placed on reducing the side effects of therapy. However, 85% of the world's children live in developing countries, where access to adequate care often is limited and health status frequently is influenced adversely by prevalent infectious diseases and malnutrition. Despite several confounding factors (different definitions of nutritional status, the wide variety of measures used for its assessment, the selection biases by disease and stage, treatment protocols of variable dose intensity and efficacy, small sample sizes of the studies conducted in the last 20 years), it is accepted that the prevalence of malnutrition at diagnosis averages 50% in children with cancer in developing countries; whereas, in industrialized countries, it is related to the type of tumor and the extent of the disease, ranging from < 10% in patients with standard-risk acute lymphoblastic leukemia to 50% in patients with advanced neuroblastoma. The importance of nutritional status in children with cancer is related to its possible influence on the course of the disease and survival. Some authors have described decreased tolerance of chemotherapy associated with altered metabolism of antineoplastic drugs, increased infection rates, and poor clinical outcome in malnourished children. In this article, the authors review methods of nutritional assessment and the pathogenesis of nutritional morbidity in children with cancer as well as correlations of nutritional status with diagnosis, treatment, and outcome.","[""Service of Hematology-Oncology, McMaster Children's Hospital, Hamilton Health Sciences, and McMaster University, Hamilton, Ontario, Canada.""]",,,100,,,['Copyright 2004 American Cancer Society.'],,,,
14770419,NLM,MEDLINE,20040309,20211203,0008-543X (Print) 0008-543X (Linking),100,4,2004 Feb 15,Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.,657-66,"['Panwalkar, Amit', 'Verstovsek, Srdan', 'Giles, Francis J']","['Panwalkar A', 'Verstovsek S', 'Giles FJ']",['eng'],"['Journal Article', 'Review']",,United States,Cancer,Cancer,0374236,"['0 (Immunosuppressive Agents)', '0 (Tumor Suppressor Proteins)', '624KN6GM2T (temsirolimus)', '9HW64Q8G6G (Everolimus)', 'EC 2.7.- (Protein Kinases)', 'EC 2.7.1.1 (MTOR protein, human)', 'EC 2.7.11.1 (TOR Serine-Threonine Kinases)', 'EC 2.7.11.22 (Cyclin-Dependent Kinases)', 'EC 3.1.3.2 (Phosphoric Monoester Hydrolases)', 'EC 3.1.3.67 (PTEN Phosphohydrolase)', 'EC 3.1.3.67 (PTEN protein, human)', 'W36ZG6FT64 (Sirolimus)']",IM,"['Apoptosis', 'Cell Division', 'Cell Survival', 'Cyclin-Dependent Kinases/pharmacology', 'Enzyme Activation/drug effects', 'Everolimus', 'Gene Expression Regulation, Neoplastic/*drug effects', 'Genes, Tumor Suppressor', 'Germ-Line Mutation', 'Hematologic Neoplasms/*drug therapy', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'PTEN Phosphohydrolase', 'Phosphoric Monoester Hydrolases/biosynthesis/pharmacology', 'Protein Kinases/pharmacology/*therapeutic use', 'Signal Transduction', 'Sirolimus/*analogs & derivatives/therapeutic use', 'TOR Serine-Threonine Kinases', 'Tumor Suppressor Proteins/biosynthesis/pharmacology']",,,,2004/02/11 05:00,2004/03/10 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Cancer. 2004 Feb 15;100(4):657-66. doi: 10.1002/cncr.20026.,['10.1002/cncr.20026 [doi]'],,"The mammalian target of rapamycin (mTOR) is a downstream effector of the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signaling pathway, which mediates cell survival and proliferation. mTOR regulates essential signal-transduction pathways, is involved in the coupling of growth stimuli with cell cycle progression, and initiates mRNA translation in response to favorable nutrient environments. mTOR is involved in regulating many aspects of cell growth, including membrane traffic, protein degradation, protein kinase C signaling, ribosome biogenesis, and transcription. Because mTOR activates both the 40S ribosomal protein S6 kinase (p70s6k) and the eukaryotic initiation factor 4E-binding protein 1, its inhibitors cause G1-phase cell cycle arrest. Inhibitors of mTOR also prevent cyclin dependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which may help cause G1-phase arrest. It is known that the phosphatase and tensin homologue tumor suppressor gene (PTEN) plays a major role in embryonic development, cell migration, and apoptosis. Malignancies with PTEN mutations, which are associated with constitutive activation of the PI3K/Akt pathway, are relatively resistant to apoptosis and may be particularly sensitive to mTOR inhibitors. Rapamycin analogs with relatively favorable pharmaceutical properties, including CCI-779, RAD001, and AP23573, are under investigation in patients with hematologic malignancies.","['Section of Developmental Therapeutics, Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.']",,,116,['Cancer. 2004 Sep 15;101(6):1478; author reply 1478. PMID: 15368336'],,['Copyright 2004 American Cancer Society.'],,,,
14770183,NLM,MEDLINE,20040503,20061115,1061-4036 (Print) 1061-4036 (Linking),36,3,2004 Mar,Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation.,257-63,"['Stegmaier, Kimberly', 'Ross, Kenneth N', 'Colavito, Sierra A', ""O'Malley, Shawn"", 'Stockwell, Brent R', 'Golub, Todd R']","['Stegmaier K', 'Ross KN', 'Colavito SA', ""O'Malley S"", 'Stockwell BR', 'Golub TR']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Nat Genet,Nature genetics,9216904,,IM,"['Acute Disease', 'Cell Differentiation', 'Gene Expression', 'Genetic Techniques', 'HL-60 Cells', 'Humans', 'Leukemia, Myeloid/*genetics/pathology', 'Protein Array Analysis']",,,,2004/02/11 05:00,2004/05/05 05:00,['2004/02/11 05:00'],"['2003/12/18 00:00 [received]', '2004/01/21 00:00 [accepted]', '2004/02/11 05:00 [pubmed]', '2004/05/05 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Nat Genet. 2004 Mar;36(3):257-63. doi: 10.1038/ng1305. Epub 2004 Feb 8.,"['10.1038/ng1305 [doi]', 'ng1305 [pii]']",,"Chemical genomics involves generating large collections of small molecules and using them to modulate cellular states. Despite recent progress in the systematic synthesis of structurally diverse compounds, their use in screens of cellular circuitry is still an ad hoc process. Here, we outline a general, efficient approach called gene expression-based high-throughput screening (GE-HTS) in which a gene expression signature is used as a surrogate for cellular states, and we describe its application in a particular setting: the identification of compounds that induce the differentiation of acute myeloid leukemia cells. In screening 1,739 compounds, we identified 8 that reliably induced the differentiation signature and, furthermore, yielded functional evidence of bona fide differentiation. The results indicate that GE-HTS may be a powerful, general approach for chemical screening.","[""Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA.""]",20040208,,,['Nat Genet. 2004 Mar;36(3):214-5. PMID: 14988717'],,,"['Nat Genet. 2004 Apr;36(4):427', 'Nat Genet. 2005 Mar;37(3):328']",,,
14770087,NLM,MEDLINE,20041122,20191108,1524-9557 (Print) 1524-9557 (Linking),27,2,2004 Mar-Apr,Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion.,156-60,"['Kircher, Brigitte', 'Wolf, Maria', 'Stevanovic, Stefan', 'Rammensee, Hans-Georg', 'Grubeck-Loebenstein, Beatrix', 'Gastl, Gunther', 'Nachbaur, David']","['Kircher B', 'Wolf M', 'Stevanovic S', 'Rammensee HG', 'Grubeck-Loebenstein B', 'Gastl G', 'Nachbaur D']",['eng'],['Journal Article'],,United States,J Immunother,"Journal of immunotherapy (Hagerstown, Md. : 1997)",9706083,"['0 (HA-1 antigen)', '0 (HLA-A Antigens)', '0 (HLA-A*02:01 antigen)', '0 (HLA-A2 Antigen)', '0 (Minor Histocompatibility Antigens)', '0 (Oligopeptides)', '0 (Peptides)']",IM,"['Cell Division', '*Cell Lineage', '*Cell Transplantation', 'Dendritic Cells/cytology', 'Dimerization', 'Flow Cytometry', '*Graft vs Leukemia Effect', 'HLA-A Antigens/*chemistry', 'HLA-A2 Antigen', 'Hematopoietic Stem Cells/*cytology', 'Humans', 'Immunotherapy/*methods', 'Leukemia/*therapy', 'Lymphocytes/*cytology', 'Minor Histocompatibility Antigens/*immunology', 'Oligopeptides', 'Peptides/chemistry', 'Phenotype', 'Protein Binding', 'T-Lymphocytes/metabolism']",,,,2004/02/11 05:00,2004/12/16 09:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/12/16 09:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,J Immunother. 2004 Mar-Apr;27(2):156-60. doi: 10.1097/00002371-200403000-00009.,"['00002371-200403000-00009 [pii]', '10.1097/00002371-200403000-00009 [doi]']",,"Immunocompetent alloreactive donor lymphocytes directed against minor histocompatibility antigens are supposed to be responsible for graft-versus-host disease (GvHD) and graft-versus-leukemia (GvL) activity after allogeneic stem cell transplantation. The authors describe the detection of HA-1-specific T cells by peptide-loaded dimers and flow cytometry in the peripheral blood of a patient in complete remission but without GvHD after donor lymphocyte infusion for chemotherapy-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia. The HA-1-specific T cells were sorted and an alloreactive, polyclonal T-cell line with specific lytic activity against HA-1-positive target cells, including leukemic cells, was established. Although P190 bcr/abl peptide-specific CD8positive T cells were detected in the peripheral blood at the same time, these T cells could not be expanded. Furthermore, no P190 bcr/abl peptide-specific T-cell response could be induced in vitro, even when peptide-loaded dendritic cells were used as stimulator cells. The authors conclude that in the absence of GvHD, HA-1-specific rather than P190 bcr/abl-specific T cells are responsible for ongoing GvL activity.","['Laboratory for Tumor and Immunobiology, Bone Marrow Transplant Unit, Division of Hematology & Oncology, Department of Internal Medicine, Innsbruck University Hospital, Innsbruck, Austria. brigitte.kircher@uklibk.ac.at']",,,,,,,,,,
14770008,NLM,MEDLINE,20040420,20071114,1064-3745 (Print) 1064-3745 (Linking),257,,2004,Application of ligation-mediated reverse transcription polymerase chain reaction to the identification of in vivo endonuclease-generated messenger RNA decay intermediates.,213-22,"['Hanson, Mark N', 'Schoenberg, Daniel R']","['Hanson MN', 'Schoenberg DR']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Methods Mol Biol,"Methods in molecular biology (Clifton, N.J.)",9214969,"['0 (RNA, Messenger)', 'EC 3.1.- (Endonucleases)']",IM,"['Animals', 'Base Sequence', 'Electrophoresis, Polyacrylamide Gel', 'Endonucleases/*metabolism', 'Genes, myc/*genetics', 'Humans', 'Leukemia, Erythroblastic, Acute/*metabolism', 'Mice', 'Molecular Sequence Data', 'RNA, Messenger/genetics/*metabolism', 'Reverse Transcriptase Polymerase Chain Reaction/*methods', 'Tumor Cells, Cultured']",,,,2004/02/11 05:00,2004/04/21 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/04/21 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Methods Mol Biol. 2004;257:213-22. doi: 10.1385/1-59259-750-5:213.,"['1-59259-750-5:213 [pii]', '10.1385/1-59259-750-5:213 [doi]']",,"Most approaches to studying messenger RNA (mRNA) decay in vivo lack sufficient sensitivity to identify decay intermediates. The identification of such intermediates using in vitro decay systems can provide suggestive evidence for endonuclease-mediated degradation in vivo; to validate conclusions drawn from in vitro experiments one must demonstrate cleavage of the mRNA in vivo. Primer extension or S1 nuclease protection assays work best on relatively abundant mRNAs and even then require long exposure times. We describe a facile approach using ligation-mediated polymerase chain reaction to identify in vivo mRNA decay intermediates. In this procedure, total cellular RNA is ligated to a primer bearing a 5' phosphate and 3' amino group. Reverse transcription is primed using a complementary primer, and mRNA-specific decay intermediates are identified by polymerase chain reaction amplification using a 5'- [32P]-labeled gene-specific primer. Products generated in this manner are gel purified, reamplified, and the 3' end of each decay intermediate is identified by the sequence junction of the specific mRNA and the initial ligation primer. We show an example of the time-course of appearance of several specific decay intermediates of c-myc mRNA in differentiating murine erythroleukemia cells.","['Department of Biochemistry and Biophysics, University of Rochester, NY, USA.']",,"['GM38277/GM/NIGMS NIH HHS/United States', 'GM55407/GM/NIGMS NIH HHS/United States']",,,,,,,,
14769944,NLM,MEDLINE,20040316,20181113,0027-8424 (Print) 0027-8424 (Linking),101,7,2004 Feb 17,The promyelocytic leukemia zinc finger protein down-regulates apoptosis and expression of the proapoptotic BID protein in lymphocytes.,1898-903,"['Parrado, Antonio', 'Robledo, Macarena', 'Moya-Quiles, M Rosa', 'Marin, Luis A', 'Chomienne, Christine', 'Padua, Rose Ann', 'Alvarez-Lopez, M Rocio']","['Parrado A', 'Robledo M', 'Moya-Quiles MR', 'Marin LA', 'Chomienne C', 'Padua RA', 'Alvarez-Lopez MR']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Proc Natl Acad Sci U S A,Proceedings of the National Academy of Sciences of the United States of America,7505876,"['0 (BH3 Interacting Domain Death Agonist Protein)', '0 (BID protein, human)', '0 (Carrier Proteins)', '0 (Culture Media, Serum-Free)', '0 (DNA-Binding Proteins)', '0 (Kruppel-Like Transcription Factors)', '0 (Promyelocytic Leukemia Zinc Finger Protein)', '0 (Proto-Oncogene Proteins c-bcl-2)', '0 (RNA, Messenger)', '0 (Transcription Factors)', '147855-37-6 (ZBTB16 protein, human)']",IM,"['*Apoptosis/drug effects', 'BH3 Interacting Domain Death Agonist Protein', 'Carrier Proteins/*genetics', 'Culture Media, Serum-Free/pharmacology', 'DNA-Binding Proteins/genetics/*metabolism', '*Down-Regulation', 'Electrophoretic Mobility Shift Assay', 'Humans', 'Jurkat Cells', 'Kinetics', 'Kruppel-Like Transcription Factors', 'Lymphocytes/*cytology/*metabolism', 'Membrane Potentials', 'Promoter Regions, Genetic/genetics', 'Promyelocytic Leukemia Zinc Finger Protein', 'Proto-Oncogene Proteins c-bcl-2/metabolism', 'RNA, Messenger/genetics/metabolism', 'Transcription Factors/genetics/*metabolism']",,,,2004/02/11 05:00,2004/03/18 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/03/18 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1898-903. doi: 10.1073/pnas.0308358100. Epub 2004 Feb 9.,"['10.1073/pnas.0308358100 [doi]', '0308358100 [pii]']",PMC357024,"The promyelocytic leukemia zinc finger (PLZF) gene, involved in rare cases of acute promyelocytic leukemia, encodes a Kruppel-type zinc finger transcription factor. It has been reported that PLZF affects myeloid cell growth, differentiation, and apoptosis. However, the function of PLZF in the lymphoid compartment, where PLZF is also expressed, remains largely unknown. To investigate a potential relationship between PLZF expression in lymphocytes and programmed cell death, an inducible model of stable clones of the lymphoid Jurkat cell line was created by using the tet-off system. Although induction of PLZF expression by itself did not produce changes in the basal levels of apoptosis, PLZF had a significant anti-apoptotic effect in Jurkat cells cultured in conditions of serum starvation, as measured by annexin V staining and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling. In addition, retarded loss of mitochondrial transmembrane potential was observed in the PLZF-expressing clones, suggesting that PLZF protects from cell death through a mitochondrial-dependent mechanism. To identify apoptosis-related targets of PLZF, a screen for differential expression identified BID, a proapoptotic member of the Bcl2 family, as significantly down-regulated by PLZF. Furthermore, a high-affinity PLZF-binding site element was identified upstream of the BID transcriptional start site, as assessed by electrophoretic mobility-shift assays. These results suggest that BID is a target of PLZF repression and a candidate gene to mediate the PLZF-induced resistance to apoptosis.","['Servicio de Inmunologia, Hospital Universitario Virgen de la Arrixaca, 31020 Murcia, Spain. antonio.parrado@carm.es']",20040209,,,,,,,,,
14769860,NLM,MEDLINE,20040920,20181113,0021-9525 (Print) 0021-9525 (Linking),164,4,2004 Feb 16,Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects.,613-23,"['Kenner, Lukas', 'Hoebertz, Astrid', 'Beil, F Timo', 'Keon, Niamh', 'Karreth, Florian', 'Eferl, Robert', 'Scheuch, Harald', 'Szremska, Agnieszka', 'Amling, Michael', 'Schorpp-Kistner, Marina', 'Angel, Peter', 'Wagner, Erwin F']","['Kenner L', 'Hoebertz A', 'Beil FT', 'Keon N', 'Karreth F', 'Eferl R', 'Scheuch H', 'Szremska A', 'Amling M', 'Schorpp-Kistner M', 'Angel P', 'Wagner EF']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,J Cell Biol,The Journal of cell biology,0375356,"['0 (Biomarkers)', '0 (Proto-Oncogene Proteins c-jun)']",IM,"['Animals', 'Biomarkers', 'Bone Diseases, Metabolic/genetics/metabolism', 'Bone and Bones/cytology/metabolism/pathology', 'Cell Differentiation/physiology', 'Cell Division', 'Cell Lineage', 'Cells, Cultured', 'Female', 'Mice', 'Mice, Inbred C57BL', 'Mice, Knockout', 'Osteoblasts/cytology/*physiology', 'Osteoclasts/cytology/*physiology', 'Phenotype', 'Proto-Oncogene Proteins c-jun/genetics/*metabolism', 'Tissue Distribution']",,,,2004/02/11 05:00,2004/09/21 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/09/21 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,J Cell Biol. 2004 Feb 16;164(4):613-23. doi: 10.1083/jcb.200308155. Epub 2004 Feb 9.,"['10.1083/jcb.200308155 [doi]', 'jcb.200308155 [pii]']",PMC2171977,"Because JunB is an essential gene for placentation, it was conditionally deleted in the embryo proper. JunBDelta/Delta mice are born viable, but develop severe low turnover osteopenia caused by apparent cell-autonomous osteoblast and osteoclast defects before a chronic myeloid leukemia-like disease. Although JunB was reported to be a negative regulator of cell proliferation, junBDelta/Delta osteoclast precursors and osteoblasts show reduced proliferation along with a differentiation defect in vivo and in vitro. Mutant osteoblasts express elevated p16(INK4a) levels, but exhibit decreased cyclin D1 and cyclin A expression. Runx2 is transiently increased during osteoblast differentiation in vitro, whereas mature osteoblast markers such as osteocalcin and bone sialoprotein are strongly reduced. To support a cell-autonomous function of JunB in osteoclasts, junB was inactivated specifically in the macrophage-osteoclast lineage. Mutant mice develop an osteopetrosis-like phenotype with increased bone mass and reduced numbers of osteoclasts. Thus, these data reveal a novel function of JunB as a positive regulator controlling primarily osteoblast as well as osteoclast activity.","['Research Institute of Molecular Pathology, Dr. Bohr-Gasse 7, A-1030 Vienna, Austria.']",20040209,,,,,['Copyright The Rockefeller University Press'],"['J Cell Biol. 2011 Dec 12;195(6):1063. Beil, Timo [corrected to Beil, F Timo]']",,,
14769641,NLM,MEDLINE,20040406,20190513,0002-9262 (Print) 0002-9262 (Linking),159,4,2004 Feb 15,Cancer incidence among pesticide applicators exposed to alachlor in the Agricultural Health Study.,373-80,"['Lee, Won Jin', 'Hoppin, Jane A', 'Blair, Aaron', 'Lubin, Jay H', 'Dosemeci, Mustafa', 'Sandler, Dale P', 'Alavanja, Michael C R']","['Lee WJ', 'Hoppin JA', 'Blair A', 'Lubin JH', 'Dosemeci M', 'Sandler DP', 'Alavanja MC']",['eng'],"['Comparative Study', 'Journal Article']",,United States,Am J Epidemiol,American journal of epidemiology,7910653,"['0 (Acetamides)', '0 (Herbicides)', '24S2S61PXL (alachlor)']",IM,"['*Acetamides', 'Adult', ""Agricultural Workers' Diseases/*epidemiology"", 'Causality', 'Cohort Studies', 'Female', '*Herbicides', 'Humans', 'Incidence', 'Iowa/epidemiology', 'Male', 'Middle Aged', 'Neoplasms/*epidemiology', 'North Carolina/epidemiology', 'Occupational Exposure/*statistics & numerical data', 'Prospective Studies', 'Reference Values']",,,,2004/02/11 05:00,2004/04/07 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/04/07 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Am J Epidemiol. 2004 Feb 15;159(4):373-80. doi: 10.1093/aje/kwh040.,['10.1093/aje/kwh040 [doi]'],,"The authors evaluated the incidence of cancer among pesticide applicators with exposure to alachlor in the Agricultural Health Study, a prospective cohort study of licensed pesticide applicators in Iowa and North Carolina. A total of 49,980 pesticide applicators are included in this analysis; 26,510 applicators (53%) reported use of alachlor on the enrollment questionnaire. Detailed pesticide exposure and other information were obtained from a self-administered questionnaire completed at the time of enrollment (1993-1997). Poisson regression analysis was used to evaluate the exposure-response relations between alachlor and cancer incidence controlled for the effects of potential confounding factors. A total of 1,466 incident malignant neoplasms were diagnosed during the study period, 1993-2000. Among alachlor-exposed applicators, the authors found a significant increasing trend for incidence of all lymphohematopoietic cancers associated with lifetime exposure-days (p for trend = 0.02) and intensity-weighted exposure-days (p for trend = 0.03) to alachlor. The risks of leukemia (rate ratio = 2.83, 95% confidence interval: 0.74, 10.9) and multiple myeloma (rate ratio = 5.66, 95% confidence interval: 0.70, 45.7) were increased among applicators in the highest alachlor exposure category. Our findings suggest a possible association between alachlor application and incidence of lymphohematopoietic cancers among applicators in the Agricultural Health Study.","['Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA.']",,,,['Am J Epidemiol. 2005 Jan 1;161(1):101-2; author reply 102-3. PMID: 15615921'],,,,,,
14769541,NLM,MEDLINE,20040610,20131121,0163-5581 (Print) 0163-5581 (Linking),47,1,2003,Mechanism of activation of caspase cascade during beta-carotene-induced apoptosis in human tumor cells.,76-87,"['Palozza, Paola', 'Serini, Simona', 'Torsello, Angela', 'Di Nicuolo, Fiorella', 'Maggiano, Nicola', 'Ranelletti, Franco O', 'Wolf, Federica I', 'Calviello, Gabriella']","['Palozza P', 'Serini S', 'Torsello A', 'Di Nicuolo F', 'Maggiano N', 'Ranelletti FO', 'Wolf FI', 'Calviello G']",['eng'],['Journal Article'],,United States,Nutr Cancer,Nutrition and cancer,7905040,"['0 (BH3 Interacting Domain Death Agonist Protein)', '0 (BID protein, human)', '0 (Carrier Proteins)', '0 (Enzyme Inhibitors)', '0 (NF-kappa B)', '0 (Proto-Oncogene Proteins c-bcl-2)', '01YAE03M7J (beta Carotene)', '9007-43-6 (Cytochromes c)', 'EC 3.4.22.- (CASP3 protein, human)', 'EC 3.4.22.- (CASP8 protein, human)', 'EC 3.4.22.- (CASP9 protein, human)', 'EC 3.4.22.- (Caspase 3)', 'EC 3.4.22.- (Caspase 8)', 'EC 3.4.22.- (Caspase 9)', 'EC 3.4.22.- (Caspases)']",IM,"['Adenocarcinoma/pathology', 'Apoptosis/*drug effects', 'BH3 Interacting Domain Death Agonist Protein', 'Carrier Proteins/analysis', 'Caspase 3', 'Caspase 8', 'Caspase 9', 'Caspases/*metabolism', 'Colonic Neoplasms/pathology', 'Cytochromes c/metabolism', 'Enzyme Activation/drug effects', 'Enzyme Inhibitors/pharmacology', 'HL-60 Cells/pathology', 'Humans', 'Melanoma/pathology', 'Membrane Potentials', 'Mitochondria/metabolism/ultrastructure', 'NF-kappa B/physiology', 'Neoplasms/*pathology', 'Proto-Oncogene Proteins c-bcl-2/analysis', 'Tumor Cells, Cultured', 'beta Carotene/*pharmacology']",,,,2004/02/11 05:00,2004/06/21 10:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/06/21 10:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Nutr Cancer. 2003;47(1):76-87. doi: 10.1207/s15327914nc4701_10.,['10.1207/s15327914nc4701_10 [doi]'],,"In this study, we examined possible mechanisms of caspase activation during carotenoid-induced apoptosis in tumor cells. We found that beta-Carotene induces apoptosis by the activation of caspase-3 in human leukemia (HL-60), colon adenocarcinoma (HT-29) as well as melanoma (SK-MEL-2) cell lines. This activation is dose dependent and follows that of caspase-8 and caspase-9. Although caspase-8 cleavage is an early event, reaching its maximum activation at 3 h, caspase-9 reaches its maximum activation only at 6 h. The addition of IETD-CHO, a caspase-8-specific inhibitor, completely prevents beta-Carotene-induced apoptosis, whereas only a partial prevention was observed in the presence of LEHD-CHO, a caspase-9-specific inhibitor. beta-Carotene activates caspase-9 via cytochrome c release from mitochondria and loss of mitochondrial membrane potential (Dym). Concomitantly, a dose-dependent decrease in the antiapoptotic protein Bcl-2 and a dose-dependent increase in the cleaved form of BID (t-BID) are observed. Moreover, NF-kB activation is involved in beta-Carotene-induced caspase cascade. These results support a pharmacological role for beta-Carotene as a candidate antitumor agent and show a possible sequence of molecular events by which this molecule may induce apoptosis in tumor cells.","['Institute of General Pathology, Catholic University, Largo F. Vito 1, 00168 Rome, Italy. p.palozza@rm.unicatt.it']",,,,,,,,,,
14769215,NLM,MEDLINE,20040730,20191210,1671-4083 (Print) 1671-4083 (Linking),25,2,2004 Feb,Effects of chebulinic acid on differentiation of human leukemia K562 cells.,231-8,"['Yi, Zong-chun', 'Wang, Zhao', 'Li, Hai-xia', 'Liu, Ming-jie', 'Wu, Rong-cong', 'Wang, Xiao-hui']","['Yi ZC', 'Wang Z', 'Li HX', 'Liu MJ', 'Wu RC', 'Wang XH']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Acta Pharmacol Sin,Acta pharmacologica Sinica,100956087,"['0 (DNA-Binding Proteins)', '0 (Erythroid-Specific DNA-Binding Factors)', '0 (GATA1 Transcription Factor)', '0 (GATA1 protein, human)', '0 (GATA2 Transcription Factor)', '0 (GATA2 protein, human)', '0 (Glycophorins)', '0 (Hydrolyzable Tannins)', '0 (ITGB3 protein, human)', '0 (Integrin beta3)', '0 (NF-E2 Transcription Factor)', '0 (NF-E2 Transcription Factor, p45 Subunit)', '0 (NFE2 protein, human)', '0 (RNA, Messenger)', '0 (Tannins)', '0 (Transcription Factors)', '18942-26-2 (chebulinic acid)', '9004-22-2 (Globins)', 'EC 3.1.1.7 (Acetylcholinesterase)']",IM,"['Acetylcholinesterase/biosynthesis/genetics', 'Cell Differentiation/drug effects', 'DNA-Binding Proteins/biosynthesis/genetics', 'Erythrocytes/metabolism/pathology', 'Erythroid-Specific DNA-Binding Factors', 'GATA1 Transcription Factor', 'GATA2 Transcription Factor', 'Gene Expression Regulation', 'Globins/biosynthesis/genetics', 'Glycophorins/*biosynthesis/genetics', 'Humans', '*Hydrolyzable Tannins', 'Integrin beta3/*biosynthesis/genetics', 'K562 Cells', 'Megakaryocytes/metabolism/pathology', 'NF-E2 Transcription Factor', 'NF-E2 Transcription Factor, p45 Subunit', 'RNA, Messenger/genetics', 'Tannins/*pharmacology', 'Transcription Factors/biosynthesis/genetics']",,,,2004/02/11 05:00,2004/07/31 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/07/31 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Acta Pharmacol Sin. 2004 Feb;25(2):231-8.,,,"AIM: To study effects of chebulinic acid on erythroid and megakaryocytic differentiation in K562 cells. METHODS: The benzidine staining method was used to evaluate hemoglobin synthesis; the expression of erythroid specific glycophorin A (GPA) protein and megakaryocytic surface marker CD61 was determined by flow cytometry using fluorescence labeled antibodies; erythroid and megakaryocytic mRNA expression was analyzed by RT-PCR. RESULTS: During erythroid differentiation induced by butyric acid (BA) or hemin, chebulinic acid not only inhibited the hemoglobin synthesis of BA- and hemin-treated K562 cells in concentration-dependent manner with IC50 of 4 micromol/L and 40 micromol/L respectively, but also inhibited another erythroid differentiation marker acetylcholinesterase at the concentration of 50 micromol/L in the cells either treated or untreated with each erythroid differentiation inducers, whereas chebulinic acid 50 micromol/L did not change GPA protein expression in these cells significantly. When K562 cells were treated with TPA 50 microg/L for 72 h to induce megakaryocytic differentiation, the presence of chebulinic acid 50 micromol/L slightly provoked the decrease of GPA protein expression induced by TPA. Chebulinic acid did not change the TPA-induced CD61 expression at the same concentration. Chebulinic acid also reduced the mRNA levels of erythroid relative genes including gamma-globin, PBGD, NF-E2, and GATA-1 genes in K562 cells either treated or untreated with BA, whereas chebulinic acid upregulated the mRNA levels of GATA-2 transcription factor in these cells. CONCLUSION: Chebulinic acid had inhibitory effect on erythroid differentiation likely through changing transcriptional activation of differentiation relative genes, which suggests that chebulinic acid or other tannins might influence the efficiency of some anti-tumor drugs-induced differentiation or the hematopoiesis processes.","['Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing 100084, China.']",,,,,,,,,,
14769211,NLM,MEDLINE,20040730,20131121,1671-4083 (Print) 1671-4083 (Linking),25,2,2004 Feb,Effects of tacrolimus on infection of Friend murine leukemia virus to Fv-4 gene heterozygous mice.,208-12,"['Zhang, Feng-min', 'Yang, Bao-feng', 'Gu, Hong-xi', 'Chen, Xiao-bei', 'Zhong, Zhao-hua', 'Cheng, Zhi']","['Zhang FM', 'Yang BF', 'Gu HX', 'Chen XB', 'Zhong ZH', 'Cheng Z']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Acta Pharmacol Sin,Acta pharmacologica Sinica,100956087,"['0 (Fv4 protein, mouse)', '0 (Immunosuppressive Agents)', '0 (Membrane Proteins)', 'WM0HAQ4WNM (Tacrolimus)']",IM,"['Animals', 'Friend murine leukemia virus/*growth & development', 'Genetic Predisposition to Disease', 'Immunosuppressive Agents/*pharmacology', 'Leukemia, Experimental/virology', 'Membrane Proteins/*biosynthesis/genetics', 'Mice', 'Mice, Inbred BALB C', 'Mice, Transgenic', 'Retroviridae Infections/virology', 'Spleen/*metabolism/pathology', 'Tacrolimus/*pharmacology', 'Tumor Virus Infections/virology', 'Virus Replication/drug effects']",,,,2004/02/11 05:00,2004/07/31 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/07/31 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Acta Pharmacol Sin. 2004 Feb;25(2):208-12.,,,"AIM: To investigate the effect of tacrolimus (FK506) on the infection of Friend murine leukemia virus (Friend MuLV) in vivo. METHODS: Three kinds of mice were used including Friend MuLV-sensitive BALB/c mice, Friend MuLV-resistant Fv-4 gene-homozygous mice (Fv-4 mice), and Friend MuLV-resistant Fv-4 gene-heterozygous mice (F1 mice). Tacrolimus was administrated i.p. to those mice in every 2 d. Those treated mice were inoculated i.p. with Friend MuLV once on d 3. The symptoms and viral proliferations in those mice were observed to recognize the Friend MuLV infection. The expression and genotype of Fv-4 gene that resistant against the infection of Friend MuLV were analyzed to confirm the genomic background and related mechanism of the resistance. RESULTS: BALB/c mice and F1 mice, but not Fv-4 mice, appeared obvious early death, spleenomegaly, and viral proliferation after both treatments of viral inoculation and tacrolimus administration, whereas the expression and genotype of Fv-4 gene was not changed in F1 mice and Fv-4 mice with treatment of tacrolimus. Compared to the virus-inoculated control, the Friend MuLV-sensitivity of tacrolimus-treated BALB/c mice and the Friend MuLV-resistance of tacrolimus-treated Fv-4 mice were the same as the controls, but only F1 mice became the symptoms and viral proliferation after both treatments. It suggested the Friend MuLV-resistant F1 mice could be converted to be Friend MuLV-sensitive by treatment of tacrolimus, and this conversion was not depended on the expression and genotype of Fv-4 gene. CONCLUSION: Tacrolimus could not inhibit the infection of Friend MuLV in all mice, furthermore, it could enhance the infection of Friend MuLV in F1 mice. The enhancement may be related to the immunosuppressive effect of tacrolimus.","['Department of Microbiology, Harbin Medical University, Harbin 150086, China. zhangfm@ems.hrbmu.edu.cn']",,,,,,,,,,
14769131,NLM,MEDLINE,20041026,20181130,1470-8728 (Electronic) 0264-6021 (Linking),380,Pt 1,2004 May 15,Isolation and characterization of lipid rafts with different properties from RBL-2H3 (rat basophilic leukaemia) cells.,219-30,"['Radeva, Galina', 'Sharom, Frances J']","['Radeva G', 'Sharom FJ']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,England,Biochem J,The Biochemical journal,2984726R,"['0 (Detergents)', '0 (Plant Oils)', '0 (Proto-Oncogene Proteins)', '0 (Thy-1 Antigens)', '3WJQ0SDW1A (Polyethylene Glycols)', '9002-93-1 (Octoxynol)', '9004-98-2 (polyethylene glycol oleyl ether)', '97C5T2UQ7J (Cholesterol)', 'EC 2.7.10.2 (Proto-Oncogene Proteins c-yes)', 'EC 2.7.10.2 (lyn protein-tyrosine kinase)', 'EC 2.7.10.2 (src-Family Kinases)']",IM,"['Animals', 'Cell Fractionation', 'Cell Line, Tumor/chemistry/drug effects/ultrastructure', 'Centrifugation, Density Gradient', 'Chemical Phenomena', 'Chemistry, Physical', 'Cholesterol/analysis', 'Chromatography, Gel', 'Detergents/pharmacology', 'Leukemia, Basophilic, Acute/metabolism/*pathology', 'Membrane Microdomains/*chemistry', 'Octoxynol/pharmacology', 'Phosphorylation', 'Plant Oils/pharmacology', 'Polyethylene Glycols/pharmacology', 'Protein Processing, Post-Translational', 'Proto-Oncogene Proteins/analysis', 'Proto-Oncogene Proteins c-yes', 'Rats', 'Thy-1 Antigens/analysis', 'src-Family Kinases/analysis/chemistry']",,,,2004/02/11 05:00,2004/10/27 09:00,['2004/02/11 05:00'],"['2004/02/09 00:00 [accepted]', '2004/02/03 00:00 [revised]', '2003/09/03 00:00 [received]', '2004/02/11 05:00 [pubmed]', '2004/10/27 09:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Biochem J. 2004 May 15;380(Pt 1):219-30. doi: 10.1042/BJ20031348.,"['10.1042/BJ20031348 [doi]', 'BJ20031348 [pii]']",PMC1224147,"Lipid rafts are plasma-membrane microdomains that are enriched in certain lipids (sphingolipids, glycosphingolipids and cholesterol), as well as in lipid-modified proteins. Rafts appear to exist in the liquid-ordered phase, which contributes to their partitioning from the surrounding liquid-disordered glycerophospholipid environment. DRM (detergent-resistant membrane) fractions isolated from cells are believed to represent coalesced lipid rafts. We have employed extraction using two different non-ionic detergents, Brij-96 and Triton X-100, to isolate detergent-resistant lipid rafts from rat basophilic leukaemia cell line RBL-2H3, and compared their properties with each other and with plasma-membrane vesicles. DRM fractions were isolated as sealed unilamellar vesicles of similar size (135-170 nm diameter), using either sucrose-density-gradient sedimentation or gel-filtration chromatography. Lipid rafts isolated using Brij-96 and Triton X-100 differed in density, protein content and the distribution between high- and low-density fractions of the known raft constituents, Thy-1, and the non-receptor protein tyrosine kinases, Yes and Lyn. Lyn was found in the raft microdomains in predominantly phosphorylated form. The level of enrichment of the protein constituents of the isolated lipid rafts seemed to depend on the ratio of cell lipid/protein to detergent. As indicated by reactivity with anti-Thy-1 antibodies, lipid rafts prepared using Brij-96 appeared to consist of vesicles with primarily right-side-out orientation. Both Brij-96 and Triton X-100 appear to isolate detergent-insoluble raft microdomains from the rat basophilic leukaemia cell line RBL-2H3, but the observed differences suggest that either the detergents themselves play a role in determining the physicochemical characteristics of the resulting DRM fractions, or different subsets of rafts are isolated by the two detergents.","['Department of Chemistry and Biochemistry, University of Guelph, Guelph, ON, Canada N1G 2W1.']",,,,,,,,,,
14768856,NLM,MEDLINE,20040330,20190117,1726-4901 (Print) 1726-4901 (Linking),66,11,2003 Nov,Delayed rejection after initial engraftment in non-myeloablative bone marrow transplantation.,682-8,"['Yang, Muh-Hwa', 'Chiou, Tzeon-Jye', 'Chao, Ta-Chung', 'Hsiao, Liang-Tsai', 'Chen, Po-Min']","['Yang MH', 'Chiou TJ', 'Chao TC', 'Hsiao LT', 'Chen PM']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,Netherlands,J Chin Med Assoc,Journal of the Chinese Medical Association : JCMA,101174817,,IM,"['Adult', 'Bone Marrow Transplantation/*methods', 'Female', '*Graft Rejection', 'Humans', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/surgery', 'Middle Aged', 'Myelodysplastic Syndromes/surgery', 'Time Factors', 'Transplantation Conditioning/methods']",,,,2004/02/11 05:00,2004/03/31 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/03/31 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,J Chin Med Assoc. 2003 Nov;66(11):682-8.,,,"Non-myeloablative bone marrow transplantation (NM-BMT) is a newly developed therapeutic strategy for malignant and non-malignant hematological diseases, as well as immunotherapy-responsive solid tumors. The graft-versus-leukemia (GVL) or graft-versus-tumor (GVT) effect is the major therapeutic effect of this procedure, which also decreases transplant-related mortality (TRM) while remaining relatively safe for older patients. Graft rejection may be a main concern for NM-BMT in high-risk patients such as unrelated-donor BMT and elder recipients, however, very few literatures have mentioned this issue. Here we report 2 cases of NM-BMT where delayed rejection developed after initial engraftment. The first case was a victim of chronic myelogenous leukemia (CML) in chronic phase receiving HLA-matched unrelated-donor (MUD) BMT using the non-myeloablative regimen (fludarabine/busulphan/ATG). Chimerism study after BMT revealed successful initial engraftment, however, pancytopenia developed since day +38. Bone marrow examination on day +47 revealed only 15% of donor-type cells, with subsequent salvage haploidentical BMT failing to engraft. The patient expired on day +71. The second case was a victim of myelodysplastic syndrome, received HLA-matched sibling-donor allogeneic BMT using the same regimen as for Case 1, with successful initial engraftment proved by chimerism study. Pancytopenia was noted since day +124, and chimerism study on day +127 revealed only 25% of donor-type cells. The patient expired on day +151. We recommend that the suitability of NM-BMT for high-risk patients such as unrelated-donor BMT and elder recipients needs further studies to confirm.","['Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.']",,,,,,,,,,
14768711,NLM,MEDLINE,20040224,20190708,0020-7136 (Print) 0020-7136 (Linking),25,6,1980 Jun 15,Cytogenetic studies on abelson-virus-induced mouse leukemias.,805-11,"['Klein, G', 'Ohno, S', 'Rosenberg, N', 'Wiener, F', 'Spira, J', 'Baltimore, D']","['Klein G', 'Ohno S', 'Rosenberg N', 'Wiener F', 'Spira J', 'Baltimore D']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Int J Cancer,International journal of cancer,0042124,,IM,"['Abelson murine leukemia virus/genetics/*pathogenicity', 'Animals', 'Chromosome Banding', '*Chromosome Mapping', 'Crosses, Genetic', 'Female', 'Genotype', 'Karyotyping', 'Leukemia, Experimental/*genetics/pathology', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Mice, Inbred Strains', 'Retroviridae Infections/genetics/pathology', 'Tumor Virus Infections/genetics/pathology']",,,,1980/06/15 00:00,2005/03/25 09:00,['1980/06/15 00:00'],"['1980/06/15 00:00 [pubmed]', '2005/03/25 09:00 [medline]', '1980/06/15 00:00 [entrez]']",ppublish,Int J Cancer. 1980 Jun 15;25(6):805-11. doi: 10.1002/ijc.2910250617.,['10.1002/ijc.2910250617 [doi]'],,"The karyotype of Abelson-virus-induced murine leukemias was studied by G-banding. In contrast to the regular trisomy of chromosome 15 in most murine T-cell leukemias, Abelson leukemias were purely diploid, and remained diploid for up to seven consecutive passages in vivo. The hypothesis is advanced that integration into the recipient cell of the DNA copy of the large cellular insert, carried by the Abelson virus, may perform a function similar to the effects of gene duplication by trisomy in the more slowly developing murine leukemias.","['Department of Tumor Biology, Karolinska Institutet, S-104 01 Stockholm 60, Sweden.']",,"['2 R01 CA 14054-07A1/CA/NCI NIH HHS/United States', 'CA-14051/CA/NCI NIH HHS/United States', 'CA-24220/CA/NCI NIH HHS/United States', 'CA-24530/CA/NCI NIH HHS/United States']",,,,,,,,
14768708,NLM,MEDLINE,20040224,20190708,0020-7136 (Print) 0020-7136 (Linking),25,6,1980 Jun 15,Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. X. Immunoselection of tumor variants differing in tumor antigen expression and metastatic capacity.,781-8,"['Schirrmacher, V', 'Bosslet, K']","['Schirrmacher V', 'Bosslet K']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Int J Cancer,International journal of cancer,0042124,"['0 (Antigens, Neoplasm)', '0 (Immunoglobulin Fc Fragments)']",IM,"['Animals', 'Antigens, Neoplasm/*analysis', 'Cell Division', 'Genetic Variation', 'Immunity, Cellular/*immunology', 'Immunoglobulin Fc Fragments/analysis', 'Leukemia L5178/genetics/*immunology/*pathology', 'Mice', 'Mice, Inbred DBA', 'Neoplasm Metastasis/pathology', 'T-Lymphocytes, Cytotoxic/*immunology']",,,,1980/06/15 00:00,2005/03/25 09:00,['1980/06/15 00:00'],"['1980/06/15 00:00 [pubmed]', '2005/03/25 09:00 [medline]', '1980/06/15 00:00 [entrez]']",ppublish,Int J Cancer. 1980 Jun 15;25(6):781-8. doi: 10.1002/ijc.2910250614.,['10.1002/ijc.2910250614 [doi]'],,"We previously described morphological, functional and antigenic differences between a chemically-induced DBA/2 lymphoma, Eb, and a spontaneous variant, ESb, which arose in 1968 and had highly increased metastatic capacity. Now we present evidence that the two cell lines, in spite of the differences observed, are still related. (1) Shifts from Eb to ESb can be reproduced after 11 years. They occur during routine i.p. transplantation, especially when high cell numbers are passaged. (2) ESb variant cells can be recovered from Eb tumor populations after immunoselection in vivo with specific anti-Eb cytolytic T lymphocytes (CTL). (3) Parental-type Eb cells can be isolated from ESb tumor populations after immunoselection in vitro with specific anti-ESb CTL Ten ESb cells mixed with 10(6) Eb cells and inoculated s.c. caused a shift in the mortality curve suggesting that a possible contamination of the Eb population with pre-existing ESb variant cells was less than 1 in 100,000.","['Institut fur Immunologie und Genetik am Deutschen Krebsforschungszentrum, Heidelberg, W. Germany.']",,,,,,,,,,
14768706,NLM,MEDLINE,20040224,20190708,0020-7136 (Print) 0020-7136 (Linking),25,6,1980 Jun 15,Separation of different molecular forms of macrophage- and granulocyte-inducing proteins for normal and leukemic myeloid cells.,763-71,"['Lotem, J', 'Lipton, J H', 'Sachs, L']","['Lotem J', 'Lipton JH', 'Sachs L']",['eng'],['Journal Article'],,United States,Int J Cancer,International journal of cancer,0042124,"['143011-72-7 (Granulocyte Colony-Stimulating Factor)', '83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)']",IM,"['Animals', 'Bone Marrow Cells/cytology/pathology', 'Granulocyte Colony-Stimulating Factor/blood/*isolation & purification', 'Granulocyte-Macrophage Colony-Stimulating Factor/blood/*isolation & purification', 'Humans', 'Leukemia, Experimental/*blood/pathology', 'Leukemia, Myeloid/*blood/pathology', 'Mice', 'Reference Values']",,,,1980/06/15 00:00,2005/03/25 09:00,['1980/06/15 00:00'],"['1980/06/15 00:00 [pubmed]', '2005/03/25 09:00 [medline]', '1980/06/15 00:00 [entrez]']",ppublish,Int J Cancer. 1980 Jun 15;25(6):763-71. doi: 10.1002/ijc.2910250612.,['10.1002/ijc.2910250612 [doi]'],,"It is shown that serum of mice treated with endotoxin (ES) contains three separable and functionally distinct forms of macrophage- and granulocyte-inducing (MGI) proteins. One form (MGI-1M) induced the formation of macrophage colonies from normal bone-marrow cells and showed on gel filtration an apparent molecular weight of 300,000; a second form (MGI-1G) induced the formation of granulocyte colonies from normal bone-marrow cells and had an apparent molecular weight of 45-100,000; and the third form (MGI-2) induced the normal differentiation of MGI+D+ myeloid leukemic cells to macrophages and granulocytes and had an apparent molecular weight of 28,000. Studies on the time course of the decrease of these three activities in ES have indicated that MGI-2 was more readily inactivated in vivo than MGI-1M and MGI-1G. The MGI-1M in ES isolated after gel filtration was completely neutralized by an antiserum to MGI-1 from mouse L-cells, whereas the isolated MGI-1G and MGI-2 were not affected by this antiserum. Gel filtration under dissociating conditions (6 M guanidinium chloride) resulted in a reduction of the apparent molecular weights of MGI-1M from 300,000 to 42,000, and of MGI-1G from 45-100,000 to 28,000, while it produced no change in the 28,000 apparent molecular weight of MGI-2. Similar studies with conditioned medium produced in vitro from mouse lung and peritoneal macrophages showed that in these conditioned media, MGI-1 (both G and M) in the native form had an apparent molecular weight of 41,000 and MGI-2 of 24,000, and that both MGI-1 and 2 had an apparent molecular weight of 24,000 under dissociating conditions. The results indicate that MGI-1 exists in serum in vivo and in these conditioned media as aggregated proteins, whereas MGI-2 does not, and that macrophages and lung tissue are not the only source of the MGI proteins found in ES. It is suggested that all three forms of MGI activity are derived from one precursor protein; that only the MGI-2 form assayed on leukemic cells should be used for treatment based on the induction of normal cell differentiation in myeloid leukemia; and that MGI-2 may serve as a survey mechanism for inducing differentiation in myeloid leukemic cells that have lost their responsiveness to the MGI-1 molecules that control the viability, proliferation and differentiation of normal myeloblasts.","['Department of Genetics, Weizmann Institute of Science, Rehovoth, Israel.']",,,,,,,,,,
14768705,NLM,MEDLINE,20040224,20190708,0020-7136 (Print) 0020-7136 (Linking),25,6,1980 Jun 15,Restricted expression of endogenous N-tropic XC-positive leukemia virus in hybrids between G and AKR mice: an effect of the Fv-4r gene.,757-62,"['Odaka, T', 'Ikeda, H', 'Akatsuka, T']","['Odaka T', 'Ikeda H', 'Akatsuka T']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Int J Cancer,International journal of cancer,0042124,"['0 (Fv4 protein, mouse)', '0 (Membrane Proteins)']",IM,"['Animals', 'Crosses, Genetic', 'Embryo, Mammalian', 'Female', 'Fibroblasts/cytology/physiology', 'Friend murine leukemia virus/*genetics/isolation & purification', 'Leukemia, Experimental/genetics/*virology', 'Male', 'Membrane Proteins/*genetics', 'Mice', 'Mice, Inbred AKR', 'Mice, Inbred BALB C', 'Mice, Inbred Strains', 'Pedigree']",,,,1980/06/15 00:00,2005/03/25 09:00,['1980/06/15 00:00'],"['1980/06/15 00:00 [pubmed]', '2005/03/25 09:00 [medline]', '1980/06/15 00:00 [entrez]']",ppublish,Int J Cancer. 1980 Jun 15;25(6):757-62. doi: 10.1002/ijc.2910250611.,['10.1002/ijc.2910250611 [doi]'],,"G mice carrying the Fv-4r gene are resistant to exogenous infections of various strains of ecotropic MuLVs (Suzuki, 1975). The expression of endogenous N-tropic XC-positive virus was studied in the progency of a cross between G and AKR mice. In the F1 mice, the virus expression was almost completely supressed, and no leukemia developed during 1 year of observation. Results of successive backcrossings with AKR mice indicated that a single dominant gene, the Fv-4r suffices for supression. It can be concluded that the extensive growth of N-tropic XC-positive virus is a prerequisite for leukemia development in AKR mice.","['Institute of Medical Science, Shirokanedai 4-6-1, Minato-ku, Tokyo 108, Japan.']",,,,,,,,,,
14768701,NLM,MEDLINE,20040224,20190708,0020-7136 (Print) 0020-7136 (Linking),25,6,1980 Jun 15,Potential diagnostic and prognostic significance of the transformation-enhancing factor(s) in the plasma cryoprecipitate of tumor patients.,727-34,"['Mignatti, P', 'Ascari, E', 'Barlati, S']","['Mignatti P', 'Ascari E', 'Barlati S']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Int J Cancer,International journal of cancer,0042124,"['0 (Biomarkers, Tumor)']",IM,"['Animals', 'Avian Sarcoma Viruses/genetics/isolation & purification', 'Biomarkers, Tumor/*blood', 'Cell Transformation, Neoplastic', 'Chick Embryo', 'Female', 'Freezing', 'Humans', 'Leukemia/blood/virology', 'Lymphoma/blood/virology', 'Neoplasms/*blood/virology']",,,,1980/06/15 00:00,2005/03/25 09:00,['1980/06/15 00:00'],"['1980/06/15 00:00 [pubmed]', '2005/03/25 09:00 [medline]', '1980/06/15 00:00 [entrez]']",ppublish,Int J Cancer. 1980 Jun 15;25(6):727-34. doi: 10.1002/ijc.2910250607.,['10.1002/ijc.2910250607 [doi]'],,"A biological activity which enhances cell transformation (TEF) in Rous sarcoma virus temperature-sensitive mutant-infected cultures has been evidenced in the plasma cryoprecipitate from patients affected with different types of neoplastic disease. In the present paper we report data on the analysis of TEF activity in the plasma cryoprecipitates from leukemic and tumor patients tested either before or during specific antineoplastic treatments. The screening of 57 cases of different neoplastic diseases and of 57 controls, healthy subjects or patients affected with other non-neoplastic diseases indicates that TEF activity is generally related to the presence of neoplasia. Furthermore, a follow-up of patients from the onset of the disease through its evolution during therapy suggests that variations of TEF activity in the plasma cryoprecipitate correlate well with the clinical and pathological conditions, thus indicating the TEF as a potential marker for monitoring cancer patients.","['Laboratorio di Genetica Biochimica ed Evoluzionistica del CNR, and Istituto di Genetica, University of Pavia, 27100 Pavia, Italy.']",,,,,,,,,,
14768700,NLM,MEDLINE,20040224,20190708,0020-7136 (Print) 0020-7136 (Linking),25,6,1980 Jun 15,Antibodies reactive with the mouse mammary tumor virus in sera of breast cancer patients.,721-5,"['Witkin, S S', 'Sarkar, N H', 'Kinne, D W', 'Good, R A', 'Day, N K']","['Witkin SS', 'Sarkar NH', 'Kinne DW', 'Good RA', 'Day NK']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Int J Cancer,International journal of cancer,0042124,"['0 (Antibodies, Viral)', '0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)']",IM,"['Antibodies, Viral/*blood', 'Breast Diseases/blood/immunology', 'Breast Neoplasms/*blood/*immunology/virology', 'Female', 'Humans', 'Immunoglobulin A/blood', 'Immunoglobulin G/blood', 'Immunoglobulin M/blood', 'Mammary Tumor Virus, Mouse/*immunology', 'Reference Values']",,,,1980/06/15 00:00,2005/03/25 09:00,['1980/06/15 00:00'],"['1980/06/15 00:00 [pubmed]', '2005/03/25 09:00 [medline]', '1980/06/15 00:00 [entrez]']",ppublish,Int J Cancer. 1980 Jun 15;25(6):721-5. doi: 10.1002/ijc.2910250606.,['10.1002/ijc.2910250606 [doi]'],,"IgG binding to purified mouse mammary tumor virus (MuMTV) was quantitated by an enzyme-linked immunoassay (ELISA) using sera from patients with breast cancer or benign breast disease, or from healthy age-matched controls. Significantly greater binding (p<0.01) was found in breast-cancer-derived sera than in the other categories. In addition to IgG reactivity, three breast cancer sera also possessed IgA and IgM reactive with MuMTV by the ELISA assay. Only IgG was reactive in the majority of sera while two sera possessed MuMTV binding activity only in the IgM fraction. Both IgG binding and virolysis of MuMTV were greatly reduced by preincubation of sera with MuMTV. The specificity for MuMTV was further explored with IgG of serum from one breast cancer patient. Human antibody reactive with MuMTV was progressively diminished by preincubating the human serum with increasing concentrations of MuMTV but not by incubation with the type-C AKR murine leukemia virus. Preincubation of MuMTV with a breast cancer serum partially blocked the reactivity of gp52 antiserum with the virus. The results suggest that an antigen related to an MuMTV envelope component is expressed in breast cancer.","['Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.']",,"['AI-11843/AI/NIAID NIH HHS/United States', 'CA-08748/CA/NCI NIH HHS/United States']",,,,,,,,
14768698,NLM,MEDLINE,20040224,20190708,0020-7136 (Print) 0020-7136 (Linking),25,6,1980 Jun 15,Establishment and characterization of a new leukaemic T-cell line (Peer) with an unusual phenotype.,705-10,"['Ravid, Z', 'Goldblum, N', 'Zaizov, R', 'Schlesinger, M', 'Kertes, T', 'Minowada, J', 'Verbi, W', 'Greaves, M']","['Ravid Z', 'Goldblum N', 'Zaizov R', 'Schlesinger M', 'Kertes T', 'Minowada J', 'Verbi W', 'Greaves M']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Int J Cancer,International journal of cancer,0042124,"['0 (Antigens, Neoplasm)']",IM,"['Antigens, Neoplasm/blood', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Cell Culture Techniques/methods', 'Cell Nucleus/pathology', 'Child, Preschool', 'Fatal Outcome', 'Female', 'Humans', 'Phenotype', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/immunology/*pathology', 'Rosette Formation', 'Tumor Cells, Cultured']",,,,1980/06/15 00:00,2005/03/25 09:00,['1980/06/15 00:00'],"['1980/06/15 00:00 [pubmed]', '2005/03/25 09:00 [medline]', '1980/06/15 00:00 [entrez]']",ppublish,Int J Cancer. 1980 Jun 15;25(6):705-10. doi: 10.1002/ijc.2910250604.,['10.1002/ijc.2910250604 [doi]'],,"We report the isolation and establishment in continuous culture of a human lymphoid cell line (Peer) from a case of T-leukemia. The Peer cell line lacks some typical cell-surface properties of T cells, namely sheep erythrocyte rosette formation and reactivity with two anti-T-cell sera, but has focal acid phosphatase and does express two other T-cell antigens, one defined by a monoclonal antibody, the other related to a T-cell subset (TH2). The cells are negative for B-cell markers (SmIg or cytoplasmic mu Fcgamma and C3 receptors, mouse erythrocyte rosettes) and EBV (EBNA). In addition, the Peer cell does not possess the typical phenotypic markers of ""non-B, non-T"" leukemia: cALL and Ia-like antigens, and the cytoplasmic hexosaminidase isoenzyme I, but is positive for terminal deoxynucleotidyl transferase by enzymatic and immunofluorescent criteria. The cell line requires exogenous L-asparagine for adequate growth in culture, a property known to be characteristic of certain T cells but not of B cells. The Peer cell line appears to have a maturation arrest at a developmental stage intermediate between the cortical thymocyte and a mature T-cell subset and to have lost some T-cell differentiation features.","['Chanock Centre for Virology, Hebrew University-Hadassah Medical School, Jerusalem, Israel.']",,,,,,,,,,
14768697,NLM,MEDLINE,20040224,20190708,0020-7136 (Print) 0020-7136 (Linking),25,6,1980 Jun 15,Incidence of childhood leukemia in Shanghai.,701-3,"['Li, F P', 'Jin, F', 'Tu, C T', 'Gao, Y T']","['Li FP', 'Jin F', 'Tu CT', 'Gao YT']",['eng'],"['Comparative Study', 'Journal Article']",,United States,Int J Cancer,International journal of cancer,0042124,,IM,"['Adolescent', 'Child', 'Child, Preschool', 'China/epidemiology', 'Female', 'Humans', 'Incidence', 'Infant', 'Leukemia/classification/*epidemiology', 'Male', 'Norway/epidemiology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology', 'Registries', 'Sex Characteristics', 'United States/epidemiology']",,,,1980/06/15 00:00,2005/03/25 09:00,['1980/06/15 00:00'],"['1980/06/15 00:00 [pubmed]', '2005/03/25 09:00 [medline]', '1980/06/15 00:00 [entrez]']",ppublish,Int J Cancer. 1980 Jun 15;25(6):701-3. doi: 10.1002/ijc.2910250603.,['10.1002/ijc.2910250603 [doi]'],,"Data of the Shanghai Tumor Registry were examined for incidence rates of leukemia among children, ages 0-14 years. Between 1972 and 1978, leukemia developed in 344 children; 175 (52%) had acute lymphocytic leukemia. The incidence rates were 4.5 per 100,000 boys and 3.3 per 100,000 girls. The incidence of leukemia peaked between 2 and 7 years of age.","['Clinical Epidemiology Branch, National Cancer Institute, 44 Binney Street, Boston, Mass. 02115, USA.']",,,,,,,,,,
14768407,NLM,MEDLINE,20040421,20071115,0890-9091 (Print) 0890-9091 (Linking),18,1,2004 Jan,Clinical trials referral resource. Current phase III clinical trials for adults with leukemia or lymphoma.,"62, 65, 69","['Davis, Thomas', 'Schoenfeldt, Mason']","['Davis T', 'Schoenfeldt M']",['eng'],['Directory'],,United States,Oncology (Williston Park),"Oncology (Williston Park, N.Y.)",8712059,,IM,"['*Clinical Trials, Phase III as Topic', 'Humans', 'Leukemia/*drug therapy', 'Lymphoma/*drug therapy', 'Referral and Consultation']",,,,2004/02/11 05:00,2004/04/22 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/04/22 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,"Oncology (Williston Park). 2004 Jan;18(1):62, 65, 69.",,,,"['National Cancer Institute, Bethesda, MD, USA.']",,,,,,,,,,
14768187,NLM,MEDLINE,20040423,20170306,,109,5,2003 May,"[CD-133, a new marker for normal hematopoietic progenitor and stem cells, their leukemic counterparts and endothelial precursors].",551-5,"['Poreba, Malgorzata', 'Usnarska-Zubkiewicz, Lidia', 'Kuliczkowski, Kazimierz']","['Poreba M', 'Usnarska-Zubkiewicz L', 'Kuliczkowski K']",['pol'],"['Journal Article', 'Review']","CD133, nowy znacznik prawidlowych komorek krwiotworczych, ich bialaczkowych odpowiednikow oraz komorek prekursorowych srodblonka.",Poland,Pol Arch Med Wewn,Polskie Archiwum Medycyny Wewnetrznej,0401225,"['0 (AC133 Antigen)', '0 (Antigens, CD)', '0 (Biomarkers)', '0 (Glycoproteins)', '0 (Peptides)']",IM,"['AC133 Antigen', 'Antigens, CD', 'Biomarkers', 'Endothelium/immunology', 'Glycoproteins/*immunology', 'Hematopoietic Stem Cells/*immunology', 'Humans', 'Peptides/*immunology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*immunology']",,,,2004/02/11 05:00,2004/04/24 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/04/24 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Pol Arch Med Wewn. 2003 May;109(5):551-5.,,,,"['Katedra i Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku AM we Wroclawiu.']",,,36,,,,,,,
14768185,NLM,MEDLINE,20040423,20170306,,109,5,2003 May,[Thiopurine methyltransferase (TPMP) polymorphism: a model of clinical application for pharmacogenetics].,535-40,"['Kurzawski, Mateusz', 'Drozdzik, Marek']","['Kurzawski M', 'Drozdzik M']",['pol'],"['Journal Article', 'Review']",Polimorfizm metylotransferazy tiopuryny (TPMT) modelowym przykladem klinicznego znaczenia badan farmakogenetycznych.,Poland,Pol Arch Med Wewn,Polskie Archiwum Medycyny Wewnetrznej,0401225,"['EC 2.1.1.- (Methyltransferases)', 'EC 2.1.1.67 (thiopurine methyltransferase)']",IM,"['Chromosomes, Human, Pair 18/genetics', 'Chromosomes, Human, Pair 6/genetics', 'Gene Expression/genetics', 'Genotype', 'Humans', 'Methyltransferases/*genetics/metabolism', 'Polymorphism, Genetic/*genetics', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/enzymology']",,,,2004/02/11 05:00,2004/04/24 05:00,['2004/02/11 05:00'],"['2004/02/11 05:00 [pubmed]', '2004/04/24 05:00 [medline]', '2004/02/11 05:00 [entrez]']",ppublish,Pol Arch Med Wewn. 2003 May;109(5):535-40.,,,,['Katedra Farmakologii Pomorskiej AM w Szczecinie.'],,,44,,,,,,,
14768046,NLM,MEDLINE,20040330,20061115,0014-2980 (Print) 0014-2980 (Linking),34,2,2004 Feb,Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts.,418-26,"['Chaperot, Laurence', 'Perrot, Ivan', 'Jacob, Marie-Christine', 'Blanchard, Dominique', 'Salaun, Veronique', 'Deneys, Veronique', 'Lebecque, Serge', 'Briere, Francine', 'Bensa, Jean-Claude', 'Plumas, Joel']","['Chaperot L', 'Perrot I', 'Jacob MC', 'Blanchard D', 'Salaun V', 'Deneys V', 'Lebecque S', 'Briere F', 'Bensa JC', 'Plumas J']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,Germany,Eur J Immunol,European journal of immunology,1273201,"['0 (Antigens, Surface)', '0 (Cytokines)', '0 (Interleukin-3)', '0 (blood dendritic cell antigen 4, human)', '147205-72-9 (CD40 Ligand)']",IM,"['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antigen Presentation', 'Antigens, Surface/immunology', 'CD40 Ligand/immunology', 'Cell Differentiation/immunology', 'Child', 'Cytokines/immunology/metabolism', 'Dendritic Cells/cytology/*immunology', 'Female', 'Flow Cytometry', 'Humans', 'Immunophenotyping', 'Interleukin-3/immunology', 'Leukemia/*immunology/pathology', 'Male', 'Middle Aged', 'Orthomyxoviridae/immunology']",,,,2004/02/10 05:00,2004/03/31 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/03/31 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,Eur J Immunol. 2004 Feb;34(2):418-26. doi: 10.1002/eji.200324531.,['10.1002/eji.200324531 [doi]'],,"This work aims to further characterize the newly described leukemic plasmacytoid dendritic cells (LPDC), for which we had previously demonstrated their normal, PDC-like ability to produce IFN-alpha. In addition, LPDC also express the specific antigens BDCA-2 and BDCA-4. Importantly, they become fully competent antigen-presenting cells (APC) after a short maturation induced by IL-3 + CD40L or virus, exhibiting a characteristic APC phenotype (high expression of CD83 and of the costimulatory molecules CD40, CD80, CD86). Whereas IL-3 + CD40L-activated LPDC prime naive CD4(+) T cells towards a Th2 pathway (IL-4-secreting T cells), virus-activated LPDC drive a Th1 profile (IFN-gamma-secreting T cells). Moreover, we show in one case that LPDC are able to capture, process and present exogenous antigens, leading to the activation of both CD4(+) and CD8(+) T cell clones in an antigen-specific manner. This study further characterizes the phenotype and immunological functions of LPDC.","['Department of Research and Development, EFS Rhone-Alpes Grenoble, La Tronche, France. laurence.chaperot@efs.sante.fr']",,,,,,,,,,
14767917,NLM,MEDLINE,20040429,20061115,1003-9406 (Print) 1003-9406 (Linking),21,1,2004 Feb,"[Cytogenetic and molecular genetic studies on a variant of t(15;17), ins(17;15)(q21;q14q22), in an acute promyelocytic leukemia patient].",77-9,"['Chen, Su-ning', 'Xue, Yong-quan', 'Wu, Ya-fang', 'Pan, Jin-lan']","['Chen SN', 'Xue YQ', 'Wu YF', 'Pan JL']",['chi'],"['Case Reports', 'English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,China,Zhonghua Yi Xue Yi Chuan Xue Za Zhi,Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics,9425197,"['0 (Neoplasm Proteins)', '0 (Oncogene Proteins, Fusion)', '0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)']",IM,"['Adult', 'Chromosome Painting/*methods', 'Chromosomes, Human, Pair 15/*genetics', 'Chromosomes, Human, Pair 17/*genetics', 'Humans', 'Leukemia, Promyelocytic, Acute/diagnosis/*genetics', 'Male', 'Neoplasm Proteins/genetics', 'Oncogene Proteins, Fusion/genetics', 'Reverse Transcriptase Polymerase Chain Reaction', 'Transcription, Genetic/genetics', '*Translocation, Genetic']",,,,2004/02/10 05:00,2004/04/30 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/04/30 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004 Feb;21(1):77-9.,['940621020 [pii]'],,"OBJECTIVE: To report a rare variant of t(15;17), ins(17;15)(q21;q14q22) in an acute promyelocytic leukemia (APL) patient and the results of cytogenetic and molecular genetic studies. METHODS: Chromosomes were prepared after 24 hours culture of bone marrow cells and peripheral blood cells. R-banding technique was used to analyze karyotypes. Chromosome painting analysis was performed using whole chromosome paints for chromosomes 15 and 17. PML-RAR alpha and RAR alpha-PML fusion transcripts were detected by reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: Karyotypic analysis using both specimens from bone marrow and peripheral blood leukemic cells revealed 15q- and 17q+. Chromosome painting analysis confirmed that the karyotypic abnormality was ins(17;15). PML-RAR alpha fusion transcript (S type) was detected by RT-PCR, while RAR alpha-PML fusion transcript was not detected. CONCLUSION: Chromosome painting and RT-PCR are reliable methods for characterization of the insertion involving chromosomes 15 and 17 in APL patients.","['First Affiliated Hospital of Suzhou University, Jiangsu Institute of Hematology, Suzhou Jiangsu, PR China.']",,,,,,,,,,
14767751,NLM,MEDLINE,20040826,20181113,0941-4355 (Print) 0941-4355 (Linking),12,4,2004 Apr,Does vitamin A prevent high-dose-methotrexate-induced D-xylose malabsorption in children with cancer?,263-7,"['Dagdemir, Ayhan', 'Yildirim, Hasan', 'Aliyazicioglu, Yuksel', 'Kanber, Yilmaz', 'Albayrak, Davut', 'Acar, Sabri']","['Dagdemir A', 'Yildirim H', 'Aliyazicioglu Y', 'Kanber Y', 'Albayrak D', 'Acar S']",['eng'],"['Clinical Trial', 'Comparative Study', 'Journal Article', 'Randomized Controlled Trial']",,Germany,Support Care Cancer,Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,9302957,"['0 (Antimetabolites, Antineoplastic)', '0 (Protective Agents)', '0 (Retinol-Binding Proteins)', '11103-57-4 (Vitamin A)', 'A1TA934AKO (Xylose)', 'YL5FZ2Y5U1 (Methotrexate)']",IM,"['Adolescent', 'Antimetabolites, Antineoplastic/administration & dosage/*adverse effects', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Intestinal Absorption/drug effects', 'Intestinal Mucosa/drug effects', 'Lymphoma, Non-Hodgkin/*drug therapy', 'Malabsorption Syndromes/*chemically induced', 'Male', 'Methotrexate/administration & dosage/*adverse effects', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy', 'Prospective Studies', 'Protective Agents/administration & dosage/*therapeutic use', 'Retinol-Binding Proteins/analysis', 'Vitamin A/administration & dosage/*therapeutic use', 'Xylose/*metabolism']",,,,2004/02/10 05:00,2004/08/27 05:00,['2004/02/10 05:00'],"['2003/11/04 00:00 [received]', '2004/01/12 00:00 [accepted]', '2004/02/10 05:00 [pubmed]', '2004/08/27 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,Support Care Cancer. 2004 Apr;12(4):263-7. doi: 10.1007/s00520-004-0591-8. Epub 2004 Feb 6.,['10.1007/s00520-004-0591-8 [doi]'],,"PURPOSE: Our aim was to explore whether vitamin A has protective effect on high-dose-methotrexate (HDMTX)-induced intestinal D-xylose malabsorption in children with leukemia and lymphoma. PATIENTS AND METHODS: We performed a prospective randomized un-blinded study of vitamin A in 35 children with leukemia and lymphoma who were planned to receive HDMTX 3 g/m(2) and 5 g/m(2), respectively. Twenty-two patients (group 1) received a single dose of 180,000 IU a day before HDMTX was given, and 13 (group 2) received only HDMTX. The vitamin A group received the vitamin only once. Oral D-xylose absorption tests before and 7 days after HDMTX were carried out to evaluate intestinal absorption. Retinol-binding protein (RBP) levels prior to therapy were also measured for vitamin A status. RESULTS: Although we observed no difference of HDMTX-induced toxicity, including hematological, dermatological, systemic, and other toxicities, between groups, the D-xylose absorption test was significantly better in-group 1 ( p=0.030). Absorption was decreased in five of 22 patients (23%) who received vitamin A comparing to eight of 13 (62%) who received only HDMTX ( p=0.033). RBP levels were lower than normal in 13 of 22 patients in-group 1 and nine of 13 in group 2. In patients whose RBP levels were lower than normal, HDMTX-induced toxicity was lower in the group 1 than group 2 but not statistically significant. No sign of vitamin A toxicity was observed throughout the study. CONCLUSION: The administration of vitamin A before HDMTX may protect against drug-induced D-xylose malabsorption in children with cancer. Further studies are apparently needed to clarify the full benefits of vitamin A in preventing HDMTX-induced mucosal damage.","['Medical Faculty, Department of Pediatric Oncology, Ondokuz Mayis University, 55139 Kurupelit-Samsun, Turkey. ayhandag@omu.edu.tr']",20040206,,,,,,,,,
14767581,NLM,MEDLINE,20040504,20131121,1107-3756 (Print) 1107-3756 (Linking),13,3,2004 Mar,Comparative study of the growth-inhibitory and apoptosis-inducing activities of black tea theaflavins and green tea catechin on murine myeloid leukemia cells.,465-71,"['Lung, Hong-Lok', 'Ip, Wai-Ki', 'Chen, Zhen-Yu', 'Mak, Nai-Ki', 'Leung, Kwok-Nam']","['Lung HL', 'Ip WK', 'Chen ZY', 'Mak NK', 'Leung KN']",['eng'],"['Comparative Study', 'Journal Article']",,Greece,Int J Mol Med,International journal of molecular medicine,9810955,"['0 (Biflavonoids)', '0 (Tea)', '1IA46M0D13 (theaflavin)', '8R1V1STN48 (Catechin)', 'BQM438CTEL (epigallocatechin gallate)']",IM,"['Animals', 'Apoptosis/*drug effects', 'Biflavonoids/*pharmacology', 'Catechin/*analogs & derivatives/*pharmacology', 'Cell Division/*drug effects', 'Cell Line, Tumor', 'Female', 'Leukemia, Myeloid/*drug therapy/pathology', 'Mice', 'Mice, Inbred BALB C', 'Tea', 'Tumor Stem Cell Assay']",,,,2004/02/10 05:00,2004/05/05 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/05/05 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,Int J Mol Med. 2004 Mar;13(3):465-71.,,,"Among the black tea polyphenols, theaflavins are generally considered to be the more effective components for the inhibition of carcinogenesis. In this study, we attempted to compare the growth-inhibitory and apoptosis-inducing activities of the four black tea theaflavins (TF-1, TF-2A, TF-2B and TF-3) with the major green tea catechin epigallocatechin-3-gallate (EGCG) on the murine myeloid leukemia WEHI-3B JCS cells. All the four black tea theaflavins were shown to exert potent anti-proliferative and cytotoxic effects on the leukemia WEHI-3B JCS cells in a dose-dependent manner. The observed anti-proliferative and cytotoxic effects were in the following order of potency: EGCG > TF-2B > TF-3 > TF-2A > TF-1. In addition, all theaflavins were capable of inducing apoptosis in the leukemia WEHI-3B JCS cells. Among the four theaflavins tested, TF-2B and TF-3 were found to be slightly more potent in inducing apoptosis of the WEHI-3B JCS cells than that of TF-2A and TF-1 but were comparable to the major green tea epicatechin EGCG. More interestingly, both TF-2B and TF-3 were found to be much more effective than TF-1 and TF-2B in reducing both the in vitro clonogenicity and in vivo tumorigenicity of the WEHI-3B JCS cells, suggesting that these two black tea theaflavins might represent potential candidates for the treatment of some forms of leukemia.","['Department of Biochemistry, The Chinese University of Hong Kong, Shatin, China.']",,,,,,,,,,
14767525,NLM,MEDLINE,20041007,20131121,1021-335X (Print) 1021-335X (Linking),11,3,2004 Mar,Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.,699-705,"['Kobylinska, Agnieszka', 'Blonski, Jerzy Z', 'Hanausek, Malgorzata', 'Walaszek, Zbigniew', 'Robak, Tadeusz', 'Kilianska, Zofia M']","['Kobylinska A', 'Blonski JZ', 'Hanausek M', 'Walaszek Z', 'Robak T', 'Kilianska ZM']",['eng'],"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,Greece,Oncol Rep,Oncology reports,9422756,"['0 (Antineoplastic Agents)', '0 (Antineoplastic Agents, Alkylating)', '0 (BAX protein, human)', '0 (Proto-Oncogene Proteins)', '0 (Proto-Oncogene Proteins c-bcl-2)', '0 (bcl-2-Associated X Protein)', '47M74X9YT5 (Cladribine)', '8N3DW7272P (Cyclophosphamide)', 'BZ114NVM5P (Mitoxantrone)']",IM,"['Aged', 'Aged, 80 and over', 'Antineoplastic Agents/administration & dosage', 'Antineoplastic Agents, Alkylating/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Apoptosis', 'Blotting, Western', 'Cell Nucleus/metabolism', 'Cladribine/*administration & dosage', 'Cyclophosphamide/*administration & dosage/therapeutic use', 'DNA Fragmentation', 'Densitometry', 'Electrophoresis, Polyacrylamide Gel', 'Female', 'Humans', 'Immunoblotting', 'Leukemia, B-Cell/*drug therapy', 'Leukocytes, Mononuclear/metabolism', 'Male', 'Middle Aged', 'Mitoxantrone/*administration & dosage', 'Proto-Oncogene Proteins/*metabolism', 'Proto-Oncogene Proteins c-bcl-2/*metabolism', 'Subcellular Fractions', 'bcl-2-Associated X Protein']",,,,2004/02/10 05:00,2004/10/08 09:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/10/08 09:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,Oncol Rep. 2004 Mar;11(3):699-705.,,,"The present study investigated a correlation between expression of Bcl-2 family members, Bax and Bcl-2 (the Bax/Bcl-2 ratio values) in B-CLL cells in vivo and the response of these cells to chemotherapy. Western blot technique combined with videodensitometry was used for Bax and Bcl-2 determination in homogenate, nuclear and postnuclear fractions of mononuclear cells isolated from peripheral blood of B-CLL patients treated with cladribine alone (C), and in combination with cyclophosphamide (CC) or mitoxantrone and cyclophosphamide (CMC). The Bax/Bcl-2 ratio values were changed in B-CLL cells originated from blood samples of patients treated by the three therapy protocols, and was the most elevated in the case of CMC treatment. High degree of B-CLL cell apoptosis induction with cladribine combined with mitoxantrone and cyclophosphamide was confirmed by DNA fragmentation and an appearance of apoptotic morphology among leukemic cells from the blood of patients treated with this form of combined therapy.","['Department of Cytobiochemistry, University of Lodz, 90-237 Lodz, Poland.']",,,,,,,,,,
14767498,NLM,MEDLINE,20041112,20131121,0268-3369 (Print) 0268-3369 (Linking),33,8,2004 Apr,Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.,781-7,"['Phillips, G L', 'Meisenberg, B R', 'Reece, D E', 'Adams, V R', 'Badros, A Z', 'Brunner, J L', 'Fenton, R G', 'Filicko, J', 'Grosso, D L', 'Hale, G A', 'Howard, D S', 'Johnson, V P', 'Kniska, A', 'Marshall, K W', 'Mookerjee, B', 'Nath, R', 'Rapoport, A P', 'Sarkodee-Adoo, C', 'Takebe, N', 'Vesole, D H', 'Wagner, J L', 'Flomenberg, N']","['Phillips GL', 'Meisenberg BR', 'Reece DE', 'Adams VR', 'Badros AZ', 'Brunner JL', 'Fenton RG', 'Filicko J', 'Grosso DL', 'Hale GA', 'Howard DS', 'Johnson VP', 'Kniska A', 'Marshall KW', 'Mookerjee B', 'Nath R', 'Rapoport AP', 'Sarkodee-Adoo C', 'Takebe N', 'Vesole DH', 'Wagner JL', 'Flomenberg N']",['eng'],"['Clinical Trial', 'Clinical Trial, Phase I', 'Clinical Trial, Phase II', 'Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,England,Bone Marrow Transplant,Bone marrow transplantation,8702459,"['0 (Antineoplastic Agents, Alkylating)', '0 (Radiation-Protective Agents)', 'M487QF2F4V (Amifostine)', 'Q41OR9510P (Melphalan)']",IM,"['Adult', 'Amifostine/*administration & dosage', 'Antineoplastic Agents, Alkylating/*administration & dosage', 'Combined Modality Therapy', 'Female', '*Hematopoietic Stem Cell Transplantation', 'Hodgkin Disease/*therapy', 'Humans', 'Lymphoma, Non-Hodgkin/*therapy', 'Male', 'Melphalan/*administration & dosage', 'Middle Aged', 'Radiation-Protective Agents/*administration & dosage', 'Transplantation Conditioning/methods', 'Transplantation, Autologous']",,,,2004/02/10 05:00,2004/11/13 09:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/11/13 09:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,Bone Marrow Transplant. 2004 Apr;33(8):781-7. doi: 10.1038/sj.bmt.1704424.,"['10.1038/sj.bmt.1704424 [doi]', '1704424 [pii]']",,"High-dose chemotherapy using melphalan (HDMEL) is an important component of many conditioning regimens that are given before autologous hematopoietic stem cell transplantation (AHSCT). In contrast to the situation in myeloma, and to a lesser degree acute leukemia, only a very limited published experience exists with the use of HDMEL conditioning as a single agent in doses requiring AHSCT for lymphoma, both Hodgkin lymphoma (HL) and especially non-Hodgkin lymphoma (NHL). Thus, we report results of treating 26 lymphoma patients (22 with NHL and four with HL) with HDMEL 220-300 mg/m(2) plus amifostine (AF) cytoprotection and AHSCT as part of a phase I-II trial. Median age was 51 years (range 24-62 years); NHL histology was varied, but was aggressive (including transformed from indolent) in 19 patients, indolent in two patients and mantle cell in one. All 26 patients had been extensively treated; 11 were refractory to the immediate prior therapy on protocol entry and two had undergone prior AHSCT. All were deemed ineligible for other, 'first-line' AHSCT regimens. Of these 26 patients, 22 survived to initial tumor evaluation on D +100. At this time, 13 were in complete remission, including four patients who were in second CR before HDMEL+AF+AHSCT. Responses occurred at all HDMEL doses. Currently, seven patients are alive, including five without progression, with a median follow-up in these latter patients of D +1163 (range D +824 to D +1630); one of these patients had a nonmyeloablative allograft as consolidation on D +106. Conversely, 14 patients relapsed or progressed, including five who had previously achieved CR with the AHSCT procedure. Two patients, both with HL, remain alive after progression; one is in CR following salvage radiotherapy. Six patients died due to nonrelapse causes, including two NHL patients who died while in CR. We conclude that HDMEL+AF+AHSCT has significant single-agent activity in relapsed or refractory NHL and HL. This experience may be used as a starting point for subsequent dose escalation of HDMEL (probably with AF) in established combination regimens.","['Blood and Marrow Transplant Program, University of Kentucky, Lexington, KY, USA. gordon_phillips@urmc.rochester.edu']",,['R03CA80666/CA/NCI NIH HHS/United States'],,,,,,,,
14767474,NLM,MEDLINE,20040414,20061115,0950-9232 (Print) 0950-9232 (Linking),23,13,2004 Mar 25,Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes.,2379-84,"['Neben, Kai', 'Tews, Bjorn', 'Wrobel, Gunnar', 'Hahn, Meinhard', 'Kokocinski, Felix', 'Giesecke, Christian', 'Krause, Ulf', 'Ho, Anthony D', 'Kramer, Alwin', 'Lichter, Peter']","['Neben K', 'Tews B', 'Wrobel G', 'Hahn M', 'Kokocinski F', 'Giesecke C', 'Krause U', 'Ho AD', 'Kramer A', 'Lichter P']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,England,Oncogene,Oncogene,8711562,,IM,"['*Aneuploidy', 'Centrosome/*metabolism', '*Gene Expression Profiling', 'Humans', 'Leukemia, Myeloid/*genetics/metabolism', 'Translocation, Genetic']",,,,2004/02/10 05:00,2004/04/15 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/04/15 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,Oncogene. 2004 Mar 25;23(13):2379-84. doi: 10.1038/sj.onc.1207401.,"['10.1038/sj.onc.1207401 [doi]', '1207401 [pii]']",,"Centrosomes, which mediate accurate chromosome segregation during mitosis, undergo duplication precisely once per cell division at the G1/S boundary. Recently, we described centrosome aberrations as a possible cause of aneuploidy in acute myeloid leukemia (AML) and found a correlation of the percentage of cells carrying abnormal centrosomes to their cytogenetic risk profile. To elucidate the molecular events responsible for the development of centrosome aberrations in AML, tumor RNA of 29 AML samples was hybridized to cDNA microarrays. The microarrays comprised some 2800 different genes with relevance to hematopoiesis, tumorigenesis and mitosis and included a set of 359 centrosome-associated genes. We identified two gene expression signatures, which allowed an accurate classification according to the extent of centrosome aberrations and the ploidy status in 28 of 29 patients each. Specifically, 18 genes were present in both signatures, including genes that code for cell cycle regulatory proteins (cyclin A2, cyclin D3, cyclin H, CDK6, p18INK4c, p21Cip1, PAK1) and centrosome-associated proteins (pericentrin, alpha2-tubulin, NUMA1, TUBGCP2, PRKAR2A). In conclusion, the high expression of centrosome-associated genes matches the description of centrosome aberrations in several tumor types. Moreover, in AML the identification of G1/S-phase stimulatory genes suggests that one mechanism of aneuploidy induction might be the deregulation of centrosome replication at the G1/S boundary.","['Division of Molecular Genetics (B060), Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.']",,,,,,,,,,
14767205,NLM,MEDLINE,20040309,20190917,1077-4114 (Print) 1077-4114 (Linking),26,2,2004 Feb,Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after a cord blood stem cell transplantation presenting with pulmonary nodules.,124-7,"['Shimasaki, Noriko', 'Mori, Tetsuya', 'Shimada, Hiroyuki', 'Sugita, Mayumi', 'Higuchi, Masataka', 'Mukai, Makio', 'Morio, Tomohiro', 'Okamoto, Shinichiro']","['Shimasaki N', 'Mori T', 'Shimada H', 'Sugita M', 'Higuchi M', 'Mukai M', 'Morio T', 'Okamoto S']",['eng'],"['Case Reports', 'Journal Article']",,United States,J Pediatr Hematol Oncol,Journal of pediatric hematology/oncology,9505928,"['0 (Antibodies, Monoclonal)', '0 (Antibodies, Monoclonal, Murine-Derived)', '0 (Antineoplastic Agents)', '0 (DNA, Viral)', '4F4X42SYQ6 (Rituximab)']",IM,"['Antibodies, Monoclonal/therapeutic use', 'Antibodies, Monoclonal, Murine-Derived', 'Antineoplastic Agents/therapeutic use', 'Blast Crisis', 'Child', 'Cord Blood Stem Cell Transplantation/*adverse effects', 'DNA, Viral/blood/genetics', 'Epstein-Barr Virus Infections/drug therapy/*transmission', 'Female', 'Fetal Blood/cytology', 'Herpesvirus 4, Human/genetics/*isolation & purification', 'Humans', 'Lung Neoplasms/diagnosis/drug therapy/*virology', 'Lymphoproliferative Disorders/diagnosis/drug therapy/*virology', 'Rituximab', 'Solitary Pulmonary Nodule/diagnosis/drug therapy/*virology', 'Tomography, X-Ray Computed']",,,,2004/02/10 05:00,2004/03/10 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,J Pediatr Hematol Oncol. 2004 Feb;26(2):124-7. doi: 10.1097/00043426-200402000-00015.,"['00043426-200402000-00015 [pii]', '10.1097/00043426-200402000-00015 [doi]']",,"Sixteen months after a cord blood stem cell transplantation, a 6-year-old girl was diagnosed with Epstein-Barr virus-associated posttransplant lymphoproliferative disorder (EBV-PTLD). A CT scan revealed nodules in both lungs, but the patient had neither lymphadenopathy nor other lesions. The diagnosis was confirmed by histopathologic evaluation and the increased level of EBV DNA in the peripheral blood. The patient was successfully treated with rituximab, and a complete regression of the tumors was achieved. This case reveals the need to include EBV-PTLD in the differential diagnosis of pulmonary nodules, as well as demonstrating that rituximab may be effective treatment of EBV-PTLD after cord blood stem cell transplantation.","['Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.']",,,,,,,,,,
14767202,NLM,MEDLINE,20040309,20190917,1077-4114 (Print) 1077-4114 (Linking),26,2,2004 Feb,Successful treatment of invasive aspergillosis with oral voriconazole following intravenous liposomal amphotericin in a child with acute lymphoblastic leukemia.,117-9,"['Lassaletta, Alvaro', 'Perez, A', 'Diaz, M A', 'Sevilla, J', 'Gonzalez-Vicent, M', 'Madero, L']","['Lassaletta A', 'Perez A', 'Diaz MA', 'Sevilla J', 'Gonzalez-Vicent M', 'Madero L']",['eng'],"['Case Reports', 'Letter']",,United States,J Pediatr Hematol Oncol,Journal of pediatric hematology/oncology,9505928,"['0 (Antifungal Agents)', '0 (Liposomes)', '0 (Pyrimidines)', '0 (Triazoles)', '7XU7A7DROE (Amphotericin B)', 'JFU09I87TR (Voriconazole)']",IM,"['Administration, Oral', 'Amphotericin B/*administration & dosage', 'Antifungal Agents/*administration & dosage', 'Aspergillosis/diagnosis/*drug therapy/microbiology', 'Child', 'Humans', 'Infusions, Intravenous', 'Liposomes', 'Male', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/microbiology', 'Pyrimidines/*administration & dosage', 'Tomography, X-Ray Computed', 'Treatment Outcome', 'Triazoles/*administration & dosage', 'Voriconazole']",,,,2004/02/10 05:00,2004/03/10 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,J Pediatr Hematol Oncol. 2004 Feb;26(2):117-9. doi: 10.1097/00043426-200402000-00012.,"['00043426-200402000-00012 [pii]', '10.1097/00043426-200402000-00012 [doi]']",,,,,,,['J Pediatr Hematol Oncol. 2004 Feb;26(2):79-80. PMID: 14767192'],,,,,,
14767200,NLM,MEDLINE,20040309,20190917,1077-4114 (Print) 1077-4114 (Linking),26,2,2004 Feb,Unusual presentation of childhood acute lymphoblastic leukemia: a case presenting with hypercalcemia symptoms only.,116-7,"['Turker, Meral', 'Oren, Hale', 'Yilmaz, Sebnem', 'Cakmakci, Handan', 'Demircioglu, Fatih', 'Irken, Gulersu']","['Turker M', 'Oren H', 'Yilmaz S', 'Cakmakci H', 'Demircioglu F', 'Irken G']",['eng'],"['Case Reports', 'Letter']",,United States,J Pediatr Hematol Oncol,Journal of pediatric hematology/oncology,9505928,,IM,"['Adolescent', 'Female', 'Humans', 'Hypercalcemia/*diagnosis', 'Incidence', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis', 'Prognosis']",,,,2004/02/10 05:00,2004/03/10 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,J Pediatr Hematol Oncol. 2004 Feb;26(2):116-7. doi: 10.1097/00043426-200402000-00011.,['10.1097/00043426-200402000-00011 [doi]'],,,,,,,,,,,,,
14767199,NLM,MEDLINE,20040309,20190917,1077-4114 (Print) 1077-4114 (Linking),26,2,2004 Feb,Reactivation of the bacille Calmette-Guerin scar following immune reconstitution during treatment of infant acute lymphoblastic leukemia.,112-5,"['Swinson, Sophie', 'Hall, Georgina', 'Pollard, Andrew J']","['Swinson S', 'Hall G', 'Pollard AJ']",['eng'],"['Case Reports', 'Journal Article']",,United States,J Pediatr Hematol Oncol,Journal of pediatric hematology/oncology,9505928,['0 (BCG Vaccine)'],IM,"['Antineoplastic Combined Chemotherapy Protocols/*adverse effects', 'BCG Vaccine/*administration & dosage', 'Cicatrix/*etiology', 'Fatal Outcome', 'Female', 'Humans', '*Immunocompromised Host', 'Infant, Newborn', 'Mycobacterium bovis/*physiology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/congenital/*drug therapy', 'Tuberculosis/prevention & control', 'Vaccination', 'Virus Activation/*drug effects']",,,,2004/02/10 05:00,2004/03/10 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,J Pediatr Hematol Oncol. 2004 Feb;26(2):112-5. doi: 10.1097/00043426-200402000-00009.,"['00043426-200402000-00009 [pii]', '10.1097/00043426-200402000-00009 [doi]']",,The authors describe an infant presenting at 2 weeks of age with congenital acute lymphoblastic leukemia who had previously received routine bacille Calmette-Guerin (BCG) vaccination at birth. The risk of BCG dissemination in immunocompromised infants is discussed and the use of antimycobacterial prophylaxis in such cases considered.,"['Department of Pediatrics, University of Oxford, Oxford, United Kingdom.']",,,,,,,,,,
14767195,NLM,MEDLINE,20040309,20190917,1077-4114 (Print) 1077-4114 (Linking),26,2,2004 Feb,Successful unrelated cord blood transplantation following reduced-intensity conditioning for refractory acute myeloid leukemia.,98-100,"['Berger, Massimo', 'Vassallo, Elena', 'Nesi, Francesca', 'Venturi, Claudio', 'Madon, Enrico', 'Fagioli, Franca']","['Berger M', 'Vassallo E', 'Nesi F', 'Venturi C', 'Madon E', 'Fagioli F']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,J Pediatr Hematol Oncol,Journal of pediatric hematology/oncology,9505928,,IM,"['Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Child, Preschool', '*Cord Blood Stem Cell Transplantation', 'Graft vs Host Disease/prevention & control', 'Graft vs Leukemia Effect/immunology', 'Humans', 'Leukemia, Myelomonocytic, Acute/*therapy', 'Male', 'Neoplasm Recurrence, Local/*therapy', 'Remission Induction', '*Transplantation Conditioning', 'Treatment Outcome']",,,,2004/02/10 05:00,2004/03/10 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,J Pediatr Hematol Oncol. 2004 Feb;26(2):98-100. doi: 10.1097/00043426-200402000-00005.,"['00043426-200402000-00005 [pii]', '10.1097/00043426-200402000-00005 [doi]']",,"Patients with relapsed acute myeloid leukemia following autograft have a poor prognosis. The possibility of allograft is frequently time-limited, as the disease reappears before a stem cell donor can be found in the worldwide registries. Cord blood transplantation is a new therapeutic approach, since cord blood units are rapidly available. The authors show how a relapsed chemotherapy-refractory patient was successful transplanted with a mismatched cord blood unit after reduced-intensity conditioning. Twenty-three months after transplantation, the child is in continuous complete remission and has full donor chimerism and no signs of chronic graft-versus-host disease.","[""Department of Paediatrics, Regina Margherita Children's Hospital, University of Turin, Italy.""]",,,,,,,,,,
14767194,NLM,MEDLINE,20040309,20190917,1077-4114 (Print) 1077-4114 (Linking),26,2,2004 Feb,Busulfan and cyclophosphamide as a conditioning regimen for pediatric acute lymphoblastic leukemia patients undergoing bone marrow transplantation.,91-7,"['Shah, Ami J', 'Lenarsky, Carl', 'Kapoor, Neena', 'Crooks, Gay M', 'Kohn, Donald B', 'Parkman, Robertson', 'Epport, Karen', 'Wilson, Kathy', 'Weinberg, Ken']","['Shah AJ', 'Lenarsky C', 'Kapoor N', 'Crooks GM', 'Kohn DB', 'Parkman R', 'Epport K', 'Wilson K', 'Weinberg K']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,J Pediatr Hematol Oncol,Journal of pediatric hematology/oncology,9505928,"['8N3DW7272P (Cyclophosphamide)', 'G1LN9045DK (Busulfan)']",IM,"['Adolescent', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', '*Bone Marrow Transplantation', 'Busulfan/administration & dosage', 'Child', 'Child, Preschool', 'Combined Modality Therapy', 'Cyclophosphamide/administration & dosage', 'Disease-Free Survival', 'Female', 'Follow-Up Studies', 'Humans', 'Infant', 'Male', 'Neoplasm Recurrence, Local/*therapy', 'Neuropsychological Tests', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy', 'Remission Induction', 'Transplantation Conditioning/*methods', 'Treatment Outcome', 'Whole-Body Irradiation']",,,,2004/02/10 05:00,2004/03/10 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,J Pediatr Hematol Oncol. 2004 Feb;26(2):91-7. doi: 10.1097/00043426-200402000-00004.,"['00043426-200402000-00004 [pii]', '10.1097/00043426-200402000-00004 [doi]']",,"Bone marrow transplantation (BMT) has become the standard therapy for children with relapsed acute lymphoblastic leukemia. The authors report their experience with histocompatible BMT for 52 children with acute lymphoblastic leukemia conditioned with a non-total body irradiation (TBI) regimen using busulfan and cyclophosphamide (Bu/Cy). The efficacy and long-term toxicity of the Bu/Cy regimen were determined. Overall survival was 35%. One-year, 3-year, and 7-year event-free survival rates were 54%, 33%, and 23%, respectively. Of the 52 BMT recipients, 26 relapsed. Thirteen of the relapsed patients received a second BMT and three were surviving as of this writing. The most frequent cause of death was leukemia relapse. An initial remission duration of less than 18 months was a factor in decreasing the event-free survival. The Bu/Cy regimen was well tolerated, with minimal transplant-related mortality. Neurocognitive function was tested before BMT and 1 year after BMT. When 1-year posttransplant neurocognitive test scores were compared with pretransplant scores, there was no decrease. However, there was a significant decrease in the pretransplant neurocognitive test scores in BMT recipients compared with their normal siblings. The use of Bu/Cy as a conditioning regimen for BMT does not appear to affect posttransplant neurocognitive function. Other long-term side effects, such as endocrinopathies and secondary malignancies, were also minimal. These data show that the Bu/Cy regimen is well tolerated, but the overall survival rate remains low.","['Department of Pediatrics, Keck School of Medicine, Dallas, Texas, USA. Ashah@chla.usc.edu']",,['M01 RR00043/RR/NCRR NIH HHS/United States'],,,,,,,,
14767193,NLM,MEDLINE,20040309,20190917,1077-4114 (Print) 1077-4114 (Linking),26,2,2004 Feb,Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation.,81-90,"['Hoffmeister, Paul A', 'Storer, Barry E', 'Sanders, Jean E']","['Hoffmeister PA', 'Storer BE', 'Sanders JE']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,J Pediatr Hematol Oncol,Journal of pediatric hematology/oncology,9505928,,IM,"['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Diabetes Mellitus, Type 1/epidemiology/*etiology', 'Diabetes Mellitus, Type 2/epidemiology/*etiology', 'Female', 'Follow-Up Studies', 'Hematopoietic Stem Cell Transplantation/*adverse effects/mortality', 'Humans', 'Incidence', 'Infant', 'Male', 'Neoplasms/therapy', 'Retrospective Studies', 'Risk Factors', 'Survival Rate', '*Survivors', 'Time Factors']",,,,2004/02/10 05:00,2004/03/10 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,J Pediatr Hematol Oncol. 2004 Feb;26(2):81-90. doi: 10.1097/00043426-200402000-00003.,"['00043426-200402000-00003 [pii]', '10.1097/00043426-200402000-00003 [doi]']",,"To identify risk factors associated with the development of diabetes mellitus and to describe the prevalence of diabetes in pediatric hematopoietic cell transplant (HCT) survivors. The follow-up records of 748 patients who survived for at least 2 years after pediatric HCT were retrospectively reviewed for diagnosis of diabetes. Risk factors for type 2 diabetes were analyzed using multivariate statistics. Among 748 patients with a median of 11 years of follow-up, 38 developed diabetes after HCT. Four patients (three leukemia and one neuroblastoma) developed type 1 diabetes 8 to 14 years after HCT, at between 10 and 19 years of age. Thirty-four patients (32 leukemia and 2 aplastic anemia) developed type 2 diabetes 1 to 24 years after HCT, at between 11 and 41 years of age. Of the 34 patients with type 2 diabetes, 23 were non-Hispanic white, 3 had experienced asparaginase toxicity (hyperglycemia and/or pancreatitis), and 26 had a family history of diabetes. Risk factors associated with type 2 diabetes were diagnosis of acute or chronic leukemia, race/ethnicity other than non-Hispanic white, family history of diabetes, and asparaginase toxicity. The prevalence of type 1 diabetes among all surviving patients was 0.52%, or three times higher than the general U.S. population. The prevalence of type 2 diabetes was 9% among leukemia survivors and 2% among aplastic anemia survivors, both higher than expected. Pediatric HCT survivors are more likely to develop diabetes than the general population.","['Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.']",,['CA-18029/CA/NCI NIH HHS/United States'],,,,,,,,
14766942,NLM,MEDLINE,20050321,20181113,0022-3751 (Print) 0022-3751 (Linking),556,Pt 3,2004 May 1,"Leukocytes, cytokines, growth factors and hormones in human skeletal muscle and blood after uphill or downhill running.",983-1000,"['Malm, Christer', 'Sjodin, The Late Bertil', 'Sjoberg, Berit', 'Lenkei, Rodica', 'Renstrom, Per', 'Lundberg, Ingrid E', 'Ekblom, Bjorn']","['Malm C', 'Sjodin TL', 'Sjoberg B', 'Lenkei R', 'Renstrom P', 'Lundberg IE', 'Ekblom B']",['eng'],"['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]",,England,J Physiol,The Journal of physiology,0266262,"['0 (ARNT protein, human)', '0 (Antigens, CD)', '0 (Antigens, Differentiation, Myelomonocytic)', '0 (CD11b Antigen)', '0 (CD163 antigen)', '0 (CD3 Complex)', '0 (CD56 Antigen)', '0 (Cytokines)', '0 (DNA-Binding Proteins)', '0 (Growth Substances)', '0 (Hormones)', '0 (Interleukin-6)', '0 (Ki-67 Antigen)', '0 (LIF protein, human)', '0 (LIFR protein, human)', '0 (Leukemia Inhibitory Factor)', '0 (Leukemia Inhibitory Factor Receptor alpha Subunit)', '0 (Proteins)', '0 (Receptors, Aryl Hydrocarbon)', '0 (Receptors, Cell Surface)', '0 (Receptors, Cytokine)', '0 (Receptors, OSM-LIF)', '0 (Transcription Factors)', '0 (fas Receptor)', '138391-32-9 (Aryl Hydrocarbon Receptor Nuclear Translocator)', '3XMK78S47O (Testosterone)', '67763-96-6 (Insulin-Like Growth Factor I)', '9007-41-4 (C-Reactive Protein)', 'EC 2.7.3.2 (Creatine Kinase)']",IM,"['Adolescent', 'Adult', 'Antigens, CD/analysis/metabolism', 'Antigens, Differentiation, Myelomonocytic/analysis/metabolism', 'Aryl Hydrocarbon Receptor Nuclear Translocator', 'C-Reactive Protein/analysis/metabolism', 'CD11b Antigen/analysis/metabolism', 'CD3 Complex/analysis/metabolism', 'CD56 Antigen/analysis/metabolism', 'Creatine Kinase/blood/metabolism', 'Cytokines/analysis/blood/*metabolism', 'DNA-Binding Proteins/analysis/metabolism', 'Exercise Test/methods', 'Fascia/chemistry/metabolism', 'Female', 'Flow Cytometry', 'Granulocytes/cytology', 'Growth Substances/*metabolism', 'Heart Rate/physiology', 'Hormones/blood/*metabolism', 'Humans', 'Immunohistochemistry', 'Insulin-Like Growth Factor I/analysis/metabolism', 'Interleukin-6/analysis/blood/metabolism', 'Isometric Contraction/physiology', 'Ki-67 Antigen/analysis/metabolism', 'Leukemia Inhibitory Factor', 'Leukemia Inhibitory Factor Receptor alpha Subunit', 'Leukocyte Count', 'Leukocytes/chemistry/cytology/*metabolism', 'Lymphocytes/cytology/metabolism', 'Male', 'Middle Aged', 'Monocytes/cytology/metabolism', 'Muscle, Skeletal/chemistry/metabolism/*physiology', 'Oxygen Consumption/physiology', 'Pain/diagnosis/metabolism/physiopathology', 'Proteins/analysis/metabolism', 'Receptors, Aryl Hydrocarbon/analysis/metabolism', 'Receptors, Cell Surface/analysis/metabolism', 'Receptors, Cytokine/analysis/metabolism', 'Receptors, OSM-LIF', 'Regression Analysis', 'Running/*physiology', 'Testosterone/blood/metabolism', 'Transcription Factors/analysis/metabolism', 'fas Receptor/analysis/metabolism']",,,,2004/02/10 05:00,2005/03/22 09:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2005/03/22 09:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,J Physiol. 2004 May 1;556(Pt 3):983-1000. doi: 10.1113/jphysiol.2003.056598. Epub 2004 Feb 6.,"['10.1113/jphysiol.2003.056598 [doi]', 'jphysiol.2003.056598 [pii]']",PMC1664987,"Muscular adaptation to physical exercise has previously been described as a repair process following tissue damage. Recently, evidence has been published to question this hypothesis. The purpose of this study was to investigate inflammatory processes in human skeletal muscle and epimysium after acute physical exercise with large eccentric components. Three groups of subjects (n= 19) performed 45 min treadmill running at either 4 deg (n= 5) or 8 deg (n= 9) downhill or 4 deg uphill (n= 5) and one group served as control (n= 9). One biopsy was taken from each subject 48 h post exercise. Blood samples were taken up to 7 days post exercise. Compared to the control group, none of the markers of inflammation in muscle and epimysium samples was different in any exercised group. Only subjects in the Downhill groups experienced delayed onset of muscle soreness (DOMS) and increased serum creatine kinase activity (CK). The detected levels of immunohistochemical markers for T cells (CD3), granulocytes (CD11b), leukaemia inhibitory factor (LIF) and hypoxia-inducible factor 1beta (HIF-1beta) were greater in epimysium from exercised subjects with DOMS ratings >3 (0-10 scale) compared to exercised subjects without DOMS but not higher than controls. Eccentric physical exercise (downhill running) did not result in skeletal muscle inflammation 48 h post exercise, despite DOMS and increased CK. It is suggested that exercise can induce DOMS by activating inflammatory factors present in the epimysium before exercise. Repeated physical training may alter the content of inflammatory factors in the epimysium and thus reduce DOMS.","['Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. Christer.malm@anatomy.umu.se']",20040206,,,,,,,,,
14766899,NLM,MEDLINE,20040610,20210206,0021-9258 (Print) 0021-9258 (Linking),279,18,2004 Apr 30,Cytoprotective effect of glucosylceramide synthase inhibition against daunorubicin-induced apoptosis in human leukemic cell lines.,18256-61,"['Grazide, Solene', 'Terrisse, Anne-Dominique', 'Lerouge, Sandra', 'Laurent, Guy', 'Jaffrezou, Jean-Pierre']","['Grazide S', 'Terrisse AD', 'Lerouge S', 'Laurent G', 'Jaffrezou JP']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,J Biol Chem,The Journal of biological chemistry,2985121R,"['0 (Antineoplastic Agents)', '0 (Enzyme Inhibitors)', '0 (Morpholines)', '0 (Protective Agents)', '04079A1RDZ (Cytarabine)', '73257-80-4 (RV 538)', 'EC 2.4.1.- (Glucosyltransferases)', 'EC 2.4.1.80 (ceramide glucosyltransferase)', 'ZS7284E0ZP (Daunorubicin)']",IM,"['Antineoplastic Agents/pharmacology', 'Apoptosis/*drug effects', 'Cell Line, Tumor', 'Cytarabine/pharmacology', 'Daunorubicin/*pharmacology', '*Drug Resistance, Neoplasm', 'Enzyme Inhibitors/pharmacology', 'Glucosyltransferases/*antagonists & inhibitors', 'Glycosylation', 'HL-60 Cells', 'Humans', 'Leukemia, Myeloid/*pathology', 'Morpholines/pharmacology', 'Protective Agents/pharmacology', 'U937 Cells']",,,,2004/02/10 05:00,2004/06/21 10:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/06/21 10:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,J Biol Chem. 2004 Apr 30;279(18):18256-61. doi: 10.1074/jbc.M314105200. Epub 2004 Feb 6.,"['10.1074/jbc.M314105200 [doi]', 'S0021-9258(19)75371-X [pii]']",,"Several studies have shown that ceramide (CER) glucosylation contributes to drug resistance in multidrug-resistant cells and that inhibition of glucosylceramide synthase sensitizes cells to various drug treatments. However, the role of glucosylceramide synthase has not been studied in drug-sensitive cancer cells. We have demonstrated previously that the anthracycline daunorubicin (DNR) rapidly induces interphasic apoptosis through neutral sphingomyelinase-mediated CER generation in human leukemic cell lines. We now report that inhibition of glucosylceramide synthase using d,l-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) or 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) protected U937 and HL-60 cells from DNR-induced apoptosis. Moreover, blocking CER glucosylation did not lead to increased CER levels but to increased CER galactosylation. We also observed that pretreating cells with galactosylceramide (GalCER) significantly inhibited DNR-induced apoptosis. Finally, we show that GalCER-enriched lymphoblast cells (Krabbe's disease) were significantly more resistant to DNR- and cytosine arabinoside-induced apoptosis as compared with normal lymphoblasts, whereas glucosylceramide-enriched cells (Gaucher's disease) were more sensitive. In conclusion, this study suggests that sphingomyelin-derived CER in itself is not a second messenger but rather a precursor of both an apoptosis second messenger (GD3) and an apoptosis ""protector"" (GalCER).","['INSERM U563-Centre de Physiopathologie Toulouse Purpan, Institut Claudius Regaud, Toulouse 31052, France.']",20040206,,,,,,,,,
14766732,NLM,MEDLINE,20041210,20151119,0006-3363 (Print) 0006-3363 (Linking),70,6,2004 Jun,Clonogenicity of human endometrial epithelial and stromal cells.,1738-50,"['Chan, Rachel W S', 'Schwab, Kjiana E', 'Gargett, Caroline E']","['Chan RW', 'Schwab KE', 'Gargett CE']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Biol Reprod,Biology of reproduction,0207224,"['0 (Biomarkers)', '0 (Culture Media)', '0 (Culture Media, Serum-Free)', '0 (Growth Substances)']",IM,"['Biomarkers/metabolism', 'Cell Differentiation', 'Clone Cells/cytology', 'Colony-Forming Units Assay', 'Culture Media', 'Culture Media, Serum-Free', 'Endometrium/*cytology/metabolism', 'Epithelial Cells/cytology/drug effects/metabolism', 'Female', 'Growth Substances/pharmacology', 'Humans', 'In Vitro Techniques', 'Phenotype', 'Stromal Cells/cytology/drug effects/metabolism']",,,,2004/02/10 05:00,2004/12/16 09:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/12/16 09:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,Biol Reprod. 2004 Jun;70(6):1738-50. doi: 10.1095/biolreprod.103.024109. Epub 2004 Feb 6.,"['10.1095/biolreprod.103.024109 [doi]', 'biolreprod.103.024109 [pii]']",,"The human endometrium regenerates from the lower basalis layer, a germinal compartment that persists after menstruation to give rise to the new upper functionalis layer. Because adult stem cells are present in tissues that undergo regeneration, we hypothesized that human endometrium contains small populations of epithelial and stromal stem cells responsible for cyclical regeneration of endometrial glands and stroma and that these cells would exhibit clonogenicity, a stem-cell property. The aims of this study were to determine 1) the clonogenic activity of human endometrial epithelial and stromal cells, 2) which growth factors support this clonogenic activity, and 3) determine the cellular phenotypes of the clones. Endometrial tissue was obtained from women undergoing hysterectomy. Purified single- cell suspensions of epithelial and stromal cells were cultured at cloning density (300-500/cm(2)) in serum medium or in serum- free medium supplemented with one of eight growth factors. Small numbers of epithelial (0.22%) and stromal cells (1.25%) initiated colonies in serum-containing medium. The majority of colonies were small, containing large, loosely arranged cells, and 37% of epithelial and 1 in 60 of stromal colonies were classified as large, comprising small, densely packed cells. In serum-free medium, transforming growth factor-alpha (TGF alpha), epidermal growth factor (EGF), platelet-derived growth factor-BB (PDGF-BB) strongly supported clonogenicity of epithelial cells, while leukemia-inhibitory factor (LIF), hepatocyte growth factor (HGF), stem-cell factor (SCF), insulin-like growth factor-I (IGF- I) were weakly supportive, and basic fibroblast growth factor (bFGF) was without effect. TGF alpha, EGF, PDGF-BB, and bFGF supported stromal cell clonogenicity, while HGF, SCF, LIF, and IGF- I were without effect. Small epithelial colonies expressed three epithelial markers but not stromal markers; however, large epithelial colonies showed little reactivity for all markers except alpha(6)-integrin. All stromal colonies contained fibroblasts, expressing stromal markers, and in some colonies, myofibroblasts were also identified. This analysis of human endometrium has demonstrated the presence of rare clonogenic epithelial and stromal cells with high proliferative potential, providing the first evidence for the existence of putative endometrial epithelial and stromal stem cells.","[""Centre for Women's Health Research, Monash University Department of Obstetrics and Gynaecology, Monash Medical Centre, Clayton, Victoria 3168, Australia.""]",20040206,,,,,,,,,
14766128,NLM,MEDLINE,20040310,20071115,0305-7372 (Print) 0305-7372 (Linking),30,1,2004 Feb,Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life.,103-17,"['Redaelli, Alberto', 'Stephens, Jennifer M', 'Brandt, Suzanne', 'Botteman, Marc F', 'Pashos, Chris L']","['Redaelli A', 'Stephens JM', 'Brandt S', 'Botteman MF', 'Pashos CL']",['eng'],"['Comparative Study', 'Journal Article', 'Review']",,Netherlands,Cancer Treat Rev,Cancer treatment reviews,7502030,,IM,"['Adolescent', 'Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Bone Marrow Transplantation/adverse effects/methods', 'Combined Modality Therapy', 'Female', 'Humans', 'Leukemia, Myeloid, Acute/*diagnosis/*therapy', 'Male', 'Middle Aged', 'Prognosis', '*Quality of Life', 'Risk Assessment', 'Severity of Illness Index', 'Sickness Impact Profile', 'Time', 'Time Factors']",,,,2004/02/10 05:00,2004/03/11 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/03/11 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,Cancer Treat Rev. 2004 Feb;30(1):103-17. doi: 10.1016/S0305-7372(03)00142-7.,"['10.1016/S0305-7372(03)00142-7 [doi]', 'S0305737203001427 [pii]']",,"OBJECTIVES: Patients with acute myeloid leukemia (AML) may receive aggressive therapies (e.g., chemotherapy and bone marrow transplantation (BMT)) that are thought to significantly affect HRQL. Therefore, the goal of this study was to assess the HRQL impact on patients of AML and its treatments. MATERIALS AND METHODS: An electronically assisted literature survey and synthesis was conducted of English-language literature published worldwide between 1990 and 2002. The review was enhanced by inclusion of articles, including those published before 1990, which were manually identified from the bibliographies of the electronically identified publications. Articles were analyzed with respect to HRQL instruments used, HRQL domains assessed, aspects of disease and treatment evaluated, and outcomes observed. RESULTS: The survey identified 21 articles that warranted review. AML and associated treatments have a substantial negative impact on patient HRQL as has been measured by several different leukemia-specific, cancer-specific and generic instruments. The most negative HRQL burden is apparent soon after the diagnosis of the disease and during the course of therapy. Long-term survivors appear to recover HRQL almost completely with respect to physical, psychological and emotional well being, but incur continued sexual dysfunction. CONCLUSION: Clinicians responsible for the care of patients with AML should be aware of the HRQL impact of the disease and its treatment, in the long-term as well as the short-term. Researchers should evaluate the HRQL impact of new and investigational therapies.","['Global Outcomes Research-Oncology, Pharmacia Corporation, Via Robert Koch 1.2, Milan 20152, Italy. alberto.redaelli@pharmacia.com']",,,21,,,,,,,
14766125,NLM,MEDLINE,20040310,20071115,0305-7372 (Print) 0305-7372 (Linking),30,1,2004 Feb,Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?,37-51,"['Plasschaert, Sabine L A', 'Kamps, Willem A', 'Vellenga, Edo', 'de Vries, Elisabeth G E', 'de Bont, Eveline S J M']","['Plasschaert SL', 'Kamps WA', 'Vellenga E', 'de Vries EG', 'de Bont ES']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']",,Netherlands,Cancer Treat Rev,Cancer treatment reviews,7502030,,IM,"['Adolescent', 'Adult', 'Age Distribution', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Biopsy, Needle', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Immunohistochemistry', 'Male', 'Netherlands/epidemiology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis/*drug therapy/*epidemiology', 'Prevalence', 'Prognosis', 'Randomized Controlled Trials as Topic', 'Risk Factors', 'Sex Distribution', 'Survival Analysis']",,,,2004/02/10 05:00,2004/03/11 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/03/11 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,Cancer Treat Rev. 2004 Feb;30(1):37-51. doi: 10.1016/S0305-7372(03)00140-3.,"['10.1016/S0305-7372(03)00140-3 [doi]', 'S0305737203001403 [pii]']",,"Acute lymphoblastic leukaemia (ALL) is a disease diagnosed in children as well as adults. Progress in the treatment of ALL has led to better survival rates, however, children have benefited more from improved treatment modalities than adults. Recent evidence has underscored that the difference in characteristics and biology of adult versus childhood ALL might be the result of a different origin. According to the two-hit paradigm of Knudson, to develop cancer two genetic events are necessary. It has been suggested, that in childhood ALL the first genetic event happens in the more mature lymphoid committed progenitor cells, whereas in adult ALL the first hit occurs in multipotent stem cells. This review compares patient characteristics, the extent of the disease, leukaemic cell characteristics and treatment between childhood and adult ALL. This is discussed in relation to the hypothesis that the maturation stage of the cells, from which the leukaemia arises, is responsible for the differential behaviour of adult and childhood ALL.","['Department of Paediatric Haematology and Oncology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, Netherlands.']",,,152,,,,,,,
14766066,NLM,MEDLINE,20040408,20061115,0412-4081 (Print) 0412-4081 (Linking),39,11,2003 Nov,[Dry eye in graft-versus-host disease].,686-90,"['Fei, Wen-lei', 'Chen, Jia-qi', 'Du, Xin', 'Liu, Yan-hui', 'Sun, Ming-xia', 'Lin, Jian-xian', 'Weng, Jian-yu', 'Luo, Tian-zhen', 'Yin, Dong-ming', 'Luo, Xiao-yang']","['Fei WL', 'Chen JQ', 'Du X', 'Liu YH', 'Sun MX', 'Lin JX', 'Weng JY', 'Luo TZ', 'Yin DM', 'Luo XY']",['chi'],"['English Abstract', 'Journal Article']",,China,Zhonghua Yan Ke Za Zhi,[Zhonghua yan ke za zhi] Chinese journal of ophthalmology,16210540R,,IM,"['Adult', 'Diagnosis, Differential', 'Dry Eye Syndromes/*etiology', 'Female', 'Graft vs Host Disease/*complications/pathology', 'Humans', 'Leukemia/*therapy', 'Male', 'Peripheral Blood Stem Cell Transplantation/*adverse effects', 'Transplantation, Homologous']",,,,2004/02/10 05:00,2004/04/09 05:00,['2004/02/10 05:00'],"['2004/02/10 05:00 [pubmed]', '2004/04/09 05:00 [medline]', '2004/02/10 05:00 [entrez]']",ppublish,Zhonghua Yan Ke Za Zhi. 2003 Nov;39(11):686-90.,,,"OBJECTIVE: To investigate patients who had ocular presentations after allogeneic hematopoietic stem cell transplantation. METHODS: The eyes of 20 patients of leukemia who had undergone allogeneic hematopoietic stem cell transplantation were examined. The ocular surface of these patients was examined by slit-lamp. The eye examination also included evaluation of tear break-up time, Schirmer tests with and without nasal stimulation, and fluorescein staining, rose bengal staining, etc. Conjunctival impression cytology and pathological examination of surgical specimens from 3 patients were performed. RESULTS: Fourteen of 20 patients developed chronic graft-versus-host disease (cGVHD). Eight patients suffered from dry eye accompanied by GVHD simultaneously. The incidence of dry eye in GVHD was 57%. Among them, 4 cases were severe dry eye associated with significant decrease of visual acuity and even development of corneal ulcer. Ophthalmic pathology findings were as follows: loss of conjunctival goblet cells or significant reduction in amount; conjunctival and corneal epithelial keratinization and squamous metaplasia; and dominance of T cell in conjunctival inflammatory infiltration cells. CONCLUSION: Dry eye is the major ocular complication after allogeneic hematopoietic stem cell transplantation. It affected the patients' life quality severely. The high incidence and potentially severe ocular problems in these patients suggest that close ophthalmic monitoring is important in allogeneic hematopoietic stem cell transplantation.","['Zhongshan Ophthalmic Center, Zhongshan University, Guangzhou 510060, China.']",,,,,,,,,,
14764878,NLM,MEDLINE,20040304,20190605,1095-9203 (Electronic) 0036-8075 (Linking),303,5659,2004 Feb 6,Genome-wide RNAi analysis of growth and viability in Drosophila cells.,832-5,"['Boutros, Michael', 'Kiger, Amy A', 'Armknecht, Susan', 'Kerr, Kim', 'Hild, Marc', 'Koch, Britta', 'Haas, Stefan A', 'Paro, Renato', 'Perrimon, Norbert']","['Boutros M', 'Kiger AA', 'Armknecht S', 'Kerr K', 'Hild M', 'Koch B', 'Haas SA', 'Paro R', 'Perrimon N']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Science,"Science (New York, N.Y.)",0404511,"['0 (Core Binding Factor Alpha 2 Subunit)', '0 (DIAP1 protein, Drosophila)', '0 (DNA-Binding Proteins)', '0 (Drosophila Proteins)', '0 (Inhibitor of Apoptosis Proteins)', '0 (Proteome)', '0 (Proto-Oncogene Proteins)', '0 (RNA, Double-Stranded)', '0 (RUNX1 protein, human)', '0 (Transcription Factors)']",IM,"['Animals', 'Apoptosis', 'Cell Cycle', 'Cell Survival', 'Cells, Cultured', 'Computational Biology', 'Core Binding Factor Alpha 2 Subunit', 'DNA-Binding Proteins/genetics', 'Drosophila Proteins/genetics/metabolism/physiology', 'Drosophila melanogaster/*genetics/*growth & development', 'Genes, Essential', '*Genes, Insect', '*Genome', 'Humans', 'Inhibitor of Apoptosis Proteins', 'Phenotype', 'Proteome', 'Proto-Oncogene Proteins/genetics', '*RNA Interference', 'RNA, Double-Stranded/genetics', 'Reproducibility of Results', 'Sequence Homology', 'Transcription Factors/genetics/metabolism']",,,,2004/02/07 05:00,2004/03/05 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/03/05 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Science. 2004 Feb 6;303(5659):832-5. doi: 10.1126/science.1091266.,"['10.1126/science.1091266 [doi]', '303/5659/832 [pii]']",,"A crucial aim upon completion of whole genome sequences is the functional analysis of all predicted genes. We have applied a high-throughput RNA-interference (RNAi) screen of 19,470 double-stranded (ds) RNAs in cultured cells to characterize the function of nearly all (91%) predicted Drosophila genes in cell growth and viability. We found 438 dsRNAs that identified essential genes, among which 80% lacked mutant alleles. A quantitative assay of cell number was applied to identify genes of known and uncharacterized functions. In particular, we demonstrate a role for the homolog of a mammalian acute myeloid leukemia gene (AML1) in cell survival. Such a systematic screen for cell phenotypes, such as cell viability, can thus be effective in characterizing functionally related genes on a genome-wide scale.","['Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.']",,['R01 GM078176/GM/NIGMS NIH HHS/United States'],,,,,,['Heidelberg Fly Array Consortium'],,
14764729,NLM,MEDLINE,20040615,20211203,0022-1767 (Print) 0022-1767 (Linking),172,4,2004 Feb 15,Microtubule-associated serine/threonine kinase-205 kDa and Fc gamma receptor control IL-12 p40 synthesis and NF-kappa B activation.,2559-68,"['Zhou, Hui', 'Xiong, Huabao', 'Li, Hongxing', 'Plevy, Scott E', 'Walden, Paul D', 'Sassaroli, Massimo', 'Prestwich, Glenn D', 'Unkeless, Jay C']","['Zhou H', 'Xiong H', 'Li H', 'Plevy SE', 'Walden PD', 'Sassaroli M', 'Prestwich GD', 'Unkeless JC']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,J Immunol,"Journal of immunology (Baltimore, Md. : 1950)",2985117R,"['0 (Antigens, CD)', '0 (Fc gamma receptor IIA)', '0 (Interleukin-12 Subunit p40)', '0 (Ligands)', '0 (Lipopolysaccharides)', '0 (Microtubule-Associated Proteins)', '0 (Mtssk protein, mouse)', '0 (NF-kappa B)', '0 (Protein Subunits)', '0 (Receptors, IgG)', '187348-17-0 (Interleukin-12)', 'EC 2.7.11.1 (Protein Serine-Threonine Kinases)']",IM,"['Animals', 'Antigens, CD/immunology/metabolism', 'Cell Line, Tumor', 'Cells, Cultured', 'Interleukin-12/antagonists & inhibitors/*biosynthesis', 'Interleukin-12 Subunit p40', 'Leukemia P388', 'Ligands', 'Lipopolysaccharides/antagonists & inhibitors/pharmacology', 'Macrophages, Peritoneal/enzymology/immunology/metabolism', 'Mice', 'Mice, Inbred C57BL', 'Microtubule-Associated Proteins/biosynthesis/genetics/isolation & purification/*physiology', 'NF-kappa B/antagonists & inhibitors/*metabolism', 'Protein Serine-Threonine Kinases/biosynthesis/genetics/isolation & purification/*physiology', 'Protein Subunits/antagonists & inhibitors/*biosynthesis', 'RNA Interference/immunology', 'Receptors, IgG/immunology/metabolism/*physiology']",,,,2004/02/07 05:00,2004/06/16 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/06/16 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,J Immunol. 2004 Feb 15;172(4):2559-68. doi: 10.4049/jimmunol.172.4.2559.,['10.4049/jimmunol.172.4.2559 [doi]'],,"Stimulation of murine macrophages with LPS results in the coordinated activation of a set of proinflammatory cytokines and costimulatory molecules, including TNF-alpha, IL-6, IL-1, IL-8, IL-12, and CD80. Macrophage LPS-induced synthesis of IL-12 is inhibited following FcgammaR ligation; TNF-alpha secretion is unchanged. We report that microtubule-associated serine/threonine kinase-205 kDa (MAST205) is required for LPS-induced IL-12 synthesis. RNA interference-mediated suppression of MAST205 results in the inhibition of LPS-stimulated IL-12 promoter activity and IL-12 secretion, from both J774 cells and bone marrow-derived macrophages. Similarly, dominant-negative MAST205 mutants inhibit LPS-stimulated IL-12 synthesis and NF-kappaB activation, but do not affect IL-1 or TNF-alpha signaling. Finally, macrophage FcgammaR ligation regulates MAST205 by inducing the rapid ubiquitination and proteasomal degradation of the protein.","['Immunobiology Center and Department of Physiology and Biophysics, Mount Sinai School of Medicine, New York, NY 10029, USA.']",,"['AI-24322/AI/NIAID NIH HHS/United States', 'AI-52325/AI/NIAID NIH HHS/United States', 'NS-29632/NS/NINDS NIH HHS/United States']",,,,,,,,
14764709,NLM,MEDLINE,20040615,20191210,0022-1767 (Print) 0022-1767 (Linking),172,4,2004 Feb 15,Activation/division of lymphocytes results in increased levels of cytoplasmic activation/proliferation-associated protein-1: prototype of a new family of proteins.,2389-400,"['Grill, Brock', 'Wilson, Gary M', 'Zhang, Kai-Xin', 'Wang, Bin', 'Doyonnas, Regis', 'Quadroni, Manfredo', 'Schrader, John W']","['Grill B', 'Wilson GM', 'Zhang KX', 'Wang B', 'Doyonnas R', 'Quadroni M', 'Schrader JW']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,J Immunol,"Journal of immunology (Baltimore, Md. : 1950)",2985117R,"['0 (CAPRIN1 protein, Xenopus)', '0 (CAPRIN1 protein, human)', '0 (CAPRIN2 protein, human)', '0 (Caprin1 protein, mouse)', '0 (Cell Cycle Proteins)', '0 (Growth Inhibitors)', '0 (Growth Substances)', '0 (Insect Proteins)', '0 (Luminescent Proteins)', '0 (Phosphoproteins)', '0 (RNA-Binding Proteins)', '0 (Xenopus Proteins)', '147336-22-9 (Green Fluorescent Proteins)']",IM,"['Amino Acid Sequence', 'Animals', 'B-Lymphocytes/*cytology/*immunology/metabolism', 'Cell Cycle Proteins/*biosynthesis/chemistry/genetics', 'Cell Differentiation/immunology', 'Cell Division/immunology', 'Cell Line', 'Cell Line, Tumor', 'Conserved Sequence', 'Cytoplasm/immunology/metabolism', 'Green Fluorescent Proteins', 'Growth Inhibitors/chemistry', 'Growth Substances/deficiency', 'Hematopoiesis', 'Humans', 'Insect Proteins/chemistry', 'Luminescent Proteins/genetics', '*Lymphocyte Activation', 'Lymphopoiesis', 'Mice', 'Mice, Inbred C57BL', 'Mice, Inbred CBA', 'Molecular Sequence Data', 'Molecular Weight', 'NIH 3T3 Cells', 'Organ Specificity/immunology', 'Phosphoproteins/biosynthesis/*chemistry/genetics', 'Protein Structure, Tertiary', 'RNA-Binding Proteins', '*Sequence Homology, Amino Acid', 'T-Lymphocytes/*cytology/*immunology/metabolism', 'Up-Regulation/immunology', 'Xenopus Proteins/*biosynthesis/chemistry/genetics']",,,,2004/02/07 05:00,2004/06/16 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/06/16 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,J Immunol. 2004 Feb 15;172(4):2389-400. doi: 10.4049/jimmunol.172.4.2389.,['10.4049/jimmunol.172.4.2389 [doi]'],,"We purified from activated T lymphocytes a novel, highly conserved, 116-kDa, intracellular protein that occurred at high levels in the large, dividing cells of the thymus, was up-regulated when resting T or B lymphocytes or hemopoietic progenitors were activated, and was down-regulated when a monocytic leukemia, M1, was induced to differentiate. Expression of the protein was highest in the thymus and spleen and lowest in tissues with a low proportion of dividing cells such as kidney or muscle, although expression was high in the brain. The protein was localized to the cytosol and was phosphorylated, which is consistent with a previous report that the Xenopus laevis ortholog was phosphorylated by a mitotically activated kinase (1 ). The cDNA was previously mischaracterized as encoding p137, a 137-kDa GPI-linked membrane protein (2 ). We propose that the authentic protein encoded by this cDNA be called cytoplasmic activation/proliferation-associated protein-1 (caprin-1), and show that it is the prototype of a novel family of proteins characterized by two novel protein domains, termed homology regions-1 and -2 (HR-1, HR-2). Although we have found evidence for caprins only in urochordates and vertebrates, two insect proteins exhibit well-conserved HR-1 domains. The HR-1 and HR-2 domains have no known function, although the HR-1 of caprin-1 appeared necessary for formation of multimeric complexes of caprin-1. Overexpression of a fusion protein of enhanced green fluorescent protein and caprin-1 induced a specific, dose-dependent suppression of the proliferation of NIH-3T3 cells, consistent with the notion that caprin-1 plays a role in cellular activation or proliferation.","['The Biomedical Research Centre, University of British Columbia, Vancouver, British Columbia, Canada.']",,,,,,,,,"['GENBANK/BK001103', 'GENBANK/BK001104', 'GENBANK/BK001105', 'GENBANK/BK001106']",
14764674,NLM,MEDLINE,20040615,20190516,0022-1767 (Print) 0022-1767 (Linking),172,4,2004 Feb 15,Transgenic expression of a human polyreactive Ig expressed in chronic lymphocytic leukemia generates memory-type B cells that respond to nonspecific immune activation.,2092-9,"['Widhopf, George F 2nd', 'Brinson, Diana C', 'Kipps, Thomas J', 'Tighe, Helen']","['Widhopf GF 2nd', 'Brinson DC', 'Kipps TJ', 'Tighe H']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,J Immunol,"Journal of immunology (Baltimore, Md. : 1950)",2985117R,"['0 (Immunoglobulin M)', '0 (Immunoglobulin kappa-Chains)', '0 (Ligands)', '0 (Receptors, Antigen, B-Cell)', '9009-79-4 (Rheumatoid Factor)']",IM,"['Animals', 'Antibody Formation/genetics', 'Arterioles/cytology/immunology/metabolism', 'B-Lymphocyte Subsets/cytology/*immunology/metabolism', 'Female', 'Humans', 'Immunoglobulin M/*biosynthesis/*genetics', 'Immunoglobulin kappa-Chains/biosynthesis/genetics', '*Immunologic Memory/genetics', 'Immunophenotyping', 'Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/*immunology', 'Ligands', '*Lymphocyte Activation/genetics', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Mice, Transgenic', 'Peritoneum/cytology/immunology/metabolism', 'Receptors, Antigen, B-Cell/genetics/immunology/metabolism', 'Rheumatoid Factor/biosynthesis/genetics', 'Spleen/blood supply/cytology/immunology/metabolism', 'T-Lymphocytes, Helper-Inducer/immunology', 'Transgenes/*immunology']",,,,2004/02/07 05:00,2004/06/16 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/06/16 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,J Immunol. 2004 Feb 15;172(4):2092-9. doi: 10.4049/jimmunol.172.4.2092.,['10.4049/jimmunol.172.4.2092 [doi]'],,"We generated transgenic mice, designated SMI, expressing unmutated H and L chain Ig genes encoding a low-affinity, polyreactive human (h)IgM/kappa rheumatoid factor. These animals were compared with control AB29 transgenic mice expressing a hIgM/kappa rheumatoid factor specific for human IgG, with no detectable reactivity with mouse proteins. SMI B cells expressed significantly lower levels of surface hIgM/kappa than did the B cells of AB29 mice, but still could be induced to proliferate by surface Ig cross-linking in vitro and could be deleted with anti-Id mAb in vivo. Transgene-expressing B cells of AB29 mice had a B-2 phenotype and were located in the primary follicle. In contrast, a relatively high proportion of hIgM-expressing B cells of SMI mice had the phenotype of B-1 B cells in the peritoneum or marginal zone B cells in the spleen, where they were located in the periarteriolar sheath, marginal zone, and interfollicular areas that typically are populated by memory-type B cells. Although the relative proportions of transgene-expressing B cells in both types of transgenic mice declined with aging, SMI mice experienced progressive increases in the serum levels of IgM transgene protein over time. Finally, SMI transgene-expressing B cells, but not AB29 transgene-expressing B cells, were induced to secrete Ab when cultured with alloreactive T cells. These results indicate that expression of polyreactive autoantibodies can allow for development of B cells that are neither deleted nor rendered anergic, but instead have a phenotype of memory-type or Ag-experienced B cells that respond to nonspecific immune activation.","['Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.']",,['R3749870/PHS HHS/United States'],,,,,,,,
14764605,NLM,MEDLINE,20040722,20210206,0021-9258 (Print) 0021-9258 (Linking),279,16,2004 Apr 16,"PDX1, a cellular homeoprotein, binds to and regulates the activity of human cytomegalovirus immediate early promoter.",16111-20,"['Chao, Sheng-Hao', 'Harada, Josephine N', 'Hyndman, Francie', 'Gao, Xiaoqi', 'Nelson, Christian G', 'Chanda, Sumit K', 'Caldwell, Jeremy S']","['Chao SH', 'Harada JN', 'Hyndman F', 'Gao X', 'Nelson CG', 'Chanda SK', 'Caldwell JS']",['eng'],['Journal Article'],,United States,J Biol Chem,The Journal of biological chemistry,2985121R,"['0 (Antigens, Viral)', '0 (Homeodomain Proteins)', '0 (Immediate-Early Proteins)', '0 (PKNOX1 protein, human)', '0 (Pknox1 protein, mouse)', '0 (Trans-Activators)', '0 (immediate-early proteins, cytomegalovirus)', '0 (pancreatic and duodenal homeobox 1 protein)']",IM,"['Animals', 'Antigens, Viral/*genetics/metabolism', 'Base Sequence', 'Cell Line', 'Cytomegalovirus/genetics/metabolism', 'Gene Expression Regulation, Viral', 'Homeodomain Proteins/*genetics/metabolism', 'Humans', 'Immediate-Early Proteins/*genetics/metabolism', 'Mice', 'Molecular Sequence Data', 'Promoter Regions, Genetic/*genetics', 'Protein Binding', 'Trans-Activators/*genetics/metabolism', 'Transcriptional Activation']",,,,2004/02/07 05:00,2004/07/23 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/07/23 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,J Biol Chem. 2004 Apr 16;279(16):16111-20. doi: 10.1074/jbc.M312304200. Epub 2004 Feb 5.,"['10.1074/jbc.M312304200 [doi]', 'S0021-9258(20)88331-8 [pii]']",,"Cellular homeoproteins have been shown to regulate the transcription of several viruses, including herpes simplex viruses, human papillomaviruses, and mouse mammary tumor viruses. Previous studies investigating the anti-viral mechanisms of several cyclin-dependent kinase inhibitors showed that the homeoproteins, pre B-cell leukemia transcription factor 1 (PBX1) and PBX-regulating protein-1 (PREP1), function as transcriptional activators of Moloney murine leukemia virus. Here, we examined the involvement of cellular homeoproteins in regulating the activity of the human cytomegalovirus immediate early (CMV IE) promoter. We identified a 45-bp element located at position -593 to -549 upstream of the transcription start site of the CMV IE gene, which contains multiple putative homeoprotein binding motifs. Gel shift assays demonstrated the physical association between a homeodomain protein, pancreatic-duodenal homeobox factor-1 (PDX1) and the 45-bp cytomegalovirus (CMV) region. We further determined that PDX1 represses the CMV IE promoter activity in 293 cells. Overexpression of PDX1 resulted in a decrease in transcription of the CMV IE gene. Conversely, blocking PDX1 protein synthesis and mutating the PDX1 binding sites enhanced CMV IE-dependent transcription. Collectively, our results represent the first work demonstrating that a cellular homeoprotein, PDX1, may be a repressor involved in regulation of human CMV gene expression.","['Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, USA.']",20040205,,,,,,,,,
14764538,NLM,MEDLINE,20040625,20210206,0006-4971 (Print) 0006-4971 (Linking),103,10,2004 May 15,Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts.,3982-5,"['Lang, Peter', 'Barbin, Karin', 'Feuchtinger, Tobias', 'Greil, Johann', 'Peipp, Matthias', 'Zunino, Susan J', 'Pfeiffer, Matthias', 'Handgretinger, Rupert', 'Niethammer, Dietrich', 'Fey, Georg H']","['Lang P', 'Barbin K', 'Feuchtinger T', 'Greil J', 'Peipp M', 'Zunino SJ', 'Pfeiffer M', 'Handgretinger R', 'Niethammer D', 'Fey GH']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Blood,Blood,7603509,"['0 (Antibodies)', '0 (Antigens, CD19)', '0 (Recombinant Fusion Proteins)']",IM,"['Antibodies/*pharmacology', 'Antibody-Dependent Cell Cytotoxicity/*drug effects', 'Antigens, CD19/*immunology', 'Child', 'Cytotoxicity Tests, Immunologic', 'Humans', 'Killer Cells, Natural/immunology/transplantation', 'Lymphocyte Depletion', 'Peripheral Blood Stem Cell Transplantation/*methods', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology/*therapy', 'Recombinant Fusion Proteins/biosynthesis/pharmacology', 'T-Lymphocytes, Regulatory/*immunology', 'Transplantation, Homologous']",,,,2004/02/07 05:00,2004/06/26 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/06/26 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Blood. 2004 May 15;103(10):3982-5. doi: 10.1182/blood-2003-05-1735. Epub 2004 Feb 5.,"['10.1182/blood-2003-05-1735 [doi]', 'S0006-4971(20)43691-2 [pii]']",,"Relapse is a major problem after transplantation in children with acute B-lineage leukemias, and new therapies are needed to increase graft-versus-leukemia (GvL) effects without inducing graft-versus-host disease (GvHD). Here, we studied the ability of effector cells recovered from patients after transplantation with positive-selected stem cells from alternative donors to induce antibody-dependent cellular cytotoxicity (ADCC). For this purpose, a chimeric CD19 antibody, CD19-4G7chim, was generated. This antibody efficiently mediated ADCC against primary acute lymphoblastic leukemia (ALL) blasts by using purified natural killer (NK) cells from healthy donors or mononuclear cells from patients as effector cells. Increased lysis was obtained after stimulation of effector cells with interleukin-2 (IL-2). ADCC was not prevented by inhibitory effects mediated by HLA class I. We propose that treatment with chimeric CD19 antibodies leading to ADCC by donor-derived NK cells may become a therapeutic option for the post-transplantation treatment of minimal residual B-lineage ALLs.","[""Department of Pediatric Oncology, University Children's Hospital, University of Tubingen, Tubingen, Germany. prlang@med.uni-tuebingen.de""]",20040205,,,,,,,,,
14764536,NLM,MEDLINE,20040625,20210206,0006-4971 (Print) 0006-4971 (Linking),103,10,2004 May 15,Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.,3905-14,"['Liem, Natalia L M', 'Papa, Rachael A', 'Milross, Christopher G', 'Schmid, Michael A', 'Tajbakhsh, Mayamin', 'Choi, Seoyeon', 'Ramirez, Carole D', 'Rice, Alison M', 'Haber, Michelle', 'Norris, Murray D', 'MacKenzie, Karen L', 'Lock, Richard B']","['Liem NL', 'Papa RA', 'Milross CG', 'Schmid MA', 'Tajbakhsh M', 'Choi S', 'Ramirez CD', 'Rice AM', 'Haber M', 'Norris MD', 'MacKenzie KL', 'Lock RB']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Blood,Blood,7603509,"['0 (Antineoplastic Agents)', '5J49Q6B70F (Vincristine)', '7S5I7G3JQL (Dexamethasone)', 'YL5FZ2Y5U1 (Methotrexate)']",IM,"['Adolescent', 'Animals', 'Antineoplastic Agents/*pharmacology/therapeutic use', 'Child', 'Child, Preschool', 'Dexamethasone/pharmacology/therapeutic use', '*Disease Models, Animal', 'Drug Evaluation, Preclinical', 'Female', 'Gene Rearrangement, T-Lymphocyte', 'Genes, Immunoglobulin', 'Humans', 'Immunophenotyping', 'Male', 'Methotrexate/pharmacology/therapeutic use', 'Mice', 'Mice, SCID', 'Neoplasm Transplantation', 'Neoplasms, Experimental/drug therapy', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/*pathology', '*Transplantation, Heterologous', 'Treatment Outcome', 'Vincristine/pharmacology/therapeutic use']",,,,2004/02/07 05:00,2004/06/26 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/06/26 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Blood. 2004 May 15;103(10):3905-14. doi: 10.1182/blood-2003-08-2911. Epub 2004 Feb 5.,"['10.1182/blood-2003-08-2911 [doi]', 'S0006-4971(20)43680-8 [pii]']",,"Continuous xenografts from 10 children with acute lymphoblastic leukemia (ALL) were established in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Relative to primary engrafted cells, negligible changes in growth rates and immunophenotype were observed at second and third passage. Analysis of clonal antigen receptor gene rearrangements in 2 xenografts from patients at diagnosis showed that the pattern of clonal variation observed following tertiary transplantation in mice exactly reflected that in bone marrow samples at the time of clinical relapse. Patients experienced diverse treatment outcomes, including 5 who died of disease (median, 13 months; range, 11-76 months, from date of diagnosis), and 5 who remain alive (median, 103 months; range, 56-131 months, following diagnosis). When stratified according to patient outcome, the in vivo sensitivity of xenografts to vincristine and dexamethasone, but not methotrexate, differed significantly (P =.028, P =.029, and P =.56, respectively). The in vitro sensitivity of xenografts to dexamethasone, but not vincristine, correlated significantly with in vivo responses and patient outcome. This study shows, for the first time, that the biologic and genetic characteristics, and patterns of chemosensitivity, of childhood ALL xenografts accurately reflect the clinical disease. As such, they provide powerful experimental models to prioritize new therapeutic strategies for future clinical trials.","[""Children's Cancer Institute Australia for Medical Research, Sydney, Australia.""]",20040205,,,,,,,,,
14764532,NLM,MEDLINE,20040625,20210206,0006-4971 (Print) 0006-4971 (Linking),103,10,2004 May 15,Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity.,3970-8,"['Zhang, Yi', 'Joe, Gerard', 'Zhu, Jiang', 'Carroll, Richard', 'Levine, Bruce', 'Hexner, Elizabeth', 'June, Carl', 'Emerson, Stephen G']","['Zhang Y', 'Joe G', 'Zhu J', 'Carroll R', 'Levine B', 'Hexner E', 'June C', 'Emerson SG']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Blood,Blood,7603509,"['0 (Hyaluronan Receptors)', '0 (fas Receptor)']",IM,"['Acute Disease', 'Animals', 'Antigen Presentation/*immunology', 'Bone Marrow Transplantation/immunology/methods', 'CD8-Positive T-Lymphocytes/*immunology', 'Cytotoxicity, Immunologic', 'Dendritic Cells/*immunology', 'Graft vs Host Disease/etiology/immunology/*prevention & control', 'Graft vs Leukemia Effect/immunology', '*Hyaluronan Receptors', 'Lymphocyte Depletion/methods', 'Mice', 'Mice, Inbred Strains', 'T-Lymphocyte Subsets/immunology', 'fas Receptor']",,,,2004/02/07 05:00,2004/06/26 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/06/26 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Blood. 2004 May 15;103(10):3970-8. doi: 10.1182/blood-2003-09-3135. Epub 2004 Feb 5.,"['10.1182/blood-2003-09-3135 [doi]', 'S0006-4971(20)43689-4 [pii]']",,"Graft versus host disease (GVHD) is triggered by host antigen-presenting cells (APCs) that activate donor T cells to proliferate and differentiate, but which APC-activated donor T-cell subsets mediate GVHD versus beneficial antitumor effects is not known. Using a CD8(+) T cell-dependent mouse model of human GVHD, we found that host dendritic cell (DC)-induced CD44(hi)CD8(+) effector/memory T cells were functionally defective in inducing GVHD, whereas CD44(lo)CD8(+) naive phenotype T cells were extremely potent GVHD inducers. Depletion of CD44(lo)CD8(+) T cells from host DC-stimulated T cells before transplantation prevented GVHD without impairing their antitumor activity in vivo. Compared with CD44(lo)CD8(+) T cells, CD44(hi)CD8(+) T cells expressed high levels of Fas and were efficiently deleted in vivo following transplantation. These results suggest that ex vivo allogeneic DC stimulation of donor CD8(+) T cells may be useful for the prevention of GVHD and for optimizing antitumor therapies in vivo.","['Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.']",20040205,,,,,,,,,
14764521,NLM,MEDLINE,20040729,20210206,0006-4971 (Print) 0006-4971 (Linking),103,12,2004 Jun 15,Dynamics of cytokine expression in HIV productively infected primary CD4+ T cells.,4581-7,"['Bahbouhi, Bouchaib', 'Landay, Alan', 'Al-Harthi, Lena']","['Bahbouhi B', 'Landay A', 'Al-Harthi L']",['eng'],['Journal Article'],,United States,Blood,Blood,7603509,"['0 (Cytokines)', 'EC 2.7.1.- (Phosphatidylinositol 3-Kinases)']",IM,"['Apoptosis', 'CD4-Positive T-Lymphocytes/cytology/*immunology/*virology', 'Cytokines/*genetics', 'Flow Cytometry', 'Gene Expression Regulation/immunology', 'HIV-1/immunology/*physiology', 'Humans', 'Immunoassay', 'In Vitro Techniques', 'Phosphatidylinositol 3-Kinases/metabolism', 'Signal Transduction', 'Virus Replication']",,,,2004/02/07 05:00,2004/07/30 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/07/30 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Blood. 2004 Jun 15;103(12):4581-7. doi: 10.1182/blood-2003-12-4172. Epub 2004 Feb 5.,"['10.1182/blood-2003-12-4172 [doi]', 'S0006-4971(20)54580-1 [pii]']",,"Using intracellular p24 staining to discriminate between bystander and HIV productively infected cells, we evaluated the properties of HIV productively infected cells in terms of cytokine expression, activation status, apoptosis, and cell proliferation. We demonstrate that HIV productively infected primary CD4(+) T cells express 12- to 47-fold higher type 1 cytokines than bystander or mock-infected cells. The frequency of HIV productive replication occurred predominantly in T-helper 1 (Th1), followed by Th0, then by Th2 cells. These productively infected cells expressed elevated levels of CD95, CD25, CXC chemokine receptor 4 (CXCR4), and CC chemokine receptor 5 (CCR5). While productively infected cells were only 1.8-fold higher in apoptosis frequency, they up-regulated the antiapoptotic protein B-cell leukemia 2 (Bcl-2) by 10-fold. Up-regulation of interleukin-2 (IL-2) and Bcl-2 were dependent on phosphatidylinositol-3-kinase signal transduction, given that it was down-regulated by Wortmanin treatment. Additionally, 60% of productively infected cells entered the cell cycle, as evaluated by Ki67 staining, but none divided, as evaluated by carboxyfluoresccin diacetate succinimidyl ester (CFSE) staining. Evaluation of cell cycle progression by costaining for DNA and RNA indicated that the cells were arrested in G(2)/M. Collectively, these data indicate that HIV replication occurs predominantly in Th1 cells and is associated with immune activation and up-regulation of Bcl-2, conferring a considerable degree of protection against apoptosis in the productively infected subpopulation.","['Department of Immunology/Microbiology, Rush University Medical Center, 1653 W Congress Parkway, Chicago, IL 60612, USA.']",20040205,,,,,,,,,
14764263,NLM,MEDLINE,20040601,20071115,1022-386X (Print) 1022-386X (Linking),14,1,2004 Jan,Extradural Granulocytic sarcoma causing acute paraparesis.,45-7,"['Siddiqui, Arshad A', 'Rehman, Naim-ur']","['Siddiqui AA', 'Rehman NU']",['eng'],"['Case Reports', 'Journal Article']",,Pakistan,J Coll Physicians Surg Pak,Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,9606447,,IM,"['Child', 'Female', 'Humans', 'Leukemia, Myeloid, Acute/complications', 'Magnetic Resonance Imaging', 'Paraparesis/*etiology', 'Sarcoma, Myeloid/complications/*diagnosis', 'Spinal Cord Compression/*etiology', 'Spinal Neoplasms/complications/*diagnosis']",,,,2004/02/07 05:00,2004/06/02 05:00,['2004/02/07 05:00'],"['2003/09/19 00:00 [received]', '2003/11/17 00:00 [accepted]', '2004/02/07 05:00 [pubmed]', '2004/06/02 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,J Coll Physicians Surg Pak. 2004 Jan;14(1):45-7. doi: 11.2004/JCPSP.661662.,"['11.2004/JCPSP.661662 [doi]', '040579197 [pii]']",,A case of 9 years old female presenting with rapidly progressive paraparesis during remission phase of acute myeloblastic leukemia is reported. Radiological imaging revealed an extradural mass in the upper dorsal spine producing significant cord compression. The patient showed a dramatic neurological recovery after spinal cord decompression and subsequently treated with appropriate chemotherapy and local radiotherapy.,"['Department of Neurosurgery, The Aga Khan University Hospital, Karachi. doc4brains@yahoo.com']",,,,,,,,,,
14763433,NLM,MEDLINE,20040409,20150804,0014-6722 (Print) 0014-6722 (Linking),60,2,2003,"[Infection outbreak due to resistant Enterococcus faecium to glycopeptides in a Hospital of Rosario, Argentina].",55-9,"['All, Laura', 'Vera Blanch, Marcela', 'Mocarbel, Nicolas', 'Limansky, Alejandro M', 'Viale, Alejandro M', 'Notario, Rodolfo D']","['All L', 'Vera Blanch M', 'Mocarbel N', 'Limansky AM', 'Viale AM', 'Notario RD']",['spa'],"['Case Reports', 'English Abstract', 'Journal Article']","Brote de infeccion por Enterococcus faecium resistentes a glicopeptidos en un hospital de Rosario, Argentina.",Argentina,Rev Fac Cien Med Univ Nac Cordoba,"Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)",8303003,,IM,"['Aged', 'Argentina', 'Cross Infection/*microbiology', 'Disease Outbreaks', '*Drug Resistance, Multiple, Bacterial', 'Enterococcus faecium/drug effects/genetics/*isolation & purification', 'Female', 'Gram-Positive Bacterial Infections/epidemiology/*microbiology', 'Humans', 'Male', 'Microbial Sensitivity Tests', 'Middle Aged', 'Risk Factors', 'Vancomycin Resistance']",,,,2004/02/07 05:00,2004/04/10 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/04/10 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Rev Fac Cien Med Univ Nac Cordoba. 2003;60(2):55-9.,,,"Enterococci causes serious illness in immunocompromised patients and in severely ill, hospitalized patients. They are commonly isolated from the human gastrointestinal tract, and resistance to vancomycin has increased in frequency during the past few years. We report three cases of nosocomial vancomycin resistant Entrococcus faecium (VRE) infections from September to December of 2000. A 54-year-old man presented post surgical wound infection due to VRE after 2 months of hospitalization. The second is a 65-year-old neutropenic patient with a medical history of acute myeloid leukemia and esophageal carcinoma. In this case, central venous catheter was colonized with EVR. The third, a 65-year-old woman who received therapy with ceftriaxone, ciprofloxacin and clindamicin had a urinary tract infection due to EVR. The three isolates were resistant to vancomycin (MIC value > 256 micrograms/ml). The DNA amplification pattern obtained by OD-PCR were similar in the three cases.","['Facultad de Ciencias Medicas, Universidad Nacional de Rosario, Santa Fe 3100, 2000 Rosario, Argentina. lauraall@arnet.com.ar']",,,,,,,,,,
14763309,NLM,MEDLINE,20040224,20191210,0025-682X (Print) 0025-682X (Linking),63,4-5,2003,"[Epidemiology and prognosis of childhood cancers in Dakar, Senegal].",521-6,"['Ka, A S', 'Imbert, P', 'Moreira, C', 'Niang, A', 'Baujat, G', 'Seye, M N', 'Guyon, P']","['Ka AS', 'Imbert P', 'Moreira C', 'Niang A', 'Baujat G', 'Seye MN', 'Guyon P']",['fre'],['Journal Article'],"Epidemiologie et pronostic des affections malignes de l'enfant a Dakar, Senegal.",France,Med Trop (Mars),Medecine tropicale : revue du Corps de sante colonial,8710146,,IM,"['Adolescent', 'Child', 'Child, Preschool', '*Developing Countries', 'Female', 'Humans', 'Incidence', 'Infant', 'Infant, Newborn', 'Infections', 'Male', 'Malnutrition', 'Neoplasms/*epidemiology/pathology/*therapy', 'Patient Admission/statistics & numerical data', 'Prognosis', 'Recurrence', 'Retrospective Studies', 'Senegal', 'Survival Analysis', 'Time Factors']",,,,2004/02/07 05:00,2004/02/26 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/02/26 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Med Trop (Mars). 2003;63(4-5):521-6.,,,"Childhood cancer has often been considered as a problem mainly affecting industrialized countries. In reality more than half of cases occur in developing countries where management and diagnosis are major issues. This retrospective study includes 130 children (0.3% of admissions) between the ages of 0 and 15 years hospitalized for malignant disease at the Principal Hospital in Dakar, Senegal between January 1, 1990 and December 31, 2000. Mean age was 97 months and M/F sex ratio was 1.2. Mean delay for admission was 3 months. The five most frequent cancers, accounting for 75% of cases, were leukemia (n = 28), lymphoma (n = 21), nephroblastoma (n = 21), retinoblastoma (n = 16) and osteochondrosarcoma (n = 10). Treatment was completed in 18% of cases. Half of patient were lost from follow-up. The cure rate was 10% overall and 50% for patients receiving complete treatment. The highest cure rate was achieved for nephroblastoma, i.e., 58% of cases treated. Management of childhood cancer in Africa is confronted with numerous problems, namely, paucity of specialized staff, absence of expert centers, shortage of anticancer drugs, lack of financial resources, and delay in treatment. These factors associated with frequent malnutrition and recurrent infectious diseases, greatly lower cure rates in comparison with industrialized countries.","['Service de pediatrie, Hopital Principal de Dakar, BP 3006, Dakar, Senegal. kasidy@refer.sn']",,,,,,,,,,
14763161,NLM,MEDLINE,20040708,20091119,1127-0020 (Print) 1127-0020 (Linking),7,2,2003 Jun,The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies.,160-90,"['Milella, Michele', 'Kornblau, Steven M', 'Andreeff, Michael']","['Milella M', 'Kornblau SM', 'Andreeff M']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S."", 'Review']",,Italy,Rev Clin Exp Hematol,Reviews in clinical and experimental hematology,9815344,"['0 (Antineoplastic Agents)', 'EC 2.7.11.24 (Mitogen-Activated Protein Kinases)', 'EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)']",IM,"['Antineoplastic Agents/chemistry/*pharmacology', 'Hematologic Neoplasms/drug therapy/*metabolism', 'Humans', 'Leukemia/drug therapy/metabolism', '*MAP Kinase Signaling System/drug effects', 'Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors', 'Mitogen-Activated Protein Kinases/antagonists & inhibitors']",,,,2004/02/07 05:00,2004/07/09 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/07/09 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Rev Clin Exp Hematol. 2003 Jun;7(2):160-90.,,,"Important insights into the cellular and molecular biology of cancer in general and of hematologic malignancies in particular have been gained in the past two decades. The genes, and their protein products, involved in the transformation of cells from normal to neoplastic, as well as in the progression of neoplastic cells to a more aggressive, therapy-resistant phenotype, are being elucidated in great detail. However, most hematologic malignancies, particularly adult acute leukemias, remain associated with high mortality rates and new therapeutic approaches are urgently needed. The challenge is therefore to carefully and efficiently translate the information gained into effective therapeutic strategies. The clinical success achieved by tyrosine kinase inhibitors, such as ST1571 in chronic myelogenous leukemia, has stimulated interest for kinase-based signaling pathways as therapeutic targets in hematologic malignancies. The mitogen-activated protein kinase (MAPK) pathway is a common point of convergence of many different mitogenic and anti-apoptotic signal transduction pathways in hematopoietic, as well as epithelial, cancer cells and can now be clinically targeted by highly selective small molecule inhibitors. The mounting preclinical evidence of anti-leukemic activity of MAPK inhibitors, alone or in combination with pro-apoptotic small molecules or with conventional chemotherapeutic agents provides rationale that MAPK inhibition-based treatment strategies could soon enrich our therapeutic armamentarium against human leukemias.","['Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi, n. 53, 00144, Rome, Italy. milella@ifo.it']",,"['CA16672/CA/NCI NIH HHS/United States', 'P01 CA55164/CA/NCI NIH HHS/United States', 'P50 CA100632/CA/NCI NIH HHS/United States', 'R01 CA89346/CA/NCI NIH HHS/United States']",183,,,,,,,
14763160,NLM,MEDLINE,20040708,20091119,1127-0020 (Print) 1127-0020 (Linking),7,2,2003 Jun,Targeting aberrant transcriptional repression in acute myeloid leukemia.,139-59,"['Moe-Behrens, Gerd H', 'Pandolfi, Pier Paolo']","['Moe-Behrens GH', 'Pandolfi PP']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S."", 'Review']",,Italy,Rev Clin Exp Hematol,Reviews in clinical and experimental hematology,9815344,"['0 (Enzyme Inhibitors)', '0 (Histone Deacetylase Inhibitors)', 'EC 2.3.1.- (Acetyltransferases)', 'EC 2.3.1.48 (Histone Acetyltransferases)', 'EC 3.5.1.98 (Histone Deacetylases)']",IM,"['Acetyltransferases/metabolism/physiology', 'Acute Disease', 'Enzyme Inhibitors/pharmacology', 'Gene Expression Regulation, Neoplastic/drug effects', 'Histone Acetyltransferases', 'Histone Deacetylase Inhibitors', 'Histone Deacetylases/metabolism/physiology', 'Humans', 'Leukemia, Myeloid/drug therapy/etiology/*genetics', 'Transcription, Genetic/*drug effects']",,,,2004/02/07 05:00,2004/07/09 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/07/09 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Rev Clin Exp Hematol. 2003 Jun;7(2):139-59.,,,"Histone acetyltransferase (HAT) and histone deacetylase (HDAC) activities determine the acetylation status of histones, and have the ability to regulate gene expression through chromatin remodeling. Aberrant histone acetylation is known to play a key role in leukemogenesis. A common biologic feature, shared by genetically heterogeneous acute myeloid leukemias (AML), is a block of hematopoietic differentiation by the fusion proteins produced by chromosomal translocations. In many cases, a DNA binding fusion protein, which abnormally interacts with transcriptional co-regulators and increases local concentration of HDAC complexes, imposes a transcriptional repressive state on target gene promoters, which may become refractory to physiologic stimuli. To target this transcriptional repression, HDAC inhibitors (HDACI) have been developed, which are thought to derepress a set of genes whose transcriptional activation induces cell-cycle arrest, apoptosis and cellular differentiation and thus anti-tumoral activity. Therefore, HDACI might be utilized as effective antileukemic agents, and are currently under clinical trials.","['Molecular Biology Program, Department of Pathology, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Division, Graduate School of Medical Sciences, Cornell University, 1275 York Avenue, New York, NY 10021, USA.']",,,118,,,,,,,
14763136,NLM,MEDLINE,20040322,20181130,1472-4472 (Print) 1472-4472 (Linking),4,12,2003 Dec,Clofarabine. Bioenvision/ILEX.,1479-87,"['Sternberg, Alexander']",['Sternberg A'],['eng'],"['Journal Article', 'Review']",,England,Curr Opin Investig Drugs,"Current opinion in investigational drugs (London, England : 2000)",100965718,"['0 (Adenine Nucleotides)', '0 (Arabinonucleosides)', '0 (Drugs, Investigational)', '762RDY0Y2H (Clofarabine)']",IM,"['Adenine Nucleotides', 'Animals', 'Arabinonucleosides/chemistry/pharmacology/*therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'Clofarabine', 'Drugs, Investigational/chemistry/pharmacology/*therapeutic use', 'Humans', 'Neoplasms/*drug therapy/metabolism', 'Technology, Pharmaceutical/methods']",,,,2004/02/07 05:00,2004/03/23 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/03/23 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Curr Opin Investig Drugs. 2003 Dec;4(12):1479-87.,,,"Clofarabine is a purine nucleoside antimetabolite under development by Bioenvision (under license from the Southern Research Institute) and ILEX for the potential treatment of solid tumors, acute myelogenous leukemia, non-Hodgkin's lymphoma, and acute lymphoblastic and chronic lymphocytic leukemia. In September 2003, Bioenvision initiated a phase II trial in Europe in pediatric acute lymphoblastic leukemia, and in October 2003, ILEX submitted the first part of a rolling NDA to the FDA for the treatment of acute leukemia in children.","['Academic Department of Haematology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK. stern@molbiol.ox.ac.uk']",,,64,,,,,,,
14763130,NLM,MEDLINE,20040322,20181130,1472-4472 (Print) 1472-4472 (Linking),4,12,2003 Dec,Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.,1442-50,"['Lyons, John', 'Bayar, Emel', 'Fine, Gil', 'McCullar, Michael', 'Rolens, Randee', 'Rubinfeld, Joseph', 'Rosenfeld, Craig']","['Lyons J', 'Bayar E', 'Fine G', 'McCullar M', 'Rolens R', 'Rubinfeld J', 'Rosenfeld C']",['eng'],"['Journal Article', 'Review']",,England,Curr Opin Investig Drugs,"Current opinion in investigational drugs (London, England : 2000)",100965718,"['0 (Enzyme Inhibitors)', '776B62CQ27 (Decitabine)', 'EC 2.1.1.- (DNA Modification Methylases)', 'M801H13NRU (Azacitidine)']",IM,"['Animals', 'Azacitidine/*analogs & derivatives/metabolism/pharmacology/*therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'DNA Modification Methylases/*antagonists & inhibitors/metabolism', 'Decitabine', 'Enzyme Inhibitors/metabolism/pharmacology/*therapeutic use', 'Hematologic Neoplasms/*drug therapy/enzymology', 'Humans']",,,,2004/02/07 05:00,2004/03/23 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/03/23 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Curr Opin Investig Drugs. 2003 Dec;4(12):1442-50.,,,"Decitabine (DAC) is a small molecule nucleotide analog that is incorporated into DNA and traps human DNA methyltransferases. Although initially developed as a cytotoxic agent, low-dose DAC is enjoying a revival as a specific inhibitor of hypermethylation in cancer. DAC has activity in several hematological diseases, especially myelodysplastic syndrome, chronic myelogenous leukemia and acute myeloid leukemia. Clinical and preclinical advances are presented in this review.",['jlyons1@ireland.com'],,,66,,,,,,,
14763125,NLM,MEDLINE,20040322,20061115,1472-4472 (Print) 1472-4472 (Linking),4,12,2003 Dec,Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures?,1410-5,"['Workman, Paul']",['Workman P'],['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']",,England,Curr Opin Investig Drugs,"Current opinion in investigational drugs (London, England : 2000)",100965718,['0 (Antineoplastic Agents)'],IM,"['Animals', 'Antineoplastic Agents/administration & dosage/chemistry', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/chemistry', 'Drug Delivery Systems/*methods', 'Genomics/methods/trends', 'Humans', 'Neoplasms/*drug therapy/*genetics']",,,,2004/02/07 05:00,2004/03/23 05:00,['2004/02/07 05:00'],"['2004/02/07 05:00 [pubmed]', '2004/03/23 05:00 [medline]', '2004/02/07 05:00 [entrez]']",ppublish,Curr Opin Investig Drugs. 2003 Dec;4(12):1410-5.,,,"The epidemiology, genetics/genomics and molecular biology of cancer all point to the involvement of a large number of genes in the malignant progression of the vast majority of human cancers. Our current conceptual models of cancer are discussed here and are integrated with an assessment of the strategies required for treating and potentially curing human cancers driven by multiple genome abnormalities. There are settings in which excellent responses will be seen in cancers driven primarily by single genomic abnormalities, e.g., imatinib in chronic myeloid leukemia and gastrointestinal stromal tumors. Other multigenic cancers will require drug cocktails or single drugs acting on multiple downstream targets.","['Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. paul.workman@icr.ac.uk']",,,41,,,,,,,
14762794,NLM,MEDLINE,20040326,20190707,0016-5085 (Print) 0016-5085 (Linking),126,2,2004 Feb,Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation.,576-85,"['Gallinger, Steven', 'Aronson, Melyssa', 'Shayan, Katayoon', 'Ratcliffe, Elyanne M', 'Gerstle, Justin T', 'Parkin, Patricia C', 'Rothenmund, Heidi', 'Croitoru, Marina', 'Baumann, Ewa', 'Durie, Peter R', 'Weksberg, Rosanna', 'Pollett, Aaron', 'Riddell, Robert H', 'Ngan, Bo Y', 'Cutz, Ernest', 'Lagarde, Alain E', 'Chan, Helen S L']","['Gallinger S', 'Aronson M', 'Shayan K', 'Ratcliffe EM', 'Gerstle JT', 'Parkin PC', 'Rothenmund H', 'Croitoru M', 'Baumann E', 'Durie PR', 'Weksberg R', 'Pollett A', 'Riddell RH', 'Ngan BY', 'Cutz E', 'Lagarde AE', 'Chan HS']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Gastroenterology,Gastroenterology,0374630,"['0 (Adaptor Proteins, Signal Transducing)', '0 (Carrier Proteins)', '0 (MLH1 protein, human)', '0 (Neoplasm Proteins)', '0 (Nuclear Proteins)', 'EC 3.6.1.3 (MutL Protein Homolog 1)']",IM,"['Adaptor Proteins, Signal Transducing', 'Carrier Proteins', 'Child', 'Female', 'Gastrointestinal Neoplasms/*genetics/pathology', '*Germ-Line Mutation/genetics', '*Homozygote', 'Humans', 'Male', 'Microsatellite Repeats/genetics', 'MutL Protein Homolog 1', 'Mutation, Missense', 'Neoplasm Proteins/*genetics', 'Neurofibromatosis 1/*genetics/pathology', 'Nuclear Proteins', 'Pedigree']",,,,2004/02/06 05:00,2004/03/27 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/03/27 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Gastroenterology. 2004 Feb;126(2):576-85. doi: 10.1053/j.gastro.2003.11.008.,"['S001650850301789X [pii]', '10.1053/j.gastro.2003.11.008 [doi]']",,"Heterozygous germline DNA mismatch repair gene mutations are typically associated with hereditary nonpolyposis colorectal cancer. The molecular hallmark of this syndrome is high-frequency microsatellite instability in the tumors. Rare childhood cases with homozygous or compound heterozygous DNA mismatch repair gene mutations have a described predisposition to leukemia, lymphoma, and brain tumors but not to gastrointestinal cancer. We have now characterized a family in which 2 children with a homozygous germline DNA mismatch repair gene mutation developed early-onset gastrointestinal cancers. The 11-year-old proband had cafe-au-lait macules and developed metastatic duodenal adenocarcinoma that arose in a tubulovillous adenoma. His 9-year-old sister with cafe-au-lait macules and axillary freckling presented with malignant colon polyps. A 6-year-old sister with cafe-au-lait macules, hairy nevi, and a plexiform neurofibroma of the tongue has no malignancies to date. The family history did not fulfill the Amsterdam criteria for hereditary nonpolyposis colorectal cancer, but 2 relatives in their 60s had gastric cancer and colorectal cancer, whereas the parents, who are first cousins, remain cancer free. The proband's metastatic duodenal cancer and his sister's malignant colon polyps had high-frequency microsatellite instability but had detectable MLH1, MSH2, and MSH6 proteins by immunohistochemistry. Because some germline DNA mismatch repair gene deficiencies are associated with apparently intact immunohistochemical DNA mismatch repair gene expression in tumors, we proceeded to DNA sequencing, which showed that all 3 children had a germline homozygous MLH1 missense mutation (exon 18, codon 687, CGG-->TGG), whereas both parents were heterozygous for this mutation.","['Familial Gastrointestinal Cancer Registry and Centre for Cancer Genetics and Department of Surgery, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, ON, Canada.']",,,,,,,,,,
14762685,NLM,MEDLINE,20040914,20161124,0939-5555 (Print) 0939-5555 (Linking),83,8,2004 Aug,Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias.,527-32,"['Chim, C S', 'Wong, A S Y', 'Kwong, Y L']","['Chim CS', 'Wong AS', 'Kwong YL']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,Germany,Ann Hematol,Annals of hematology,9107334,"['0 (Carrier Proteins)', '0 (DNA-Binding Proteins)', '0 (Intracellular Signaling Peptides and Proteins)', '0 (Repressor Proteins)', '0 (SOCS1 protein, human)', '0 (STAT1 Transcription Factor)', '0 (STAT1 protein, human)', '0 (Suppressor of Cytokine Signaling 1 Protein)', '0 (Suppressor of Cytokine Signaling Proteins)', '0 (Trans-Activators)', 'EC 2.7.10.1 (Protein-Tyrosine Kinases)', 'EC 2.7.10.2 (JAK1 protein, human)', 'EC 2.7.10.2 (Janus Kinase 1)', 'EC 3.1.3.48 (PTPN6 protein, human)', 'EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 6)', 'EC 3.1.3.48 (Protein Tyrosine Phosphatases)']",IM,"['Acute Disease', 'Adult', 'Aged', 'Aged, 80 and over', 'Carrier Proteins/*metabolism', 'Case-Control Studies', 'DNA Methylation', 'DNA-Binding Proteins/metabolism', '*Epigenesis, Genetic', 'Female', 'Humans', '*Intracellular Signaling Peptides and Proteins', 'Janus Kinase 1', 'Leukemia/*etiology/metabolism', 'Male', 'Methylation', 'Middle Aged', 'Prognosis', 'Protein Tyrosine Phosphatase, Non-Receptor Type 6', 'Protein Tyrosine Phosphatases/*metabolism', 'Protein-Tyrosine Kinases/metabolism', 'Repressor Proteins/*metabolism', 'STAT1 Transcription Factor', 'Signal Transduction/*genetics', 'Suppressor of Cytokine Signaling 1 Protein', 'Suppressor of Cytokine Signaling Proteins', 'Trans-Activators/metabolism']",,,,2004/02/06 05:00,2004/09/15 05:00,['2004/02/06 05:00'],"['2003/10/21 00:00 [received]', '2003/12/24 00:00 [accepted]', '2004/02/06 05:00 [pubmed]', '2004/09/15 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Ann Hematol. 2004 Aug;83(8):527-32. doi: 10.1007/s00277-004-0843-1. Epub 2004 Feb 5.,['10.1007/s00277-004-0843-1 [doi]'],,"SOCS1 and SHP1 are negative regulators of the Jak/STAT signalling pathway that is implicated in leukaemogenesis. We studied if aberrant methylation of SOCS1 and SHP1 might be involved in the pathogenesis and prognostication of acute leukaemias by methylation-specific polymerase chain reaction (MSP). At diagnosis, methylation of SHP1 occurred more frequently in acute myeloid leukaemia (AML) (n=26, 52%) than acute lymphoblastic leukaemia (ALL) (n=6, 24%) (p=0.02). Methylation of SOCS1 was absent in both AML and ALL patients. SHP1 methylation was not associated with specific clinicopathologic features and had no prognostic impact on AML patients. Frequent methylation of SHP1, but not SOCS1, may be important in the pathogenesis, but not prognosis, of acute leukaemias.","['University Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong.']",20040205,,,,,['Copyright 2004 Springer-Verlag'],,,,
14762574,NLM,MEDLINE,20040719,20190605,0100-879X (Print) 0100-879X (Linking),37,2,2004 Feb,Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after bone marrow transplantation.,201-6,"['Castro, F A', 'Palma, P V B', 'Morais, F R', 'Voltarelli, J C']","['Castro FA', 'Palma PV', 'Morais FR', 'Voltarelli JC']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,Brazil,Braz J Med Biol Res,Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,8112917,,IM,"['Adult', 'Bone Marrow Transplantation/*adverse effects/immunology', 'Female', 'Follow-Up Studies', 'Graft vs Host Disease/etiology/immunology/prevention & control', 'Humans', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology/*surgery', '*Lymphocyte Transfusion', 'Male', 'Neoplasm Recurrence, Local/immunology', 'Recurrence', 'Reverse Transcriptase Polymerase Chain Reaction', 'Transplantation Chimera/immunology', 'Treatment Outcome']",,,,2004/02/06 05:00,2004/07/20 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/07/20 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Braz J Med Biol Res. 2004 Feb;37(2):201-6. doi: 10.1590/s0100-879x2004000200006. Epub 2004 Jan 30.,"['S0100-879X2004000200006 [pii]', '10.1590/s0100-879x2004000200006 [doi]']",,"Allogeneic bone marrow transplantation (alloBMT) is the only curative therapy for chronic myelogenous leukemia (CML). This success is explained by the delivery of high doses of antineoplastic agents followed by the rescue of marrow function and the induction of graft-versus-leukemia reaction mediated by allogeneic lymphocytes against host tumor cells. This reaction can also be induced by donor lymphocyte infusion (DLI) producing remission in most patients with CML who relapse after alloBMT. The immunological mechanisms involved in DLI therapy are poorly understood. We studied five CML patients in the chronic phase, who received DLI after relapsing from an HLA-identical BMT. Using flow cytometry we evaluated cellular activation and apoptosis, NK cytotoxicity, lymphocytes producing cytokines (IL-2, IL-4 and IFN-gamma), and unstimulated (in vivo) lymphocyte proliferation. In three CML patients who achieved hematological and/or cytogenetic remission after DLI we observed an increase of the percent of activation markers on T and NK cells (CD3/DR, CD3/CD25 and CD56/DR), of lymphocytes producing IL-2 and IFN-gamma, of NK activity, and of in vivo lymphocyte proliferation. These changes were not observed consistently in two of the five patients who did not achieve complete remission with DLI. The percent of apoptotic markers (Fas, FasL and Bcl-2) on lymphocytes and CD34-positive cells did not change after DLI throughout the different study periods. Taken together, these preliminary results suggest that the therapeutic effect of DLI in the chronic phase of CML is mediated by classic cytotoxic and proliferative events involving T and NK cells but not by the Fas pathway of apoptosis.","['Departamento de Analises Clinicas, Toxicologicas e Bromatologicas, Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil.']",20040130,,,,,,,,,
14762446,NLM,MEDLINE,20040520,20201222,0887-6924 (Print) 0887-6924 (Linking),18,5,2004 May,"CD34+ progenitors from MDS patients are unresponsive to SDF-1, despite high levels of SDF-1 in bone marrow plasma.",1038-40,"['Matsuda, M', 'Morita, Y', 'Hanamoto, H', 'Tatsumi, Y', 'Maeda, Y', 'Kanamaru, A']","['Matsuda M', 'Morita Y', 'Hanamoto H', 'Tatsumi Y', 'Maeda Y', 'Kanamaru A']",['eng'],['Letter'],,England,Leukemia,Leukemia,8704895,"['0 (Antigens, CD34)', '0 (CXCL12 protein, human)', '0 (Chemokine CXCL12)', '0 (Chemokines, CXC)', '0 (Receptors, CXCR4)']",IM,"['Adult', 'Aged', 'Antigens, CD34/*analysis', 'Apoptosis', 'Chemokine CXCL12', 'Chemokines, CXC/blood/*physiology', 'Chemotaxis', 'Female', 'Hematopoietic Stem Cells/*physiology', 'Humans', 'Male', 'Middle Aged', 'Myelodysplastic Syndromes/*blood', 'Receptors, CXCR4/analysis']",,,,2004/02/06 05:00,2004/05/21 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/05/21 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Leukemia. 2004 May;18(5):1038-40. doi: 10.1038/sj.leu.2403301.,"['10.1038/sj.leu.2403301 [doi]', '2403301 [pii]']",,,,,,,,,,,,,
14762445,NLM,MEDLINE,20040503,20130304,0887-6924 (Print) 0887-6924 (Linking),18,4,2004 Apr,Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile.,875-7,"['van Stijn, A', 'Kok, A', 'van Stalborch, M A', 'van Der Pol, M A', 'Feller, N', 'Westra, A H', 'Ossenkoppele, G J', 'Schuurhuis, G J']","['van Stijn A', 'Kok A', 'van Stalborch MA', 'van Der Pol MA', 'Feller N', 'Westra AH', 'Ossenkoppele GJ', 'Schuurhuis GJ']",['eng'],['Letter'],,England,Leukemia,Leukemia,8704895,"['0 (Neoplasm Proteins)', '0 (Proto-Oncogene Proteins c-bcl-2)']",IM,"['Acute Disease', '*Apoptosis', 'Drug Resistance', 'Humans', 'Leukemia, Myeloid/*pathology', 'Neoplasm Proteins/analysis', 'Neoplasm, Residual/*etiology/pathology', 'Proto-Oncogene Proteins c-bcl-2/analysis']",,,,2004/02/06 05:00,2004/05/05 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/05/05 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Leukemia. 2004 Apr;18(4):875-7. doi: 10.1038/sj.leu.2403299.,"['10.1038/sj.leu.2403299 [doi]', '2403299 [pii]']",,,,,,,,,,,,,
14762444,NLM,MEDLINE,20040503,20130304,0887-6924 (Print) 0887-6924 (Linking),18,4,2004 Apr,Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome.,809-16,"['Sekeres, M A', 'Stone, R M', 'Zahrieh, D', 'Neuberg, D', 'Morrison, V', 'De Angelo, D J', 'Galinsky, I', 'Lee, S J']","['Sekeres MA', 'Stone RM', 'Zahrieh D', 'Neuberg D', 'Morrison V', 'De Angelo DJ', 'Galinsky I', 'Lee SJ']",['eng'],"['Clinical Trial', 'Comparative Study', 'Journal Article', 'Multicenter Study']",,England,Leukemia,Leukemia,8704895,['0 (Antineoplastic Agents)'],IM,"['Acute Disease', 'Aged', 'Aged, 80 and over', 'Antineoplastic Agents/*therapeutic use', '*Choice Behavior', 'Decision Making', 'Female', 'Humans', 'Leukemia, Myeloid/*drug therapy/mortality/psychology', 'Longitudinal Studies', 'Male', 'Middle Aged', 'Myelodysplastic Syndromes/*drug therapy/mortality/psychology', 'Physician-Patient Relations', 'Prospective Studies', '*Quality of Life', 'Treatment Outcome']",,,,2004/02/06 05:00,2004/05/05 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/05/05 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Leukemia. 2004 Apr;18(4):809-16. doi: 10.1038/sj.leu.2403289.,"['10.1038/sj.leu.2403289 [doi]', '2403289 [pii]']",,"Older patients with acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (aMDS) must decide between receiving intensive induction chemotherapy (IC) or nonintensive chemotherapy/best supportive care (NIC). Little information exists about what factors influence treatment decisions and what quality of life (QOL) is associated with treatment choices. We prospectively examined 43 patients 60 years or older who were interviewed at diagnosis and periodically over 1 year. IC choice was associated with younger age (66 vs 76 years, P=0.01) and AML diagnosis, but not with performance status, comorbidities, or QOL. In total, 63% of all patients reported not being offered other treatment options despite physician documentation of alternatives. Patient and physician estimates of cure differed significantly: 74% of patients estimated their chance of cure to be 50% or greater, yet for 89% of patients physician estimates of cure were 10% or less. IC patients experienced decreased QOL at 2 weeks, but rebounded to baseline and to NIC levels by 6 weeks. Initial QOL is not associated with treatment choice in older AML and aMDS patients. Regardless of treatment choice, patients report not being offered treatment options and overestimate their chances of cure. In IC patients, QOL decreases during hospitalization but rebounds after discharge.","['Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA. sekerem@ccf.org']",,,,,,,,,,
14762443,NLM,MEDLINE,20040503,20130304,0887-6924 (Print) 0887-6924 (Linking),18,4,2004 Apr,Incidence and prognostic value of respiratory events in acute leukemia.,670-5,"['Chaoui, D', 'Legrand, O', 'Roche, N', 'Cornet, M', 'Lefebvre, A', 'Peffault de Latour, R', 'Sanhes, L', 'Huchon, G', 'Marie, J-P', 'Rabbat, A']","['Chaoui D', 'Legrand O', 'Roche N', 'Cornet M', 'Lefebvre A', 'Peffault de Latour R', 'Sanhes L', 'Huchon G', 'Marie JP', 'Rabbat A']",['eng'],['Journal Article'],,England,Leukemia,Leukemia,8704895,['0 (Anti-Infective Agents)'],IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anti-Infective Agents/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Female', 'Humans', 'Incidence', 'Leukemia/*complications/*diagnosis/epidemiology', 'Male', 'Middle Aged', 'Prognosis', 'Prospective Studies', 'Remission Induction', 'Respiration Disorders/epidemiology/*etiology', 'Risk Factors', 'Survival Rate']",,,,2004/02/06 05:00,2004/05/05 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/05/05 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Leukemia. 2004 Apr;18(4):670-5. doi: 10.1038/sj.leu.2403270.,"['10.1038/sj.leu.2403270 [doi]', '2403270 [pii]']",,"Acute respiratory failure and infectious pneumonia are the major causes of death during induction chemotherapy of acute leukemia. However, the causes, incidence and prognostic value of all respiratory events (REs) occurring in this context have never been assessed prospectively. We recruited 65 consecutive patients with newly diagnosed acute leukemia into a 1-year prospective study (December 2000-November 2001) to evaluate the incidence and prognostic value of these events. REs were frequent: 38 were recorded in 30 patients. There was a significant relationship between REs and pre-existing respiratory disease and/or smoking. REs were caused by infection in 34% of cases, by an established cause other than infection in 42% and had an undetermined cause in 24%. Poor early outcome (death within 45 days of starting induction chemotherapy) in patients experiencing an RE was independently associated with a >25/min respiratory rate (P=0.003) and the nonachievement of complete remission (CR) (P<0.0001). Predictors of overall survival in the entire patient population were the absence of CR (P<0.0001), REs (P=0.02) and a > or =2 performance status (P=0.03). In conclusion, REs are frequent during induction chemotherapy of acute leukemia and represent an independent prognostic factor of poor outcome, regardless of their cause.","['Department of Hematology, Hotel-Dieu, Paris, France.']",,,,,,,,,,
14761668,NLM,MEDLINE,20040315,20061115,0024-3205 (Print) 0024-3205 (Linking),74,15,2004 Feb 27,Nucleic acid synthesis in cancerous cells under the effect of gnidilatimonoein from Daphne mucronata.,1869-76,"['Yazdanparast, Razieh', 'Sadeghi, Heibatollah']","['Yazdanparast R', 'Sadeghi H']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,Netherlands,Life Sci,Life sciences,0375521,"['0 (Diterpenes)', '0 (Nucleic Acid Synthesis Inhibitors)', '0 (Plant Preparations)', '0 (gnidilatimonoein)', '9007-49-2 (DNA)', 'EC 1.1.1.205 (IMP Dehydrogenase)']",IM,"['Animals', 'Cell Cycle/*drug effects', 'Cell Line, Tumor/ultrastructure', 'DNA/*biosynthesis', '*Daphne', 'Diterpenes/*pharmacology', 'Electrophoresis, Agar Gel', 'Flow Cytometry', 'IMP Dehydrogenase/drug effects/metabolism', 'Microscopy, Electron', 'Nucleic Acid Synthesis Inhibitors/*pharmacology', 'Plant Preparations/pharmacology']",,,,2004/02/06 05:00,2004/03/17 05:00,['2004/02/06 05:00'],"['2003/02/11 00:00 [received]', '2003/08/13 00:00 [accepted]', '2004/02/06 05:00 [pubmed]', '2004/03/17 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Life Sci. 2004 Feb 27;74(15):1869-76. doi: 10.1016/j.lfs.2003.08.039.,"['10.1016/j.lfs.2003.08.039 [doi]', 'S0024320503011068 [pii]']",,"Cytotoxicity evaluation of gnidilatimonoein, the most active isolated diterpene ester from Daphne mucronata [Sadeghi H, Mianabadi M, Yazdanparast R, (2002) Journal of Tropical. Medicinal Plant1 3: 169-173], revealed the strong antiproliferative activity among several different human cancer cell lines (K562, CCRF-CEM, HL-60 and MOLT-4 leukemia cell lines, LNCaP-FGC-10 a prostate cancer cell line) and a mouse BALB/C fibrosarcoma cell line (WEHI-164). Using flow cytometry technique, it was found that treatment of the most responsive cells (K562) with gnidilatimonoein inhibited the progression of cells through G1 phase by almost 15% compared to the untreated cells. The population of the treated cells in the S and G2 phases also reduced by 8.3% and 5.4%, respectively. Based on the extent of [3H]-thymidine and [3H]-uridine incorporation into DNA and RNA, respectively, the major metabolic effects of gnidilatimonoein were found to be mainly on DNA and to a less extent on RNA synthesis. Additionally, the activity of inosine-5'-monophosphate dehydrogenase (IMPDH), under the effects of genidilatimonoein, was reduced in the treated cells by 44%. These data strongly suggest that the purine biosynthetic pathway is significantly affected by gnidilatimonoein.","['Institute of Biochemistry and Biophysics, University of Tehran, P. O. Box 13145-1384, Tehran, Iran. yazdan@ibb.ut.ac.ir']",,,,,,,,,,
14761613,NLM,MEDLINE,20040512,20171116,0253-2727 (Print) 0253-2727 (Linking),24,12,2003 Dec,[Activating effects of protein transduction domain mediated BCR/ABL protein on CML T cells].,644-7,"['Liu, Qiang', 'Liang, Ying-min', 'Zheng, Jin', 'Li, Xue-yi', 'Hao, Miao-wang', 'Liu, Li', 'Chen, Ren-an']","['Liu Q', 'Liang YM', 'Zheng J', 'Li XY', 'Hao MW', 'Liu L', 'Chen RA']",['chi'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,China,Zhonghua Xue Ye Xue Za Zhi,Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,8212398,"['0 (Antigens, CD)', '0 (Antigens, Differentiation, T-Lymphocyte)', '0 (CD4 Antigens)', '0 (CD69 antigen)', '0 (CD8 Antigens)', '0 (Gene Products, tat)', '0 (Lectins, C-Type)', '0 (Recombinant Fusion Proteins)', 'EC 2.7.10.2 (Fusion Proteins, bcr-abl)']",IM,"['Adolescent', 'Adult', 'Aged', 'Amino Acid Sequence', 'Antigens, CD/analysis', 'Antigens, Differentiation, T-Lymphocyte/analysis', 'CD4 Antigens/analysis', 'CD8 Antigens/analysis', 'Dose-Response Relationship, Drug', 'Female', 'Flow Cytometry', 'Fusion Proteins, bcr-abl/*genetics/metabolism', 'Gene Products, tat/*genetics/metabolism', 'Humans', 'Lectins, C-Type', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood', 'Male', 'Middle Aged', 'Recombinant Fusion Proteins/immunology/metabolism/*pharmacology', 'T-Lymphocytes/*drug effects/immunology']",,,,2004/02/06 05:00,2004/05/13 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/05/13 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Zhonghua Xue Ye Xue Za Zhi. 2003 Dec;24(12):644-7.,,,"OBJECTIVE: To study the activating effect of protein transduction domain (PTD) mediated BCR/ABL protein on T cells from CML patients. METHODS: The plasmid containing PTD and b3a2 bcr/abl of CML was constructed by genetic engineering and expressed in E. coli. The peripheral blood mononuclear cells from CML patients were stimulated in vitro with purified PTD-BCR/ABL protein and the expression of the early activation antigen CD(69) on CD(8)(+) and CD(4)(+) T cells was detected by flow cytometry (FCM). RESULTS: The optimal concentration of PTD-BCR/ABL protein for activating CD(8)(+) T cells in vitro was 100 micro g/ml, CD(69) expression peaked in three days stimulation. CD(8)(+) T cells were activated in 10 of 15 CML patients, the expression rate of CD(69) was (15.01 +/- 3.75)%. CD(4)(+) T cells were activated in 4 of 15 patients, the expression rate of CD(69) was (10.32 +/- 3.08)%. Both CD(8)(+) and CD(4)(+) T cells were activated simultaneously in 3 of them. However, neither CD(4)(+) nor CD(8)(+) T cells was activated by stimulation with BCR/ABL protein in all 15 specimens, the expression rate of CD(69) on CD(8)(+) and CD(4)(+) T cells was (1.36 +/- 0.31)% and (1.41 +/- 0.43)%, respectively. There was no difference compared with that of PBS control group (P > 0.05). CONCLUSION: By using a PTD-mediated antigen delivering system, exogenous BCR/ABL protein can be delivered into APC, processed and presented onto surface of APC to activate Ag-specific CD(8)(+) and CD(4)(+) T cells in vitro.","['Department of Hematology of Tangdu Hospital, Fourth Military Medical University, Xi-an 710038, China.']",,,,,,,,,,
14761612,NLM,MEDLINE,20040512,20061115,0253-2727 (Print) 0253-2727 (Linking),24,12,2003 Dec,[New insight into the mechanism of p53 inducing leukemia cell apoptosis].,640-3,"['Chen, Yuan-zhong', 'Wu, Yong', 'Liang, Min', 'Li, Nai-nong', 'Zhang, Zhao-xiu', 'Lu, Lian-huang']","['Chen YZ', 'Wu Y', 'Liang M', 'Li NN', 'Zhang ZX', 'Lu LH']",['chi'],"['English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,China,Zhonghua Xue Ye Xue Za Zhi,Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,8212398,"['0 (DNA, Antisense)', '0 (DNA-Binding Proteins)', '0 (Proto-Oncogene Proteins c-bcl-2)', '0 (RNA, Messenger)', '0 (TGFB1 protein, human)', '0 (Transforming Growth Factor beta)', '0 (Transforming Growth Factor beta1)', '0 (Tumor Necrosis Factor-alpha)', '0 (Tumor Suppressor Protein p53)', 'EC 2.7.7.49 (Telomerase)']",IM,"['Apoptosis/drug effects/*genetics', 'DNA, Antisense/pharmacology', 'DNA-Binding Proteins', 'Gene Expression Regulation, Neoplastic', 'HL-60 Cells', 'Humans', 'K562 Cells', 'Leukemia/genetics/pathology', 'Mutation', 'Plasmids/genetics', 'Proto-Oncogene Proteins c-bcl-2/genetics', 'RNA, Messenger/drug effects/genetics/metabolism', 'Reverse Transcriptase Polymerase Chain Reaction', 'Telomerase/genetics', 'Transfection/methods', 'Transforming Growth Factor beta/genetics', 'Transforming Growth Factor beta1', 'Tumor Necrosis Factor-alpha/genetics', 'Tumor Suppressor Protein p53/genetics/*physiology']",,,,2004/02/06 05:00,2004/05/13 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/05/13 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Zhonghua Xue Ye Xue Za Zhi. 2003 Dec;24(12):640-3.,,,"OBJECTIVE: To investigate the expression changes of intrinsic cytokines TGF-beta(1) and TNF-alpha, telomerase activity and bcl-2 during ongoing apoptosis of HL-60 and K562 cells induced by p53. METHODS: pN53cG (Val135), a temperature sensitive p53 mutant, which behaved like wild type p53 (wt-p53) at 32.5 degrees C, were introduced into p53-null HL-60 and K562 cells respectively by lipofectin. In the presence of G418, HL-60-pN53cG and K562 pN53cG clones expressing p53 protein were selected. The ongoing expression of intrinsic cytokines (TGF-beta(1) and TNF-alpha), bcl-2 oncogene and hTERT mRNA during the apoptosis of HL-60 and K562 cells induced by p53 and the effects of exogenous p53 gene, TGF-beta(1) and TNF-alpha antisense PS-ODNS on the apoptosis of HL-60 and K562 cells and the expression of bcl-2 were studied by RT-PCR, quantitative RT-PCR, DNA fragmentation, TdT-mediated dUTP nick end labeling (TUNEL) and flow cytometery. The levels of secreted TGF-beta(1) and telomerase activity were detected by ELISA and PCR-ELISA, respectively. RESULTS: (1) The expressions of intrinsic TGF-beta(1) and TNF-alpha mRNA were up-regulated, while that of bcl-2 and hTERT down-regulated. The levels of TGF-beta(1) in the supernatant of HL-60 and K562 cells were increased, and the level of telomerase activity decreased. (2) Antisense PS-ODNS of TGF-beta(1) and TNF-alpha could obviously inhibit the p53 inducing cell apoptosis, and restore bcl-2 mRNA and protein to pre-treated level. CONCLUSIONS: Exogenous p53 induces leukemia cell apoptosis via up-regulating the expression of intrinsic TGF-beta(1) and TNF-alpha and down-regulating the expression of hTERT and bcl-2.","['Fujian Institute of Hematology, Union Hospital, Fujian Medical University, Fuzhou 350001, China.']",,,,,,,,,,
14761609,NLM,MEDLINE,20040512,20131121,0253-2727 (Print) 0253-2727 (Linking),24,12,2003 Dec,[Indomethacin-induced HL-60 cell apoptosis is associated with inhibition of beta-catenin/c-myc signal transduction pathway].,629-31,"['Zhang, Guang-sen', 'Wang, Zhao-yi']","['Zhang GS', 'Wang ZY']",['chi'],"['English Abstract', 'Journal Article']",,China,Zhonghua Xue Ye Xue Za Zhi,Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,8212398,"['0 (Anti-Inflammatory Agents, Non-Steroidal)', '0 (CTNNB1 protein, human)', '0 (Cytoskeletal Proteins)', '0 (Proto-Oncogene Proteins c-myb)', '0 (Trans-Activators)', '0 (beta Catenin)', 'EC 3.4.22.- (CASP3 protein, human)', 'EC 3.4.22.- (Caspase 3)', 'EC 3.4.22.- (Caspases)', 'XXE1CET956 (Indomethacin)']",IM,"['Anti-Inflammatory Agents, Non-Steroidal/pharmacology', 'Apoptosis/*drug effects', 'Blotting, Western', 'Caspase 3', 'Caspases/metabolism', 'Cytoskeletal Proteins/*metabolism', 'Dose-Response Relationship, Drug', 'HL-60 Cells', 'Humans', 'Indomethacin/*pharmacology', 'Proto-Oncogene Proteins c-myb/*metabolism', 'Signal Transduction/*drug effects', 'Time Factors', 'Trans-Activators/*metabolism', 'beta Catenin']",,,,2004/02/06 05:00,2004/05/13 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/05/13 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Zhonghua Xue Ye Xue Za Zhi. 2003 Dec;24(12):629-31.,,,"OBJECTIVE: To investigate the effects of indomethacin on HL-60 cell proliferation and apoptosis, and elucidate partly the molecular mechanism about the anti-leukemia effect of indomethacin by studying beta-catenin signal transduction pathway. METHODS: HL-60 cells were treated with indomethacin at different concentrations (0, 25, 50, 100, 200, 400 micro mol/L). Cells viability and proliferation were determined by Trypan blue staining and cell counting respectively. DNA ladder pattern and cell morphology were used to identify cell apoptosis. The expression and cleavage of caspase-3, beta-catenin, c-myc were detected by Western blot techniques. RESULTS: Indomethacin could significantly inhibit HL-60 cells proliferation and induce cells apoptosis with a time and dose dependent manner. An up-regulating expression and cleavage of caspase-3 were observed. Indomethacin could inhibit beta-catenin expression and induce its degradation, c-myc protein exhibited a down-regulation with a concentration dependent manner. CONCLUSION: Indomethacin could inhibit HL-60 cell proliferation and induce cells apoptosis. Anti-leukemia effect of indomethacin was associated with the inhibition of ""beta-catenin --> c-myc"" signal pathway.","['Division of Hematology, the Second Xiangya Hospital, Central South University, Changsha 410011, China.']",,,,,,,,,,
14761199,NLM,MEDLINE,20040405,20061115,0022-2623 (Print) 0022-2623 (Linking),47,4,2004 Feb 12,Synthesis of mono- and bisdihydrodipyridopyrazines and assessment of their DNA binding and cytotoxic properties.,978-87,"['Blanchard, Stephanie', 'Rodriguez, Ivan', 'Tardy, Christelle', 'Baldeyrou, Brigitte', 'Bailly, Christian', 'Colson, Pierre', 'Houssier, Claude', 'Leonce, Stephane', 'Kraus-Berthier, Laurence', 'Pfeiffer, Bruno', 'Renard, Pierre', 'Pierre, Alain', 'Caubere, Paul', 'Guillaumet, Gerald']","['Blanchard S', 'Rodriguez I', 'Tardy C', 'Baldeyrou B', 'Bailly C', 'Colson P', 'Houssier C', 'Leonce S', 'Kraus-Berthier L', 'Pfeiffer B', 'Renard P', 'Pierre A', 'Caubere P', 'Guillaumet G']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,J Med Chem,Journal of medicinal chemistry,9716531,"['0 (Antineoplastic Agents)', '0 (DNA, Superhelical)', '0 (Dihydropyridines)', '0 (Intercalating Agents)', '0 (Pyrazines)', '9007-49-2 (DNA)', 'EC 5.99.1.2 (DNA Topoisomerases, Type I)', 'EC 5.99.1.3 (DNA Topoisomerases, Type II)']",IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis/chemistry/pharmacology', 'Cell Line, Tumor', 'DNA/*chemistry/metabolism', 'DNA Topoisomerases, Type I/chemistry', 'DNA Topoisomerases, Type II/chemistry', 'DNA, Superhelical/chemistry', 'Dihydropyridines/*chemical synthesis/chemistry/pharmacology', 'Drug Screening Assays, Antitumor', 'Humans', 'Intercalating Agents/*chemical synthesis/chemistry/pharmacology', 'Leukemia P388/drug therapy/mortality', 'Mice', 'Pyrazines/*chemical synthesis/chemistry/pharmacology', 'Structure-Activity Relationship']",,,,2004/02/06 05:00,2004/04/06 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/04/06 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,J Med Chem. 2004 Feb 12;47(4):978-87. doi: 10.1021/jm0309351.,['10.1021/jm0309351 [doi]'],,"Aminoalkyl-substituted monomeric and dimeric dihydrodipyridopyrazines have been synthesized and evaluated as antitumor agents. Potent cytotoxic compounds were identified in both series. Biochemical and biophysical studies indicated that all these compounds strongly stabilized the duplex structure of DNA and some of them elicited a selectivity for GC-rich sequences. Sequence recognition by of the dimeric dihydrodipyridopyrazines is reminiscent of that of certain antitumor bisnaphthalimides. Compared to monomers, corresponding dimeric derivatives showed higher affinity for DNA. This property was attributed to a bisintercalative binding to DNA. This assumption was indirectly probed by electric linear dichroism and DNA relaxation experiments. DNA provides a bioreceptor for these dihydrodipyridopyrazine derivatives, but no poisoning of human topoisomerases I or II was detected. Most of the compounds efficiently inhibited the growth of L1210 murine leukemia cells and perturbed the cell cycle progression (with a G2/M block in most cases). A weak but noticeable in vivo antitumor activity was observed with one of the dimeric compounds. This studies identifies monomeric and dimeric dihydrodipyridopyrazines as a new class of DNA-targeted antitumor agents.","[""Institut de Chimie Organique et Analytique UMR-CNRS 6005, UFR de Sciences, Universite d'Orleans, rue de Chartres, BP 6759, 45067 Orleans Cedex 2, France.""]",,,,,,,,,,
14760961,NLM,MEDLINE,20040916,20170214,1352-4585 (Print) 1352-4585 (Linking),10,1,2004 Feb,Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis.,92,"['Delisse, B', 'de Seze, J', 'Mackowiak, A', ""N'Kendjuo, J B"", 'Verier, A', 'Derepeer, O', 'Boisselier, C', 'Devos, P', 'Hautecoeur, P', 'Vermersch, P']","['Delisse B', 'de Seze J', 'Mackowiak A', ""N'Kendjuo JB"", 'Verier A', 'Derepeer O', 'Boisselier C', 'Devos P', 'Hautecoeur P', 'Vermersch P']",['eng'],"['Case Reports', 'Comment', 'Letter']",,England,Mult Scler,"Multiple sclerosis (Houndmills, Basingstoke, England)",9509185,['BZ114NVM5P (Mitoxantrone)'],IM,"['Adult', 'Female', 'Humans', 'Leukemia, Myeloid, Acute/*chemically induced', 'Mitoxantrone/*adverse effects', 'Multiple Sclerosis/*drug therapy']",,,,2004/02/06 05:00,2004/09/17 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/09/17 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Mult Scler. 2004 Feb;10(1):92. doi: 10.1191/1352458504ms977xx.,['10.1191/1352458504ms977xx [doi]'],,,,,,,,['Mult Scler. 2003 Mar;9(2):213-4. PMID: 12708818'],,,['G-SEP'],,
14760735,NLM,MEDLINE,20041021,20061115,1439-4227 (Print) 1439-4227 (Linking),5,2,2004 Feb 6,Lipase-specific foldases.,152-61,"['Rosenau, Frank', 'Tommassen, Jan', 'Jaeger, Karl-Erich']","['Rosenau F', 'Tommassen J', 'Jaeger KE']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']",,Germany,Chembiochem,Chembiochem : a European journal of chemical biology,100937360,"['0 (Interleukin-6)', '0 (Leukemia Inhibitory Factor)', '0 (Proteins)']",IM,"['Amino Acid Sequence', 'Gene Expression Regulation, Bacterial', 'Gram-Negative Bacteria/enzymology/genetics/metabolism', 'Interleukin-6', 'Leukemia Inhibitory Factor', 'Molecular Sequence Data', 'Protein Folding', 'Proteins/chemistry/genetics/*metabolism', 'Substrate Specificity']",,,,2004/02/05 05:00,2004/10/22 09:00,['2004/02/05 05:00'],"['2004/02/05 05:00 [pubmed]', '2004/10/22 09:00 [medline]', '2004/02/05 05:00 [entrez]']",ppublish,Chembiochem. 2004 Feb 6;5(2):152-61. doi: 10.1002/cbic.200300761.,['10.1002/cbic.200300761 [doi]'],,"Lipases represent the most important class of enzymes used in biotechnology. Many bacteria produce and secrete lipases but the enzymes originating from Pseudomonas and Burkholderia species seem to be particularly useful for a wide variety of different biocatalytic applications. These enzymes are usually encoded in an operon together with a second gene which codes for a lipase-specific foldase, Lif, which is necessary to obtain enzymatically active lipase. A detailed analysis based on amino acid homology has suggested the classification of Lif proteins into four different families and also revealed the presence of a conserved motif, Rx1x2FDY(F/C)L(S/T)A. Recent experimental evidence suggests that Lifs are so-called steric chaperones, which exert their physiological function by lowering energetic barriers during the folding of their cognate lipases, thereby providing essential steric information needed to fold lipases into their enzymatically active conformation.","['Institut fur Molekulare Enzymtechnologie, Heinrich-Heine-Universitat Dusseldorf, Forschungszentrum Julich, 52428 Julich, Germany.']",,,83,,,,,,,
14760540,NLM,MEDLINE,20040608,20181113,0934-9723 (Print) 0934-9723 (Linking),23,3,2004 Mar,Gordonia polyisoprenivorans septicemia in a bone marrow transplant patient.,226-8,"['Kempf, V A J', 'Schmalzing, M', 'Yassin, A F', 'Schaal, K P', 'Baumeister, D', 'Arenskotter, M', 'Steinbuchel, A', 'Autenrieth, I B']","['Kempf VA', 'Schmalzing M', 'Yassin AF', 'Schaal KP', 'Baumeister D', 'Arenskotter M', 'Steinbuchel A', 'Autenrieth IB']",['eng'],"['Case Reports', 'Journal Article']",,Germany,Eur J Clin Microbiol Infect Dis,European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,8804297,"['0 (Anti-Bacterial Agents)', '0 (DNA, Bacterial)']",IM,"['Actinomycetales Infections/*diagnosis/drug therapy', 'Adult', 'Anti-Bacterial Agents', 'Base Sequence', 'Bone Marrow Transplantation/*adverse effects/*immunology', 'DNA, Bacterial/analysis', 'Drug Therapy, Combination/administration & dosage', 'Female', 'Follow-Up Studies', 'Gordonia Bacterium/*isolation & purification', 'Humans', '*Immunocompromised Host', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/surgery', 'Molecular Sequence Data', 'Polymerase Chain Reaction', 'Risk Assessment', 'Sepsis/*diagnosis/drug therapy', 'Severity of Illness Index', 'Transplantation, Homologous/adverse effects', 'Treatment Outcome']",,,,2004/02/05 05:00,2004/06/21 10:00,['2004/02/05 05:00'],"['2004/02/05 05:00 [pubmed]', '2004/06/21 10:00 [medline]', '2004/02/05 05:00 [entrez]']",ppublish,Eur J Clin Microbiol Infect Dis. 2004 Mar;23(3):226-8. doi: 10.1007/s10096-003-1087-z. Epub 2004 Feb 4.,['10.1007/s10096-003-1087-z [doi]'],,,"['Institut fur Medizinische Mikrobiologie und Krankenhaushygiene, Eberhard-Karls-Universitat, Elfriede-Aulhorn Strasse 6, 72076 Tubingen, Germany. volkhard.kempf@med.uni-tuebingen.de']",20040204,,,,,,,,,
14760137,NLM,MEDLINE,20040601,20200203,0923-7534 (Print) 0923-7534 (Linking),15,2,2004 Feb,Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.,358-9,"['Arora, B', 'Kumar, L', 'Sharma, A', 'Wadhwa, J', 'Kochupillai, V']","['Arora B', 'Kumar L', 'Sharma A', 'Wadhwa J', 'Kochupillai V']",['eng'],"['Clinical Trial', 'Letter']",,England,Ann Oncol,Annals of oncology : official journal of the European Society for Medical Oncology,9007735,"['0 (Antineoplastic Agents)', '0 (Benzamides)', '0 (Piperazines)', '0 (Pyrimidines)', '8A1O1M485B (Imatinib Mesylate)']",IM,"['Antineoplastic Agents/*adverse effects/*therapeutic use', 'Benzamides', 'Exanthema/chemically induced', 'Humans', 'Imatinib Mesylate', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy', 'Pigmentation Disorders/*chemically induced/physiopathology', 'Piperazines/*adverse effects/*therapeutic use', 'Pyrimidines/*adverse effects/*therapeutic use']",,,,2004/02/05 05:00,2004/06/02 05:00,['2004/02/05 05:00'],"['2004/02/05 05:00 [pubmed]', '2004/06/02 05:00 [medline]', '2004/02/05 05:00 [entrez]']",ppublish,Ann Oncol. 2004 Feb;15(2):358-9. doi: 10.1093/annonc/mdh068.,"['10.1093/annonc/mdh068 [doi]', 'S0923-7534(19)65630-9 [pii]']",,,,,,,,,,,,,
14760072,NLM,MEDLINE,20041004,20191108,1078-0432 (Print) 1078-0432 (Linking),10,2,2004 Jan 15,CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas.,508-20,"['Aldinucci, Donatella', 'Poletto, Dalisa', 'Lorenzon, Debora', 'Nanni, Paola', 'Degan, Massimo', 'Olivo, Karin', 'Rapana, Barbara', 'Pinto, Antonio', 'Gattei, Valter']","['Aldinucci D', 'Poletto D', 'Lorenzon D', 'Nanni P', 'Degan M', 'Olivo K', 'Rapana B', 'Pinto A', 'Gattei V']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Clin Cancer Res,Clinical cancer research : an official journal of the American Association for Cancer Research,9502500,"['0 (Antibiotics, Antineoplastic)', '0 (Biomarkers, Tumor)', '395575MZO7 (Pentostatin)', '63231-63-0 (RNA)', 'EC 3.4.14.5 (Dipeptidyl Peptidase 4)']",IM,"['Antibiotics, Antineoplastic/pharmacology', '*Apoptosis', 'Biomarkers, Tumor', 'Blotting, Western', 'Bone Marrow Cells/metabolism', 'Cell Division', 'Cell Line', 'Cell Line, Tumor', 'Cell Survival', 'Cells, Cultured', 'Cytosol/metabolism', 'Dipeptidyl Peptidase 4/*biosynthesis', 'Flow Cytometry', 'Humans', 'Leukemia/metabolism', 'Leukemia, T-Cell/metabolism/*pathology', 'Lymphoma/metabolism/*pathology', 'Pentostatin/*pharmacology', 'Prognosis', 'RNA/metabolism', 'Reverse Transcriptase Polymerase Chain Reaction', 'T-Lymphocytes/metabolism', 'Transfection']",,,,2004/02/05 05:00,2004/10/05 09:00,['2004/02/05 05:00'],"['2004/02/05 05:00 [pubmed]', '2004/10/05 09:00 [medline]', '2004/02/05 05:00 [entrez]']",ppublish,Clin Cancer Res. 2004 Jan 15;10(2):508-20. doi: 10.1158/1078-0432.ccr-0755-03.,['10.1158/1078-0432.ccr-0755-03 [doi]'],,"PURPOSE AND EXPERIMENTAL DESIGN: dCF (2'-deoxycoformycin) is a potent inhibitor of ADA (adenosine deaminase), an enzyme regulating intra- and extracellular concentrations of purine metabolites. ADA exists as cytosolic and extracellular forms, the latter colocalized on the cell surface with CD26. Once the surface expression of CD26 and ADA in a panel of cell lines and primary samples of T-cell leukemia/lymphoma was defined, we correlated this expression with the antiproliferative and apoptotic effect of dCF. RESULTS: Surface expression of CD26 inversely correlated with the capability of dCF to inhibit cell growth and induce apoptosis both in T-cell lines and primary samples of T-cell malignancies. This conclusion was sustained by a decreased sensitivity to dCF-mediated proapoptotic and/or antiproliferative in vitro effects of: (a) leukemia/lymphoma T-cell lines expressing surface CD26/ADA complex; (b) primary CD26(+) T cell malignancies; and (c) normal T cells (CD26(+)) as compared with tumor T cells (CD26(-)) in unpurified samples from three cases of T-cell receptor gammadelta(+) T-cell malignancies characterized by a mixture of normal and neoplastic cells. This latter point was confirmed in vivo, in a patient affected by CD26(-) T-cell receptor gammadelta(+) hepatosplenic gammadelta(+) T-cell lymphomas treated on a compassionate basis with dCF. The inverse correlation between CD26 expression and sensitivity to dCF was also demonstrated in a lymphoblastic lymphoma case in which CD26 was expressed on circulating blasts at relapse but not at diagnosis, as well as in two H9 T-cell clones expressing or not expressing CD26 mRNA and protein. CONCLUSIONS: This study corroborates the notion of CD26 as a marker of poor prognosis for T-cell malignancies and delineates a role for CD26 as a predictor of poor response to dCF.","['Clinical and Experimental Hematology Research Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy. daldinucci@cro.it']",,,,,,,,,,
14759799,NLM,MEDLINE,20040917,20170120,1525-0016 (Print) 1525-0016 (Linking),9,2,2004 Feb,Efficient gene transfer to hematopoietic repopulating cells using concentrated RD114-pseudotype vectors produced by human packaging cells.,157-9,"['Neff, Tobias', 'Peterson, Laura J', 'Morris, Julia C', 'Thompson, Jesse', 'Zhang, Xiaobing', 'Horn, Peter A', 'Thomasson, Bobbie M', 'Kiem, Hans-Peter']","['Neff T', 'Peterson LJ', 'Morris JC', 'Thompson J', 'Zhang X', 'Horn PA', 'Thomasson BM', 'Kiem HP']",['eng'],['Letter'],,United States,Mol Ther,Molecular therapy : the journal of the American Society of Gene Therapy,100890581,,IM,"['Animals', 'Cell Line', 'Dogs', 'Genetic Vectors/*genetics', 'Hematopoietic Stem Cells/*virology', 'Humans', 'Leukemia Virus, Feline/*genetics/*physiology', 'Mice', 'NIH 3T3 Cells', '*Virus Assembly']",,,,2004/02/05 05:00,2004/09/21 05:00,['2004/02/05 05:00'],"['2004/02/05 05:00 [pubmed]', '2004/09/21 05:00 [medline]', '2004/02/05 05:00 [entrez]']",ppublish,Mol Ther. 2004 Feb;9(2):157-9. doi: 10.1016/j.ymthe.2003.11.011.,"['10.1016/j.ymthe.2003.11.011 [doi]', 'S1525-0016(03)00376-9 [pii]']",,,,,,,,,,,,,
14759363,NLM,MEDLINE,20040310,20190917,1097-2765 (Print) 1097-2765 (Linking),13,2,2004 Jan 30,The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.,169-78,"['Griffith, James', 'Black, James', 'Faerman, Carlos', 'Swenson, Lora', 'Wynn, Michael', 'Lu, Fan', 'Lippke, Judith', 'Saxena, Kumkum']","['Griffith J', 'Black J', 'Faerman C', 'Swenson L', 'Wynn M', 'Lu F', 'Lippke J', 'Saxena K']",['eng'],['Journal Article'],,United States,Mol Cell,Molecular cell,9802571,"['0 (Proto-Oncogene Proteins)', 'EC 2.7.10.1 (FLT3 protein, human)', 'EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)', 'EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)']",IM,"['Amino Acid Sequence', 'Animals', 'Binding Sites', 'Cloning, Molecular', 'Gene Library', 'Humans', 'Models, Molecular', 'Molecular Sequence Data', 'Mutation', 'Point Mutation', 'Protein Conformation', 'Protein Structure, Secondary', 'Protein Structure, Tertiary', 'Proto-Oncogene Proteins/*chemistry/*physiology', 'Receptor Protein-Tyrosine Kinases/*chemistry/*physiology', 'Sequence Homology, Amino Acid', 'fms-Like Tyrosine Kinase 3']",,,,2004/02/05 05:00,2004/03/11 05:00,['2004/02/05 05:00'],"['2003/09/16 00:00 [received]', '2003/11/20 00:00 [revised]', '2003/11/24 00:00 [accepted]', '2004/02/05 05:00 [pubmed]', '2004/03/11 05:00 [medline]', '2004/02/05 05:00 [entrez]']",ppublish,Mol Cell. 2004 Jan 30;13(2):169-78. doi: 10.1016/s1097-2765(03)00505-7.,"['S1097-2765(03)00505-7 [pii]', '10.1016/s1097-2765(03)00505-7 [doi]']",,"FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis. Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant numbers of patients with acute myelogenous leukemia (AML). The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain. To further understand the nature of FLT3 autoinhibition and regulation, we have determined the crystal structure of the autoinhibited form of FLT3. This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases. The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.","['Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA. james_griffith@vrtx.com']",,,,,,,,,['PDB/1RJB'],
14759131,NLM,MEDLINE,20040317,20131121,0021-8561 (Print) 0021-8561 (Linking),52,3,2004 Feb 11,Polyozellin isolated from Polyozellus multiplex induces phase 2 enzymes in mouse hepatoma cells and differentiation in human myeloid leukaemic cell lines.,451-5,"['Kim, Jeong Hyun', 'Lee, Jeong Soon', 'Song, Kyung-Sik', 'Kwon, Chong-Suk', 'Kim, Young Kyoon', 'Kim, Jong-Sang']","['Kim JH', 'Lee JS', 'Song KS', 'Kwon CS', 'Kim YK', 'Kim JS']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,J Agric Food Chem,Journal of agricultural and food chemistry,0374755,"['0 (Anticarcinogenic Agents)', '0 (Furans)', '0 (polyozellin)', 'EC 2.5.1.18 (Glutathione Transferase)', 'GAN16C9B8O (Glutathione)', 'Y4S76JWI15 (Methanol)']",IM,"['Agaricales/*chemistry', 'Animals', 'Anticarcinogenic Agents', 'Cell Differentiation/drug effects', 'Dose-Response Relationship, Drug', 'Enzyme Induction/drug effects', 'Furans/isolation & purification/*pharmacology', 'Glutathione/analysis', 'Glutathione Transferase/biosynthesis', 'Humans', 'Leukemia, Myeloid/*pathology', 'Liver Neoplasms, Experimental/*enzymology', 'Methanol', 'Mice', 'Tumor Cells, Cultured']",,,,2004/02/05 05:00,2004/03/18 05:00,['2004/02/05 05:00'],"['2004/02/05 05:00 [pubmed]', '2004/03/18 05:00 [medline]', '2004/02/05 05:00 [entrez]']",ppublish,J Agric Food Chem. 2004 Feb 11;52(3):451-5. doi: 10.1021/jf034748n.,['10.1021/jf034748n [doi]'],,"Induction of cellular phase 2 detoxifying enzymes is associated with cancer preventive potential. Quinone reductase (QR) has been used as a prototype for anticarcinogenic phase 2 enzymes because of its widespread distribution in mammalian systems, large amplitude of inducer response, and ease of measurement in murine hepatoma cells. Methanol extract of Polyozellus multiplex, which shows a strong QR induction potential, was subjected to bioassay-guided fractionation, and polyozellin (PM1) appeared to be a major active component. In in vitro cultured cells (hepa1c1c7 and BPRc1 cells), polyozellin enhanced QR, glutathione S-transferase (GST) activities, and glutathione (GSH) content in a dose-dependent manner. The compound also significantly promoted differentiation of HL-60 human promyelocytic emia cells. In conclusion, polyozellin deserves further in vivo study to evaluate its potential as a cancer preventive agent.","['Department of Animal Science and Biotechnology, Kyungpook National University, Daegu 702-701, Korea.']",,,,,,,,,,
14758881,NLM,MEDLINE,20040218,20131121,0019-509X (Print) 0019-509X (Linking),38,1,2001 Mar,Fusarium solani fungemia in a patient with acute lymphoblastic leukemia.,19-21,"['Sridhar, H', 'Subramanyam, J R', 'Appaji, L', 'Shafiulla, M', 'Vijaykumar, B R']","['Sridhar H', 'Subramanyam JR', 'Appaji L', 'Shafiulla M', 'Vijaykumar BR']",['eng'],"['Case Reports', 'Journal Article', 'Review']",,India,Indian J Cancer,Indian journal of cancer,0112040,"['0 (Antifungal Agents)', '8VZV102JFY (Fluconazole)']",IM,"['Antifungal Agents/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects', 'Child', 'Fluconazole/therapeutic use', 'Fungemia/*chemically induced/drug therapy', '*Fusarium', 'Humans', 'Immunocompromised Host', 'Male', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*complications/*drug therapy']",,,,2004/02/05 05:00,2004/02/19 05:00,['2004/02/05 05:00'],"['2004/02/05 05:00 [pubmed]', '2004/02/19 05:00 [medline]', '2004/02/05 05:00 [entrez]']",ppublish,Indian J Cancer. 2001 Mar;38(1):19-21.,,,A patient with ALL on anticancer chemotherapy developed fever which was later attributed to be due to Fusarium fungemia. The details of the case & a review of literature follows.,"['Department of Microbiology, Kidwai Memorial Institute of Oncology, Hosur Road, Bangalore 560 029, Karnataka, India.']",,,9,,,,,,,
14758732,NLM,MEDLINE,20040819,20121115,0258-851X (Print) 0258-851X (Linking),17,6,2003 Nov-Dec,"Effects of 6-gingerol, an antioxidant from ginger, on inducing apoptosis in human leukemic HL-60 cells.",641-5,"['Wang, Ching-Chiung', 'Chen, Lih-Geeng', 'Lee, Lain-Tze', 'Yang, Ling-Ling']","['Wang CC', 'Chen LG', 'Lee LT', 'Yang LL']",['eng'],['Journal Article'],,Greece,In Vivo,"In vivo (Athens, Greece)",8806809,"['0 (Antioxidants)', '0 (Catechols)', '0 (Cytotoxins)', '0 (Fatty Alcohols)', '0 (Reactive Oxygen Species)', '925QK2Z900 (gingerol)']",IM,"['Antioxidants/*toxicity', 'Apoptosis/*drug effects', 'Catechols', 'Cytotoxins/toxicity', 'Dose-Response Relationship, Drug', 'Fatty Alcohols/*toxicity', 'Flow Cytometry', '*Ginger', 'HL-60 Cells', 'Humans', 'Reactive Oxygen Species/metabolism']",,,,2004/02/05 05:00,2004/08/20 05:00,['2004/02/05 05:00'],"['2004/02/05 05:00 [pubmed]', '2004/08/20 05:00 [medline]', '2004/02/05 05:00 [entrez]']",ppublish,In Vivo. 2003 Nov-Dec;17(6):641-5.,,,"6-Gingerol, a naturally occurring plant phenol, is one of the major components of fresh ginger. In this paper, the antioxidative effects of 6-gingerol were detected by DPPH and DCFH assays and, as predicted, 6-gingerol as an antioxidant was shown to protect HL-60 cells from oxidative stress. Moreover, it induced cell death in promyelocytic leukemia HL-60 cells, caused DNA fragmentation and inhibited Bcl-2 expression in HL-60 cells. These results suggested that the inhibition of Bcl-2 expression in HL-60 cells might account for the mechanism of 6-gingerol-induced apoptosis. In the inhibitory assay, the cytotoxic effect of 6-gingerol could be prevented by catalase. We suggest that 6-gingerol induced cell death by mediating reactive oxygen species such as hydrogen peroxide and the superoxide anion. Therefore, the results showed that 6-gingerol induced apoptosis in HL-60 cells, not due to its antioxidative activity.","['Graduate Institute of Pharmacognosy Science, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan, R.O.C.']",,,,,,,,,,
14758725,NLM,MEDLINE,20040819,20131121,0258-851X (Print) 0258-851X (Linking),17,6,2003 Nov-Dec,Effect of endodontic agents on cytotoxicity induction by sodium fluoride.,583-91,"['Tokunaga, Takashi', 'Morshed, Sufi Reza Md', 'Otsuki, Sumiko', 'Takayama, Fumitoshi', 'Hashimoto, Ken', 'Kashimata, Masanori', 'Nakamura, Yuko', 'Nishikawa, Hirofumi', 'Yasui, Toshikazu', 'Yokote, Yoshiko', 'Akahane, Kiso', 'Sakagami, Hiroshi']","['Tokunaga T', 'Morshed SR', 'Otsuki S', 'Takayama F', 'Hashimoto K', 'Kashimata M', 'Nakamura Y', 'Nishikawa H', 'Yasui T', 'Yokote Y', 'Akahane K', 'Sakagami H']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,Greece,In Vivo,"In vivo (Athens, Greece)",8806809,"['0 (Dental Cements)', '0 (Drug Combinations)', '0 (Root Canal Filling Materials)', '0 (Vinyl Compounds)', '0 (calcium sulfate, zinc oxide, vinyl acetate, zinc phosphate root canal filling)', '8ZYQ1474W7 (Sodium Fluoride)', 'AE28F7PNPL (Methionine)', 'EC 3.4.22.- (CASP3 protein, human)', 'EC 3.4.22.- (CASP8 protein, human)', 'EC 3.4.22.- (CASP9 protein, human)', 'EC 3.4.22.- (Caspase 3)', 'EC 3.4.22.- (Caspase 8)', 'EC 3.4.22.- (Caspase 9)', 'EC 3.4.22.- (Caspases)', 'IY9XDZ35W2 (Glucose)', 'SOI2LOH54Z (Zinc Oxide)', 'WAT0DDB505 (Calcium Sulfate)']",IM,"['Apoptosis/*drug effects', 'Calcium Sulfate/pharmacology', '*Carcinoma, Squamous Cell', 'Caspase 3', 'Caspase 8', 'Caspase 9', 'Caspases/metabolism', 'Dental Cements', 'Drug Combinations', 'Glucose/metabolism', 'HL-60 Cells', 'Humans', '*Leukemia, Promyelocytic, Acute', 'Methionine/metabolism', '*Mouth Neoplasms', 'Oral Hygiene', 'Oxidation-Reduction', 'Root Canal Filling Materials', 'Sodium Fluoride/*pharmacology', 'Vinyl Compounds/pharmacology', 'Zinc Oxide/pharmacology']",,,,2004/02/05 05:00,2004/08/20 05:00,['2004/02/05 05:00'],"['2004/02/05 05:00 [pubmed]', '2004/08/20 05:00 [medline]', '2004/02/05 05:00 [entrez]']",ppublish,In Vivo. 2003 Nov-Dec;17(6):583-91.,,,"We investigated six endodontic agents for their ability to induce apoptosis and modify the cytotoxic activity of NaF against human squamous cell carcinoma (HSC-2) and human promyelocytic leukemia (HL-60) cell lines. Four Group I agents (Form Cresol, Cam Phenic, Eucaly Soft, GC Fuji Varnish), but not two Group II agents (Caviton, Canals-N), induced internucleosomal DNA fragmentation and activated caspases 3, 8 and 9 in HL-60 cells. Only Cam Phenic among these agents additively enhanced the cytotoxic activity of NaF in HSC-2 and HL-60 cells. Form Cresol and Cam Phenic reduced the glucose consumption at early stage, possibly due to their toxic effect. Amino acid analysis suggests that the higher cytotoxicity of Form Cresol may be derived, at least in part, from its oxidizing action.","['Department of Dental Pharmacology, Meikai University School of Dentistry, Sakado, Saitama, 350-0283, Japan.']",,,,,,,,,,
14758289,NLM,MEDLINE,20040226,20150624,0032-1052 (Print) 0032-1052 (Linking),113,2,2004 Feb,Erythema annulare centrifugum: an unusual presentation for acute leukemia.,798-9,"['Gundeslioglu, A Ozlem', 'Ertas, Nilgun Markal', 'Celebioglu, Selim', 'Hucumenoglu, Sema']","['Gundeslioglu AO', 'Ertas NM', 'Celebioglu S', 'Hucumenoglu S']",['eng'],"['Case Reports', 'Letter']",,United States,Plast Reconstr Surg,Plastic and reconstructive surgery,1306050,,IM,"['Adult', 'Diagnosis, Differential', 'Erythema/complications/diagnosis/*pathology', 'Humans', 'Male', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications/*diagnosis']",,,,2004/02/06 05:00,2004/02/27 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/02/27 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Plast Reconstr Surg. 2004 Feb;113(2):798-9. doi: 10.1097/01.PRS.0000104551.91023.DE.,['10.1097/01.PRS.0000104551.91023.DE [doi]'],,,,,,,,,,,,,
14758254,NLM,MEDLINE,20040226,20150624,0032-1052 (Print) 0032-1052 (Linking),113,2,2004 Feb,A case of adult T-cell leukemia/lymphoma.,757-8,"['Takagi, Satoshi', 'Shirakawa, Yuji']","['Takagi S', 'Shirakawa Y']",['eng'],"['Case Reports', 'Letter']",,United States,Plast Reconstr Surg,Plastic and reconstructive surgery,1306050,,IM,"['Aged', '*Eyelid Neoplasms/diagnosis/therapy', 'Humans', '*Leukemia-Lymphoma, Adult T-Cell/diagnosis/therapy', 'Male']",,,,2004/02/06 05:00,2004/02/27 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/02/27 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Plast Reconstr Surg. 2004 Feb;113(2):757-8. doi: 10.1097/01.PRS.0000104501.82920.64.,"['10.1097/01.PRS.0000104501.82920.64 [doi]', '00006534-200402000-00060 [pii]']",,,,,,,,,,,,,
14758137,NLM,MEDLINE,20040225,20190906,1537-453X (Electronic) 0277-3732 (Linking),27,1,2004 Feb,Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.,73-80,"['Chronowski, Gregory M', 'Wilder, Richard B', 'Levy, Larry B', 'Atkinson, Edward N', 'Ha, Chul S', 'Hagemeister, Fredrick B', 'Barista, Ibrahim', 'Rodriguez, Maria A', 'Sarris, Andreas H', 'Hess, Mark A', 'Cabanillas, Fernando', 'Cox, James D']","['Chronowski GM', 'Wilder RB', 'Levy LB', 'Atkinson EN', 'Ha CS', 'Hagemeister FB', 'Barista I', 'Rodriguez MA', 'Sarris AH', 'Hess MA', 'Cabanillas F', 'Cox JD']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Am J Clin Oncol,American journal of clinical oncology,8207754,"['0 (Antineoplastic Agents, Alkylating)', '5J49Q6B70F (Vincristine)', '5V9KLZ54CY (Vinblastine)', 'BZ114NVM5P (Mitoxantrone)', 'VB0R961HZT (Prednisone)', 'NOVP protocol']",IM,"['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Agents, Alkylating/administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/therapeutic use', 'Combined Modality Therapy', 'Dose Fractionation, Radiation', 'Female', 'Hodgkin Disease/*drug therapy/*radiotherapy', 'Humans', 'Male', 'Middle Aged', 'Mitoxantrone/administration & dosage/adverse effects', 'Neoplasms, Second Primary/*epidemiology/etiology', 'Prednisone/administration & dosage/adverse effects', 'Retrospective Studies', 'Vinblastine/administration & dosage/adverse effects', 'Vincristine/administration & dosage/adverse effects']",,,,2004/02/06 05:00,2004/02/26 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/02/26 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Am J Clin Oncol. 2004 Feb;27(1):73-80. doi: 10.1097/01.coc.0000045853.73233.42.,"['00000421-200402000-00013 [pii]', '10.1097/01.coc.0000045853.73233.42 [doi]']",,"The purpose of this preliminary study was to determine the incidence of second malignancies after combined-modality therapy for adults with Hodgkin disease and relate it to the details of initial treatment. We retrospectively studied 286 patients ranging in age from 16 to 88 years with stage I or II Hodgkin disease who were treated between 1980 and 1995 with chemotherapy followed 3 to 4 weeks later by radiotherapy. Patients received a median of three cycles of induction chemotherapy. Mitoxantrone, vincristine, vinblastine, and prednisone was used in 161 cases, mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) in 67 cases, Adriamycin, bleomycin, vinblastine, and dacarbazine in 19 cases, lomustine, vinblastine, procarbazine, and prednisone/doxorubicin, bleomycin, dacarbazine, and lomustine in 18 cases, and other chemotherapeutic regimens in the remaining 21 cases. The median radiotherapy dose was 40 Gy given in 20 daily 2-Gy fractions. Median follow-up of surviving patients was 7.4 years. There were 2,230 person-years of observation. Significantly increased relative risks (RR) were observed for acute myeloid leukemia (RR, 69.3; 95% CI, 14.3-202.6) and melanoma (RR, 7.3; 95% CI, 1.5-21.3). The 5-, 10-, and 15-year actuarial risks of acute myeloid leukemia were 0.8%, 1.3%, and 1.3%, respectively. Patients treated with MOPP had the highest 15-year actuarial risk of leukemia (1.6%). The 5-, 10-, and 15-year actuarial risks of solid tumors were 1.9%, 9.3%, and 16.8%, respectively. Consolidative radiotherapy to both sides of the diaphragm resulted in a trend toward an increased risk of solid tumors relative to radiotherapy to only one side of the diaphragm (p = 0.08). In an effort to reduce the risk of second malignancies, we have stopped using the alkylating agents nitrogen mustard and procarbazine and elective paraaortic and splenic radiotherapy after chemotherapy.","['Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.']",,"['CA 16672/CA/NCI NIH HHS/United States', 'CA 6294/CA/NCI NIH HHS/United States']",,,,,,,,
14758109,NLM,MEDLINE,20040520,20191210,1040-8703 (Print) 1040-8703 (Linking),16,1,2004 Feb,Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production.,15-22,"['Geddis, Amy E', 'Kaushansky, Kenneth']","['Geddis AE', 'Kaushansky K']",['eng'],"['Journal Article', 'Review']",,United States,Curr Opin Pediatr,Current opinion in pediatrics,9000850,"['0 (DNA-Binding Proteins)', '0 (HOXA11 protein, human)', '0 (Homeobox A10 Proteins)', '0 (Homeodomain Proteins)', '140441-81-2 (HOXA10 protein, human)']",IM,"['Animals', 'Blood Platelet Disorders/*genetics/pathology', 'DNA-Binding Proteins/genetics', 'Genetic Diseases, X-Linked/genetics/pathology', 'Hematopoietic Stem Cells/pathology', 'Homeobox A10 Proteins', 'Homeodomain Proteins/genetics', 'Humans', 'Megakaryocytes/metabolism/pathology', 'Mutation', 'Syndrome', 'Thrombocytopenia/*genetics/pathology', 'Thrombopoiesis/genetics']",,,,2004/02/06 05:00,2004/05/21 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/05/21 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Curr Opin Pediatr. 2004 Feb;16(1):15-22. doi: 10.1097/00008480-200402000-00005.,"['00008480-200402000-00005 [pii]', '10.1097/00008480-200402000-00005 [doi]']",,"PURPOSE OF REVIEW: To review the defined syndromes of inherited thrombocytopenia and discuss new genetic data for several disorders that shed light on the process of megakaryopoiesis. RECENT FINDINGS: The genes responsible for several inherited thrombocytopenias have been recently discovered, including congenital amegakaryocytic leukemia, amegakaryocytic thrombocytopenia with radio-ulnar synostosis, familial platelet syndrome with predisposition to acute myelogenous leukemia, Paris-Trousseau, Wiskott-Aldrich syndrome, and the May-Hegglin, Sebastian, Epstein, and Fechner syndromes. These clinical syndromes, combined with studies in mouse and in vitro models, reveal the importance of these genes for normal hematopoiesis. SUMMARY: Although inherited syndromes of thrombocytopenia are rare, characterization of mutations in these disorders has contributed greatly to our understanding of megakaryocyte and platelet development. A systematic registry of congenitally thrombocytopenic individuals would almost certainly lead to new genetic discoveries.","['Department of Pediatrics, University of California, San Diego, USA. Ageddis@ucsd.edu']",,,155,,,,,,,
14758108,NLM,MEDLINE,20040520,20211203,1040-8703 (Print) 1040-8703 (Linking),16,1,2004 Feb,Influence of race and socioeconomic status on outcome of children treated for childhood acute lymphoblastic leukemia.,9-14,"['Bhatia, Smita']",['Bhatia S'],['eng'],"['Journal Article', 'Review']",,United States,Curr Opin Pediatr,Current opinion in pediatrics,9000850,,IM,"['Child', 'Cohort Studies', 'Ethnicity', 'Humans', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*ethnology/mortality/*therapy', 'Retrospective Studies', '*Social Class', 'Survival Analysis', 'Survival Rate']",,,,2004/02/06 05:00,2004/05/21 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/05/21 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Curr Opin Pediatr. 2004 Feb;16(1):9-14. doi: 10.1097/00008480-200402000-00004.,"['00008480-200402000-00004 [pii]', '10.1097/00008480-200402000-00004 [doi]']",,"PURPOSE OF REVIEW: Overall, childhood acute lymphoblastic leukemia is associated with an excellent outcome. The improvement in survival achieved during the last three decades is partially attributed to the identification of risk factors predicting a poor outcome and risk-stratified treatment of patients placed on well-designed therapeutic trials. Accordingly, it is important to continue to identify patient subgroups with differences in outcome to focus efforts to improve overall survival. Black children historically have been reported to have a poorer survival rate compared with whites, but limited information is available for children from other racial/ethnic backgrounds. RECENT FINDINGS: Several groups have published reports on ethnic and racial differences in survival after childhood acute lymphoblastic leukemia, with poorer outcomes reported for black children compared with whites reported by the majority of the studies. Limited information is available for children from other racial/ethnic backgrounds, such as Hispanics and Asians, but data indicate that Hispanics have poorer survival than whites, whereas Asians from the United States have outcomes that are as good or better than those of the whites, especially among the high-risk group treated with contemporary risk-based therapy. The influence of race and ethnicity on survival should be closely linked with socioeconomic status. However, few studies have specifically investigated the influence of nutrition and socioeconomic factors on the prognosis of children with acute lymphoblastic leukemia, and the results are conflicting. SUMMARY: Future studies need to focus on the reasons for these differences, including racial and ethnic differences in adherence with therapeutic protocols, and ethnic differences in drug metabolism and bioavailability of the agents commonly used in acute lymphoblastic leukemia, so that drug administration can be modified if needed.","['Division of Peciatrics, City of Hope Cancer Center, Duarte, California 91010, USA. sbhatia@coh.org']",,,36,,,,,,,
14758029,NLM,MEDLINE,20041207,20190719,0918-6158 (Print) 0918-6158 (Linking),27,2,2004 Feb,Growth-inhibitory effects of the red alga Gelidium amansii on cultured cells.,180-4,"['Chen, Yue-Hwa', 'Tu, Ching-Jung', 'Wu, Hsiao-Ting']","['Chen YH', 'Tu CJ', 'Wu HT']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,Japan,Biol Pharm Bull,Biological & pharmaceutical bulletin,9311984,"['0 (Annexin A5)', '0 (Anticarcinogenic Agents)', '0 (Biological Products)', 'Y4S76JWI15 (Methanol)', 'YOW8V9698H (Dimethyl Sulfoxide)']",IM,"['Animals', 'Annexin A5/metabolism', 'Anticarcinogenic Agents/*pharmacology', 'Apoptosis/drug effects', 'Biological Products/*pharmacology', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Dimethyl Sulfoxide', 'Humans', 'Methanol', 'Mice', 'NIH 3T3 Cells', 'Rhodophyta/*chemistry', 'Time Factors']",,,,2004/02/06 05:00,2004/12/16 09:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/12/16 09:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Biol Pharm Bull. 2004 Feb;27(2):180-4. doi: 10.1248/bpb.27.180.,['10.1248/bpb.27.180 [doi]'],,"The objective of this study was to investigate the effects of Gelidium amansii, an edible red agar cultivated off the northeast coast of Taiwan, on the growth of two lines of cancer cells, murine hepatoma (Hepa-1) and human leukemia (HL-60) cells, as well as a normal cell line, murine embryo fibroblast cells (NIH-3T3). The potential role of G. amansii on the induction of apoptosis was also examined. The results indicated that all extracts from G. amansii, including phosphate-buffered saline (PBS) and methanol extracts from dried algae as well as the dimethyl sulfoxide (DMSO) extract from freeze-dried G. amansii agar, inhibited the growth of Hepa-1 and NIH-3T3 cells, but not the growth of HL-60 cells. Annexin V-positive cells were observed in methanol and DMSO extract-treated, but not PBS extract-treated Hepa-1 and NIH-3T3 cells, suggesting that the lipid-soluble extracts of G. amansii induced apoptosis. In summary, extracts of G. amansii from various preparations exhibited antiproliferative effects on Hepa-1 and NIH-3T3 cells, and apoptosis may play a role in the methanol and DMSO extract-induced inhibitory effects. However, the antiproliferative effects of PBS extracts was not through apoptosis. Moreover, the growth-inhibitory effects of G. amansii were not specific to cancer cells.","['School of Nutrition and Health Sciences, Taipei Medical University, 250 Wu-Hsing Street, Taipei, Taiwan 110, ROC. yuehwa@tmu.edu.tw']",,,,,,,,,,
14757768,NLM,MEDLINE,20040722,20210209,0021-9258 (Print) 0021-9258 (Linking),279,16,2004 Apr 16,C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation.,15897-907,"['Kamao, Maya', 'Tatematsu, Syuichiro', 'Hatakeyama, Susumi', 'Sakaki, Toshiyuki', 'Sawada, Natsumi', 'Inouye, Kuniyo', 'Ozono, Keiichi', 'Kubodera, Noboru', 'Reddy, G Satyanarayana', 'Okano, Toshio']","['Kamao M', 'Tatematsu S', 'Hatakeyama S', 'Sakaki T', 'Sawada N', 'Inouye K', 'Ozono K', 'Kubodera N', 'Reddy GS', 'Okano T']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,J Biol Chem,The Journal of biological chemistry,2985121R,"['1C6V77QF41 (Cholecalciferol)', '40013-87-4 (24,25-Dihydroxyvitamin D 3)', 'P6YZ13C99Q (Calcifediol)']",IM,"['24,25-Dihydroxyvitamin D 3/metabolism', 'Animals', 'Calcifediol/*metabolism', 'Cell Line, Tumor', 'Cholecalciferol/*metabolism', 'Humans', 'Hydroxylation', 'Magnetic Resonance Spectroscopy', 'Male', 'Rats', 'Rats, Wistar', 'Stereoisomerism']",,,,2004/02/06 05:00,2004/07/23 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/07/23 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,J Biol Chem. 2004 Apr 16;279(16):15897-907. doi: 10.1074/jbc.M311473200. Epub 2004 Feb 2.,"['10.1074/jbc.M311473200 [doi]', 'S0021-9258(20)88305-7 [pii]']",,"Recently, it was revealed that 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) and 24R,25-dihydroxyvitamin D3 (24,25(OH)2D3) were metabolized to their respective epimers of the hydroxyl group at C-3 of the A-ring. We now report the isolation and structural assignment of 3-epi-25-hydroxyvitamin D3 (3-epi-25(OH)D3 as a major metabolite of 25-hydroxyvitamin D3 (25(OH)D3) and the further metabolism of C-3 epimers of vitamin D3 metabolites. When 25(OH)D3 was incubated with various cultured cells including osteosarcoma, colon adenocarcinoma, and hepatoblastoma cell lines, 3-epi-25(OH)D3 and 24,25 (OH)2D3 were commonly observed as a major and minor metabolite of 25(OH)D3, respectively. 25(OH)D3 was at least as sensitive to C-3 epimerization as 1alpha, 25(OH)2D3 which has been reported as a substrate for the C-3 epimerization reaction. Unlike these cultured cells, LLC-PK1 cells, a porcine kidney cell line, preferentially produced 24,25(OH)2D3 rather than 3-epi-25(OH)D3. We also confirmed the existence of 3-epi-25(OH)D3 in the serum of rats intravenously given pharmacological doses of 25(OH)D3. The cultured cells metabolized 3-epi-25OHD3 and 3-epi-1alpha,25(OH)2D3 to 3-epi-24,25(OH)2D3 and 3-epi-1alpha,24,25(OH)3D3, respectively. In addition, we demonstrated that 3-epi-25(OH)D3 was metabolized to 3-epi-1alpha,25(OH)2D3 by CYP27B1 and to 3-epi-24,25(OH)2D3 by CYP24 using recombinant Escherichia coli cell systems. 3-Epi-25(OH)D3, 3-epi-1alpha,25(OH)2D3, and 3-epi-24,25(OH)2D3 were biologically less active than 25(OH)D3, 1alpha,25(OH)2D3, and 24,25(OH)2D3, but 3-epi-1alpha,25(OH)2D3 showed to some extent transcriptional activity toward target genes and anti-proliferative/differentiation-inducing activity against human myeloid leukemia cells (HL-60). These results indicate that C-3 epimerization may be a common metabolic pathway for the major metabolites of vitamin D3.","['Department of Hygienic Sciences, Kobe Pharmaceutical University, Kobe 658-8558, Japan.']",20040202,,,,,,,,,
14757560,NLM,MEDLINE,20041007,20181130,0031-3025 (Print) 0031-3025 (Linking),36,1,2004 Feb,B cell chronic lymphocytic leukaemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon-gamma.,69-76,"['Juffs, Helen', 'Fowler, Nina', 'Saal, Russell', 'Grimmett, Karen', 'Beasley, Shannon', ""O'Sullivan, Brendan"", 'Frazer, Ian', 'Gill, Devinder', 'Thomas, Ranjeny']","['Juffs H', 'Fowler N', 'Saal R', 'Grimmett K', 'Beasley S', ""O'Sullivan B"", 'Frazer I', 'Gill D', 'Thomas R']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,England,Pathology,Pathology,0175411,"['0 (ATP Binding Cassette Transporter, Subfamily B, Member 2)', '0 (ATP Binding Cassette Transporter, Subfamily B, Member 3)', '0 (ATP-Binding Cassette Transporters)', '0 (Histocompatibility Antigens Class I)', '0 (TAP1 protein, human)', '145892-13-3 (TAP2 protein, human)', '82115-62-6 (Interferon-gamma)']",IM,"['ATP Binding Cassette Transporter, Subfamily B, Member 2', 'ATP Binding Cassette Transporter, Subfamily B, Member 3', 'ATP-Binding Cassette Transporters/biosynthesis/immunology', 'Aged', 'Antigen Presentation/immunology', 'Flow Cytometry', 'Histocompatibility Antigens Class I/*biosynthesis/drug effects/*immunology', 'Humans', 'Interferon-gamma/immunology/*pharmacology', 'Leukemia, Lymphocytic, Chronic, B-Cell/immunology/*metabolism', 'Polymerase Chain Reaction']",,,,2004/02/06 05:00,2004/10/08 09:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/10/08 09:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Pathology. 2004 Feb;36(1):69-76. doi: 10.1080/00313020310001644499.,"['10.1080/00313020310001644499 [doi]', '15MG3TJ3MG6D6JYU [pii]']",,"AIMS: An important consideration in the design of a tumour vaccine is the ability of tumour-specific cytotoxic T lymphocytes (CTL) to recognise unmanipulated tumour cells in vivo. To determine whether B-CLL might use an escape strategy, the current studies compared B-CLL and normal B cell MHC class I expression. METHODS: Flow cytometry, TAP allele PCR and MHC class I PCR were used. RESULTS: While baseline expression of MHC class I did not differ, upregulation of MHC class I expression by B-CLL cells in response to IFN-gamma was reduced. No deletions or mutations of TAP 1 or 2 genes were detected. B-CLL cells upregulated TAP protein expression in response to IFN-gamma. Responsiveness of B-CLL MHC class I mRNA to IFN-gamma was not impaired. CONCLUSIONS: The data suggest that MHC class I molecules might be less stable at the cell surface in B-CLL than normal B cells, as a result of the described release of beta(2)m and beta(2)m-free class I heavy chains from the membrane. This relative MHC class I expression defect of B-CLL cells may reduce their susceptibility to CTL lysis in response to immunotherapeutic approaches.","['Centre for Immunology and Cancer Research, University of Queensland, Brisbane, Qld., Australia.']",,,,,,,,,,
14757535,NLM,MEDLINE,20040916,20191108,1044-579X (Print) 1044-579X (Linking),14,1,2004 Feb,Targeted therapies in myeloid leukemia.,41-62,"['John, Alison M', 'Thomas, N Shaun B', 'Mufti, Ghulam J', 'Padua, Rose Ann']","['John AM', 'Thomas NS', 'Mufti GJ', 'Padua RA']",['eng'],"['Journal Article', 'Review']",,England,Semin Cancer Biol,Seminars in cancer biology,9010218,"['0 (Growth Substances)', '0 (Proto-Oncogene Proteins)']",IM,"['Animals', 'Cell Division', 'Gene Silencing', 'Growth Substances/metabolism', 'Humans', 'Immunotherapy/methods', 'Leukemia, Myeloid/genetics/*metabolism/pathology/*therapy', 'Proto-Oncogene Proteins/genetics/metabolism', 'Translocation, Genetic/genetics']",,,,2004/02/06 05:00,2004/09/17 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/09/17 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Semin Cancer Biol. 2004 Feb;14(1):41-62. doi: 10.1016/j.semcancer.2003.11.006.,"['S1044579X03001093 [pii]', '10.1016/j.semcancer.2003.11.006 [doi]']",,"Targeted therapies for hematological malignancies have come of age since the advent of all trans retinoic acid (ATRA) for treating APL and STI571/Imatinib Mesylate/Gleevec for CML. There are good molecular targets for other malignancies and several new drugs are in clinical trials. In this review, we will concentrate on individual abnormalities that exist in the myelodysplastic syndromes (MDS) and myeloid leukemias that are targets for small molecule therapies (summarised in Fig. 1). We will cover fusion proteins that are produced as a result of translocations, including BCR-ABL, the FLT3 tyrosine kinase receptor and RAS. Progression of diseases such as MDS to secondary AML occur as a result of changes in the balance between cell proliferation and apoptosis and we will review targets in both these areas, including reversal of epigenetic silencing of genes such as p15(INK4B).","[""Leukaemia Sciences Laboratories, Department of Haematological Medicine, Guy's, King's and St Thomas' School of Medicine, King's College London, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK.""]",,,337,,,,,,,
14757533,NLM,MEDLINE,20040916,20191108,1044-579X (Print) 1044-579X (Linking),14,1,2004 Feb,Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.,23-31,"['Coutre, Steven', 'Gotlib, Jason']","['Coutre S', 'Gotlib J']",['eng'],"['Journal Article', 'Review']",,England,Semin Cancer Biol,Seminars in cancer biology,9010218,"['0 (Benzamides)', '0 (Piperazines)', '0 (Pyrimidines)', '8A1O1M485B (Imatinib Mesylate)', 'EC 2.7.10.1 (Protein-Tyrosine Kinases)']",IM,"['Animals', 'Benzamides', 'Eosinophilia/classification/diagnosis/*drug therapy/metabolism', 'Humans', 'Hypereosinophilic Syndrome/classification/diagnosis/*drug therapy/*metabolism', 'Imatinib Mesylate', 'Leukemia/classification/diagnosis/*drug therapy/metabolism', 'Piperazines/*therapeutic use', 'Protein-Tyrosine Kinases/antagonists & inhibitors/metabolism', 'Pyrimidines/*therapeutic use', 'Substrate Specificity']",,,,2004/02/06 05:00,2004/09/17 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/09/17 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Semin Cancer Biol. 2004 Feb;14(1):23-31. doi: 10.1016/j.semcancer.2003.11.004.,"['S1044579X0300107X [pii]', '10.1016/j.semcancer.2003.11.004 [doi]']",,"Idiopathic hypereosinophilic syndrome (HES) and chronic eosinophilia leukemia (CEL) represent the most recent additions to the list of molecularly defined chronic myeloproliferative disorders. Beginning with the observation that imatinib mesylate (Gleevec) could elicit rapid and complete hematologic remissions in a proportion of patients with HES, a reverse bedside-to-bench translational research effort led to the discovery of FIP1L1-PDGFRA, a novel fusion gene on chromosome 4q12 whose product is an imatinib-sensitive protein tyrosine kinase. FIP1L1-PDGFRA is the first description of a gain-of-function fusion gene derived from an interstitial chromosomal deletion rather than a reciprocal translocation. Empiric use of imatinib in HES and CEL provides a dramatic example of how the development of targeted therapeutics can provide tremendous insight into the molecular etiology of what appear to be a diverse and otherwise indecipherable collection of diseases. In this review, we discuss the role of imatinib in HES/CEL and other malignancies characterized by constitutively activated tyrosine kinases, and examine molecular features of the FIP1L1-PDGFRA fusion.","['Division of Hematology, Stanford University School of Medicine, 703 Welch Road, Suite G-1, Stanford, CA 94305-5750, USA. coutre@stanford.edu']",,,78,,,,['Semin Cancer Biol. 2004 Aug;14(4):306'],,,['Semin Cancer Biol. 2004 Aug;14(4):307-15. PMID: 15305431']
14757500,NLM,MEDLINE,20041126,20191108,0928-0987 (Print) 0928-0987 (Linking),21,2-3,2004 Feb,Reversal of P-glycoprotein mediated vincristine resistance of L1210/VCR cells by analogues of pentoxifylline. A QSAR study.,283-93,"['Kupsakova, Ivana', 'Rybar, Alfons', 'Docolomansky, Peter', 'Drobna, Zuzana', 'Stein, Ulrike', 'Walther, Wolfgang', 'Barancik, Miroslav', 'Breier, Albert']","['Kupsakova I', 'Rybar A', 'Docolomansky P', 'Drobna Z', 'Stein U', 'Walther W', 'Barancik M', 'Breier A']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,Netherlands,Eur J Pharm Sci,European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,9317982,"['0 (ATP Binding Cassette Transporter, Subfamily B, Member 1)', '0 (Antineoplastic Agents, Phytogenic)', '5J49Q6B70F (Vincristine)', 'SD6QCT3TSU (Pentoxifylline)']",IM,"['ATP Binding Cassette Transporter, Subfamily B, Member 1/*metabolism', 'Animals', 'Antineoplastic Agents, Phytogenic/chemistry/*pharmacology', 'Cell Line, Tumor', 'Crystallization', 'Drug Resistance, Neoplasm/*drug effects', 'Inhibitory Concentration 50', 'Leukemia L1210', 'Linear Models', 'Mice', 'Models, Biological', 'Pentoxifylline/*analogs & derivatives/chemistry/*pharmacology', 'Quantitative Structure-Activity Relationship', 'Vincristine/chemistry/*pharmacology']",,,,2004/02/06 05:00,2004/12/16 09:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/12/16 09:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Eur J Pharm Sci. 2004 Feb;21(2-3):283-93. doi: 10.1016/j.ejps.2003.10.019.,"['S092809870300294X [pii]', '10.1016/j.ejps.2003.10.019 [doi]']",,"In our previous papers we described the ability of methylxanthine pentoxifylline (PTX) to depress the P-glycoprotein (P-gp) mediated multidrug resistance (MDR) of the mouse leukemic cell line L1210/VCR. Other methylxanthines like caffeine and theophylline were found to be ineffective in this respect. In the present paper we have analysed the capability of 25 methylxanthines to depress MDR of L1210/VCR cells. These methylxanthines structurally differ in substituents located in positions N1, N3, N7 and C8. The results indicate that for an effective reversal of P-gp mediated MDR of our cells the existence of a longer polar substituent in the position N1 plays a crucial role. The elongation of the substituent in the positions N3 and N7 (from methyl to propyl) increases and in the position C8 (from H to propyl) decreases the efficacy of xanthines to reverse the vincristine resistance of L1210/VCR cells. The multiple linear regression for effectiveness of methylxanthines in reversal of P-gp mediated MDR of L1210/VCR cells (expressed as respective IC(50r) values) has been computed, with molar weight: M(w), molar volume: V(M), molar refractivity: R(M), crystal density: d and partition coefficient n-octanol/water: logP as descriptors. A high intercorrelation of M(W), V(M) and R(M) was found for the tested group of methylxanthines indicating that only one of these parameters is necessary for testing a potential correlation. The best fit in the multiple linear regression was obtained for R(M) applied together with d and logP and resulted in a QSAR model given by the following equation: IC(50r)=-[(32.3+/-7.2)x10(-3)xR(M)]+[(10.1+/-2.3)xd]+[(0.74+/-0.10)xlogP]-[10.5+/ -3.2]. Model revealed that: (i) the molar refractivity influences the effectiveness of xanthine positively; (ii) the crystal density and partition coefficient influence the MDR reversal effectiveness of xanthine negatively.","['Institute for Heart Research, Slovak Academy of Sciences, Dubravska cesta 9, 84233, Bratislava, Slovak Republic. albert.breier@savba.sk']",,,,,,,,,,
14757443,NLM,MEDLINE,20040930,20191108,1079-9796 (Print) 1079-9796 (Linking),32,1,2004 Jan-Feb,Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis.,262-9,"['Grebenova, Dana', 'Kuzelova, Katerina', 'Fuchs, Ota', 'Halada, Petr', 'Havlicek, Vladimir', 'Marinov, Iuri', 'Hrkal, Zbynek']","['Grebenova D', 'Kuzelova K', 'Fuchs O', 'Halada P', 'Havlicek V', 'Marinov I', 'Hrkal Z']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Blood Cells Mol Dis,"Blood cells, molecules & diseases",9509932,"['0 (Cytokines)', '0 (Interferon-alpha)', '0 (Ubiquitins)', '60267-61-0 (ISG15 protein, human)', 'EC 2.7.10.1 (Protein-Tyrosine Kinases)', 'EC 2.7.10.2 (Fusion Proteins, bcr-abl)']",IM,"['Apoptosis/*drug effects', 'Cell Adhesion', 'Cell Division/drug effects', 'Cytokines/biosynthesis/drug effects', 'Fusion Proteins, bcr-abl', 'Humans', 'Interferon-alpha/*pharmacology', 'K562 Cells/pathology', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*pathology', 'Protein-Tyrosine Kinases/analysis', 'Proteomics', 'S Phase/*drug effects', 'Ubiquitins/analogs & derivatives/biosynthesis/drug effects', 'Up-Regulation/drug effects']",,,,2004/02/06 05:00,2004/10/01 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/10/01 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Blood Cells Mol Dis. 2004 Jan-Feb;32(1):262-9. doi: 10.1016/j.bcmd.2003.10.008.,"['S1079979603002730 [pii]', '10.1016/j.bcmd.2003.10.008 [doi]']",,"We examined the effects of interferon-alpha (IFN-alpha) treatment on the growth, cell cycle, proliferation, and apoptotic parameters as well as adhesive properties and proteome of chronic myelogenous leukemia (CML)-derived K562 cells. IFN-alpha treatment (200 to 600 U/ml, 24 to 72 h) suppressed growth and caused accumulation of K562 cells in the S-phase of cell cycle (increase in S-phase cells by up to 52% in comparison with the untreated controls) at the expenses of cells in G1-phase. No transition of cells to G0-phase occurred as followed from Ki-67 protein determination. Although the level of chimeric gene product, BCR-ABL mRNA coding for BCR-ABL protein with anti-apoptotic properties, decreased by 30%, apoptosis was not triggered as judged from Annexin-V, APO2.7, and TUNEL assays. Adhesion of K562 cells to fibronectin-coated surfaces increased by up to 52% as determined by calcein assay. The proteomic analysis (2-D electrophoresis in combination with mass spectrometry, MALDI-MS) revealed a single protein, ubiquitine cross-reactive protein (UBCR), whose level markedly increased due to IFN-alpha treatment. The ubiquitination-like directed degradation processes may thus play a role in the mechanism of IFN-alpha antiproliferative effects.","['Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, 128 20, Prague-2, Czech Republic']",,,,,,,,,,
14757442,NLM,MEDLINE,20040930,20191108,1079-9796 (Print) 1079-9796 (Linking),32,1,2004 Jan-Feb,"Familial (inherited) leukemia, lymphoma, and myeloma: an overview.",246-61,"['Segel, George B', 'Lichtman, Marshall A']","['Segel GB', 'Lichtman MA']",['eng'],"['Journal Article', 'Review']",,United States,Blood Cells Mol Dis,"Blood cells, molecules & diseases",9509932,,IM,"['Data Collection', '*Family Health', 'Genetic Predisposition to Disease', 'Germ-Line Mutation', 'Hematologic Neoplasms/*epidemiology/genetics', 'Humans', 'Inheritance Patterns', 'Leukemia/epidemiology/genetics', 'Lymphoma/epidemiology/genetics', 'Multiple Myeloma/epidemiology/genetics']",,,,2004/02/06 05:00,2004/10/01 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/10/01 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Blood Cells Mol Dis. 2004 Jan-Feb;32(1):246-61. doi: 10.1016/j.bcmd.2003.10.005.,"['S1079979603002699 [pii]', '10.1016/j.bcmd.2003.10.005 [doi]']",,"We have reviewed the world's literature that addresses familial leukemia, lymphoma, and myeloma. We have catalogued the phenotypic abnormalities associated with an increased risk of developing a hematological malignancy. These syndromes, such as Fanconi anemia or familial platelet syndrome, have been well characterized and in many cases the gene responsible for the predisposition has been defined. We have focused, however, on reports of a familial incidence of hematological malignancy in which no prior predisposing syndrome was reported. In this circumstance, so-called pure familial leukemia, lymphoma, or myeloma, the intergenerational incidence of disease occurred in ostensibly healthy persons. These families have been grouped into sets in which (a) anticipation, (b) immune abnormalities, (c) linkage to HLA phenotypes, (d) linkage to chromosome abnormalities, or (e) gene abnormalities have been reported. They have also been grouped by type of leukemia. Purely descriptive reports, not accompanied by some information on pathogenesis, have not been included. They are catalogued in some of the references cited in this paper. Anticipation is a prominent feature of familial leukemia, lymphoma, and myeloma, supporting the concept of germline transmission of a susceptibility gene. Although linkage to an HLA phenotype occurs in some families, no consistent intrafamilial pattern has emerged. Deletion of chromosome 7 is associated with familial acute myelogenous leukemia, but no other recurring localization has been established. Although putative susceptibility genes have been identified in some families, the likelihood is that the mode of inheritance is different in different families and different genes are involved even within a specific Mendelian pattern. Although as yet not reported, the frequency of familial CLL and the intensity of its study indicates that the gene or genes involved in that familial disorder(s) should be identified conclusively soon if sufficient families for study can be assembled through international cooperation.","['Department of Pediatrics, University of Rochester Medical Center, Rochester, NY 14642, USA.']",,,176,,,,,,,
14757439,NLM,MEDLINE,20040930,20191108,1079-9796 (Print) 1079-9796 (Linking),32,1,2004 Jan-Feb,A novel retrovirus provides the cooperating oncogenic event(s) required to demonstrate the tumor suppressor activity of p15Ink4b in myeloid cells in vivo.,226-31,"['Wolff, Linda', 'Garin, Matthew T', 'Koller, Richard', 'Bies, Juraj', 'Tessarollo, Lino', 'Anver, Miriam R', 'Powell, Douglas', 'Perella, Christine']","['Wolff L', 'Garin MT', 'Koller R', 'Bies J', 'Tessarollo L', 'Anver MR', 'Powell D', 'Perella C']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Blood Cells Mol Dis,"Blood cells, molecules & diseases",9509932,"['0 (Cdkn2b protein, mouse)', '0 (Cell Cycle Proteins)', '0 (Cyclin-Dependent Kinase Inhibitor p15)', '0 (Tumor Suppressor Proteins)']",IM,"['Animals', 'Cell Cycle Proteins/genetics/*physiology', 'Cyclin-Dependent Kinase Inhibitor p15', 'Leukemia/*etiology/genetics/virology', 'Leukemia, B-Cell/etiology/genetics/virology', 'Leukemia, Myeloid/etiology/genetics/virology', 'Leukemia, T-Cell/etiology/genetics/virology', 'Mice', 'Mice, Transgenic', 'Myeloid Cells/metabolism', 'Retroviridae/*physiology', 'Transgenes', 'Tumor Suppressor Proteins/genetics/*physiology']",,,,2004/02/06 05:00,2004/10/01 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/10/01 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Blood Cells Mol Dis. 2004 Jan-Feb;32(1):226-31. doi: 10.1016/j.bcmd.2003.09.006.,"['S1079979603002444 [pii]', '10.1016/j.bcmd.2003.09.006 [doi]']",,"Cancer is a multistep process resulting from an accumulation of several genetic changes. The determination of cooperating events in experimental models can help scientists decipher specific neoplastic pathways and place genes with similar functions in complementation groups. In leukemia models, retrovirus tagging is a powerful approach to determine genes that cooperate with oncogenic transgenes or tumor suppressors that have undergone targeted deletion. Experimental models for B and T cell leukemias involving transgenic c-myc were the first to show the utility of retroviral tagging. Here we review these experiments and present examples of new models of myeloid leukemia where retroviruses have collaborated with a transgene [Cbfbeta-MYH111 from Inv(16)] and with loss of a tumor suppressor (Ink4b) mice to induce disease.","['Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-4255, USA. lwolff@helix.nih.gov']",,['N01-CO-12400/CO/NCI NIH HHS/United States'],,,,,,,,
14757377,NLM,MEDLINE,20040309,20190906,0013-9351 (Print) 0013-9351 (Linking),94,2,2004 Feb,Weak electromagnetic fields (50 Hz) elicit a stress response in human cells.,145-51,"['Tokalov, Sergey V', 'Gutzeit, Herwig O']","['Tokalov SV', 'Gutzeit HO']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,Netherlands,Environ Res,Environmental research,0147621,['0 (Heat-Shock Proteins)'],IM,"['Acute Disease', 'Blotting, Western', 'Electromagnetic Fields/*adverse effects', 'Flow Cytometry', '*Gene Expression Regulation', 'Heat-Shock Proteins/analysis/*biosynthesis', 'Humans', 'Leukemia, Myeloid/*pathology', 'Reverse Transcriptase Polymerase Chain Reaction', 'Temperature', 'Tumor Cells, Cultured']",,,,2004/02/06 05:00,2004/03/10 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Environ Res. 2004 Feb;94(2):145-51. doi: 10.1016/s0013-9351(03)00088-4.,"['S0013935103000884 [pii]', '10.1016/s0013-9351(03)00088-4 [doi]']",,"The aim of this study was to demonstrate the expression of heat shock (HS) genes in human cells in response to extremely low-frequency electromagnetic fields (ELF-EMF) alone and in combination with thermal stress. After exposing human myeloid leukemia (HL-60) cells to the stressor(s) for 30 min we quantified the expression of the HS genes HSP27, HSP60, HSP70 (A, B, and C), HSC70, HSP75, HSP78, and HSP90 (alpha and beta) by RT-PCR. The results clearly show that HS genes, in particular the three HSP70 genes (A, B, and C), are induced by ELF-EMF, a reaction that is enhanced by simultaneous HS (43 degrees C for 30 min). The results show similarities and some significant differences to previous experiments in which transgenic nematodes were used to monitor the induction of the HSP70 gene under similar stress conditions. We also studied the effect of different flux densities on gene expression in the range of 10-140 microT. Even the lowest dose tested (10 microT) resulted in a significant induction of the genes HSP70A, HSP70B, and HSP70C. The reaction to ELF-EMF shows a maximum at a flux density of 60-80 microT. The unusual dose-response relation reveals an interesting difference to other stressors that elicit the HS response.","['Institut fur Zoologie, Technische Universitat Dresden, Mommsenstr. 13, D-01062 Dresden, Germany.']",,,,,,,,,,
14757322,NLM,MEDLINE,20040316,20190819,0378-4274 (Print) 0378-4274 (Linking),147,2,2004 Mar 1,Influence of altered apoptosis in human lymphoblastoid cell lines on micronucleus frequency.,187-95,"['Vukicevic, Vladimir', 'Kampfinger, Katja', 'Stopper, Helga']","['Vukicevic V', 'Kampfinger K', 'Stopper H']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,Netherlands,Toxicol Lett,Toxicology letters,7709027,['0 (Oligonucleotides)'],IM,"['Animals', 'Apoptosis/genetics/*physiology', 'Blotting, Western', 'Cell Division/physiology', 'Cell Line, Tumor', 'Cell Survival', 'Chromosome Aberrations', 'Flow Cytometry', 'Genes, bcl-2/genetics', 'Humans', 'Leukemia, Lymphoid/genetics/*pathology', 'Mice', 'Mice, Knockout', '*Micronucleus Tests', 'Oligonucleotides/immunology', 'Transfection']",,,,2004/02/06 05:00,2004/03/18 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/03/18 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Toxicol Lett. 2004 Mar 1;147(2):187-95. doi: 10.1016/j.toxlet.2003.11.005.,"['S0378427403004259 [pii]', '10.1016/j.toxlet.2003.11.005 [doi]']",,"Defects in apoptosis play a decisive role in both tumorigenesis and drug resistance in tumor treatment. The purpose of this study was to investigate the balance between formation of genomic damage and induction of apoptosis upon genotoxic stress. For this, we influenced the apoptotic response and measured the amount of genomic damage expressed as micronucleus formation after treatment with the topoisomerase II inhibitor etoposide. Apoptosis was reduced by the addition of pifithrin (PFT) alpha and enhanced by transient transfection with bcl-2 antisense-oligonucleotide in Bcl-2-overexpressing cells. We used three human lymphoblastoid cell lines with different p53 status (TK6, wild-type p53; WTK1, mutated p53; NH32, p53 double knockout). Under conditions of reduced apoptosis, micronucleus formation was also reduced. When apoptosis was increased, micronucleus formation remained unchanged or was also increased. Overall, we did not find an expected inverse correlation between induction of apoptosis and genomic damage.","['Department of Toxicology, University of Wurzburg, D-97078 Wurzburg, Germany.']",,,,,,,,,,
14757314,NLM,MEDLINE,20040316,20191210,0378-4274 (Print) 0378-4274 (Linking),147,2,2004 Mar 1,Inhibitory effect of tellimagrandin I on chemically induced differentiation of human leukemia K562 cells.,109-19,"['Yi, Zongchun', 'Wang, Zhao', 'Li, Haixia', 'Liu, Mingjie']","['Yi Z', 'Wang Z', 'Li H', 'Liu M']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,Netherlands,Toxicol Lett,Toxicology letters,7709027,"['0 (Benzidines)', '0 (Cholinesterase Inhibitors)', '0 (DNA Primers)', '0 (DNA-Binding Proteins)', '0 (Erythroid-Specific DNA-Binding Factors)', '0 (GATA1 Transcription Factor)', '0 (GATA1 protein, human)', '0 (GATA2 Transcription Factor)', '0 (GATA2 protein, human)', '0 (Glucosides)', '0 (Glycophorins)', '0 (Hemoglobins)', '0 (NF-E2 Transcription Factor)', '0 (NF-E2 Transcription Factor, p45 Subunit)', '0 (NFE2 protein, human)', '0 (RNA, Messenger)', '0 (Transcription Factors)', '2X02101HVF (benzidine)', '632XD903SP (Gallic Acid)', '79786-08-6 (tellimagrandin I)', 'EC 2.5.1.61 (Hydroxymethylbilane Synthase)', 'EC 3.1.1.7 (Acetylcholinesterase)', 'NI40JAQ945 (Tetradecanoylphorbol Acetate)']",IM,"['Acetylcholinesterase/metabolism', 'Benzidines/chemistry', 'Cell Differentiation/*drug effects', 'Cholinesterase Inhibitors/pharmacology', 'DNA Primers', 'DNA-Binding Proteins/physiology', 'Erythroid Precursor Cells/drug effects', 'Erythroid-Specific DNA-Binding Factors', 'Flow Cytometry', 'GATA1 Transcription Factor', 'GATA2 Transcription Factor', 'Gallic Acid/*analogs & derivatives/*pharmacology', 'Glucosides/*pharmacology', 'Glycophorins/metabolism', 'Hematopoiesis/drug effects', 'Hemoglobins/biosynthesis', 'Humans', 'Hydroxymethylbilane Synthase/metabolism', 'K562 Cells', 'Megakaryocytes/drug effects', 'NF-E2 Transcription Factor', 'NF-E2 Transcription Factor, p45 Subunit', 'RNA, Messenger/biosynthesis', 'Reverse Transcriptase Polymerase Chain Reaction', 'Tetradecanoylphorbol Acetate/pharmacology', 'Transcription Factors/physiology']",,,,2004/02/06 05:00,2004/03/18 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/03/18 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Toxicol Lett. 2004 Mar 1;147(2):109-19. doi: 10.1016/j.toxlet.2003.12.008.,"['S0378427403004703 [pii]', '10.1016/j.toxlet.2003.12.008 [doi]']",,"Tellimagrandin I is a hydrolysable tannin compound widely present in plants. In this study, the effect of tellimagrandin I on chemically induced erythroid and megakaryocytic differentiation was investigated using K562 cells as differentiation model. It was found that tellimagrandin I not only inhibited the hemoglobin synthesis in butyric acid (BA)- and hemin-induced K562 cells with IC50 of 3 and 40microM, respectively, but also inhibited other erythroid differentiation marker including acetylcholinesterase (AChE) and glycophorin A (GPA) in BA-induced K562 cells. Tellimagrandin I also inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced expression of CD61 protein, a megakaryocytic marker. RT-PCR analysis showed that tellimagrandin I decreased the expression of erythroid genes (gamma-globin and porphobilinogen deaminase (PBGD)) and related transcription factors (GATA-1 and NF-E2) in BA-induced K562 cells, whereas tellimagrandin I induced the overexpresison of GATA-2 transcription factor that played negative regulation on erythroid differentiation. These results indicated that tellimagrandin I had inhibitory effects on erythroid and megakaryocytic differentiation, which suggested that tannins like tellimagrandin I might influence the anti-tumor efficiency of some drugs and the hematopoiesis processes.","['Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing 100084, China.']",,,,,,,,,,
14757120,NLM,MEDLINE,20041005,20190624,0014-2999 (Print) 0014-2999 (Linking),485,1-3,2004 Feb 6,Differentiation-inducing factor-1-induced growth arrest of K562 leukemia cells involves the reduction of ERK1/2 activity.,21-9,"['Akaishi, Emi', 'Narita, Torao', 'Kawai, Shinjiro', 'Miwa, Yoshikazu', 'Sasaguri, Toshiyuki', 'Hosaka, Kohei', 'Kubohara, Yuzuru']","['Akaishi E', 'Narita T', 'Kawai S', 'Miwa Y', 'Sasaguri T', 'Hosaka K', 'Kubohara Y']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,Netherlands,Eur J Pharmacol,European journal of pharmacology,1254354,"['0 (Antineoplastic Agents)', '0 (Caenorhabditis elegans Proteins)', '0 (Carrier Proteins)', '0 (Differentiation-inducing factor-1, Dictyostelium)', '0 (Enzyme Inhibitors)', '0 (Hexanones)', '0 (Hydrocarbons, Chlorinated)', '0 (Proteins)', 'EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)', 'EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)', 'EC 2.7.11.24 (Mitogen-Activated Protein Kinases)']",IM,"['Antineoplastic Agents/chemistry/*pharmacology', 'Caenorhabditis elegans Proteins/chemistry/*pharmacology', 'Carrier Proteins/chemistry/*pharmacology', 'Cell Division/drug effects/physiology', 'Dose-Response Relationship, Drug', 'Enzyme Inhibitors/chemistry/pharmacology', 'Hexanones', 'Humans', 'Hydrocarbons, Chlorinated', 'K562 Cells', 'Leukemia/pathology/prevention & control', 'Mitogen-Activated Protein Kinase 1/*antagonists & inhibitors/*metabolism', 'Mitogen-Activated Protein Kinase 3', 'Mitogen-Activated Protein Kinases/*antagonists & inhibitors/*metabolism', '*Proteins']",,,,2004/02/06 05:00,2004/10/06 09:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/10/06 09:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Eur J Pharmacol. 2004 Feb 6;485(1-3):21-9. doi: 10.1016/j.ejphar.2003.11.041.,"['S001429990302689X [pii]', '10.1016/j.ejphar.2003.11.041 [doi]']",,"The differentiation-inducing factor-1 (DIF-1) is a signal molecule that induces stalk cell differentiation in the cellular slime mold Dictyostelium discoideum. In addition, DIF-1 is a potent antileukemic agent that induces growth arrest in K562 cells. In this study, we investigated the mechanism of action of DIF-1 in K562 cells in the light of cell-cycle regulators such as cyclins, retinoblastoma protein (pRb), and the mitogen-activated protein kinase (MAPK) family. DIF-1 down-regulated cyclins D/E and a phosphorylated form of pRb (p-pRb), and thereby induced G(1) arrest of the cell cycle. DIF-1 inactivated the extracellular signal-regulated kinase (ERK) in a biphasic manner but did not affect the c-Jun N-terminal kinase (JNK) or p38 MAPK. The MEK (MAPK kinase) inhibitor, U0126, which has been shown to induce growth arrest, inactivated ERK and down-regulated cyclins D and E. Although DIF-1 activated the phosphatidylinositol 3-kinase (PI-3K)/Akt pathway, neither wortmannin nor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002; PI-3K inhibitors) cancelled DIF-1-induced growth arrest. The present results suggest that ERK inactivation may be involved in DIF-1-induced growth arrest and that PI-3K activity is not required for DIF-1-induced growth arrest in K562 cells.","['Department of Basic Sciences for Medicine, Gunma University School of Health Sciences, Maebashi 371-8514, Japan.']",,,,,,,,,,
14756952,NLM,MEDLINE,20040422,20181130,0578-1310 (Print) 0578-1310 (Linking),41,3,2003 Mar,[Summary of China National Pediatric Hematology Conference (2002)].,185-7,,,['chi'],['Congress'],,China,Zhonghua Er Ke Za Zhi,Zhonghua er ke za zhi = Chinese journal of pediatrics,0417427,,IM,"['Anemia/therapy', 'Child', 'China', 'Hematologic Diseases/therapy', 'Hematologic Neoplasms/therapy', '*Hematology', 'Humans', 'Leukemia/therapy', '*Pediatrics', 'Stem Cell Transplantation']",,,,2004/02/06 05:00,2004/04/23 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/04/23 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Zhonghua Er Ke Za Zhi. 2003 Mar;41(3):185-7.,,,,,,,,,,,,"['Editorial Board, Chinese Journal of Pediatrics', 'Subspecialty Group of Pediatric Hematology, Pediatric Society, Chinese Medical', 'Association']",,
14756933,NLM,MEDLINE,20040506,20111117,1094-9313 (Print) 1094-9313 (Linking),6,6,2003 Dec,Use of virtual reality as a distractor for painful procedures in a patient with pediatric cancer: a case study.,657-61,"['Gershon, Jonathan', 'Zimand, Elana', 'Lemos, Rosemarie', 'Rothbaum, Barbara Olasov', 'Hodges, Larry']","['Gershon J', 'Zimand E', 'Lemos R', 'Rothbaum BO', 'Hodges L']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Cyberpsychol Behav,"Cyberpsychology & behavior : the impact of the Internet, multimedia and virtual reality on behavior and society",9804397,,IM,"['Analgesia/*methods', 'Anxiety/therapy', 'Attention', 'Catheters, Indwelling/*adverse effects', 'Child', 'Computer Graphics', 'Computer Simulation', 'Humans', 'Leukemia, Lymphoid/psychology/*therapy', 'Male', 'Pain/etiology', '*Pain Management', 'Pain Measurement', 'Therapy, Computer-Assisted/instrumentation/*methods', 'Treatment Outcome', '*User-Computer Interface']",,,,2004/02/06 05:00,2004/05/07 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/05/07 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Cyberpsychol Behav. 2003 Dec;6(6):657-61. doi: 10.1089/109493103322725450.,['10.1089/109493103322725450 [doi]'],,"Virtual reality (VR) has been demonstrated as an effective tool to help people overcome a variety of anxiety disorders. In this case study, the use of VR as a distractor to alleviate pain and anxiety associated with an invasive medical procedure for a pediatric cancer patient was explored. An A-B-C-A design during four consecutive medical appointments in an outpatient oncology clinic compared no distraction (A), non-VR distraction on a computer screen (B), and VR distraction with a head set (C). Behavioral observations of distress by the researcher and reports of pain and anxiety by the patient, parent, and nurse were taken before and during the procedure. The child's pulse was monitored throughout the procedure. The findings from this case study suggest benefit from using VR distraction, as indicated by lower pain and anxiety ratings, reduced pulse, and fewer observed behavioral indices of distress. The need for larger scale studies and application of VR with younger children is discussed in the context of confirming effectiveness of this technique and providing more generalizable information about efficacy.","['Department of Psychiatry and Human Behavior, Brown University School of Medicine, Providence, Rhode Island, USA.']",,,,,,,,,,
14756686,NLM,MEDLINE,20040928,20190827,0305-1870 (Print) 0305-1870 (Linking),31,1-2,2004 Jan-Feb,"Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth.",65-9,"['Lin, Chun-Ching', 'Ng, Lean Teik', 'Hsu, Fen-Fang', 'Shieh, Den-En', 'Chiang, Lien-Chai']","['Lin CC', 'Ng LT', 'Hsu FF', 'Shieh DE', 'Chiang LC']",['eng'],['Journal Article'],,Australia,Clin Exp Pharmacol Physiol,Clinical and experimental pharmacology & physiology,0425076,"['0 (Antimetabolites, Antineoplastic)', '0 (Antineoplastic Agents, Phytogenic)', '0 (Flavonoids)', '0 (Plant Extracts)', '0 (Solutions)', '0GCL71VN14 (coptisine)', '0I8Y3P32UF (Berberine)', 'U3P01618RT (Fluorouracil)', 'VNM47R2QSQ (icariin)']",IM,"['Antimetabolites, Antineoplastic/pharmacology', 'Antineoplastic Agents, Phytogenic/*pharmacology', 'Berberine/*analogs & derivatives/*pharmacology', 'Carcinoma, Hepatocellular/*drug therapy/pathology', 'Cell Line, Tumor', 'Coptis/*chemistry', 'Enzyme-Linked Immunosorbent Assay', 'Epimedium/*chemistry', 'Flavonoids/*pharmacology', 'Fluorouracil/pharmacology', 'Humans', 'Leukemia, Experimental/*drug therapy/pathology', 'Plant Extracts/pharmacology', 'Solutions']",,,,2004/02/06 05:00,2004/09/29 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/09/29 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Clin Exp Pharmacol Physiol. 2004 Jan-Feb;31(1-2):65-9. doi: 10.1111/j.1440-1681.2004.03951.x.,['10.1111/j.1440-1681.2004.03951.x [doi]'],,"1. The present study was conducted to evaluate the cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents on hepatoma and leukaemia cells in vitro. 2. Four human liver cancer cell lines, namely HepG2, Hep3B, SK-Hep1 and PLC/PRF/5, and four leukaemia cell lines, namely K562, U937, P3H1 and Raji, were used in the present study. 3. Of the two crude drugs, C. chinensis exhibited the strongest activity against SK-Hep1 (IC50 = 7 microg/mL) and Raji (IC50 = 4 microg/mL) cell lines. The IC50 values for C. chinensis on HepG2, Hep3B and PLC/PRF/5 cell lines were 20, 55 and 35 microg/mL, respectively. The IC50 values for C. chinensis on K562, U937 and P3H1 cell lines were 29, 29 and 31 microg/mL, respectively. 4. With the exception of HepG2 and Hep3B, the E. sagittatum extract inhibited the proliferation of all cell lines (SK-Hep1, PLC/PRF/5, K562, U937, P3H1 and Raji), with IC50 values of 15, 57, 74, 221, 40 and 80 microg/mL, respectively. 5. Interestingly, the two major compounds of C. chinensis, berberine and coptisine, showed a strong inhibition on the proliferation of both hepatoma and leukaemia cell lines, with IC50 values varying from 1.4 to 15.2 microg/mL and from 0.6 to 14.1 microg/mL, respectively. However, icariin (the major compound of E. sagittatum) showed no inhibition of either the hepatoma or leukaemia cell lines. 6. The results of the present study suggest that the C. chinensis extract and its major constituents berberine and coptisine possess active antihepatoma and antileukaemia activities.","['Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 807, Taiwan, ROC. aalin@ms24.hinet.net']",,,,,,,,,,
14756449,NLM,MEDLINE,20040817,20191026,0265-6736 (Print) 0265-6736 (Linking),19,6,2003 Nov-Dec,Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours.,575-89,"['Griffin, R J', 'Monzen, H', 'Williams, B W', 'Park, H', 'Lee, S H', 'Song, C W']","['Griffin RJ', 'Monzen H', 'Williams BW', 'Park H', 'Lee SH', 'Song CW']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",,England,Int J Hyperthermia,"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group",8508395,"['0 (Antineoplastic Agents)', '0 (Arsenicals)', '0 (Oxides)', '0 (Rubidium Radioisotopes)', '126547-89-5 (Intercellular Adhesion Molecule-1)', 'S7V92P67HO (Arsenic Trioxide)']",IM,"['Animals', 'Antineoplastic Agents/*pharmacology', 'Arsenic Trioxide', 'Arsenicals/*pharmacology', 'Cell Line, Tumor/drug effects/metabolism', 'Endothelium, Vascular/cytology', 'Female', 'Humans', '*Hyperthermia, Induced', 'Intercellular Adhesion Molecule-1/metabolism', '*Mammary Neoplasms, Animal', 'Mice', 'Mice, Inbred C3H', 'Oxidative Stress/*drug effects', 'Oxides/*pharmacology', 'Rubidium Radioisotopes', 'Umbilical Veins/cytology']",,,,2004/02/06 05:00,2004/08/18 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/08/18 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Int J Hyperthermia. 2003 Nov-Dec;19(6):575-89. doi: 10.1080/0265673031000124316.,['10.1080/0265673031000124316 [doi]'],,"It has previously been found that the anti-leukaemia agent Arsenic Trioxide (ATO) causes vascular shutdown in solid tumours and markedly sensitizes tumours to hyperthermia. The present study was designed to evaluate the mechanism of action and dose-dependence of ATO-induced thermosensitization in FSaII and SCK murine tumours. The role of oxidative stress was studied by observing ATO-induced vascular shutdown in vivo and ATO-induced endothelial cell adhesion molecule expression in vitro in the presence or absence of an anti-oxidant. It was found that a dose as low as 2 mg/kg ATO impaired vascular function, as estimated by 86Rb uptake, in the tumour. The degree of tumour growth delay induced by 1 h of hyperthermia at 42.5 degrees C, applied 2 h after ATO injection, was proportional to the dose of ATO administered. In addition, it was found that ATO can directly thermosensitize tumour cells in vitro. The development of massive tissue necrosis in the tumour was observed in the days after treatment, especially with the combination of ATO and heating. ATO-induced adhesion molecule expression in vitro was abolished when the anti-oxidant n-acetyl-cysteine (NAC) was introduced prior to exposure, while the addition of NAC in vivo partially blocked ATO-induced vascular shutdown. These results suggest that the expression of adhesion molecules by the vasculature due to oxidative stress contribute to the ATO-induced selective tumour vascular effects observed and that the clinical use of ATO to increase tumour thermosensitivity via direct cellular and vascular effects appears feasible.","['Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota Medical School, 420 Delaware St. S.E., MMC 494, Minneapolis, MN 55455, USA. griff007@umn.edu']",,"['CA13353/CA/NCI NIH HHS/United States', 'CA44114/CA/NCI NIH HHS/United States']",,,,,,,,
14755968,NLM,MEDLINE,20040629,20110113,0048-7848 (Print) 0048-7848 (Linking),107,1,2003 Jan-Mar,[Antisense oligonucleotides with pharmacologic action].,40-5,"['Tauser, Roxana-Georgiana', 'Stoica, Ortansa']","['Tauser RG', 'Stoica O']",['rum'],"['English Abstract', 'Journal Article', 'Review']",Oligonucleotide antisens cu activitate farmacologica.,Romania,Rev Med Chir Soc Med Nat Iasi,Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,0413735,"['0 (Oligonucleotides, Antisense)']",IM,"['Arteriosclerosis/drug therapy', 'Clinical Trials as Topic', 'Cytomegalovirus Retinitis/drug therapy', 'Humans', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy', 'Oligonucleotides, Antisense/*therapeutic use', 'Treatment Outcome']",,,,2004/02/06 05:00,2004/06/30 05:00,['2004/02/06 05:00'],"['2004/02/06 05:00 [pubmed]', '2004/06/30 05:00 [medline]', '2004/02/06 05:00 [entrez]']",ppublish,Rev Med Chir Soc Med Nat Iasi. 2003 Jan-Mar;107(1):40-5.,,,"The potential therapeutic applications of the antisense strategy are illustrated by numerous examples of the oligonucleotides investigated in preclinical and clinical trials especially for antiviral, antiinflammatory, anticancer and antiatherosclerotic activity. The main advantages of the antisense oligonucleotides therapeutic candidates are comparatively discussed with the classical drugs.","['Disciplina de Chimie farmaceutica, Facultatea de Farmacie, Universitatea de Medicina si Farmacie Gr.T. Popa Iasi.']",,,30,,,,,,,
14755760,NLM,MEDLINE,20040923,20041117,8755-1039 (Print) 1097-0339 (Linking),30,2,2004 Feb,Cutaneous alternariosis: cytohistological findings in a case diagnosed by fine-needle aspiration biopsy.,103-4,"['Ortiz, J', 'Abad, M', 'Bullon, A', 'Garcia, I']","['Ortiz J', 'Abad M', 'Bullon A', 'Garcia I']",['eng'],"['Case Reports', 'Journal Article']",,United States,Diagn Cytopathol,Diagnostic cytopathology,8506895,['0 (Antifungal Agents)'],IM,"['Alternaria', 'Antifungal Agents/therapeutic use', 'Biopsy, Fine-Needle', 'Bone Marrow Transplantation', 'Dermatomycoses/etiology/*immunology/*pathology', 'Diagnosis, Differential', 'Female', 'Granuloma/etiology/pathology', 'Humans', '*Immunocompromised Host', 'Leukemia/complications/therapy', 'Middle Aged', 'Mycoses/etiology/*immunology/*pathology']",,,,2004/02/03 05:00,2004/09/24 05:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/09/24 05:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Diagn Cytopathol. 2004 Feb;30(2):103-4. doi: 10.1002/dc.10323.,['10.1002/dc.10323 [doi]'],,,"['Servicio de Anatomia Patologica, Hospital Universitario, Salamanca, Spain. jortiz@usal.es']",,,,,,,,,,
14755542,NLM,MEDLINE,20040312,20151119,0021-9541 (Print) 0021-9541 (Linking),198,3,2004 Mar,Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells.,370-6,"['Kohmura, Kanoko', 'Miyakawa, Yoshitaka', 'Kawai, Yoko', 'Ikeda, Yasuo', 'Kizaki, Masahiro']","['Kohmura K', 'Miyakawa Y', 'Kawai Y', 'Ikeda Y', 'Kizaki M']",['eng'],"['Comparative Study', 'Journal Article']",,United States,J Cell Physiol,Journal of cellular physiology,0050222,"['0 (Benzamides)', '0 (Biomarkers)', '0 (DNA Primers)', '0 (Enzyme Inhibitors)', '0 (Hemoglobins)', '0 (Piperazines)', '0 (Proto-Oncogene Proteins c-myb)', '0 (Pyrimidines)', '0 (Transcription Factors)', '8A1O1M485B (Imatinib Mesylate)', 'EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases)', 'EC 2.7.11.24 (Mitogen-Activated Protein Kinases)', 'EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)']",IM,"['Benzamides', 'Biomarkers/analysis', 'Blotting, Western', 'Cell Differentiation/*physiology', 'Cell Lineage', 'DNA Primers', 'Enzyme Inhibitors/*pharmacology', 'Hemoglobins/biosynthesis/drug effects', 'Humans', 'Imatinib Mesylate', 'JNK Mitogen-Activated Protein Kinases', 'K562 Cells', 'Mitogen-Activated Protein Kinases/drug effects/*metabolism', 'Phosphorylation', 'Piperazines/*pharmacology', 'Proto-Oncogene Proteins c-myb/drug effects/metabolism', 'Pyrimidines/*pharmacology', 'Signal Transduction/physiology', 'Transcription Factors/drug effects/metabolism', 'p38 Mitogen-Activated Protein Kinases']",,,,2004/02/03 05:00,2004/03/16 05:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/03/16 05:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,J Cell Physiol. 2004 Mar;198(3):370-6. doi: 10.1002/jcp.10426.,['10.1002/jcp.10426 [doi]'],,"STI571 is a specific tyrosine kinase inhibitor of Abl kinase. It was previously reported that STI571 induced hemoglobin synthesis in the chronic myelogenous leukemia (CML) cell line K562. However, its mechanisms remain unknown. In this study, we demonstrated that STI571 induced the phosphorylation of p38 mitogen-activated protein kinase (MAPK) and dephosphorylation of extracellular signal-regulated kinase (ERK) in K562 cells. In contrast, the phosphorylation of c-Jun N-terminal kinases (JNK) in K562 cells was not altered by STI571. We also found that STI571 induced all the myeloid (CD11b, CD13), megakaryocytic (CD41a, CD42), and erythroid (glycophorin-A) markers on K562 cells. A p38 MAPK-specific inhibitor, SB203580, inhibited the STI571-induced multi-lineage differentiation of K562 cells, indicating that p38 MAPK is crucial for this differentiation. In contrast, SB203580 did not overcome the inhibitory effect for proliferation of K562 cells, indicating that p38 MAPK activation by STI571 does not affect cell numbers. Among the hematopoietic transcription factors, the expression level of c-myb mRNA was clearly downregulated after incubation with STI571 in K562 cells. STI571-induced downregulation of c-myb mRNA was prevented by the pretreatment of K562 cells by SB203580. Our data provides insights into how p38 MAPK and ERK pathways are involved in STI571-induced differentiation of K562 cells.","['Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.']",,,,,,"['Copyright 2003 Wiley-Liss, Inc.']",,,,
14755378,NLM,MEDLINE,20040305,20151119,0361-8609 (Print) 0361-8609 (Linking),75,2,2004 Feb,Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL).,107-9,"['Sokol, Lubomir', 'Agosti, Steven J']","['Sokol L', 'Agosti SJ']",['eng'],"['Case Reports', 'Journal Article']",,United States,Am J Hematol,American journal of hematology,7610369,"['0 (Antibodies, Monoclonal)', '0 (Antibodies, Monoclonal, Murine-Derived)', '0 (Antigens, CD)', '0 (Antineoplastic Agents)', '4F4X42SYQ6 (Rituximab)']",IM,"['Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal/therapeutic use', 'Antibodies, Monoclonal, Murine-Derived', 'Antigens, CD/blood', 'Antineoplastic Agents/therapeutic use', 'Female', 'Flow Cytometry', 'Humans', 'Immunophenotyping', 'Leukemia, Hairy Cell/complications/*diagnosis/immunology', 'Leukemia, Lymphocytic, Chronic, B-Cell/complications/*diagnosis/immunology', 'Neoplasms, Second Primary/*diagnosis/immunology', 'Rituximab', 'Treatment Outcome']",,,,2004/02/03 05:00,2004/03/06 05:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/03/06 05:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Am J Hematol. 2004 Feb;75(2):107-9. doi: 10.1002/ajh.10459.,['10.1002/ajh.10459 [doi]'],,"We report a unique case of 83-year-old Caucasian male with the initial simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). The patient presented with absolute lymphocytosis in the blood, asymptomatic generalized lymphadenopathy, and mild splenomegaly. The diagnosis of CLL was suggested from the blood film, but subsequent flow cytometric (FC) analysis on peripheral blood mononuclear cells (PBMNC) revealed two distinct abnormal clones of mature B cells. A small subpopulation (7%) of lymphoid cells expressed CD20, CD11c, FMC-7, CD103, CD25, and kappa surface light chain, consistent with HCL. The larger subpopulation (75%) of lymphoid cells expressed CD19, CD20, CD23, CD5, and lambda light chain, consistent with CLL. The expression of different immunoglobulin light chains on the circulating CLL (lambda) and HCL (kappa) cells suggested two, independent, malignant B-cell clones. Interestingly, FC analysis of bone marrow (BM) cells done 6 months later revealed bright lambda light chain expression on the HCL cells. Despite administration of several different courses of chemotherapy, the HCL subpopulation was not eliminated from the BM but remained stable between 7% and 10% of total BM lymphoid cells. The CLL, responsible for most of clinical symptoms in our patient, responded to combination chemotherapy with fludarabine and cytoxan, and later to monotherapy with rituximab.","['Department of Interdisciplinary Oncology, University of South Florida, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.']",,,,,,"['Copyright 2004 Wiley-Liss, Inc.']",,,,
14755375,NLM,MEDLINE,20040305,20151119,0361-8609 (Print) 0361-8609 (Linking),75,2,2004 Feb,Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.,92-5,"['Snyder, David S', 'McMahon, Ross', 'Cohen, Sandra R', 'Slovak, Marilyn L']","['Snyder DS', 'McMahon R', 'Cohen SR', 'Slovak ML']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Am J Hematol,American journal of hematology,7610369,"['0 (Antineoplastic Agents)', '0 (Benzamides)', '0 (DNA Primers)', '0 (Piperazines)', '0 (Pyrimidines)', '8A1O1M485B (Imatinib Mesylate)', 'EC 2.7.10.2 (Fusion Proteins, bcr-abl)']",IM,"['Adult', 'Antineoplastic Agents/therapeutic use', 'Base Sequence', 'Benzamides', 'DNA Primers', 'Fusion Proteins, bcr-abl/*genetics', 'Humans', 'Imatinib Mesylate', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/*genetics', 'Male', '*Mutation', 'Piperazines/*therapeutic use', 'Pyrimidines/*therapeutic use', 'Reverse Transcriptase Polymerase Chain Reaction', 'Treatment Outcome']",,,,2004/02/03 05:00,2004/03/06 05:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/03/06 05:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Am J Hematol. 2004 Feb;75(2):92-5. doi: 10.1002/ajh.10456.,['10.1002/ajh.10456 [doi]'],,A case of a patient with chronic myeloid leukemia whose cells expressed an e13a3 (b2a3) variant BCR-ABL p210 mRNA is presented. The variant splice was detected by a qualitative reverse transcriptase polymerase chain reaction using primers complementary to BCR exon 13 (b2) and ABL exon 3 (a3). The patient responded well to imatinib and achieved a complete cytogenetic response.,"['Division of Hematology/Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, California 91010, USA. dsnyder@coh.org']",,"['CA 30206/CA/NCI NIH HHS/United States', 'CA 33572/CA/NCI NIH HHS/United States']",,,,"['Copyright 2004 Wiley-Liss, Inc.']",,,,
14755372,NLM,MEDLINE,20040305,20071115,0361-8609 (Print) 0361-8609 (Linking),75,2,2004 Feb,Th1/Th2 cytokine profiles and their relationship to clinical features in patients following nonmyeloablative allogeneic stem cell transplantation.,78-83,"['Guo, Hongfeng', 'Qiao, Zhenhua', 'Zhu, Lei', 'Wang, Hongwei', 'Su, Liping', 'Lu, Yujin', 'Cui, Yuee', 'Jiang, Bo', 'Zhu, Qioujuan', 'Xu, Lianrong']","['Guo H', 'Qiao Z', 'Zhu L', 'Wang H', 'Su L', 'Lu Y', 'Cui Y', 'Jiang B', 'Zhu Q', 'Xu L']",['eng'],['Journal Article'],,United States,Am J Hematol,American journal of hematology,7610369,['0 (Cytokines)'],IM,"['Adolescent', 'Adult', 'Cytokines/*blood', 'Female', 'Humans', 'Leukemia/immunology/therapy', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood/immunology/therapy', 'Leukemia, Myeloid, Acute/blood/immunology/therapy', 'Male', 'Middle Aged', 'Multiple Myeloma/immunology/therapy', '*Stem Cell Transplantation', 'Th1 Cells/*immunology', 'Th2 Cells/*immunology', 'Transplantation, Homologous/immunology']",,,,2004/02/03 05:00,2004/03/06 05:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/03/06 05:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Am J Hematol. 2004 Feb;75(2):78-83. doi: 10.1002/ajh.10443.,['10.1002/ajh.10443 [doi]'],,"An imbalance in helper T-cell type 1 (Th1) and type 2 (Th2) cytokines is suggested to play an important role in the pathogenesis of acute graft-versus-host disease (aGVHD). The aim of this study was to investigate the cytokine bias acquired by T cells after transplantation and its possible influence on relapse of original malignancy. Cytokine levels by peripheral CD4 and CD8 T cells were tested at various pre- and post-transplant time points with fluorescein isothiocyanate-based intracellular cytokine assay after short-term in vitro mitogenic stimulation (phorbol myristate acetate + ionomycin). In both CD4+ and CD8+ cells, interferon (IFN)-gamma-producing cell populations increased, indicating a shift to a Th1 cytokine profile with aGVHD. IFN-gamma-producing T cells was significantly lower in patients who experienced relapse of original disease compared to those who showed no signs of relapse and compared to normal controls. Our studies demonstrate that aGVHD correlates with a Th1 bias and that Th1 response may potentiate an effective immune surveillance.","[""Hematology Department, The Second Teaching Hospital of Shanxi Medical University, Taiyuan, People's Republic of China. guohongf2000@yahoo.com.cn""]",,,,,,"['Copyright 2004 Wiley-Liss, Inc.']",,,,
14755324,NLM,MEDLINE,20041209,20071115,0268-3369 (Print) 0268-3369 (Linking),33,6,2004 Mar,A myeloablative allograft after rejection of two consecutive nonmyeloablative transplants from two different HLA identical siblings.,659-60,"['Papineschi, F', 'Benedetti, E', 'Galimberti, S', 'Caracciolo, F', 'Fazzi, R', 'Petrini, M']","['Papineschi F', 'Benedetti E', 'Galimberti S', 'Caracciolo F', 'Fazzi R', 'Petrini M']",['eng'],"['Case Reports', 'Journal Article']",,England,Bone Marrow Transplant,Bone marrow transplantation,8702459,,IM,"['Female', 'Graft Rejection/*immunology', 'Histocompatibility Testing', 'Humans', 'Leukemia, Myeloid, Acute/*therapy', 'Middle Aged', '*Stem Cell Transplantation', 'Transplantation Chimera', 'Transplantation Conditioning/methods', 'Transplantation, Homologous/*immunology', 'Treatment Outcome']",,,,2004/02/03 05:00,2004/12/16 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/12/16 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Bone Marrow Transplant. 2004 Mar;33(6):659-60. doi: 10.1038/sj.bmt.1704356.,"['10.1038/sj.bmt.1704356 [doi]', '1704356 [pii]']",,"A 55-year-old female with standard risk AML in second CR received an allogenic transplant from an HLA-matched sibling, using a nonmyeloablative conditioning regimen (NMST). On day +139, she rejected her graft with autologous reconstitution. She received a second NMST from a different HLA-matched sibling with an identical conditioning regimen and immunosuppression. On day +110, she rejected the second graft, with autologous reconstitution with blasts. She received a third allograft from the first sibling with a myeloablative busulfan-based conditioning regimen. She is now day +270, in CR, with full donor chimerism.","['UO Ematologia, Universita degli Studi di Pisa e Azienda Ospedaliera Pisana, Pisa, Italy. f.papineschi@do.med.unipi.it']",,,,,,,,,,
14755322,NLM,MEDLINE,20041014,20181130,0268-3369 (Print) 0268-3369 (Linking),33,7,2004 Apr,"Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus.",691-6,"['Bacigalupo, A']",['Bacigalupo A'],['eng'],"['Congress', ""Research Support, Non-U.S. Gov't""]",,England,Bone Marrow Transplant,Bone marrow transplantation,8702459,,IM,"['Age Factors', 'Antigen-Presenting Cells', 'Epstein-Barr Virus Infections/etiology', 'Graft vs Host Disease/etiology', 'Hematopoietic Stem Cell Transplantation/adverse effects/*methods/mortality', 'Humans', 'Lymphocyte Transfusion', 'Risk', 'Transplantation Conditioning/*methods', 'Transplantation, Homologous']",,,,2004/02/03 05:00,2004/10/16 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/10/16 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Bone Marrow Transplant. 2004 Apr;33(7):691-6. doi: 10.1038/sj.bmt.1704416.,"['10.1038/sj.bmt.1704416 [doi]', '1704416 [pii]']",,"The Third Workshop on reduced intensity conditioning allogeneic stem cell transplants (RIC-HSCT) was convened by EBMT/AMGEN in Zurich in February 2003. Three general issues were addressed: the age effect, graft-versus-host disease (GvHD) and donor lymphocyte infusions (DLI). An age effect is seen and has a negative impact on survival; GvHD remains an issue that needs to be addressed, and DLI were shown to be a powerful tool against minimal residual disease, but not with rapidly progressing leukemia. The role of host antigen-presenting cells in the development of acute GvHD was outlined and discussed in the animal model. The emerging importance of Epstein Barr Virus infections was also discussed. Retrospective and prospective studies from the EBMT, national groups and single institutions included over 1800 patients: the incidence of acute GvHD grade III-IV was 11% extensive chronic GvHD 22% and TRM 20%. Most conditioning regimens include fludarabine in association with a reduced dose of a myeloablative agent (busulfan, TBI, thiotepa or melphalan). Most transplants were from HLA-identical siblings (77%), and used peripheral blood (90%) as a stem cell source. A consensus discussion on current evidence in RIC transplants is reported in this paper.","['Divisione Ematologia 2, Ospedale San Martino, Genova, Italy. apbacigalupo@smartino.ge.it']",,,,,,,,,,
14755312,NLM,MEDLINE,20041112,20171116,0268-3369 (Print) 0268-3369 (Linking),33,8,2004 Apr,Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.,833-7,"['Khouri, I F', 'Albitar, M', 'Saliba, R M', 'Ippoliti, C', 'Ma, Y C', 'Keating, M J', 'Champlin, R E']","['Khouri IF', 'Albitar M', 'Saliba RM', 'Ippoliti C', 'Ma YC', 'Keating MJ', 'Champlin RE']",['eng'],['Journal Article'],,England,Bone Marrow Transplant,Bone marrow transplantation,8702459,"['0 (Antibodies, Monoclonal)', '0 (Antibodies, Monoclonal, Humanized)', '0 (Antibodies, Neoplasm)', '0 (Antigens, CD)', '0 (Antigens, Neoplasm)', '0 (CD52 Antigen)', '0 (CD52 protein, human)', '0 (Glycoproteins)', '3A189DH42V (Alemtuzumab)']",IM,"['Acute Disease', 'Adult', 'Aged', 'Alemtuzumab', 'Antibodies, Monoclonal/*administration & dosage/blood', 'Antibodies, Monoclonal, Humanized', 'Antibodies, Neoplasm/*administration & dosage/blood', 'Antigens, CD/metabolism', 'Antigens, Neoplasm/metabolism', 'Burkitt Lymphoma/immunology/therapy', 'CD52 Antigen', 'Female', 'Glycoproteins/metabolism', 'Graft vs Host Disease/prevention & control', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Male', 'Middle Aged', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology/therapy', 'Transplantation, Homologous']",,,,2004/02/03 05:00,2004/11/13 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/11/13 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Bone Marrow Transplant. 2004 Apr;33(8):833-7. doi: 10.1038/sj.bmt.1704435.,"['10.1038/sj.bmt.1704435 [doi]', '1704435 [pii]']",,"Alemtuzumab is effective in reducing the risk of acute graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (ASCT). Alemtuzumab may also delay immune reconstitution and reduce graft-versus-leukemia effects. The optimal dose has not been established. We investigated engraftment, acute GVHD incidence and severity, and pharmacokinetics of alemtuzumab associated with the use of low-dose alemtuzumab/cyclophosphamide/total body irradiation and ASCT for patients with aggressive CD52-positive hematologic malignancies. In all, 12 patients were treated. Alemtuzumab 10 mg daily on days -7 to -3 was given intravenously. Tacrolimus and methotrexate were used for GVHD prophylaxis. Alemtuzemab was not detected in any of the 36 sequential serum samples tested between days -1 and +21 of transplant. All patients engrafted rapidly; the median time to an absolute neutrophil count >0.5 x 10(9)/l was 14 days (range 11-17 days), and the median time to a platelet count >20 x 10(9)/l was 16 days (range 6-30 days). By 1 month after transplant, nine patients had 100% donor chimerism, while three had mixed donor chimerism. At 3 months, 11 had achieved 100% donor chimerism. No cases of grade III/IV acute GVHD occurred. At a median follow-up interval of 14.7 months (range 4-24), seven patients remained alive, and five remained free of disease.","['Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ikhouri@mdanderson.org']",,,,['Bone Marrow Transplant. 2004 Dec;34(12):1101-2. PMID: 15516944'],,,,,,
14755311,NLM,MEDLINE,20041112,20160422,0268-3369 (Print) 0268-3369 (Linking),33,8,2004 Apr,Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience.,805-14,"['Yusuf, U', 'Frangoul, H A', 'Gooley, T A', 'Woolfrey, A E', 'Carpenter, P A', 'Andrews, R G', 'Deeg, H J', 'Appelbaum, F R', 'Anasetti, C', 'Storb, R', 'Sanders, J E']","['Yusuf U', 'Frangoul HA', 'Gooley TA', 'Woolfrey AE', 'Carpenter PA', 'Andrews RG', 'Deeg HJ', 'Appelbaum FR', 'Anasetti C', 'Storb R', 'Sanders JE']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",,England,Bone Marrow Transplant,Bone marrow transplantation,8702459,,IM,"['Adolescent', 'Anemia, Sideroblastic/therapy', '*Bone Marrow Transplantation/adverse effects', 'Child', 'Child, Preschool', 'Chromosomes, Human, Pair 7/genetics', 'Female', 'Graft vs Host Disease/etiology', 'Humans', 'Infant', 'Leukemia, Myelomonocytic, Acute/genetics/*therapy', 'Leukemia, Myelomonocytic, Chronic/therapy', 'Male', 'Monosomy', 'Myelodysplastic Syndromes/genetics/*therapy', 'Survival Rate', 'Transplantation, Homologous', 'Washington']",,,,2004/02/03 05:00,2004/11/13 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/11/13 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Bone Marrow Transplant. 2004 Apr;33(8):805-14. doi: 10.1038/sj.bmt.1704438.,"['10.1038/sj.bmt.1704438 [doi]', '1704438 [pii]']",,"The purpose of this study was to evaluate the role of allogeneic bone marrow transplantation (BMT) in children with myelodysplastic syndrome (MDS). In total, 94 consecutive pediatric patients with MDS received an allogeneic BMT from 1976 to 2001 for refractory anemia (RA) (n=25), RA with ringed sideroblasts (RARS) (n=2), RA with excess blasts (RAEB) (n=20), RAEB in transformation (RAEB-T) (n=14), juvenile myelomonocytic leukemia (JMML) (n=32) or chronic myelomonocytic leukemia (CMML) (n=1). The estimated 3-year probabilities of survival, event-free survival (EFS), nonrelapse mortality and relapse were 50, 41, 28 and 29%, respectively. Patients with RA/RARS had an estimated 3-year survival of 74% compared to 68% in those with RAEB and 33% in patients with JMML/CMML. In multivariable analysis, patients with RAEB-T or JMML were 3.9 and 3.7 times more likely to die compared to those with RA/RARS and RAEB (P=0.005 and 0.004, respectively). Patients with RAEB-T were 5.5 times more likely to relapse (P=0.01). The median follow-up among the 43 surviving patients is 10 years (range 1-25). We conclude that allogeneic BMT for children with MDS is well tolerated and can be curative.","['Fred Hutchinson Cancer Research Center and University of Washington Department of Pediatrics, Seattle, WA 98109, USA.']",,"['CA 15704/CA/NCI NIH HHS/United States', 'CA 18029/CA/NCI NIH HHS/United States', 'CA 18221/CA/NCI NIH HHS/United States', 'CA 47748/CA/NCI NIH HHS/United States', 'HL 36444/HL/NHLBI NIH HHS/United States']",,,,,,,,
14755251,NLM,MEDLINE,20040513,20071115,0950-9232 (Print) 0950-9232 (Linking),23,10,2004 Mar 11,The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.,1911-21,"['Jones, Gillian G', 'Reaper, Philip M', 'Pettitt, Andrew R', 'Sherrington, Paul D']","['Jones GG', 'Reaper PM', 'Pettitt AR', 'Sherrington PD']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,England,Oncogene,Oncogene,8711562,"['0 (DNA Primers)', '0 (DNA, Neoplasm)', '0 (Tumor Suppressor Protein p53)']",IM,"['Base Sequence', 'Cell Cycle', 'Cells, Cultured', 'DNA Damage', 'DNA Primers', 'DNA, Neoplasm/genetics/radiation effects', 'Humans', 'Leukemia, Lymphocytic, Chronic, B-Cell/genetics/immunology', 'Lymphocytes/*cytology/*pathology', 'Mitosis', 'Reference Values', 'Reverse Transcriptase Polymerase Chain Reaction', 'Tumor Cells, Cultured', 'Tumor Suppressor Protein p53/*genetics', 'Ultraviolet Rays']",,,,2004/02/03 05:00,2004/05/14 05:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/05/14 05:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Oncogene. 2004 Mar 11;23(10):1911-21. doi: 10.1038/sj.onc.1207318.,"['10.1038/sj.onc.1207318 [doi]', '1207318 [pii]']",,"Chronic lymphocytic leukaemia (CLL) results from the accumulation of apoptosis-resistant clonal B cells that are arrested in G0/G1, and is heterogeneous with respect to clinical outcome. An aggressive form of the disease is identified by an impaired p53 response to ionizing radiation (IR). This is associated with inactivating mutations of either p53 or ATM, a regulator of p53 activated by IR-induced DNA damage. Since other forms of DNA damage activate p53 via ATR, a kinase closely related to ATM, abnormalities of the ATR-p53 pathway also have the potential to result in p53 dysfunction. We therefore tested cases of CLL for abnormal p53 responses to ultraviolet irradiation (UVC), a known activator of ATR, to screen for additional forms of p53 dysfunction. CLL cells and normal peripheral blood mononuclear cell (PBMC) preparations (predominantly noncycling lymphocytes) were treated with UVC and assessed for p53 responses. In all of the CLL cases and PBMC preparations tested, we were unable to detect p53 accumulation, phosphorylation or transcriptional consequences in response to UVC-induced DNA damage. The most likely explanation for the absence of UVC-induced p53 activation in CLL and normal lymphocytes was that, in contrast to other cell types, the UVC-induced ATR pathway was inactive. This notion was confirmed by showing that ATR protein was absent or undetectable in all of the cases of CLL and normal PBMCs screened. This was an unexpected finding because ATR was thought to be essential for the viability of somatic cells and for normal human and murine embryonic development. An obvious difference between the cell lines used as positive controls for ATR antibodies and the CLL cells/PBMCs was that the former were actively cycling while the latter were quiescent. We therefore hypothesized that the ATR-p53 pathway is selectively downregulated in noncycling lymphocytes. To test this, we induced cycling in the T-cell fraction of PBMC preparations and demonstrated that ATR protein expression was restored. Furthermore, p53 was upregulated and phosphorylated in response to UVC in these cells. Our data support the conclusion that the ATR-p53 pathway is suppressed in noncycling lymphocytes via ATR downregulation. We tentatively suggest that this repressed DNA damage response may have evolved to protect quiescent lymphocytes from the potential for p53-dependent apoptosis in the face of some forms of endurable genotoxic stress. If this is the case, DNA repair and genome stability might be compromised in quiescent lymphocytes with potentially negative consequences.","['Department of Haematology, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK.']",,,,,,,,,,
14755244,NLM,MEDLINE,20040414,20061115,0950-9232 (Print) 0950-9232 (Linking),23,13,2004 Mar 25,The c-Rel transcription factor and B-cell proliferation: a deal with the devil.,2275-86,"['Gilmore, Thomas D', 'Kalaitzidis, Demetrios', 'Liang, Mei-Chih', 'Starczynowski, Daniel T']","['Gilmore TD', 'Kalaitzidis D', 'Liang MC', 'Starczynowski DT']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S."", 'Review']",,England,Oncogene,Oncogene,8711562,"['0 (NF-kappa B)', '0 (Proto-Oncogene Proteins c-rel)']",IM,"['Animals', 'B-Lymphocytes/*physiology', 'Cell Division/*physiology', 'Humans', 'Leukemia, B-Cell/genetics', 'NF-kappa B/physiology', 'Proto-Oncogene Proteins c-rel/genetics/*physiology', 'Signal Transduction/physiology']",,,,2004/02/03 05:00,2004/04/15 05:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/04/15 05:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Oncogene. 2004 Mar 25;23(13):2275-86. doi: 10.1038/sj.onc.1207410.,"['10.1038/sj.onc.1207410 [doi]', '1207410 [pii]']",,"Activation of the Rel/NF-kappaB signal transduction pathway has been associated with a variety of animal and human malignancies. However, among the Rel/NF-kappaB family members, only c-Rel has been consistently shown to be able to malignantly transform cells in culture. In addition, c-rel has been activated by a retroviral promoter insertion in an avian B-cell lymphoma, and amplifications of REL (human c-rel) are frequently seen in Hodgkin's lymphomas and diffuse large B-cell lymphomas, and in some follicular and mediastinal B-cell lymphomas. Phenotypic analysis of c-rel knockout mice demonstrates that c-Rel has a normal role in B-cell proliferation and survival; moreover, c-Rel nuclear activity is required for B-cell development. Few mammalian model systems are available to study the role of c-Rel in oncogenesis, and it is still not clear what features of c-Rel endow it with its unique oncogenic activity among the Rel/NF-kappaB family. In any event, REL may provide an appropriate therapeutic target for certain human lymphoid cell malignancies.","['Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA. gilmore@bu.edu']",,,151,,,,,,,
14754972,NLM,MEDLINE,20040303,20190605,1098-4275 (Electronic) 0031-4005 (Linking),113,2,2004 Feb,Interpreting epidemiologic research and childhood leukemia.,430-1,"['Roff, Sue Rabbitt']",['Roff SR'],['eng'],"['Comment', 'Letter']",,United States,Pediatrics,Pediatrics,0376422,['0 (Petroleum)'],IM,"['Adult', 'Child, Preschool', 'Construction Materials/*adverse effects', 'Humans', 'Infant', 'Leukemia/*etiology', 'Male', 'Paternal Exposure/*adverse effects', 'Petroleum/adverse effects', 'Risk Factors']",,,,2004/02/03 05:00,2004/03/05 05:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/03/05 05:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Pediatrics. 2004 Feb;113(2):430-1. doi: 10.1542/peds.113.2.430.,['10.1542/peds.113.2.430 [doi]'],,,,,,,['Pediatrics. 2004 Jul;114(1):330-1. PMID: 15231965'],['Pediatrics. 2003 Jul;112(1 Pt 2):218-32. PMID: 12837914'],,,,,
14754622,NLM,MEDLINE,20050301,20071115,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,Immunological reconstitution after autologous peripheral blood stem cell transplantation in patients with chronic lymphocytic leukemia. Comparison with an historical non-Hodgkin's lymphoma group.,120-2,"['Laurenti, Luca', 'Piccirillo, Nicola', 'Sora, Federica', 'Piccioni, Paola', 'Tarnani, Michela', 'Leone, Giuseppe', 'Sica, Simona']","['Laurenti L', 'Piccirillo N', 'Sora F', 'Piccioni P', 'Tarnani M', 'Leone G', 'Sica S']",['eng'],"['Comparative Study', 'Letter']",,Italy,Haematologica,Haematologica,0417435,,IM,"['Adult', 'Female', 'Hematopoiesis/*physiology', 'Humans', 'Leukemia, Lymphocytic, Chronic, B-Cell/therapy', 'Lymphoma, Non-Hodgkin/*therapy', 'Male', 'Middle Aged', 'Peripheral Blood Stem Cell Transplantation/*methods', 'Transplantation, Autologous']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):120-2.,,,,,,,,,,,,,,
14754617,NLM,MEDLINE,20050301,20071115,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,Dendritic cell deficiency in early B cell chronic lymphocytic leukemia.,111-2,"['Strunk, Dirk', 'Grube, Regina', 'Stadelmeyer, Elke', 'Linkesch, Werner']","['Strunk D', 'Grube R', 'Stadelmeyer E', 'Linkesch W']",['eng'],"['Comparative Study', 'Letter']",,Italy,Haematologica,Haematologica,0417435,,IM,"['Dendritic Cells/metabolism/*pathology/physiology', 'Humans', 'Leukemia, Lymphocytic, Chronic, B-Cell/blood/genetics/*pathology', 'Phenotype']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):111-2.,,,,,,,,,,,,,,
14754616,NLM,MEDLINE,20050301,20211203,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,ATM mutations in B-cell chronic lymphocytic leukemia.,109-10,"['Lahdesmaki, Aleksi', 'Kimby, Eva', 'Duke, Veronique', 'Foroni, Letizia', 'Hammarstrom, Lennart']","['Lahdesmaki A', 'Kimby E', 'Duke V', 'Foroni L', 'Hammarstrom L']",['eng'],['Letter'],,Italy,Haematologica,Haematologica,0417435,"['0 (Cell Cycle Proteins)', '0 (DNA-Binding Proteins)', '0 (Tumor Suppressor Proteins)', 'EC 2.7.11.1 (ATM protein, human)', 'EC 2.7.11.1 (Ataxia Telangiectasia Mutated Proteins)', 'EC 2.7.11.1 (Protein Serine-Threonine Kinases)']",IM,"['Adult', 'Aged', 'Aged, 80 and over', 'Ataxia Telangiectasia Mutated Proteins', 'Cell Cycle Proteins', 'DNA-Binding Proteins', 'Female', 'Humans', 'Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/pathology', 'Male', 'Middle Aged', 'Mutation/*genetics/physiology', 'Polymorphism, Single-Stranded Conformational', 'Protein Serine-Threonine Kinases/*genetics/physiology', 'Tumor Suppressor Proteins']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):109-10.,,,,,,,,,,,,,,
14754615,NLM,MEDLINE,20050301,20151119,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.,107-8,"['Fouillard, Loic', 'Labopin, Myriam', 'Meloni, Giovanna', 'Polge, Emmanuelle', 'Gorin, Norbert-Claude', 'Frassoni, Francesco']","['Fouillard L', 'Labopin M', 'Meloni G', 'Polge E', 'Gorin NC', 'Frassoni F']",['eng'],"['Comparative Study', 'Letter', 'Multicenter Study']",,Italy,Haematologica,Haematologica,0417435,"['0 (Drug Combinations)', '00DPD30SOY (Amsacrine)', '04079A1RDZ (Cytarabine)', '6PLQ3CP4P3 (Etoposide)', '8N3DW7272P (Cyclophosphamide)', 'G1LN9045DK (Busulfan)', 'U68WG3173Y (Carmustine)', 'BAVC protocol']",IM,"['Adolescent', 'Adult', 'Aged', 'Amsacrine/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Busulfan/therapeutic use', 'Carmustine/*therapeutic use', 'Combined Modality Therapy/methods', 'Cyclophosphamide/therapeutic use', 'Cytarabine/*therapeutic use', 'Drug Combinations', 'Etoposide/*therapeutic use', 'Female', 'Humans', 'Leukemia, Erythroblastic, Acute/drug therapy/therapy', 'Leukemia, Megakaryoblastic, Acute/drug therapy/therapy', 'Leukemia, Monocytic, Acute/drug therapy/therapy', 'Leukemia, Myeloid/*drug therapy/*therapy', 'Leukemia, Myeloid, Acute/drug therapy/therapy', 'Leukemia, Myelomonocytic, Acute/drug therapy/therapy', 'Leukemia, Promyelocytic, Acute/drug therapy/therapy', 'Male', 'Middle Aged', 'Retrospective Studies', 'Stem Cell Transplantation/*methods', 'Transplantation, Autologous']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):107-8.,,,,,,,,,,,,,,
14754614,NLM,MEDLINE,20050301,20091119,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16).,106,"['Valk, Peter J M', 'Bowen, David T', 'Frew, Marion E', 'Goodeve, Anne C', 'Lowenberg, Bob', 'Reilly, John T']","['Valk PJ', 'Bowen DT', 'Frew ME', 'Goodeve AC', 'Lowenberg B', 'Reilly JT']",['eng'],['Letter'],,Italy,Haematologica,Haematologica,0417435,"['EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)', 'EC 3.6.5.2 (HRAS protein, human)', 'EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))']",IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Chromosome Inversion/*genetics', 'Chromosomes, Human, Pair 16/*genetics', 'Female', 'Humans', 'Leukemia, Myeloid/*genetics', 'Male', 'Middle Aged', 'Mutation/*genetics', 'Proto-Oncogene Proteins p21(ras)/*genetics', 'Receptor Protein-Tyrosine Kinases/*genetics', 'Signal Transduction/*genetics']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):106.,,,,,,,,,,,,,,
14754613,NLM,MEDLINE,20050301,20171116,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in complete hematologic remission.,103-5,"['Buonamici, Silvia', 'Ottaviani, Emanuela', 'Visani, Giuseppe', 'Bonifazi, Francesca', 'Fiacchini, Mauro', 'Baccarani, Michele', 'Martinelli, Giovanni']","['Buonamici S', 'Ottaviani E', 'Visani G', 'Bonifazi F', 'Fiacchini M', 'Baccarani M', 'Martinelli G']",['eng'],['Letter'],,Italy,Haematologica,Haematologica,0417435,"['0 (AML1-ETO fusion protein, human)', '0 (Core Binding Factor Alpha 2 Subunit)', '0 (Oncogene Proteins, Fusion)', '0 (RUNX1 Translocation Partner 1 Protein)', '0 (Transcription Factors)']",IM,"['Adult', 'Chromosomes, Human, Pair 21/*genetics', 'Chromosomes, Human, Pair 8/*genetics', 'Core Binding Factor Alpha 2 Subunit', 'Female', 'Humans', 'Karyotyping', 'Leukemia, Myeloid, Acute/*genetics', 'Male', 'Middle Aged', 'Oncogene Proteins, Fusion/*genetics', 'RUNX1 Translocation Partner 1 Protein', 'Remission Induction', 'Transcription Factors/*genetics', 'Translocation, Genetic/genetics']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):103-5.,,,,,,,,,,,,,,
14754608,NLM,MEDLINE,20050301,20071115,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,"Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.",70-6,"['Bianco, Elvira', 'Marcucci, Fabrizio', 'Mele, Alfonso', 'Musto, Pellegrino', 'Cotichini, Rodolfo', 'Sanpaolo, Maria Grazia', 'Iannitto, Emilio', 'De Renzo, Amalia', 'Martino, Bruno', 'Specchia, Giorgina', 'Montanaro, Marco', 'Barbui, Anna Maria', 'Nieddu, Rosa', 'Pagano, Livio', 'Rapicetta, Maria', 'Franceschi, Silvia', 'Mandelli, Franco', 'Pulsoni, Alessandro']","['Bianco E', 'Marcucci F', 'Mele A', 'Musto P', 'Cotichini R', 'Sanpaolo MG', 'Iannitto E', 'De Renzo A', 'Martino B', 'Specchia G', 'Montanaro M', 'Barbui AM', 'Nieddu R', 'Pagano L', 'Rapicetta M', 'Franceschi S', 'Mandelli F', 'Pulsoni A']",['eng'],"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]",,Italy,Haematologica,Haematologica,0417435,['0 (Hepatitis C Antibodies)'],IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Case-Control Studies', 'Female', 'Hepacivirus/immunology/isolation & purification', 'Hepatitis C/*epidemiology', 'Hepatitis C Antibodies/blood', 'Hodgkin Disease/blood/virology', 'Humans', 'Leukemia, Lymphocytic, Chronic, B-Cell/blood/virology', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood/virology', 'Leukemia, Myeloid/blood/virology', 'Lymphoma, B-Cell/blood/*virology', 'Lymphoma, T-Cell/blood/virology', 'Lymphoproliferative Disorders/blood/*virology', 'Male', 'Middle Aged', 'Multiple Myeloma/blood/virology', 'Myeloproliferative Disorders/blood/*virology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood/virology']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):70-6.,,,"BACKGROUND AND OBJECTIVES: Infection with hepatitis C virus (HCV) is associated with type II mixed cryoglobulinemia (MC), a lymphoproliferative disorder which, in some patients, evolves into overt B-cell non-Hodgkin's lymphoma (B-NHL). Recently, also the association between HCV infection and B-NHL, which had long been controversial, was confirmed in a large case-control study. Little knowledge is, however, available on possible associations between HCV infection and other lymphoid or myeloid malignancies. The present study was set up in order to investigate this aspect. DESIGN AND METHODS: The study was conducted in hematology departments of ten hospitals in different Italian cities. The cases consisted of consecutive patients with a new diagnosis of T-NHL, Hodgkin's disease (HD), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). The controls were patients in other departments of the same hospitals. HCV infection was investigated by testing for HCV antibodies and HCV-RNA in serum samples. RESULTS: The prevalence of HCV infection was not higher in patients with HD (3.2%, 5 out of 157 cases) or MM (4.7%, 5 out of 107) than in controls. On the other hand, it was consistently higher in T-NHL (13.8%, 4 out of 30), CLL (9.0%, 9 out of 100), ALL (7.6%, 5 out of 54), AML (7.9%, 11 out of 140), and CML (12.2%, 6 out of 49) patients. These patient groups were not, however, large enough to render statistically significant results. INTERPRETATION AND CONCLUSIONS: Our data suggest that HCV infection may be associated not only with B-NHL but also with some other lymphoid and myeloid malignancies.","['Istituto Superiore di Sanita, Rome, Italy.']",,,,['Haematologica. 2004 Nov;89(11):ELT17. PMID: 15533850'],,,,['Italian Multi-Center case-control study'],,
14754607,NLM,MEDLINE,20050301,20171116,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies.,58-69,"['Bueno, Clara', 'Almeida, Julia', 'Lucio, Paulo', 'Marco, Josefa', 'Garcia, Raimundo', 'de Pablos, Jose Maria', 'Parreira, Antonio', 'Ramos, Fernando', 'Ruiz-Cabello, Francisco', 'Suarez-Vilela, Dimas', 'San Miguel, Jesus F', 'Orfao, Alberto']","['Bueno C', 'Almeida J', 'Lucio P', 'Marco J', 'Garcia R', 'de Pablos JM', 'Parreira A', 'Ramos F', 'Ruiz-Cabello F', 'Suarez-Vilela D', 'San Miguel JF', 'Orfao A']",['eng'],['Journal Article'],,Italy,Haematologica,Haematologica,0417435,"['0 (CD4 Antigens)', '0 (HLA-DR Antigens)']",IM,"['Acute Disease', 'Aged', 'Aged, 80 and over', 'CD4 Antigens/*biosynthesis/immunology', 'Dendritic Cells/*chemistry/*pathology', 'Female', 'Flow Cytometry/methods', 'HLA-DR Antigens/*biosynthesis/immunology', 'Humans', 'Immunophenotyping', 'Incidence', 'Leukemia/epidemiology', 'Leukemia, Myeloid, Acute/*epidemiology/*genetics/pathology', 'Lymphoma, Non-Hodgkin/*epidemiology/*genetics/pathology', 'Male', 'Middle Aged', 'Molecular Epidemiology/*methods', 'Phenotype', 'Treatment Outcome']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):58-69.,,,"BACKGROUND AND OBJECTIVES: Recent reports suggest that CD4(+)/CD56(+)/lineage(-) hematopoietic neoplasias are aggressive types of malignancies involving lymphoplasmacytoid/DC2 dendritic cells (DC). Here, we report on the incidence of DC malignancies and their clinical, biological, phenotypic and cytogenetic characteristics. DESIGN AND METHODS: From a large series of 392 patients with acute myeloblastic leukemia (AML) and 739 with non-Hodgkin's lymphoma (NHL), five cases (three presenting as acute leukemia and two as NHL) showed clinical, morphologic and phenotypic features compatible with a DC malignancy. RESULTS: The overall incidence of DC malignancies among all AML and NHL cases was 0.76% and 0.27%, respectively. At presentation, these patients displayed cutaneous nodules, splenomegaly and lymph node involvement with variable levels of peripheral blood (PB) and/or bone marrow (BM) infiltration in association with anemia and thrombocytopenia. Cytologic studies showed immature appearing blast cells with negative cytochemistry reactions for both myeloperoxidase and esterases. A highly suggestive DC phenotype based on co-expression of CD123(hi)/HLADR(+)/lin(-)/CD56(+)/CD45(dim) associated with a germline configuration of both the IgH and TCRgamma genes was found in all except one patient who was CD56(-). Expression of other markers compatible with a DC origin was found in all cases. INTERPRETATION AND CONCLUSIONS: We show that DC-derived malignancies can present as either cutaneous lymphoma or acute leukemia, although their incidence is extremely low (<< >1%). While most of these DC neoplasias probably correspond to the malignant counterpart of DC2/lymphoplasmacytoid DC, neoplasias of myeloid DC might also exist, chemotherapy followed by consolidation with ASCT is apparently the most effective strategy for achieving a durable remission in these individuals.","[""Servicios de Citometria y Hematologia, Hospital Universitario de Salamanca, Centro de Investigacio' del Cancer, Universidad de Salamanca, Salamanca, Spain.""]",,,,,,,,,,
14754606,NLM,MEDLINE,20050301,20151119,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.,49-57,"['Lange, Thoralf', 'Bumm, Thomas', 'Otto, Sandra', 'Al-Ali, Haifa-Kathrin', 'Kovacs, Ines', 'Krug, Daniela', 'Kohler, Thomas', 'Krahl, Rainer', 'Niederwieser, Dietger', 'Deininger, Michael W N']","['Lange T', 'Bumm T', 'Otto S', 'Al-Ali HK', 'Kovacs I', 'Krug D', 'Kohler T', 'Krahl R', 'Niederwieser D', 'Deininger MW']",['eng'],"['Journal Article', 'Multicenter Study']",,Italy,Haematologica,Haematologica,0417435,"['0 (Benzamides)', '0 (Piperazines)', '0 (Pyrimidines)', '8A1O1M485B (Imatinib Mesylate)', 'EC 1.2.1.- (Glyceraldehyde-3-Phosphate Dehydrogenases)', 'EC 2.7.10.2 (Fusion Proteins, bcr-abl)']",IM,"['Adult', 'Aged', 'Benzamides', 'Bone Marrow/chemistry/metabolism/pathology', 'Cytogenetic Analysis/*methods/statistics & numerical data', 'Disease-Free Survival', 'Female', 'Fusion Proteins, bcr-abl/blood/genetics', 'Glyceraldehyde-3-Phosphate Dehydrogenases/blood/genetics', 'Humans', 'Imatinib Mesylate', 'In Situ Hybridization, Fluorescence/methods/statistics & numerical data', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood/*drug therapy/*genetics', 'Male', 'Middle Aged', 'Multivariate Analysis', 'Philadelphia Chromosome', 'Piperazines/*therapeutic use', 'Prognosis', 'Pyrimidines/*therapeutic use', 'Remission Induction/methods', 'Reverse Transcriptase Polymerase Chain Reaction/*methods/statistics & numerical data']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):49-57.,,,"BACKGROUND AND OBJECTIVES: Imatinib is the new standard drug treatment for patients with chronic myelogenous leukemia (CML). Quantitative reverse transcription-polymerase chain reaction (qPCR) for detection of BCR-ABL transcripts is frequently used for monitoring patients in addition to or instead of conventional cytogenetics, although its place in the overall diagnostic framework is not yet clear. In this study, we compared qPCR and conventional cytogenetics for monitoring of patients during the early phases of imatinib therapy. DESIGN AND METHODS: One hundred and seventeen patients treated with imatinib for CML in chronic or accelerated phase were prospectively followed with qPCR and karyotyping. Comparisons were made between both methods and between qPCR results from bone marrow and peripheral blood. To determine the prognostic impact of qPCR and cytogenetics during the early phase of imatinib treatment on subsequent cytogenetic response and progression-free survival (PFS), a multivariate model was generated that included established prognostic baseline variables. RESULTS: We found a significant correlation between the proportion of Philadelphia (Ph) chromosome-positive metaphases and qPCR in the bone marrow and peripheral blood. Low qPCR values after 3 months of therapy were correlated with major cytogenetic response (MCyR) at 6 months and PFS at 2 years. However, in multivariate analysis, the cytogenetic response at 3 months emerged as the only independent parameter predictive of MCyR at 6 months and PFS at 2 years. INTERPRETATION AND CONCLUSIONS: Our data suggest that conventional karyotyping should remain the standard method for following patients on imatinib during the early phases of therapy.","['Department of Hematology, University of Leipzig, Germany.']",,,,['Haematologica. 2004 Jan;89(1):6-9. PMID: 14754599'],,,,,,
14754605,NLM,MEDLINE,20050301,20161124,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha.,42-8,"['Roman-Gomez, Jose', 'Jimenez-Velasco, Antonio', 'Castillejo, Juan A', 'Cervantes, Francisco', 'Barrios, Manuel', 'Colomer, Dolors', 'Heiniger, Anabel', 'Torres, Antonio']","['Roman-Gomez J', 'Jimenez-Velasco A', 'Castillejo JA', 'Cervantes F', 'Barrios M', 'Colomer D', 'Heiniger A', 'Torres A']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,Italy,Haematologica,Haematologica,0417435,"['0 (Interferon-alpha)', '0 (Intracellular Signaling Peptides and Proteins)', '0 (Repressor Proteins)', '0 (SOCS1 protein, human)', '0 (Suppressor of Cytokine Signaling 1 Protein)', '0 (Suppressor of Cytokine Signaling Proteins)']",IM,"['Adult', 'Drug Resistance, Neoplasm/genetics', 'Female', 'Humans', 'Interferon-alpha/*metabolism/*therapeutic use', 'Intracellular Signaling Peptides and Proteins/metabolism', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/drug therapy/*genetics', 'Male', 'Middle Aged', 'Philadelphia Chromosome', 'Prognosis', 'Repressor Proteins/*biosynthesis/metabolism', 'Signal Transduction', 'Suppressor of Cytokine Signaling 1 Protein', 'Suppressor of Cytokine Signaling Proteins', 'Survival Rate', 'Treatment Outcome']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):42-8.,,,"BACKGROUND AND OBJECTIVES: Interferon-alpha (IFN-alpha) has proven useful for treating chronic myeloid leukemia (CML). However, only 7% of patients achieve a complete cytogenetic response. Although efforts to understand the molecular basis of this resistance to IFN-alpha have been made, the mechanism is still unknown. Because suppressor of cytokine signaling (SOCS) proteins are negative regulators of cytokine-induced signaling, it has been hypothesized that aberrant SOCS expression could confer resistance against cytokine therapy. DESIGN AND METHODS: In order to analyze the role of SOCS-1 in the acquisition of IFN-alpha resistance in this setting, we examined SOCS-1 mRNA expression using reverse transcription polymerase chain reaction (RT-PCR) in 75 newly diagnosed chronic phase-CML patients who received IFN-alpha therapy. RESULTS: SOCS-1 was constitutively expressed in 49 (65%) of 75 CML patients at diagnosis. Constitutive SOCS-1 expression was more frequently observed among Hasford high-risk patients (p = 0.05) and was also independently associated with a shorter median progression-free survival time (p = 0.001) and poor cytogenetic response to IFN-alpha treatment (p 0.0001). INTERPRETATION AND CONCLUSIONS: Our data indicate that constitutive expression of SOCS-1 occurs at an early stage in CML pathogenesis and probably influences the clinical behavior of the disease.","['Hematology Department, Reina Sofia Hospital, Cordoba, Spain. peperosa@teleline.es']",,,,,,,,,,
14754604,NLM,MEDLINE,20050301,20181130,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups.,34-41,"['Legrand, Ollivier', 'Zompi, Simona', 'Perrot, Jean-Yves', 'Faussat, Anne-Marie', 'Benderra, Zineb', 'Chaoui, Driss', 'Marie, Jean-Pierre']","['Legrand O', 'Zompi S', 'Perrot JY', 'Faussat AM', 'Benderra Z', 'Chaoui D', 'Marie JP']",['eng'],['Journal Article'],,Italy,Haematologica,Haematologica,0417435,"['0 (ATP Binding Cassette Transporter, Subfamily B, Member 1)', '0 (Multidrug Resistance-Associated Proteins)', '0 (Neoplasm Proteins)', '0 (Vault Ribonucleoprotein Particles)', '0 (major vault protein)', 'Y49M64GZ4Q (multidrug resistance-associated protein 1)']",IM,"['ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis/*metabolism', 'Acute Disease', 'Adult', 'Chromosome Inversion/genetics', 'Cytogenetics/*methods', 'Humans', 'Immunophenotyping/methods', 'Leukemia, Erythroblastic, Acute/genetics/pathology', 'Leukemia, Megakaryoblastic, Acute/genetics/pathology', 'Leukemia, Monocytic, Acute/genetics/pathology', 'Leukemia, Myeloid/*genetics/*pathology', 'Leukemia, Myeloid, Acute/genetics/pathology', 'Leukemia, Myelomonocytic, Acute/genetics/pathology', 'Leukemia, Promyelocytic, Acute/genetics/pathology', 'Multidrug Resistance-Associated Proteins/biosynthesis/*metabolism/physiology', 'Neoplasm Proteins/biosynthesis', 'Prognosis', 'Risk Factors', 'Translocation, Genetic/genetics', 'Vault Ribonucleoprotein Particles/biosynthesis']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):34-41.,,,"BACKGROUND AND OBJECTIVES: We studied the function of both Pgp and MRP1 to identify subgroups of patients who could benefit from Pgp reversion, and to clarify in different FAB subtypes and in cytogenetic risk groups their expression and function. DESIGN AND METHODS: We examined 132 adults with de novo acute myeloid leukemia (AML) for Pgp and MRP1 expression and function. We correlated our finding with the FAB subtypes and the cytogenetics, and clinical data of our patients. RESULTS: Among FAB subtypes and cytogenetic subgroups, patients with good risk cytogenetics have a low expression and activity of Pgp and MRP1 except patients with inv(16) who have a higher activity of MRP1 than t(8;21) and t(15;17) (p=0.05). All other AML patients, except M5, have a high expression and activity of Pgp. In contrast, M5 have a high expression, but a low activity of Pgp. In this subgroup, M5 with MLL gene rearrangement did not express an active Pgp. Others patients with M5 AML did not have a functional Pgp. Monosomy 7, 11q2.3 gene rearrangement and complex cytogenetic have a higher activity of MRP1 than other cytogenetic (p=0.03). INTERPRETATION AND CONCLUSIONS: Resistance mechanism in M5 was not mediated by Pgp. In contrast, MRP1 may play a role in patients who have a 11q2.3 gene rearrangement, or in M4E with inv(16). Thus trials that modulate Pgp are likely to achieve limited success in AML with low activity of Pgp, i.e., M5 and, AML with good risk cytogenetics.","['Laboratoire E 03-55 INSERM, EA 1529, Universite Paris VI, France. ollivier.legrand@htd.ap-hop-paris.fr']",,,,,,,,,,
14754603,NLM,MEDLINE,20050301,20151119,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.,29-33,"['Breccia, Massimo', 'Diverio, Daniela', 'Noguera, Nelida Ines', 'Visani, Giuseppe', 'Santoro, Alessandra', 'Locatelli, Franco', 'Damiani, Daniela', 'Marmont, Filippo', 'Vignetti, Marco', 'Petti, Maria C', 'Lo Coco, Francesco']","['Breccia M', 'Diverio D', 'Noguera NI', 'Visani G', 'Santoro A', 'Locatelli F', 'Damiani D', 'Marmont F', 'Vignetti M', 'Petti MC', 'Lo Coco F']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,Italy,Haematologica,Haematologica,0417435,"['0 (Biomarkers, Tumor)', '0 (DNA, Neoplasm)', '0 (Neoplasm Proteins)', '0 (Oncogene Proteins, Fusion)', '0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)', '5688UTC01R (Tretinoin)', 'ZRP63D75JW (Idarubicin)', 'AIDA protocol']",IM,"['Adolescent', 'Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Biomarkers, Tumor/genetics', 'Child', 'Child, Preschool', 'DNA, Neoplasm/genetics', 'Female', 'Humans', 'Idarubicin/*therapeutic use', 'Leukemia, Promyelocytic, Acute/*drug therapy/*genetics', 'Male', 'Middle Aged', 'Molecular Diagnostic Techniques/methods', 'Neoplasm Proteins/genetics', 'Neoplasm, Residual', 'Oncogene Proteins, Fusion/genetics', 'Polymerase Chain Reaction/*methods', 'Remission Induction', 'Treatment Outcome', 'Tretinoin/*therapeutic use']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):29-33.,,,"BACKGROUND AND OBJECTIVES: Front line treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) and chemotherapy (CHT) results in molecular remission in approximately 95% of patients tested after consolidation. The small fraction of patients with persistence of molecular disease (i.e. those in whom polymerase chain reaction (PCR) is positive for PML/RARalpha) after such therapy are thought to have a dismal prognosis but has not yet been investigated in detail. DESIGN AND METHODS: We analyzed the clinico-biological features at presentation of APL patients who showed PCR-detectable residual disease and compared them to those of patients achieving molecular remission after AIDA induction and consolidation. Furthermore, we report the outcome of patients with molecularly persistent disease treated with salvage therapy. RESULTS: Patients attaining molecular remission (n=650) and patients who tested PCR+ve at the end of consolidation (n=23) were not statistically significantly different as regards median age, white cell and platelet counts, morphologic subtype (M3 or M3v), fibrinogen levels or PML/RARalpha transcript type. As to treatment outcome after salvage therapy, 7 patients were treated before morphologic relapse [3 with chemotherapy and autologous stem cell transplantation (SCT) and 4 with allogeneic SCT], and are alive after 64-118 months. Of 16 patients treated at the time of morphologic relapse, only 2 patients are alive, both of whom received an allogeneic SCT. INTERPRETATION AND CONCLUSIONS: Our findings indicate that APL patients who are molecularly resistant to the AIDA protocol have no distinguishing features at presentation. Their outcome suggests the need for early therapeutic intervention with aggressive treatment prior to the occurrence of hematologic relapse.","['Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Roma, Italy.']",,,,,,,,,,
14754600,NLM,MEDLINE,20050301,20071115,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,Chronic lymphocytic leukemia 2003.,9-10,"['Morra, Enrica', 'Montillo, Marco']","['Morra E', 'Montillo M']",['eng'],['Editorial'],,Italy,Haematologica,Haematologica,0417435,,IM,"['Humans', 'Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology/*genetics']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):9-10.,,,,,,,,,,,,,,
14754599,NLM,MEDLINE,20050301,20071115,1592-8721 (Electronic) 0390-6078 (Linking),89,1,2004 Jan,Conventional and novel tools for defining the risk of the individual patient with chronic myeloid leukemia and for monitoring treatment.,6-9,"['Saglio, Giuseppe', 'Cilloni, Daniela']","['Saglio G', 'Cilloni D']",['eng'],"['Comment', 'Editorial', 'Review']",,Italy,Haematologica,Haematologica,0417435,,IM,"['Disease-Free Survival', 'Humans', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*epidemiology/*genetics', 'Neoplasm Recurrence, Local/*epidemiology/genetics/*mortality', 'Remission Induction/methods', 'Risk Factors']",,,,2004/02/03 05:00,2005/03/02 09:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2005/03/02 09:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Haematologica. 2004 Jan;89(1):6-9.,,,,,,,24,,['Haematologica. 2004 Jan;89(1):49-57. PMID: 14754606'],,,,,
14754516,NLM,MEDLINE,20040415,20200225,1582-1838 (Print) 1582-1838 (Linking),7,4,2003 Oct-Dec,Interleukin-17 in acute myeloid leukemia.,472-4,"['Wrobel, T', 'Mazur, G', 'Jazwiec, Bozena', 'Kuliczkowski, K']","['Wrobel T', 'Mazur G', 'Jazwiec B', 'Kuliczkowski K']",['eng'],['Journal Article'],,England,J Cell Mol Med,Journal of cellular and molecular medicine,101083777,['0 (Interleukin-17)'],IM,"['Adult', 'Aged', 'Aged, 80 and over', 'CD4-Positive T-Lymphocytes/immunology', 'Female', 'Humans', 'Interleukin-17/*blood', 'Leukemia, Myeloid, Acute/*blood/immunology', 'Male', 'Middle Aged', 'Neovascularization, Pathologic']",,,,2004/02/03 05:00,2004/04/16 05:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/04/16 05:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,J Cell Mol Med. 2003 Oct-Dec;7(4):472-4. doi: 10.1111/j.1582-4934.2003.tb00250.x.,"['007.004.14 [pii]', '10.1111/j.1582-4934.2003.tb00250.x [doi]']",PMC6740244,There are several reports that angiogenesis plays important roles in hematological malignancies including acute myeloid leukemia (AML). Human interleukin-17 (IL-17) is a proinflammatory cytokine produced by activated CD4 T cells. IL-17 plays a potential role in T cell mediated angiogenesis. The role of IL-17 in pathologic angiogenesis has not been evaluated yet. The aim of the study was to determine plasma level of IL-17 in patients with AML. IL-17 levels were measured by ELISA in plasma samples taken from 68 adult patients with AML before chemotherapy was administered. In addition 20 out of 68 patients were reanalysed after achieving complete remission (CR). Ten samples from healthy volunteers were evaluated as the control. In this study we have demonstrated that serum level of IL-17 is not elevated in AML patients. These results suggest that angiogenesis in AML is not mediated by CD4 T cells. To our knowledge this is the first report about IL-17 serum level in acute leukemias. We are currently evaluating IL-17 levels in others haematological malignancies.,"['Department of Haematology, Wroclaw Medical University, Wroclaw, Poland. wrobelt@hemat.am.wroc.pl']",,,,,,,,,,
14754410,NLM,MEDLINE,20040730,20191108,1568-0118 (Print) 1568-0118 (Linking),4,1,2004 Jan,Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.,31-42,"['Han, B', 'Zhang, J-T']","['Han B', 'Zhang JT']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, Non-P.H.S."", ""Research Support, U.S. Gov't, P.H.S."", 'Review']",,Netherlands,Curr Med Chem Anticancer Agents,Current medicinal chemistry. Anti-cancer agents,101123597,"['0 (ABCG2 protein, human)', '0 (ATP Binding Cassette Transporter, Subfamily G, Member 2)', '0 (ATP-Binding Cassette Transporters)', '0 (Antineoplastic Agents)', '0 (Neoplasm Proteins)', '0 (Xenobiotics)']",IM,"['ATP Binding Cassette Transporter, Subfamily G, Member 2', 'ATP-Binding Cassette Transporters/antagonists & inhibitors/chemistry/*metabolism', 'Animals', 'Antineoplastic Agents/chemistry/*pharmacology', 'Dimerization', 'Drug Resistance, Multiple/*drug effects/genetics', 'Drug Resistance, Neoplasm/*drug effects/genetics', 'Humans', 'Neoplasm Proteins/antagonists & inhibitors/chemistry/*metabolism', 'Neoplasms/drug therapy/metabolism', 'Organ Specificity', 'Polymorphism, Genetic', 'Structure-Activity Relationship', 'Xenobiotics/chemistry/*pharmacology']",,,,2004/02/03 05:00,2004/07/31 05:00,['2004/02/03 05:00'],"['2004/02/03 05:00 [pubmed]', '2004/07/31 05:00 [medline]', '2004/02/03 05:00 [entrez]']",ppublish,Curr Med Chem Anticancer Agents. 2004 Jan;4(1):31-42. doi: 10.2174/1568011043482205.,['10.2174/1568011043482205 [doi]'],,"ABCG2, also termed BCRP/MXR/ABCP, is a half ATP-binding cassette (ABC) transporter expressed on plasma membranes. ABCG2 was independently cloned from placenta as well as cell lines selected for resistance to mitoxantrone or anthracyclines. ABCG2 consists of a nucleotide-binding domain (NBD) at the amino terminus and a transmembrane domain (TMD) at the carboxyl terminus and it is postulated to form a homodimer to perform its biological functions. Over-expression of ABCG2 in cell lines confers resistance on a wide variety of anticancer drugs including mitoxantrone, daunorubicin, doxorubicin, topotecan and epirubicin. The expression of ABCG2 has been implicated in multidrug resistance (MDR) of acute myeloid leukemia and some solid tumors. In addition, ABCG2 can transport several fluorescent dyes or toxins. ABCG2 is found to be expressed in epithelial cells of intestine and colon, liver canaliculi, and renal tubules, where it serves to eliminate the plasma level of orally administered anticancer drugs as well as ingested toxins. ABCG2 is found to be highly expressed in placenta and the luminal surface of microvessel endothelium blood-brain barrier where it may play a role in limiting the penetration of drugs, such as topotecan from the maternal plasma into the fetus and from blood to brain. A variety of inhibitors for ABCG2 including GF120918 may prove useful for sensitizing cancer cells to chemotherapy or altering the distribution of orally administered drug substrates of ABCG2. Interestingly, ABCG2 is also expressed highly in hematopoietic stem cells. However, the function of ABCG2 in stem cells is currently unknown, although it may provide protection to stem cells from a variety of xenobiotics.","['Department of Pharmacology and Toxicology, Walther Oncology Center/Walther Cancer Institute and I.U. Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA.']",,"['CA64539/CA/NCI NIH HHS/United States', 'GM59475/GM/NIGMS NIH HHS/United States']",74,,,,,,,
14752887,NLM,MEDLINE,20040302,20151013,1545-5009 (Print) 1545-5009 (Linking),42,2,2004 Feb,Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis.,195-9,"['Styczynski, Jan', 'Wysocki, Mariusz']","['Styczynski J', 'Wysocki M']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Pediatr Blood Cancer,Pediatric blood & cancer,101186624,['0 (Antineoplastic Agents)'],IM,"['Acute Disease', 'Adolescent', 'Antineoplastic Agents/*pharmacology/therapeutic use', 'Cell Division/drug effects', 'Child', 'Child, Preschool', 'Cytogenetic Analysis', '*Drug Resistance, Neoplasm', 'Drug Screening Assays, Antitumor', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia, Myeloid/diagnosis/*drug therapy/genetics', 'Male', 'Neoplasm Recurrence, Local/diagnosis/*drug therapy/genetics']",,,,2004/01/31 05:00,2004/03/03 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/03/03 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Pediatr Blood Cancer. 2004 Feb;42(2):195-9. doi: 10.1002/pbc.10457.,['10.1002/pbc.10457 [doi]'],,"Relapsed pediatric patients with acute myeloid leukemia (AML) have a poor clinical prognosis. The aim of this study was the analysis of the ex vivo drug resistance profile on relapse in childhood AML in comparison to newly diagnosed AML. The results of 98 pediatric AML samples tested by the MTT assay were analyzed. Eighteen samples (18%) were excluded from the further analysis due to spontaneous apoptosis of blasts in 4-days culture, low percentage of myeloblasts in the sample either in the beginning or at the end of the assay, infection, or formation of clots in the sample. Finally, ex vivo drug resistance of 20 relapsed samples were compared with that of 60 de novo AML, including 9 matched pairs. Up to 18 drugs were tested for each patient. No significant differences between drug resistance at diagnosis and at relapse in AML was found, neither for the whole groups of patients, nor for matched pairs only. Possibly, relatively good sensitivity of myeloblasts on relapse was found against melphalan, thiotepa, 4-HOO-ifosfamide, and cladribine. In summary, cellular drug resistance in childhood AML at relapse is not higher than at first diagnosis. These observations suggest that other, than cellular drug resistance, factors play a key role in therapy failure of relapsed childhood AML.","['Department of Pediatric Hematology and Oncology, Medical University Bydgoszcz, Bydgoszcz, Poland. jan_styczynski@wp.pl']",,,,,,"['Copyright 2003 Wiley-Liss, Inc.']",,,,
14752875,NLM,MEDLINE,20040302,20151013,1545-5009 (Print) 1545-5009 (Linking),42,2,2004 Feb,Effects of physical therapy intervention for children with acute lymphoblastic leukemia.,127-33,"['Marchese, Victoria G', 'Chiarello, Lisa A', 'Lange, Beverly J']","['Marchese VG', 'Chiarello LA', 'Lange BJ']",['eng'],"['Clinical Trial', 'Comparative Study', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]",,United States,Pediatr Blood Cancer,Pediatric blood & cancer,101186624,,IM,"['Adolescent', 'Ankle/physiology', 'Case-Control Studies', 'Child', 'Child, Preschool', '*Exercise', '*Exercise Therapy', 'Female', 'Gait/*physiology', 'Humans', 'Knee/physiology', 'Male', 'Physical Endurance', 'Physical Therapy Modalities', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy', 'Range of Motion, Articular']",,,,2004/01/31 05:00,2004/03/03 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/03/03 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Pediatr Blood Cancer. 2004 Feb;42(2):127-33. doi: 10.1002/pbc.10481.,['10.1002/pbc.10481 [doi]'],,"BACKGROUND: The purpose of this study was to examine the effects of physical therapy intervention in children with acute lymphoblastic leukemia (ALL). PROCEDURE: Twenty-eight children aged 4-15 years were randomly assigned to an intervention or control group. The intervention group received five sessions of physical therapy and was instructed to perform an individualized home exercise program consisting of ankle dorsiflexion stretching, lower extremity strengthening, and aerobic exercise. RESULTS: After 4 months children who received physical therapy intervention had significantly improved ankle dorsiflexion active range of motion and knee extension strength (P < 0.01). Differences were not found between the two groups for any of the other dependent variables. CONCLUSIONS: Physical therapy intervention for children with ALL receiving maintenance chemotherapy improved two body functions important for normal gait. Physical therapy programs initiated earlier in treatment and with greater emphasis on endurance activities may also improve stamina and quality of life (QOL).","[""Department of Rehabilitation Services, St. Jude Children's Research Hospital, Tennessee, USA. victoria.marchese@stjude.org""]",,,,,,"['Copyright 2003 Wiley-Liss, Inc.']",,,,
14752873,NLM,MEDLINE,20040302,20151013,1545-5009 (Print) 1545-5009 (Linking),42,2,2004 Feb,Leukemic cells and the cytokine patchwork.,113-21,"['Kiss, Csongor', 'Benko, Ilona', 'Kovacs, Peter']","['Kiss C', 'Benko I', 'Kovacs P']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']",,United States,Pediatr Blood Cancer,Pediatric blood & cancer,101186624,"['0 (Cytokines)', '0 (Hematopoietic Cell Growth Factors)']",IM,"['Animals', 'Cell Differentiation', 'Cell Division', 'Cytokines/*physiology', 'Hematopoietic Cell Growth Factors/physiology', 'Humans', 'Leukemia, Myeloid, Acute/*physiopathology', 'Myelodysplastic Syndromes/physiopathology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*physiopathology']",,,,2004/01/31 05:00,2004/03/03 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/03/03 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Pediatr Blood Cancer. 2004 Feb;42(2):113-21. doi: 10.1002/pbc.10436.,['10.1002/pbc.10436 [doi]'],,"BACKGROUND: In leukemia, the clonal population is characterized by a hierarchical organization. Although the majority of the leukemic population is generated after post-determinic divisions, a subset of cells retain undifferentiated ""blast"" morphology. In addition, leukemic cells often have numerical or structural chromosomal abnormalities, aberrant gene expression patterns, and abnormal cell surface marker profiles. Despite these differences when compared to normal bone marrow and blood cells, leukemic cell survival and proliferation, just like that of normal progenitor cells, is influenced by hematopoietic growth factors. A major issue is whether differential regulation of normal and leukemic hematopoietic cells by cytokines can be exploited in antileukemic treatment or, in contrast, whether in vivo cytokine therapy may even be harmful to the patients. PROCEDURE: Here we review the results of recent experimental and clinical observations that investigated the influence of cytokines on leukemic cell growth and differentiation in vitro and in vivo. RESULTS: The majority of studies indicate that hematopoietic growth factors are involved in the regulation of proliferation and terminal differentiation of leukemic blast cells. Genetic aberrations involving cytokines or their receptors may contribute to leukemogenesis. Abundant interactions, cross-lineage stimulation, and aberrant response patterns seem to transform the complex cytokine network regulation of normal hematopoiesis into an even more interlaced ""patchwork"" that controls leukemic hematopoiesis. CONCLUSIONS: Since hematopoietic growth factors are present in high serum concentrations in patients with acute leukemia and myelodysplastic syndromes, consequences of possible interactions should be kept in mind even when well-defined human recombinant factors in single application are to be involved in antileukemic protocols.","['Department of Pediatrics, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary. kisscs@jaguar.dote.hu']",,,119,,,"['Copyright 2003 Wiley-Liss, Inc.']",,,,
14752871,NLM,MEDLINE,20040317,20151013,1545-5009 (Print) 1545-5009 (Linking),42,3,2004 Mar,Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia.,289-91,"['Kersun, Leslie S', 'Wimmer, Robert S', 'Hoot, Andrew C', 'Meadows, Anna T']","['Kersun LS', 'Wimmer RS', 'Hoot AC', 'Meadows AT']",['eng'],"['Case Reports', 'Journal Article']",,United States,Pediatr Blood Cancer,Pediatric blood & cancer,101186624,['8N3DW7272P (Cyclophosphamide)'],IM,"['Adolescent', 'Child', 'Cyclophosphamide/*adverse effects/therapeutic use', 'Female', 'Hematuria', 'Humans', 'Leukemia-Lymphoma, Adult T-Cell/drug therapy', 'Neoplasm Invasiveness/pathology', 'Neoplasms, Second Primary/*chemically induced/diagnosis/therapy', 'Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy', 'Urinary Bladder Neoplasms/*chemically induced/diagnosis/therapy', 'Urinary Incontinence']",,,,2004/01/31 05:00,2004/03/18 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/03/18 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Pediatr Blood Cancer. 2004 Mar;42(3):289-91. doi: 10.1002/pbc.10451.,['10.1002/pbc.10451 [doi]'],,,"[""Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, PA 19104, USA. segall@email.chop.edu""]",,,,,,,,,,
14752867,NLM,MEDLINE,20040317,20151013,1545-5009 (Print) 1545-5009 (Linking),42,3,2004 Mar,Association of cytogenetic abnormalities with detection of BCR-ABL fusion transcripts in children with T-lineage lymphoproliferative diseases (T-ALL and T-NHL).,278-80,"['Lo Nigro, Luca', 'Sainati, Laura', 'Mirabile, Elena', 'Lanciotti, Marina', 'Poli, Amelia', 'Leszl, Anna', 'Basso, Giuseppe']","['Lo Nigro L', 'Sainati L', 'Mirabile E', 'Lanciotti M', 'Poli A', 'Leszl A', 'Basso G']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Pediatr Blood Cancer,Pediatric blood & cancer,101186624,"['0 (RNA, Neoplasm)', 'EC 2.7.10.2 (Fusion Proteins, bcr-abl)']",IM,"['Adolescent', 'Cell Lineage', 'Child', '*Chromosome Aberrations', 'Clone Cells/pathology', 'Fusion Proteins, bcr-abl/*genetics', 'Humans', 'Leukemia-Lymphoma, Adult T-Cell/diagnosis/*genetics/pathology', 'Lymphoma, T-Cell/diagnosis/*genetics/pathology', 'Male', 'Neoplasm, Residual/pathology', 'Philadelphia Chromosome', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis/*genetics/pathology', 'RNA, Neoplasm/analysis']",,,,2004/01/31 05:00,2004/03/18 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/03/18 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Pediatr Blood Cancer. 2004 Mar;42(3):278-80. doi: 10.1002/pbc.10453.,['10.1002/pbc.10453 [doi]'],,"Detection of Philadelphia chromosome (Ph) in childhood T-lineage acute lymphoproliferative disorders is a rare event. Additional cytogenetic abnormalities are particularly uncommon in ALL. We here report two cases with T lineage acute lymphoproliferative disorders (T-ALL and T-NHL) presenting with both cytogenetic alterations and BCR-ABL fusion transcripts, associated with an aggressive presentation and a poor outcome. We point out firstly on the cytogenetic aberrations, supporting the hypothesis of multi-lineage involvement of ALL expressing Ph chromosome; secondly, on the persistence of T-cell leukemic clone detected by minimal residual disease (MRD) analysis, despite of the early disappearance of BCR-ABL fusion transcript.","['Center of Pediatric Hematology and Oncology, University of Catania, Italy. lucaln@yahoo.com']",,,,,,"['Copyright 2003 Wiley-Liss, Inc.']",,,,
14752866,NLM,MEDLINE,20040317,20151013,1545-5009 (Print) 1545-5009 (Linking),42,3,2004 Mar,Clonal proliferation of T-Cell large granular lymphocytes.,275-7,"['Boeckx, Nancy', 'Uyttebroeck, Anne', 'Langerak, Anton W', 'Brusselmans, Caroline', 'Goossens, Willy', 'Bossuyt, Xavier']","['Boeckx N', 'Uyttebroeck A', 'Langerak AW', 'Brusselmans C', 'Goossens W', 'Bossuyt X']",['eng'],"['Case Reports', 'Journal Article']",,United States,Pediatr Blood Cancer,Pediatric blood & cancer,101186624,,IM,"['Child', 'Clone Cells/pathology', 'Female', 'Flow Cytometry', 'Gene Rearrangement, T-Lymphocyte', 'Humans', 'Immunophenotyping', 'Leukemia, Lymphoid/diagnosis/*pathology', 'Lymphocyte Activation/*physiology', 'Molecular Diagnostic Techniques', 'Neutropenia/etiology', 'Red-Cell Aplasia, Pure/etiology', 'Reverse Transcriptase Polymerase Chain Reaction', 'T-Lymphocytes/pathology']",,,,2004/01/31 05:00,2004/03/18 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/03/18 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Pediatr Blood Cancer. 2004 Mar;42(3):275-7. doi: 10.1002/pbc.10378.,['10.1002/pbc.10378 [doi]'],,"BACKGROUND: T-cell large granular lymphocyte (T-LGL) leukemia is a disorder only rarely reported in children. We diagnosed a new case of a clonal T-LGL proliferation in a 6-year-old girl presenting with severe neutropenia and pure red blood cell aplasia (PRCA). PROCEDURE: Flow cytometric analysis including TCR-Vbeta repertoire analysis and molecular studies using reverse transcriptase polymerase chain reaction (RT-PCR), PCR heteroduplex analysis and GeneScan analysis were performed to investigate the clonal nature of the T-LGL. RESULTS: Flow cytometric analysis revealed a Vbeta3 clonal nature. Molecular studies identified a clonal Vbeta3-Cbeta RT-PCR product. Both PCR heteroduplex analysis and GeneScan analysis found clonal TCRB and TCRG gene rearrangements. CONCLUSIONS: An underlying T-LGL leukemia should be investigated in the diagnostic evaluation of acquired PRCA and neutropenia in young children. Both flow cytometric and molecular analyses can be used to establish the clonal nature of T-LGL.","['Department of Laboratory Medicine, Laboratory of Haematology, University Hospital Gasthuisberg, Leuven, Belgium. nancy.boeckx@uz.kuleuven.ac.be']",,,,,,"['Copyright 2003 Wiley-Liss, Inc.']",,,,
14752860,NLM,MEDLINE,20040317,20211203,1545-5009 (Print) 1545-5009 (Linking),42,3,2004 Mar,Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study.,230-40,"['Seitzman, Robin L', 'Glover, Dorie A', 'Meadows, Anna T', 'Mills, James L', 'Nicholson, H Stacy', 'Robison, Leslie L', 'Byrne, Julianne', 'Zeltzer, Lonnie K']","['Seitzman RL', 'Glover DA', 'Meadows AT', 'Mills JL', 'Nicholson HS', 'Robison LL', 'Byrne J', 'Zeltzer LK']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Pediatr Blood Cancer,Pediatric blood & cancer,101186624,,IM,"['Adolescent', 'Adult', 'Case-Control Studies', 'Child', 'Combined Modality Therapy', 'Data Collection', 'Employment', 'Ethnicity', 'Follow-Up Studies', 'Humans', 'Male', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality/*psychology/therapy', 'Risk Factors', '*Self Concept', 'Siblings', 'Survivors/*psychology']",,,,2004/01/31 05:00,2004/03/18 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/03/18 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Pediatr Blood Cancer. 2004 Mar;42(3):230-40. doi: 10.1002/pbc.10434.,['10.1002/pbc.10434 [doi]'],,"BACKGROUND: Self-concept was compared between adult survivors of childhood acute lymphoblastic leukemia (ALL) and sibling controls. Adult survivor subgroups at greatest risk for negative self-concept were identified. PROCEDURE: Survivors (n = 578) aged > or =18 years, treated before age 20 years on Children's Cancer Group (CCG) ALL protocols, and 396 sibling controls completed a telephone interview and the Harter Adult Self-Perception Profile (ASPP). RESULTS: Survivors global self-worth scores were significantly lower than sibling controls (mean 3.09 vs. 3.18; P = 0.022). Unemployed survivors reported lower global self-worth scores than employed (mean 2.77 vs. 3.12; P = 0.0001), whereas employment status was not associated with self-worth in controls. Among survivors, predictors of negative self-concept included unemployment (odds ratio (OR) = 2.87; 95% CI: 1.50-5.50), and believing that cancer treatment limited employability (OR = 3.17; 95% CI: 1.79-5.62). Unemployment increased the odds for negative self-concept among survivors who received combinations of central nervous system (CNS) irradiation (CRT) and intrathecal methotrexate (IT-MTX), except high CRT with no or low dose IT-MTX. Employed survivors who perceived that treatment limited their employability showed increased odds of negative self-concept for all treatment groups compared to those who did not. Minority ethnic group membership was a borderline significant predictor of negative self-concept (OR = 1.79; 95% CI: 0.94-3.33). CONCLUSIONS: Global self-worth was significantly lower in ALL survivors than sibling controls, however, 81% of survivors had positive self-concept. Survivor subgroups most vulnerable to negative self-concept were the unemployed survivors, believing that cancer treatment affected employability, and ethnic minority group members. Targeted intervention may have greater clinical relevance for these subgroups.","['Department of Pediatrics, University of California at Los Angeles, California, USA. seitzman@ucla.edu']",,"['CA 02649/CA/NCI NIH HHS/United States', 'CA 02971/CA/NCI NIH HHS/United States', 'CA 07306/CA/NCI NIH HHS/United States', 'CA 11796/CA/NCI NIH HHS/United States', 'CA 13809/CA/NCI NIH HHS/United States', 'CA 14560/CA/NCI NIH HHS/United States', 'CA 17829/CA/NCI NIH HHS/United States', 'CA 20549/CA/NCI NIH HHS/United States', 'CA 26270/CA/NCI NIH HHS/United States', 'CA 27678/CA/NCI NIH HHS/United States', 'CA 28882/CA/NCI NIH HHS/United States', 'CA 29013/CA/NCI NIH HHS/United States', 'CA 42764/CA/NCI NIH HHS/United States', 'CA 55362/CA/NCI NIH HHS/United States', 'CA 79753/CA/NCI NIH HHS/United States']",,,,"['Copyright 2003 Wiley-Liss, Inc.']",,,,
14752792,NLM,MEDLINE,20040217,20151013,1545-5009 (Print) 1545-5009 (Linking),42,1,2004 Jan,Immune responses to influenza immunization in children receiving maintenance chemotherapy for acute lymphoblastic leukemia.,36-40,"['Porter, Christopher C', 'Edwards, Kathryn M', 'Zhu, Yuwei', 'Frangoul, Haydar']","['Porter CC', 'Edwards KM', 'Zhu Y', 'Frangoul H']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Pediatr Blood Cancer,Pediatric blood & cancer,101186624,"['0 (Antibodies, Viral)', '0 (Antigens, Viral)', '0 (Antineoplastic Agents)', '0 (Influenza Vaccines)']",IM,"['Antibodies, Viral/analysis', 'Antigens, Viral/immunology/metabolism', 'Antineoplastic Agents/*therapeutic use', 'Case-Control Studies', 'Child', 'Female', 'Hemagglutination Inhibition Tests', 'Humans', '*Immunization', 'Influenza B virus/*immunology', 'Influenza Vaccines/*immunology/therapeutic use', 'Male', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/*immunology', 'Serologic Tests', 'Vaccination']",,,,2004/01/31 05:00,2004/02/18 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/02/18 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Pediatr Blood Cancer. 2004 Jan;42(1):36-40. doi: 10.1002/pbc.10459.,['10.1002/pbc.10459 [doi]'],,"PURPOSE: To compare the immune responses to influenza vaccine in children with acute lymphoblastic leukemia (ALL) receiving maintenance chemotherapy with those in healthy children. METHODS: Hemagglutinin-inhibition (HAI) antibody titers were determined before and after influenza vaccination in children with ALL and healthy controls. Immune responses were measured as geometric mean titers (GMT) and 4-fold rises in HAI titers. RESULTS: Although post-immunization GMT were lower in children with ALL compared to healthy children for the H1N1 antigen (P<0.001), the H3N2 antigen (P=0.03), and for the influenza B antigen (P=0.003), at least 60% of children with ALL had at least a 4-fold rise in HAI titers to each of the influenza antigens. CONCLUSIONS: While the GMT after trivalent influenza immunization in children with ALL were significantly lower than those seen in healthy children, the majority of children with ALL had 4-fold rises in HAI titers. Children receiving maintenance chemotherapy for ALL should receive yearly influenza vaccine.","['Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Colorado Health Sciences Center, Denver, Colarado 80218, USA. porter.christopher@tchden.org']",,,,,,"['Copyright 2003 Wiley-Liss, Inc.']",,,,
14752791,NLM,MEDLINE,20040217,20151013,1545-5009 (Print) 1545-5009 (Linking),42,1,2004 Jan,"Favorable outcome in 20-year follow-up of children with very-low-risk ALL and minimal standard therapy, with special reference to TEL-AML1 fusion.",30-5,"['Kanerva, Jukka', 'Saarinen-Pihkala, Ulla M', 'Niini, Tarja', 'Riikonen, Pekka', 'Mottonen, Merja', 'Makipernaa, Anne', 'Salmi, Toivo T', 'Vettenranta, Kim', 'Knuutila, Sakari']","['Kanerva J', 'Saarinen-Pihkala UM', 'Niini T', 'Riikonen P', 'Mottonen M', 'Makipernaa A', 'Salmi TT', 'Vettenranta K', 'Knuutila S']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Pediatr Blood Cancer,Pediatric blood & cancer,101186624,"['0 (Antineoplastic Agents)', '0 (Core Binding Factor Alpha 2 Subunit)', '0 (Oncogene Proteins, Fusion)', '0 (TEL-AML1 fusion protein)']",IM,"['Adolescent', 'Antineoplastic Agents/*administration & dosage/therapeutic use', 'Child', 'Child, Preschool', 'Cohort Studies', 'Core Binding Factor Alpha 2 Subunit', 'Female', 'Follow-Up Studies', 'Humans', 'In Situ Hybridization, Fluorescence', 'Infant', 'Male', 'Oncogene Proteins, Fusion/*genetics', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/*drug therapy/genetics', 'Prognosis', 'Remission Induction', 'Retrospective Studies', 'Risk Factors', 'Survival Rate', 'Treatment Outcome']",,,,2004/01/31 05:00,2004/02/18 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/02/18 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Pediatr Blood Cancer. 2004 Jan;42(1):30-5. doi: 10.1002/pbc.10417.,['10.1002/pbc.10417 [doi]'],,"BACKGROUND: As the treatment results of childhood ALL have improved, avoidance of late effects has become increasingly important. Identification of favorable prognostic factors helps to achieve this goal. PROCEDURE: We studied the prognostic value of TEL-AML1 fusion and a risk factor composed of age, white blood cell count (WBC), lymphomatous features, and hemoglobin level (Hb). We also compared outcome between two cohorts; cohort 1 (n=100) diagnosed 1975-1981, and cohort 2 (n=102) 1989-1991. Both cohorts were retrospectively divided in two groups: very-low-risk (WBC <10 x 10(9)/L, age 2 to <10 years, no lymphomatous features, Hb <90 g/L), and non-low-risk (=the remainder). We performed fluorescent in situ hybridization (FISH) of TEL-AML1 fusion of the marrow samples obtained at diagnosis. RESULTS: The median follow-up is 20 years in cohort 1, and 8 years in cohort 2. In both cohorts, the very-low-risk category comprised one-fourth of the children. TEL-AML1 fusion was more frequent in the very-low-risk (35%) than in the non-low-risk group (17%) (P=0.03). The 8-year event-free survival (EFS) of children with the fusion was better than of those without, 74 vs. 54% (P=0.040). The 8-year EFS in the very-low-risk group was 76% in cohort 1, and 79% in cohort 2 (n.s.). In the non-low-risk groups, EFS was 39 vs. 64% (P=0.02), respectively. CONCLUSIONS: Our data support the reported association of TEL-AML1 fusion with a favorable outcome although the risk group had a greater impact. These very-long-term follow-up data also indicate that children with very-low-risk ALL (slow disease) had a favorable outcome already in the late 1970s, and may be over treated with the contemporary ALL protocols.","['Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland. jukka.kanerva@hus.fi']",,,,,,"['Copyright 2003 Wiley-Liss, Inc.']",,,,
14752790,NLM,MEDLINE,20040217,20151013,1545-5009 (Print) 1545-5009 (Linking),42,1,2004 Jan,CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation.,24-9,"['Nathan, Paul C', 'Maze, Ronnen', 'Spiegler, Brenda', 'Greenberg, Mark L', 'Weitzman, Sheila', 'Hitzler, Johann K']","['Nathan PC', 'Maze R', 'Spiegler B', 'Greenberg ML', 'Weitzman S', 'Hitzler JK']",['eng'],"['Comparative Study', 'Journal Article']",,United States,Pediatr Blood Cancer,Pediatric blood & cancer,101186624,"['0 (Antimetabolites, Antineoplastic)', 'YL5FZ2Y5U1 (Methotrexate)']",IM,"['Antimetabolites, Antineoplastic/administration & dosage/*therapeutic use', 'Central Nervous System Neoplasms/*radiotherapy', 'Child, Preschool', 'Cohort Studies', '*Cranial Irradiation', 'Female', 'Humans', 'Infant', 'Leukemia, T-Cell/*therapy', 'Male', 'Methotrexate/administration & dosage/*therapeutic use', 'Neoplasm Recurrence, Local/prevention & control', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy', 'Retrospective Studies', 'Survival Rate']",,,,2004/01/31 05:00,2004/02/18 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/02/18 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Pediatr Blood Cancer. 2004 Jan;42(1):24-9. doi: 10.1002/pbc.10392.,['10.1002/pbc.10392 [doi]'],,"BACKGROUND: Prophylactic use of cranial radiation therapy (CRT) in young children with acute lymphoblastic leukemia (ALL) is associated with significant long-term morbidity. Therefore, current treatment protocols for pediatric B-precursor ALL have abandoned prophylactic CRT in favor of intrathecal chemotherapy, combined with either high-dose methotrexate infusions (HD-MTX) or intensive systemic chemotherapy. In contrast, prophylactic CRT continues to be used in children with T-lineage ALL (T-ALL), who historically have had an inferior prognosis. We conducted a retrospective cohort study to determine the effect on survival of substituting HD-MTX for CRT in young children with T-ALL, a group that faces a high risk of long-term sequelae from CRT. PROCEDURE: Twenty-six children, diagnosed with T-ALL between the ages of 1 and 5 years, were treated on the same high-risk leukemia protocol. Central nervous system (CNS) directed therapy consisted of either CRT (1,800 cGy) or HD-MTX (three doses of 8 g/m2), depending on the treatment era in which patients were diagnosed. RESULTS: Of the 24 patients who entered remission, 12 received CRT and 12 received HD-MTX. Five-year event-free survival (EFS) (+/-SE) was 92 +/- 8% in the HD-MTX group versus 75 +/- 13% in the CRT group (P=0.23). Five-year overall survival (OS) was 100% in the HD-MTX group versus 75 +/- 13% in the CRT group (P=0.07). There were no CNS recurrences in the HD-MTX group. One patient treated with CRT developed a brain tumor. CONCLUSIONS: The use of HD-MTX instead of CRT as CNS-directed therapy in very young children with T-ALL does not compromise survival, while avoiding the adverse long-term effects of cranial irradiation.","['Department of Paediatrics, Division of Haematology/Oncology, The Hospital for Sick Children Research Institute, The University of Toronto, Toronto, Ontario, Canada.']",,,,,,"['Copyright 2003 Wiley-Liss, Inc.']",,,,
14752789,NLM,MEDLINE,20040217,20151013,1545-5009 (Print) 1545-5009 (Linking),42,1,2004 Jan,Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation.,8-23,"['Saarinen-Pihkala, Ulla M', 'Gustafsson, G', 'Carlsen, N', 'Flaegstad, T', 'Forestier, E', 'Glomstein, A', 'Kristinsson, J', 'Lanning, M', 'Schroeder, H', 'Mellander, L']","['Saarinen-Pihkala UM', 'Gustafsson G', 'Carlsen N', 'Flaegstad T', 'Forestier E', 'Glomstein A', 'Kristinsson J', 'Lanning M', 'Schroeder H', 'Mellander L']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Pediatr Blood Cancer,Pediatric blood & cancer,101186624,"['04079A1RDZ (Cytarabine)', 'YL5FZ2Y5U1 (Methotrexate)']",IM,"['Adolescent', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use', 'Central Nervous System Neoplasms/*therapy', 'Child', 'Child, Preschool', 'Cohort Studies', 'Combined Modality Therapy', '*Cranial Irradiation', 'Cytarabine/administration & dosage', 'Disease-Free Survival', 'Female', 'Humans', 'Infant', 'Male', 'Methotrexate/administration & dosage', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy', 'Risk Factors', 'Stem Cell Transplantation', 'Transplantation, Homologous', 'Treatment Outcome']",,,,2004/01/31 05:00,2004/02/18 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/02/18 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Pediatr Blood Cancer. 2004 Jan;42(1):8-23. doi: 10.1002/pbc.10461.,['10.1002/pbc.10461 [doi]'],,"BACKGROUND: Improvement in outcome of childhood high-risk (HR) ALL was sought with a very intensive Nordic protocol leaving most patients without CNS-RT. METHODS: A total of 426 consecutive children entered the NOPHO-92 HR-ALL program. HR criteria included WBC > or =50 x 10(9)/L, CNS or testicular involvement, T-cell, lymphomatous features, t(9;22), t(4;11), or slow response. Of these, 152 children had very high risk (VHR) with special definitions. CNS consolidation was based on high-dose MTX (8 g/m2) and ARA-C (12 g/m2) alternating. VHR patients also received cranial RT. RESULTS: The 9-year EFS was 61 +/- 3%, OS 74 +/- 2%, and EFS for T-ALL 62 +/- 4%. Cumulative incidence of isolated CNS relapse was 4.7 +/- 1%, and CNS relapse in total 9.9 +/- 2%. Poor prognostic factors were WBC > or =200 x 10(9)/L and a very slow response. CONCLUSIONS: HR-ALL was successfully treated on the NOPHO-92 regimen, with a relatively low CNS relapse rate for non-irradiated children. WBC > or =200 x 10(9)/L and very slow response emerged as strong poor prognostic factors.","['Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland. ulla.pihkala@hus.fi']",,,,,,"['Copyright 2003 Wiley-Liss, Inc.']",,['Nordic Society of Pediatric Hematology and Oncology'],,
14752779,NLM,MEDLINE,20040930,20041117,1083-8791 (Print) 1083-8791 (Linking),10,1,2004 Jan,Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.,49-57,"['Nakamura, Ryotaro', 'Battiwalla, Minoo', 'Solomon, Scott', 'Follmann, Dean', 'Chakrabarti, Sakti', 'Cortez, Karoll', 'Hensel, Nancy', 'Childs, Richard', 'Barrett, A John']","['Nakamura R', 'Battiwalla M', 'Solomon S', 'Follmann D', 'Chakrabarti S', 'Cortez K', 'Hensel N', 'Childs R', 'Barrett AJ']",['eng'],['Journal Article'],,United States,Biol Blood Marrow Transplant,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,9600628,"['0 (Antigens, Viral)']",IM,"['Adolescent', 'Adult', 'Antigens, Viral/*blood/immunology', 'Child', 'Cytomegalovirus/*immunology', 'Cytomegalovirus Infections/etiology/immunology', 'Disease-Free Survival', 'Female', 'Follow-Up Studies', 'Hematopoietic Stem Cell Transplantation/*adverse effects/methods', 'Humans', 'Leukemia/therapy', 'Lymphocyte Activation/*immunology', 'Lymphocyte Count', 'Lymphocyte Depletion', 'Male', 'Middle Aged', 'Recurrence', 'Transplantation, Homologous', 'Treatment Failure', 'Virus Activation/immunology']",,,,2004/01/31 05:00,2004/10/01 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/10/01 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Biol Blood Marrow Transplant. 2004 Jan;10(1):49-57. doi: 10.1016/j.bbmt.2003.08.011.,"['10.1016/j.bbmt.2003.08.011 [doi]', 'S1083879103003318 [pii]']",,"Numerous clinical studies link cytomegalovirus (CMV) infection with incomplete posttransplantation T-cell recovery. We hypothesized that the inability of transplant recipients to handle CMV reactivation might correlate with a defective graft-versus-leukemia response and increased posttransplantation morbidity. Between May 1995 and August 2001, 82 patients who were CMV seropositive and survived the first 100 days after transplantation were identified for a day 100 landmark analysis of the effect of CMV reactivation patterns on eventual transplantation outcome. All patients underwent a myeloablative HLA-identical sibling donor T cell-depleted stem cell transplantation with scheduled donor T-cell add-back on day 45. Median follow-up was 1032 days. Forty-two patients who had either no reactivation or only 1 positive test with quick clearance were designated as a CMV immune competent group. Forty patients designated as CMV immune deficient (ID) had at least 2 positive tests. Apart from younger age (33 versus 38 years; P =.05) in the ID group, the 2 groups were balanced for clinical characteristics. In multivariate analysis, ID patients had a significantly higher incidence of leukemia relapse (58% versus 21%; P =.03) and worse disease-free survival (31% versus 66%; P =.04). There was no significant difference in week 1 to 14 posttransplantation lymphocyte counts between the 2 groups. In 67 patients tested 3 to 6 months after transplantation, a proliferative response to CMV antigen (stimulation index > or =2) occurred in 27 of 36 immune competent patients compared with 15 of 31 ID patients (P =.006). These results show that recurrent CMV reactivation in the first 100 days after transplantation predicts for reduced disease-free survival and increased leukemic relapse beyond 100 days and correlates with inferior proliferative responses to CMV. The higher relapse rate may reflect poor immune reconstitution in ID patients or an adverse effect of prolonged antiviral treatment.","['Stem Cell Allogenetic Transplant Unit, Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA.']",,,,,,,,,,
14752625,NLM,MEDLINE,20040826,20181113,0941-4355 (Print) 0941-4355 (Linking),12,4,2004 Apr,Measuring mucosal damage induced by cytotoxic therapy.,227-33,"['Blijlevens, N M A', ""van't Land, B"", 'Donnelly, J P', ""M'Rabet, L"", 'de Pauw, B E']","['Blijlevens NM', ""van't Land B"", 'Donnelly JP', ""M'Rabet L"", 'de Pauw BE']",['eng'],['Journal Article'],,Germany,Support Care Cancer,Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,9302957,"['0 (Antibiotics, Antineoplastic)', '0 (Antineoplastic Agents)', '0 (Antineoplastic Agents, Alkylating)', '146-72-5 (3-O-Methylglucose)', '4618-18-2 (Lactulose)', '8N3DW7272P (Cyclophosphamide)', 'A1TA934AKO (Xylose)', 'QN34XC755A (Rhamnose)', 'ZRP63D75JW (Idarubicin)']",IM,"['3-O-Methylglucose/pharmacokinetics', 'Acute Disease', 'Adult', 'Antibiotics, Antineoplastic/adverse effects', 'Antineoplastic Agents/*adverse effects', 'Antineoplastic Agents, Alkylating/adverse effects', 'Cyclophosphamide/adverse effects', 'Female', 'Gastric Mucosa/*drug effects/radiation effects', 'Hematopoietic Stem Cell Transplantation', 'Humans', 'Idarubicin/adverse effects', 'Intestinal Mucosa/*drug effects/radiation effects', 'Lactulose/pharmacokinetics', 'Leukemia, Myeloid/therapy', 'Male', 'Middle Aged', 'Mouth Mucosa/*drug effects/radiation effects', 'Myelodysplastic Syndromes/therapy', 'Permeability', 'Rhamnose/pharmacokinetics', 'Stomatitis/chemically induced/etiology', 'Transplantation Conditioning/*adverse effects', 'Whole-Body Irradiation', 'Xylose/pharmacokinetics']",,,,2004/01/31 05:00,2004/08/27 05:00,['2004/01/31 05:00'],"['2003/08/20 00:00 [received]', '2003/11/10 00:00 [accepted]', '2004/01/31 05:00 [pubmed]', '2004/08/27 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Support Care Cancer. 2004 Apr;12(4):227-33. doi: 10.1007/s00520-003-0572-3. Epub 2004 Jan 30.,['10.1007/s00520-003-0572-3 [doi]'],,"We scored oral mucositis and gut toxicity and measured sugar permeability testing among 56 recipients of a haematopoietic stem cell transplant (HSCT) given myeloablative conditioning with idarubicin, cyclophosphamide and TBI, and a group of 18 patients given cytotoxic chemotherapy for newly diagnosed acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS). Gut integrity was already disturbed in the AML/MDS group as measured by the lactulose/rhamnose ratio (L/R ratio=0.09) before therapy and was severely perturbed (L/R ratio >0.13) for a month after HSCT. Oral mucositis and to a lesser extent gut toxicity was only significantly correlated with disturbed permeability in the transplant group. The data suggest that sugar permeability, oral mucositis and gut toxicity measure different features of mucosal damage after intensive cytotoxic therapy.","['Department of Haematology, University Medical Centre St. Radboud Nijmegen, PO Box 9101, 6500 HB Wageningen, The Netherlands. N.Blijlevens@hemat.umcn.nl']",20040130,,,,,,,,,
14752277,NLM,MEDLINE,20041119,20200930,1538-4047 (Print) 1538-4047 (Linking),3,2,2004 Feb,The cyclin D3 knockout: a pound of redundancy with a dash of tissue specificity.,162-4,"['Diehl, J Alan']",['Diehl JA'],['eng'],"['Journal Article', 'Review']",,United States,Cancer Biol Ther,Cancer biology & therapy,101137842,"['0 (CCND3 protein, human)', '0 (Ccnd3 protein, mouse)', '0 (Cyclin D3)', '0 (Cyclins)']",IM,"['Animals', '*Cell Cycle', 'Cyclin D3', 'Cyclins/genetics/*physiology', 'Humans', 'Leukemia, T-Cell/etiology/*metabolism/pathology', 'Lymphocytes/*metabolism', 'Mice', 'Mice, Knockout']",,,,2004/01/31 05:00,2004/12/16 09:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/12/16 09:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Cancer Biol Ther. 2004 Feb;3(2):162-4. doi: 10.4161/cbt.3.2.774. Epub 2004 Feb 1.,"['744 [pii]', '10.4161/cbt.3.2.774 [doi]']",,"Progression through each phase of the cell division cycle is driven by specific cyclin/CDK holoenzymes complexes, each complex having a discrete subset of critical substrates. Phosphorylation of these substrates by the appropriate cyclin/CDK complex in turn directs regulated cell cycle progression. Based on this notion, a reasonable assumption is that elimination of any one of these complexes would be catastrophic with regard to cellular and organismal development. Over the past year however, we have witnessed elegant work that challenges the notion that cyclin/CDK holoenzymes target unique and specific substrates. Indeed in the most recent work, Sicinska et al. report that targeted deletion of the G1 cyclin, cyclin D3, disrupts proliferation of immature T lymphocytes, but does not provide a function essential for organismal development or survival.","['The Leonard and Madlyn Abramson Family Cancer Research Institute and Cancer Center, Department of Cancer Biology, 21 Curie Boulevard, 454 BRB II/III, Philadelphia, Pennsylvania 19104, USA. adiehl@mail.med.upenn.edu']",20040201,,14,,,,,,,
14752084,NLM,MEDLINE,20040224,20210105,0732-183X (Print) 0732-183X (Linking),22,3,2004 Feb 1,Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference.,569-70; author reply 570-1,"['Herold, Ralf', 'von Stackelberg, Arend', 'Hartmann, Reinhard', 'Eisenreich, Bernhard', 'Henze, Gunter']","['Herold R', 'von Stackelberg A', 'Hartmann R', 'Eisenreich B', 'Henze G']",['eng'],"['Comment', 'Letter']",,United States,J Clin Oncol,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,8309333,,IM,"['Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Disease-Free Survival', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Neoplasm Recurrence, Local/*prevention & control', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/*therapy', 'Remission Induction', 'Risk Factors']",,,,2004/01/31 05:00,2004/02/26 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/02/26 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,J Clin Oncol. 2004 Feb 1;22(3):569-70; author reply 570-1. doi: 10.1200/JCO.2004.99.153.,"['10.1200/JCO.2004.99.153 [doi]', 'JCO.2004.99.153 [pii]']",,,,,,,,['J Clin Oncol. 2003 Mar 1;21(5):760-1. PMID: 12610169'],,,,,
14752080,NLM,MEDLINE,20040224,20171116,0732-183X (Print) 0732-183X (Linking),22,3,2004 Feb 1,Unusual lymphoma manifestations: case 3. CD8+ T-cell prolymphocytic leukemia.,560-2,"['Nakajima, Hikaru', 'Oki, Masayuki', 'Ando, Kiyoshi']","['Nakajima H', 'Oki M', 'Ando K']",['eng'],"['Case Reports', 'Journal Article']",,United States,J Clin Oncol,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,8309333,['0 (CD8 Antigens)'],IM,"['Adult', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'CD8 Antigens/*metabolism', 'Female', 'Humans', 'Immunophenotyping', 'Leukemia, Prolymphocytic/drug therapy/*pathology', 'Leukemia, T-Cell/drug therapy/*pathology', 'Sezary Syndrome']",,,,2004/01/31 05:00,2004/02/26 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/02/26 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,J Clin Oncol. 2004 Feb 1;22(3):560-2. doi: 10.1200/JCO.2004.03.060.,"['10.1200/JCO.2004.03.060 [doi]', 'JCO.2004.03.060 [pii]']",,,"['Division of Hematology/Medical Oncology, Department of Medicine, Tokai University School of Medicine, Isehara, Japan.']",,,,,,,,,,
14752078,NLM,MEDLINE,20040224,20071115,0732-183X (Print) 0732-183X (Linking),22,3,2004 Feb 1,Unusual lymphoma manifestations: case 1. Natural killer cell leukemia with dermal erythema and vascular epidermal growth factor production.,557-8,"['Gear, Robin B', 'Heffelfinger, Sue', 'Flessa, Herbert C']","['Gear RB', 'Heffelfinger S', 'Flessa HC']",['eng'],"['Case Reports', 'Journal Article']",,United States,J Clin Oncol,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,8309333,['0 (Vascular Endothelial Growth Factor A)'],IM,"['Aged', 'Dermatitis, Exfoliative/etiology/metabolism/*pathology', 'Humans', 'Killer Cells, Natural/metabolism/*pathology', 'Leukemia, Lymphoid/etiology/metabolism/*pathology', 'Male', 'Vascular Endothelial Growth Factor A/*metabolism']",,,,2004/01/31 05:00,2004/02/26 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/02/26 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,J Clin Oncol. 2004 Feb 1;22(3):557-8. doi: 10.1200/JCO.2004.10.176.,"['10.1200/JCO.2004.10.176 [doi]', 'JCO.2004.10.176 [pii]']",,,"['Department of Internal Medicine, Division of Hematology-Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.']",,,,,,,,,,
14751972,NLM,MEDLINE,20040804,20191210,1367-4803 (Print) 1367-4803 (Linking),20,6,2004 Apr 12,mdclust--exploratory microarray analysis by multidimensional clustering.,931-6,"['Dugas, M', 'Merk, S', 'Breit, S', 'Dirschedl, P']","['Dugas M', 'Merk S', 'Breit S', 'Dirschedl P']",['eng'],"['Comparative Study', 'Evaluation Study', 'Journal Article', 'Validation Study']",,England,Bioinformatics,"Bioinformatics (Oxford, England)",9808944,,IM,"['*Cluster Analysis', 'Computer Graphics', 'Gene Expression Profiling/*methods', 'Humans', 'Leukemia/*genetics', 'Oligonucleotide Array Sequence Analysis/*methods', 'Pattern Recognition, Automated', 'Reproducibility of Results', 'Sensitivity and Specificity', 'Sequence Alignment/*methods', 'Sequence Analysis, DNA/*methods', '*Software']",,,,2004/01/31 05:00,2004/08/05 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/08/05 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Bioinformatics. 2004 Apr 12;20(6):931-6. doi: 10.1093/bioinformatics/bth009. Epub 2004 Jan 29.,"['10.1093/bioinformatics/bth009 [doi]', 'bth009 [pii]']",,"MOTIVATION: Unsupervised clustering of microarray data may detect potentially important, but not obvious characteristics of samples, for instance subgroups of diagnoses with distinct gene profiles or systematic errors in experimentation. RESULTS: Multidimensional clustering (mdclust) is a method, which identifies sets of sample clusters and associated genes. It applies iteratively two-means clustering and score-based gene selection. For any phenotype variable best matching sets of clusters can be selected. This provides a method to identify gene-phenotype associations, suited even for settings with a large number of phenotype variables. An optional model based discriminant step may reduce further the number of selected genes.","['Department of Medical Informatics, Marchioninistr. 15, D-81377 Munich, Germany. dug@ibe.med.uni-muenchen.de']",20040129,,,,,,,,,
14751929,NLM,MEDLINE,20040625,20210206,0006-4971 (Print) 0006-4971 (Linking),103,10,2004 May 15,"Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia.",3897-904,"['Jiang, Xiaoyan', 'Zhao, Yun', 'Chan, Wing-Yiu', 'Vercauteren, Suzanne', 'Pang, Emily', 'Kennedy, Sean', 'Nicolini, Frank', 'Eaves, Allen', 'Eaves, Connie']","['Jiang X', 'Zhao Y', 'Chan WY', 'Vercauteren S', 'Pang E', 'Kennedy S', 'Nicolini F', 'Eaves A', 'Eaves C']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Blood,Blood,7603509,"['0 (AHI1 protein, human)', '0 (Adaptor Proteins, Signal Transducing)', '0 (Adaptor Proteins, Vesicular Transport)', '0 (Ahi1 protein, mouse)', '0 (Neoplasm Proteins)', '0 (Proto-Oncogene Proteins)']",IM,"['Adaptor Proteins, Signal Transducing', 'Adaptor Proteins, Vesicular Transport', 'Adult', 'Animals', 'Bone Marrow Cells/chemistry', 'Cell Differentiation', 'Cell Line, Tumor', 'Disease Models, Animal', '*Gene Expression Regulation, Neoplastic', 'Hematopoietic Stem Cells/chemistry', 'Humans', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/*pathology', 'Mice', 'Mice, Inbred C57BL', 'Middle Aged', '*Mutagenesis, Insertional', 'Neoplasm Proteins/genetics', 'Proto-Oncogene Proteins/analysis/*genetics', 'RNA Splicing']",,,,2004/01/31 05:00,2004/06/26 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/06/26 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Blood. 2004 May 15;103(10):3897-904. doi: 10.1182/blood-2003-11-4026. Epub 2004 Jan 29.,"['10.1182/blood-2003-11-4026 [doi]', 'S0006-4971(20)43679-1 [pii]']",,"Ahi-1/AHI-1 (Abelson helper integration site-1) encodes a family of protein isoforms containing one Src homology 3 (SH3) domain and multiple tryptophan-aspartic acid 40 (WD40)-repeat domains. The function of these proteins is unknown, but involvement in leukemogenesis has been suggested by the high frequency of Ahi-1 mutations seen in certain virus-induced murine leukemias. Here we show that in both mice and humans, Ahi-1/AHI-1 expression is highest in the most primitive hematopoietic cells with specific patterns of down-regulation in different lineages. Cells from patients with chronic myeloid leukemia (CML; n = 28) show elevated AHI-1 transcripts in all disease phases and, in chronic phase, in the leukemic cells at all stages of differentiation, including quiescent (G(0)) CD34(+) cells as well as terminally differentiating cells. In the most primitive lin(-)CD34(+)CD38(-) CML cells, transcripts for the 2 shorter isoforms of AHI-1 are also increased. Although 15 of 16 human lymphoid and myeloid leukemic cell lines showed aberrant control of AHI-1 expression, this was not seen in blasts obtained directly from patients with acute Philadelphia chromosome-negative (Ph(-)) leukemia (n = 15). Taken together, our results suggest that down-regulation of AHI-1 expression is an important conserved step in primitive normal hematopoietic cell differentiation and that perturbations in AHI-1 expression may contribute to the development of specific types of human leukemia.","['Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada. xjiang@bccancer.bc.ca']",20040129,,,,,,,,,
14751928,NLM,MEDLINE,20040625,20210206,0006-4971 (Print) 0006-4971 (Linking),103,10,2004 May 15,The small oligomerization domain of gephyrin converts MLL to an oncogene.,3876-82,"['Eguchi, Mariko', 'Eguchi-Ishimae, Minenori', 'Greaves, Mel']","['Eguchi M', 'Eguchi-Ishimae M', 'Greaves M']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,United States,Blood,Blood,7603509,"['0 (Carrier Proteins)', '0 (DNA-Binding Proteins)', '0 (KMT2A protein, human)', '0 (Membrane Proteins)', '0 (Oncogene Proteins, Fusion)', '0 (Recombinant Fusion Proteins)', '0 (Transcription Factors)', '0 (gephyrin)', '149025-06-9 (Myeloid-Lymphoid Leukemia Protein)', 'EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)', 'EC 2.1.1.43 (Kmt2a protein, mouse)']",IM,"['Animals', 'Carrier Proteins/chemistry/genetics/*physiology', '*Cell Transformation, Neoplastic', 'DNA-Binding Proteins/genetics/*physiology', 'Dimerization', 'Hematopoietic Stem Cell Transplantation', 'Hematopoietic Stem Cells/metabolism/*pathology', 'Histone-Lysine N-Methyltransferase', 'Humans', 'Leukemia, Lymphoid/etiology', 'Leukemia, Myeloid/etiology', 'Membrane Proteins/chemistry/genetics/*physiology', 'Mice', 'Mice, Inbred BALB C', 'Mice, SCID', 'Myeloid-Lymphoid Leukemia Protein', 'Neoplasms, Experimental/etiology', 'Oncogene Proteins, Fusion', '*Oncogenes', 'Protein Structure, Tertiary', '*Proto-Oncogenes', 'Recombinant Fusion Proteins/genetics/physiology', '*Transcription Factors', 'Transduction, Genetic']",,,,2004/01/31 05:00,2004/06/26 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/06/26 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Blood. 2004 May 15;103(10):3876-82. doi: 10.1182/blood-2003-11-3817. Epub 2004 Jan 29.,"['10.1182/blood-2003-11-3817 [doi]', 'S0006-4971(20)43676-6 [pii]']",,"The MLL (mixed lineage leukemia) gene forms chimeric fusions with a diverse set of partner genes as a consequence of chromosome translocations in leukemia. In several fusion partners, a transcriptional activation domain appears to be essential for conferring leukemogenic capacity on MLL protein. Other fusion partners, however, lack such domains. Here we show that gephyrin (GPHN), a neuronal receptor assembly protein and rare fusion partner of MLL in leukemia, has the capacity as an MLL-GPHN chimera to transform hematopoietic progenitors, despite lack of transcriptional activity. A small 15-amino acid tubulin-binding domain of GPHN is necessary and sufficient for this activity in vitro and in vivo. This domain also confers oligomerization capacity on MLL protein, suggesting that such activity may contribute critically to leukemogenesis. The transduction of MLL-GPHN into hematopoietic progenitor cells caused myeloid and lymphoid lineage leukemias in mice, suggesting that MLL-GPHN can target multipotent progenitor cells. Our results, and other recent data, provide a mechanism for oncogenic conversion of MLL by fusion partners encoding cytoplasmic proteins.","['Leukaemia Research Fund Centre, Institute of Cancer Research, Chester Beatty Laboratories, London, United Kingdom.']",20040129,,,,,,,,,
14751924,NLM,MEDLINE,20040625,20210206,0006-4971 (Print) 0006-4971 (Linking),103,10,2004 May 15,Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival.,3655-61,"['Neudorf, Steven', 'Sanders, Jean', 'Kobrinsky, Nathan', 'Alonzo, Todd A', 'Buxton, Allen B', 'Gold, Stuart', 'Barnard, Dorothy R', 'Wallace, Joetta D', 'Kalousek, Dagmar', 'Lange, Beverly J', 'Woods, William G']","['Neudorf S', 'Sanders J', 'Kobrinsky N', 'Alonzo TA', 'Buxton AB', 'Gold S', 'Barnard DR', 'Wallace JD', 'Kalousek D', 'Lange BJ', 'Woods WG']",['eng'],"['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, Non-P.H.S."", ""Research Support, U.S. Gov't, P.H.S.""]",,United States,Blood,Blood,7603509,"['0 (Antineoplastic Agents)', '8N3DW7272P (Cyclophosphamide)', 'G1LN9045DK (Busulfan)', 'YL5FZ2Y5U1 (Methotrexate)']",IM,"['Adolescent', 'Antineoplastic Agents/*administration & dosage', 'Bone Marrow Transplantation/immunology/*methods/mortality', 'Busulfan/administration & dosage', 'Child', 'Child, Preschool', 'Cyclophosphamide/administration & dosage', 'Disease-Free Survival', 'Female', 'Graft vs Host Disease/drug therapy/prevention & control', '*Graft vs Leukemia Effect', 'Hepatomegaly', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia, Myeloid, Acute/complications/mortality/*therapy', 'Male', 'Methotrexate/administration & dosage', 'Remission Induction/methods', 'Risk Factors', 'Survival Analysis', 'Transplantation, Homologous']",,,,2004/01/31 05:00,2004/06/26 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/06/26 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Blood. 2004 May 15;103(10):3655-61. doi: 10.1182/blood-2003-08-2705. Epub 2004 Jan 29.,"['10.1182/blood-2003-08-2705 [doi]', 'S0006-4971(20)43646-8 [pii]']",,"In Children's Cancer Group (CCG) study 2891, patients who were recently diagnosed with acute myelocytic leukemia (AML) were assigned randomly to standard- or intensive-timing induction chemotherapy. Patients in first complete remission (CR1) and who had a human leukocyte antigen (HLA)-identical, related donor or a donor disparate at a single class I or II locus were nonrandomly assigned to receive a bone marrow transplant (BMT) by using oral busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg). Methotrexate only was given for graft-versus-host disease (GVHD) prophylaxis. One hundred fifty patients received transplants. Grade 3 or 4 acute GVHD occurred in 9% of patients. Patients younger than 10 years had a lower incidence of grade 3 or 4 GVHD (4.6%) compared with patients 10 years or older (17.4%) (P =.044). Disease-free survival (DFS) at 6 years was 67% and 42% for recipients of intensive- and standard-timing induction therapies, respectively. Multivariate analysis showed that receiving intensive-timing induction therapy (P =.027) and having no hepatomegaly at diagnosis (P =.009) was associated with favorable DFS, and grades 3 and 4 acute GVHD were associated with inferior DFS. Multivariate analysis showed that grades 1 or 2 GVHD (P =.008) and no hepatomegaly at diagnosis (P =.014) were associated with improved relapse-free survival (RFS). Our results show that children older than 10 years are at higher risk for developing severe GVHD; acute GVHD is associated with favorable RFS.","[""American Family Life Assurance Company (AFLAC) Cancer Center, Emory University/Children's Healthcare, Atlanta, GA, USA. sneudorf@choc.org""]",20040129,"['CA 02971/CA/NCI NIH HHS/United States', 'CA 03750/CA/NCI NIH HHS/United States', 'CA 07306/CA/NCI NIH HHS/United States', 'CA 10382/CA/NCI NIH HHS/United States', 'CA 11796/CA/NCI NIH HHS/United States', 'CA 17829/CA/NCI NIH HHS/United States', 'CA 26044/CA/NCI NIH HHS/United States', 'CA 26126/CA/NCI NIH HHS/United States', 'CA 27678/CA/NCI NIH HHS/United States', 'CA 29013/CA/NCI NIH HHS/United States', 'CA 29314/CA/NCI NIH HHS/United States', 'CA 36015/CA/NCI NIH HHS/United States', 'CA 42764/CA/NCI NIH HHS/United States', 'CA 61833/CA/NCI NIH HHS/United States', 'CA 69274/CA/NCI NIH HHS/United States', 'CA 79726/CA/NCI NIH HHS/United States', 'CA 79753/CA/NCI NIH HHS/United States']",,,,,,,,
14751666,NLM,MEDLINE,20040309,20190819,0300-483X (Print) 0300-483X (Linking),195,2-3,2004 Feb 15,The selective effect of genistein on the toxicity of bleomycin in normal lymphocytes and HL-60 cells.,87-95,"['Lee, Rami', 'Kim, Yang Jee', 'Lee, Young Joon', 'Chung, Hai Won']","['Lee R', 'Kim YJ', 'Lee YJ', 'Chung HW']",['eng'],['Journal Article'],,Ireland,Toxicology,Toxicology,0361055,"['0 (Antibiotics, Antineoplastic)', '0 (DNA, Neoplasm)', '11056-06-7 (Bleomycin)', 'DH2M523P0H (Genistein)']",IM,"['Antibiotics, Antineoplastic/*toxicity', 'Bleomycin/*toxicity', 'Cell Division/drug effects', 'Comet Assay', 'DNA Damage', 'DNA, Neoplasm/drug effects', 'Dose-Response Relationship, Drug', 'Drug Synergism', 'Female', 'Genistein/*pharmacology', 'HL-60 Cells/*drug effects', 'Humans', 'Lymphocytes/*drug effects', 'Micronucleus Tests']",,,,2004/01/31 05:00,2004/03/10 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/03/10 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Toxicology. 2004 Feb 15;195(2-3):87-95. doi: 10.1016/j.tox.2003.08.011.,"['S0300483X03004128 [pii]', '10.1016/j.tox.2003.08.011 [doi]']",,"This study was carried out to find whether genistein might enhance bleomycin induced cytotoxicity in human leukemia (HL-60) while protecting normal blood lymphocytes. Despite the excellent chemotherapeutic effect of bleomycin, its cytotoxicity and genotoxicity in normal cells remains a major problem in chemotherapy. Genistein, one of the major Soy isoflavones, is particularly effective in quenching free radicals generated by toxic agents. In this study, the protective and enhancement effects of genistein on bleomycin induced cytotoxicity in HL-60 cells and blood lymphocytes were demonstrated. HL-60 cells were treated with various concentrations of genistein for 3 h followed by treatment with various concentrations of bleomycin during the G1 phase. Pretreatment of genistein increased micronuclei (MN) frequency and DNA damage as a result of bleomycin treatment. However, when human lymphocytes were pretreated with genistein prior to bleomycin treatment during the G2 or G0 phase, the frequencies of bleomycin induced MN was decreased. Although the extent of bleomycin induced DNA damage determined by single cell gel electrophoresis was increased through the pretreatment of genistein in HL-60 cells, it was decreased in normal lymphocytes. The result of this study may therefore provide great impact on the potential activity of genistein as a therapeutic agent.","['School of Public Health and Institute of Health and Environmental Sciences, Seoul National University, 28 Yunkeun-dong, Chongno-ku, Seoul 110-460, South Korea.']",,,,,,,,,,
14751243,NLM,MEDLINE,20040323,20190612,0006-291X (Print) 0006-291X (Linking),314,4,2004 Feb 20,Transient posttranslational up-regulation of telomerase activity during megakaryocytic differentiation of K562 cells.,1080-5,"['Nakatake, M', 'Sasaki, N', 'Murakami-Murofushi, K', 'Yamada, O']","['Nakatake M', 'Sasaki N', 'Murakami-Murofushi K', 'Yamada O']",['eng'],['Journal Article'],,United States,Biochem Biophys Res Commun,Biochemical and biophysical research communications,0372516,"['0 (DNA Primers)', '0 (Enzyme Inhibitors)', 'EC 2.7.11.13 (Protein Kinase C)', 'EC 2.7.7.49 (Telomerase)']",IM,"['Base Sequence', 'DNA Primers', 'Enzyme Inhibitors/pharmacology', 'Humans', 'K562 Cells', 'Protein Kinase C/antagonists & inhibitors', '*Protein Processing, Post-Translational', 'Telomerase/*metabolism', '*Up-Regulation']",,,,2004/01/31 05:00,2004/03/24 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/03/24 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Biochem Biophys Res Commun. 2004 Feb 20;314(4):1080-5. doi: 10.1016/j.bbrc.2003.12.199.,"['S0006291X04000105 [pii]', '10.1016/j.bbrc.2003.12.199 [doi]']",,"Telomerase is active in immature somatic cells, but not in differentiated cells. However, the mechanism by which telomerase is regulated in relation to cell differentiation is not well understood. In this study, the human erythroid leukemia cell line K562 was induced to differentiate into megakaryocytes by TPA and into erythroid by STI571. The human acute myeloblastic leukemia cell line HL60 was also induced to differentiate into monocytes by TPA. Telomerase activity, the expression of human telomerase reverse transcriptase, hTERT, and the cell cycle were examined. TPA induced a transient increase in telomerase activity during the megakaryocytic differentiation while the message of hTERT decreased gradually throughout the same period. This suggests the existence of a regulatory mechanism other than transcription of hTERT. Cell cycle analysis revealed that cells in G(2)/M phase increased in number in accordance with the changes in telomerase activity. Pretreatment with PKC inhibitors inhibited the megakaryocytic differentiation, transient increase in telomerase activity, and G(2)/M arrest. These results suggest that PKC acts as a transient post-translational activator of telomerase during megakaryocytic differentiation.","['Department of Biology, Faculty of Science, Ochanomizu University, Japan.']",,,,,,,,,,
14751230,NLM,MEDLINE,20040323,20190612,0006-291X (Print) 0006-291X (Linking),314,4,2004 Feb 20,"A mushroom (Ganoderma capense) lectin with spectacular thermostability, potent mitogenic activity on splenocytes, and antiproliferative activity toward tumor cells.",988-93,"['Ngai, Patrick H K', 'Ng, T B']","['Ngai PH', 'Ng TB']",['eng'],['Journal Article'],,United States,Biochem Biophys Res Commun,Biochemical and biophysical research communications,0372516,"['0 (Lectins)', '0 (Mitogens)']",IM,"['Amino Acid Sequence', 'Animals', 'Cell Division/*drug effects', 'Cell Line, Tumor', 'Chromatography, Gel', 'Chromatography, Ion Exchange', 'Electrophoresis, Polyacrylamide Gel', 'Ganoderma/*chemistry', 'Lectins/chemistry/isolation & purification/*pharmacology', 'Mice', 'Mitogens/chemistry/isolation & purification/*pharmacology', 'Molecular Sequence Data', 'Sequence Homology, Amino Acid', 'Spleen/cytology/*drug effects']",,,,2004/01/31 05:00,2004/03/24 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/03/24 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Biochem Biophys Res Commun. 2004 Feb 20;314(4):988-93. doi: 10.1016/j.bbrc.2003.12.196.,"['S0006291X03028183 [pii]', '10.1016/j.bbrc.2003.12.196 [doi]']",,"An 18-kDa lectin, with an N-terminal sequence displaying slight similarity to some lectins and fungal immunomodulatory proteins, was isolated from the mushroom Ganoderma capense (Lloyd) Teng. It exhibited more potent mitogenic activity than that of concanavalin A toward mouse splenocytes, and antiproliferative activity toward leukemia (L1210 and M1) cells and hepatoma (HepG2) cells. The isolation procedure entailed ion exchange chromatography on Q-Sepharose, fast protein liquid chromatography (FPLC)-ion exchange chromatography on Mono S, and FPLC-gel filtration on Superdex 75. D(+)-galactose and D(+)-galactosamine specifically inhibited the hemagglutinating activity of the lectin. The hemagglutinating activity of the lectin was not affected over the temperature range 0-100 degrees C and after exposure to 100 degrees C for 60min. The activity was stable in the pH range of 4-11, and after incubation with solutions of various chlorides (from 3.125 to 50mM) including NaCl, KCl, CaCl(2), MgCl(2), ZnCl(2), MnCl(2), and AlCl(3). However, it was potentiated by 12.5-50mM FeCl(3). The lectin was devoid of HIV-1 reverse transcriptase inhibitory and antifungal activities.","['Department of Biochemistry, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China.']",,,,,,,,,,
14751076,NLM,MEDLINE,20040504,20160607,0578-1310 (Print) 0578-1310 (Linking),41,5,2003 May,[Resistance mechanisms to Methotrexate].,388-90,"['Jin, Mei', 'Wu, Min-yuan']","['Jin M', 'Wu MY']",['chi'],"['Journal Article', 'Review']",,China,Zhonghua Er Ke Za Zhi,Zhonghua er ke za zhi = Chinese journal of pediatrics,0417427,"['0 (Antimetabolites, Antineoplastic)', 'YL5FZ2Y5U1 (Methotrexate)']",IM,"['Antimetabolites, Antineoplastic/*pharmacology/therapeutic use', '*Drug Resistance, Neoplasm', 'Humans', 'Methotrexate/*pharmacology/therapeutic use', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy']",,,,2004/01/31 05:00,2004/05/05 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/05/05 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Zhonghua Er Ke Za Zhi. 2003 May;41(5):388-90.,,,,,,,21,,,,,,,
14751063,NLM,MEDLINE,20040504,20160607,0578-1310 (Print) 0578-1310 (Linking),41,5,2003 May,[Expression of myeloid antigen in childhood acute lymphoblastic leukemia].,370-1,"['Hu, Qun', 'Zhang, Liu-qing', 'Liu, Shuang-you', 'Guo, Yi-jie', 'Tao, De-ding']","['Hu Q', 'Zhang LQ', 'Liu SY', 'Guo YJ', 'Tao DD']",['chi'],['Journal Article'],,China,Zhonghua Er Ke Za Zhi,Zhonghua er ke za zhi = Chinese journal of pediatrics,0417427,"['0 (Antigens, CD)', '0 (Antigens, Neoplasm)']",IM,"['Antigens, CD/blood', 'Antigens, Neoplasm/*blood', 'Bone Marrow/immunology', 'Child', 'Child, Preschool', 'Female', 'Flow Cytometry/methods', 'Humans', 'Male', 'Myeloid Cells', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*immunology/mortality', 'Survival Rate']",,,,2004/01/31 05:00,2004/05/05 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/05/05 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Zhonghua Er Ke Za Zhi. 2003 May;41(5):370-1.,,,,,,,,,,,,,,
14751057,NLM,MEDLINE,20040504,20211203,0578-1310 (Print) 0578-1310 (Linking),41,5,2003 May,"[Expression of Bc1-2, P16 proto-oncogene and PCNA in childhood acute leukemia].",360-1,"['Chai, Yi-huan', 'Cao, You-fu', 'Li, Shi-gang', 'Deng, Hai-zhen', 'Chai, Yu-hai', 'Li, Jian-qin', 'Kong, Xiao-xing', 'Zhu, Ling-li']","['Chai YH', 'Cao YF', 'Li SG', 'Deng HZ', 'Chai YH', 'Li JQ', 'Kong XX', 'Zhu LL']",['chi'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,China,Zhonghua Er Ke Za Zhi,Zhonghua er ke za zhi = Chinese journal of pediatrics,0417427,"['0 (Biomarkers, Tumor)', '0 (Cyclin-Dependent Kinase Inhibitor p16)', '0 (MAS1 protein, human)', '0 (Proliferating Cell Nuclear Antigen)', '0 (Proto-Oncogene Mas)', '0 (Proto-Oncogene Proteins c-bcl-2)']",IM,"['Acute Disease', 'Biomarkers, Tumor/*analysis', 'Child', 'Cyclin-Dependent Kinase Inhibitor p16/analysis', 'Histocytochemistry', 'Humans', 'Leukemia/metabolism/*pathology', 'Proliferating Cell Nuclear Antigen/analysis', 'Proto-Oncogene Mas', 'Proto-Oncogene Proteins c-bcl-2/analysis']",,,,2004/01/31 05:00,2004/05/05 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/05/05 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Zhonghua Er Ke Za Zhi. 2003 May;41(5):360-1.,,,,,,,,,,,,,,
14751050,NLM,MEDLINE,20040504,20160607,0578-1310 (Print) 0578-1310 (Linking),41,5,2003 May,[Immunophenotyping of 222 children with acute leukemia by multi-color flow cytometry].,334-7,"['Shen, Hong-qiang', 'Tang, Yong-min', 'Yang, Shi-long', 'Qian, Bo-qin', 'Song, Hua', 'Shi, Shu-wen', 'Xu, Wei-qun']","['Shen HQ', 'Tang YM', 'Yang SL', 'Qian BQ', 'Song H', 'Shi SW', 'Xu WQ']",['chi'],"['English Abstract', 'Journal Article']",,China,Zhonghua Er Ke Za Zhi,Zhonghua er ke za zhi = Chinese journal of pediatrics,0417427,,IM,"['Acute Disease', 'Adolescent', 'Child', 'Child, Preschool', 'Female', 'Flow Cytometry/*methods', 'Humans', '*Immunophenotyping', 'Infant', 'Leukemia/*classification/diagnosis/immunology', 'Male']",,,,2004/01/31 05:00,2004/05/05 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/05/05 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Zhonghua Er Ke Za Zhi. 2003 May;41(5):334-7.,,,"OBJECTIVE: Acute leukemia (AL) is one of the most common malignant diseases in children. AL immunophenotypes are known to be benefit to the predictable prognoses and specific therapy. Recently, the accuracy of AL immunophenotyping was dramatically improved with the application of the flow cytometry, the new monoclonal antibodies, the improvement of the gating strategies and the multi-parameter analytic techniques. The aim of this study was to evaluate the value of multi-color flow cytometry in the immunophenotyping of acute leukemia in children. METHODS: Three- or four-color flow cytometry and CD(45)/Side Scatter (SSC) gating were used to analyze the surface and cytoplasmic (Cy) antigen expressions in 222 successive cases of childhood acute leukemia. RESULTS: Cells from 222 cases of children with acute leukemia were analyzed. Based on the diagnostic criterion proposed by European Group for the Immunological Characterization of Leukemia (EGIL), four categories could be identified: the undifferentiated type accounted for 0.9%, acute myeloid leukemia (AML) 35.1%, acute lymphoblastic leukemia (ALL) 55.9%, and mixed lineage AL 8.1%. Of 124 patients with ALL, 94 patients (75.8%) were classified as B lineage and 30 patients (24.2%) T lineage ALL. Antigen aberrant expressions were found in AML (24.4%), B lineage ALL (36.2%) and T lineage ALL (30.0%). CD(7) was the most commonly expressed lymphoid antigen in AML (12.8%), followed by CD(19) (6.4%) and CD(2) (5.1%). CD(13) was the most commonly expressed myeloid antigen in ALL (18.5%), followed by CD(15) (11.3%), CD(11b) (6.5%) and CD(33) (4.3%). CD(117) and CD(56) presented in 73.3% and 38.0% cases of AML, respectively, but were generally absent on blast cells of ALL. CyCD(22), CyCD(3) and CyMPO were specifically expressed in B lineage, T lineage and myeloid lineage leukemia, respectively, and the first two could be more sensitively detected than they were on cell membrane surface. CONCLUSIONS: Multi-color flow cytometry is a reliable technique in the diagnosis, differential diagnosis and classification of acute leukemia in children.","[""Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.""]",,,,,,,,,,
14751048,NLM,MEDLINE,20040504,20171116,0578-1310 (Print) 0578-1310 (Linking),41,5,2003 May,[Analysis of 21 children with acute non-lymphoid leukemia carrying AML1/ETO fusion gene].,325-8,"['Zhao, Wei', 'Li, Zhi-gang', 'Wu, Min-yuan', 'Geng, Lan-zeng', 'Shi, Hui-wen', 'Zhang, Yong-hong', 'Wu, Ruen-hui']","['Zhao W', 'Li ZG', 'Wu MY', 'Geng LZ', 'Shi HW', 'Zhang YH', 'Wu RH']",['chi'],['Journal Article'],,China,Zhonghua Er Ke Za Zhi,Zhonghua er ke za zhi = Chinese journal of pediatrics,0417427,"['0 (AML1-ETO fusion protein, human)', '0 (Core Binding Factor Alpha 2 Subunit)', '0 (Oncogene Proteins, Fusion)', '0 (RNA, Neoplasm)', '0 (RUNX1 Translocation Partner 1 Protein)', '0 (Transcription Factors)']",IM,"['Adolescent', 'Child', 'Child, Preschool', 'Core Binding Factor Alpha 2 Subunit', 'Female', 'Humans', 'Leukemia, Myeloid, Acute/classification/drug therapy/*genetics', 'Male', 'Oncogene Proteins, Fusion/*genetics', 'Prognosis', 'RNA, Neoplasm/genetics/metabolism', 'RUNX1 Translocation Partner 1 Protein', 'Reverse Transcriptase Polymerase Chain Reaction', 'Transcription Factors/*genetics']",,,,2004/01/31 05:00,2004/05/05 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/05/05 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Zhonghua Er Ke Za Zhi. 2003 May;41(5):325-8.,,,"OBJECTIVE: It was revealed that t(8; 21) (q22; q22) was one of the most common chromosomal aberrations in acute non-lymphoid leukemia. The translocation was found to be involved in the AML1 gene on the chromosome 21 and the ETO gene on the chromosome 8, and resulted in the formation of AML1/ETO fusion gene on the derivative chromosome 8. The fusion gene was a transcription factor and played a direct role in the leukemogenesis. The translocation was mainly observed in M(2), accidentally in M(4) and M(1) and rarely in MDS. Here we studied the main clinical data in children with acute non-lymphoid leukemia (ANLL) carrying the AML1/ETO fusion gene. In addition, we discussed the significance of the detection of AML1/ETO fusion gene in the diagnosis and prognosis of children with ANLL. METHODS: The authors investigated 29 patients in our hospital from December 2000 to March 2002. The patients were divided into two groups. Group A included 21 patients, 14 males and 7 females. They were 3.6 to 14 years old and the median was 9. Group B included 8 patients, 6 males and 2 females. They were 0.8 to 14 years old and the median was 6. Diagnosis was made according to FAB and MIC criteria and the expression of AML1/ETO fusion gene was detected with nested RT-PCR. The patients were treated according to DA, DAE or BFM regimen, respectively. The main clinical indexes including age, Hb, white blood count, platelet, blasts in PBC and BM, and time of arrival at complete remission (CR), were compared statistically between the two groups with t test of independent samples. RESULTS: All the 21 patients in group A were found carrying AML1/ETO, and 17 patients (81%) were classified as M(2), the other 4 cases were of M(2) developed from MDS-RAEB-T, M(4Eo), M(5) and eosinophil leukemia, respectively. Eighteen out of 20 patients whose effects could be assessed reached CR, and the CR ratio was 90%. Two patients in group B were of AML-M(1), 3 M(2), 1 M(3), 1 M(4), and 1 M(5), respectively. None of them was found carrying AML1/ETO. Seven cases reached CR and the ratio was 87.5%. There was no significant difference between the two groups in the above clinical indices. CONCLUSIONS: Between the two groups of patients there was no significant difference in the above clinical indices. RT-PCR for the detection of AML1/ETO in children with ANLL was quick, convenient and sensitive, and could be regarded as a useful method for the diagnosis and prognosis of ANLL.","[""Hematological Center, Beijing Children's Hospital, Beijing 100045, China.""]",,,,,,,,,,
14750750,NLM,MEDLINE,20040322,20161124,0024-6921 (Print) 0024-6921 (Linking),155,6,2003 Nov-Dec,Essential thrombocytosis: diagnostic and treatment dilemmas.,306-13,"['Dugan, Veronica', 'Higginbotham, Raphael', 'Gilbert, Jill', 'Lipscomb, Gary', 'Lopez, Fred A']","['Dugan V', 'Higginbotham R', 'Gilbert J', 'Lipscomb G', 'Lopez FA']",['eng'],"['Journal Article', 'Review']",,United States,J La State Med Soc,The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society,7505618,"['0 (Interferon-alpha)', '0 (Quinazolines)', 'K9X45X0051 (anagrelide)', 'R16CO5Y76E (Aspirin)', 'X6Q56QN5QC (Hydroxyurea)']",IM,"['Aspirin/therapeutic use', 'Chronic Disease', 'Hemorrhage/etiology/prevention & control', 'Humans', 'Hydroxyurea/therapeutic use', 'Interferon-alpha/therapeutic use', 'Male', 'Middle Aged', 'Quinazolines/therapeutic use', 'Risk Assessment', 'Thrombocytosis/complications/*diagnosis/*therapy', 'Thrombopoiesis/physiology']",,,,2004/01/31 05:00,2004/03/23 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/03/23 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,J La State Med Soc. 2003 Nov-Dec;155(6):306-13.,,,"Essential thrombocytosis is one of the chronic myeloproliferative disorders that includes polycythemia vera, chronic myelogenous leukemia, and agnogenic myeloid metaplasia. Despite established diagnostic criteria and greater than a quarter century of study, there are still several diagnostic and management dilemmas that plague researchers and clinicians alike. We present a case of essential thrombocytosis in a patient with multiple sequelae.","['Department of Internal Medicine, Louisiana State University, School of Medicine, New Orleans, USA.']",,,18,,,,,,,
14750694,NLM,MEDLINE,20040513,20191108,0952-4746 (Print) 0952-4746 (Linking),23,4,2003 Dec,Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997.,457-9,"['Charles, M W']",['Charles MW'],['eng'],['News'],,England,J Radiol Prot,Journal of radiological protection : official journal of the Society for Radiological Protection,8809257,,IM,"['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Child', 'Child, Preschool', 'Cohort Studies', 'Dose-Response Relationship, Radiation', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Japan/epidemiology', 'Leukemia/mortality', 'Male', 'Middle Aged', 'Neoplasms, Radiation-Induced/*mortality', '*Nuclear Warfare', 'Radiometry/*methods', 'Sex Factors', 'Survival Analysis', 'Survivors/*statistics & numerical data', 'Topography, Medical/methods']",,,,2004/01/31 05:00,2004/05/14 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/05/14 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,J Radiol Prot. 2003 Dec;23(4):457-9. doi: 10.1088/0952-4746/23/4/m02.,['10.1088/0952-4746/23/4/m02 [doi]'],,,,,,,,,,,,,
14750693,NLM,MEDLINE,20040513,20041117,0952-4746 (Print) 0952-4746 (Linking),23,4,2003 Dec,Selection of healthy workers in underground metal ore miners--possible effect on leukaemia mortality.,450-1,"['Eatough, Jonathan']",['Eatough J'],['eng'],['Letter'],,England,J Radiol Prot,Journal of radiological protection : official journal of the Society for Radiological Protection,8809257,,IM,"['*Healthy Worker Effect', 'Humans', 'Leukemia, Radiation-Induced/*mortality', 'Lung Neoplasms/*mortality', '*Mining', 'Neoplasms, Radiation-Induced/*mortality', 'Occupational Diseases/*mortality', '*Occupational Exposure']",,,,2004/01/31 05:00,2004/05/14 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/05/14 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,J Radiol Prot. 2003 Dec;23(4):450-1.,,,,,,,,,,,,,,
14750687,NLM,MEDLINE,20040513,20191108,0952-4746 (Print) 0952-4746 (Linking),23,4,2003 Dec,Comparison of Health and Safety Executive and Cumbrian birth cohort studies of risk of leukaemia/non-Hodgkin's lymphoma in relation to paternal preconceptional irradiation.,385-403,"['Dickinson, H O', 'Hodgson, J T', 'Parker, L']","['Dickinson HO', 'Hodgson JT', 'Parker L']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",,England,J Radiol Prot,Journal of radiological protection : official journal of the Society for Radiological Protection,8809257,,IM,"['Adolescent', 'Adult', 'Child', 'Cohort Studies', 'Dose-Response Relationship, Radiation', 'England', 'Female', 'Humans', 'Leukemia/*etiology', 'Lymphoma, Non-Hodgkin/*etiology', 'Male', 'Neoplasms, Radiation-Induced/*etiology', 'Nuclear Reactors', '*Occupational Exposure', 'Paternal Exposure', 'Pregnancy', 'Prenatal Exposure Delayed Effects', 'Radiation Dosage', 'Risk Factors']",,,,2004/01/31 05:00,2004/05/14 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/05/14 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,J Radiol Prot. 2003 Dec;23(4):385-403. doi: 10.1088/0952-4746/23/4/003.,['10.1088/0952-4746/23/4/003 [doi]'],,"In 1993, a case-control study by the Health and Safety Executive (HSE) assessed the risk of leukaemia and non-Hodgkin's lymphoma (LNHL) among children of fathers employed at the Sellafield nuclear installation in relation to paternal preconceptional irradiation (PPI). It concluded that the statistical association between risk of LNHL and PPI was confined to children born in the village of Seascale, where the dose-response was extremely high and very significant. In contrast, in 2002, a Cumbrian birth cohort study, investigating largely the same cases, concluded that this statistical association was not significantly different among children born inside and outside Seascale and estimated the dose-response inside Seascale to be much lower. This review makes a detailed comparison of the two studies, considering their design, data and analyses. The differences between their findings are due to: (i) differences in the distribution of offspring-years which are differential with respect to dose category and Seascale birth status, (ii) a non-Seascale high-dose case included in the Cumbrian but not the HSE study, (iii) differences between analyses using categorical and continuous PPI dose and (iv) the presence of Seascale controls with PPI over 200 mSv in the Cumbrian but not the HSE study.","[""North of England Children's Cancer Research Unit, Paediatric and Lifecourse Epidemiology Research Group, Sir James Spence Institute of Child Health, University of Newcastle, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK.""]",,,,['J Radiol Prot. 2003 Dec;23(4):359-62. PMID: 14750684'],,,,,,
14750684,NLM,MEDLINE,20040513,20191108,0952-4746 (Print) 0952-4746 (Linking),23,4,2003 Dec,"Childhood leukaemia and radiation exposure of fathers--the end of the road, perhaps?",359-62,"['Wakeford, Richard']",['Wakeford R'],['eng'],"['Comment', 'Editorial']",,England,J Radiol Prot,Journal of radiological protection : official journal of the Society for Radiological Protection,8809257,,IM,"['England/epidemiology', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia, Radiation-Induced/epidemiology/*etiology', 'Male', '*Nuclear Reactors', '*Occupational Exposure', '*Paternal Exposure', 'Pregnancy', 'Prenatal Exposure Delayed Effects', 'Radiation Dosage', 'Risk Factors']",,,,2004/01/31 05:00,2004/05/14 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/05/14 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,J Radiol Prot. 2003 Dec;23(4):359-62. doi: 10.1088/0952-4746/23/4/e02.,['10.1088/0952-4746/23/4/e02 [doi]'],,,,,,,,['J Radiol Prot. 2003 Dec;23(4):385-403. PMID: 14750687'],,,,,
14750642,NLM,MEDLINE,20040429,20190814,0036-5521 (Print) 0036-5521 (Linking),38,12,2003 Dec,In vitro sensitivity of human gastric cancer cells (HGC-27) to Helicobacter pylori cytotoxin.,1228-34,"['Pessina, A', 'Bayo, M', 'Croera, C', 'Meringolo, F', 'Neri, M G', 'Montesissa, L', 'Raimondi, A']","['Pessina A', 'Bayo M', 'Croera C', 'Meringolo F', 'Neri MG', 'Montesissa L', 'Raimondi A']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,England,Scand J Gastroenterol,Scandinavian journal of gastroenterology,0060105,"['0 (Anti-Inflammatory Agents, Non-Steroidal)', '0 (Bacterial Proteins)', '0 (Bacterial Toxins)', '0 (Cytotoxins)', '0 (Topoisomerase I Inhibitors)', '0 (VacA protein, Helicobacter pylori)']",IM,"['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/toxicity', 'Bacterial Proteins/*pharmacology', 'Bacterial Toxins/*pharmacology', 'Cell Division/drug effects', 'Cell Line', 'Cell Line, Tumor/drug effects', 'Cell Survival/drug effects', 'Colony-Forming Units Assay', 'Cytotoxins/*pharmacology', 'Dose-Response Relationship, Drug', 'Epithelial Cells/drug effects/physiology/ultrastructure', 'HeLa Cells', '*Helicobacter pylori', 'Humans', 'Stomach Neoplasms/pathology/*ultrastructure', 'Topoisomerase I Inhibitors', 'Vacuoles/*drug effects']",,,,2004/01/31 05:00,2004/04/30 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/04/30 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Scand J Gastroenterol. 2003 Dec;38(12):1228-34. doi: 10.1080/00365520310007143.,['10.1080/00365520310007143 [doi]'],,"BACKGROUND: The VacA cytotoxin produced by Helicobacter pylori is considered an important co-factor in the pathogenesis of chronic gastritis, peptic ulcer and gastric carcinoma. The toxin remains partly bound on the bacterial surface, but a certain amount is secreted and can bind receptors on gastric epithelium. The vacuolizing activity of this toxin is related to alteration of endo-lysosomic function and pore formation into plasmatic membrane. METHODS: We investigated the 'in vitro' effect of filtrates obtained from two broth cultures of H. pylori with different genotype (vacA+ and vacA-) as verified by PCR. The effect was studied on three cell lines of epithelial origin: HeLa cells (reference strain for testing vacuolization), human transformed keratinocytes HaCaT, human gastric carcinoma cells HGC-27, and on a murine leukaemia WEHI-3B. The filtrate concentrations capable of giving vacuolization (NRU test), antiproliferative and cytotoxic effects (MTT test) were determined. The modulating effect of filtrates on drug toxicity was investigated on HeLa and HGC-27 cells by testing topoisomerase inhibitors (Ciprofloxacin and Camptothecin) and non-steroidal anti-inflammatory molecules (Aspirin and Indomethacin). RESULTS: Our results confirm that vacuolizing activity is present only in VacA+ filtrate and that HaCaT and HeLa cells show a similar sensitivity, whereas gastric HGC-27 cells appear significantly resistant to VacA+ activity. Although VacA filtrate does not produce vacuolisation, it affects the cell proliferation and is cytotoxic to the four cell lines. Both the VacA+ and VacA- filtrates (at non-cytotoxic concentrations) produce a decrease in drug toxicity with the unique exception of Ciprofloxacin to gastric HGC-27 cells, which in the presence of VacA+ and VacA- produces a significant increase in toxicity. CONCLUSIONS: These data suggest that products from H. pylori (other than those that have antiproliferative and toxic activity) may modulate the sensitivity of cells to drugs 'in vitro'. If this also occurs 'in vivo', we can assume that H. pylori products interfere with drug activity on gastric tissue and also with other factors (such as cytokines) with a role in the genesis of diseases in which Helicobacters are potentially involved.","['Institute of Microbiology, University of Milan, Italy. augusto.pessina@unimi.it']",,,,,,,,,,
14750323,NLM,MEDLINE,20040211,20121115,0385-0684 (Print) 0385-0684 (Linking),31,1,2004 Jan,[Clinical evaluation of cefozopran as treatment for febrile neutropenia].,61-5,"['Saito, Takashi', 'Hara, Masamichi', 'Shinagawa, Katsuji', 'Nawa, Yuichiro', 'Nakase, Koichi', 'Takeuchi, Makoto', 'Miyata, Akira', 'Fukuda, Shunnichi', 'Sunami, Kazutaka', 'Imajoh, Kenji', 'Yano, Tomofumi', 'Kojima, Kensuke', 'Teshima, Takanori', 'Fujii, Nobuharu', 'Ishimaru, Fumihiko', 'Ikeda, Kazuma', 'Harada, Mine', 'Tanimoto, Mitsune']","['Saito T', 'Hara M', 'Shinagawa K', 'Nawa Y', 'Nakase K', 'Takeuchi M', 'Miyata A', 'Fukuda S', 'Sunami K', 'Imajoh K', 'Yano T', 'Kojima K', 'Teshima T', 'Fujii N', 'Ishimaru F', 'Ikeda K', 'Harada M', 'Tanimoto M']",['jpn'],"['Clinical Trial', 'English Abstract', 'Journal Article', 'Multicenter Study']",,Japan,Gan To Kagaku Ryoho,Gan to kagaku ryoho. Cancer & chemotherapy,7810034,"['0 (Anti-Bacterial Agents)', '0 (Cephalosporins)', '1LG87K28LW (cefozopran)']",IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Anti-Bacterial Agents/*therapeutic use', 'Cephalosporins/*therapeutic use', 'Female', 'Fever/*drug therapy/etiology', 'Humans', 'Leukemia/drug therapy', 'Male', 'Middle Aged', 'Neutropenia/chemically induced/*complications']",,,,2004/01/31 05:00,2004/02/12 05:00,['2004/01/31 05:00'],"['2004/01/31 05:00 [pubmed]', '2004/02/12 05:00 [medline]', '2004/01/31 05:00 [entrez]']",ppublish,Gan To Kagaku Ryoho. 2004 Jan;31(1):61-5.,,,"Clinical effects and safety of cefozopran (CZOP) were evaluated by the Okayama Bone Marrow Transplantation Group. Twenty-five patients expected to experience febrile neutropenia during induction chemotherapy or consolidation chemotherapy of acute leukemia were enrolled between July 2000 and November 2002. CZOP was administrated by drip infusion at 4g/day bid for a minimum of 3 days. The clinical effects and safety were evaluated in 20 patients with fever of 37.5 degrees C or more from a clinically suspected infection. The underlying disease was acute myeloid leukemia in 17 patients, acute lymphoid leukemia in 1 and acute promyelogeneous leukemia in 1. The complicating infections were sepsis and suspected sepsis. Clinical efficacy was excellent in 11 patients, good in 1, fair in 2 and poor in 6, with an efficacy rate of 60.0%. The efficacy rate in patients whose albumin levels before therapy were less than 3.8 g/dl was 37.5%, whereas the rate in patients whose albumin levels before therapy were between 3.8 g/dl and 5.3 g/dl was 80.0%. The efficacy rate in patients whose neutrophil counts before therapy were less than 100/microliter was 50.0%, whereas the rate in patients whose neutrophil counts after therapy were less than 100/microliter was 53.8%. The efficacy rate in patients whose neutrophil counts both before and after therapy were less than 100/microliter was 37.5%. Side effect of exanthema was observed in 1 patient. These results indicate that CZOP is an effective and safe antibiotic for the treatment of febrile neutropenia in patients with hematological malignancies.","['Dept. of Internal Medicine II, Okayama University Medical School.']",,,,,,,,,,
14750206,NLM,MEDLINE,20040304,20161124,0951-418X (Print) 0951-418X (Linking),18,1,2004 Jan,"Anti-inflammatory activity, cytotoxicity and active compounds of Tinospora smilacina Benth.",78-83,"['Li, Rachel W', 'Leach, David N', 'Myers, Stephen P', 'Leach, Gregory J', 'Lin, G David', 'Brushett, Donald J', 'Waterman, Peter G']","['Li RW', 'Leach DN', 'Myers SP', 'Leach GJ', 'Lin GD', 'Brushett DJ', 'Waterman PG']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",,England,Phytother Res,Phytotherapy research : PTR,8904486,"['0 (Anti-Inflammatory Agents, Non-Steroidal)', '0 (Antineoplastic Agents, Phytogenic)', '0 (Isoenzymes)', '0 (Membrane Proteins)', '0 (Plant Extracts)', 'EC 1.13.11.12 (Lipoxygenase)', 'EC 1.14.99.1 (Cyclooxygenase 1)', 'EC 1.14.99.1 (Cyclooxygenase 2)', 'EC 1.14.99.1 (PTGS1 protein, human)', 'EC 1.14.99.1 (PTGS2 protein, human)', 'EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)', 'EC 3.1.1.32 (Phospholipases A)']",IM,"['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology/therapeutic use', 'Antineoplastic Agents, Phytogenic/administration & dosage/*pharmacology/therapeutic use', 'Cattle', 'Cell Line, Tumor/drug effects', 'Cyclooxygenase 1', 'Cyclooxygenase 2', 'HL-60 Cells/drug effects', 'Humans', 'Inhibitory Concentration 50', 'Isoenzymes/antagonists & inhibitors/drug effects', 'Lipoxygenase/drug effects', 'Membrane Proteins', 'Phospholipases A/antagonists & inhibitors/drug effects', '*Phytotherapy', 'Plant Extracts/administration & dosage/*pharmacology/therapeutic use', 'Plant Roots', 'Plant Stems', 'Prostaglandin-Endoperoxide Synthases/drug effects', 'Sheep', '*Tinospora']",,,,2004/01/30 05:00,2004/03/05 05:00,['2004/01/30 05:00'],"['2004/01/30 05:00 [pubmed]', '2004/03/05 05:00 [medline]', '2004/01/30 05:00 [entrez]']",ppublish,Phytother Res. 2004 Jan;18(1):78-83. doi: 10.1002/ptr.1373.,['10.1002/ptr.1373 [doi]'],,"Tinospora smilacina Benth. has been used in Australian indigenous medicine for the treatment of headache, rheumatoid arthritis and other inflammatory disorders. As part of an investigation into the anti-inflammatory potential of plants using an ethnopharmacological approach, the present study sought to evaluate the efficacy and safety of Tinospora smilacina. An ethanol extract of this plant was evaluated in vitro for anti-inflammatory activities on cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LO) and phospholipase A(2) (PA(2)). The ethanol extract of Tinospora smilacina showed inhibitory activities on COX-1, COX-2, 5-LO and PA(2) with the IC(50) values of 63.5, 81.2, 92.1 and 30.5 micro g/mL respectively. Cytotoxic effect of the extracts of Tinospora smilacina was investigated in vitro using ATP-based luminescence assay and the results showed no cytotoxic effect on cell lines of skin fibroblasts (1BR3), human Caucasian hepatocyte carcinoma (Hep G2) and human Caucasian promyelocytic leukaemia (HL-60). This paper also describes the results of fractionations and bioassay guided chemical studies, suggesting that the anti-inflammatory activity is due to triterpene-fatty acid esters and free fatty acids.","['Division of Medical Technology, John A Burns School of Medicine, University of Hawaii 96822, USA. rachelli@hawaii.edu']",,,,,,"['Copyright 2004 John Wiley & Sons, Ltd.']",,,,
